0 Mitotic_Metaphase 0.41 4.67 3.34 5 1.69 7.24 4.78 3.58 9.62 4.64 7.05 1.45 2.81 8.27 9.61 4.91 9.95 9.42 
1 Ubiquitin-Dependent_Degradation_of_Cyclin_E 8.27 4.36 3.91 6.04 9.02 1.53 2.92 3.82 4.21 7.16 7.18 8.95 4.47 7.26 7.71 5.38 8.69 9.12 
2 Activation_of_the_pre-replicative_complex 6.67 2.99 0.35 8.94 7.03 8.11 3.22 3.33 6.73 6.64 1.41 7.11 2.53 8.68 5.47 6.44 6.62 7.57 
3 Assembly_of_the_ORC_complex_at_the_origin_of_replication 0.37 8.59 7.23 7.41 5.29 7.78 3.16 0.35 1.9 8.42 2.88 1.06 0.4 9.42 2.64 6.48 4.46 8.05 
4 Assembly_of_the_ORC_complex_at_the_origin_of_replication 8.9 7.29 3.7 3.5 0.06 1.01 3.93 5.48 6.29 6.23 0.84 9.54 7.56 8.4 9.66 3.76 9.31 3.08 
5 CDC6_association_with_the_ORC:origin_complex 9.44 4.39 6.26 3.23 5.37 5.38 1.18 0.82 9.29 5.41 8.33 1.15 6.39 6.58 7.04 9.3 9.77 3.06 
6 CDT1_association_with_the_CDC6:ORC:origin_complex 6.73 3.86 0.21 7.45 9.24 0.72 2.7 8.29 7.77 5.73 0.97 5.12 9.86 2.9 1.61 6.36 3.55 7.67 
7 Association_of_licensing_factors_with_the_pre-replicative_complex 6.55 5.74 0.31 0.52 3.5 1.5 9.41 7.24 9.66 4.3 1.07 1.91 0.07 3.37 4.57 2.87 7.53 3.83 
8 CDC6_association_with_the_ORC:origin_complex 9.45 9.09 2.09 7.58 2.21 5.88 4.22 9.46 5.06 0.3 4.13 1.68 9 5.91 7.62 6.55 4.1 3.59 
9 CDK-mediated_phosphorylation_and_removal_of_Cdc6 6.24 5.37 5.48 4.83 5.95 0.41 6.02 3.5 2.91 8.36 3.74 0.2 5.96 0.21 3.48 1.99 6.68 4.84 
10 CDT1_association_with_the_CDC6:ORC:origin_complex 2.81 7.34 0.53 9.99 4.18 9.38 9 7.88 1.27 4.67 7.28 8.93 6.48 4.83 8.07 4.21 3.1 6.17 
11 Activation_of_the_pre-replicative_complex 8.13 5.14 3.09 6.16 9.35 4.51 6 2.49 5.19 5.56 7.98 3.03 2.24 0.08 8.44 6.09 9.89 7.02 
12 Assembly_of_the_ORC_complex_at_the_origin_of_replication 1.95 4.85 0.93 3.43 5.23 5.87 3.14 5.03 4.48 2 4.58 6.18 5.8 7.96 7.98 2.81 5.89 7.98 
13 CDC6_association_with_the_ORC:origin_complex 0.09 1.57 4.72 6.22 5.38 2.92 0.38 1.79 1.9 6.57 9.58 1.91 8.15 8.88 1.56 5.11 2.02 6.34 
14 CDT1_association_with_the_CDC6:ORC:origin_complex 2.72 0.55 3.28 6.46 3.62 8.86 8.75 4.33 8.69 1.42 8.44 4.16 8.81 9.98 3.22 6.51 0.21 6.99 
15 DNA_replication_initiation 5.57 4.76 8.92 3.89 0.75 7.12 6 5.1 0.03 8.69 8.61 6.88 4.01 7.89 2.55 4.23 0.02 5.85 
16 Polymerase_switching 1.82 2.85 0.88 4.26 6.17 7.57 8.32 9.32 1.69 1.54 7.21 1.89 9.76 3.29 3.68 6.92 4.25 5.55 
17 Removal_of_the_Flap_Intermediate 4.34 5.49 4.41 5.12 1.45 0.6 7.18 7.53 1.39 4.23 2.79 9.96 6.87 5.29 5.49 4.37 8.66 9.49 
18 Unwinding_of_DNA 1.93 1.95 2.97 4.16 2.86 1.05 4.88 2.82 4.55 7.34 1.14 7.01 3.16 6.71 7.86 2.63 3.13 3.55 
19 Polymerase_switching 1.85 0.53 9.12 8.08 8.32 9.45 3.13 7.56 3.21 5.58 6.46 9.82 4.81 1.44 1.96 2.22 1.29 1.61 
20 Removal_of_the_Flap_Intermediate 5.35 4.5 1.73 4.66 0.44 6.59 2.92 4.39 2.53 0.24 1.54 5.1 7.45 6.49 1.86 3.13 4.74 0.22 
21 Polymerase_switching 1.68 0.18 7.87 9.05 9.58 3.91 2.02 6.25 4.77 4.14 3.14 8.24 3.34 8.74 3.72 1.59 8.33 0.7 
22 Activation_of_the_pre-replicative_complex 4.87 2.97 5.18 1.77 7.73 2.7 7.63 6.68 1.92 9.85 1.02 4.8 2.13 6.27 8.02 0.99 5.27 6.25 
23 Assembly_of_the_ORC_complex_at_the_origin_of_replication 5.43 9.24 0.23 9.72 0.61 1.81 0.03 4.32 5.05 5.93 7.25 0.31 4.92 1.42 2.22 2.86 0.64 9 
24 CDC6_association_with_the_ORC:origin_complex 1.87 3.6 4.13 9.74 2.7 1.7 2.35 8.33 7.11 7.6 8.96 6.67 2.85 5.5 1.4 6.94 6.95 6.24 
25 CDT1_association_with_the_CDC6:ORC:origin_complex 0.19 1.25 5.76 6.94 6.58 3.02 3.71 4.66 6.78 5.93 8.51 4.84 0.18 4.64 1.19 1.52 8 0.87 
26 Orc1_removal_from_chromatin 0.6 9.26 0.1 7.57 1.7 3.15 5.76 2.27 0.43 7.58 1.64 1.09 8.82 0.86 5.65 4.87 5.77 4.74 
27 Polymerase_switching 6.25 6.27 6.29 9.28 4.23 5.2 9.02 9.62 1.23 5.96 7.37 2.61 1.95 5.25 2.64 2.6 2.02 1.16 
28 Removal_of_the_Flap_Intermediate 0.3 3.26 0.11 7.71 4.11 5.47 1.53 5.2 7.9 9.24 1.88 7.63 9.4 8.51 6.62 8.29 9 7.13 
29 Association_of_licensing_factors_with_the_pre-replicative_complex 9.58 5.78 3.65 0.07 4.77 2 0.58 4.39 3.03 7.6 3.57 3.24 4.77 1.08 1.13 8.87 8.01 8.5 
30 CDK-mediated_phosphorylation_and_removal_of_Cdc6 4.6 4.28 9.93 3.84 4.05 5.4 1.11 7.04 8.35 3.56 0.72 3.5 8.23 4.85 5.56 2.16 6.26 3.57 
31 Orc1_removal_from_chromatin 5.26 3.57 3.37 2.71 8.69 3.61 8.96 0.22 6.17 1.12 7.17 6.96 5.85 0.41 4.23 1.29 2.29 5.65 
32 CDK-mediated_phosphorylation_and_removal_of_Cdc6 5.59 9.32 2.96 8.55 0.53 9.62 5.84 7.34 6.54 9.72 4.57 3.69 5.32 9.63 6.07 4.83 9.11 6.35 
33 Orc1_removal_from_chromatin 0.67 8.48 6.75 9.38 2.23 1.42 7.54 5.11 7.41 1.75 4.59 8.25 2.21 8.7 6.26 9.34 2.05 7.83 
34 Removal_of_the_Flap_Intermediate 8.5 3.98 2.79 7.01 1.93 7.34 6.37 5.34 5.56 9.93 1.76 7.05 9.62 5.48 8.81 3 4.13 6.41 
35 CDK-mediated_phosphorylation_and_removal_of_Cdc6 8.55 8.55 1.42 4.62 6.11 8.77 4.24 6.78 7.52 4.43 2.96 6.73 0.4 3.13 8.75 0.72 8.18 6.1 
36 Orc1_removal_from_chromatin 0.17 9.32 1.12 6.95 1.69 8.31 0.4 4.88 6.85 0.9 4.97 5.89 9.9 1.45 3.53 3.14 6.51 7.4 
37 CDK-mediated_phosphorylation_and_removal_of_Cdc6 0.44 2.58 3.35 7.59 1.92 6.05 2.64 1.81 5.03 8.29 7.75 6.08 2.92 9.97 5.49 5.56 5.61 6.27 
38 DNA_replication_initiation 4.67 5.41 1.29 2.4 8.13 1.74 6.01 0.77 2.15 6.83 2.13 9.92 8.24 6.01 3.92 7.59 6.7 4.28 
39 Orc1_removal_from_chromatin 0.27 0.84 0.75 7.86 4.98 9.7 2.87 8.47 6.04 5.03 2.21 6.63 7.06 3.63 0.1 1.71 4.89 2.4 
40 Polymerase_switching 1.64 5.42 6.19 9.13 5.91 7.04 8.18 2.32 7.5 2.05 9.75 5.39 3.03 4.22 0.98 2.47 5.84 6.48 
41 Removal_of_the_Flap_Intermediate 9.71 8.64 9.13 0.75 5.45 7.12 5.46 6.78 7.69 2.62 5.19 9.85 2.89 9.44 8.65 5.4 2.45 5.08 
42 Unwinding_of_DNA 3.18 8.7 6.01 3.23 1.32 4.72 1.52 0.87 5.7 7.63 9.01 1.03 4.23 5.27 6 9.69 0.15 5.65 
43 Unwinding_of_DNA 0.28 5.43 3.47 0.88 9.43 6.37 4.09 4.63 0.49 6.81 5.88 3.42 6.08 0.6 2.21 7.58 9.54 8.88 
44 Pyrophosphate_hydrolysis 1.46 6.9 9.49 8.43 4.3 6.2 7.48 0.67 5.36 7.83 0.35 2.26 1.85 0.38 8.53 6.29 2.24 7.48 
45 Cap-independent_Translation_Initiation 9.23 3.59 2.57 7.66 9.44 9.55 3.18 7.26 4.11 0.25 3.55 0.01 5.49 4.96 5.84 5.15 9.64 3.42 
46 ABH2_mediated_Reversal_of_Alkylation_Damage 0.75 9.13 1.42 1.96 9.48 0.72 4.26 6.06 1.73 4.29 4.04 7.05 6.26 8.12 3.75 0.93 5.65 0.36 
47 ABH3_mediated_Reversal_of_Alkylation_Damage 7.36 1.41 8.14 9.94 2.56 6.52 9.36 8.38 4.82 3.55 0.15 1.31 2.3 8.41 6.25 0.11 6.37 1.86 
48 ATM_mediated_phosphorylation_of_repair_proteins 6.9 6.5 6.62 6.34 8.93 3.53 4.16 4.52 0.08 2.62 2.33 4.54 3.03 6.34 3.03 2.56 1.48 1.24 
49 ATM_mediated_phosphorylation_of_repair_proteins 3.17 2.13 1.09 0.28 2 0.8 3.18 8.58 0.5 1.55 3.61 2.64 9.03 6.76 6.43 9.09 9.02 5.61 
50 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 4.89 9.48 2.82 6.53 6.74 2.2 4.02 9.23 8.31 3.69 8.78 2.59 0.08 6.19 9.71 0.03 9.45 7.81 
51 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 5.04 3.92 6.85 3.13 6.98 5.89 7.22 9.38 0.37 4.1 4.61 2.34 5.08 9.61 9.59 4.93 5.15 2.69 
52 Cleavage_of_the_damaged_purine 9.37 8.69 0.58 7 9.71 2.64 1.17 2.15 5.55 8.15 3.3 0.39 2.12 2.88 0.82 9.54 0.85 7.1 
53 Cleavage_of_the_damaged_pyrimidine_ 4.84 7.74 3.8 8.15 9.51 5.41 1.15 6.79 1.1 8.98 0.73 7.88 9.77 1.32 9.56 6.89 1.13 0.08 
54 Displacement_of_DNA_glycosylase_by__APE1 9.41 7.9 7.23 3.63 0.28 1.84 7.78 2 0.71 8.85 9.74 0.71 3.33 8.67 1.53 2.95 1.68 8.25 
55 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_purine 6.76 6.29 6.5 5.98 3.09 6.93 6.86 0.8 1.16 2.49 6.67 5.28 6.79 8.64 4.21 4.05 8.26 8.16 
56 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_pyrimidine 5.16 7.26 6.66 0.87 6.81 9.64 3.4 6.86 0.21 6.62 7.21 0.64 3.09 4.15 9.02 8.73 1.24 9.41 
57 Cleavage_of_the_damaged_purine 7.45 7.62 4.23 5.31 8.06 2.68 3.18 6.02 9.07 3.07 4.81 0.12 1.36 6.3 1.14 8.09 0.84 5.56 
58 Cleavage_of_the_damaged_pyrimidine_ 2.9 2.93 9.96 1.52 0.54 3.45 7.08 2.48 4.91 7.12 1.31 1.14 4.39 9.58 7.22 7.04 9.95 0.52 
59 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_purine 2.69 4.79 2.38 4.23 9.18 8.66 6.59 4.98 4.86 1.96 4.62 6.33 1.58 0.22 1.46 3.92 0.37 9.25 
60 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_pyrimidine 6.47 4.58 6.02 8.07 0.98 8.3 2.92 6 2.78 7.99 3.52 4.48 8.82 5.4 3.15 5.75 7.62 5.67 
61 Displacement_of_DNA_glycosylase_by__APE1 3.36 3.97 4.18 8.97 8.28 8.51 8.16 2.3 4.49 9.25 6.58 2.29 5.2 9.4 5.6 1.47 1.62 6.55 
62 Cleavage_of_the_damaged_purine 6.75 7.92 3.61 7.54 3.98 1.46 7.14 9.46 1.88 5.69 6.38 6.63 0.75 5.15 5.21 4.75 6.15 5.28 
63 Cleavage_of_the_damaged_pyrimidine_ 2.34 5.7 9.05 4.64 5.57 9.62 1.61 5.24 5.49 4.69 3.3 9.23 3.5 3.33 9.25 9.1 7.37 3.36 
64 Translesion_synthesis_by_HREV1 3.37 2.78 3.93 6.36 7.14 1.64 5.91 9.49 1.35 5.05 3.37 0.04 3.37 6.23 6.64 9.7 6.08 5.68 
65 Translesion_synthesis_by_Pol_eta__ 2.81 0.85 1.52 3.73 6.52 1.94 8.76 8.26 3.96 5.72 2.49 6.4 1.74 8.19 9.43 6.11 9.41 2.89 
66 Translesion_synthesis_by_Pol_zeta 4.19 5.65 8.05 5.85 2.16 4.5 6.15 6.09 0.64 1.66 8.93 0.74 5.09 3 6.95 5.73 5.89 1.61 
67 DNA_Damage_Recognition_in_GG-NER 1.72 9.68 3.58 0.31 2.68 4.26 5.1 4.22 7.74 7.79 9.1 5.52 1.82 3.91 4.95 7.64 8.74 3.64 
68 ABH2_mediated_Reversal_of_Alkylation_Damage 9.02 2.55 4.6 4.74 9.72 8.21 1.22 5.47 5.77 7.89 6.05 1.95 5.94 9.5 3.43 7.54 4.81 0.12 
69 ABH3_mediated_Reversal_of_Alkylation_Damage 6.72 4.39 4.28 9.12 7.62 9.67 4.08 4.15 9.08 2.23 7.59 4.34 2.04 4.86 3.19 9.58 9.45 8.06 
70 Cleavage_of_the_damaged_purine 1.66 7 3.67 6.92 7.87 5.32 5.56 9.74 4.47 0.21 2.83 2.22 3.31 3.76 5.83 9.48 7.23 9.82 
71 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_purine 0.18 7.76 2.2 1.11 1.82 8.56 4.9 9.25 3.24 4.86 6.77 9.69 6.43 5.34 6.77 6.68 0.68 9.91 
72 Cleavage_of_the_damaged_pyrimidine_ 1.96 7.83 8.28 7.27 4.26 8.71 6.97 6.12 7.03 0.27 4.08 5.45 5.08 1.85 2.38 2.37 4.43 3.13 
73 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_pyrimidine 5.01 8.5 1.28 1.11 6.5 1.49 1.92 4.54 8.69 6.81 4.65 2.67 7.13 7.93 6.34 4.72 9.72 8.3 
74 Displacement_of_DNA_glycosylase_by__APE1 9.01 4.42 1.77 8.77 7.7 7.02 3.64 3.81 5.9 8.23 2.37 0.23 1.79 5.95 1.69 3.27 0.42 3.1 
75 ATM_mediated_phosphorylation_of_repair_proteins 1.82 0.58 9.26 4.87 6.7 5.28 6.51 2.58 2.13 8.6 7.83 2.86 7.42 6.1 4.72 1.28 4.34 8.41 
76 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 7.18 5.03 8.67 8.65 9.38 8.81 2.57 7.5 6.14 5.98 4.58 6.61 0.63 7.56 8.07 2.78 4.89 4.35 
77 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 3.65 0.75 5.86 3.86 8.33 3.6 3.3 0.48 9.28 4.92 4.33 8.4 7.66 7.35 8.1 5.99 8.37 8.92 
78 Processing_of_DNA_double-strand_break_ends 9.82 3.28 3.52 3.69 2.44 7.94 6.08 2.52 6.47 4.32 5.35 2.08 2.64 4.97 2.43 6.49 0.15 8.41 
79 Processing_of_DNA_ends_prior_to_end_rejoining 1.89 1 8.12 6.48 5.23 8.51 4.74 6.33 8.91 2 8.54 9.9 6.97 9.19 7.8 5.78 9.31 5.44 
80 Resolution_of_D-loop_structures_through_Holliday_junction_intermediates 3.4 4.87 8.99 5.25 4.83 5.38 4.92 1.93 2.52 0.11 5.6 8.34 8.4 4.97 7.85 5.29 5.4 8.05 
81 Resolution_of_D-loop_structures_through_synthesis-dependent_strand-annealing 7.91 3.92 2.1 5.49 5.78 9.79 9.71 2.77 0.73 1.93 6.2 4.97 8.26 2.76 7.9 5.82 5.78 1.59 
82 Dual_incision_reaction_in_GG-NER 4.18 4.89 1.59 4.49 9.24 0.72 3.8 0.08 9.67 2.08 4.77 5.03 3.7 6.07 1.96 0.74 7.22 6.11 
83 Dual_incision_reaction_in_TC-NER 0.19 7.61 0.56 8.9 1.63 6.83 7.16 9.32 4.52 7.41 9.54 8.13 8.62 3.96 4.6 6.15 9.04 5.99 
84 Regulation_of_the_Fanconi_anemia_pathway 1.36 6.8 1.98 0.32 3.87 5.84 2.4 5.17 0.06 6.7 2.41 8.82 2.49 5.23 7.58 1.05 6.21 0.95 
85 Formation_of_incision_complex_in_GG-NER 2.96 9.16 6.78 1.78 5.79 0.58 5.77 7.5 0.07 7.29 0.81 9.95 6.78 6.76 7.53 8.99 7.84 5.65 
86 Formation_of_transcription-coupled_NER_(TC-NER)_repair_complex 0.93 6.08 1.72 2.43 9.29 5.14 1.68 0.55 1.91 9.73 9.22 7.48 6.51 9.86 1.44 4.46 5.77 5.17 
87 Repair_synthesis_of_patch_~27-30_bases_long__by_DNA_polymerase 6.29 9.16 8.74 7.91 4.69 9.12 1.46 6.93 0.91 8.15 9.49 8.57 6.4 0.52 2.36 5.51 4.87 2.26 
88 Repair_synthesis_for_gap-filling_by_DNA_polymerase_in_TC-NER 1.62 9.55 1.83 3.94 1.8 0.97 0.65 0.65 5.13 2.61 5.78 0.78 8.78 1.4 6.11 9.47 4.45 1.7 
89 DNA_Damage_Recognition_in_GG-NER 9.75 4.89 7.5 1.49 3.33 8.65 2.14 2.82 0.07 4.32 8.96 3.67 5.22 8.82 8.1 6.41 2.31 1.87 
90 Dual_incision_reaction_in_GG-NER 7.05 4.79 3.21 5.38 3.51 4.47 2.08 6.46 2.76 7.59 1.89 4.22 6.66 4.86 4.55 0.28 6.14 8.6 
91 Formation_of_incision_complex_in_GG-NER 2.53 7.77 3.48 5.03 8.61 4.31 0.82 4.55 1.97 1.06 7.52 8.21 2.96 2.81 0.21 4.55 9.47 1.24 
92 Repair_synthesis_of_patch_~27-30_bases_long__by_DNA_polymerase 3.18 1.35 3.76 7.74 8.59 9.98 0.74 2.53 9.22 6.35 6.43 8.88 1.53 2.32 7.47 6.8 9.26 6.78 
93 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 4.5 8.01 9.61 1.99 8.55 3.63 7.16 5.73 5.61 2.45 4.73 2.74 5.5 3.53 1.81 2.87 6.99 1.1 
94 ATM_mediated_phosphorylation_of_repair_proteins 6.43 4.65 1.72 5.29 9.81 1.12 4.76 3.81 2.47 8.9 6.71 8.05 3.72 0.32 9.89 3.2 1.65 4.31 
95 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 6.58 2.93 2.06 5.78 9.48 2.06 1.71 1.66 3.96 6.97 0.2 6.94 5.29 7.88 1.09 9.84 9.69 9.78 
96 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 6.17 0.15 6.26 6.84 1.68 9.06 9.28 0.97 1.18 3.9 1.99 7.85 4.86 1.99 4.2 7.1 2.71 8.13 
97 Processing_of_DNA_double-strand_break_ends 4.15 0.85 3.18 5.8 3.31 2.67 3.87 4.44 1.86 5.07 3.6 8.27 0.74 4.31 1.52 2.71 2.68 6.93 
98 Resolution_of_D-loop_structures_through_Holliday_junction_intermediates 8.85 3.37 3.11 6.04 6.77 4.06 7.68 0.22 4.13 0 5.42 5.37 0.38 3.88 3.55 2.89 6.47 1.81 
99 Resolution_of_D-loop_structures_through_synthesis-dependent_strand-annealing 0.93 5.84 9.87 7.61 4.93 2.17 5.01 4.82 4.47 6.65 7.53 1.04 0.84 0.95 5.25 2.21 9.64 7.81 
100 ATM_mediated_phosphorylation_of_repair_proteins 8.72 1.06 6.56 3.43 5.93 0.8 0.8 8.68 4.11 7.13 9.68 2.51 2.16 0.79 7.68 0.4 5.31 9.33 
101 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 7.79 6.63 2.59 6.53 9.36 0.95 3.65 8.74 7.2 8.35 6.8 9.76 4.55 7.25 0.71 8.08 5.59 1.56 
102 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 6.02 8.32 9.05 4.4 3.75 5.62 8.85 9.62 0.8 8.36 7.97 2.02 5.08 0.8 3.4 0.76 0.58 4.93 
103 Processing_of_DNA_double-strand_break_ends 7.4 5.46 4.74 7.73 0.97 8.8 3.35 0.72 4 7.07 9.55 6.66 1.41 5.88 4.81 1.68 3.15 3.96 
104 Resolution_of_D-loop_structures_through_Holliday_junction_intermediates 2.25 0.09 0.12 1.36 4.55 7.62 0.43 7.42 0.21 9.22 5.12 2.48 0.18 3.68 7.17 7.14 6.5 2.9 
105 Resolution_of_D-loop_structures_through_synthesis-dependent_strand-annealing 3.35 7.59 1.69 8.95 3.03 6.4 9.79 1.99 1.05 7.91 6.61 6.81 6.52 7.53 0.33 0.29 9.87 0.42 
106 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 2.53 0.83 4.2 8.14 7.18 2.44 0.63 2.29 6.52 8.64 7.69 4.7 0.05 0.47 5.94 4.87 3.26 2.76 
107 Processing_of_DNA_ends_prior_to_end_rejoining 3.23 5.4 6.79 9.9 5.88 7.1 2.71 9.45 2.21 4.7 1.83 5.89 9.55 9.78 7.79 0.06 2.62 1.35 
108 DNA_Damage_Recognition_in_GG-NER 4.87 1.96 0.33 0.88 9.35 7.79 9.93 7.9 9.62 9.65 0.01 1.05 8.07 5.67 6.69 1.34 6.71 4.57 
109 Dual_incision_reaction_in_GG-NER 9.98 5.45 5.97 2.18 8.38 8.44 3.72 5.63 0.28 2.64 8.01 7.23 4.9 6.04 6.01 2.27 1.97 6.92 
110 Dual_incision_reaction_in_TC-NER 7.71 3.63 3.01 3.63 7.21 5.65 4.21 4.45 6.1 4.95 7.41 0.22 8.12 1.51 0.15 0.55 3.93 7.38 
111 Formation_of_incision_complex_in_GG-NER 2.79 8.82 6.08 6.54 8.22 7.07 2.45 3.38 1.44 2.9 3.39 1.54 6.04 6.23 2.25 0.78 7.24 9.81 
112 Formation_of_transcription-coupled_NER_(TC-NER)_repair_complex 3.3 7.33 2.23 5.94 1.3 8.46 9.87 4.45 8.05 6.16 7.5 4.89 3.38 9.63 1.35 6.97 2.09 6.3 
113 Repair_synthesis_for_gap-filling_by_DNA_polymerase_in_TC-NER 2.24 9.08 7.37 4.74 9.2 3.72 2.93 8.55 7.34 5.61 0.56 6.06 1.84 0.75 3.82 1.19 7.41 4.32 
114 Repair_synthesis_of_patch_~27-30_bases_long__by_DNA_polymerase 6.84 7.79 2.79 2.83 6.67 8.36 1.25 1.18 7.37 0.28 1.19 5.77 7.37 0.91 5.56 7.95 0.6 9.01 
115 Assembly_of_the_RAD51-ssDNA_nucleoprotein_complex 7.93 4.32 1.36 5.8 8.75 9.07 1.84 0.74 7.19 7.9 4.76 0.41 3.51 3.29 2.9 9.74 0.72 5.91 
116 Processing_of_DNA_double-strand_break_ends 1.89 7.87 4.9 2.39 8.93 0.53 0.63 6.81 9.03 0.05 1.76 4.79 6.95 1.39 4.68 9.98 0.83 6.39 
117 Processing_of_DNA_ends_prior_to_end_rejoining 5.15 6.21 9.93 8.26 7.22 8.38 8.28 5.81 3.99 9.78 8.91 0.23 9.43 8.34 2.43 3.49 7.02 7.07 
118 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_purine 5.02 1.41 6.87 3.46 8.91 6.37 4.13 4 8.16 6.9 1.62 9.35 1.26 4.1 8.77 3.82 2.6 1.89 
119 Recognition_and_association_of_DNA_glycosylase_with_site_containing_an_affected_pyrimidine 7.05 8.74 6.63 7.22 1.95 5.66 3.6 0.38 5.88 8.11 2.45 4.67 4.25 8.67 1.89 5.42 0.63 5.47 
120 Assembly_of_the_RAD50-MRE11-NBS1_complex_at_DNA_double-strand_breaks 5.02 6.17 0.99 0.23 2.26 2.03 0.48 0.51 5.7 6.36 4.58 9.67 4.56 4.05 5.31 9.62 8.19 9.75 
121 Regulation_of_the_Fanconi_anemia_pathway 5.56 5.31 4.95 0.44 5.91 8.03 3.88 9.15 4.5 3.19 2.72 7.91 3.83 1.33 7.75 6.42 5.69 3 
122 Displacement_of_DNA_glycosylase_by__APE1 9.54 0.78 5.85 2.57 3.33 8.93 4.9 1.03 7.5 2.33 7.22 2.71 6.11 9.9 3.38 6.41 2.58 0.47 
123 Repair_synthesis_for_gap-filling_by_DNA_polymerase_in_TC-NER 3.52 6.58 4.79 3.02 6.83 9.9 0.02 5.68 4.22 8.95 1.35 0.08 3.61 7.42 1.94 6.99 1.88 1.78 
124 Repair_synthesis_of_patch_~27-30_bases_long__by_DNA_polymerase 0.42 3.57 9.41 8.47 4.69 3.45 3.8 9.13 9.64 7.1 0.61 3.85 0.73 5.04 4.62 7.03 1.02 0.69 
125 Displacement_of_DNA_glycosylase_by__APE1 1.54 5.29 5.52 0.74 1.49 7.3 2.44 8.44 0.49 1.18 0.65 3.63 5.52 7.73 4.7 7.31 7.47 5.11 
126 Displacement_of_DNA_glycosylase_by__APE1 8.69 3.98 4.98 1.03 3.52 6.79 0.53 0.43 5.22 0.88 5.63 8.34 8.5 0.22 2.4 9.11 4.92 6.51 
127 Displacement_of_DNA_glycosylase_by__APE1 5.8 4.77 6.16 8.76 1.78 2.2 6.15 3.48 7.98 1.79 6.35 8.57 8.83 6.62 9.02 2.62 4.2 7.7 
128 Resolution_of_D-loop_structures_through_Holliday_junction_intermediates 0.22 2.73 8.41 6.86 8.88 9.17 7.17 8.92 6.98 2.67 7.49 0.65 3.89 9.32 6.19 0.81 0.03 1.3 
129 Resolution_of_D-loop_structures_through_synthesis-dependent_strand-annealing 0.28 6.31 5.89 1.52 6.3 1.72 8.64 4.07 2.95 4.28 6.81 4.9 6.1 1.77 0.71 2.36 4.59 6.43 
130 Resolution_of_D-loop_structures_through_Holliday_junction_intermediates 8.4 6.33 0.37 8.93 6.3 2.74 9.93 7.82 2.03 4.61 2.9 6.62 3.07 9.97 1.51 4.23 8.9 7.17 
131 Resolution_of_D-loop_structures_through_synthesis-dependent_strand-annealing 6.4 7.03 5.66 8.83 6.61 6.59 2.45 3.86 6.51 7.65 6.01 8.4 2.09 4.97 2.83 2.5 0.58 4.21 
132 ABH2_mediated_Reversal_of_Alkylation_Damage 1.75 5.81 7.87 2.71 2.87 9.99 5.04 9.79 1.38 7 5.3 4.61 1.18 2.05 5.4 8.28 4.59 6.22 
133 ABH3_mediated_Reversal_of_Alkylation_Damage 3.98 7.6 0.98 9.35 4.81 6.14 5.67 4.93 5.96 1.61 7.46 5.38 6.7 5.38 4.76 5.55 9.17 3.71 
134 Dual_incision_reaction_in_TC-NER 7.6 7.52 7.58 4.33 2.55 0.65 7.26 4.01 0.34 7.59 3.93 5.48 2.73 7.92 1.93 9.33 1.37 1.03 
135 Formation_of_transcription-coupled_NER_(TC-NER)_repair_complex 6.9 2.11 6.94 6.68 6.27 4.98 9.89 2.48 8.79 6.47 1.49 9.31 6.69 8.75 5.98 4.49 4.36 5.99 
136 Repair_synthesis_for_gap-filling_by_DNA_polymerase_in_TC-NER 1.23 4.43 7.31 1.54 8.61 4.34 3.85 9.67 8.16 3.93 7.04 8.66 9.53 3.08 2.23 6.84 7.92 6.67 
137 Translesion_synthesis_by_HREV1 0.48 4.69 9.3 8.11 8.14 0.9 4.27 7.43 6.04 5.99 4.74 1.95 5.06 1.58 5.89 8.58 8.09 8.89 
138 Translesion_synthesis_by_Pol_eta__ 4.47 0.4 8.18 3.64 9.75 0.26 0.89 5.03 0.66 4.12 8.4 5.7 6.76 3.95 6.41 9.86 6.51 1.09 
139 Translesion_synthesis_by_Pol_zeta 1.87 0.83 0.85 3.9 2.5 6.86 7.55 3.81 1.28 5.02 2.77 8.62 4.24 5.65 8.72 8.32 8.85 4.28 
140 Translesion_synthesis_by_HREV1 6.46 8.89 4.78 8.83 9.25 2.65 2.6 0.45 7.78 8.21 8.55 5.2 9.27 7.73 1.34 2.51 6.75 3.36 
141 Translesion_synthesis_by_Pol_eta__ 3.34 0.01 7.37 3.1 9.74 5.9 3.56 0.71 0.8 9.35 1.45 2.82 8.25 7.18 5.73 7.12 0.37 9.98 
142 Translesion_synthesis_by_Pol_zeta 9.05 1.62 7.17 6.92 5.39 0.47 9.46 1.03 2.31 1.15 8.39 8.58 8.29 6.45 3.94 1.99 6.45 2.72 
143 Homologous_recombination_repair_of_replication-dependent_double-strand_breaks 6.75 8.62 0.72 7.73 4.8 2.38 8.97 5.42 6.08 2.03 2.77 1.25 1.34 4.01 0.78 3.82 1.69 7.36 
144 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 4.78 9.39 1.38 7.21 4.26 6.63 6.77 5.75 7.24 9.81 7 9.61 8.62 0.02 4.48 0.95 6.84 0.16 
145 Formation_of_RNA_Pol_II_elongation_complex_ 1.37 5.07 9.93 2.84 9.44 2.59 8.21 0.58 6.43 6.68 6.77 1.19 8.57 0.41 8.91 2.64 6.23 9.15 
146 Formation_of_the_Early_Elongation_Complex 0.72 9.29 8.41 7.15 6.15 5.36 9.57 7.59 7 4.52 0.93 2.41 8.29 4.48 2.27 7.98 2.24 3.24 
147 Mitochondrial_transcription_initiation 2.74 1.33 8.85 0.38 1.7 8.62 6.29 0.84 9.09 8.78 9.23 0.85 4 0.24 1.93 1.05 4.12 7.65 
148 Mitochondrial_transcription_termination 7.67 4.07 6.77 7.84 7.04 7.9 8.34 8.91 6.21 0.85 7.34 1.9 5.42 9.98 0.86 0.18 6.21 4.24 
149 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 5.97 3.76 2.54 6.69 1.08 9.27 4.93 0.68 3.66 1.02 4.38 6 8.19 3.18 2.9 9.84 3.39 5.56 
150 RNA_Polymerase_I_Chain_Elongation 8.08 6.32 4.78 8.14 7.87 2.39 0.74 0.2 8.27 5.54 9.88 4.41 7.98 6.42 0.02 3.21 1.04 9.46 
151 RNA_Polymerase_I_Promoter_Escape 0.56 5.09 8.33 7.08 7.61 5.33 6.86 8.04 3.85 1.42 8.42 2.6 1.61 6.2 3.43 5.78 1.87 1.13 
152 RNA_Polymerase_I_Promoter_Opening 0.63 5.91 9.34 4.15 6.56 7.61 0.12 4.11 9.59 2.51 7.38 3.7 1.24 5.07 0.07 5.84 9.51 1.01 
153 RNA_Polymerase_I_Transcription_Initiation 4.89 9.58 4.41 7.9 0.13 4.12 8.55 0.6 0.93 4.72 4.02 6.76 5.43 3.73 2.66 6.51 2.75 5.28 
154 RNA_Polymerase_I_Promoter_Escape 5.32 7.61 4.69 5.03 7.29 1.07 8.92 4.51 9.53 3.92 5.7 5.19 4.72 4.07 4.94 5.05 4.4 3.83 
155 RNA_Polymerase_I_Promoter_Opening 2.62 4.09 6.07 0.38 3.6 4.71 1.71 6.54 9.47 5.14 5.23 2.29 4.89 7.66 8.87 7.56 6.32 4.7 
156 RNA_Polymerase_I_Chain_Elongation 7.39 6.66 5.22 2.83 1.6 5.53 7.05 0.91 2.59 3.86 6.87 6.29 0.42 3.17 0.45 3.56 3.88 4.52 
157 RNA_Polymerase_I_Promoter_Escape 1.54 4.66 8.33 7.6 9.19 6.31 7.38 2.67 7.76 0.98 3.14 3.2 0.53 0.07 4.69 2.16 7.22 8.42 
158 RNA_Polymerase_I_Promoter_Opening 0.07 4.63 2.6 9.47 7.93 6.3 7.17 0.43 3.76 3.14 6.26 1.17 3.34 6.2 1.71 7.92 9.64 1.54 
159 RNA_Polymerase_I_Transcription_Initiation 8.66 6.93 6.64 7.75 0 2.12 1 5.51 4.76 3.79 9.43 8.77 7.89 3.61 3.85 2.72 4.34 1.44 
160 RNA_Polymerase_I_Transcription_Termination 5.61 5.63 5.04 9.46 8.88 3.08 1.57 4.3 1.23 4.64 0.74 3.46 8.37 9.81 3.18 6.11 2.92 5.91 
161 RNA_Polymerase_I_Transcription_Initiation 8.32 1.23 4.61 9.91 4.61 3.3 4.98 3.69 2.91 4 1.79 1.17 3.17 9.14 5.95 4.41 9.36 8.67 
162 RNA_Polymerase_I_Transcription_Termination 0.28 4.53 9.09 9.73 9.81 5.03 5.69 8.16 8.83 3.67 3.85 4.02 2.3 1.57 6.81 5.67 3.1 8.66 
163 Mitochondrial_transcription_initiation 6.87 1.71 4.77 2.45 7.64 2.38 6.71 0.47 1.15 5.92 3.11 6.57 4.05 0.53 1.71 5.8 7.4 5.3 
164 Mitochondrial_transcription_termination 6.75 3.2 7.9 3.77 9.98 5.86 6.04 4.89 6.31 7.44 3.88 6.1 7.18 9.19 2.59 9.27 6.09 1.19 
165 RNA_Polymerase_I_Chain_Elongation 4.79 7.16 3 3.96 8.53 4.58 8.3 5.93 8.06 8.49 8.54 2.72 1.6 2.94 0.54 3.33 1.46 2.29 
166 RNA_Polymerase_I_Promoter_Escape 4.71 4.28 5.59 2.41 4.21 6.88 3.66 0.33 6.85 2.7 3.29 2.61 8.6 2.08 9.82 1.62 5.06 8.78 
167 RNA_Polymerase_I_Promoter_Opening 9.79 8.97 8.87 5.38 4.69 7.83 5.4 7.95 2.66 6.33 5.09 5.57 3.17 1.34 0.53 1.35 2.58 5.93 
168 RNA_Polymerase_I_Transcription_Initiation 8.43 6.93 4.66 9.51 1.4 0.94 9.37 1.74 5.12 0.97 5.51 6.95 8.17 4.92 2.92 2.37 5.3 6.13 
169 RNA_Polymerase_I_Transcription_Termination 2.96 7.1 3.89 6.28 8.09 7.86 7.44 8.4 1.82 5.69 1.2 3.93 2.92 9.62 2.14 5.27 8.07 1.94 
170 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 7.05 7.13 0.11 9.13 6.93 6.64 2.03 9.95 7.62 3.81 9.46 9.09 0.48 7.68 6.24 5.11 9.54 2.35 
171 RNA_Polymerase_III_Chain_Elongation 1.27 6.33 2.4 8.62 1.27 5.77 8.17 3.4 1.42 1 4 5.58 4.76 1.54 9.35 4.3 8.31 2.95 
172 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 5.37 6.23 9.22 9.27 0.29 2.11 2.11 7.54 8.8 2.53 2.93 3.21 7.85 5.28 4.43 0 5.55 6.71 
173 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 2.7 4.52 3.75 6.31 6.4 9.34 0.4 9.86 8.34 2.48 5.39 7.65 7.96 3.12 2.62 0.52 7.31 9.87 
174 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 4.64 5.57 2.48 5.56 1.7 4.5 1.82 3.01 2.93 0.99 3.32 0.44 3.31 0.75 0.04 0.5 0.26 0.66 
175 RNA_Polymerase_III_Transcription_Termination 7.38 8.01 6.23 8.43 4.41 3.8 6.95 9.18 6.59 3.63 6.28 3.29 0.88 8.54 6.13 9.79 5.69 6.66 
176 RNA_Polymerase_II_Pre-transcription_Events 6.79 5.77 8.37 4.02 1.15 2.92 7.23 8.72 4.48 3.23 1.53 9.48 3.95 1.97 5.08 9.08 4.11 9.93 
177 RNA_Polymerase_II_Promoter_Escape 6.65 7.81 2.02 6.1 8.28 2.56 7.05 9.65 0.23 7.69 7.15 2.53 8.05 6.84 4.78 1.45 8.4 8.33 
178 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 2.85 9 9.68 9.94 6.33 8.85 3.48 2.81 0.32 2.56 9.1 8.72 9.82 9.01 3.06 6.35 8.6 4.71 
179 Formation_of_RNA_Pol_II_elongation_complex_ 5.27 1.37 3.43 7.68 2.33 9.95 1.71 6.03 9.42 0.11 8.79 0.34 5.12 5.93 5.3 1.61 2.34 2.58 
180 Formation_of_the_Early_Elongation_Complex 9.26 9.06 1.91 4.43 1.88 2.27 7.19 4.84 2.24 0.93 4.35 2.24 0.94 5.82 8.67 6.27 0.05 1.46 
181 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 6.86 5.89 5.4 2.37 8.5 7.59 5.78 9.56 6.77 4.03 0.42 3 8.11 2.25 1.43 5.95 0.16 6.15 
182 RNA_Polymerase_II_Pre-transcription_Events 8.04 0.06 3.68 6.41 3.35 6.98 3.25 3.13 0.23 3.12 6.18 4.57 3.96 3.39 0.86 0.94 8.46 0.43 
183 RNA_Polymerase_II_Promoter_Escape 5.22 9.11 2.8 4.55 3.58 8.47 8.7 9.9 8.73 3.27 4.13 4.54 8.96 4.72 4.5 2.41 6.41 6.46 
184 RNA_Polymerase_II_Transcription_Initiation 5.25 2.13 8.24 9.29 6.95 4.03 5.94 9.93 0.67 1.87 6.4 0.79 0.41 1.25 5.34 8.6 0 9.07 
185 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 6.21 6.92 2.93 1.17 7.17 4.03 9.43 8.93 6.39 0.11 9.25 0.28 9.78 7.48 8.5 8.92 4.44 6.54 
186 Formation_of_RNA_Pol_II_elongation_complex_ 6.23 3.53 0.36 5.47 3.46 8.26 0.61 9.04 2.38 5.71 8.86 4.05 2.99 0.56 7.28 2.67 7.51 0.19 
187 Formation_of_the_Early_Elongation_Complex 9.91 1.66 7.17 8.46 0.93 1.87 4.21 9.12 8.67 2.99 4.44 8.97 2.01 3.28 9.42 1.04 7.68 7.68 
188 RNA_Polymerase_II_Transcription_Initiation 6.41 2.96 2.62 7.2 2.44 9.18 6.25 2.19 5.84 1.74 9.84 4.59 1.49 0.14 6.95 5.03 0.32 8.51 
189 RNA_Polymerase_II_Promoter_Escape 5.37 8.14 3.63 6.51 2.19 2.9 9.17 6.83 9.18 5.84 2.52 5.86 2.69 2.48 1.37 3.97 4.24 1.68 
190 RNA_Polymerase_II_Transcription_Initiation 0.27 1.48 9.93 3.82 2.71 6.69 8.93 8.77 0.14 1.04 4.84 9.43 4.95 8.11 2.93 8.92 7.98 9.9 
191 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 2.99 8.9 4.93 0.74 5.49 7.74 3.14 1.73 0.69 2.18 8.65 8.33 2.38 9.11 2.52 4.63 5.08 1.49 
192 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 0.88 2.45 2.31 9.2 1.06 2.71 3.68 4.21 2.58 1.57 6.47 9.82 2.38 1.22 7.23 9.06 7.06 1.89 
193 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 1.56 3.45 3.51 9.23 1.18 5.5 0.97 8.36 5.91 4.06 5.1 8.13 6.51 8.8 8.44 7.43 7.41 2.45 
194 RNA_Polymerase_III_Chain_Elongation 5.78 9.49 7.05 5.14 7.85 2.27 6.24 2.04 3.56 9.17 2.27 5.55 1.02 2.86 4.68 6.98 9.79 4.11 
195 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 4.89 7.58 4.9 7.75 4.1 1.32 0.89 2.96 9.5 1.12 1.22 5.29 6.72 8.36 2.77 5.53 9.76 6.7 
196 RNA_Polymerase_III_Chain_Elongation 0.85 6.52 7.51 3.97 7.51 0.01 4.35 6.93 0.72 9.16 7.16 3.28 5.11 1.25 8.38 2.96 9.39 5.44 
197 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 0.56 8.26 9.02 7.58 5.88 0.21 5.86 1.08 7.77 6.28 9.79 9.47 5.49 2.8 2.45 1.28 0.62 4.26 
198 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 7.19 6.77 0.91 0.47 7.85 2.31 4.06 6.84 9.54 7.69 7.09 9.56 4.21 9.45 4.65 0.16 8.6 4.97 
199 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 3.35 1.9 6.77 0.49 0.05 8.86 3.88 6.75 1.43 3.77 1.3 4.87 5.55 4.82 2.53 0 7.54 2.89 
200 RNA_Polymerase_III_Transcription_Termination 4.88 2.15 0.08 3.1 9.4 7.99 9.97 7.07 4.54 3.04 2.37 4.85 4.99 7.92 6.13 6.12 6.82 9.83 
201 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 3.51 1.29 1.37 0.33 6 8.64 6.83 8.57 9.68 7.1 9.68 7.08 6.41 7.32 4.37 6.84 4.99 7.01 
202 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 8.69 5.83 2.56 6.92 6.4 0.87 0.12 8.1 8.2 8.35 6.63 6.15 8.97 6.77 7.74 1.34 5.53 5.33 
203 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 8.78 2.86 6.24 7.34 0.75 3.49 7.12 9.84 6.24 7.92 5.04 8.22 0.55 9.13 4.62 4.73 0.84 1.6 
204 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 1.22 0.53 3.97 8.22 7.5 3.37 9.17 0.06 9.31 1.97 5.05 2.36 3.57 5.99 2.9 8.98 9.85 4.47 
205 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 0.84 5.92 7.25 9.96 8.55 8.28 3.38 3.42 4.28 7.95 7.42 0.37 5.06 7.67 0.53 7.93 5.05 1.46 
206 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 6.09 9.24 8.54 4.65 2.39 2.06 2.09 4.92 4.99 1.75 0.36 0.61 6.47 6.18 0.13 7.27 7.12 8.96 
207 RNA_Polymerase_III_Transcription_Termination 9.09 8.41 1.3 0.9 0.34 9.15 2.86 5.23 6.66 3.44 7.36 0.37 4.16 8.93 9.49 9.71 8.44 7.77 
208 Mitochondrial_transcription_initiation 2.85 2 5.9 2.85 3.25 1.18 6.68 0.06 7.29 0.08 5.41 2.25 5.36 9.8 7.16 4.7 3.84 7.47 
209 Mitochondrial_transcription_termination 3.28 9.36 2.04 7 5.23 3.64 4.11 0.4 2.5 5.04 4.83 7.66 1.41 6.7 8.45 5.06 0.88 2.56 
210 Translation_initiation_complex_formation 1.07 2.66 8.57 6.78 1.99 6.74 1.55 1.91 9.9 8.32 8.58 9.96 9.17 2.9 9.67 7.07 2.34 2.46 
211 Binding_of_RNA_by_Insulin-like_Growth_Factor-2_mRNA_Binding_Proteins_(IGF2BPs/IMPs/VICKZs) 4.62 4.02 2.39 4.26 0.95 9.06 3.14 3.5 5.86 2.79 7.76 8.22 8.79 3.01 8.12 6.76 1.64 3.57 
212 C6_deamination_of_adenosine 5.7 0.38 3.12 1.44 5.61 1.8 2 6.43 8.56 0.61 6.47 9.39 8.08 2.9 4.52 9.79 6.18 4.19 
213 Formation_of_a_pool_of_free_40S_subunits 0.07 2.84 5.47 9.77 6.75 6.13 7.09 3.71 6.42 3.39 3.36 6.21 5.01 0.34 1.29 3.58 4.36 4.69 
214 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 8.97 5.04 7.98 2.02 1.05 2.38 0.32 0.65 5.16 4.81 5.79 0.23 7.27 7.71 3.13 3.82 1.4 8.16 
215 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 4.88 3.19 5.89 5.13 2.59 8.51 2.71 2.83 3.64 0.38 0.12 1.84 7.59 5.01 5.74 7.33 0.59 7.14 
216 Recycling_of_eIF2:GDP 6.49 5.95 5.22 5.41 4.16 3.77 0.52 5.65 8.91 1.38 3.1 9.67 0.55 7.87 2.24 2.22 4.39 4.41 
217 Ribosomal_scanning_and_start_codon_recognition 6.48 8.04 8.34 3.68 4.41 8.72 6.68 9.74 1.76 1.37 6.33 2.41 7.45 0.18 0.15 9.74 2.52 8.46 
218 Translation_initiation_complex_formation 9.56 5.24 9.66 5.81 1.44 2.4 3.34 2.96 8.76 0.27 2.05 0.18 2.91 6.41 4.65 1.91 4.71 2.59 
219 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 7 2.17 0.16 9.43 6.24 0.64 5.05 1.57 5.02 6.66 2.75 0.46 6.32 7.89 0.46 1.45 0.03 1.52 
220 Cytosolic_tRNA_aminoacylation 9.01 3.26 1.53 1.84 6.49 3.5 4.05 3.46 0.25 9.7 3.36 7.95 7.93 3.23 5.32 8.56 8.96 2.1 
221 Deadenylation_of_mRNA 7.76 6.92 5.5 2.9 7.95 8.52 3.5 3.15 0.36 3.61 7.6 9.84 7.29 5.34 0.5 0.82 8.06 9.36 
222 Deadenylation_of_mRNA 5.84 7.9 6.17 1.82 0.66 1.16 3.88 4.25 1.01 6.1 4.5 9.82 6.21 1.93 0.38 7.54 5.93 8.95 
223 mRNA_Decay_by_3_to_5_Exoribonuclease 2.8 6.38 1.67 4.2 3.45 8.83 8.65 6.96 8.33 3.9 6.32 1.89 8.39 1.83 8.17 1.29 7.53 6.79 
224 mRNA_Decay_by_5_to_3_Exoribonuclease 6.13 6 2.52 1.45 8.61 1.51 3.18 9.63 8.13 9.07 5.54 4.76 6.17 2.11 4.29 2.64 9.66 5.31 
225 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 9.42 6.98 5.22 1.55 5.87 2.57 1.58 4.64 7.62 5.1 9.46 0.65 3.8 1.65 9.46 5.4 2.97 0.42 
226 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 4.64 1.94 5.84 2.7 7.15 2 2.06 1.06 3.02 6.96 8.33 6.11 0.67 4.15 6.45 1.75 3.54 4.48 
227 Destabilization_of_mRNA_by_KSRP 9.19 0.79 9.88 3.21 5.92 5.97 1.97 5.09 6.52 0.71 6.58 1.22 8.59 9.97 9.99 8.99 1.2 3.2 
228 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 0.36 9.84 9.12 9.15 9.53 4.85 7.41 1.99 5.67 2.08 8.44 1.69 6.81 8.79 1.08 2.07 2.59 7.06 
229 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 8.49 0.75 0.26 1.24 6.07 7.74 8.84 1.28 5.46 1.45 4.81 7.14 1.49 1.68 3.38 3.07 7.93 5.04 
230 Peptide_chain_elongation 1.05 6.97 2.17 9.55 6.41 3.43 1.33 0.97 6.79 7.36 5.55 6.33 9.54 9.3 2.52 9.04 2.79 4.88 
231 Formation_of_a_pool_of_free_40S_subunits 8.7 7.54 0.72 1.76 7.01 4.15 0.86 2.31 4.8 9.75 2.6 5.14 9.38 6.57 9.9 4.38 9.81 4.47 
232 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 2.42 6.18 0.7 6.31 0.61 2.19 7.81 9.9 8.33 6.72 5.63 3.02 5.02 9.28 7.21 8.98 4.47 9.45 
233 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 4.06 2.22 6.86 7.94 5.77 8.44 6.83 5.47 2.4 4.85 4.64 7.23 3.37 6.53 1.68 1.3 2.55 4.66 
234 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 8.58 5.12 6.56 3.18 2.01 1.42 2.76 5.06 7.02 6.84 0.23 2.7 3.12 2.5 4.75 3.11 8.5 1.95 
235 Recycling_of_eIF2:GDP 4.88 5.2 1.01 1.83 7.98 8.92 8.48 7.84 2.45 1.87 4.62 3.43 2.58 8.59 8.71 0.16 1.72 8.32 
236 Ribosomal_scanning_and_start_codon_recognition 4.41 6.83 0.88 0.15 9.76 5.16 2.98 0.39 2.83 2.05 9.97 1.46 7.69 6.75 9.17 3.87 0.2 0.3 
237 Translation_initiation_complex_formation 4.42 7.35 3.89 3.73 4.8 0.73 7.77 7.86 3.81 7.85 5.22 3.45 9.79 0.85 7.13 9.35 7.35 8.83 
238 Eukaryotic_Translation_Termination 1.86 0.96 6.48 0.85 7.52 5.21 2.6 9.82 6.36 6.88 9.19 2.36 7.92 0.65 2.78 1.98 4.96 3.86 
239 Formation_of_RNA_Pol_II_elongation_complex_ 0.11 9.76 5.47 1.21 2.02 2.45 7.02 5.64 5.39 5.72 2.57 3.7 9.2 6.54 3.59 0.8 2.98 3.91 
240 Formation_of_a_pool_of_free_40S_subunits 9.6 5.1 5.91 8.67 0.33 6.75 1.36 4.99 7.75 7.9 3.76 2.56 2.72 7.03 0.86 9.67 5.15 5.42 
241 Formation_of_editosomes_by_ADAR_proteins 4.95 5.66 4.56 1.86 4.37 1.98 6.26 3.64 0.85 6.65 9.08 3.4 3.6 8.14 1.54 0.12 7.52 3.38 
242 Formation_of_the_Early_Elongation_Complex 7.06 5.25 6.3 2.49 1.79 0.79 3.13 8.38 5.17 4.21 1.45 9.91 9.69 8.39 3.08 5.65 7.62 4.73 
243 Formation_of_the_Editosome 6.81 9.7 1.47 0.53 7.08 5.08 7.15 4.29 0.66 6.89 6.63 7.71 5.41 2.59 6.31 5.72 5.14 9.66 
244 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 9.88 1.7 1.68 1.99 6.55 8.5 4.44 9.36 2.78 4.06 4.27 3.13 5.23 3.71 3.27 0.73 4.61 1.73 
245 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 9.34 1.02 5.87 4.17 4.63 1.53 1.26 5.95 4.95 2.13 4.06 3.7 8.59 3.05 4.96 8.33 2.23 8.52 
246 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 8.79 5.19 1.26 7.93 5.85 4.65 3.71 4.44 1.07 2.71 0.87 0.99 5.19 5.96 7.15 5.52 4.92 7.53 
247 Notch-HLH_transcription_pathway 2.57 5.9 9.59 3.57 8.86 8.09 8.65 6.86 0.19 2.59 3.13 4.35 0.28 1.01 4.68 8.69 4.56 7.31 
248 Nuclear_Receptor_transcription_pathway 5.78 0.74 3.95 8.43 2.74 3.16 0.24 5.11 5.85 7.22 9.71 0.57 0.95 1.74 0.38 1.83 6.58 2.95 
249 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 7.22 9.83 2.31 5.03 2.32 3 5.9 4.8 4.08 5.05 7.02 8.58 8.18 5.57 5.61 1.2 0.28 6.56 
250 YAP1-_and_WWTR1_(TAZ)-stimulated_gene_expression 7.13 3.32 0.92 1.82 4.67 3.2 3.58 0.74 9.87 0.94 9.83 3.64 2.64 7.14 7.46 3.9 4.25 2.55 
251 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 1.63 4.67 7.92 2.31 6.19 8.8 7.18 1.28 9.48 7.2 0.79 0.91 7.66 5.87 8.08 1.26 8.25 1.59 
252 MicroRNA_(miRNA)_Biogenesis 5.18 2.2 0.35 3.14 4.56 1.47 1.56 1.34 3.6 7.51 2.08 4.78 2.94 5.89 5.24 9.76 6.94 0.9 
253 Mitochondrial_tRNA_aminoacylation 1.89 3.72 4.19 3.01 7.02 8.44 5.23 5.39 6.09 8.27 6.37 1.86 4.16 8.27 1.69 6.23 8.99 5.14 
254 Mitochondrial_transcription_initiation 4.15 6.44 4.36 6.69 3.78 6.76 8.58 9.52 8.46 1.37 9.15 9.88 6.16 2.88 3.82 0.74 3.33 9.15 
255 Mitochondrial_transcription_termination 0.56 6.56 0.62 6.16 5.24 1.29 4.42 9.84 8.72 0.49 3.96 0.26 5.82 2.02 7.75 4.16 6.65 5.52 
256 snRNP_Assembly 7.59 7.55 4.17 8.44 5.54 4.43 8.24 9.99 4.22 1.21 7.33 4.13 9.17 7.93 8.73 0.6 1.75 0.74 
257 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 9.85 5.01 6.22 2.08 3.95 0.26 7.2 2.91 9.88 9.29 0.72 9.77 1.93 0.08 2.54 9.22 8.76 1.37 
258 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 8.16 8.03 0.9 9.12 2.89 2.53 9.79 2.99 3.22 9.02 6.02 3.69 6.54 7.29 7.34 4.38 2.74 2.26 
259 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 4.63 1.34 9.72 3.48 4.53 5.03 3.07 5.18 3.33 4.37 6.95 1.79 6.61 1.44 6.59 9.61 9.07 5.76 
260 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 4.72 6.45 5.92 9.72 6.28 1.96 8.11 5.35 8.35 2.29 7.16 5.32 9.56 1.58 7.49 6.2 2.96 7.24 
261 Notch-HLH_transcription_pathway 1.2 5.26 4.06 9.83 4.45 5.74 6.91 5.88 5.38 6.64 1.04 8.77 3.53 9.42 0.04 6.23 8.52 6.25 
262 Nuclear_Receptor_transcription_pathway 6.11 8.42 7.24 1.49 1.35 5.9 1.46 3.28 8.55 8.04 7.41 9.09 3.81 7.79 1.02 0.83 6.92 5.32 
263 Peptide_chain_elongation 3.12 0.99 1.61 0.47 4.05 2.9 5.69 9.59 6.28 1.39 2.28 5.8 4.71 7.78 4.4 4.56 1.48 4.44 
264 Post-transcriptional_Silencing_By_Small_RNAs 7.45 1.25 2.1 6.98 6.16 1.8 8.15 0.64 2.26 4.72 4.79 5.93 4.82 0.05 5.36 3.33 1.05 5.87 
265 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 7.32 6.38 1.65 0.64 5.18 3.99 0.32 5.08 8.96 4.38 9.78 6.38 2.45 0.59 1.69 7.44 3.62 7.69 
266 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 0.49 5.18 4.67 5.58 1.43 0.61 6.03 1.9 1.86 2.26 6.03 0.04 3 7.68 4.23 3.47 3.96 5.66 
267 Transport_of_the_SLBP_Dependant_Mature_mRNA 2.3 6.65 1.52 0 6.17 1.73 7.86 6.68 5.97 5.79 2.24 7.28 2.6 1.58 4.25 2.67 3.12 7.34 
268 Transport_of_the_SLBP_independent_Mature_mRNA 4.52 1.69 5.62 5.7 2.11 2.35 8.9 7.11 0.64 7.5 9.6 5.45 7.67 7.54 7.87 2.17 5.65 9.42 
269 mRNA_Splicing_-_Minor_Pathway 0.88 2.73 8.15 5.79 8.37 3.88 2.69 8.86 8.3 8.09 6.4 3.21 3.19 8.81 6.26 0.2 4.11 4.54 
270 mRNA_3-end_processing 8.93 9.84 3.57 9.99 3.36 8.29 9.5 4.57 4.05 3.65 3.34 0.49 0.94 5.92 2.7 1.19 0.17 3.13 
271 mRNA_Splicing_-_Major_Pathway 2.53 1.17 9.77 1.6 5.05 1.53 5.91 5.62 5.76 8.54 0.72 1.34 0.16 0.5 1.93 9.45 8.52 7.47 
272 Processing_of_Intronless_Pre-mRNAs 5.21 0.61 3.44 2.59 3.66 8.85 4.39 7.18 1.07 2.68 5.54 0.5 4.32 7.99 0.2 7.35 0.98 7.92 
273 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 9.16 1.82 0.29 3.16 0.59 7.58 5.83 3.99 1.35 3.57 0.7 2.71 3.42 7.8 8.77 4.06 2.95 6.86 
274 SLBP_independent_Processing_of_Histone_Pre-mRNAs 4.03 2.52 7.18 0.35 2.85 4.28 6.78 9.6 1.01 9.49 3.64 3.85 6.26 1.57 7.37 8.41 9.38 5.93 
275 Processing_of_Intronless_Pre-mRNAs 0.96 0.33 4.93 7.68 8.73 9.35 1.09 0.96 3.81 5.61 7.39 5.84 9.23 4.99 7.31 8.49 4.42 6.06 
276 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 8.5 2.87 0.4 7.69 2.23 5.88 4.67 0.83 4 1.58 6.06 9.38 4.63 9.2 3.66 7.58 6.85 0.23 
277 RNA_Polymerase_I_Chain_Elongation 2.29 2.98 3.56 4.7 1.75 1.96 6.83 9.88 6.19 9.46 1.9 2.75 4.69 5.19 3.41 1.97 5.45 6.54 
278 RNA_Polymerase_I_Promoter_Escape 1.58 0.58 7.94 7.91 3.41 8.37 9 2.32 6.75 7.36 4.38 9.58 5.8 0.85 0.13 2.84 2.53 7.27 
279 RNA_Polymerase_I_Promoter_Opening 2.85 4.26 6.7 5.36 2.81 3.7 5.49 3.48 0.77 1.99 8.35 5.73 1.37 3.51 7.31 6.17 2.33 5.71 
280 RNA_Polymerase_I_Transcription_Initiation 3.76 5.29 7.31 0.44 3.42 4.67 0 5.28 9.16 6.34 9.99 7.57 2.4 5.81 6.23 9.41 1.31 7.49 
281 RNA_Polymerase_I_Promoter_Escape 5.39 2.99 5.75 0.99 3.63 2.45 7.26 2.01 4.24 0.83 3.89 7.35 0.24 8.95 7.45 1.7 4.83 7.17 
282 RNA_Polymerase_I_Promoter_Opening 3.92 7.52 3.24 7.73 7.4 2.55 4.68 0.7 8.43 0.3 7.56 7.65 1.14 9.8 4.58 3.58 1.24 0.08 
283 RNA_Polymerase_I_Chain_Elongation 3.11 6.67 7.17 9.28 5.9 0.99 5.8 8.7 9.9 4.12 0 0.64 2.75 0.84 6.82 9.11 1.06 8.68 
284 RNA_Polymerase_I_Promoter_Escape 6.44 8.26 4.36 3.66 5.92 9.88 8.38 8.65 2.12 9.47 4.46 6.59 0.52 7.71 2.56 1.1 0.57 6.66 
285 RNA_Polymerase_I_Promoter_Opening 2.5 6.7 1.45 9.25 1.48 8.74 7.74 0.43 4.29 5.36 7.63 0.16 8.58 9.34 3.01 0.61 6.55 8.15 
286 RNA_Polymerase_I_Transcription_Initiation 1.74 5.82 1.39 0.82 0.24 9 5.75 3.37 3.76 3 4.24 8.64 5.37 6.95 5.25 6.29 8.51 7.88 
287 RNA_Polymerase_I_Transcription_Termination 7.94 7.44 7.06 0.75 0.71 4.9 8.84 8.19 9.79 1.95 1.58 8.07 8.45 3.74 4.38 1.56 8.2 4.32 
288 RNA_Polymerase_I_Transcription_Initiation 7.66 2.22 9.57 5.53 2.71 9.55 3.89 6.25 0.29 1.28 0.39 5.27 3.94 4.9 6.48 0.54 5.17 1.92 
289 RNA_Polymerase_I_Transcription_Termination 5.3 6.18 1.48 0.56 9.9 2.82 7.43 4.39 3.01 4.93 9.27 2.69 3.93 0.33 4.31 5.92 1.35 0.26 
290 Mitochondrial_transcription_initiation 8.42 0.8 6.16 9.61 7.17 9.07 9.2 2.45 1.66 1.21 7.82 7.82 0.06 4.91 8.7 6.15 1.95 1.43 
291 Mitochondrial_transcription_termination 7.63 7.71 5.92 9.35 2.17 4.12 8.81 4.67 7.21 9.52 3.22 8.28 2.3 4.29 4.24 6.99 1.53 1.51 
292 RNA_Polymerase_I_Chain_Elongation 7.94 0.41 2.64 3.83 7.2 1.44 3.88 0.77 2.13 2.02 6.58 2.02 7.53 2.49 0.58 5.75 0.9 6.38 
293 RNA_Polymerase_I_Promoter_Escape 8.23 3.95 7.01 2.05 5.58 1.23 2.87 0.41 0.26 5.3 2.09 8.2 9.35 0.43 5.31 6.74 9.02 1 
294 RNA_Polymerase_I_Promoter_Opening 0.71 7.75 0.09 4.3 7.94 6.22 7.36 8.9 0.15 4.52 7.54 7.82 9.33 1.88 8.55 9.6 9.45 9.23 
295 RNA_Polymerase_I_Transcription_Initiation 5.42 6.59 4.87 9.43 3.47 5.84 3.89 6.68 7.88 1.98 2.8 4.79 7.07 8.13 8.6 4.47 8.46 2.71 
296 RNA_Polymerase_I_Transcription_Termination 1.82 3.44 1.42 4.48 6.36 3.53 5.49 8.88 8.23 8.25 2.51 1.9 6.39 0.46 3.62 7.75 6.24 0.78 
297 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 9.85 1.03 7.81 3.77 3.5 0.48 1.7 4.94 2.16 7.29 7.26 0.38 9.15 6.72 3.52 8.62 4.21 6.67 
298 RNA_Polymerase_III_Chain_Elongation 1.28 4.65 3.29 2.59 0.82 3.89 9.86 4.19 7.35 1.4 6.66 6.32 4.85 8.22 0.03 1.61 8.96 1.41 
299 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 1.5 4.32 8.72 3.61 7.7 3.13 1.65 6.45 1.2 8.1 1.28 9.7 6.21 5.96 0.04 5.14 7.99 2.1 
300 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 2.69 5.52 2.35 4.71 3.44 8.3 3.82 2.61 3.95 1.51 6.66 0.83 7.1 7.58 3.72 2.95 9.06 0.14 
301 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 4.52 2.84 9.05 8.12 0.21 3.41 5.75 2.9 5.25 6.11 1.67 9.82 7.83 3.87 7.93 0.5 6.79 2.68 
302 RNA_Polymerase_III_Transcription_Termination 2.74 8.84 6.29 3.35 4.6 1.05 5.11 9.92 8.24 5.5 0.16 0.6 8.01 7.59 3.09 9.23 0.67 3 
303 RNA_Polymerase_II_Pre-transcription_Events 2.25 2.56 1.4 0.48 6.55 8.07 4.49 4.91 7.6 3.82 8.36 2.19 2.7 6.79 7.25 5.19 8.09 7.01 
304 RNA_Polymerase_II_Promoter_Escape 6.31 3.24 8.07 7.25 3.01 2.83 9.69 4.88 1.64 9.63 1.24 5.34 7.7 8.51 9.97 7.24 5.11 0.67 
305 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 2.65 8.4 3.79 9.55 0.28 6.61 4.32 2.27 1.6 1.39 6.66 2.37 0.48 8.48 4.04 0.48 5.65 2.21 
306 Formation_of_RNA_Pol_II_elongation_complex_ 1.33 1.75 2.41 5.14 1.47 3.62 9.54 6.76 4.54 6.58 7.21 7.84 6.88 4.66 1.16 8.56 1.8 4.29 
307 Formation_of_the_Early_Elongation_Complex 5.37 6.29 3.89 8.43 0.04 1.01 3.84 9.2 9.87 1.36 0.52 5.82 5.28 3.66 4.72 1.93 9.58 1.79 
308 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 9.83 9.87 8.23 3.97 0.96 5.94 9.01 6.53 5.2 5.03 4.72 0.2 9.32 9.53 8.24 0.33 0.57 6.65 
309 RNA_Polymerase_II_Pre-transcription_Events 7.32 2.8 1.67 9.66 6.9 8.68 9.26 8.28 4.79 1.44 7.03 4.49 8.33 0.03 9.1 2.4 0.27 6.1 
310 RNA_Polymerase_II_Promoter_Escape 5.27 2.82 3.93 1.87 8.63 9.61 5.65 5.99 2.51 3.18 0.81 5.58 1.03 3.58 2.38 1.78 4.64 4.57 
311 RNA_Polymerase_II_Transcription_Initiation 5.72 2.21 9.22 7.56 8.67 2.6 2.98 3.43 2.34 8.41 0.19 3.52 0.62 4.11 8.11 7.93 4.05 8.81 
312 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 6.51 7.6 8.98 2.71 8.42 6.94 0.84 5.35 5 9.55 1.55 3.23 6.5 6.88 9.39 0.1 0.17 9.32 
313 Formation_of_RNA_Pol_II_elongation_complex_ 9.48 2.1 4.95 4.19 6.48 1.89 1.71 8.51 6.95 2.23 6.37 6.49 8 4.07 1.34 8.84 1.77 8.12 
314 Formation_of_the_Early_Elongation_Complex 6.41 3.04 4.96 1.62 5.37 5.51 8.51 7.32 5.65 9.38 4.45 2.28 1.94 5.26 1.78 7.45 9.28 2.05 
315 RNA_Polymerase_II_Transcription_Initiation 1.49 2.57 3.12 4.01 1.99 7.27 6.92 3.53 7.95 5.42 5.67 1.49 3.76 2.55 7.42 7.48 1.03 8.15 
316 RNA_Polymerase_II_Promoter_Escape 0.47 0.73 9.65 7.49 1.37 1.69 3.31 9.7 0.53 7.68 0.52 1.78 1.56 9.81 6.95 5.86 9.29 7.31 
317 RNA_Polymerase_II_Transcription_Initiation 2.78 8.59 7.52 0.89 9.58 2.38 0.54 9.72 2.08 6.56 1.71 1.47 5.03 5.11 1.74 8.19 1.07 2.05 
318 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 5.99 7.88 2.61 0.45 4.35 4.92 7.32 0.76 6.67 4.03 3.67 8.99 0.54 1.67 2.12 1.14 1.29 7.93 
319 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 9.77 8.54 0.12 8.31 8.89 3.26 6.47 2.99 4.89 6.74 8.36 6.12 3.87 9.57 5.03 4.91 4.82 8.29 
320 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 0.27 3.61 9.52 4.96 6.46 1.83 5.97 5.54 0.32 1.02 9.45 4.76 2.24 0.81 1.95 6.23 6.32 3.43 
321 RNA_Polymerase_III_Chain_Elongation 6.02 3.69 2.82 9.89 4.37 5.99 0.35 1.79 6.54 6.52 3.99 3.5 1.32 9.45 2.93 8.71 6.49 5.9 
322 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 2.04 1.77 7.05 3.19 7.5 5.28 2.28 7.22 6.68 7.85 7.74 1.84 6.51 8.84 0.37 9.15 1.89 6.81 
323 RNA_Polymerase_III_Chain_Elongation 0.74 7.59 8.5 5.46 2.6 4.27 2.33 4.21 1.61 8.18 5.46 3.5 2.63 4.61 8.46 4.58 5.94 3.71 
324 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 9.45 5.02 2.46 4.2 2.54 9.53 7.6 5.86 4.19 7.35 6.16 1.13 3.35 5.92 0.18 2.65 3.7 3.36 
325 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 5.25 7.46 6.44 5.12 4.82 8.15 1.05 7.26 2.01 7.73 3.06 0.8 5.93 9.9 5.91 2.14 2.23 8.57 
326 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 7 8.49 3.22 2.85 7.62 7.02 2.68 3.74 1.52 8.48 2.35 6.38 7.62 2.37 2.72 7.92 2 3.43 
327 RNA_Polymerase_III_Transcription_Termination 5.19 4.81 3.7 9.91 1.45 9.84 7.14 0.85 0.79 3.99 2.82 3.86 1.19 6.5 1.93 1.85 5.16 6.08 
328 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 8.88 4.99 4.25 8.96 7.69 3.31 8.14 5.02 9.7 5.37 5.98 0.77 3.98 8.51 8.88 4.63 0.53 5.05 
329 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 7.41 2.67 6.62 6.55 0.81 6.95 6.18 8.72 0.94 6.7 5.38 1.21 4.45 5.23 2.43 3.65 7.18 1.35 
330 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 9.37 5.99 4.99 1.92 5.54 1.24 0.31 0.66 4.29 7.22 5.56 8.18 8.75 6.92 9.1 3.61 1.32 7.28 
331 RNA_Polymerase_III_Transcription_Initiation_From_Type_1_Promoter 5.22 1.49 2.77 8.26 3.48 2.78 7.77 3.38 1.75 9.44 1.25 1.39 8.21 3.4 6.4 9.66 0.81 1.48 
332 RNA_Polymerase_III_Transcription_Initiation_From_Type_2_Promoter 5.47 9.51 9.07 5.51 1.1 5.57 0.77 0.09 4.03 5.76 5.4 0.23 5.74 4.54 3.69 9.06 4.85 9.99 
333 RNA_Polymerase_III_Transcription_Initiation_From_Type_3_Promoter 0.48 9.3 5.73 6.58 8.16 8.84 3.73 0.31 6.04 7.83 7.91 4.22 0.1 9.87 3.64 5.68 9.94 5.79 
334 RNA_Polymerase_III_Transcription_Termination 0.23 7.09 6.57 1.41 2.85 4.77 0.23 2.72 8.28 4.35 5.49 5.17 0.09 7.43 8.67 2.65 5.9 8.91 
335 Recycling_of_eIF2:GDP 3.69 5.38 6.04 7.76 2.12 9.91 6.93 4.09 6.2 1.97 6.62 1.28 1 7.59 8.42 4.4 0.89 4.94 
336 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 6.42 6.2 4.86 1.46 9.64 4.86 2.71 9.43 4.66 4.74 4.45 7.88 3.49 8.27 9.54 5.04 2.81 2.46 
337 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 7.57 2.85 1.14 3.5 8.32 6.73 9.43 3.12 2.32 8.83 2.39 7.68 5.89 6.83 2.09 9.87 7.95 2.45 
338 Destabilization_of_mRNA_by_KSRP 9.12 6.39 9.35 2.48 4.79 2.07 2.3 9.54 6.01 9.4 0.43 7.18 4.12 3.77 6.23 4.72 9.83 8.85 
339 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 6.86 7.2 2.57 7.02 4.39 6.06 2.76 9.24 6.52 0.37 0.35 6.99 3.16 8.9 3.67 6.06 2.21 9.75 
340 Stabilization_of_mRNA_by_HuR 5.2 7.92 5.65 5.47 2.58 6.84 5.31 8.29 7.82 7.05 1.62 6.89 9.23 8.7 3.42 2.82 1.96 1.8 
341 MicroRNA_(miRNA)_Biogenesis 9.69 0.72 7.15 0.51 7.36 7.55 1.74 4.77 1.54 7.29 8.82 8.51 7.69 2.37 3.01 6.76 6.04 0.73 
342 Post-transcriptional_Silencing_By_Small_RNAs 1.61 1.97 5.95 1.25 4.85 0.62 2.29 5.6 7.18 0.73 0.79 7.09 6.62 2.24 5.74 6.82 4.75 8.15 
343 Small_Interfering_RNA_(siRNA)_Biogenesis 3.43 4.46 5.32 5.68 6.84 3.61 4.72 2.86 2.66 0.89 1.51 6.04 2.33 5.94 0.76 5.98 6.04 5.33 
344 Ribosomal_scanning_and_start_codon_recognition 4.68 1.84 4.17 9.64 6.16 0.14 0.66 9.96 8.73 1.48 5.1 3.96 9.41 7.91 8.66 5.89 0.2 3.55 
345 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 9.48 2.51 0.81 2.71 8.25 2.28 1.73 4.54 3.09 4.3 2.38 9.91 7.39 8.53 4.48 5.67 0.54 8.77 
346 SLBP_independent_Processing_of_Histone_Pre-mRNAs 4.9 1.97 0.56 7.73 5.89 8.62 5.36 4.29 8.88 5.39 5.85 8.41 1.67 5.2 5.6 0.47 5.81 3.82 
347 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 6.06 9.89 7.84 4.03 9.6 4.62 7.32 3.92 8.43 0.63 9.23 6.11 7.4 6.92 4.43 2.7 9.19 8.49 
348 SRP-dependent_cotranslational_protein_targeting_to_membrane 1.12 5.76 8.45 4.86 5.56 6.03 3.64 4.98 5.08 8.78 3.38 7.23 0.05 4.11 1.93 1.17 9.43 2.27 
349 Small_Interfering_RNA_(siRNA)_Biogenesis 5.14 2.9 4.16 8.01 3.39 5.44 2.36 0.12 2.74 4.33 7.4 4.01 1.83 1.35 8.28 6.33 4.37 1.34 
350 Stabilization_of_mRNA_by_HuR 5.77 6.71 7.22 2.63 6.59 5.4 3.68 2.82 8.48 3.66 2.9 2.27 4.58 0.71 1.06 3.05 0.01 4.34 
351 Mitochondrial_transcription_initiation 7.7 5.55 5.07 2.99 7.3 0.75 8.03 4.39 1.94 4.88 6.64 6.73 0.48 3.58 2.8 4.87 7.64 7.13 
352 Mitochondrial_transcription_termination 0.13 4.52 1.7 9.78 7.66 7.04 4.16 6.49 3.77 8.37 5.37 4.59 4.32 9.55 1.05 5.26 9.37 3.66 
353 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 9.14 1.55 2.9 4.46 1.82 6.35 0.93 9.36 8.46 2.38 4.56 4.03 7.14 5.99 0.41 9.25 0.74 3.24 
354 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 3.44 8.63 7.49 2.76 5.97 3.34 6.47 4.26 0.43 2.44 5.92 7.61 2.69 1.75 1.39 6.96 4.81 4.71 
355 Eukaryotic_Translation_Termination 2.68 7.13 6.66 0.3 8.06 1.09 2.9 0.59 6.84 5.46 7.59 1.03 6.06 3.91 0.93 1.96 5.83 9.5 
356 Formation_of_a_pool_of_free_40S_subunits 5.57 4.35 0.12 6.67 8.69 1.65 9.03 9.73 7.91 5.16 1.49 5.15 1.18 2.43 3.88 4.97 7.11 0.91 
357 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 8.74 5.63 1.25 0.07 3.7 1.21 7.27 6.58 3.36 2.75 2.21 5.76 7.99 9.19 2.41 6.11 7.12 2.09 
358 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 6.35 2.63 8.3 5.14 3.36 7.83 0.32 9.88 3.39 7.05 6.7 9.4 8.68 3.91 7.28 9.85 5.37 3.2 
359 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 1.24 9.97 3.54 7.03 4.94 5.62 8.65 5.54 7 3.02 7.14 6.29 7.94 0.26 4.63 5.28 7.48 6.79 
360 Peptide_chain_elongation 3.51 1.99 0.03 4.42 2.8 0.16 2.9 0.98 8.58 7.3 5.53 5.51 2.62 4.44 6.49 4.85 0.55 5.72 
361 Recycling_of_eIF2:GDP 8.89 8.58 5.52 1.29 6.4 8.6 0.46 6.27 0.44 4.22 9.36 4.73 1.54 3.33 7.56 0.51 3.91 5.34 
362 Ribosomal_scanning_and_start_codon_recognition 9.31 3.22 0.79 2.02 1.76 5.8 2.69 3.88 4.29 8.85 0.02 6.1 3.27 2.74 7.6 0.99 0.42 0.55 
363 SRP-dependent_cotranslational_protein_targeting_to_membrane 3.93 0.65 9.28 5.72 2.84 7.26 7.98 5.23 2.01 5.87 0.88 9.97 6.52 1.75 7.5 6.78 4.55 8.93 
364 Translation_initiation_complex_formation 6.3 4.06 5.31 4.89 1.65 5.21 1.27 9.64 4.4 1.13 3.89 7.1 4.88 7.63 3.2 1.88 8.21 2.64 
365 Translation_initiation_complex_formation 0.03 7.54 7.22 3.16 8.54 5.86 4.25 5.24 8.18 3.02 1.2 6.59 4.88 6.82 3.41 5.74 5 5.66 
366 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 2.22 7.54 5.52 8.5 5.16 2.26 4.86 6.02 7.37 9.01 9.01 7.49 9.67 1.02 2.65 8.81 8.43 7.1 
367 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 5.08 4.89 8.58 1.84 1.21 1.06 5.86 9.87 3.71 4.9 9.72 5.18 0.73 3.53 2.81 6.62 9.96 2.13 
368 Transport_of_the_SLBP_Dependant_Mature_mRNA 4.51 1.15 8.04 7.85 3.33 5.64 5.04 8.37 4.53 7.84 3.33 9.72 9.21 5.44 3.7 2.57 0.88 1.29 
369 Transport_of_the_SLBP_independent_Mature_mRNA 2.97 3.4 9.23 9.01 3.43 8.76 7.31 5 6.48 6.13 2.53 3.11 6.93 3.32 4.51 8.14 5.99 2.16 
370 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 2.12 8.34 8.49 2.52 9.12 1.41 2.09 4.5 1.8 5.69 5.35 5.62 3.65 1.11 8.17 0.11 7.63 3.21 
371 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 6.06 3.45 4.43 8.5 5.93 6.64 4.42 4.44 8.33 7.36 5.02 0.25 5.59 9.53 0.07 0.06 5.43 1.29 
372 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 7.51 0.7 3.95 2.28 5.41 0.59 2.2 7.15 9.44 1.78 6.58 3.84 7.38 3.83 6.38 7.37 6.35 0.3 
373 Transport_of_the_SLBP_Dependant_Mature_mRNA 7.82 3.15 0.8 0.21 4.25 7.52 2.04 4.46 4.12 0.04 0.45 8.25 2.44 5.49 9.94 5.29 1.32 0.09 
374 Transport_of_the_SLBP_independent_Mature_mRNA 3.16 4.29 7.61 1.33 9.3 7.46 5.32 2.83 8.73 4.39 8.8 8.35 9.87 5.7 5.89 6.29 5.6 5.21 
375 Transport_of_the_SLBP_Dependant_Mature_mRNA 5.97 1.89 1.63 4.44 6.21 7.05 8.15 7.13 3.34 9.99 1.37 6.15 1.64 0.58 5.11 3.83 8.46 9.43 
376 Transport_of_the_SLBP_independent_Mature_mRNA 7.37 8.31 6.55 2.51 3.51 2.9 0.52 2.95 4.2 0.61 3.6 7.67 2.73 0.34 1.33 1.91 3.01 3.78 
377 mRNA_Splicing_-_Minor_Pathway 3.87 8.79 5 6.15 7.09 0.72 0.61 9.52 9.7 8.23 0.64 5.37 0.5 6.1 7.91 9.78 4.43 1.61 
378 YAP1-_and_WWTR1_(TAZ)-stimulated_gene_expression 8.21 7.18 2.98 1.83 9.33 6.95 7.09 0.72 4.68 7.03 8.64 8.45 8.49 0.5 6.46 1.42 4.44 1.55 
379 mRNA_3-end_processing 4.59 7.68 8.85 3.01 7.68 8.47 6.06 1.87 5.35 3.09 3.64 6.33 3.51 1.4 6.25 7.24 3.46 2 
380 mRNA_Capping 8.38 0.31 2.21 2.17 6.24 5.84 8.15 3.44 3.52 0.19 0.7 3.67 9.19 1.74 4.87 0.3 3.45 7.16 
381 mRNA_Decay_by_3_to_5_Exoribonuclease 0.44 6.99 1.62 6.85 1.15 3.21 5.02 5.41 8.04 5.73 7.33 4.52 8.11 2.29 2.24 1.59 9.83 6.65 
382 mRNA_Decay_by_5_to_3_Exoribonuclease 8.45 9.5 8.26 5.91 8.97 2.13 3.71 9.86 6.62 1.9 5.84 9.06 4.18 6.22 7.19 6.66 2.18 9.91 
383 C6_deamination_of_adenosine 9.59 5.66 1.03 2.79 4.98 8.67 3.45 1.03 4.3 0.2 0.25 5.34 8.21 8.33 2.35 2.87 3.93 8.27 
384 Formation_of_editosomes_by_ADAR_proteins 3.48 6.24 6.92 9.18 8 2.44 4.31 0.86 6.95 5.08 7.53 5.97 1.92 1.21 8.19 9.07 0.71 0.22 
385 Formation_of_the_Editosome 5.61 9.91 0.52 2.51 5.23 9.65 9.56 9.8 0.61 4.65 5.23 3 8.28 2.35 9.53 6.12 6.82 8.76 
386 C6_deamination_of_adenosine 1.57 2.89 2.92 1.99 7.76 4.61 8.42 1.31 6.6 7 6.38 0.8 6.2 5.45 9.29 1.68 1.41 7.62 
387 Formation_of_editosomes_by_ADAR_proteins 8.34 6.33 2.7 0.82 0 5.6 3.64 1.41 0.99 3.36 6.65 8.33 0.29 8.27 2.54 0.28 3.19 9.84 
388 Formation_of_the_Editosome 1.1 1.68 4.17 3.97 1.25 4.06 4.1 4.63 0.48 6.9 9.69 3.44 5.99 6.43 1.55 4.64 5.37 5.58 
389 mRNA_Splicing_-_Minor_Pathway 2.06 9.11 4.14 9.47 2.93 1.29 5.87 0.8 0.85 7.64 2.34 0.76 0.15 1.18 3.84 8.47 6.48 5.47 
390 mRNA_Splicing_-_Major_Pathway 5.55 8.32 7.81 8.37 4.27 8.96 8.59 3.24 7.99 6.53 7.01 8.41 4.04 7.29 2.15 5.65 6.5 5.32 
391 mRNA_Splicing_-_Major_Pathway 0.83 7.19 2.96 4.39 7.78 2.38 2.41 8.03 0.06 6.2 6.7 8.49 2.05 5.24 0.78 7.87 9.84 6.29 
392 snRNP_Assembly 1.39 8.98 9.73 6.38 8.15 0.02 0.41 4.85 0.63 2.11 0.66 8.27 5.83 9.3 5.65 0.82 9.82 8.31 
393 Cytosolic_tRNA_aminoacylation 2.35 2.9 8.12 2.56 8.02 4.48 5.13 1.26 4.97 0.64 2.15 2.93 9.07 4.37 4.18 3.38 4.24 0.7 
394 Mitochondrial_tRNA_aminoacylation 1.83 3.45 3.28 0.59 4.83 2.21 5.37 5.6 3.49 9.23 8.83 9.05 8.47 3.13 7.86 9.84 4.09 2.34 
395 C6_deamination_of_adenosine 5 9.7 8.39 1.57 6.68 8.56 4.85 5.92 0.22 7.33 7.35 3.83 8.27 4.99 0.61 0.9 1.35 1 
396 Formation_of_editosomes_by_ADAR_proteins 4.79 5.73 9.06 8.85 2.45 2.09 8.36 9.81 9.39 6.99 1.01 4.07 1.95 2.19 0.84 4.27 3.55 5.6 
397 Formation_of_the_Editosome 1.33 4.52 8 6.03 6.88 3.98 8.75 5.69 3.04 9.9 8.43 5.57 8.57 3.19 8.75 1.49 1.9 9.46 
398 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 7.98 4.67 3.46 5.09 0.8 4.79 9.81 2.07 7.19 1.38 4.25 6.99 7.7 0.14 5.1 3.55 2.32 7.65 
399 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 6.18 7.2 2.37 2.64 7.09 7.03 5.44 0.5 5.41 3.01 3.44 4.27 1.41 9.1 6.96 8.24 6.83 0.98 
400 Transport_of_the_SLBP_Dependant_Mature_mRNA 6.4 1.31 5.7 7.54 5.35 9.03 4.45 6.09 4.14 0.32 9.17 6.3 3.18 4.32 4.13 0.9 4.61 1.32 
401 Transport_of_the_SLBP_independent_Mature_mRNA 6.35 5.17 6.45 3.21 8.18 8.05 3.33 7.21 2.46 9.7 7.88 3.94 0.08 2.27 8.35 5.77 6.75 2.05 
402 mRNA_Splicing_-_Minor_Pathway 0.5 6.42 2.54 3.18 3.9 7.24 9.79 3.65 7.54 1.71 0.22 8.44 2.67 5.09 4.1 8.72 5.52 8.74 
403 mRNA_3-end_processing 9.77 6.97 3.7 9.41 2.67 3.41 6.17 9.68 0.65 3.21 6.55 7.27 9.14 2.83 1.37 9.32 5.49 1.62 
404 mRNA_Splicing_-_Major_Pathway 8.82 0.35 5.92 1.35 9.3 5.34 5.2 7.28 6.88 7.24 6.34 2.33 6.03 1.25 1.22 7.82 7.6 0.65 
405 Processing_of_Intronless_Pre-mRNAs 9.3 2.64 4.23 3.22 4.86 9.08 6.38 6.31 5.65 4.26 3.62 5.63 3.78 4.19 8.51 7.41 3.15 0.76 
406 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 1.68 5.21 0.98 5.87 5.31 2.39 3.39 5.52 8.3 4.74 7.81 7.42 1.18 9 7 2.34 6.06 6.8 
407 SLBP_independent_Processing_of_Histone_Pre-mRNAs 7.9 9.23 3.99 1.68 4.85 6.34 4.55 5.44 4.44 7.08 8 2.19 5.18 3.49 9.47 5.8 2.99 4.48 
408 Processing_of_Intronless_Pre-mRNAs 6.84 1.19 1.32 3.4 8.88 7.7 2.97 4.33 1.4 6.22 5.45 5.4 7.27 2.5 0.82 2.47 0.99 0.5 
409 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 7.3 3.96 3.04 3.31 8.05 0.51 0.82 1.39 7.67 3.7 6.76 1.43 5.56 9.73 1.16 9.57 2.86 3.66 
410 SLBP_independent_Processing_of_Histone_Pre-mRNAs 4.33 8.43 6.72 8.14 2.98 4.71 9.37 2.61 8.09 9.2 5.86 3.27 4.41 0.53 3.23 5.28 4.91 5.97 
411 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 0.99 8.81 8.23 3.1 6.71 5.78 9.93 0.9 6.53 2.34 2.66 2.47 1.13 4.22 7.45 9.74 4.88 0.22 
412 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 3.77 5.19 0.83 9.66 8.05 7.94 6.46 3.24 4.41 0.89 0.98 7.97 0.66 4.6 3.91 5.73 4.65 6.05 
413 Transport_of_the_SLBP_Dependant_Mature_mRNA 8.06 4.38 3.96 5.18 2.62 9.44 7.26 0.15 8.93 3.23 5.69 1.24 2.18 3.69 4.72 6.7 1.61 0.15 
414 Transport_of_the_SLBP_independent_Mature_mRNA 8.25 7.29 4.94 0.37 1.95 8.3 5.49 3 7.01 7.94 5.61 3.03 9.92 9.59 9.48 2.06 6.13 9.69 
415 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 6.39 4.55 5.61 6.51 4.1 6.77 5.76 5.39 2.22 5.02 2.24 1.96 8.49 0.23 9.12 7.23 7.14 3.71 
416 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 8.08 6.2 9.81 1.56 2.98 1.49 1.45 4.97 4.66 4.43 4.48 3.92 5.31 2.04 6.95 2.94 4.5 1.49 
417 Transport_of_Mature_mRNA_Derived_from_an_Intronless_Transcript 9.51 5.81 5.98 8.45 6.75 2.45 5.84 4.33 1 3.99 5.67 2.97 0.09 9.41 2.31 0.99 8.98 9.74 
418 Transport_of_the_SLBP_Dependant_Mature_mRNA 3.87 7.59 2.62 1.45 7.29 6.59 3.24 7.67 9.66 9.68 9.27 0.94 8.49 7.96 5.42 9.23 3.96 4.17 
419 Transport_of_the_SLBP_independent_Mature_mRNA 4.11 3.68 0.48 7.81 8.33 5.74 6.88 8.84 6.68 4.68 4.25 2.04 8.44 9.21 9.6 9.11 9.22 9.51 
420 Transport_of_the_SLBP_Dependant_Mature_mRNA 7 3.42 6.3 4.25 4.3 4.51 7.2 1.98 5.27 4.8 4.05 3.82 4.25 6.14 6.12 2.04 1.92 0.09 
421 Transport_of_the_SLBP_independent_Mature_mRNA 9.38 0.05 8.66 6.66 1.71 0.8 9.64 5.41 0.26 8.86 9.35 7.33 2.51 7.24 0.76 2.92 1.59 9.51 
422 mRNA_Splicing_-_Minor_Pathway 5.96 5.27 8.07 2.87 0.27 9.2 8.05 1.27 8.37 7.1 5.83 8.03 1.37 4.83 3.41 6.35 6.21 2.77 
423 mRNA_3-end_processing 2.78 0.8 4.34 7.11 2.29 8.53 9.3 4.08 7.3 4.48 6.32 1.41 6.7 4.16 0.63 8.18 8.15 9.84 
424 mRNA_Capping 5.09 9.74 7.41 8.85 4.08 9.6 7.48 0.85 7.78 1.01 1.71 5.05 4.01 7.96 1.72 1.09 7.31 9.87 
425 C6_deamination_of_adenosine 6.7 5.25 1.84 8.02 7.27 7.46 6.88 3.52 1.97 9.89 8.95 3.98 9.51 0.18 3.73 2.57 7.19 8.73 
426 Formation_of_editosomes_by_ADAR_proteins 9.15 0.68 8.83 6.1 8.59 1.25 5.96 8.39 5.83 5.18 1.59 5.18 0.61 1.67 6.03 1.66 9.38 2.26 
427 Formation_of_the_Editosome 1.93 8.82 8.76 7.6 7.38 5.57 7.8 5.54 0.78 0.61 8.68 5.21 6.73 0.98 7.57 2.58 4.19 3.45 
428 C6_deamination_of_adenosine 9.01 1.89 2.16 9.56 2.39 7.25 1.25 5.32 1.78 4.21 7.16 7.62 2.87 2.08 7.38 5.3 6.05 4.9 
429 Formation_of_editosomes_by_ADAR_proteins 7.99 5.69 4.07 2.53 4.13 6.56 7.85 5.83 3.48 5.93 7.99 3.62 6.06 6.66 7.35 2.19 6.71 6.64 
430 Formation_of_the_Editosome 5.99 6.08 8.47 0.14 9.14 2.12 5.07 6.22 3.27 4.92 3.2 9.99 8.98 2.71 3.86 1.92 5.52 2.17 
431 mRNA_Splicing_-_Minor_Pathway 5.24 9.88 6.93 0.89 6.88 4.14 2.96 2.68 3.46 3.58 7.37 7.45 5.68 7.97 8.25 6.47 2.21 2.37 
432 mRNA_Splicing_-_Major_Pathway 6.43 9.07 6.7 5.49 5.46 0.39 2.52 0.12 0.2 4.31 4.76 6.91 5.25 8.45 0.99 4.16 7.74 0.56 
433 mRNA_Splicing_-_Major_Pathway 6.77 8.72 7.36 0.08 8.96 3.09 1.32 3.58 7.88 7.44 0.04 9.3 7.27 6.49 5.19 8.68 1.74 9.01 
434 mRNA_3-end_processing 3.61 2.55 9.66 9.27 3.13 3.62 7.8 8.18 7.28 2.89 7.13 9.41 2.23 7.96 7.31 8.4 2.31 1.35 
435 Processing_of_Intronless_Pre-mRNAs 6.32 5.82 3.82 2.5 6.44 8.52 4.57 6.01 2.68 0.33 7.73 8.94 4.19 5.26 8.83 5.33 7.82 5.12 
436 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 4.36 8.25 0.52 8.12 0.24 8.45 2.96 2.02 7.73 7.58 3.05 6.77 3.58 1.11 2.81 6.5 5.7 9.8 
437 SLBP_independent_Processing_of_Histone_Pre-mRNAs 2.53 3.27 3.59 7.16 7.97 1.18 7.18 7.77 3.81 0.65 1.52 7.13 3.71 1.76 5.86 8.74 2.42 2.41 
438 Processing_of_Intronless_Pre-mRNAs 5.09 0.97 6.62 2.48 2.42 1.48 5.92 5.36 6.2 6.17 2.29 6.24 7.81 6.38 7.06 5.61 3.5 5.47 
439 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 4.58 0.39 9.05 9.81 4.68 4.14 6.01 3.16 2.94 9.67 0.45 1.67 0.39 1.63 6 7.74 4.44 9.99 
440 SLBP_independent_Processing_of_Histone_Pre-mRNAs 5.25 0.8 2.17 8.24 4.49 0.86 6.74 2.57 1.85 2.15 0.58 2.75 2.3 5.82 2.11 0.37 2.7 9.62 
441 Processing_of_Intronless_Pre-mRNAs 5.91 0.28 6.61 6.12 6.96 8.76 1 9.58 1.71 1.91 2.48 1.22 6.98 5.5 7.58 7.28 1.45 7.42 
442 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 4.38 8.6 4.73 4.77 4.93 6.95 4.04 2.13 0.32 5.25 9.04 2.95 2.21 8.48 1.68 0.84 6.2 0.91 
443 SLBP_independent_Processing_of_Histone_Pre-mRNAs 8.38 2.32 1.19 3.37 5.66 4.32 2.62 5.34 8.31 6.37 6.94 1.02 0.11 5.14 6.42 2.69 8.34 5.47 
444 mRNA_3-end_processing 7.3 5.03 0.41 6.06 4.11 2.97 7.37 1.02 0.15 0.63 1.17 3.17 9.99 1.51 6.43 5.38 7.82 4.54 
445 Activation_and_oligomerization_of_BAK_protein 8.87 0.12 9.12 9.22 8.37 1.74 0.91 8.08 7.18 8.51 2.77 6.23 8.52 2.11 2.3 5.89 0.01 0.15 
446 Activation_of_BAD_and_translocation_to_mitochondria_ 4.87 7.28 0.29 9.21 9.87 8.63 3.27 4.88 4.77 7.14 8.46 4.75 0.82 8.31 8.39 6.19 1.69 6.47 
447 Activation_of_BAD_and_translocation_to_mitochondria_ 3.62 4.06 5.6 7.52 9.05 5.61 7.2 3.8 4.41 5.5 3.39 7.38 1.24 9.51 0.05 9.4 9.89 6.25 
448 Activation_of_BIM_and_translocation_to_mitochondria_ 4.82 1.04 6.53 3.8 4.3 6.11 6.06 0.58 7.87 0.51 3.27 4.3 6.22 7.47 4.07 2.96 7.14 2.05 
449 Activation_of_BMF_and_translocation_to_mitochondria 9.49 4.06 8.1 5.15 9.35 5.88 7.85 3.34 9.13 0.23 4.76 9.63 1.77 7.26 9.22 7.07 5.29 2.66 
450 Activation_of_NOXA_and_translocation_to_mitochondria 6.27 4.25 9 2.48 9.75 5.3 7.57 4.13 0.96 0.16 0.92 9.05 2.51 8.07 7.3 7.03 5.47 4.52 
451 Activation_of_PUMA_and_translocation_to_mitochondria 2.55 6.84 5.35 5.94 1.46 7.9 0.36 0.47 5.05 6.07 2.78 9.58 2.81 7.46 2.99 4.22 5.92 4.13 
452 Activation,_myristolyation_of_BID_and_translocation_to_mitochondria 8.08 0.52 0.41 7.91 5.76 9.24 6.57 7.08 9.46 9.58 6.32 2.63 6.27 8.31 4.41 6.79 6.37 1 
453 Activation_of_BIM_and_translocation_to_mitochondria_ 6.37 9.09 7.5 6.54 5.4 5.97 8.27 9.79 0.46 1.39 8.38 0.81 8.98 7.92 2.21 6.97 2.93 8.13 
454 Activation_of_BMF_and_translocation_to_mitochondria 2.06 9.29 6.93 3.51 8.16 1.94 2.38 9.88 6.75 9.71 4.21 9.8 6.83 9.66 0.99 7.56 6.09 4.66 
455 Activation_of_DNA_fragmentation_factor 6.68 3.59 3.95 1.84 9.28 0.94 3.32 8.66 4.58 2.66 4.63 9.13 4.31 2.86 3.6 1.66 4.49 1.22 
456 Activation_of_NOXA_and_translocation_to_mitochondria 2.6 8.83 1.73 9.66 7.06 9.46 4.74 7.08 3.46 6.7 8.2 2.66 0.69 3.78 9.27 0.38 8.84 3.59 
457 Activation_of_PUMA_and_translocation_to_mitochondria 7.67 9.78 0.3 9.21 1.91 8.9 0.93 4.44 8.09 5.07 0.4 5.23 2.22 6.47 1.5 2.25 2.62 3.82 
458 Activation_of_caspases_through_apoptosome-mediated_cleavage 9.69 7.4 0.01 8.55 3.05 5.26 2.87 8.63 9.79 9.66 4.78 3.45 2.09 8.86 9.06 7.2 6.43 6.06 
459 Activation,_translocation_and_oligomerization_of_BAX 4.42 3.61 9.83 9.38 8.17 7.95 7.09 7.99 4.97 7.95 7.42 2.52 3.67 1.4 1.03 8.55 7.55 0.52 
460 Activation_of_DNA_fragmentation_factor 8.56 4.45 2.62 9.97 6.5 7.89 0.65 7.05 1.27 4.47 4.27 5.03 2.76 2.65 6.75 2.46 7.81 8.03 
461 Apoptotic_cleavage_of_cell_adhesion__proteins 8.15 2.63 7.6 3.16 5.81 7.77 5.33 8.28 7.84 7.03 4.44 4.76 3.74 1.08 5.35 4.02 9.35 4.41 
462 Apoptotic_cleavage_of_cell_adhesion__proteins 7.86 3.93 3.2 4.14 9.44 8.57 9.12 3.04 4.96 6.91 7.06 8.26 2.16 5.83 1.33 5.11 9.76 3.05 
463 Breakdown_of_the_nuclear_lamina 6.65 2.06 0.98 4.18 6.19 7.91 0.24 4.67 8.5 9.34 4.95 9.75 0.75 6.94 7.87 4.65 7.62 6.39 
464 Caspase-mediated_cleavage_of_cytoskeletal_proteins 5.08 4.6 6.82 5.86 4.95 1.22 9.35 9.48 5.59 1.19 1.38 4.66 3.73 7.5 0.6 3.41 0.93 5.48 
465 Activation_of_DNA_fragmentation_factor 4.06 9.18 2.68 2.12 0.65 6.19 1.27 5.71 1.14 0.42 7.5 7.49 7.28 2.61 9.77 7.36 0.25 6.06 
466 Apoptotic_cleavage_of_cell_adhesion__proteins 4.65 7.83 9.53 4.05 6.26 1.53 1.65 5.45 1.27 7.8 4.31 3.8 1.83 3.47 7.23 0.81 0.63 5.44 
467 Breakdown_of_the_nuclear_lamina 2.49 4.26 4.4 6.62 2.91 0.29 6.98 5.98 9.78 7.27 8.25 4.6 2.69 1.8 2.23 3.47 4.02 1.65 
468 Caspase-mediated_cleavage_of_cytoskeletal_proteins 0.82 4.23 0.55 1.87 8.07 8.09 3.3 0.91 1.11 5.44 3.44 0.75 6.89 2.05 7.56 7.24 2.17 8.56 
469 Stimulation_of_the_cell_death_response_by_PAK-2p34 0.48 7.6 2.8 6.5 0.88 9.66 0.67 7.78 1.73 8.43 0.48 9.32 5.76 7.63 5.98 3.35 6.16 8.57 
470 Activation_of_caspases_through_apoptosome-mediated_cleavage 9.8 1.66 6.61 4.91 9.33 9.29 0.85 2.5 8.91 6.93 2.88 2.88 7.86 0.57 5.59 8.27 9.1 2.26 
471 Formation_of_apoptosome 2.9 2.41 2.64 6.66 0.74 6.92 1.48 4.12 8.92 2.16 1.58 8.27 1.59 0.42 8.39 1.63 4.48 3.96 
472 SMAC_binds_to_IAPs_ 2.5 8.96 1.96 6.78 1.08 4.86 4.37 3.03 3.23 0.01 0.41 8.45 6.3 0.94 4 9.93 0.54 3.94 
473 SMAC-mediated_dissociation_of_IAP:caspase_complexes_ 2.04 5.42 1.24 5.69 5.81 6.43 8.27 2.01 5.02 0.23 0.38 5.61 8.34 1.01 2.05 9 7.32 4.56 
474 BH3-only_proteins_associate_with_and_inactivate_anti-apoptotic_BCL-2_members 6.36 2.1 9.17 5.93 4.77 7.92 9.1 9.9 4.08 7.75 8.89 0.69 3.91 1.39 8.35 3.06 0.39 1.73 
475 Breakdown_of_the_nuclear_lamina 0.69 5.73 4.44 8.27 1.95 3.36 3.95 1.02 3.16 0.07 0.22 7.64 9.48 0.08 7.72 0.08 7.9 1.57 
476 Dimerization_of_procaspase-8 0.47 8.31 0.86 6.96 9.06 4.67 8.14 1.9 4.67 6.05 5.11 3.83 6.53 4.39 8.26 9.42 9.29 4.4 
477 Caspase-mediated_cleavage_of_cytoskeletal_proteins 5.27 5.4 8.86 4.43 0.47 1.53 4.7 6.1 6.05 7.09 9.71 4.71 2.42 3.32 8.42 4.2 2.25 8.81 
478 Activation_of_caspases_through_apoptosome-mediated_cleavage 7.18 5.88 3.51 2.52 8.57 8.65 9.75 4.3 3.51 1.02 7.5 7.88 7.47 0.72 2.9 2.19 7.17 9.93 
479 Formation_of_apoptosome 7.6 7.56 0.92 6.93 1.99 0.32 8.49 8.73 3.43 9.33 4.44 8.56 4.86 0.25 3.64 0 3.32 0.22 
480 FasL/_CD95L_signaling 1.45 0.53 7.09 8.95 7.47 5.08 3.19 6.34 1.36 1.23 2.44 9.82 4.9 3.75 5.46 4.39 0.48 5.65 
481 TNF_signaling 9.62 1.68 7.19 4.69 9.82 1.13 2.87 3.4 7.66 6.33 2.9 3.21 6.36 6.77 9.95 9.06 4.63 2.49 
482 TRAIL__signaling 6.2 0.56 1.33 5.66 9.55 0.57 4.21 4.61 5.01 6.6 9.16 1.63 7.38 3.78 3.97 3.34 5.88 4.99 
483 Dimerization_of_procaspase-8 4.7 1.99 1.15 3.66 4.65 2.32 8.74 0.78 3.37 8 8.48 9.93 9.58 7.57 6.71 0.58 6.82 6.17 
484 Dimerization_of_procaspase-8 0.65 7.06 8.2 3.12 2.04 6.02 1.97 1.36 6.43 1.16 9.78 3.06 6.24 1.15 4.73 1.6 6.78 3.36 
485 FasL/_CD95L_signaling 7.19 6.08 1.88 7.82 3.21 6.16 2.23 7.12 1.86 1.7 7.66 0.42 2.68 4.58 8.76 6.62 9.46 9.81 
486 Regulation_by_c-FLIP 7.53 7.04 8.38 5.97 3.22 5.95 9.11 1.15 3.87 2.21 2.37 6.04 5.78 6.4 8.64 5.66 6.94 9.31 
487 TNF_signaling 3.65 7.56 1.84 0.65 1.06 2.65 0 9.84 3.89 4.02 4.11 9.57 8.07 4.07 2.27 6.86 9.43 0.35 
488 TRAIL__signaling 1.12 2.31 6.77 0.49 2.06 4.01 4.35 5.46 9.59 5.76 8.11 7.08 0.9 1.64 5.97 7.25 1.07 8.83 
489 FasL/_CD95L_signaling 4.15 3.77 0.94 3.8 3.55 1.68 9.34 3.83 6.11 3.16 4.03 9.48 2 0.41 6.6 2.73 7.23 1.89 
490 Formation_of_apoptosome 0.32 2.23 7.87 1.78 7.39 5.03 1.37 8.9 4.63 1.77 8.01 2.03 9.13 8.3 3.14 0.99 9.98 1.03 
491 Activation_and_oligomerization_of_BAK_protein 5.98 1.17 7.9 8.68 3.74 6.92 4.48 1.06 1.84 8.48 9.26 5.67 2.35 4.07 9.77 4.71 2.05 0.3 
492 Activation_of_BAD_and_translocation_to_mitochondria_ 9.2 8.45 4.58 7.59 5.98 0.42 8.08 2.77 0.66 6.33 5.05 2.78 2.9 3.11 4.4 0.17 4.02 8.69 
493 Activation,_myristolyation_of_BID_and_translocation_to_mitochondria 5.43 8.48 2.26 7.6 0.57 8.63 6.46 4.9 6.68 5.26 3.86 6.1 6.49 3.39 8.13 1.62 3.58 2.2 
494 Activation_of_BIM_and_translocation_to_mitochondria_ 4.37 8.15 8.75 3.72 8.76 3.9 4.29 5.55 0.1 0.77 7.84 2.75 4.35 9.76 8.4 0.48 5.29 1.9 
495 Activation_of_BMF_and_translocation_to_mitochondria 6.33 3.67 6.37 3.23 4.45 0.03 9.94 0.86 7.34 4.52 2.75 5.41 9.25 2.01 8.55 3.04 3.78 3.91 
496 Activation_of_NOXA_and_translocation_to_mitochondria 4.33 2.6 7.25 8.26 1.25 6.9 1.89 7.07 9.35 8.47 7.19 8.83 6.14 4.28 3.13 0.48 0.26 6.4 
497 Activation_of_PUMA_and_translocation_to_mitochondria 7.27 7.09 4.66 5.65 9.65 8.87 4.73 9.76 7.5 6.53 9.53 2.29 5.09 3.43 6 7.71 6.11 7.78 
498 Activation_of_caspases_through_apoptosome-mediated_cleavage 7.63 1.88 5.68 0.02 9.6 9.68 3.73 6.66 3.6 4.18 3.85 0.01 4.85 6.19 9.46 6.13 6.96 3.89 
499 Activation,_translocation_and_oligomerization_of_BAX 8.94 8.04 1.19 2.19 6.27 0.88 4.61 2.95 6.52 6.43 0.9 7.47 9.65 1.24 2.84 5.25 9.53 7.92 
500 BH3-only_proteins_associate_with_and_inactivate_anti-apoptotic_BCL-2_members 1.1 1.97 4.97 8.05 1.12 8.56 2.56 7.3 2.31 0.34 5.01 1.71 4.38 6.56 2.65 2.36 4.69 9.24 
501 Formation_of_apoptosome 3.86 9.72 8.02 6.52 4.71 5.8 9.25 3.8 7.08 5.99 1.37 8.67 7.28 8.12 8.31 6.84 2.93 6.58 
502 Release_of_apoptotic_factors_from_the_mitochondria 1.4 8.87 6.88 0.77 5.59 9.59 5.3 6.3 6.76 1.4 6.38 3.91 8.6 2.76 0.6 0.94 3.28 4.37 
503 SMAC_binds_to_IAPs_ 0.53 3.85 1.39 9.27 7.28 1.96 3.04 3.68 3.96 9.75 8.13 1.83 3.91 1.48 6.46 3.33 5.59 1.27 
504 SMAC-mediated_dissociation_of_IAP:caspase_complexes_ 7.73 6.01 2.07 4.95 5.52 8.35 4.6 6.52 1.71 5.95 7.2 2.73 0.88 4.67 3.75 1.63 6.12 4.74 
505 Regulation_by_c-FLIP 6.49 9.3 6.28 3.95 5.83 8.33 1.27 0.45 0 9.85 9.9 7.72 6.38 7.71 7.93 6.96 3.73 0.61 
506 Regulation_of_PAK-2p34_activity_by_PS-GAP/RHG10 9.08 7.16 3 7.39 8.27 4.97 8.72 5.78 2.89 7.72 6.93 6.58 9.99 4.78 3.66 6.1 6.42 9.95 
507 Regulation_of_activated_PAK-2p34_by_proteasome_mediated_degradation 5.67 5.77 8.54 4.54 9.92 6.02 2.26 9.94 0.45 3.74 5.48 8.83 4.44 8.81 9.75 6.7 8.47 3.18 
508 Role_of_DCC_in_regulating_apoptosis 0.98 9.67 5.94 5.72 0.67 1.38 9.91 7.89 2.68 4.6 5.12 3 8.12 4.34 6.77 5.75 6.17 8.9 
509 Regulation_of_PAK-2p34_activity_by_PS-GAP/RHG10 0.47 9.9 3.4 7.05 4.84 6.43 8.14 5.64 5 2.98 6.82 8.75 3.7 9.23 4.98 0.51 8.64 6.77 
510 Regulation_of_activated_PAK-2p34_by_proteasome_mediated_degradation 0.23 2.6 7.64 1.17 4.67 7.7 9.19 8.55 2.97 7.27 6.65 3 8.88 9.69 8.13 3.98 2.44 3.59 
511 Release_of_apoptotic_factors_from_the_mitochondria 8.5 4.56 6.05 8.1 4.28 9.13 4.2 8.82 0.32 2.66 3.87 6.31 4.64 5.01 3.8 5.85 7.02 0.73 
512 Role_of_DCC_in_regulating_apoptosis 6.53 5.94 2.27 3.88 9.54 8.02 8.66 1.68 1.47 3.71 1.37 6.33 3.12 8.62 3.2 1.01 5.55 6.85 
513 SMAC_binds_to_IAPs_ 0.86 1.17 7.41 7.63 6.48 9.32 6.67 9.53 1.46 2.13 5.94 7.07 0.75 2.66 7.29 4.82 5.08 8.02 
514 SMAC_binds_to_IAPs_ 4.94 5.71 5.06 6.98 9.55 1.44 4.44 2.24 7.78 1.01 0.31 7.4 3.03 9.25 5.28 5.59 5.89 2.7 
515 SMAC-mediated_dissociation_of_IAP:caspase_complexes_ 8.49 9.12 7.88 5.63 4 5.41 5.14 5.05 0.44 7.11 3.75 2.84 1.06 2.58 3.97 3.94 1.59 1.23 
516 SMAC-mediated_dissociation_of_IAP:caspase_complexes_ 4.15 0.96 8.22 2.58 8.73 8.76 3.96 7.06 1.05 7.95 3.87 1.43 1.41 1.39 3.88 8.39 2.77 3.72 
517 Stimulation_of_the_cell_death_response_by_PAK-2p34 7.52 3.96 6.82 7.71 5.85 5.29 5.84 4.47 8.68 9.39 9.99 6.15 5.22 2.42 7.12 7.07 6.31 8.48 
518 TNF_signaling 4.54 9.71 4.9 2.09 4.58 9.25 7.27 8.68 9.64 5.55 9.05 2.89 2.07 3.55 3.96 3.23 3.41 0.49 
519 TRAIL__signaling 6.34 7.84 4.26 7.86 6.11 8.22 8.69 2.58 4.11 8 8.04 9.85 5.03 3.62 6.08 9.22 0.4 4.01 
520 ADP_signalling_through_P2Y_purinoceptor_1 9.37 0.12 3.47 9.19 0.91 1.48 1.6 4.05 4.25 0.9 3.3 2.81 8.88 7.95 6.38 4.11 9.84 6.47 
521 ADP_signalling_through_P2Y_purinoceptor_12 6.55 3.71 5.02 1 7.61 7.17 9.65 5.39 5.01 4.23 8.15 4.09 0.53 0.02 4.31 5.85 0.89 8.07 
522 Adrenaline_signalling_through_Alpha-2_adrenergic_receptor 9.44 5.35 2.64 8.12 6.27 9.84 7.55 0.95 8.85 4.49 2.38 7.55 4.15 7.41 0.56 6.09 0.19 8.27 
523 Arachidonate_production_from_DAG 8.62 2.48 7.79 3.43 7.31 7.51 2.51 0.96 4.98 9.79 1.38 3.06 9.91 3.01 4.13 7.81 4.51 4.69 
524 Basigin_interactions 2.86 2.77 1.42 5.41 3.55 4.35 6.58 7.99 9.61 3.8 3.74 5.84 5.38 1.13 6.56 5.93 3.73 6.71 
525 Basigin_interactions 0.31 2.52 2.53 3.99 6.23 1 0.36 6 3.66 1.92 5.46 1.64 3.03 2.81 9.52 8.09 9.33 7.22 
526 PECAM1_interactions 4.82 0.89 2.42 7.04 8.69 9.4 1.36 0.65 8.05 6.12 6.72 8.26 9.55 6.25 2.1 1.56 3.88 6.46 
527 Tie2_Signaling 8.68 6.14 4.13 7.96 7.26 0.65 0.85 1.81 8.29 2.56 1.88 7.16 8.38 9.98 9.15 4.99 2.22 7.33 
528 Common_Pathway 4.68 6.29 1.43 9.16 0.28 6.61 7.9 4.24 7.41 4.47 3.47 7.19 0.81 3.82 4.89 1.05 4.03 7.49 
529 Disinhibition_of_SNARE_formation 3.9 9.91 1.68 5.45 3.17 3.45 1.67 2.7 5.38 9.86 9.25 2.02 1.82 0.95 6.28 2.55 3.96 7.2 
530 Dissolution_of_Fibrin_Clot 3.41 8.13 5.46 2.78 0.27 9.03 7.24 6.86 9.86 3.65 3.97 8.68 6.16 2.18 3.44 6.04 1.63 8.79 
531 Arachidonate_production_from_DAG 0.15 3.72 8.43 8.07 2.17 3.26 0.17 1.8 0.57 8.69 5.36 4.58 7 6.22 2.74 8.35 8.28 9.14 
532 Elevation_of_cytosolic_Ca2+_levels 9.58 8.99 4.27 5.92 9.21 3.4 0.89 5.36 0.43 4.93 1.46 0.21 8.28 0.94 2.18 8.02 9.43 4.96 
533 Extrinsic_Pathway 0.27 2.17 0.85 4.03 6.72 7.76 6.85 7.11 0.66 2.54 3.54 9.42 6.43 5 1.5 8.66 2.09 5.34 
534 Kinesins 3.98 5 1.82 9.16 6.85 6.93 2.53 9.24 6.21 2.48 1.11 2.75 0.43 1.03 6.23 1.16 7.23 2.85 
535 Common_Pathway 2.03 7.12 1.17 0.84 4.69 8.07 9.66 1.04 5.84 3.81 0.65 3.72 6.3 5.6 0.87 7.15 9.45 9.93 
536 Extrinsic_Pathway 6.21 8.42 4.65 2.49 1.58 1.48 7.66 0.7 4.96 6.93 7.03 9.67 6.83 4.6 7.14 4.44 4.15 7.14 
537 Intrinsic_Pathway 9.24 9.61 7.25 2 6.67 7.72 2.49 8.17 2.18 8.13 3.58 3.79 4.69 0.86 4.75 7.24 2.46 1.87 
538 GP1b-IX-V_activation_signalling 5.17 2.82 0.71 3.4 5.01 2.35 6.25 2.73 9.47 0.06 3.88 9.17 2.43 3.38 1.84 9.57 6.39 0.94 
539 GPVI-mediated_activation_cascade 2.6 5.31 2.53 6.65 2.37 3.9 9.71 0.27 4.97 4.6 1.84 4.91 0.99 4.91 9.4 8.9 1.06 4.13 
540 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 4.98 2.23 7.9 5.62 1.25 2.21 9.95 9.46 5.78 7.54 2.01 5.23 4.13 0.98 5.46 6.87 4.78 2.12 
541 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 9.18 4.82 6.84 7.14 3.56 0.19 4.58 1.27 7.3 4.01 8.26 8.92 7.66 0.24 5.44 7.55 1.02 6.19 
542 p130Cas_linkage_to_MAPK_signaling_for_integrins 2.88 3.84 4.21 7.56 6.35 6.68 1.99 4.1 2.13 5.08 1.35 9.15 5.62 3.54 3.02 2.34 1.15 4.1 
543 Intrinsic_Pathway 2.63 0.74 0.92 9.84 8.81 9.48 0.4 4.24 3.01 7.81 7.02 2.93 8.96 0.2 9.01 4.55 9.79 9.78 
544 Kinesins 0.14 0.07 6.73 6.99 0.66 0.68 9.85 5.24 7.64 5.87 6.29 1.18 1.11 6.02 3.22 0.42 1.87 9.42 
545 cGMP_effects 4.97 1.88 3.72 8.38 6.13 9.33 3.48 8.31 5.5 5.96 6.59 6.09 0.29 1.17 3.24 9.06 3.21 1.89 
546 PECAM1_interactions 2.25 7.38 4.09 4.69 8.81 2.39 1.07 6.29 9.13 1.54 6.85 0.5 3.93 2.49 7.94 2.02 0.08 9.34 
547 Platelet_Adhesion_to_exposed_collagen 7.27 6.72 7.07 4.96 9.42 9.72 6.5 0.08 8.19 6.21 4.83 7.27 5.73 7.05 6.44 1.58 3.75 6.44 
548 Adrenaline_signalling_through_Alpha-2_adrenergic_receptor 4.91 9.34 7.52 9.83 2.24 9.86 4.63 3.31 9.01 7.53 9.55 3.26 5.96 7.28 2.51 0.61 0.1 4.8 
549 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 1.53 0.27 8.91 4.91 2.52 8.09 7.26 2.69 1.34 8.63 1.3 7.21 6.67 0.49 0.17 6.65 0.11 7.25 
550 p130Cas_linkage_to_MAPK_signaling_for_integrins 9.08 1.62 0.5 5.24 2.15 5.99 6.7 4.55 7.11 2.21 6.8 0.37 5.69 8.07 5.35 6.66 0.92 8.82 
551 ADP_signalling_through_P2Y_purinoceptor_1 0.49 1.06 5.94 3.24 4.44 0.7 2.59 0.33 9.56 0.93 8.91 0.22 6.05 8.87 7.57 4.98 0.28 4.46 
552 ADP_signalling_through_P2Y_purinoceptor_12 9.2 2.97 1.29 9.74 0.89 8.59 8.64 4.79 4.72 8.69 4.08 8.17 6.63 2.22 8.18 1.83 1.77 8.2 
553 Adrenaline_signalling_through_Alpha-2_adrenergic_receptor 6.78 4.54 4.64 8.47 8.03 8.24 6.26 6.63 9.91 2.92 4.92 9.54 0.3 2.49 3.75 4.25 4.93 2.91 
554 Arachidonate_production_from_DAG 1.62 7.71 5.37 1.4 8.88 3.54 3.63 9.67 6.36 4.61 5.19 5.13 1.06 2.85 7.5 7.04 6.4 9.72 
555 Disinhibition_of_SNARE_formation 3.53 4.65 0.45 3.06 1.26 5.57 2.96 5.46 8.8 7.96 4.84 6.93 1.94 6.05 0.59 8.38 5.56 1.79 
556 GP1b-IX-V_activation_signalling 2.96 7.82 7.29 5.56 0.42 8.4 5.36 2.79 0.94 5.43 3.06 5.32 3.79 5.9 6.35 8.81 5.16 5.77 
557 GPVI-mediated_activation_cascade 1.73 0.17 9.78 2.03 6.81 8.23 2.32 5.75 6.32 1.4 5.31 3.86 3.61 3.97 9.53 8.09 0.35 1.21 
558 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 5.37 7.43 5.33 3.06 3.96 7.86 0.35 6.73 4.34 4.07 8.04 8.07 9.52 6.26 3.31 5.69 8.08 5.31 
559 Platelet_degranulation_ 7.31 7.07 1.46 6.78 9.42 1.45 3.3 9.61 0.47 7.7 4.26 3.87 6.14 6.86 7.05 5.39 3.65 5.21 
560 Thrombin_signalling_through_proteinase_activated_receptors_(PARs) 0.44 5.02 0.57 1.2 7.16 0.38 1.31 3.88 3.44 4.39 5.35 9.01 9.88 8.91 1.4 2.32 8.34 4.41 
561 Thromboxane_signalling_through_TP_receptor 7.65 3.56 8.33 7.86 5.28 6.09 3.63 3 0.05 5.3 1.31 8.1 7.05 7.97 9.18 3.16 9.96 8.89 
562 p130Cas_linkage_to_MAPK_signaling_for_integrins 8.33 6.18 7.03 7.11 4.6 1.35 6.9 4.2 6.46 8.6 4.45 5.9 1.45 3.7 0.13 8.36 1.1 0.68 
563 Elevation_of_cytosolic_Ca2+_levels 9.06 7.07 9.56 7.01 4.79 4.94 2.54 1.26 1.13 6.46 4.43 9.14 5.15 7.87 0.9 1.97 5.69 4.33 
564 Reduction_of_cytosolic_Ca++_levels 1.48 1.3 2.04 8.62 8.36 4.6 2.3 6.11 3.09 5.68 0.3 1.38 9.32 0.01 1.02 1.91 4.06 8.04 
565 Platelet_degranulation_ 5.79 6.73 2.1 9.65 0.37 2.19 8.18 0.49 7.12 6.46 7.18 0.38 2.89 6.9 0.33 6.72 9.89 4.53 
566 Elevation_of_cytosolic_Ca2+_levels 5.44 1.65 5.03 7.7 5.69 7.39 9.68 8.37 2.24 4.56 3.88 3.66 2.96 6.58 5.86 4.2 8.32 0.25 
567 Platelet_sensitization_by_LDL 2.76 3.09 0.91 8.42 7.21 7.87 1.09 3.89 3.83 7.21 5.87 3.77 9.24 4.38 9.14 6.62 8.55 1.77 
568 Prostacyclin_signalling_through_prostacyclin_receptor 7.06 4.19 6.43 3.02 6.12 5.21 6.92 4.07 2.18 1.44 7.48 4.15 8.79 5.21 4.48 6.51 0.87 4.75 
569 Reduction_of_cytosolic_Ca++_levels 8.79 8.58 5.83 9.46 1.87 4.07 2.88 9.25 3.95 8.6 3.2 3.9 7.67 6.56 3.54 6.72 4.46 1.56 
570 cGMP_effects 8.79 5 2.93 2.03 3.09 5.08 5.85 2.89 2.71 5.8 1.27 5.5 9.41 5.02 7.93 9.94 1.57 6.21 
571 Platelet_sensitization_by_LDL 1.56 8.03 4.66 8.28 2.88 0.12 7.64 9.35 0.72 8.33 9.2 0.02 2.02 0.48 5.06 9.13 3.61 2.1 
572 Prostacyclin_signalling_through_prostacyclin_receptor 7.84 0.64 5.85 7.71 3.92 0.12 9.38 7.89 1.01 7.69 8.09 5.88 7.74 7.74 8.67 8.38 4.56 1.98 
573 Reduction_of_cytosolic_Ca++_levels 2.28 7.53 7.09 8.64 7.2 8.09 1.25 9.05 0.07 4.18 9 7.28 8.78 8.27 4.03 9.55 7.39 5.4 
574 Disinhibition_of_SNARE_formation 0.19 6.8 3.93 2.57 7.92 7.26 2.37 3.59 5.39 9.81 5.52 3.83 4.42 9.79 8.07 8.89 7.8 2.65 
575 Platelet_degranulation_ 7.83 7.94 4.63 0.13 9.25 9.61 3.97 3.61 4.85 0.95 0.07 1.56 5.44 6.05 6.24 0.56 8.92 2.5 
576 ADP_signalling_through_P2Y_purinoceptor_1 0.85 4.2 4.31 5.16 7.86 0.34 4.91 6.47 6.17 9.47 8.89 0.92 2.96 8.34 2.23 1.72 0.48 0.23 
577 ADP_signalling_through_P2Y_purinoceptor_12 2.91 1.66 2.61 9.81 9.41 4.61 4.43 2.45 6.96 2.29 3.73 9 6.5 7.03 8.28 7.31 9.41 5.23 
578 Thromboxane_signalling_through_TP_receptor 9.42 7.1 3.88 0.13 7.88 4.79 0.73 2.2 7.37 5.55 8.14 4.31 0 9.97 4.11 0.08 9.17 2.02 
579 Thrombin_signalling_through_proteinase_activated_receptors_(PARs) 1.28 2.45 6.39 6.29 6.99 9.33 5.96 8.84 0.76 7.29 4.13 6.03 5.91 4.03 9.64 6.95 2.98 0.42 
580 Thromboxane_signalling_through_TP_receptor 5.4 2.45 4.64 2.22 8.15 8.6 9.89 7.7 7.49 2.97 0.91 0.24 2.52 3.21 7.4 7.13 8.35 3.16 
581 Tie2_Signaling 4.89 7.96 5.48 6.64 8.58 5.43 0.81 5.8 4.07 4.36 6.7 6.62 8.63 1.66 4.63 0.55 5.98 7.72 
582 cGMP_effects 3.31 8.61 3 4.93 0.41 6.49 6.44 2.37 0.82 6.19 6.67 4.63 8.16 6.1 0.42 6.19 4.13 8.8 
583 p130Cas_linkage_to_MAPK_signaling_for_integrins 1.08 3.06 8.47 8.06 4.52 6.96 5.71 5 3.77 4.56 5.35 0.11 5.87 1.02 0.84 4.23 8.83 3.13 
584 Permeabilization_of_mitochondria 9.32 0.79 5.82 0 6.16 3.58 8.43 8.07 9.09 4.15 7.65 5.3 0.72 3.17 0.58 2.81 2.72 2.57 
585 ATP_sensitive_Potassium_channels 7.57 7.4 1.07 3.11 2.57 3.93 9.71 5.87 7.43 4.68 8.02 0.88 2.98 5.82 2.52 9.77 4.57 3.85 
586 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 2.93 7.16 6.28 3.94 2.91 7.71 1.07 9.12 3.32 5.09 2.92 6.77 2.27 2.05 0.91 6.91 1.83 8.81 
587 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 2.7 6.32 6.04 3.18 1.14 6.13 3.74 8.49 1.52 8.27 9.15 3.37 7.88 2.55 1.77 8.51 9.68 5.84 
588 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 3.77 2.46 0.2 4.06 1.62 7.45 7.45 3.41 4.32 0.58 4.94 1.54 0.94 5.13 5.38 3.98 5.05 3.39 
589 Acetylcholine_Neurotransmitter_Release_Cycle 2.51 0.73 8.47 2.19 4.79 2.17 1.45 4.46 6 4.98 7.97 1.41 9.25 8.4 1.99 0.09 6.56 4.43 
590 Activation_of_AMPA_receptors 9.92 6.9 4.74 4.58 0.79 2.88 9.73 3 0.64 6.54 0.67 9.3 8.26 8.52 6.75 1.77 7.34 6.2 
591 Activation_of_Ca-permeable_Kainate_Receptor 8.93 0.23 9.4 9.59 1.18 0.28 3.76 9.45 4.53 0.35 5.65 8.26 6.7 7.12 8.8 5.26 9.59 4.6 
592 Activation_of_CaMK_IV 9.77 2 2.74 7.83 7.81 5.06 9.87 5.01 5.68 1.92 7.14 7.41 7.05 6.94 1.3 2.3 6.14 5.98 
593 Activation_of_G_protein_gated_Potassium_channels 1.39 5.46 7.62 7.67 8.54 4.48 8.28 5.3 2.24 6.92 1.14 8.87 9.6 1.14 2.45 4.64 6.43 8.19 
594 Adenylate_cyclase_inhibitory_pathway 3.26 9.48 5.44 8.63 9.7 4.55 3.6 9.08 8.98 0.63 5.84 9.25 5.58 9.14 1.3 4.79 8.03 3.99 
595 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 7.85 0 6.51 5.54 9.8 8.88 9.08 8.52 6.6 8.29 2.43 2.82 0.65 8.81 4.74 3.8 5.7 6.39 
596 Activation_of_Ca-permeable_Kainate_Receptor 3.52 6.41 6.44 7.75 0.72 0.33 6.94 1.41 7.09 5.95 8.26 3.45 2.04 7.77 7.89 2.5 7.78 1.6 
597 Activation_of_Na-permeable_Kainate_Receptors 5.71 0.6 1.04 7.16 5.97 1.88 7.16 7.56 0.28 9.29 9.3 3.46 7.87 0.94 1.14 2.78 5.68 5.33 
598 Presynaptic_function_of_Kainate_receptors 2.2 8.91 3.23 2.46 7.78 0.89 6.98 6.16 9 3.57 5.32 7.03 9.62 9.82 5.96 7.59 5.41 7.61 
599 Activation_of_CaMK_IV 4.25 1.84 4.15 7.52 5.24 0.18 0.93 3.74 5.69 8.99 8.97 7.98 6.34 3.27 7.25 3.72 6.88 5.51 
600 CREB_phosphorylation_through_the_activation_of_Adenylate_Cyclase 5.57 9.8 4.91 8.61 9.88 7.39 2.6 1.99 5.7 4.11 2.33 0.26 4.52 9.46 9.21 6.8 6.36 0.36 
601 CREB_phosphorylation_through_the_activation_of_CaMKII 7.45 9.25 5.23 9.76 3.42 5.99 7.24 9.29 8.51 6.28 6.67 1.98 3.57 2.41 1.5 4.52 1.49 6 
602 RSK_activation 4.91 8.11 4.14 7.53 2.1 7.42 5.53 2.28 7.64 2.15 2.13 9.49 5.24 4.42 1.54 2.17 9.4 1.12 
603 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 1.84 4.49 6.28 4.63 9.63 3.97 2.87 0 7.86 4.43 4.38 2.18 1.2 9.12 8.97 6.05 9.46 7.89 
604 Unblocking_of_NMDA_receptor,_glutamate_binding_and_activation 5.7 3.37 4.35 9.9 7.97 1.92 3.17 9.03 2.3 8.65 9.52 7.19 2.97 6.54 5.28 2.74 1.83 5.61 
605 Activation_of_Na-permeable_Kainate_Receptors 9.13 1.54 8.24 6.98 5.5 3.9 1.48 3.56 1.24 9.01 3.18 9.05 7.68 1.4 1.87 1.55 7.28 6.55 
606 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 3.35 4.85 6 6.29 7.54 8.01 0.75 8.15 9.37 5.31 4.61 6.1 0.47 9.81 4.55 6.74 8.38 5.88 
607 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 8.11 7.21 0.16 3.15 3.12 6.97 3.31 9.43 6.08 9.74 0.69 4.52 0.16 6.64 8.59 6.86 5.51 0.87 
608 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 8.72 3.45 9.63 3.76 9.01 8.13 8.89 6.32 1.88 0.12 5.39 9.9 6.57 7.18 6.15 7.17 8.59 0.72 
609 Adenylate_cyclase_inhibitory_pathway 6.45 4.49 6.71 1.68 0.81 1.71 6.06 8.52 3.86 9.44 2.4 5.31 7.78 8.79 6.73 6.59 7.92 2.98 
610 Astrocytic_Glutamate-Glutamine_Uptake_And_Metabolism 3.87 0.21 6.02 6.2 1.16 8.47 6.22 9.25 0.02 1.2 8.99 8.34 8.04 9.69 2.83 5.68 5.38 4.74 
611 CREB_phosphorylation_through_the_activation_of_Adenylate_Cyclase 1.56 0.17 2 5.79 4.32 4.48 0.47 0.44 0.09 5.46 5.56 2.7 2.41 0.39 2.93 1.96 5.13 0.31 
612 CREB_phosphorylation_through_the_activation_of_CaMKII 1.21 9.72 8.96 3.28 2.88 7.39 4.15 3.99 7.55 1.84 6.58 4.84 5.25 9.75 6.89 3.71 7.94 3.85 
613 Activation_of_CaMK_IV 9.44 9.2 7.75 1.61 3.24 9.71 4.66 2.35 9.59 5.4 4.43 0.56 6.54 4.97 3.39 7.09 0.57 3.02 
614 RSK_activation 3.23 0.37 3.38 9.16 6.97 4.91 4.02 1.89 6.87 9.97 1.2 5.67 9.49 9.26 5.23 5.91 8.48 0.35 
615 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 6.91 7.44 6.58 5.12 0.98 7.72 3.55 7.71 4.09 7.53 4.48 7.45 3.04 5.12 9.16 8.55 1.98 7.62 
616 Ca2+_activated_K+_channels 1.57 1.96 4.18 1.64 7.04 3.18 5.45 8.13 6.95 1.54 4.33 2.54 6.18 8 4.29 5.61 9.32 3.58 
617 Classical_Kir_channels 5.46 2.6 9.43 7.23 8.17 7.12 9.06 8.31 0.39 1.09 7.3 0.9 3.37 7.21 9.75 2.74 1.16 6.81 
618 Enzymatic_degradation_of_Dopamine_by_monoamine_oxidase 2.57 4.65 6.43 9.59 4.5 6.21 9.78 9.56 1.34 2.74 7.47 2.95 4 8.61 4.63 2.55 8.14 0.5 
619 Enzymatic_degradation_of_dopamine_by_COMT 9.68 9.26 0.17 7.85 9.32 2.7 8.94 0.12 2.92 9.84 5.36 4.61 1.02 4.99 4.17 1.09 7.52 4.9 
620 Metabolism_of_serotonin 6.38 9.44 9.66 7.7 6.03 2.55 4.37 9.22 4.87 4.77 2.09 5.63 2.73 0.31 3.72 5.86 0.91 5.58 
621 Degradation_of_GABA 3.92 9.63 4.62 1.83 4.15 8.48 5.35 3.97 0.25 7.07 1.84 4.44 0.22 0.73 9.94 8.73 4.04 5.59 
622 Depolarization_of_the_Presynaptic_Terminal_Triggers_the_Opening_of_Calcium_Channels 9.29 9.93 9.47 3.61 9.28 9.59 4.15 0.16 0.15 4.66 6.62 2.92 0.58 3.98 3.31 1.79 1.88 0.73 
623 Dopamine_Neurotransmitter_Release_Cycle 9.46 0.89 9.8 4.81 5 8.8 4.87 3.41 2.61 2.41 7.98 6.89 5.73 9.08 4.09 9.5 3.08 9.41 
624 Electric_Transmission_Across_Gap_Junctions 4.67 4.25 4.5 7.04 7.36 0.67 0.54 2.85 0.85 9.21 6.28 9.35 2.15 6.04 2.44 0.5 6.55 0.19 
625 Enzymatic_degradation_of_Dopamine_by_monoamine_oxidase 8.81 6.19 9.48 6.56 6.31 9.41 1.78 2.73 4.89 4.97 3.38 5.76 6.74 3.25 4.65 8.29 6.5 7.36 
626 Enzymatic_degradation_of_dopamine_by_COMT 9.89 2.98 8.83 7.49 4.21 0.39 4.37 7.34 3.84 2.15 0.22 7.87 1.93 8.42 0.22 3.16 1.22 9.25 
627 Activation_of_G_protein_gated_Potassium_channels 1.79 2.91 2.71 8.71 9.04 4.93 1 4.62 0.83 8.9 2.89 4.17 3.91 0.18 0.2 3.03 3.75 6.67 
628 GABA_A_(rho)_receptor_activation 3.92 0.32 1.08 6.41 9.98 2.58 1.13 6.93 0.01 6.87 5.16 6.18 7.18 6.68 5.36 7.47 5.23 7.97 
629 GABA_A_receptor_activation 0.73 5.52 6.15 2.56 9.28 1.15 6.19 3.43 2.48 7.1 5.44 2.1 1.04 0.4 3.37 0.12 0.34 7.44 
630 Adenylate_cyclase_inhibitory_pathway 2.17 0.68 2.35 1.04 0.32 8.16 6.91 1.97 1.46 8.53 2.23 4.78 2.33 9.62 9.9 4.28 1.24 9.81 
631 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 4.89 4.25 9.84 2.86 5.35 9.96 6.62 3.63 5.35 6.67 4.37 1.55 5.75 1.54 9.7 6.63 4.6 7.63 
632 Adenylate_cyclase_inhibitory_pathway 3.16 0.94 1.47 5.18 5.09 6.64 1.12 5.24 9.34 8.06 3.81 5.9 6.34 4.15 8.62 5.8 9.19 5.26 
633 GABA_A_(rho)_receptor_activation 3.7 8.5 9.44 0.18 7.16 0.61 4.22 0.06 8.26 7.03 0.39 8.1 2.14 7.51 4.32 9.85 6.84 3.01 
634 GABA_A_receptor_activation 5.35 5.02 9.63 5.64 0.12 4.4 7.11 5.37 7.78 7.81 3.34 0.51 0.4 7.1 5.38 5.07 3.49 9.51 
635 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 3.5 6.06 7.95 1.71 6.21 0.88 6.75 7.25 8.07 6.28 2.65 7.86 3.73 2.89 1.85 9.81 6.55 6.87 
636 GABA_synthesis 3.94 5.06 7.16 0.91 6.51 2.87 2.42 1.82 9.71 5.52 0.95 2.21 3.01 3.87 7.27 3.25 1.4 0.91 
637 Degradation_of_GABA 8.3 9.57 0.51 3.04 6.72 5.21 0.17 8.55 0.23 2.51 5.78 3.98 8.86 3.88 3.21 0.11 1 0.28 
638 GABA_synthesis 5.09 8.22 5.78 9.59 9.53 0.59 3.68 0.41 6.17 4.6 2.53 6.5 5.86 8.07 5.26 7.49 2.73 9.64 
639 Reuptake_of_GABA 8.25 2.7 8.95 9.22 9.46 7.46 5.31 5.7 3.1 2.68 8.08 2.59 0.7 4.53 3.04 2.56 4.54 0.03 
640 Activation_of_AMPA_receptors 0.01 1.43 1.19 7.34 3.44 8.28 9.93 1.91 3.4 9.57 5.17 4.65 3.72 0.31 7.06 5.88 9.55 5.45 
641 Trafficking_of_GluR2-containing_AMPA_receptors 6.54 8.23 0.18 6.87 0.96 4.07 9.51 9.22 8.04 1.9 3.81 9.1 7.98 1.17 4.44 0.12 9.14 1.64 
642 Glutamate_Neurotransmitter_Release_Cycle 1.54 5.93 0.59 6.57 3.86 4.79 1.15 0.56 5.4 2.82 3.39 8.27 5.66 5.82 9.31 0.9 7.13 2.31 
643 HCN_channels 6.04 6.84 1.58 5.04 7.48 1.58 0.83 5.52 4.98 5.07 1.53 4.74 5.22 6.85 1.84 5.41 7.55 9.39 
644 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 2.53 6.76 9.03 8.03 4.34 7.82 3.31 7.46 8.7 2.55 0.64 4.1 6.8 3.6 7.78 2.27 3.82 1.1 
645 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 0.87 2.3 8.42 7.03 9.53 7.17 3.12 1.7 2.15 6.71 7.29 2.06 2.01 7.94 0.84 9.15 6.67 0.1 
646 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 6.37 9.69 4.84 2.82 3.26 1.58 3.11 9.04 4.45 4.52 6.81 7.33 3.5 1.38 9.72 8.37 8.59 5.61 
647 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 7.56 0.04 6.49 5.7 2.33 7.54 5.49 8.06 4.04 9.29 4.95 1.66 9.25 4.68 1.25 8.04 6.44 7.06 
648 Adenylate_cyclase_inhibitory_pathway 6.99 6.42 1.98 2.51 2.34 5.62 0.34 8.42 4.07 5.89 5.97 4.36 1.89 5.44 8.51 2.64 9.73 9.79 
649 ATP_sensitive_Potassium_channels 8.55 1.27 7.97 5.4 7.25 1.5 4.86 9.96 0.06 7.61 3.39 9.28 3.15 2.35 0.71 9.63 4.54 3.88 
650 Activation_of_G_protein_gated_Potassium_channels 4.3 2.66 6.05 0.65 9.03 8.32 5.84 7.38 8.88 2.82 5.34 4.96 8.67 3.02 3.31 4.7 3.2 2.88 
651 Classical_Kir_channels 4.12 4.41 5.3 0.37 9.02 0.35 8.78 4.28 3.55 4.92 2.97 6.73 0.78 2.74 8.1 8.19 5.86 0.91 
652 Potassium_transport_channels 5.04 5.29 5.98 2.48 6.37 8.57 4.52 6.45 9.95 2.73 8.75 0.22 8.94 6.82 8.33 6.6 2.5 9.85 
653 Activation_of_Ca-permeable_Kainate_Receptor 6.44 3.83 8.06 9.11 5.07 2.06 0.82 6.92 8.08 8.94 3.81 1.59 7.53 4.8 4.18 7.13 2.71 4.94 
654 Activation_of_Na-permeable_Kainate_Receptors 0.43 5.64 6.79 2.94 7.98 6.94 7.44 5.11 2.23 0.34 9.39 6.04 9.75 4.4 2.34 2.32 8.12 1.31 
655 Metabolism_of_serotonin 0.98 2.81 3.69 4.68 8.82 7.19 0.79 9.73 7.69 1.98 4.67 4.81 7.39 4.91 7.14 6.82 3.33 9 
656 Enzymatic_degradation_of_Dopamine_by_monoamine_oxidase 7.95 4.99 3.93 2.27 9.4 6.4 5.72 4.11 4.16 7.62 9.42 4.91 5.83 5.91 3.45 0.28 4.86 3.53 
657 Enzymatic_degradation_of_dopamine_by_COMT 7.42 0.86 4.64 9.33 6.52 6.24 1.81 7.6 8.74 3.51 3.47 1.73 9.59 8.62 8.18 1.54 5.52 9.43 
658 Metabolism_of_serotonin 6.04 4.76 6.9 1.61 2.93 4.47 0.09 6.35 8.95 4.75 3.52 4 0.01 7.63 6.34 7.47 8.65 0.88 
659 Activation_of_AMPA_receptors 3.04 0.04 2.4 0.77 0.51 6.03 6.37 2.12 6.85 6.85 7.08 2.58 9.15 4.62 4.72 5.02 3.74 8.06 
660 Activation_of_Ca-permeable_Kainate_Receptor 4.06 8.23 6.43 3.9 0.61 4.87 2.71 9.88 3.31 4.1 4.7 5.49 4.65 7.72 2.14 2.99 3.3 7.94 
661 Activation_of_CaMK_IV 6.16 1.75 9.04 9.59 5.27 2.81 9.2 9.38 6.83 9.1 7.27 1.26 8.24 2.4 3.32 5.15 8.59 7.4 
662 Activation_of_Na-permeable_Kainate_Receptors 4.79 7.07 4.45 0.25 6.67 9.11 7.4 5.97 1.45 7.7 5.26 2.68 9.17 8.7 4.15 6.43 7 0.22 
663 Adenylate_cyclase_inhibitory_pathway 8.52 5.05 1.5 2.28 5.6 3.67 9.45 7.4 8.24 4.66 2.62 0.49 1.07 4.63 0.16 7.35 8.04 9.18 
664 CREB_phosphorylation_through_the_activation_of_Adenylate_Cyclase 5.13 4.08 5.94 0.18 2.47 5.46 7.35 1.52 8.48 5.61 5.68 2.13 9.7 6.89 1.49 7.81 7.11 4.55 
665 CREB_phosphorylation_through_the_activation_of_CaMKII 2.18 7.06 9.34 4.17 5.81 1.22 0.92 7.14 8.73 1.24 9.97 3.87 3.94 9.48 6.86 4.14 9.94 4.29 
666 GABA_A_(rho)_receptor_activation 7.41 7.81 9.23 0.62 4.44 2.59 6.29 0.48 3.53 7.68 2.58 2.47 9.21 7.79 6.01 1.27 1.27 2.11 
667 GABA_A_receptor_activation 3.52 7.93 6.39 9.35 0.78 0.13 1.44 1.59 6.16 8.02 3.13 5.06 0.98 7.73 8.27 9.05 8.24 7.51 
668 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 8.72 6.52 1.89 8.66 4.18 9.79 4.43 6.76 1.83 9.6 8.52 7.81 9.55 3.96 0.5 9.34 4.22 1.98 
669 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 4.5 7.46 3.36 9.95 5.26 3.46 2.98 6.26 5.7 2.51 8.63 2.64 2.95 3.78 3.8 0.28 8.07 8.76 
670 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 6.59 0.27 0.16 7.19 2.06 5.9 1.57 1.49 4.74 1.54 2.41 6.42 5.77 3.61 9.17 1.95 6.85 3.59 
671 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 7.63 5.45 8.58 0.16 8.12 5.51 3.71 9.52 5.44 7.44 6.88 2.75 3.16 8.45 2.71 0.62 9.45 4.3 
672 Presynaptic_function_of_Kainate_receptors 4.8 0.93 8.98 4.3 6.69 9.59 7.73 4.2 7.85 5.75 6.78 7.19 6.96 6.28 0.89 7.77 0.56 2.83 
673 RSK_activation 7.27 4.56 5.67 9.79 8.98 0.57 6.69 3.45 7.48 5.65 0.67 2.21 7.81 0.41 8.04 4.93 7.32 3.85 
674 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 9.87 1.93 6.88 1.81 5.01 5.91 3.67 0.06 5.68 3.92 1.5 3.62 1.96 0.98 7.22 9.34 1.29 8.71 
675 Trafficking_of_GluR2-containing_AMPA_receptors 8.07 1.64 6.66 7.9 6.39 3.18 8.65 3.21 2.69 8.89 0.58 8.79 2.82 0.29 8.04 6.9 6.08 4.76 
676 Unblocking_of_NMDA_receptor,_glutamate_binding_and_activation 7.97 7.63 1.9 0.01 4.29 2.29 9.47 1.87 4.31 5.03 4.06 0.5 5.95 0.7 0.69 3.22 6.39 9.95 
677 Acetylcholine_Neurotransmitter_Release_Cycle 5.64 1.74 6.4 1.6 6.65 4.86 6.67 7.05 2.14 9.39 8.88 2.65 2.78 4.98 2.18 5.06 7.88 9.04 
678 Degradation_of_GABA 3.36 1.61 6 6.21 2.24 8.33 6.59 3.56 7.32 9.99 6.05 1.94 3.25 1.74 5.33 9.97 9.92 7.56 
679 Dopamine_Neurotransmitter_Release_Cycle 1.85 7.51 8.3 7.24 8.54 1.79 4.72 7.18 7.94 8.47 9.23 8.36 0.72 9.38 5.04 6.62 5.81 3.68 
680 GABA_synthesis 2.79 0.24 8.65 4.27 2.37 5.3 9.91 5.49 2.35 3.76 0.56 1.4 2.9 0.36 8.6 4.77 8.27 0.57 
681 Glutamate_Neurotransmitter_Release_Cycle 1.07 8.36 9.48 7.61 9.08 7.62 8.48 6.01 6.92 8.88 6.13 4.18 2.49 3.07 4.52 6.12 3.75 6.32 
682 Norepinephrine_Neurotransmitter_Release_Cycle 7.33 5.19 6.19 0.98 2.66 2.5 9.18 5.14 7.56 2.15 8.44 8.63 2.51 8.86 5.41 0.22 4.02 0.9 
683 Reuptake_of_GABA 9.56 6.59 7.77 4.81 4.94 2.57 2.72 8.71 3.17 4.94 3.04 1.97 0.46 3.63 2.36 2.7 5.36 4.26 
684 Serotonin_Neurotransmitter_Release_Cycle 5.52 2.75 1.03 2.88 8.49 6.55 9.43 7.5 2.37 9.97 5.32 6.43 0.84 3.85 1.61 8.28 7.35 7.56 
685 Astrocytic_Glutamate-Glutamine_Uptake_And_Metabolism 9.04 1.1 4.8 6.04 1.54 3.22 7.78 7.47 7.03 4.99 2.27 5.35 3.76 2.93 7.75 7.62 6.34 8.86 
686 Norepinephrine_Neurotransmitter_Release_Cycle 4.14 6.99 0.14 9.21 4.65 0.05 6.56 8.56 7.05 2.38 1 1.94 8.25 0.02 0.08 5.34 9.33 9.53 
687 Activation_of_CaMK_IV 9.42 3.59 5.95 5.26 2.08 4.8 8.8 2.82 6.57 3.3 9.98 6.25 7.37 2.91 7.65 4.43 3.37 4.97 
688 CREB_phosphorylation_through_the_activation_of_Adenylate_Cyclase 9.28 3.57 7.6 6.16 3.69 7.61 4.69 8.64 0 4.67 9.34 1.06 7.92 7.02 9.85 1.16 2.5 1.67 
689 CREB_phosphorylation_through_the_activation_of_CaMKII 6.25 0.04 5.33 6.95 0.2 5.77 9.9 0.71 9.06 9.76 6.05 3.59 3.12 7.74 6.97 1.03 6.61 3.61 
690 RSK_activation 8.77 2.1 0.84 5.8 4.5 6.24 7.8 7.3 6.07 6.19 0.13 6.74 8.55 1.32 2.92 5.56 9.14 9.42 
691 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 4.56 4.84 9.02 6.75 6.06 9.72 3.35 2.07 1.54 4.55 8.52 3.54 9.11 8.59 9.56 3.61 8.81 9.58 
692 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 4.49 6.15 1.45 7.97 8.61 3.84 8 8.25 7.62 1.82 7.43 8.82 7.5 8.72 8.47 3.68 6.62 6.15 
693 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 8.05 8 0.5 6.59 5.04 1.16 3.22 8.22 1.02 8.31 0.31 9.03 9.15 5.59 5.81 8.81 1.32 7.24 
694 ATP_sensitive_Potassium_channels 4.95 1.97 7.79 2.31 1.72 9.82 5.56 9.82 3.93 5.47 6.55 7.28 7.43 3.62 2.07 0.04 7.74 3.71 
695 Activation_of_G_protein_gated_Potassium_channels 5.86 2.79 8.09 8.19 4.9 0.93 9.16 2.74 3.64 0.47 5.08 4.63 0.46 9.5 8.47 9.38 7.34 4.31 
696 Ca2+_activated_K+_channels 8.28 9.54 5.05 1.84 6.59 4.8 2.34 6.98 9.27 7.56 7.87 6.87 1.55 9.83 7.44 5.65 1 9.53 
697 Classical_Kir_channels 6.74 9.48 8.93 3.63 2.18 2.61 3.68 2.31 4.63 7.08 9.48 9.35 1.05 4.39 0.18 4.28 4.07 7.67 
698 HCN_channels 2.93 7.04 8.22 0.54 3.13 7.01 7.22 2.09 6.1 2.79 4.42 0.09 9.84 4.32 3.83 9.57 4.02 2.75 
699 Potassium_transport_channels 4.3 4.5 4.49 1.23 4.63 7.17 5.26 5 3.8 0.72 3.43 7.94 0.45 1.07 6.62 6.26 4.75 9.81 
700 TWIK_related_potassium_channel_(TREK) 5.38 4.69 6.92 1.88 4.1 5.64 0.32 0.49 8.71 6 6.89 4.71 8.09 0.25 0 9.65 2.77 9.78 
701 TWIK-related_alkaline_pH_activated_K+_channel_(TALK) 8.61 0.26 7.02 3.94 7.02 6.25 7.14 7.42 1.73 3.01 9.02 1.73 6.75 3.03 3.24 6.29 6.49 0.29 
702 TWIK-related_spinal_cord_K+_channel_(TRESK) 0.59 5.88 4.49 7.65 1.76 5.61 0.96 4.03 9.48 9.16 0.47 1.03 6.94 6.27 6.74 6.34 2.91 3.59 
703 TWIK-releated_acid-sensitive_K+_channel_(TASK) 1.05 7.31 5.87 8.63 8.13 0.05 7.74 7.23 4.85 2.51 3.98 3.47 7.45 3.99 6.86 7.85 7.5 4.14 
704 Tandem_of_pore_domain_in_a_weak_inwardly_rectifying_K+_channels_(TWIK) 3.95 3.23 3.8 6.16 8.11 1.66 3.48 0.31 3.88 8.08 9.59 6.38 5.73 0.53 2.03 1.97 4.98 2.77 
705 Tandem_pore_domain_halothane-inhibited_K+_channel_(THIK) 7.26 3.62 9.64 8.67 0.88 4.65 5.68 3.92 6.36 7.51 4.18 1.05 6.47 3.56 5.69 6.55 5.16 3.03 
706 Voltage_gated_Potassium_channels 0.12 9.74 0.32 3.26 0.53 3.2 2.74 6.22 4.53 6.5 5 0.08 2.24 7.03 4.08 0.77 6.27 8.76 
707 Potassium_transport_channels 0.21 6.91 4.91 3.65 2.49 3.36 0.07 6.46 4.36 1.26 0.49 2.27 5.22 1.44 7.05 2.2 8.09 7.4 
708 Presynaptic_function_of_Kainate_receptors 6.99 5.63 6.11 4.25 2.98 2.4 0.86 4.83 9.25 9.99 6.27 5.73 3.04 7.76 2.44 6.15 2.94 6.96 
709 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 7.13 3.52 1.34 2.54 5.32 9.01 7.31 7.77 6.12 1.46 1.29 7.67 2.79 5.92 4.13 2.33 0.04 6.8 
710 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 4.04 6.62 7.04 6.55 5.35 7.8 5.82 3.71 2.37 2.7 7.64 5.65 9.53 1.15 6.6 0.95 7.1 9.95 
711 RSK_activation 7.05 2.64 0.56 8.71 8.11 5.01 5.25 6.97 7 4.51 0.6 1.62 4.51 8.1 2.28 4.35 6.81 6.6 
712 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 0 0.3 5.15 7.1 3.61 2.78 2.47 7.42 5.25 0.2 7.62 1.18 0.39 3.8 1.45 6.72 3.11 1.43 
713 Reuptake_of_GABA 8.07 0.35 2.2 5.37 1.42 4.52 5.82 4.78 2.25 4.96 6.89 2.97 7.7 0.41 8.79 1.01 4 6.23 
714 Serotonin_Neurotransmitter_Release_Cycle 0.05 4.72 7.07 2.89 0.73 3.41 5.87 4.61 5.86 3.69 0.93 5.24 5.6 3.59 0.95 9.85 8.46 0.32 
715 TWIK_related_potassium_channel_(TREK) 5.67 6.76 7.02 6.77 7.99 6.74 3.31 1.99 0.03 7.51 2.76 6.42 9.5 3.98 7.28 6.68 0.49 4.56 
716 TWIK-related_alkaline_pH_activated_K+_channel_(TALK) 9.73 0.68 0.46 7.23 2.78 1.37 4.45 0.93 6.44 5.85 8.37 6.9 5.87 9.08 2.85 8.42 2.17 3.19 
717 TWIK-related_spinal_cord_K+_channel_(TRESK) 6.82 0.71 9.3 0.77 3.72 1.49 0.72 3.63 8.45 6.5 9.46 4.35 5.29 6.64 4.5 0.99 4.84 5.29 
718 TWIK-releated_acid-sensitive_K+_channel_(TASK) 7.39 0.78 4.49 5.23 0.18 2.52 5.35 7.4 1.64 0.38 2.65 3.11 4.73 7.97 5.89 2.07 1.91 7.79 
719 Tandem_of_pore_domain_in_a_weak_inwardly_rectifying_K+_channels_(TWIK) 1.48 2.36 2.26 6.49 5.72 1.8 8.43 7.87 5.23 2.11 7.35 6.25 7.49 7.58 2.17 3.35 0.08 6.69 
720 Tandem_pore_domain_halothane-inhibited_K+_channel_(THIK) 9.14 3.2 5.9 7.51 1.52 5.82 5.22 0.82 1.25 8.69 5.02 0.91 2.09 9.05 7.97 1.15 2.43 8.77 
721 TWIK_related_potassium_channel_(TREK) 2.85 8.83 4.6 4.93 7.59 3.37 3.72 9.02 4.25 3.15 4.25 4.28 0.75 9.55 3.41 6.53 2.1 5.96 
722 TWIK-related_alkaline_pH_activated_K+_channel_(TALK) 5.91 8.45 2.66 1 6.05 5.92 6.07 5.23 7.77 5.03 5.97 3.71 1.69 5.57 1.74 9.12 3 6.97 
723 TWIK-related_spinal_cord_K+_channel_(TRESK) 8.52 3.85 2.17 3.22 3.68 8.96 0.02 3.98 0.26 2.87 1.54 4.11 5.7 9.39 2.18 4.17 2.87 6.45 
724 TWIK-releated_acid-sensitive_K+_channel_(TASK) 1.94 3.91 8.94 5.58 1.5 0.69 7.17 9.23 9.02 0.34 1.68 4.42 7.95 0.64 5.39 8.76 4.39 5.73 
725 Tandem_of_pore_domain_in_a_weak_inwardly_rectifying_K+_channels_(TWIK) 6.33 4.52 5.17 4.99 5.89 6.7 9.85 3.54 8.16 6.99 6.24 0.35 4.98 1.72 9.47 7.52 5.56 8.13 
726 Tandem_pore_domain_halothane-inhibited_K+_channel_(THIK) 2.08 3.15 4.45 1.01 1.14 4.85 9.31 1.38 3.06 2.4 1.4 4.34 5.17 7.11 5.5 9.59 4.64 6.68 
727 Trafficking_of_GluR2-containing_AMPA_receptors 6.12 9.87 5.46 0.74 8.98 5.89 9.37 4.2 3.95 3.14 2.32 7.65 7.52 3.91 2.95 7.06 4.2 1.74 
728 Trafficking_of_GluR2-containing_AMPA_receptors 2.51 9.17 8.62 9.92 3.52 0.19 3.99 1.62 7.08 0.88 4.13 4.18 2.69 0.57 5.27 5.96 0.94 7.63 
729 Acetylcholine_Neurotransmitter_Release_Cycle 4.33 3.44 3.74 7.38 8.98 8.06 7.3 3.49 4.52 9.57 6.84 0.8 1.72 7.52 8.43 1.69 6.35 4.83 
730 Activation_of_AMPA_receptors 9.17 9.44 1.08 7.32 5.79 1.92 5.59 6.21 0.52 8.03 4.21 4.25 4.28 1.41 0.77 7.25 3.82 9.11 
731 Activation_of_Ca-permeable_Kainate_Receptor 2.78 5.61 8.96 2.55 0.54 1.27 8.06 3.34 3.47 6.19 2.65 6.83 3.52 8.83 1.46 7.74 2.5 7.62 
732 Activation_of_CaMK_IV 7.78 8.07 7.56 8.47 3.23 7.2 7.35 3.47 6.6 3.68 2.22 9.79 8.01 7.7 3.93 3.63 8.02 0.69 
733 Activation_of_Na-permeable_Kainate_Receptors 9.99 3.8 7.89 5.09 4.1 7.34 3.66 9.62 1.58 7.22 8.78 9.51 8.59 7.37 9.61 3.18 0.43 9.37 
734 Adenylate_cyclase_inhibitory_pathway 0.6 6.1 7.97 1.06 4.47 8.29 7.63 6.83 7.04 8.99 9.85 9.39 9.92 2.06 9.27 9.16 4.58 6.27 
735 Astrocytic_Glutamate-Glutamine_Uptake_And_Metabolism 0.17 3.94 6.09 8.78 7.01 5.49 3.45 6.66 6.21 5.55 4.01 9.39 9.65 9.87 3.99 7.19 5.19 6.21 
736 CREB_phosphorylation_through_the_activation_of_Adenylate_Cyclase 5.24 5.78 0.29 1.33 5.54 7.93 6.87 1.21 3.95 2.18 9.82 7.29 0.28 9.3 6.4 8.39 2.34 3.67 
737 CREB_phosphorylation_through_the_activation_of_CaMKII 8.29 4.79 4.75 0.23 5.77 2.88 3.77 4.88 0.35 1.16 9.38 2.81 7 6.85 1.72 2 9.25 1.84 
738 Degradation_of_GABA 9.75 4.7 7.15 1.5 1.78 4.17 5.8 2.96 4.11 8.73 8.7 7.16 5.62 1.97 8.93 3.42 6.61 8.78 
739 Depolarization_of_the_Presynaptic_Terminal_Triggers_the_Opening_of_Calcium_Channels 6.54 1.12 2.49 0.75 0.35 4.68 9.03 4.39 4.94 4.97 9.81 6.48 5.52 7.17 8.23 8.57 1.72 6.74 
740 Dopamine_Neurotransmitter_Release_Cycle 3.58 4.83 1.04 6.6 2.16 8.23 1.88 7.77 6.87 7.36 2.87 5.3 4.54 5.35 1.34 3.78 3.86 7.18 
741 Enzymatic_degradation_of_Dopamine_by_monoamine_oxidase 1.81 2.12 7.5 8.56 9.39 6.66 5.53 7.05 9.85 8.67 1.15 0.98 2.84 5.16 7.26 4.64 9.07 6.51 
742 Enzymatic_degradation_of_dopamine_by_COMT 2.1 4.38 1.95 9.51 0.2 1.84 0.65 6.92 7.99 7.46 6.47 0.78 5.39 9.59 2.67 5.4 3.25 8.78 
743 GABA_A_(rho)_receptor_activation 4.28 2.07 1.03 7.54 5.67 7.95 2.58 8.57 8.57 0.69 9.22 7.04 3.81 8.21 0.89 5.17 0.73 5.74 
744 GABA_A_receptor_activation 0.46 8.05 3.24 2.68 1.03 2.47 7.14 6.13 7 9.44 7.47 8.99 9.42 2.96 4.73 2.41 8.56 7.09 
745 GABA_synthesis 9.13 4.52 8.93 1.75 3.56 9.72 8.26 1.47 8.86 2.83 4.77 6.12 8.94 8.53 0.31 9.99 8.96 9.53 
746 Glutamate_Neurotransmitter_Release_Cycle 4.7 2.22 9.75 2.55 9.42 4.16 1.19 0.66 5.36 6.54 4.74 0.64 6.51 3.85 3.04 0.47 8.19 6.1 
747 Highly_calcium_permeable_nicotinic_acetylcholine_receptors 8.29 4.34 9.35 5.7 2.86 4.05 2.31 7.23 6.2 1.73 7.82 6.94 3.48 6.99 1.64 3.03 1.9 2.19 
748 Highly_calcium_permeable_postsynaptic_nicotinic_acetylcholine_receptors 8.79 9.51 6.13 7.68 8.12 4.08 6.46 1.47 8 8.94 5.96 0.43 7.64 6.35 7.47 8.39 5.2 8.11 
749 Highly_sodium_permeable_acetylcholine_nicotinic_receptors 6.44 3.46 2.94 2.98 0.25 7.89 9.55 9.55 9.86 7.88 6.1 8.74 7.02 0.58 4.42 1.88 1.98 2.94 
750 Inhibition__of_voltage_gated_Ca2+_channels_via_Gbeta/gamma_subunits 5.6 9.98 8.62 2.98 2.32 9.47 0.77 2.33 1.52 0.1 6.32 7.46 3.97 6.15 8.34 7.54 6.11 5.37 
751 Metabolism_of_serotonin 0.78 1.34 2.15 1.4 1.52 2.17 6.95 2.32 5.13 2.67 8.68 1.37 5.77 7.23 8.07 8.48 1.14 2.71 
752 Norepinephrine_Neurotransmitter_Release_Cycle 4.18 0.9 3.07 1.29 0.32 8.72 6.58 5.87 6.95 4.87 1.58 6.07 2.85 7.84 0.27 7.44 8.41 9.79 
753 Presynaptic_function_of_Kainate_receptors 8.55 3.17 4.67 6.55 9.73 7.51 9.43 8.69 9.6 6.25 7.34 2.94 7.46 2.23 6.06 6.98 8.13 8.02 
754 RSK_activation 4.51 8.75 3.54 6.67 3.89 0.65 9.61 5.98 3.48 9.04 5.44 8.66 5.85 2.62 1.43 5.98 9.03 6.41 
755 Ras_activation_uopn_Ca2+_infux_through_NMDA_receptor 7.87 2.86 9.94 2.88 5.21 5.89 9.91 1.93 9.9 1.89 8.92 5.15 1.65 5.81 0.81 5.89 1.36 0.02 
756 Reuptake_of_GABA 9.27 2.87 7.86 2.18 9.92 2.07 6.53 0.85 5.84 6.15 7.99 2.04 6.74 1.32 5.47 5.19 4.3 8.99 
757 Serotonin_Neurotransmitter_Release_Cycle 7.09 5.37 8.49 5.43 6.62 0.71 1.49 8.14 3.61 0.49 5.95 1 0.04 7.12 1.42 2.24 2.19 5.13 
758 Trafficking_of_GluR2-containing_AMPA_receptors 6.42 4.54 2.65 6.96 2.13 0.29 1.13 2.32 6.12 2.9 1.97 5.78 2.01 8.04 7.08 5.73 0.44 8.65 
759 Unblocking_of_NMDA_receptor,_glutamate_binding_and_activation 4.65 2.53 7.92 2.33 6.74 3.51 7.52 4.1 6.14 5.55 1.05 4.75 2.74 4.83 5.77 8.54 1.1 5.64 
760 Electric_Transmission_Across_Gap_Junctions 6.96 5.59 5.71 8.02 0.14 2.58 3.36 1.6 8.06 1.72 4.38 8.96 2.41 3.6 2.24 9.2 0.86 7.81 
761 Unblocking_of_NMDA_receptor,_glutamate_binding_and_activation 1.11 8.86 3.12 7.34 2.05 4.7 5.04 7.78 5.44 2.25 8.45 3.65 3.38 0.32 8.02 3.27 7.02 3.61 
762 Voltage_gated_Potassium_channels 7.99 0.91 6.13 1.37 8.18 0.03 5.54 9.63 7.99 4.42 1.15 7.36 3.01 2.26 9.54 0.79 1.96 0.4 
763 Elongation_arrest_and_recovery 9.06 7.99 0.36 1.64 7.49 5.55 5.83 6.29 9.17 7.81 6.09 8.2 7.7 3.1 1.19 5.99 8.68 5.56 
764 PLC-mediated_hydrolysis_of_PIP2 8.23 1.3 2.18 7.17 7.02 9.77 4.34 4.68 0.23 2.41 6.81 3.78 4.82 2.07 1.97 9.9 4.76 0.33 
765 Receptor-ligand_binding_initiates_the_second_proteolytic_cleavage_of_Notch_receptor 7.21 0.8 1.58 5 2.41 4.34 2.08 1.26 2.39 3.76 2.87 0.37 7.57 5.7 0.2 7.51 3.24 1.99 
766 NICD_traffics_to_nucleus 9.35 5.8 1.32 0.61 4.52 5.6 2.77 4.86 7.17 1.01 4.46 6.68 3.76 6.17 9.56 2.01 6.34 2.84 
767 A_third_proteolytic_cleavage_releases_NICD 5.17 4.88 0.68 8.61 6.13 5.44 7.73 1.09 0.56 5.06 6.17 1.32 5.05 6.33 3.37 7.78 2.11 3.3 
768 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 4.9 9.85 9.98 6.68 8.34 8.01 3.73 6.33 1.36 2.12 4.53 8.05 7 8.04 8.4 8.47 1.35 5.45 
769 AKT_phosphorylates_targets_in_the_cytosol 5.95 8.22 7.48 5.03 1.96 1.01 9.03 3.67 8.97 3.38 5.16 8.53 0.93 5 1.95 4.5 5.32 6.75 
770 AKT_phosphorylates_targets_in_the_nucleus 4.67 8.35 0.49 0.2 1.65 7.14 7.17 5.73 0.43 2.59 4.27 0.54 7.36 4.58 6.98 4.73 8.41 1.23 
771 ERK1_activation 4.27 1.95 7.09 3.86 3.71 1.23 1.69 7.64 5.55 4.34 0.95 6.53 3.74 8.2 7.11 1.79 2.03 9.1 
772 ERK2_activation 7.18 8.51 5.24 9.76 4.39 3.71 6.14 0.62 6.72 5.52 3.3 3.21 3.1 7.85 6.51 5.71 4.11 4.83 
773 RAF_activation 3.05 5.87 2.22 4.55 9.57 1.73 5.64 9.61 4.54 9.02 2.87 3.3 1.47 0.22 8.28 9.51 3.14 9.75 
774 RAF_phosphorylates_MEK 2 3.07 0.89 4.62 1.25 3.07 2.43 6.79 1.06 8.25 8.93 6.54 4.65 0.2 8.09 8.19 5.34 5.5 
775 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 8.51 6.29 0.6 5.01 7.38 7.46 3.77 1.58 0.81 9.49 8.37 4.07 1.03 3.22 9.59 9.15 6.59 2.55 
776 Activation_of_PKB 2.89 8.04 8.52 8.83 6.45 4.92 9.93 9.71 1.04 4.2 9.64 2.34 8.86 4.25 3 1.21 2.78 3.07 
777 NGF-independant_TRKA_activation 9.31 7.35 5.59 0.56 7.89 9.95 4.03 2.09 1.06 7.92 8.83 3.31 0.22 8.48 9 9.53 6.15 8.28 
778 TRKA_activation_by_NGF 9.68 7.84 4.46 7.63 6.4 4.75 1.22 9.69 4.56 1.36 0.97 3.77 7.63 9.38 9.37 5.1 4.09 8.64 
779 Activation_of_the_phototransduction_cascade 4.78 0.31 9.58 1.83 5.08 1.86 9.97 2.99 2.24 7.54 3.08 5 1.86 6.67 5.78 1.5 6.38 1.41 
780 Adenosine_P1_receptors 6.95 8.09 6.03 4.87 4.19 9.55 0.82 9.99 3.7 3.22 4.67 1.99 3.57 6.39 9.42 6.42 7.8 7.51 
781 Adenylate_cyclase_activating_pathway 3.02 5.59 0.2 8.51 4.34 4.28 3.39 5.55 0.3 0.39 6.76 7.19 5.35 8.58 9.03 1.1 7.66 2.05 
782 Adenylate_cyclase_inhibitory_pathway 5.75 3.7 2.15 7.6 9.63 2.19 6.67 2.57 0.69 8.83 5.55 5.15 6.95 6.35 6.77 5.28 1.36 7 
783 Adrenoceptors 4.04 1.99 2.01 5.28 5.07 9.13 8.52 1.37 2.26 0.73 9.75 4.34 4.04 4.03 4.21 0.85 3.44 3.11 
784 Adrenoceptors 0.22 2.21 1.83 3.97 6.01 5.5 8.86 5.14 5.35 6.89 5.64 1.96 1.53 5.4 0.77 5.71 3.4 4.25 
785 Dopamine_receptors 3.21 7.45 6.28 1.98 9.19 8.19 4.71 9.01 3.5 7.76 3.8 0.21 2.05 2.42 2.68 7.52 7.04 8.18 
786 Histamine_receptors 4.71 3.42 7.82 9.13 5.14 0.67 3.94 6.92 3.44 9.8 4.47 9.19 2.86 8.56 6.07 7.82 7.56 2.12 
787 Muscarinic_acetylcholine_receptors 9.41 8.4 4.24 4.63 6.34 6.53 8.05 7.76 5.81 4.81 0.36 8.37 1.18 0.49 5.93 6.45 0.53 0.86 
788 Serotonin_receptors 3.22 2.87 3.34 7.03 9.08 1.49 1.6 0.28 4.15 4.92 2.38 5.29 6.1 4.05 7.42 2.15 2.49 4.41 
789 Antagonism_of_Activin_by_Follistatin 5.6 3.13 7.42 7.03 6.81 9.01 6.71 7.94 2.81 3.38 5.75 8.26 5.53 3.53 0.3 9.35 8.25 1.75 
790 Arachidonate_production_from_DAG 2.05 8.53 4.49 0.89 5.73 6.04 1.26 5.13 2.64 5.2 8.88 4.33 6.03 6.81 1.7 0.61 6.33 8.35 
791 Axonal_growth_inhibition_(RHOA_activation) 8.33 0.14 5.95 8.48 8.56 2.59 4.87 1.64 0.27 9.07 1.83 4.26 2.75 7.69 8.28 1.18 4.34 9.35 
792 Axonal_growth_stimulation 4.58 2.98 6.15 8.23 4.85 6.77 3 9.25 7.56 9.36 2.38 5.28 9.18 4.19 9.49 2.03 5.46 7.52 
793 Beta-catenin_phosphorylation_cascade 7.09 1.11 2.59 4.61 3.39 3.48 7.08 7.76 0.6 0.15 2.24 4.14 8.91 2.7 8.45 5.09 8.57 0.34 
794 CREB_phosphorylation 2.02 0.51 0.18 4.6 4.54 2.55 2.77 0.67 1.23 9.18 0.6 7.97 2.68 6.24 4.38 5.16 5.86 1.96 
795 CaMK_IV-mediated_phosphorylation_of_CREB 4.73 6.83 7.73 6.01 8.28 1.61 0.73 4.31 8.75 7.41 5.19 7.73 4.36 7.47 0.38 9.64 9.7 7.49 
796 Cam-PDE_1_activation 5.93 5.16 8.39 5.9 7.78 7.82 8.56 9.95 1.19 8.82 9.16 5.87 0.21 0.65 5.33 7.92 1.63 8.13 
797 PKA_activation 4.98 4.78 2.16 6.08 8.68 6.36 3.43 6.9 9.75 5.85 7.77 7.19 2.03 1.45 3.07 2.01 1.4 4.96 
798 phospho-PLA2_pathway 8.02 6.02 6.07 6.38 2.37 0.76 2.15 6.91 5.79 2.12 2.06 9.65 9 6.92 6.55 0.31 1.88 5.29 
799 CaMK_IV-mediated_phosphorylation_of_CREB 4.68 3.48 4.93 2.28 2.99 9.65 8.99 8.36 8.15 8.72 8.14 3.88 2.04 9.78 5.8 0.25 9.38 9.73 
800 Cam-PDE_1_activation 5.34 5.92 2.14 5.25 2.04 3.01 3.73 6.63 8.58 3.5 6.91 1.4 9.17 5.29 6.28 9.81 1.53 8.84 
801 PKA_activation 5.04 5.59 8.13 5.16 6.28 3.29 1.06 4.55 2.54 2.51 8.87 0.77 8.97 6.57 5.36 3.4 2.26 2.72 
802 CaMK_IV-mediated_phosphorylation_of_CREB 0 6.04 4.26 2.25 4.53 9.64 1.98 9.16 5.63 3.94 4.19 7.42 1.24 0.56 4.22 8.3 8.54 4.77 
803 Calcitonin-like_ligand_receptors 9.79 5.56 0.21 1.45 7.87 3.23 1.95 5.33 5.8 2.18 0.13 3.7 8.36 3.73 5.36 4.5 7.17 6.25 
804 CaMK_IV-mediated_phosphorylation_of_CREB 4.12 0.76 8.08 7.27 9.11 8.91 0.35 2.48 9.81 2.09 8.53 7.31 5.19 3.52 3.95 0.03 4.09 2.66 
805 Cam-PDE_1_activation 2.68 9.24 6.73 3.85 2.74 1.27 3.48 3.29 8.26 5.96 5.39 0.77 1.82 0.15 0.07 2.95 1.2 9.66 
806 PKA_activation 9.76 4.68 0.18 5.22 6.12 1.03 6.36 7.73 7.66 9.89 9.9 9.87 7.33 9.93 6.62 1.08 6.47 3.05 
807 Cam-PDE_1_activation 5.48 1.92 7.02 3.93 5.56 6.6 8.97 9.42 3.4 4.2 0.54 2.94 9.35 8.17 9.35 7.89 8.01 2.29 
808 NADE_modulates_death_signalling 6.82 8.67 5.8 7.25 7.17 4.53 2.26 0.07 9.3 5.68 4.44 1.87 6.08 7.18 9.3 7.03 0.1 6.42 
809 NRAGE_signals_death_through_JNK 2.84 1.49 9.63 4.86 9.05 0.4 4.5 4.15 8.61 9.51 3.55 5.03 1.68 4.41 9.34 9.95 4.61 3.78 
810 NRIF_signals_cell_death_from_the_nucleus 1.88 7.9 9.93 4.29 3.19 0.62 0.53 7.3 2.73 9.58 2.28 7.45 0.56 6.84 8.41 8.32 0.16 0.59 
811 Ceramide_signalling 8.67 1.78 8.66 2.28 4.74 1.37 8.04 7.04 7.91 8.69 1.92 5.13 3.27 3.17 3.85 4.98 2.25 5.65 
812 Chemokine_receptors_bind_chemokines 9.96 1.47 2 0.97 5.24 8.82 4.42 6.57 1.68 7.27 7.22 8.05 7.29 3.03 6.43 8.51 8.22 9.71 
813 Adenosine_P1_receptors 0.86 5.58 4.74 1.69 6.94 8.66 5.21 5.79 1.94 6.14 9.82 9.83 5.14 0.64 0.65 3.28 7.98 6.71 
814 Adrenoceptors 8.64 4.9 3.88 3.41 2.19 3.47 0 6.51 0.04 0 7.69 4.1 8.47 4.14 9.77 2.63 0.22 1.95 
815 Chemokine_receptors_bind_chemokines 2.52 9.59 6 8.83 1.17 9 5.79 7.11 5.74 5.18 7.83 4.03 0.31 8.61 5.65 3.03 0.01 6.45 
816 Dopamine_receptors 1.6 1.84 4.11 2.83 3.71 1.52 3.64 1.52 3.16 4.6 2.34 5.56 4.95 9.88 7.31 5.48 8.85 2.48 
817 Formyl_peptide_receptors_bind_formyl_peptides_and_many_other_ligands 3.54 2.95 9.34 7.52 4.68 9.26 1.09 8.45 5.87 5.62 5.24 5.19 6.42 2.9 1.84 9.43 7.3 3.33 
818 Free_fatty_acid_receptors 5.89 5.1 4.37 0.12 8.45 3.08 1.46 4.6 4.05 7.41 5.13 6.75 1.45 5.62 8.95 4.8 5.05 2.36 
819 Histamine_receptors 3.79 6.24 6.2 8.86 3.53 7.67 3.32 5.56 7.19 1.72 6.33 6.94 7.03 4.56 5.79 5.05 3.49 0.31 
820 Hormone_ligand-binding_receptors 4.34 7.6 9.69 3.28 1.93 8.63 3.35 3.22 6.91 3.13 7.73 6.23 9.07 6.66 3.8 6.62 6.66 1.27 
821 Hydroxycarboxylic_acid-binding_receptors 2.59 4.19 5.09 2.76 5.28 0.58 3.25 3.42 3.44 8.68 6.52 7.87 1.14 9.61 0.92 2.15 9.99 7.67 
822 Leukotriene_receptors 4.58 4.41 8.2 3.45 1.47 0.52 6.83 6.83 9.89 8.34 1.27 7.25 4.49 2.3 4.31 0.23 5.04 2.97 
823 Lysosphingolipid_and_LPA_receptors 2.52 8.93 1.56 6.24 8.7 0.42 3.52 2.19 7.96 6.57 3.7 3.69 4.99 1.77 7.28 5.46 9.46 4.73 
824 Muscarinic_acetylcholine_receptors 6.81 9.33 8.99 1.81 2.22 4.44 3.95 8.4 1.77 9.97 0.38 3.39 6.92 9.14 4.29 2.6 8.68 5.7 
825 Opsins 5.37 4.74 1.52 1.13 6.53 1.52 6.69 8.22 4.71 4.48 9.96 2.36 0.39 3.78 3.1 7.08 8.91 8.21 
826 Orexin_and_neuropeptides_FF_and_QRFP_bind_to_their_respective_receptors 0.06 4.16 3.86 2.77 3.68 9.86 9.12 6.86 1.45 8.7 7.13 8.48 6.79 8.86 8.01 6.83 9.14 7.65 
827 P2Y_receptors 5.23 1.17 1.64 7.02 1.85 2.58 6.45 4.78 0.84 8.35 2.89 1.91 6.36 4.02 9.74 8.86 5.78 1.08 
828 Prostanoid_ligand_receptors 8.56 4.31 2.28 3.36 3.27 8.95 1.13 0.56 1.89 0.35 3.9 6.78 9.68 9.19 6 8.65 3.43 9.69 
829 Relaxin_receptors 8.82 3.11 7.55 2.24 8.81 5.64 4.91 7.99 3.1 7.48 3.8 2.06 8.76 8.86 7.84 3.23 8.28 4.27 
830 Serotonin_receptors 9.35 9.32 5.25 9.25 2.36 8.48 2.31 5.62 8.02 7.67 1.94 3.47 4.7 7.2 3.06 3.36 5.66 4.1 
831 Tachykinin_receptors_bind_tachykinins 4.22 1.59 0.26 2.44 8.97 4.05 9.46 9.44 5.36 4.99 6.09 7.89 0.54 0.44 0.57 6.05 1.97 8.31 
832 Vasopressin-like_receptors 2.78 2.23 0.61 1.6 8.31 4.86 2.74 6.92 4.26 5.77 4.01 0.85 5.51 8.83 9.78 6.18 6.25 1.42 
833 Calcitonin-like_ligand_receptors 3.49 4.74 5.52 1.16 9.34 5.46 5.62 2.55 2.91 0.7 7.07 2.9 2.64 6.29 7.78 1.91 8.16 0.88 
834 Glucagon-type_ligand_receptors 9.35 9.3 3.91 6.67 3.3 3.01 6.86 3.33 5.73 2.46 0.15 5.81 7.89 4.06 5.85 8.53 7.73 9.55 
835 Class_C/3_(Metabotropic_glutamate/pheromone_receptors) 5.66 1.96 1.87 2.8 3.55 9.43 5.99 0.43 2.15 2.79 5.13 3.12 1.68 2.17 6.18 4.76 2.19 6.81 
836 CaMK_IV-mediated_phosphorylation_of_CREB 9.18 7.17 5.78 8.8 6.57 7.76 0.43 3.29 3.36 0.1 0.3 1.58 1.13 9.07 2.79 0.96 1.09 9.52 
837 Cam-PDE_1_activation 1.01 0.55 3.72 9.04 6.58 3.83 3.38 5.14 2.93 2.11 8.49 8.77 7.8 7.82 1.67 4.79 0.69 7.84 
838 PKA_activation 2.9 5.06 7.67 5.49 8.57 0.68 1.48 3.33 2.36 8.7 5.78 4.63 7.27 4.95 5.87 6.63 3.62 5.93 
839 DARPP-32_events 5.53 7.14 8.85 5.57 1.02 9.91 5.23 9.39 5.23 1.93 6.68 0.77 5.83 8.9 1.2 1.48 9.39 1.06 
840 Beta-catenin_phosphorylation_cascade 5.6 7.54 2.99 8.09 5.03 9.54 0.15 9.93 5.21 1.97 1.39 2.07 5.3 0.47 7.48 6.91 0.98 2.65 
841 Dopamine_receptors 7.8 0.37 2.32 0.8 1.76 2.43 0.21 3.65 5.84 0.73 2.59 6.3 7.34 7.36 8.94 3.1 4.19 8.1 
842 Downregulation_of_ERBB2:ERBB3_signaling 9.69 4.89 3.34 4.85 7.47 1.78 5.9 4.54 0.67 9.52 2.11 3.68 0.02 5.98 4.8 3.16 1.93 5.38 
843 Downregulation_of_ERBB4_signaling 1.95 9.71 9.07 4.97 7.35 2.27 4.44 3.29 1.46 0.46 3.85 1.1 4.11 8.17 3.14 0.17 8.63 3.79 
844 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 9.74 3.9 2.04 4.29 0.94 6.77 2.61 2.09 3.96 0.44 3.19 5.89 6.21 1.63 7.79 5.22 5.49 4.56 
845 Downregulation_of_TGF-beta_receptor_signaling 9.74 5.04 8.74 6.03 5.89 5.89 6.44 0.6 1.49 1.02 2.19 5.32 5.13 2.92 6.17 1.54 0.53 9.47 
846 AKT_phosphorylates_targets_in_the_cytosol 1.21 0.39 3.39 3.19 6.25 4.59 6.92 1.04 3.56 3.22 8.58 6.79 4.83 1.29 2.03 8.49 4.45 2.62 
847 AKT_phosphorylates_targets_in_the_nucleus 5.28 7.88 2.84 4.31 5.43 9.6 7.54 2.41 3.9 7.12 3.32 8.52 4.09 3.13 1.26 8.36 0.05 2.1 
848 CaMK_IV-mediated_phosphorylation_of_CREB 8.79 5.32 2.62 4.36 7.03 8.3 6.38 4.03 7.9 3.98 5.99 4.62 4.46 0.96 6.19 4.76 7.71 0.95 
849 Cam-PDE_1_activation 9.38 1.76 9.22 5.67 8.76 5.34 8.56 1.65 8.15 6.22 0.13 0.86 7.07 0.33 3.6 7.81 3.56 6.49 
850 ERK1_activation 1.25 9.53 7.52 0.62 6.29 0.46 5.38 3.34 8.6 8.11 5.66 8.93 3.44 2.2 7.17 0.93 6.48 3.84 
851 ERK2_activation 3.16 8.31 2.36 4.46 7.84 5.31 0.76 4.84 7.08 3.49 1.16 5.6 1.11 8.32 7.82 9.38 1.84 3.59 
852 Negative_regulation_of_the_PI3K/AKT_network 1.68 6.89 4.35 4.82 3.67 6.29 7.28 9.18 5.56 1.1 0.02 0.8 3.26 5.47 3.33 7.79 8.32 8.05 
853 PKA_activation 3.32 6.47 6.13 7.09 9.3 3.57 2.01 8.19 6.31 0.97 2.26 4.81 2.69 4.79 1.91 4.71 9.08 9.45 
854 RAF_activation 0.4 6.88 3.55 0.71 2.7 5.97 8.79 5.28 2.03 8.24 7.45 7.29 5.49 7.24 9.79 1.4 0.07 8.91 
855 RAF_phosphorylates_MEK 4.11 8.98 2.89 1.12 5.24 1.15 0.1 7.26 2.33 7.09 7.23 4.4 6.11 2.52 4.13 1.07 7.41 5.13 
856 AKT_phosphorylates_targets_in_the_cytosol 8.94 8.81 1.73 5.5 2.96 2.71 4.14 9.05 8.34 2.81 2.13 9.67 1.79 1.41 5.44 2.19 5.24 7.49 
857 AKT_phosphorylates_targets_in_the_nucleus 5.97 0.47 5.41 5.69 8.82 9.78 4.03 9.4 6.33 7.22 1.85 2.22 3.75 5.8 9.16 5.3 5.16 3.54 
858 CaMK_IV-mediated_phosphorylation_of_CREB 2.44 0.88 6.29 4.76 4.47 8.54 2.57 3.46 3.68 0.19 8.41 9.77 2 4.84 2.36 3.08 6.92 0.5 
859 Cam-PDE_1_activation 4.49 3.89 8.8 9.16 1.02 0.04 7.45 8.17 5.6 2.47 0.65 8.72 2.04 6.35 3.83 2.28 0.3 4.82 
860 ERK1_activation 2.29 9.54 3.76 7.49 5.82 5.33 1.66 4.68 3.19 8.28 9.51 8.75 2.61 4.97 7.5 9.19 1.12 9.1 
861 ERK2_activation 8.81 9.3 4.15 1.24 2.58 8.99 2.2 1.4 5.73 8.82 9.77 3.21 8.41 6.02 0.27 6.21 0.34 4.4 
862 Negative_regulation_of_the_PI3K/AKT_network 4.53 9.07 8.06 3.95 0.32 6.61 3.67 9.8 7.46 1.51 1.85 9.52 1.41 7.63 8.04 4.27 9.06 8.95 
863 PKA_activation 2.43 2.55 9.65 8.6 9.26 0.7 2.19 2.16 9.42 1.57 7.69 0.31 1.99 4.73 0.78 3.49 3.3 3.34 
864 RAF_activation 9.64 6.95 7.72 6.46 8.03 6.98 5.77 0.47 5.51 6.84 2.05 1.44 9.31 2.58 7.16 2.84 2.69 1.61 
865 RAF_phosphorylates_MEK 8.4 9.68 2.28 7.46 7.96 4.1 6.96 4.23 5.75 6.27 7.12 7.47 2.66 0.39 5.86 4.74 9.57 3.85 
866 SHC-mediated_cascade 2.47 3.47 3.35 6.36 4.68 7.11 9.25 5.2 0.56 8.61 6.93 5.22 8.75 0.04 3.24 9.03 8.2 1.89 
867 EGFR_Transactivation_by_Gastrin 2.92 7.3 5.9 6.39 6.01 0.04 5.4 9.73 4.22 1.31 6.82 6.06 2.2 2.71 3.58 2.19 7.55 0.24 
868 EGFR_downregulation 3.34 7.18 7.72 5.56 0.84 8 8.46 4.48 3.03 7.15 9.59 1.56 9.72 2.74 1.34 8.92 3.17 8.15 
869 CaMK_IV-mediated_phosphorylation_of_CREB 7.59 9.64 2.09 3.47 0.3 4.13 8.13 6.03 5.91 6.29 3.44 4.16 4.85 2.27 1.33 6.39 5.94 7.39 
870 Cam-PDE_1_activation 2.04 3.87 9.67 4.15 9.22 3.84 9.96 3.35 5.87 7.14 1.46 8.49 9.81 2.21 1.91 1.25 9.91 4.06 
871 PKA_activation 4.42 3.23 6.17 7.37 3.75 8.14 8.06 7.24 2.93 5.96 9.27 5.48 6.7 0.46 8.42 3.83 6.63 1.82 
872 ERK1_activation 6.43 7.7 7.21 0.71 4.97 6.68 0.4 6.57 3.01 4.26 6.18 1.24 6.22 9 8.25 9.41 7.44 6.48 
873 ERK2_activation 0.76 4.31 5.74 6.78 0.67 6.6 7.9 8.12 5.54 3.17 2.77 9.94 9.68 1.49 9.22 9.28 1.6 7.16 
874 ERKs_are_inactivated 7.67 7.43 6.47 3.15 5.41 3.66 4.23 1.64 7.67 0.3 7.72 7.56 2.26 5.76 7.02 4.19 6.43 4.93 
875 ERK1_activation 0.46 1.23 1.77 3.98 5.32 5.75 5.57 1.82 4.96 6.62 7.6 9.8 3.03 7.2 5.48 3.01 3.84 9.28 
876 ERK2_activation 7.41 8.09 8 6.98 0.17 4.45 2.27 8.96 3.34 8.26 9.96 4.32 3.94 3.71 1.27 7.92 2.49 1.08 
877 ERKs_are_inactivated 3.97 1.72 8.19 5.85 7.52 6.31 2.36 4.13 6.47 2.48 7.6 6.13 5.55 7.75 0.22 5.88 3.71 6.73 
878 Arachidonate_production_from_DAG 6.6 3.12 9.5 1.28 4.2 5.32 7.44 9.18 2.13 1.91 0.22 6.51 3.17 5.73 6.77 4.85 4.3 0.61 
879 Leukotriene_receptors 5.91 4.48 9.74 7.79 7.28 2.63 1.79 7.03 3.52 5.45 5.83 1.33 5.7 5.91 6.09 9.42 6.6 3.96 
880 Prostanoid_ligand_receptors 3.8 1.99 3.92 3.5 3.39 3.53 8.67 7.89 1.65 0.25 6.35 6.1 4.54 6.81 9.91 8.42 1.42 7.66 
881 Regulation_of_AMPK_activity_via_LKB1 9.77 7.47 5.82 5.07 7.83 7.97 0.96 7.1 2.59 9.8 0.07 6.33 3.59 2.86 6.55 6.28 1.97 4.56 
882 Regulation_of_Rheb_GTPase_activity_by_AMPK 2.45 6.33 8.46 7.74 1.94 7.6 0.41 9.7 3.48 7.32 0.46 7.17 9.89 8.22 4.03 9.4 3.68 4.81 
883 FGFR1b_ligand_binding_and_activation 0.48 5 3.86 4.13 5.74 6.25 9.26 6.64 4.69 2.52 3 9.86 6.14 5.23 3.3 0.95 5.66 7.41 
884 FGFR1c_and_Klotho_ligand_binding_and_activation 5.78 4.42 6.29 0.14 4.94 1.84 9.73 3.84 3.06 2.99 2.15 6.43 6.34 7.61 6.26 0.3 5.16 9.4 
885 FGFR1c_ligand_binding_and_activation 3.89 8.7 5.98 9.94 9.99 9.26 0.75 5.04 1.41 0.96 6.18 4.83 7.56 7.71 8.07 0.31 1.76 9.1 
886 FGFR2b_ligand_binding_and_activation 7.43 5.24 1.08 0.27 4.3 0.77 1.23 9.12 1.71 9.31 1.9 6.34 8.62 8.18 0.78 0.1 1.84 5.69 
887 FGFR2c_ligand_binding_and_activation 8.45 5.81 8.92 0.16 7.04 9.74 9.01 2.21 9.6 5.83 9.13 8.56 1.22 1.53 3.32 3.84 3.71 0.08 
888 FGFR3b_ligand_binding_and_activation 0.08 1.73 5.75 0.58 6.99 5.59 4.6 7.37 8.81 4.06 7.55 4.38 5.39 0.12 2.55 8.97 6.72 4.17 
889 FGFR3c_ligand_binding_and_activation 5.05 9.82 8.28 2.53 6.1 5.38 2.39 0.75 4.82 4.95 9.67 1.48 1.05 5.56 0 6.65 2.93 1.85 
890 FGFR4_ligand_binding_and_activation 5.62 4.29 1.16 1.7 5.72 1.3 4.98 0.33 6.8 6.99 3.64 4.25 8.79 7.38 2.46 2.72 7.42 2.04 
891 betaKlotho-mediated_ligand_binding 5.62 6.36 4.41 9.13 4.74 7.13 7.43 4.16 2.4 0.82 1.42 4.66 1.95 4.23 8.73 2.38 3.49 8.69 
892 FGFR1b_ligand_binding_and_activation 4.79 5.49 4.28 7 0.86 6.86 6.61 8.93 0.55 7.73 3.67 9.47 4.52 1.44 9.51 0.52 7.19 1.95 
893 FGFR1c_ligand_binding_and_activation 0.48 8.39 9.89 7 0.54 0.96 2.51 3.21 4.75 9.21 3.67 9.68 5.45 7.16 4.58 5.19 0.96 1.35 
894 FGFR1b_ligand_binding_and_activation 8.61 0.14 7.54 6.7 2.9 9.85 2.78 6.71 1.56 1.3 5.71 8.34 3.54 3.43 4.29 6.96 4.23 8 
895 FGFR1c_and_Klotho_ligand_binding_and_activation 7.16 5.9 2.22 5.72 5.23 3.22 7.08 7.48 9.02 4.61 4.46 7.28 8.64 5.21 1.09 4.01 6.03 7.64 
896 FGFR1c_ligand_binding_and_activation 2.15 5.98 4.25 1.34 7.52 4.35 1 2.08 8.65 8.47 0.41 9.01 9.27 6.6 2.82 3.57 1.91 3.97 
897 FGFR2b_ligand_binding_and_activation 5.39 5.92 0.25 6.91 8.13 4.96 6.18 0 5.22 3.7 7.91 7.84 0.56 3.59 3.11 9.72 9.22 0.45 
898 FGFR2c_ligand_binding_and_activation 0.64 0.09 5.71 2.67 1.56 7.93 5.8 7.89 6.13 2.09 6.23 9.01 1.43 5.7 1.57 9.55 8.37 8.91 
899 FGFR2b_ligand_binding_and_activation 1.82 3.9 7.67 6.87 1.35 9.15 0.98 6.19 3.13 9.74 2.96 7.64 2.23 6.07 0.74 7.9 5.99 5.18 
900 FGFR2c_ligand_binding_and_activation 1.4 1.03 2.45 2.57 2.16 3.57 0.37 3.65 3.73 3.97 0.48 1.24 3.6 1.26 6.4 1.19 2.28 7.41 
901 FGFR3b_ligand_binding_and_activation 2.71 9.48 1.5 7.39 2.29 6.09 7.4 7.64 4.49 3.46 0 9.29 4.58 1.02 8.08 7.6 2.06 9.93 
902 FGFR3c_ligand_binding_and_activation 4.72 9.29 6.34 7.66 9.53 8.53 8.51 1.39 2.75 3.87 1.01 9.94 1.13 4.83 2.34 7.48 2.28 7.26 
903 FGFR3b_ligand_binding_and_activation 7.09 6.01 7.55 0.61 2.23 2.78 9.13 0.25 5.38 3.42 1.6 8.83 3.65 4.04 7.41 7.34 4.15 2.95 
904 FGFR3c_ligand_binding_and_activation 0.35 4.42 1.75 5.27 1.17 6.49 3.63 0.4 6.14 2.95 5.27 9.24 7.71 3.82 8.49 4.62 7.64 3.43 
905 FGFR4_ligand_binding_and_activation 2.11 2.12 8.86 1.28 8.16 1.96 8.12 8.9 1.31 2.27 3.12 3.3 2.68 5.53 5.48 4.99 9 8.41 
906 ERK1_activation 6.54 5.7 6.51 1.52 4.68 6.26 6.96 0.36 4.51 7.21 7.93 3.43 7.35 1.31 7.39 4.43 3.82 2.69 
907 ERK2_activation 9.24 7.28 3.89 0.28 1.83 6.85 9.36 4.23 6.65 4.76 5 7.3 1.78 4.24 3.51 0.21 4.69 6.35 
908 RAF_activation 9.54 2.93 7.87 9.71 3.33 4.41 8.76 5.72 9.48 7.75 7.12 5.97 7.93 6.96 0.78 9.48 3.62 1.45 
909 RAF_phosphorylates_MEK 8.67 0.26 5.25 7 9.65 4.79 4.41 6.7 8.24 8.77 5.26 8.58 7.45 6.64 9.68 9.42 2.81 8.73 
910 Formyl_peptide_receptors_bind_formyl_peptides_and_many_other_ligands 4.08 2.21 7.16 8.15 4.6 2.29 4.66 7.83 2.08 1.05 1.5 2.69 4.44 6.89 8.69 2.92 9.19 8.32 
911 Free_fatty_acid_receptors 8.82 0.82 4.69 9.19 2.32 5.92 5.02 6.17 5.26 3.6 1.11 2.87 6.98 9.11 1.32 9.56 1.19 4.46 
912 ERK1_activation 7.1 2.75 6.09 1.39 8.73 8.72 0.59 9.81 7.3 9.4 5.43 5.45 8.87 7.09 0.14 4.46 5.27 6.77 
913 ERK2_activation 4.56 4.48 9.88 5.86 4.46 9.47 3.66 4.06 5.25 5.09 3.54 2.24 4.78 9.45 0.74 7.63 4.85 5.93 
914 RAF_activation 5.03 6.61 9.18 0.12 7.88 4.74 7.43 3.37 8.93 3.62 3.14 1.39 5.67 2.09 3.61 4.21 1.62 9.65 
915 RAF_phosphorylates_MEK 2.55 8.24 4.93 4.45 5.24 4.18 3.85 3.52 3.05 7.37 8.48 9.08 4.05 5.61 1.99 5.12 1.91 6.98 
916 G_alpha_(12/13)_signalling_events 5.7 7.72 3.66 5.49 5.59 3.43 0.85 9.04 8.54 6.81 7.78 9.04 5.91 7.06 3.62 0.31 5.65 3.79 
917 G_alpha_(i)_signalling_events 4.21 1.11 9.29 3.48 4.64 3.49 5.69 9.89 9.54 0.17 7.63 7.53 1.58 5.5 0.37 0.72 7.39 7.81 
918 Arachidonate_production_from_DAG 9.75 1.88 2.89 3.58 9.63 2.54 5.09 9.21 3.07 4.42 7.58 2.49 1.96 0.16 4.49 0.83 3.86 2.04 
919 G_alpha_(s)_signalling_events 2.42 7.19 3.17 6.56 4.52 9.64 9.22 8.57 7.55 1.84 4.6 7.51 4.64 9.6 0.84 8.09 4.68 5.24 
920 G_alpha_(z)_signalling_events 5.51 2.25 6.25 6.79 9.67 5.55 5.57 3.34 3.17 3 0.4 6.23 8.53 5.92 2.08 9.56 7.86 3.16 
921 G_beta:gamma_signalling_through_PI3Kgamma 7.23 8.88 3.32 0.46 5.74 1.61 4.23 0.18 8.75 7.34 3.67 4.06 0.55 5.31 2.8 2.56 9.33 4.83 
922 G_beta:gamma_signalling_through_PLC_beta 2.26 5.74 9.89 2.46 1.65 7.03 2.02 8.11 5.85 9.36 1.23 0.46 9.14 8.17 7.91 8.38 3.46 9.93 
923 G-protein_activation 4.86 3.77 2.87 1.43 5.81 5.45 6.22 0.91 8.34 9.87 8.96 7.72 9.78 3.56 1.33 5.48 4.08 6.55 
924 G_beta:gamma_signalling_through_PI3Kgamma 7.58 2.97 8.38 2.14 7.67 3.4 3.28 3.81 4.84 7.67 9.51 1.17 7.07 5.87 5.56 2.07 0.27 7.68 
925 G_beta:gamma_signalling_through_PLC_beta 6.22 3.9 4.19 7.29 4.77 6.03 4.55 3.34 8.08 8.83 6.62 9.71 2.84 8.04 1.91 7.54 1.97 1.92 
926 Adenylate_cyclase_activating_pathway 0.45 3.57 2.9 2.25 8.25 3.74 7.72 0.53 3.91 1.62 6.64 3.64 8.59 8.27 0.78 9.92 1.82 8.62 
927 Adenylate_cyclase_inhibitory_pathway 2.4 9.63 5.55 3.33 4.38 1.36 7.19 7.89 2.09 8.75 6.41 5.78 6.56 3.62 6.94 0.57 5.92 5.52 
928 CaMK_IV-mediated_phosphorylation_of_CREB 0.39 4.46 2.54 2.32 9.99 2.72 5.78 7.35 0.8 3.94 9.96 8.61 1.02 2.51 2.66 5.97 3.42 9.92 
929 Cam-PDE_1_activation 1.58 7.46 6.71 1.6 1.29 2.28 5.22 1.05 7 9 4.47 6.57 9.37 6.77 8.49 3.92 6.69 5.64 
930 PKA_activation 3.62 4.52 7.21 0.81 0.65 0.68 6.97 5.33 6.91 6.41 8.21 9.02 2.71 6.01 2.22 6.02 5.11 2.3 
931 phospho-PLA2_pathway 1.07 3.29 1 5.03 9.48 7.01 7.38 1.26 3.82 0.86 4.44 6.82 0.25 6.81 7.04 9.17 7.98 3.37 
932 AKT_phosphorylates_targets_in_the_cytosol 9.66 5.84 7.02 3.37 9.97 6.86 0.55 4.57 8.79 8.15 1.59 8.47 4.62 2.86 8.62 2.79 1.83 5.41 
933 AKT_phosphorylates_targets_in_the_nucleus 3.59 9.9 6.22 8.78 6.39 9.08 4.02 8.53 6.02 0.08 1.78 8.69 4.74 0.8 4.8 9.76 8.01 8.57 
934 Negative_regulation_of_the_PI3K/AKT_network 6.93 5.64 1.69 7.08 4.77 1.22 6.97 1.86 1.4 6.72 3.95 8.97 8.9 2.81 5.56 7.11 3.87 3.15 
935 Arachidonate_production_from_DAG 2.36 6.78 3.06 8.1 8.79 9.93 3.99 1.87 4.59 2.94 3.82 6.43 5.22 7 6.1 1.29 5.54 7.43 
936 G_alpha_(12/13)_signalling_events 6.89 0.74 8.36 5.78 6.26 3.4 4.34 5.64 6.53 6.92 4.36 9.03 4.82 9.8 5.89 5.72 8.2 0.55 
937 G_alpha_(i)_signalling_events 8.41 1.07 1.43 7.35 1.21 8.34 9.92 0.49 1.31 4.99 8.12 6.87 4.2 5.95 6.84 8.23 3.11 2.4 
938 G_alpha_(s)_signalling_events 6.23 0.65 2.19 3.79 9.12 2.71 1.67 7.9 0.49 7.04 0.01 1.76 3.85 3.9 2.08 8.46 1.14 3.61 
939 G_alpha_(z)_signalling_events 4.14 7.32 9.42 0.26 3.94 9.09 7.55 2.93 8.61 6.32 7.08 1.21 3.64 9.47 8.35 2.33 1.81 5.4 
940 G_beta:gamma_signalling_through_PI3Kgamma 7.24 1.12 3.49 4.61 6.27 0.01 1.29 9.44 5.2 9.81 7.4 7.32 1.77 8.25 9.44 6.62 4.09 7.02 
941 G_beta:gamma_signalling_through_PLC_beta 0.49 8.43 5.92 1.46 8.62 9.33 5.56 0.16 4.33 9.64 3.58 7.48 1.05 4.23 9.19 6.81 6.22 1.88 
942 Olfactory_Signaling_Pathway 2.13 0.62 9.81 2.76 2.89 0.62 6.28 5.38 4.27 8.71 6.73 1.65 8.8 0.37 8.7 7.72 1.71 5.04 
943 Adenosine_P1_receptors 9.91 6.82 7.93 9.24 7.67 3.47 2.17 9.6 3.6 8.13 8.76 7.37 3.61 3.38 9.69 3.67 4.53 6.77 
944 Adrenoceptors 3.01 6.95 3.38 8.35 5.85 6.91 9.11 7.32 3.88 8.96 2.97 4.25 9.62 2.3 7.04 4.73 8.37 8.61 
945 Calcitonin-like_ligand_receptors 2.78 1.75 3.63 9.02 1.99 5.98 2.8 8.71 1.43 0 9.82 7.72 7.93 0.58 2.42 3.14 3 9.81 
946 Chemokine_receptors_bind_chemokines 0.65 2.29 0.91 9.53 2.75 1.33 1.16 5.54 6.71 4.76 0.4 0.71 8.79 3.71 4.53 7.85 4.45 8.94 
947 Class_C/3_(Metabotropic_glutamate/pheromone_receptors) 7.69 6.09 9.01 0.45 3.52 5.89 5.73 6.53 1.36 2.77 1.15 4.14 9.87 0.56 5.18 1.09 3 3.64 
948 Dopamine_receptors 9.67 2.77 0.06 1.66 9.29 0.74 6.97 5.83 1.91 9.03 2.14 0.72 2.69 6.32 7.97 5.51 2.82 0.5 
949 Formyl_peptide_receptors_bind_formyl_peptides_and_many_other_ligands 8.04 0.1 1.49 0.66 2.03 7.55 1.57 3.23 3.03 4.69 6.77 4.04 4.44 3.74 1.28 6.17 6.86 0.62 
950 Free_fatty_acid_receptors 5.29 0.72 4.89 5.91 8.22 4.31 9.83 4.21 3.41 5.65 8.98 5.35 2.8 7.42 3.55 1.9 8.86 2.83 
951 Glucagon-type_ligand_receptors 3.71 3.98 9.94 9.69 9.59 8.84 0.48 1.68 3.13 0.31 8.04 3.43 3.81 8.33 4.21 9.66 0.49 2.47 
952 Histamine_receptors 8.99 8.37 6.89 0.07 8.61 3.55 0.41 3.14 2.94 5.77 0.6 0.82 8.16 7.92 3.65 4.46 4.89 3.44 
953 Hormone_ligand-binding_receptors 3.33 4.52 9.9 9.07 5.88 5.58 0.53 9.45 2.83 7.92 7.91 2.37 4.33 4.16 0.94 9.91 2.28 2.63 
954 Hydroxycarboxylic_acid-binding_receptors 6.51 1.16 3.14 0.48 0.36 8.43 0.17 6.62 2.04 0.65 5 3.15 1.23 8.08 3.75 8.86 3.27 3.39 
955 Leukotriene_receptors 7.65 0.52 7.07 7.41 5.51 5.78 2.15 8.11 2.8 8.34 6.24 4.39 3.03 4.13 0.01 4.06 4.61 3.04 
956 Lysosphingolipid_and_LPA_receptors 0.66 6.6 5.2 6.97 2.41 4.87 5.11 0.59 3.83 7.85 7.02 6.89 3.48 4.02 7.64 0.16 7.48 4.21 
957 Muscarinic_acetylcholine_receptors 9.23 3.2 1.95 0.65 3.52 8.76 0.16 0.2 5.16 9.36 8.95 5.39 2.74 5.22 4.17 5.16 6.02 2.12 
958 Opsins 5.11 1.92 7.17 6.81 0.69 5.31 7.38 0.86 1.96 4.78 0.88 5.95 0.98 9.68 0.29 7.06 7.02 1.28 
959 Orexin_and_neuropeptides_FF_and_QRFP_bind_to_their_respective_receptors 2.95 0.95 1.1 4.05 0.41 1.04 2.43 7.38 2 3.19 7.36 4.28 1.03 2.54 2.95 9.97 7.91 9.79 
960 P2Y_receptors 0.61 9.03 1.07 6.28 4.79 9.37 3.63 1.08 8.28 9.66 3.1 3.75 0.93 2.7 8.78 1.46 0.59 8.68 
961 Prostanoid_ligand_receptors 2.55 2.14 5.83 9.78 5.77 1.83 2.16 7.78 5.26 8.96 5.68 7.03 8.29 0.02 0.16 8.19 7.04 5.88 
962 Relaxin_receptors 2.69 8.26 3.31 7.48 2.51 1.34 4.06 8.31 4.26 0.53 6.85 6.3 0.21 2.8 2.7 8.18 4.5 9.17 
963 Serotonin_receptors 3.23 0.09 8.23 3.19 4.16 2.33 2.34 3.25 7.43 1.33 9.01 3.36 6.26 7.98 0.31 1.77 6.25 1.15 
964 Tachykinin_receptors_bind_tachykinins 5.26 1.86 2.29 2.99 4.51 9.47 7.24 2.5 5.43 8.09 7.02 4.91 7.73 1.94 4.79 1.02 3.75 5.64 
965 Vasopressin-like_receptors 2.86 3.86 5.9 5.58 5.65 7 7.64 2.71 2.42 1.13 3.89 4.7 6.93 4.48 8.21 5.05 6.59 0.27 
966 ERK1_activation 3.15 6.42 5.86 4.23 4.06 9.91 6.7 6.02 4.07 8.97 2.04 1.74 4.64 9.27 1.5 2.67 9.31 0.84 
967 ERK2_activation 2.14 1.37 6.62 1.1 4.22 8.77 1.97 1.69 4.06 1.64 6.88 0.03 6.15 2.86 8.55 8.09 9.85 6.69 
968 RAF_activation 7.08 4.26 0.32 7.75 9.04 3.3 7.8 8.07 9.92 8.9 5.28 2.75 4.09 7.98 7.31 2.82 7.3 3.35 
969 RAF_phosphorylates_MEK 0.06 7.64 7.05 4.18 2.22 7.82 3.84 1.92 6.82 6.77 6.09 8 2.87 3.79 6.24 0.82 3.78 4.25 
970 ERK1_activation 7.44 2.45 3.73 2.28 4.09 7.64 6.78 3.71 6.41 2.75 5.08 1.51 1.84 8.65 3.4 9.31 6.24 3.45 
971 ERK2_activation 4.83 9.99 7.8 7.21 0.2 2.16 0.4 1.82 6.77 6.58 1.07 2.23 0.37 2.24 5.68 3.78 7.36 6.03 
972 RAF_activation 2.43 9.24 0.55 2.34 1.7 8.45 2.89 4.01 2.49 6.11 5.02 7.97 2.9 7.58 1.18 9.18 0.61 9.96 
973 RAF_phosphorylates_MEK 4.53 5.5 0.05 2.77 2.26 7.13 9.55 7.13 6.09 8.7 4.79 6.81 7.41 2.05 7.96 8.84 1.54 6.41 
974 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 2.36 2.83 2.42 5.59 2.28 6.23 3.09 3.36 2.72 2.17 9.43 5.16 1.86 7.94 6.13 0.47 5.91 5.48 
975 GRB7_events_in_ERBB2_signaling 1.28 1.61 7.46 7.85 8.93 0.8 7.42 2.51 1.48 4.81 6.86 4.51 9.76 0.87 4.71 0.45 8.14 3.31 
976 Arachidonate_production_from_DAG 7.37 7.8 8.49 5.48 2.97 9.62 6.62 9.44 1.95 4.91 0.99 3.32 2.78 9.79 6.93 0.25 8.32 7.33 
977 EGFR_Transactivation_by_Gastrin 1.95 3.68 0.12 2.38 8.37 7.52 3.76 8.01 9.53 0.93 9.72 5.71 4.14 0.58 1.68 7.94 4.1 6.9 
978 ERK1_activation 2.54 2.18 5.62 2.28 3.68 2.96 7.13 3.57 4.74 2.34 5.86 7.38 1.79 1.51 8.57 5.02 7.13 7.07 
979 ERK2_activation 2.71 2.81 8.03 6.38 3.24 7.38 9.94 2.86 2.67 7.26 9.94 4.41 5.52 2.74 2.61 6.55 8.2 7.97 
980 RAF_activation 1.38 7.11 8.29 7.93 8.2 1.94 5.91 6.04 9.97 7.65 8.88 5.06 1.25 4.03 8.03 4.37 2.86 5.7 
981 RAF_phosphorylates_MEK 5.31 3.59 7.22 2.92 9.46 7.27 2.3 8.65 5.7 3.71 8.32 3.95 9.64 4.93 9.44 1.46 2.56 8.73 
982 Glucagon-type_ligand_receptors 8.11 9.53 1.48 3.34 8.78 1.37 1.04 7.31 4.57 3.56 6.73 7.63 1.53 5.01 7.48 7.8 0.34 9.1 
983 Histamine_receptors 6.86 0.93 2.05 0.42 4.98 0.78 6.39 5.4 6.42 7.96 2.34 5.35 5.37 3.17 4.08 8.24 7.45 2.8 
984 Hormone_ligand-binding_receptors 1.16 8.89 5.21 2.49 9.16 7.44 9.37 9.08 0.44 9.35 1.92 9.2 7.4 9.08 0.7 2.62 7.9 0.12 
985 Hydroxycarboxylic_acid-binding_receptors 1.02 2.1 5.84 4.12 3.9 5.93 6.09 4.16 2.58 1.71 0.33 5.67 2.93 9.72 9.29 2.47 6.58 9.25 
986 Activation_of_PKB 5.66 7.25 3.07 2.32 6.8 2.08 2.79 6.52 8.08 5.75 8.01 0.85 1.69 4.15 1.91 6.8 9.65 0.09 
987 ERK1_activation 5.6 6.45 1.39 6.92 2.01 9.74 7.36 3.91 0.58 8.07 4.69 2.66 3.08 4.15 9.35 6.77 3.82 9.66 
988 ERK2_activation 7.88 4.88 1.61 4.07 6.68 5.73 7.04 2.8 8.38 7.23 2.36 3.51 7.74 5.49 6.95 6.56 9.79 3.31 
989 Inhibition_of_TSC_complex_formation_by_PKB 6.55 5.16 2.61 2.54 6.54 5.96 0.38 6.01 4.63 8.62 4.8 9.59 8.11 2.15 9.44 5.44 7.98 6.42 
990 PDE3B_signalling 3.78 8.56 1.87 9.76 8.38 7.77 7.51 1.84 1.61 9.99 3.88 6.65 1.26 5.96 1.8 3.82 0.46 7.98 
991 RAF_activation 8.18 7.85 9.5 2.06 6.19 2.03 5.85 0.75 6.66 2.58 2.69 2.06 0.45 0.68 2.26 5.18 0.82 4.76 
992 RAF_phosphorylates_MEK 5.2 1.75 7.5 8.59 7.44 0.07 6.55 4.24 0.54 6.57 7.68 9.47 4.61 8.78 1.73 9.98 0.6 1.68 
993 Regulation_of_AMPK_activity_via_LKB1 7.76 3.97 0.24 0.48 6.03 0.16 6.58 6.75 5.67 1.9 6.58 1.77 8.05 4.2 0.12 1.91 4.5 8.47 
994 Regulation_of_Rheb_GTPase_activity_by_AMPK 5.3 9.01 5.6 7.9 8.5 9.77 2.19 8.44 0.34 3.33 4.65 7.32 0.73 6.39 6.7 1.97 3.43 3.52 
995 Release_of_eIF4E 9.34 8.16 8.56 4.48 7.64 5.36 0.52 3.6 1.23 9.3 2.91 6.23 1.07 6.44 2.24 5.29 1.27 7.95 
996 S6K1_signalling 9.15 8.52 5.32 7.28 2.19 9.17 2.52 8.91 7 8.35 7.72 0.74 1.73 9.06 5.55 3.95 1.49 6.19 
997 IRS_activation 0.04 8.89 4.8 3.46 6.93 6.92 1.08 8.73 4.09 7.72 2.25 1.87 8.91 3.42 8.88 7.14 4.44 5.12 
998 Activation_of_PKB 7.06 3.65 5.19 2.5 7.33 1.08 0.59 5.97 3.79 8.46 2.49 5.93 8.35 6.54 9.26 0.57 4.04 8.65 
999 ERK1_activation 0.59 1.06 2.95 9.39 8.52 0.05 0.93 0.83 3.49 5.12 7.93 7.56 9.63 6.67 2.7 1.65 8.34 2.97 
1000 ERK2_activation 0.44 3.39 4.75 2.86 9.83 5.24 3.85 4.25 5.93 3.12 3.72 6.42 5.22 3.24 5.81 6.77 6.93 6.55 
1001 Inhibition_of_TSC_complex_formation_by_PKB 8.99 6.79 0.84 9.45 0.45 0.24 8.94 3.04 8.33 9.22 2.24 7.16 6.53 0.9 7.46 7.74 0.04 2.2 
1002 PDE3B_signalling 7.08 7.41 2.19 0.83 5.76 1.85 2.2 2.65 1.53 1.15 0.43 0.84 7.57 6.84 2.15 6.19 8.47 1.81 
1003 RAF_activation 7.15 4.71 5.36 5.19 7.66 2.61 1.99 6.36 7.83 3.94 7.98 2.62 0.61 2.72 4.31 2.79 8.95 0.97 
1004 RAF_phosphorylates_MEK 3.19 0 3.19 2.73 8.5 6.14 0.44 4.17 9.51 7.54 2.72 4.4 4.93 4.15 6.07 3.89 1.42 3.93 
1005 Regulation_of_AMPK_activity_via_LKB1 7.45 4.59 3.63 7.57 9.22 6.2 7.04 9.47 1.04 8.01 9.62 1.39 9.08 4.72 5.98 7.83 2.53 8.72 
1006 Regulation_of_Rheb_GTPase_activity_by_AMPK 3.23 6.45 8.41 0.97 0.51 9.61 7.42 7.83 0.62 4.88 6.96 1.85 1.44 7.51 7.24 3.16 7.4 1.25 
1007 Release_of_eIF4E 3.48 5.1 0.49 1.1 3.23 1.92 5.72 4.66 1.08 0.19 2.7 3.89 1.1 9.9 6.79 7.12 2.75 0.3 
1008 S6K1_signalling 6.82 2.32 8.01 5.44 7.55 4.54 0.08 1.39 0.55 4.79 9.25 4.26 0.51 0.05 9.98 0.56 4.24 3.25 
1009 Activation_of_PKB 1.11 6.2 9.25 4.58 4.61 7.92 2.69 2.74 7.13 0.44 2.51 3.03 8.39 4.56 9.39 5.61 1.28 4.1 
1010 ERK1_activation 2.35 8.19 4.53 0.13 6.98 6.03 5.41 0.99 7.11 8.77 6.24 8.19 2.69 0.02 1.32 0.54 3.82 6.93 
1011 ERK2_activation 0.56 4.15 5.42 7.26 3.92 3.14 5.37 1.23 8.48 5.59 3.03 3.08 3.72 0.94 3.26 3.01 2.96 3.64 
1012 IRS_activation 4.41 4.41 4.99 2.07 0.65 9.01 1.69 5.35 8.01 6.83 0.9 1.82 4.62 0.33 6.37 4.57 1.1 6.33 
1013 Inhibition_of_TSC_complex_formation_by_PKB 2.09 2.63 9.6 0.9 0.37 3.93 0.29 1.27 6.85 7.95 2.45 0.7 6.88 2.35 4.29 9.15 0.01 4.15 
1014 PDE3B_signalling 6.15 2.22 8.59 3.47 5.47 6.74 5.84 2.51 9.17 4.88 7.63 1.26 5.43 9.48 1.97 4.52 6.4 8.05 
1015 RAF_activation 7.25 6.57 1.49 8.11 7.23 8.1 2.07 2.76 6.71 2.31 1.89 7.76 4.45 1.06 7.95 1.98 3.4 8.08 
1016 RAF_phosphorylates_MEK 3.47 9.5 0.23 7.65 1.24 8.16 1.16 2.69 2.56 4.53 6.59 1.6 0.9 6.21 3.53 2.21 5.43 6.8 
1017 Regulation_of_AMPK_activity_via_LKB1 1.1 6.18 8.2 2.89 5.63 2.11 9.53 3.76 2.72 9.93 2.69 8.71 3.81 8.05 5.86 2.47 7.84 7.9 
1018 Regulation_of_Rheb_GTPase_activity_by_AMPK 1.54 2.27 0.3 3.74 1.37 0.69 4.05 2.28 5.17 5.68 7.13 5.98 6.36 1.91 7.41 5.64 8.53 1.56 
1019 Release_of_eIF4E 4.13 8.29 3.38 1.3 8.9 2.76 5.55 7.99 3.34 7.07 7.27 6.69 5.12 1.07 7.75 3.76 4.26 8.75 
1020 S6K1_signalling 4.59 4.77 4.41 9.83 3.61 8.96 0.21 1.71 3.95 8.62 4.82 1.76 3.05 9.09 3.17 2.21 7.34 2.88 
1021 Activation_of_PKB 6.75 1.78 6.39 9.2 4.39 9.85 2.42 6.87 0.58 0.63 9.15 6.71 5.76 5.38 7.33 2.59 0.48 3.14 
1022 ERK1_activation 1.51 8.36 5.41 5 5.64 0.46 6.99 0.77 5.68 0.28 4.91 0.92 0.8 2.33 8.11 4.84 9.69 2.24 
1023 ERK2_activation 0.55 5.2 4.51 5.35 5.41 0.24 1.99 4.32 9.44 3.07 8.55 5.28 4.74 5.97 4.14 2.99 1.92 5.55 
1024 Inhibition_of_TSC_complex_formation_by_PKB 2.72 9.28 4.97 1.48 1.94 2.08 8.07 6.26 3.89 1.09 1.45 6.97 6.15 0.81 8.96 0.64 4.51 1.17 
1025 PDE3B_signalling 0.48 6.14 4.1 9.63 2.73 3.03 1.94 5.33 0.07 7.67 8.38 4.15 2.47 1.73 8.86 0.58 9.48 9.88 
1026 RAF_activation 7.36 5.95 9.52 3.42 4.55 9.64 5.66 8.82 3.47 1.46 7.92 0.8 4.17 0.95 9.4 7.14 0.29 7.84 
1027 RAF_phosphorylates_MEK 9.65 7.49 1.97 3.53 3.67 0.16 5.04 0.63 8.66 6.05 0.86 0.54 9.31 2.94 3.69 0.85 0.39 7.05 
1028 Regulation_of_AMPK_activity_via_LKB1 3.81 1.43 6.98 1.26 6.28 4.51 4.64 3.69 0.7 2.7 3.13 5.32 4.63 0.95 3.06 0.47 1.6 5.95 
1029 Regulation_of_Rheb_GTPase_activity_by_AMPK 0.81 7.94 4.9 2.67 5.61 7.37 6.33 5.95 5.28 2.49 1.98 2.52 2.29 2.83 3.51 3.56 9.01 7.74 
1030 Release_of_eIF4E 0.83 3.16 9.83 1.38 9.04 5.06 4.63 7.63 2.8 6.16 4.01 2.34 1.56 7.73 5.75 1.06 2.71 8.03 
1031 S6K1_signalling 9.64 4.01 8.3 9.61 7.85 8.3 7.9 1.21 8.71 8.18 3.26 8.44 0.39 1.94 0.31 9.73 7.75 5.4 
1032 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 0.34 2.67 7.26 1.27 2.8 9.79 7.77 9.92 2.64 6.94 3.83 4.51 4.76 8.95 0.58 9.98 7.57 5.67 
1033 Inhibition_of_TSC_complex_formation_by_PKB 0.23 5 1.05 4.68 1.36 4.65 5.77 7.51 9.43 5.45 9.52 4.06 1.5 0.62 5.77 0.82 1.73 3.7 
1034 Insulin_receptor_recycling 1.2 8.01 7.8 1.77 1.8 7.66 9.37 1.15 4.35 5.19 7.16 6.4 3.42 5.91 8.34 5.16 3.35 2.14 
1035 Activation_of_PKB 0.79 2.46 6.89 5.18 7.18 2.44 7.9 5.11 5.42 9.05 9.67 8.45 6.13 2.57 9.19 3.76 4.08 7.48 
1036 ERK1_activation 9.12 9.97 7.11 4.1 1.71 7.95 9.31 3.1 2.9 3.44 4.73 6.94 5.29 3.33 8.75 3.62 7.88 4.15 
1037 ERK2_activation 4.37 7.3 8.82 1.68 7.33 6.05 9.47 7.5 8.22 3.51 0.29 7.53 2.47 6.1 7.09 6.91 1.44 6.73 
1038 IRS_activation 6.37 8.27 2.76 1.69 3.84 4.34 7.74 8.01 9.66 4.1 5.17 1.16 0.84 0.84 9.05 2.36 2.59 0.09 
1039 Inhibition_of_TSC_complex_formation_by_PKB 6.27 6.41 8.05 1.23 6.16 4.66 1.23 8.93 7.67 7.71 4.34 2.88 9.47 4.96 9.43 4.71 9.86 4.8 
1040 PDE3B_signalling 1.85 6.05 7.67 9.34 8.54 3.18 9.57 7.56 7.93 9.95 9.73 2.49 6.5 0.42 0.18 3.65 9.1 8.22 
1041 RAF_activation 2.43 6.74 4.08 0.42 3.29 1.82 7.28 7.56 0.33 2.62 8.99 4.96 6.44 4.52 3.32 8.97 4.53 2.12 
1042 RAF_phosphorylates_MEK 5.62 3.76 1.95 1.72 9.77 1.5 1.52 2.82 4.05 5.64 5.12 5.39 4.04 0.69 7.58 3.76 9.48 8.26 
1043 Regulation_of_AMPK_activity_via_LKB1 1.08 4.35 5.42 9.67 3.54 1.47 7.05 8.84 9.53 3.97 2.41 9.51 8.72 2.44 1.53 8.15 1.18 1.22 
1044 Regulation_of_Rheb_GTPase_activity_by_AMPK 2.46 2.2 2.97 8.71 6.46 7.81 9.11 3.28 7.46 6.9 4.19 9.24 0.4 3.88 9.38 2.28 3.72 3.21 
1045 Release_of_eIF4E 8.3 2.81 5.59 3.72 7.38 5.7 1.76 0.05 0.32 4.29 6.19 3.89 9.68 5.42 9.83 6.37 1.61 5.75 
1046 S6K1_signalling 5.81 8.87 0.61 5.43 4.69 8.04 9.84 9.97 3.71 7.84 0.01 4.3 0.26 5.87 3.48 6.54 2.87 6.09 
1047 SHC_activation 4.07 3.31 6.42 5.96 4.44 9.6 3.45 5.29 6.39 0.09 4.21 9.68 7.68 7.46 4.16 2.88 4.67 6.29 
1048 Signal_attenuation 1.19 6.67 9.5 5.32 5.57 5.89 8.34 8.59 3.93 3.63 6.06 9.78 6.41 4.58 0.24 9.86 5.26 6.29 
1049 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 3.57 5.17 7.13 6.51 6.12 5.07 3.35 6.15 1.82 2.26 7.53 0.74 7.52 2.13 0.87 8.31 5.48 4.88 
1050 p130Cas_linkage_to_MAPK_signaling_for_integrins 6.79 2.93 3.97 8.99 3.68 3.14 1.94 9.9 6.03 5.34 5.41 9.4 1.88 8.38 9.87 5.71 7.34 0.82 
1051 FGFR1c_and_Klotho_ligand_binding_and_activation 7.18 8.91 5.09 2.73 6.66 4.12 8.88 0.84 1.26 0.21 7.74 4.48 0.52 0.82 9.75 3.67 6.98 6.46 
1052 betaKlotho-mediated_ligand_binding 6.95 7.05 0.49 2.17 0.15 3.67 1.89 7.8 3.73 5.61 5.9 6.19 1.09 6.72 2.15 4.25 1.11 0.06 
1053 Leukotriene_receptors 4.54 1.95 5.07 8.37 6.83 9.57 9.63 5.02 3.96 0.9 6.16 4.99 1.68 2.99 1.27 1.67 5.39 4.45 
1054 Lysosphingolipid_and_LPA_receptors 4.84 0.04 1.61 7.27 0.64 6.6 3.9 4.12 2.4 1.8 4.06 5.51 5.5 4.78 0.48 0.2 3 8.39 
1055 RAF_phosphorylates_MEK 6.4 3.35 1.42 8.09 3.25 5.43 6.95 0.57 0.56 2.34 2.63 0.91 5.35 4.79 7.07 8.68 4.65 4.16 
1056 Muscarinic_acetylcholine_receptors 0.93 6.73 5.79 0.31 9.18 1.18 7.86 5.78 3.13 6.5 2.25 8.26 5.78 2.73 1.01 1.04 1.83 7.85 
1057 NADE_modulates_death_signalling 7.83 7.29 2.38 3.93 2.67 4.68 2.47 5.43 6.47 4.57 6.11 6.73 9.97 3.49 8.37 8.95 6.2 5.07 
1058 NF-kB_is_activated_and_signals_survival 1.68 4.47 9 4.61 4.33 6.16 1.93 1.07 3.5 0.75 2.18 0.91 7.35 6.78 9.86 7.29 9.64 3.07 
1059 NFG_and_proNGF_binds_to_p75NTR 2.86 4.25 0 1.14 9.85 9.31 0.52 8.1 0.05 9.74 4.47 7.57 2.5 4.33 8.68 5.73 7.16 3.26 
1060 NGF_processing 7.89 2.33 2 8.47 5.51 0.93 3.34 0.61 2.21 5.69 8.86 8.79 5.21 3.52 0.28 1.68 2.89 7.63 
1061 AKT_phosphorylates_targets_in_the_cytosol 1.66 0.84 0.47 8.87 8.56 8.44 1.55 9.89 1.01 1.92 6.68 3.53 2.49 9.41 7.33 0.29 4.61 5.92 
1062 AKT_phosphorylates_targets_in_the_nucleus 0.45 9.27 3.79 6.57 6.81 1.36 4.02 0.74 9.5 9.9 6.84 6.34 6.58 7.48 0.06 0.53 0.74 1.92 
1063 CREB_phosphorylation 8.07 9.19 2.74 6.86 9.17 8.89 0.72 1.63 4.77 9.47 0.01 0.61 9.29 6.03 3.92 6.25 3.99 3.89 
1064 CaMK_IV-mediated_phosphorylation_of_CREB 1.64 5.88 4.95 4.67 5.22 6.7 1.73 7.02 9.63 6.92 3.61 7.66 0.08 5.34 6.99 3.34 3.54 7.76 
1065 Cam-PDE_1_activation 5.7 1.88 0.46 7.56 6.54 1.6 1.06 7.51 8.28 4.74 3.13 6.83 5.63 2.49 7.97 8.06 7.89 6.97 
1066 ERK1_activation 6.7 2.89 1.6 8.93 3.73 8.19 0.54 7.1 6.46 3.99 0.25 0.98 5.66 2.51 2.75 5.44 2.56 9.38 
1067 ERK2_activation 6.93 8.03 3.35 5.89 3.5 2.85 4.55 5.81 3.91 0.3 4.84 9.64 2.52 7.33 2.16 9.57 0.37 8.31 
1068 ERKs_are_inactivated 5.99 6.49 6.46 3.25 0.22 9.56 1 8.58 8.51 7.03 9.14 1.34 7.58 8.95 3.94 9.73 0.56 6.62 
1069 NGF-independant_TRKA_activation 4.23 6.76 1.63 2.48 2.9 0.04 4.42 5.36 7.48 2.63 9.86 7.72 2.44 6.19 6.66 0.7 2.01 1.49 
1070 Negative_regulation_of_the_PI3K/AKT_network 0.23 8.93 6.59 4.39 4.67 3.24 4.05 6.93 5.34 3.29 1.41 4.05 4.86 1.21 4.79 7.74 7.07 8.26 
1071 PKA_activation 7.9 7.78 7.34 8.97 7.16 0.7 4.27 7.41 1.09 1.61 3.72 0.35 2.87 2.03 5.37 5.79 0.21 0.73 
1072 RAF_activation 2.13 3.7 6.36 7.5 8.02 8.58 4.37 7.8 3.11 4.88 2.21 7.31 5.21 1.4 0.01 9.05 4.32 4.86 
1073 RAF_phosphorylates_MEK 2.62 1.23 6.84 3.91 3.11 0.74 1.36 0.94 6.72 7.7 8.45 8.28 8.59 3.27 9.69 9.3 2.33 7.85 
1074 Retrograde_neurotrophin_signalling 1.7 6.17 9.08 6.49 0.7 1.14 7.86 4.92 5.01 5.35 6.92 8.08 1.53 0.41 5.28 4.85 5.96 3.96 
1075 Signalling_to_ERK5 9.56 3.82 3.79 6.32 1.64 6.87 3.86 2.1 5.01 7.13 6.24 4.58 0.91 1.41 6.36 8.86 8.32 2.05 
1076 Signalling_to_STAT3 6.08 6.47 3.5 7.93 1.65 0.33 9.83 3.2 1.28 4.33 1.63 4.77 1.63 7.15 4.26 9.8 8.39 8.66 
1077 TRKA_activation_by_NGF 7.7 2.85 8.32 2.03 6.27 9.21 9.13 4.75 8.41 3.46 9.7 4.64 7.7 2.8 3.19 1.02 0.57 0.89 
1078 p38MAPK_events 0.35 3.4 3.46 9.12 8.29 3.66 2.46 9.06 3.14 4.52 2.98 6.37 7.95 6.1 3.07 2.18 4.8 2.73 
1079 NGF-independant_TRKA_activation 0.37 9.72 8.84 3.34 0.84 7.93 5.63 8.33 2.42 6.49 1.38 0.97 7.86 3.97 2.55 6.79 9.08 0.01 
1080 NOTCH1_Intracellular_Domain_Regulates_Transcription 5.76 8.4 6.67 1.41 6.72 6.95 7.31 0.64 3.75 9.78 4.87 8.62 6.25 0.99 1.14 8.37 8.26 9.85 
1081 NOTCH2_Activation_and_Transmission_of_Signal_to_the_Nucleus 9.24 0.58 9.68 6.88 5.83 1.93 0.82 3.11 6.91 9.88 4.31 1.85 6.15 8.03 4.66 2.23 2.8 8.05 
1082 NOTCH2_intracellular_domain_regulates_transcription 7.89 5.16 2.39 6.14 9.48 9.84 3.66 3.86 4.19 5.76 6.67 3.53 4.1 6.78 2.01 8.12 7.36 1.73 
1083 NRAGE_signals_death_through_JNK 0.19 1.99 9.42 4.89 6.58 9.27 5.65 9.8 0.65 5.49 6.74 4.83 9.11 3.15 6.09 6.67 9.88 2.79 
1084 NRIF_signals_cell_death_from_the_nucleus 2.65 4.06 8.96 2.14 4.78 0.5 0.88 7.71 5.48 5.64 0.26 4.48 5.07 1.84 3.56 1.32 8.22 2.77 
1085 Spry_regulation_of_FGF_signaling 5.44 3.01 8.88 3.99 4.43 2.72 1.53 8.84 6.53 1.11 0.77 1.16 7.31 6.9 5.5 9.22 6.04 0.97 
1086 Negative_regulation_of_the_PI3K/AKT_network 3.47 0.8 1.21 5.13 7.69 0.9 7.13 6.85 6.89 5.3 0.59 5.59 6.74 0.84 7.09 6.87 0.25 2.26 
1087 Neurophilin_interactions_with_VEGF_and_VEGFR 3.56 7.15 7.02 2.91 3.41 3.52 7.6 8.15 8.76 6.56 6.43 7.42 4.51 7.4 2.66 9.06 3.98 5.71 
1088 CREB_phosphorylation 8.4 7.7 6.12 9.64 0.83 0.01 9.44 2.25 9.23 2.22 2.48 9.89 5.27 4.61 2.3 7.27 3.61 9.34 
1089 ERKs_are_inactivated 7.74 2.95 9.23 3.96 8.79 0.88 3.93 2.09 6.69 1.74 8.65 0.56 2.06 9.54 1.45 2.51 5.08 2.85 
1090 Prolactin_receptor_signaling 6.48 6.06 9.47 2.81 3.76 7.64 5.31 8.3 6.42 3.2 6.07 8.67 7.86 5.74 7.91 6.83 7.56 7.07 
1091 Adenosine_P1_receptors 1.56 8.43 2.64 9.63 2.26 6.88 2.42 4.34 1.14 7.02 0.77 2.45 9.93 1.35 0.4 8.01 3.55 7.52 
1092 P2Y_receptors 8.49 6.84 1.24 3.95 7.78 4.67 6.89 2.64 4.1 1.08 2.02 2.85 3.81 3.49 4.02 6.48 9.58 0.12 
1093 Olfactory_Signaling_Pathway 5.94 0.58 6.52 6.96 1.15 3.34 1.06 7.6 0.9 5.62 6.12 2.59 1.13 0.7 4.71 2.55 6.36 8.91 
1094 Adenylate_cyclase_activating_pathway 5.76 7.82 4.9 9.9 9.76 4.94 7.81 8.92 8.46 0.64 9.7 6.4 2.61 6.6 2.12 1.55 2.79 4.82 
1095 Adenylate_cyclase_inhibitory_pathway 3.18 4.75 4.83 4.76 8.65 6.39 1.07 6.34 2.13 0.74 4.49 1.18 1.07 2.47 5.31 3.62 9.14 7.56 
1096 CaMK_IV-mediated_phosphorylation_of_CREB 7.72 5.26 5.76 3.21 8.93 1.18 8.68 3.62 0.36 3.47 2.58 5.71 0.04 5.77 1.9 9.24 3.01 8.33 
1097 Cam-PDE_1_activation 5.8 1.58 2.69 4.96 6.07 2.45 9.99 2.08 6.17 2.54 3.72 5.17 5.23 4.5 1.67 3.62 3.73 1.8 
1098 DARPP-32_events 1.96 4.53 3.84 4.63 1.56 8.09 9.46 9.23 6.34 0.51 3.14 1.22 4.34 6.39 5.4 0.06 9.31 1.63 
1099 G-protein_activation 5.27 7.02 9.54 8.28 9.81 8.89 9.85 2.4 9.23 0.66 5.36 6.92 6.91 5.64 8.19 2.31 9.98 3.03 
1100 PKA_activation 3.39 1.5 6.93 6.19 1.38 1.21 3.93 1.49 0.65 5.34 2.49 7.92 9.24 4.05 8.61 7.42 3.85 1.16 
1101 phospho-PLA2_pathway 9.85 4.55 1.88 0.44 3.8 0.01 8.71 3.39 5.53 1.29 0.56 0.59 7.73 3.45 0.83 7.7 1.86 0.9 
1102 Opsins 1.78 7.56 4.84 7.24 9.22 9.91 7.15 6.84 4.72 4.37 3.84 5.32 2.12 2.71 6.83 2.81 7.25 5.83 
1103 Orexin_and_neuropeptides_FF_and_QRFP_bind_to_their_respective_receptors 0.44 8.34 1.72 1.91 9.52 0.2 5.97 2.96 6.62 2.3 4.28 4.38 5.47 7.93 3.48 1.38 7.63 7.43 
1104 P2Y_receptors 8.14 3.12 4.49 3.37 4.96 4.59 4.57 6.49 9 8.61 1 1.83 0.34 2.67 1.16 2.42 7.52 7.35 
1105 PDE3B_signalling 9.2 9.41 8.25 9.84 4.33 4.69 0.28 7.52 4.7 4.4 1.68 3.65 0.62 9.76 3.24 1.7 7.01 1.99 
1106 AKT_phosphorylates_targets_in_the_cytosol 8.43 1.18 3.28 3.09 4.55 5.17 7.64 7.68 4.85 7.18 7.55 6.2 0.03 2.93 1.53 3.15 8.21 8.42 
1107 AKT_phosphorylates_targets_in_the_nucleus 0.46 2.15 7.81 3.78 0.85 7.66 3.16 0.52 7.97 3.64 1.16 5.34 4.53 5.11 5.21 2.8 8.29 1.35 
1108 Negative_regulation_of_the_PI3K/AKT_network 2 7.05 9.38 6.69 6.05 4.74 4.03 6.94 3.23 4.8 6.9 4.31 2.88 8.78 5.09 3.31 8.95 3.46 
1109 Activation_of_PKB 7.9 2.99 7.06 7.26 7.35 4.94 6.31 2.02 1.94 2.33 7.7 2.56 6.8 1.6 5.32 4.88 3.92 3.09 
1110 Inhibition_of_TSC_complex_formation_by_PKB 8.51 5.9 9.22 3.68 7.3 5.84 4.68 9.93 1.62 0.12 2.54 0.18 4.24 9.86 9.53 3.6 6.41 6.69 
1111 PDE3B_signalling 5.33 0.51 3.88 1.12 1.47 4.2 4.55 5.74 2.56 0.55 8.61 7.63 6.28 6.01 9.1 5.69 5.29 1.88 
1112 Regulation_of_AMPK_activity_via_LKB1 0.15 8.86 2.32 5.68 3.07 6.12 5.28 8.84 2.02 5.28 2.16 2.21 5.86 6.08 9.67 2.06 2.19 4.94 
1113 Regulation_of_Rheb_GTPase_activity_by_AMPK 2.74 0.81 1.35 7.46 9.82 3.65 6.74 2.56 8.87 0.17 5.58 8.29 7.92 8.71 9.78 8 1.56 6.76 
1114 Release_of_eIF4E 9.8 7.98 2.36 7.12 8.37 1.98 4.17 2.49 2.36 9.51 9.33 6.93 1.97 4.14 0.37 5.51 0.67 7.32 
1115 S6K1_signalling 7.06 8.09 7.71 2.96 9.13 5.16 1.08 3.05 1.67 2.43 8.04 3.43 9.92 1.67 6.68 3.7 4.02 1.58 
1116 AKT_phosphorylates_targets_in_the_cytosol 5.51 8.91 2.06 5.33 9.11 0.9 6.79 9.6 5.45 5.35 6.38 6.55 6.66 4.05 0.92 2.84 4.97 2.75 
1117 AKT_phosphorylates_targets_in_the_nucleus 1.85 8.5 1.91 6.13 6.93 3.04 6.84 8.27 1.58 3.74 7.16 3.45 8.66 2.88 5.78 7.99 8.93 4.88 
1118 Negative_regulation_of_the_PI3K/AKT_network 1.63 1.69 5.72 5.6 7.27 1.21 2.43 7.77 0.44 6.91 4.6 2.54 7.39 4.18 1.53 7.96 9.75 3.53 
1119 AKT_phosphorylates_targets_in_the_cytosol 6.04 6.94 1.23 1.65 3.4 4.27 0.03 7.21 8.91 8.03 2.29 1.77 5.99 0.19 1.69 4.76 8.69 2.21 
1120 AKT_phosphorylates_targets_in_the_nucleus 5.2 5 0.6 0.2 4.73 8.95 2.49 4.3 4.66 0.83 3.03 3.86 4.84 8.05 6.42 2.28 9.35 6.35 
1121 Negative_regulation_of_the_PI3K/AKT_network 7.32 4.78 9.61 4.11 0.95 8.18 3.61 4.19 8.75 0.54 1.04 2.83 4.11 3.1 7.79 8.32 2.67 8.16 
1122 AKT_phosphorylates_targets_in_the_cytosol 9.22 8.42 4.85 3.24 4.2 1.59 3.24 9.79 4.39 2.33 7.44 8.26 4.82 0.46 2.6 7.03 3.26 8.48 
1123 AKT_phosphorylates_targets_in_the_nucleus 6.76 6.19 3.73 2.12 0.83 7.76 7.69 0.78 9.23 8.36 1.36 8.77 5.43 0.86 2.86 2.66 0.78 9.29 
1124 Negative_regulation_of_the_PI3K/AKT_network 4.27 9.03 1.76 1.2 2.55 3.5 9.66 8.17 2.04 3.43 8.21 5.33 9.23 1.42 4.91 8.3 9.77 6.12 
1125 AKT_phosphorylates_targets_in_the_cytosol 7.81 4.65 6.59 3.33 2.56 4.46 5.35 9.95 7.67 7.74 3.89 8.89 8.29 3.41 8.55 6.34 5.55 2.16 
1126 AKT_phosphorylates_targets_in_the_nucleus 5.08 8.5 1.79 4.73 5.47 7.65 5.82 4.24 0.39 8.55 5.16 2.52 9.65 7.4 2.66 5.86 1.98 4.33 
1127 Negative_regulation_of_the_PI3K/AKT_network 3.77 7.33 2.33 8.42 8.6 3.83 9.84 4.13 5.85 0.63 3.82 2.71 8.92 3.96 2.39 1.1 9.13 4.01 
1128 PKA_activation 5.77 6.87 6.81 3.93 6.58 2.97 3.1 6.29 9.06 5.46 8.74 9.31 7.38 5.12 8.37 3.93 0.29 4.42 
1129 PKA_activation 7.1 9.06 9.82 4.56 1.56 2.4 4.66 3.36 5.89 8.12 1.11 7.23 0.46 3.86 8.29 0.15 5.24 1.76 
1130 Inhibition_of_TSC_complex_formation_by_PKB 1.56 6.94 5.55 2.72 9.11 5.83 6.05 7.79 5.6 3.87 8.45 5.29 8.03 6.51 7.08 3.59 5.27 3.85 
1131 PDE3B_signalling 3.96 1.92 4.1 4.12 0.84 4.07 7.89 2.63 5.79 6.19 9.92 0.2 4.88 8.36 1.42 2.53 3.53 2.05 
1132 Regulation_of_AMPK_activity_via_LKB1 9.41 0.03 0.34 7.39 4.07 6.27 1.93 6.53 9.8 3.9 7.52 3.17 3.88 0.15 0.5 3.42 5.27 9.15 
1133 Regulation_of_Rheb_GTPase_activity_by_AMPK 7.86 1.49 7.91 5.24 6.32 9.33 9.93 5.74 4.53 1.58 0.8 3.98 8.57 3.26 7.3 4.87 9.39 9.07 
1134 Release_of_eIF4E 6.47 7.11 0.97 1.51 7.59 9.45 9.36 3.08 7.95 6.12 7.5 8.26 7.44 8.61 0.71 2.64 1.03 4.4 
1135 S6K1_signalling 4.45 7.99 0.72 8.45 0.35 2.53 4.32 7.68 8.75 1.68 7.92 6.17 0.62 8.65 1.13 8.7 0.53 1.16 
1136 CaMK_IV-mediated_phosphorylation_of_CREB 4.21 9.02 6.29 9.57 1.43 6.55 9.44 3.49 2.29 0.97 1.22 7.65 1.72 0.05 3.77 0.98 5.5 1.37 
1137 Cam-PDE_1_activation 5.85 9.54 0.56 4.53 7.99 4.46 0.23 2.75 1.88 2.96 7.96 2.5 5.16 9.83 5.56 9.79 7.03 1.44 
1138 PKA_activation 5.17 3.76 5.04 0.95 2.3 0.74 7.89 9.27 3.03 5.86 3.74 1.18 5.21 2.82 9.61 6.52 5.03 9.88 
1139 phospho-PLA2_pathway 4.44 7.42 7.89 7.07 8.37 5.98 1.52 2.82 9.91 5.89 5.34 9.62 9.98 2.36 1.67 1.51 8.85 5.83 
1140 CaMK_IV-mediated_phosphorylation_of_CREB 0.76 5.33 7.26 8.11 7.99 0.71 5.7 0.18 3.96 2.48 5.21 9.96 2.54 6.61 6.76 0.48 0.76 6.91 
1141 Cam-PDE_1_activation 7.28 7.32 0.29 7.73 8.7 1.85 5.7 9.29 0.9 3.94 8.04 3.4 4.33 2.78 8.7 3.55 7.9 7.4 
1142 PKA_activation 5.88 7.95 6.14 1.35 6.6 2.99 8.26 4.26 9.47 6.73 7.81 7.65 8.76 9.05 6.23 3.77 7.4 2.85 
1143 CaMK_IV-mediated_phosphorylation_of_CREB 4.33 1.93 8.89 8.66 5.94 3.37 7.65 0.55 0.74 9.79 0.29 7.16 3.41 8.24 8.31 7.76 1.13 6.76 
1144 Cam-PDE_1_activation 8.11 0.67 4.76 6.37 1.53 7.42 6.32 9.33 2.59 3.27 2.48 3.1 9.88 1.29 3.12 3.73 7.94 2.84 
1145 PKA_activation 5.59 2.74 3.84 3.21 3.92 9.67 5.11 1.6 2.42 4.31 0.79 7.81 4.93 2.58 9.6 0.17 0.38 3.5 
1146 Chemokine_receptors_bind_chemokines 4.37 9.65 2.21 2.31 6.11 7.64 8.36 0.26 1.74 2.25 4.9 1.98 9.01 8.31 3.05 6.69 6.23 3.76 
1147 Formyl_peptide_receptors_bind_formyl_peptides_and_many_other_ligands 3.25 6.26 5.91 5.28 3.27 9.55 8.12 4.9 0.64 6.72 4.59 6.75 8.18 0.76 6.89 4.94 4.27 7.48 
1148 Orexin_and_neuropeptides_FF_and_QRFP_bind_to_their_respective_receptors 0.91 3.92 5.87 0.46 3.93 3.17 8.4 2.44 3.71 2.18 8.88 5.45 1.38 2.13 3.92 2.11 6.18 7.94 
1149 Relaxin_receptors 6.98 5.77 9.74 8.71 2.6 8.15 5.09 1.7 6.22 8.16 5.64 6.26 4.83 9.79 9.4 6.83 9.73 2.17 
1150 Tachykinin_receptors_bind_tachykinins 9.01 5.26 5.87 2.62 1.39 2.23 6.36 1.82 5.12 9.69 5.36 6.9 9.54 2.31 4.28 7.39 1.34 2.69 
1151 Vasopressin-like_receptors 8.63 7.59 0.85 2.31 9.95 1.29 3.42 6.39 5.1 0.61 9.41 2.45 2.01 5.72 8.82 7.22 8.4 6.45 
1152 CaMK_IV-mediated_phosphorylation_of_CREB 7.57 2.21 3.08 8.86 0.25 0.66 0.54 3.69 0.38 7.12 3.25 6.73 8.59 5.46 7.77 2.15 0.11 8.8 
1153 Cam-PDE_1_activation 9.85 0.64 5.36 0.31 6.74 0.02 9.58 2.14 2.16 0.07 2.17 2.26 2.98 4.24 7.85 9.57 7.05 9.82 
1154 PKA_activation 8.85 3.06 0.58 2.61 6.22 9.4 2.37 3.31 3.41 4.79 0.28 3.03 1.2 2.79 3.75 9.97 2.81 9.76 
1155 Pre-NOTCH_Processing_in_Golgi 8.72 9.85 0.95 0.94 9.31 3.69 7.13 5.74 0.8 2.72 0.96 7.01 3.63 5.93 6.92 5.43 8.52 7.21 
1156 Pre-NOTCH_Processing_in_the_Endoplasmic_Reticulum 7.7 4.5 2.11 5.28 2.37 1.32 7.58 7.84 3.23 1.15 6.87 0.23 1.77 9.4 5.11 3.7 8.41 9.89 
1157 Pre-NOTCH_Transcription_and_Translation 2.96 6.03 3.38 7.51 3.53 8.05 8.73 6.3 7.86 3.24 5.11 0.11 5.55 2.75 5.55 1.48 0.33 2.64 
1158 Pre-NOTCH_Processing_in_Golgi 5.94 1.78 2.33 0.58 0.76 7.47 9.43 0.3 7.53 9.93 4.25 8.54 9.23 0.68 4.63 8.36 7.57 4.91 
1159 Pre-NOTCH_Processing_in_the_Endoplasmic_Reticulum 9.42 9.74 6.13 6.8 7.5 3.46 3.34 6.93 9.45 8.59 6.65 2.33 9.89 6.36 9.24 3.43 0.67 9.33 
1160 Pre-NOTCH_Transcription_and_Translation 1.48 7.61 1.36 1.64 6.96 7.29 7.96 0.77 1.49 5.61 6.26 2.93 5.61 4.44 7.91 4.43 3.54 6.91 
1161 Prolactin_receptor_signaling 9.99 3.13 0.79 7.88 6.12 0.5 0.26 2.73 6.4 6.92 9 2.69 7.65 6.23 8.49 1.8 5.3 8.94 
1162 ERK1_activation 1.58 7.23 6.97 3.18 1.76 6.05 4.07 6.85 2.7 2.4 1.96 2.14 4.5 8 7.8 6.73 5.96 1.78 
1163 ERK2_activation 8.05 8.31 1.84 3.64 7.45 5.75 6.57 0.43 1.82 2.19 8.06 5.56 3.57 4.15 6.83 6.95 7.84 7.3 
1164 RAF_activation 1.31 0.97 4.71 2.85 3.33 9.61 5.73 2.28 0.29 9.73 8.46 6.67 8.92 4.94 1.23 2.92 6.9 2.74 
1165 RAF_phosphorylates_MEK 5.7 1.5 9.55 7.36 0.64 7.51 7.2 2.73 3.52 7.09 5.12 8.85 6.01 4.09 9.9 0.67 2.18 0.85 
1166 Prostanoid_ligand_receptors 1.25 6.7 2.25 3.04 8.33 3.16 9.17 0.23 4.4 0.48 0.56 2.3 1.77 5.31 8.81 0.72 0.19 4.06 
1167 RAF_activation 7.37 5.87 5.37 8.51 7.57 0.16 8.12 4.45 8.11 5.54 0.42 6.13 2.48 6.36 9.5 8.78 0.41 4.31 
1168 RAF_phosphorylates_MEK 0.8 4.59 9.85 2.6 8.71 3.68 6.75 3.19 5.88 7.99 1.84 0.22 0 7.88 6.5 0.41 5.84 5.7 
1169 ERK1_activation 7.78 1.37 2.16 0.47 4.31 5.41 8.86 4.29 2.01 7.47 5.77 5.47 5.65 4.76 1.38 6.36 4.73 9.23 
1170 ERK2_activation 7.45 9.66 7.07 1.03 4.11 8.06 4.85 4.71 7.46 0.66 6.75 8.3 4.3 6.14 1.28 1.28 2.11 5.07 
1171 RAF_activation 8.3 3.87 1.3 2.77 4.52 0.17 6.29 6.2 3.89 7.09 0.77 4.46 3.83 8.11 5.5 2.66 6.97 0.7 
1172 RAF_phosphorylates_MEK 9.1 1.12 2.24 3.8 7.3 4.07 9.64 0.12 7.21 2.31 0.23 3 5.17 1.61 7.98 7.48 9.99 2.84 
1173 Regulated_proteolysis_of_p75NTR 3.46 0.71 7.3 4.89 0.65 8.1 5.87 7.85 3.77 2.85 4.71 2.13 6.13 8.11 1.98 8.77 1.87 7.33 
1174 Regulation_of_AMPK_activity_via_LKB1 6.54 1.97 6.28 3.55 4.19 5.02 6.46 9.89 7.82 2.57 9.43 4.55 9.56 8.74 4.99 0.2 6.64 9.94 
1175 Regulation_of_KIT_signaling 1.92 3.32 6.67 1.48 9.28 9.61 6.19 4.29 0.06 8.62 1.62 3.26 0.53 0.73 1.53 2.67 2.93 2.67 
1176 Regulation_of_Rheb_GTPase_activity_by_AMPK 0.28 3.37 6.87 8.61 5.83 7.96 7.63 2.13 3.13 8.38 7.27 5.37 3.76 9.59 2.59 7.71 0.94 4.01 
1177 Relaxin_receptors 7.08 9.42 2.67 2.19 5.5 8.64 5.38 0.49 0.77 9.69 2.48 6.66 3.09 2.59 5.94 4.82 5.68 7.61 
1178 Release_of_eIF4E 8.87 4.56 1.04 1.33 6.95 8.02 6.54 3.17 5.05 4.24 6.43 9.58 1.87 1.67 8.92 6.6 6.13 1.76 
1179 Retinoid_metabolism_and_transport 2.67 4.01 5.35 7.04 4.12 9.4 1.97 6.56 3.09 7.87 0.15 2.79 9.86 4.04 6.62 9.03 4.71 9.68 
1180 Retrograde_neurotrophin_signalling 5 2.21 5.68 5.45 8.52 1.09 3.01 6.7 1.14 7.42 1.62 0.37 0.91 0.34 6.06 1.6 5.12 7.77 
1181 Rho_GTPase_cycle 5.54 3.71 1.11 1.82 3.49 9.48 1.95 9.06 8.37 2.2 7.33 2.47 1.84 1.09 4.43 3.83 7.96 1.97 
1182 S6K1_signalling 4.47 4.87 3.16 0.9 8.19 1.82 1.64 7.82 2.21 2.83 0.63 2.38 0.69 3.58 6.63 5.97 8.7 9.4 
1183 S6K1_signalling 3 7.1 1.16 3.69 2.88 8.97 1.55 8.18 4.51 6.61 5.45 6.41 4.03 8.08 9.49 9.4 4.23 5.07 
1184 SHC_activation 0.23 2.15 0.51 8.66 0.57 3.21 5.58 6.74 1.19 3.65 9.38 2.83 2.11 0.75 4.6 2.16 5.4 5.1 
1185 SHC-mediated_cascade 4.77 2.2 3.76 3.9 6 5.28 3.76 4.81 9.57 6.35 7.07 6.05 1.73 3.85 8.29 5.62 7.11 0.47 
1186 ERK1_activation 7.45 0.7 8.26 8.45 4.21 3.2 5.48 3.48 1.01 1.77 9.39 0.19 0.75 5.36 8.1 9.25 3.09 7.25 
1187 ERK2_activation 8.46 0.93 5.83 6.88 9.94 4.93 0.03 2.99 7.75 8.27 5.82 0.77 3.04 1.09 6.6 3.6 2.61 3.02 
1188 RAF_activation 2.07 2.7 1.66 2.01 1.32 0.56 5.06 7.74 1.03 1.82 8.96 5.39 7.93 2.62 9.91 8.45 8.22 6.46 
1189 RAF_phosphorylates_MEK 5.53 6.87 5.8 5.88 7.89 1.13 7.04 2.17 1.89 3.25 5.71 7.77 6.05 7.74 8.62 9.35 4.3 5.78 
1190 ERK1_activation 8.97 5.02 5.13 3.14 3.22 3.22 3.83 1.51 0.6 1.92 9.53 6.79 3.66 3.4 4.12 3.12 0.38 9.54 
1191 ERK2_activation 8.95 6.29 3.97 7.35 7.68 2.94 2.45 5.84 7.23 3.25 0.08 5.63 0.2 7.02 6.11 9.89 9.68 8.78 
1192 RAF_activation 9.71 8.91 8.87 3.36 0.39 3.89 5.41 9 4.94 0.48 0.81 2.57 7.46 8.6 3.57 9.32 7.09 7.49 
1193 RAF_phosphorylates_MEK 8.71 1.06 5.38 2.61 5.99 9.62 3.52 2.34 0.5 5.9 9.54 2.03 4.62 1.15 6.03 4.25 7.6 6.95 
1194 SHC_activation 1.2 9.4 6.82 4.51 7.98 1.88 3.45 6.66 6.94 7.53 6.3 2.25 4.62 4.45 6.03 6.38 3.07 2.72 
1195 ERK1_activation 5.68 3.33 3.71 3.96 6.7 5.13 9.99 8.18 7.09 0.09 0.81 7.56 0.89 6.2 0.9 1.49 1.22 6.85 
1196 ERK2_activation 9.51 4.7 1.88 9.38 8.05 9.95 2.19 1.13 7.94 3.73 3.39 4.92 7.98 7.61 8.56 4.96 3.95 3.29 
1197 RAF_activation 7.69 7.68 2.81 1.85 3.07 2.55 5.81 6.2 0.03 9.9 4.26 7.68 0.27 8.26 6.32 2.08 6.33 0.33 
1198 RAF_phosphorylates_MEK 6.92 6.97 5.16 0.79 3.85 3.83 6.57 1.32 7.26 0.88 2.69 3.77 5.27 3.77 2.04 2.11 4.96 8.72 
1199 ERK1_activation 2.09 1.9 2.87 5.14 8.3 0.13 5.38 3.01 9.18 0.41 1.37 3.13 9.06 1.69 9.01 4.19 8.01 7.77 
1200 ERK2_activation 7.61 1.54 6.35 9.74 4.24 3.65 8.08 3.12 4.15 4.84 3.32 4.17 2.69 1.99 4.86 0.21 7.68 8.36 
1201 RAF_activation 6.34 6.18 2.25 3.97 6.67 6.03 0.03 7.6 5.01 8.15 6.71 1.69 9.38 2.71 6.92 2.69 8.59 9.92 
1202 RAF_phosphorylates_MEK 6.94 8.48 9.85 8.14 5.56 4.26 0.2 5.22 4.54 3.98 5.64 3.65 0.63 2.83 9.82 2.93 2.87 2.22 
1203 ERK1_activation 0.34 1.91 3.81 3.59 8.83 2.38 6.35 9.39 6.78 4.98 0.25 0.74 6.47 6.53 7.99 3.14 2.72 4.98 
1204 ERK2_activation 2.21 8.12 0.98 9.19 9.98 9.17 5.21 2.45 8.28 1.51 7.16 7.81 9.17 6.25 1.31 6.61 4.31 0.53 
1205 RAF_activation 0.2 7.24 8.88 1.69 6.62 0.34 4.57 2.8 2.87 9.79 6.27 4.49 1.88 3.89 2.27 8.48 6.72 0.24 
1206 RAF_phosphorylates_MEK 8.42 9.56 0.23 3.26 4.96 0.33 8.74 8.51 4.66 4.38 1.89 5.11 6.25 5.46 6.15 3.53 9.18 7.47 
1207 ERK1_activation 5.79 6.3 9.23 1.99 3.41 2.51 9.95 6.94 6.78 4.55 7 5.76 8.12 8.12 3.24 6.27 8.52 9.12 
1208 ERK2_activation 0.42 1.91 2.33 2.94 5.19 9.42 5.61 3.39 5.16 6.78 6.46 9.26 2.13 5.45 3.06 9.11 2.07 4.39 
1209 RAF_activation 1.03 5.4 7.18 9.38 2.7 7.67 8.5 8.66 0.95 9.8 0.11 0.26 6.8 2.5 5.22 6.51 6.09 6.95 
1210 RAF_phosphorylates_MEK 5.14 0.95 4.87 6.89 4.31 1.21 2.87 8.03 3.5 8.83 3.1 4.44 8.69 9.76 3.75 4.06 7 5.15 
1211 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 8.44 8.06 4.29 4.24 8.32 0.15 3.27 4.65 7.65 9.24 5.37 8.04 7.86 1.26 6.61 3.79 2.55 5.14 
1212 ERK1_activation 5.47 6.11 2.19 1.35 1.36 0.66 1.74 6.7 5.5 6.18 9.23 2.03 0.78 7.47 7.04 6.91 1.95 7.84 
1213 ERK2_activation 8.41 4.3 9.29 9.37 0.17 4.63 9.98 1.05 2.83 2.18 2.55 1.85 1.13 8.7 2.79 2.52 3.94 5.63 
1214 RAF_activation 0.75 3.08 8.33 1.33 6.65 2.37 2.52 0.73 6.83 6.33 2.02 9.51 5.26 3.16 6.72 5.29 6.32 9.52 
1215 RAF_phosphorylates_MEK 9.34 4.99 3.61 3.8 3.57 8.6 3.61 8.88 3.56 9.88 8.91 2.13 1.96 7.5 0.64 5.78 1.12 0.88 
1216 Serotonin_receptors 4.79 8.42 1.37 4.16 9.71 3.88 8.81 2.89 5.73 5.23 8.46 6.39 1.8 1.68 8.98 6.07 3.95 5.16 
1217 Signal_attenuation 7.68 1.95 8.98 8.5 1.69 7.41 9.59 4.92 5.85 1.53 6.94 2.93 9.55 4.31 2.62 9.67 0.92 1.21 
1218 Antagonism_of_Activin_by_Follistatin 6.31 9.82 5.66 7.46 5.69 6.69 1.55 8.08 0.14 7.59 6.46 0.04 4.11 0.01 7.8 9.28 0.18 5.74 
1219 Signaling_by_BMP 6.24 4.08 0.68 6.9 4.16 2.51 7.17 0.84 6.58 1.63 3.68 5.17 3.63 9.4 7.42 0.62 0.41 3.06 
1220 AKT_phosphorylates_targets_in_the_cytosol 7.53 9.22 1.27 4.14 5.01 0.47 8.01 7.78 0.33 3.87 6.25 0.18 0.34 8.52 1.45 6.78 4.17 2.4 
1221 AKT_phosphorylates_targets_in_the_nucleus 1.22 5.49 1.18 7.98 4.05 9.96 6.93 4.61 1.67 8.08 0.8 7.24 3.7 3.6 2.13 9.78 7.94 0.86 
1222 CaMK_IV-mediated_phosphorylation_of_CREB 1.69 6.39 3.41 1.92 4.29 0.58 0.39 6.82 4.17 6.2 5.08 3.42 2.14 4.04 3.35 0.39 5.04 9.65 
1223 Cam-PDE_1_activation 1.95 9.77 4.43 1.33 7.6 2.21 1.17 0.48 8.09 4.05 8.13 9.01 1.55 4.83 2.43 2.86 5.92 3.82 
1224 EGFR_downregulation 6.16 5.34 4.93 9.27 3.35 5.66 6.09 1.37 7.48 2.8 4.23 2.72 1.79 6.32 2.21 0.99 1.4 7.03 
1225 ERK1_activation 5.98 7.01 4.86 7.94 6.61 8.8 7.3 3.55 7.15 2.83 1.06 2.62 7.71 6.61 6.17 6.31 9.64 5.54 
1226 ERK2_activation 4.2 5.94 2.31 4.39 0.82 5.62 0.26 5.92 1.44 2.22 4.91 2.26 8.48 6.34 4.09 7.89 9.78 2.42 
1227 Negative_regulation_of_the_PI3K/AKT_network 4.23 3.3 9.87 3 7.14 1.9 6.06 9.82 9.82 9.81 7.69 9.97 9.32 0.83 1.61 5.2 2.79 4.95 
1228 PKA_activation 1.28 0.12 9.83 2.97 5.58 4.49 1.33 3.97 9.41 7.57 8.88 0.56 6.18 5.84 6.39 4.74 0.81 0.64 
1229 RAF_activation 8.96 9.33 9.84 1.5 1.45 9.33 7.18 8.8 3.09 3.61 0.45 6.8 2.41 9.61 8.07 7.57 9.43 7.76 
1230 RAF_phosphorylates_MEK 2.77 7.04 1.63 7.56 5.73 7.38 2.36 0.92 0.52 4.6 2.77 4.41 1.22 8.07 9.73 2.63 9.42 6.14 
1231 AKT_phosphorylates_targets_in_the_cytosol 6.04 7.5 6.58 3.6 5.83 4.93 9.53 8.58 4.93 4.38 8.85 9.89 9.86 9.12 0.85 5.95 7.16 1.6 
1232 AKT_phosphorylates_targets_in_the_nucleus 9.75 8.4 9.25 7.45 3.95 7.99 1.21 9.99 0.01 9.86 6.96 9.58 5.78 2.06 7.5 8.4 6.29 1.18 
1233 CaMK_IV-mediated_phosphorylation_of_CREB 9.05 8.38 4.59 7.51 2.98 6.3 9.09 7.32 6.96 3.75 1.59 1.78 7.45 0.33 4.6 6.23 0.91 6.56 
1234 Cam-PDE_1_activation 4.52 1.35 8.42 7.87 4.51 9.59 2.51 0.47 2.2 9.74 1.68 2.5 9.1 1.28 2.36 5.49 3.01 8.05 
1235 Downregulation_of_ERBB2:ERBB3_signaling 7.38 1.13 7.32 6.09 1.61 3.25 6.74 7.26 3.95 5.1 3.47 7.83 4.46 7.21 6.57 2.93 0.02 6.21 
1236 ERK1_activation 4.5 3.84 8.6 3.57 8.19 9.5 4.9 9 3.97 7.36 7.36 8.01 9.11 4.53 3.15 1.73 7.56 0.78 
1237 ERK2_activation 9.72 7.15 6.63 4.93 6.23 3.68 0.36 3.12 9.01 3.95 9.05 7.78 5.11 7.26 8.21 9.79 7.16 5.01 
1238 GRB7_events_in_ERBB2_signaling 7.91 0.78 5.4 8.87 2.26 8.84 0.69 0.27 6.47 0.4 5.82 9.73 4.6 4.27 6.91 0.57 1.56 4.16 
1239 Negative_regulation_of_the_PI3K/AKT_network 2.8 0.22 7.03 0.34 1.05 6.23 0.2 3.08 4.02 4.3 9.32 6.02 7.46 8.18 7.12 2.87 4.22 7.15 
1240 PKA_activation 1.5 5.82 4.03 4.51 7.99 8.92 0.51 5.43 8.69 0.06 6.12 3.5 0.43 4.15 5.65 7.61 1.41 9.09 
1241 RAF_activation 9.78 3.72 5.23 8.21 2.9 0.04 2.31 1.71 1.52 2.02 6.23 4.87 1.99 9.91 9.27 9 1.05 5.52 
1242 RAF_phosphorylates_MEK 5.83 7.87 5.13 6.27 7.81 0.72 3.04 8.5 2.12 8.59 7.97 0.49 3.81 1.93 6.4 4.03 3.25 7 
1243 AKT_phosphorylates_targets_in_the_cytosol 4.49 3.61 4.07 6.72 8.68 3.41 1.87 5.03 2.16 2.68 1.68 0.48 3.53 6.02 1.41 2.52 1.86 7.71 
1244 AKT_phosphorylates_targets_in_the_nucleus 6.14 6.41 0.7 6.07 1.73 5.62 1.85 7.57 5.36 2.06 2.51 4.99 8.02 5.44 2.69 2.85 7.64 2.24 
1245 Downregulation_of_ERBB4_signaling 0.31 4.12 3 9.12 2.41 7.37 4.86 5.29 7.53 8.98 5.47 9.58 1 5.32 0.24 0.97 9.52 2.27 
1246 ERK1_activation 9.04 3.26 2.89 6.29 7.96 9.41 7.06 7.01 7.22 1.71 4.95 9.67 6.12 4.75 0.49 8.47 0.19 5.04 
1247 ERK2_activation 1.62 4.63 3.47 4.47 9.54 2.24 5.68 0.99 4.8 2.73 2.82 6.57 1.88 2.7 5.41 3.97 0.21 5.86 
1248 Negative_regulation_of_the_PI3K/AKT_network 5.95 6.12 3.35 8.41 0.86 3.8 2.23 5.43 6.49 2.09 6.02 1.73 5.59 2.17 6.83 9.17 7.58 5.06 
1249 Prolactin_receptor_signaling 5.71 6.92 1.33 3.14 8.3 0.63 1.32 9.03 5.96 3.93 6.82 7.77 1.81 4.2 9.81 8.77 2.72 2.38 
1250 RAF_activation 5.17 1.15 4.37 4.86 5.06 5.06 5.7 8.71 3.68 0.42 9.31 7.48 7.36 7.06 1.9 9 8.65 1.55 
1251 RAF_phosphorylates_MEK 0.78 0.81 4.7 9.49 4.21 2.03 5.53 8.41 4.56 3.3 5.44 3.82 6.22 5.4 8.72 6.08 0.09 6.76 
1252 AKT_phosphorylates_targets_in_the_cytosol 7.36 8.14 3.36 7.48 7.51 3.46 8.52 4.76 9.12 1.83 4.33 7.07 5.48 4.62 2.71 6.77 4.33 2.73 
1253 AKT_phosphorylates_targets_in_the_nucleus 4.18 6.37 8.42 2.52 5.83 9.25 6.54 4.49 9.93 1.17 3.98 0.03 6.26 9.36 1.29 8.77 7.89 5.65 
1254 CaMK_IV-mediated_phosphorylation_of_CREB 2.43 0.19 8.12 2.6 4.62 3.69 6.61 2.95 6.62 9.87 0.43 8.43 4.68 9.57 6.1 8.87 9.31 3.56 
1255 Cam-PDE_1_activation 4.9 4.53 7.59 1.56 9.6 8.94 0.39 6.6 6.34 1.95 0.24 3.43 0.17 9.45 0.76 3.96 9.96 2.05 
1256 ERK1_activation 3.38 2.96 6.66 1.04 8.48 6.98 9.12 9.8 1.03 3.76 4.52 9.36 5.98 7.12 9.21 8.01 6.17 4.89 
1257 ERK2_activation 3.73 8.26 8.99 9.23 7.27 5.56 6.02 6.2 9.16 4.65 3.38 4.93 4.75 7.5 8.05 3.64 8.16 2.96 
1258 FGFR1b_ligand_binding_and_activation 9.77 5.47 5.19 1.28 6.42 0.41 4.42 7.21 3.14 3.28 2.76 0.33 9.98 9.59 2.78 1.19 7.79 5.84 
1259 FGFR1c_and_Klotho_ligand_binding_and_activation 7.21 2.28 5.93 2.52 5.82 4.93 8.86 0.78 4.43 2.8 2.06 7.34 9.11 3.56 7.78 3.99 0.88 9.66 
1260 FGFR1c_ligand_binding_and_activation 4.7 7.62 8.1 8.09 2.48 1.96 7.7 3.18 5.17 2.14 5.32 2.37 1.74 1.16 7.86 1.31 2.68 8.48 
1261 FGFR2b_ligand_binding_and_activation 8.46 9.56 6.63 5.99 9.78 8.18 6.61 2.36 0.22 7.98 4.41 6.36 4.98 5.83 5.14 1.78 7.57 9.53 
1262 FGFR2c_ligand_binding_and_activation 7.27 9.88 8.13 5.36 1.03 4.3 6.55 2.05 7.41 2.77 7.45 2.88 4.43 6.14 8.14 5.03 1.5 4.88 
1263 FGFR3b_ligand_binding_and_activation 2.1 0.29 3.71 4.63 1.9 3.9 6.25 5.55 7.51 7.06 2.47 2.97 5.22 4.65 2.39 1.28 8.59 9.02 
1264 FGFR3c_ligand_binding_and_activation 4.59 6.87 9.74 3.03 0.62 4.36 7.73 1.31 0.15 8.24 5.56 3.41 1.46 8.57 2.25 2.16 0.79 9.12 
1265 FGFR4_ligand_binding_and_activation 4.95 9.24 6.07 9.73 4.29 2.4 2.2 9.59 7.79 4.48 5.04 7.2 2.53 0.41 8.33 3.61 0.19 6.02 
1266 Negative_regulation_of_the_PI3K/AKT_network 6.51 7.86 8.63 5.02 6.55 3.48 6.48 9.35 2.19 5.7 3.91 8.61 3.05 6.05 4.49 4.47 3.65 0.8 
1267 PKA_activation 0.05 9.61 9.93 3 2.38 7.26 8.67 0.85 2.26 2.88 0.89 8.92 3.56 6.63 7.16 1.25 1.99 8.78 
1268 RAF_activation 8.83 6.6 4.04 7.72 7.93 9.4 2.7 3.13 4.18 7.04 6.04 3.35 3.38 1.26 0.71 2.84 7.42 5.92 
1269 RAF_phosphorylates_MEK 5.8 4.53 9.03 5.25 5.96 7.8 5.64 8.56 2.18 6.05 6.23 7.75 5.49 3.82 4.6 2.94 6.39 3.65 
1270 SHC-mediated_cascade 2.93 9.57 4.68 3.34 3.29 8.96 7.11 6.85 8.22 7.33 5.7 8.01 6.52 1.71 9.89 2.66 3.48 2.57 
1271 Spry_regulation_of_FGF_signaling 8.33 1.33 2.09 8.93 6.45 8.05 6.7 5.03 8 5.39 5.29 6.2 9.04 0.17 5.34 5.99 0.19 0.92 
1272 betaKlotho-mediated_ligand_binding 4.94 7.73 7.96 3.85 6.49 2.79 3.36 9.77 7.54 2.06 6.17 8.32 3.31 2.5 7.62 0.66 5.21 7.07 
1273 Adenosine_P1_receptors 4.13 8.94 6.16 0.6 1.94 2.88 2.42 3.73 7.2 5.22 2.6 0.56 3.05 6.26 9.14 4.54 6.17 1.14 
1274 Adenylate_cyclase_activating_pathway 9.72 1.23 7.83 4.52 3.21 6.95 6.55 1.4 2.11 9.18 0.23 7.07 5.39 1.39 4.97 2.97 3.82 3.44 
1275 Adenylate_cyclase_inhibitory_pathway 8.57 2.03 5.27 5.85 6.47 2.29 1.44 7.38 2.95 1.53 6.68 4.29 6.71 0.41 9.43 5.37 9.84 5.05 
1276 Adrenoceptors 4.71 0.07 4.97 3.69 2.76 6.63 2.16 3.61 0.79 5.55 9.14 2.3 2.79 7.7 0.38 2.68 9.29 6.56 
1277 Arachidonate_production_from_DAG 4.45 5.16 5.53 4.99 6.12 2.97 3.8 2.49 7.25 1.25 1.04 5.45 5.95 2.89 4.06 0.39 2.69 7.89 
1278 CaMK_IV-mediated_phosphorylation_of_CREB 4.39 0.28 9.89 4.36 3.41 4.6 4.17 1.64 8.51 9.7 5.69 5.72 7.68 8.18 3.78 4.79 0.15 4.13 
1279 Calcitonin-like_ligand_receptors 2.34 7.85 9.86 8.34 9.81 3.51 2.33 0.82 9.28 9 5.66 5.89 1.4 1.6 8.43 6.12 8.77 5.15 
1280 Cam-PDE_1_activation 9.98 4.23 9.56 8.28 5.71 4.88 9.37 9.15 9.06 5.99 2.13 5.41 5.23 2.31 2.55 5.21 9.67 1.68 
1281 Chemokine_receptors_bind_chemokines 4.45 9.58 9.61 6.06 8.78 5.36 0.05 2.19 7.1 0.35 5.6 3.93 5.37 8.23 5.69 8.43 5.23 7.41 
1282 Class_C/3_(Metabotropic_glutamate/pheromone_receptors) 3.01 6.2 9.84 2 2.89 6.63 2.23 6.15 4.6 9.92 8.92 0.5 1.14 0.67 5.58 5.15 1.53 4.85 
1283 DARPP-32_events 4.62 5.76 7.89 1.59 3.86 2.22 0.55 8.66 5.13 2.24 8.86 9.51 0.8 2.16 3.72 1.1 9 5.08 
1284 Dopamine_receptors 4.04 7.38 1.12 9.41 9.06 3.46 4.81 0.92 9.96 1.79 8 5.42 5.99 8.37 5.85 0.34 0.62 1.71 
1285 EGFR_Transactivation_by_Gastrin 7.78 5.52 0.22 4.39 3.97 7.57 7.89 3.49 3.21 2.84 5.01 1.5 5.34 7.91 2.83 1.52 1.6 7.1 
1286 ERK1_activation 1.01 7.64 7.1 2.38 7.96 5.21 6.19 8.86 2.54 6.95 7.33 5.67 5.1 8.46 2.28 4.18 5.52 0.4 
1287 ERK2_activation 7.41 5.66 9.67 1.64 2.15 3.06 6.42 6.84 3.18 1.75 5.03 2.97 3.11 2.1 5.18 3.26 3.87 7.21 
1288 Formyl_peptide_receptors_bind_formyl_peptides_and_many_other_ligands 9.38 4.03 9.67 8.84 9.95 6.11 2.82 2.38 1.35 9.12 3.53 1.63 8.9 7.41 3.76 5.08 6.52 4.27 
1289 Free_fatty_acid_receptors 6.98 1.29 1.38 8 8.03 6.63 2.55 1.66 5.48 9.14 2.52 6.32 4.39 1.81 6.94 5.06 5.31 8.95 
1290 G_alpha_(12/13)_signalling_events 6.32 0.49 4.98 2.88 2.48 8.57 9.69 9.96 0.54 3.66 3.28 7.75 3.86 7 2.1 3.94 2.61 1.07 
1291 G_alpha_(i)_signalling_events 6.63 6.61 2.04 8.13 5.92 1.58 8.64 7.3 4.51 4.32 8.81 5.75 7.36 8.4 4.36 4.58 2.27 2.92 
1292 G_alpha_(s)_signalling_events 7.06 8.41 9.32 3.09 3.79 9.55 4.35 5.02 4.91 6.78 9.27 7.65 7.48 6.59 6.88 7.54 3.96 4.32 
1293 G_alpha_(z)_signalling_events 8.99 9.97 0.73 1.16 2.87 3.97 0.9 9.52 5.1 8.94 8.39 7.32 4.38 7.71 1.4 7.84 8.33 5.89 
1294 G_beta:gamma_signalling_through_PI3Kgamma 4.34 2.28 4.26 9.3 1.34 5.85 9.92 1.61 7.26 9.62 5.59 6.29 3.53 5.09 6.61 2.8 5.27 0.39 
1295 G_beta:gamma_signalling_through_PLC_beta 7.71 4.02 7.61 8.15 7.49 7.22 4.34 9.85 9.88 8.84 7.98 5.1 6.97 0.44 2.49 8.89 1.48 2.42 
1296 G-protein_activation 7.24 7.81 3.59 0.63 0.19 9.66 5.4 3.83 9.78 5.98 8.06 1.1 5.7 8.89 5.43 7.2 8.79 1.7 
1297 Glucagon-type_ligand_receptors 3.89 3.16 7.4 3.11 3.14 2 9.36 3.71 1.24 4.43 4.82 8.59 0.35 4.95 0.51 6.91 6.42 6.7 
1298 Histamine_receptors 3.8 3.77 0.15 0.55 4.16 1.53 5.34 1.52 7.07 5.79 3.62 7.26 2.03 8.59 5.65 3.87 5.09 4.88 
1299 Hormone_ligand-binding_receptors 2.83 3.91 8.91 3.19 9.14 0.42 4.85 5.04 9.41 3.85 9.17 3.37 4.98 7.43 4.88 5.77 0.23 0.22 
1300 Hydroxycarboxylic_acid-binding_receptors 4.26 9.28 7.8 7.9 9.05 4.7 1.09 6.69 5.73 5.53 9.19 9.75 8.86 5.07 8.05 8.4 5.42 4.42 
1301 Leukotriene_receptors 6.03 4.24 3.04 4.09 3.07 7.83 6.66 8.08 3.18 0.65 9.51 9.36 6.54 8.35 7.76 7.38 6.81 5.03 
1302 Lysosphingolipid_and_LPA_receptors 5.24 8.32 5.52 2.76 1.41 0.6 8.25 6.1 1.74 5.75 4.5 0.36 5.45 8.21 4.63 8.94 3.81 8.39 
1303 Muscarinic_acetylcholine_receptors 9.25 4.33 4.89 5.6 0 6.77 0.74 7.33 1.86 4.55 7.79 7.67 4.13 9.55 3.89 9.95 0.43 6.12 
1304 Olfactory_Signaling_Pathway 6.04 1.79 9.32 6.09 3.73 1.18 9.04 8.74 9.41 9.74 8.05 5.48 3.88 5.77 2.43 2.56 5.86 3.46 
1305 Opsins 6.38 6.43 3.2 0 7.16 4.82 3.62 7.99 1.2 9.08 9.47 8.93 8.22 1.48 4.33 1.52 0.88 5.51 
1306 Orexin_and_neuropeptides_FF_and_QRFP_bind_to_their_respective_receptors 7.15 7.75 2.08 8.91 4.73 4.14 3.74 5.05 3.87 0.86 2.93 8.12 0.05 5.16 6.01 5.86 0.81 7.53 
1307 P2Y_receptors 9.96 3.87 4.61 9.14 4.49 3.75 6.46 9.84 2.48 5.33 7.17 9.78 4.12 0.34 5.21 8.66 2.89 5.66 
1308 PKA_activation 2.7 5.58 9.54 6.77 3.72 2.8 9.94 5.32 8.03 0.24 9.93 8.51 2.13 9.2 5.93 3.54 3.24 7.92 
1309 Prostanoid_ligand_receptors 7.86 8.63 5.59 7.07 8.03 5.19 7.83 0.25 9.93 6.82 3.42 4.63 6.61 4.84 4.66 1.16 2.97 4.65 
1310 RAF_activation 7.98 0.54 8.51 0.25 6.51 4.2 1.9 3.41 1.97 6.45 7.33 9.05 5.12 9.45 0.17 2.02 2.21 8.78 
1311 RAF_phosphorylates_MEK 5.49 0.33 8.07 7.26 1.92 6.8 4.27 3.18 4.9 8.69 0.47 9.38 8.91 0.61 2.82 9.83 7.92 3.07 
1312 Relaxin_receptors 6.93 7.86 9.99 2.17 7.44 8.24 9.9 7.33 1.28 2.53 9.99 9.44 0.96 6 2.07 4.12 2.77 8.79 
1313 Serotonin_receptors 3.35 9.32 4.15 1.67 7.61 1.2 0.04 8.63 7.27 6.8 8.31 3.97 3.29 4.97 4.57 3.37 2.7 6.62 
1314 Tachykinin_receptors_bind_tachykinins 1.91 2.65 5.97 9.45 5.89 6.6 0.92 9.7 0.4 4.27 0.8 6.31 6.9 1.17 2.54 9.01 8.74 4.26 
1315 Vasopressin-like_receptors 6.5 2.77 4.1 9.38 0.7 3.31 4.53 0.71 3.26 8.91 4.8 1.2 8.17 6.53 6.41 7.6 0.66 7.47 
1316 phospho-PLA2_pathway 8.53 1.75 9.28 8.8 3.74 8.22 1.3 5.39 6.21 3.68 2.87 3.07 6.04 4.95 6.13 7.9 6.48 4.37 
1317 Signaling_by_Hippo 8.48 7.41 7.81 4.61 7.66 9.62 3.78 2.49 9.61 4.21 5.18 0.85 6.37 0.59 9.62 4.04 8.02 8.33 
1318 Activation_of_PKB 3.45 5.37 6.67 9.27 9.59 6.97 9.68 8.96 0.3 9.91 2.98 9.76 1.1 5.35 5.65 7.35 1.41 5.43 
1319 ERK1_activation 0.59 2.86 3.09 4.35 5.26 2.23 0.14 1.61 0.61 9.06 5 3.24 3.55 2.45 1.3 7 5.89 6.92 
1320 ERK2_activation 6.7 6.94 1.07 4.34 5.03 9.76 1.68 1.02 5.73 4.72 9.25 0.89 3.28 6.69 6.59 8.46 9.79 2.22 
1321 IRS_activation 5.36 3.39 7.14 9.62 0.51 7.2 5.94 2.08 8.91 3.26 8.32 7.28 2.14 9.05 1.96 6.25 7.82 4.81 
1322 Inhibition_of_TSC_complex_formation_by_PKB 6.07 7.32 5.76 7.66 0.51 0.88 5.99 1.38 7.55 2.48 9.11 0.35 4.03 9.86 0.54 8.4 3.61 0.74 
1323 Insulin_receptor_recycling 6 3.4 6.83 1.58 9.86 5.37 4.83 9.47 6.78 0.48 3.61 7.44 7.37 0.86 3.19 7.53 7.62 2.8 
1324 PDE3B_signalling 8.75 2.87 0.69 0.1 3.04 8.3 2.78 6.52 9.1 7.03 1.13 2.87 9.31 3.67 8.89 4.79 9.86 4.16 
1325 RAF_activation 9.52 6.01 2.75 6.7 0.07 7.02 7.63 2.13 2.94 8.56 5.42 9.85 5.5 2.93 4.5 5.73 0.13 5.54 
1326 RAF_phosphorylates_MEK 0.14 9.52 8.82 3.7 1.38 1.81 2.49 7.99 7.93 3.95 9.21 7.92 1 5.17 6.04 5.64 8.65 8.89 
1327 Regulation_of_AMPK_activity_via_LKB1 1.11 3.97 5.48 2.54 2.04 6.56 8.76 8.18 8.84 1.65 4.98 5.14 8.48 9.46 3.89 3.67 1.21 8.05 
1328 Regulation_of_Rheb_GTPase_activity_by_AMPK 5.06 0.61 9.66 7.53 2.42 1.56 3.51 0.4 3.31 0.6 7.28 1.94 0.68 1.17 7.2 3.01 9.39 1.57 
1329 Release_of_eIF4E 4.9 3.74 8.5 1.66 5.95 3.59 9.78 8.15 4.94 6.17 3.26 2.73 3.56 1.4 7.39 0.45 2.72 7.8 
1330 S6K1_signalling 0.38 1.72 6.5 3.9 3.67 5.51 1.46 8.2 3.96 0.08 7.52 4.53 7.05 5.77 9.13 1.53 1.51 0.84 
1331 SHC_activation 8.68 7.47 0.02 7.06 6.06 4.88 6.48 0.88 9.95 0.39 4.15 2.06 4.46 0.73 5.65 3.38 4.83 9.55 
1332 Signal_attenuation 9.02 0.21 3.47 2.58 7.54 7.4 1.76 0.7 3.89 2.34 9.69 6.98 3.95 6.11 2.4 6.11 3.87 7.88 
1333 ERK1_activation 8.81 0.38 4.11 4.42 1.02 0.39 1.17 4.49 9.7 3.12 2.08 0.7 7.94 1.83 7.14 1.02 3.95 8.83 
1334 ERK2_activation 2.77 6.32 8.47 0.08 1.51 4.48 6.58 9.68 4.31 7.73 6.68 1.01 3.32 2.62 9.12 7.72 5.28 1.85 
1335 RAF_activation 8.61 5.48 7.41 5.08 8.26 5.04 2.07 2.32 7.19 6.97 1.22 0.26 5.53 3.28 4.93 2.91 7.43 9.94 
1336 RAF_phosphorylates_MEK 3.92 3.71 7.15 9.48 7.29 0.41 1.63 0.81 8.13 6.22 6.33 2.18 9.1 8.44 2.71 1.49 7.28 1.85 
1337 AKT_phosphorylates_targets_in_the_cytosol 2.71 8.42 0.32 1.36 2.1 7.62 9.91 8.57 0.55 4.8 8.59 2.39 7.26 4.68 5.9 9.87 8.46 8.78 
1338 AKT_phosphorylates_targets_in_the_nucleus 6.92 5.67 3.88 7.52 5.83 9.66 6.44 1.59 0.93 6.98 5.25 0.67 3.65 6.46 9.93 3.81 3.17 0.78 
1339 Axonal_growth_inhibition_(RHOA_activation) 8.74 8.17 2.63 4.91 9.39 7.88 0.62 2.11 0.13 2.07 0.76 1.12 7.93 5.57 9.49 2.55 3.58 7.21 
1340 Axonal_growth_stimulation 0.09 7.57 5.87 4.04 0.77 4.77 8.63 9.34 7.16 1.25 4.87 8.98 3.89 8.02 9.04 4.07 4.29 8.88 
1341 CREB_phosphorylation 6.78 9.55 8.78 1.59 4.04 1.63 6.47 1.62 2.69 2.73 5.26 6.89 9.78 0.06 9.31 9.86 0.68 5.52 
1342 CaMK_IV-mediated_phosphorylation_of_CREB 0.23 5.88 9.49 0.21 6.22 4.52 6.82 7.28 9.68 5 3.8 2.51 5.18 3.76 0.16 7.1 6.19 2.5 
1343 Cam-PDE_1_activation 1.23 9.27 7.21 1.53 9.53 3.39 3.74 2.06 5.04 0.28 3.42 7.83 2.01 2.28 0.19 9.59 2.63 2.4 
1344 Ceramide_signalling 3.05 0.61 3.15 1.6 0.07 3.48 5.02 4.78 8.76 1.16 6.64 0.37 9.18 1.02 9.78 5 4.89 6.3 
1345 ERK1_activation 3.35 3.95 3.73 0.52 3.12 8.53 4.73 1.07 8.32 5.43 3.83 6.62 7.08 9.12 6.96 9.11 5.52 1.13 
1346 ERK2_activation 0.81 2.02 0.54 8.55 1.58 0.98 3.76 7.11 9.42 3.14 1.28 2.89 2.23 2.71 7.97 0.32 1 4.6 
1347 ERKs_are_inactivated 1.29 1.85 1 2.14 3.14 1.7 5.25 5.21 0.06 7.65 8.72 8.66 0.66 9.25 2.31 4.39 4.75 2.55 
1348 NADE_modulates_death_signalling 3.32 3.79 1.02 5.33 9.48 1.67 1.58 8.07 7.4 5.89 0.69 4.03 8.26 6.47 5.73 9.03 6.15 7.28 
1349 NF-kB_is_activated_and_signals_survival 9.66 8.04 8.52 5.76 9.95 3.98 3.87 0.86 5.68 0.25 4.23 8.09 3.27 0.3 3.75 3.84 5.31 3.26 
1350 NFG_and_proNGF_binds_to_p75NTR 1.91 9.23 4.68 2.78 6.31 1.61 5.41 9.15 6.79 7.39 6.1 9.92 4.19 1.05 6.14 6.3 9.32 5.47 
1351 NGF_processing 9.4 3.56 4.08 5.63 2.04 1.03 3.23 3.53 7.52 8.67 1.1 5.99 6.23 9.39 3.19 0.63 5.78 2.61 
1352 NGF-independant_TRKA_activation 3.36 1.61 6.46 3.05 5.56 6.17 8.65 6.12 4.55 6.33 3.52 6.24 2.62 1.39 1.52 5.18 1.12 4.25 
1353 NRAGE_signals_death_through_JNK 1.56 1.03 2.19 7.92 0.15 6.31 6.73 1.14 0.74 2.43 9.08 7.47 6.64 2.61 0.72 3.67 7.83 4.93 
1354 NRIF_signals_cell_death_from_the_nucleus 7.44 6.1 0.1 3.3 2.84 2 7.09 3.21 2.65 0.38 3.69 7.09 5.21 3.28 0.41 9.92 6.29 2.93 
1355 Negative_regulation_of_the_PI3K/AKT_network 2.67 8.25 9.77 8.48 3.15 5.99 9.99 1.2 7.17 6.53 1.34 8.5 8.58 4.94 6.91 7.25 1.4 3.54 
1356 PKA_activation 7.05 7.58 0.21 9.78 2.94 0.77 3.73 6.25 2.06 5.28 2.83 2.99 4.67 2.39 7.82 5.94 2.45 5.52 
1357 RAF_activation 2.84 4.63 2.55 5.4 6.18 2.22 8.26 8.17 5.09 0.45 5.42 2.57 4.73 7.66 5.98 0.91 0.56 4.1 
1358 RAF_phosphorylates_MEK 3.95 8.41 1.41 9.05 7.4 8.82 5.05 0.4 8.77 7.68 1.82 4.9 0.13 5.8 1.15 2.42 5.72 8.17 
1359 Regulated_proteolysis_of_p75NTR 9.03 1.59 0.69 0.06 1.13 9.77 9.04 1.12 2.71 5.87 3.87 3.52 8.53 1.54 7.78 8.96 2.33 2.93 
1360 Retrograde_neurotrophin_signalling 3.17 0.76 6.05 4.86 6.25 1.59 2.13 4.72 3.61 5.79 9.85 1.36 0.07 9.73 9.24 5.29 5.57 2.88 
1361 Signalling_to_ERK5 5.5 0.75 2.41 0.17 7.59 7.15 3.45 7.55 7.26 6.09 5.79 7.24 5.61 1.74 9.04 3.99 6.77 0.05 
1362 Signalling_to_STAT3 9.45 2.12 7.37 3.72 4.5 3.33 0.38 6.74 7.75 2.5 1.53 3.39 7.65 3.67 4.36 9.14 0.18 5.4 
1363 TRKA_activation_by_NGF 2.09 6.86 7.51 3.49 6.49 3.6 6.28 5.55 9.25 8.76 0.13 4.36 8.58 1.5 2.28 4.06 7.38 9.67 
1364 p38MAPK_events 2.15 6.9 9.21 5.68 5.56 5.66 9.49 7.02 7.78 2.43 8.9 8.63 0.9 0.73 7.81 4.44 1.97 0.15 
1365 p75NTR_negatively_regulates_cell_cycle_via_SC1 1.75 3.19 6.87 3.03 2.44 5.98 0.05 1.37 4.84 5.69 5.63 6.71 5.54 1.37 1.37 3.3 0.2 3.93 
1366 p75NTR_recruits_signalling_complexes 1.91 3.63 5.62 3.7 1.58 0.52 0.02 5.45 0.09 3.84 2.9 3.4 5.88 7.67 2.88 8.85 6.75 8.63 
1367 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 7.91 1.81 2.47 2.88 9.31 3.97 1.97 6.86 4.07 4.01 3.11 7.65 2.21 9.1 4.46 2.24 2.86 5.74 
1368 NOTCH1_Intracellular_Domain_Regulates_Transcription 6.16 4.58 1.3 3.77 2.55 7.61 8.34 1.34 1.39 3.83 2.43 0.19 2.09 5.79 9.58 6.41 4.19 7.36 
1369 NOTCH2_Activation_and_Transmission_of_Signal_to_the_Nucleus 7.75 7.95 0.74 8.12 8.75 9.92 0.73 8.75 3.81 9.75 7.88 2.53 8.42 5.79 1.05 0.29 8.35 0.31 
1370 NOTCH2_intracellular_domain_regulates_transcription 7.01 1.72 4.67 6.91 6.1 7.74 0.34 9.36 8.32 0.11 2.57 0.97 0.5 4.64 0.95 7.14 8.34 6.23 
1371 Pre-NOTCH_Processing_in_Golgi 6.52 4.77 8.39 0.68 6.28 9.31 8.38 2.34 0.69 8.96 8.87 8.62 4.85 2.02 2.18 0.33 0.62 0.51 
1372 Pre-NOTCH_Processing_in_the_Endoplasmic_Reticulum 3.06 6.84 3.87 1.09 7.84 1.67 0.88 6.13 9.07 9.86 7.08 5.95 7.42 9.12 3.22 3.69 3.38 8.89 
1373 Pre-NOTCH_Transcription_and_Translation 0.57 1.46 6.86 3.99 3.93 3.74 3.08 1.87 1.11 3.79 3.03 5.12 6.11 4.29 3.78 1.52 5.35 8.01 
1374 Signaling_by_NOTCH3 6.97 0.39 6.66 8.94 6.06 1.81 7.02 2.06 0.61 6.87 0.55 5.16 8.41 7.12 5.02 5.49 2.75 9.64 
1375 Signaling_by_NOTCH4 3.56 0.36 7.2 7.65 5.55 3.05 1.46 4.58 9.93 1.46 2.18 1.24 4.46 0.69 6.68 2.99 4.01 7.48 
1376 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 3.07 7.61 3.65 2.66 6.79 4.05 9.06 2.45 1.64 9.78 0.65 0.2 3.18 3.61 1.6 5.47 0.89 4.93 
1377 NOTCH1_Intracellular_Domain_Regulates_Transcription 8.55 9.81 8.69 7.01 6.74 9.29 8.34 0.71 8.24 6.88 9.52 3.71 9.79 6.94 4.83 2.7 0.25 5.91 
1378 NOTCH2_Activation_and_Transmission_of_Signal_to_the_Nucleus 1.81 7.36 2.82 4.52 9.72 9.6 8.19 7.66 1.49 4.7 8.19 9.78 3.93 3.29 3.24 7.34 2.88 9.86 
1379 NOTCH2_intracellular_domain_regulates_transcription 7.72 9.15 0.11 8.33 8.76 7.63 7.34 3.59 2.81 1.25 3.81 0.84 2.09 4.86 8.46 5.69 4.8 7.46 
1380 Signaling_by_NOTCH3 1.68 2.96 3.4 0.2 8.03 6.19 0.05 8.1 6.88 0.67 2.42 8.45 1.45 3.46 7.6 6.48 0.76 3.14 
1381 Signaling_by_NOTCH4 7.8 6.54 8.93 3.51 0.02 0.72 0.98 1.79 9.5 5.11 1.14 2.41 1.48 6.07 2.72 6.92 7.08 2.69 
1382 AKT_phosphorylates_targets_in_the_cytosol 0.05 8.88 7.44 8.59 8.04 8.65 3.92 6.9 8.1 9.55 6.94 3.11 6.7 0.18 7.5 9.76 4.69 3.48 
1383 AKT_phosphorylates_targets_in_the_nucleus 4.96 2.08 5.05 5.95 0.17 0.17 3.54 8.39 0.54 1.54 8.13 9.15 9.7 0.26 1.09 2.7 1.78 1.88 
1384 CaMK_IV-mediated_phosphorylation_of_CREB 4.23 4.13 2.96 1.32 4.19 9.75 0.53 9.6 5.11 2.82 2.03 1.38 9.66 6.36 6.97 3.81 0.18 7.4 
1385 Cam-PDE_1_activation 4.47 9.17 3.97 8.26 0.85 6.84 1.66 6.36 9.12 5.95 2.34 5.07 8.05 6.62 2.33 5.34 2.08 2.91 
1386 ERK1_activation 7.3 7.81 9.03 5.96 0.98 2.72 2.9 8.03 2.81 8.8 4.3 0.78 9.01 0.86 0.19 0.75 4.67 4.92 
1387 ERK2_activation 2.51 5.97 7.15 0.57 5.88 9.99 5.88 0.25 0.07 6.24 7.68 1.15 4.25 0.8 4.33 9.65 4.26 3.23 
1388 Negative_regulation_of_the_PI3K/AKT_network 0.04 7.57 2.05 1.96 0.05 0.33 8.71 4.27 4.27 1.7 7.08 6.82 7.17 9.64 9.1 2.36 6.93 2.09 
1389 PKA_activation 7.91 3.59 6.12 2.3 2.89 7.55 5.74 6.46 9.07 4.35 9.11 7.98 9.27 1.88 8.15 5.7 5.7 2.6 
1390 RAF_activation 8.9 9.58 8.52 1.97 9.47 4.3 7.61 1.86 5.3 1.93 3.11 8.17 3.39 4.92 5.12 2.82 4.41 2.12 
1391 RAF_phosphorylates_MEK 5.06 9.11 8.1 6.78 4.22 0.84 4.77 0.74 8.3 1.12 9.62 1.41 8.18 5 9.21 7.34 2.53 3.32 
1392 Rho_GTPase_cycle 3.57 3 9.31 0.6 3.78 5.09 0.54 9.65 5.09 1.38 3.21 6.32 8.35 5.77 6.36 3.55 1.09 1.31 
1393 AKT_phosphorylates_targets_in_the_cytosol 9.37 0.09 1.38 7.28 6.79 8.86 1.89 5.03 8.13 2.12 9.37 4.27 1.45 6.47 6.34 8.82 9.38 0.32 
1394 AKT_phosphorylates_targets_in_the_nucleus 2.69 7.59 6.26 7.12 2.99 4.43 6.8 8.35 0.19 3.11 7.73 9.91 4.86 2.21 4.62 6.85 2.94 4.48 
1395 ERK1_activation 3.69 0.15 4.81 7.53 4.59 6.43 7.78 5.48 6.49 3.67 5.29 5.78 0.06 6.21 3 9.35 3.33 1.93 
1396 ERK2_activation 6.54 0.71 6.31 8.01 9.11 6.85 3.66 3.64 7.33 5.32 6.67 9.1 0.41 3.7 9.17 1.07 9.73 8.18 
1397 Negative_regulation_of_the_PI3K/AKT_network 0.92 9.05 6.76 0.56 3.09 8.92 3.38 6.18 6.3 1.4 7.98 0.85 9.01 0.25 0.61 2.14 6.44 0.02 
1398 RAF_activation 0.58 6.51 5.19 4.26 4.18 7.13 8.01 7.4 9.4 8.46 9.96 4.09 2.73 2.25 8.55 2.96 7.92 8.97 
1399 RAF_phosphorylates_MEK 0.21 9.57 2.06 6.04 9.72 3.88 0.2 8.66 1.79 6.23 5.53 7.36 4.64 3.99 2.33 6.09 9.2 0 
1400 Regulation_of_KIT_signaling 7.26 7.78 3.12 4.89 4.06 6.76 3.24 1.14 0.69 3.36 8.62 9.73 9.81 4.62 2.65 0.1 0.52 8.95 
1401 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 7.66 1.9 3.81 2.2 0.63 8.84 4.72 2.62 5.7 7.44 1.42 9.43 3.77 6.23 3.12 2.72 3.83 0.26 
1402 Downregulation_of_TGF-beta_receptor_signaling 6.24 4.13 0.45 5.17 3.62 3.42 9.59 2.83 2.6 3.59 1.76 3.72 1.08 2.91 1.81 6.98 2.25 0.04 
1403 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 6.4 5.76 2.44 7.82 1.8 5.8 1.12 4.85 8.17 3.98 2.16 4.11 4.72 7.13 6.32 7.51 6.57 0.91 
1404 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 4.64 0.35 9.62 6.64 3.4 6.44 0.12 2.35 1.5 1.2 4.25 2.47 5.92 8.26 8.16 5.7 3.01 1.21 
1405 Activation_of_PKB 0.12 9.39 4.72 2.83 0.57 1.42 4.87 4.04 2.33 7.02 9.37 1.39 0.06 9.47 2.29 2.71 4.97 2.76 
1406 ERK1_activation 8.61 5.89 8.43 7.34 2.67 7.74 9.05 2.69 6.83 9.75 9.17 2.19 3.85 7.04 7.55 8.79 9.4 6.01 
1407 ERK2_activation 2.65 5.43 2.52 3.61 5.95 4.01 2 2.42 8.3 0.7 8.27 2.74 8.51 8.4 3.91 2.19 1.66 8.78 
1408 Inhibition_of_TSC_complex_formation_by_PKB 8.58 7.81 5.35 4.53 9.29 9.53 5.52 2.1 8.58 0.17 1.37 0.13 9.34 1.51 1.93 9.28 4.15 4.6 
1409 PDE3B_signalling 7.58 0.09 5.51 1.7 2.15 1.55 2.01 5.64 1.19 3.32 4.27 9.32 8.28 0.82 8.68 9.65 4.97 7.43 
1410 RAF_activation 6.18 2.5 0.57 4.07 7.84 3.82 0.86 4.48 2.62 0.94 0.17 0.34 7.29 9.4 5.86 9.82 2.77 2.53 
1411 RAF_phosphorylates_MEK 3.69 4.67 3.76 2.61 3.66 5.19 3.92 4.17 2.63 4.03 5.52 2.86 1.76 8.74 5.03 2.64 2.8 5.48 
1412 Regulation_of_AMPK_activity_via_LKB1 3.77 4.86 2.65 8.46 9.63 1.08 4.96 7.72 9.53 4.08 9.82 3.37 5.94 0.33 6.22 7.5 4.54 0.85 
1413 Regulation_of_Rheb_GTPase_activity_by_AMPK 6.24 6.58 6.38 0.43 3.25 3.05 7.1 2.32 9.96 8.39 0.31 9.17 2.61 3.11 0.95 3.12 3.79 8.23 
1414 Release_of_eIF4E 4.69 2.5 5.11 3.9 9.27 3.06 3.55 8.1 8.78 7.36 4.2 0.83 7.81 5.88 1.97 5.64 2.14 6.24 
1415 S6K1_signalling 6.87 8.91 2.22 6.59 0.45 4.22 8.1 8.08 8.55 4.8 4.74 9.82 3.33 6.28 6.76 8.65 0.62 8.5 
1416 Neurophilin_interactions_with_VEGF_and_VEGFR 0.36 1.37 8.49 4.64 7.38 3.37 3.33 9.55 3.17 1.55 8.92 3.1 3.27 7.3 6.77 4.41 7.45 2.56 
1417 VEGF_binds_to_VEGFR_leading_to_receptor_dimerization 7.54 6.62 3.77 7.53 8.07 2.48 3.6 1.43 7.65 1.57 8.73 9.75 0.37 2.14 9.75 7.73 8.08 0.84 
1418 Beta-catenin_phosphorylation_cascade 4.06 4.92 2.79 7.97 0.28 0 9.51 2.23 1.13 8.39 2.07 5.72 0.14 5.41 4.53 3.91 1.94 2.47 
1419 WNT_ligand_biogenesis_and_trafficking 5.17 7.51 3.79 5.79 3.55 7.05 2.75 0.54 9.08 7.22 7.52 3.82 6.16 7.81 8.08 6.09 2.99 1.46 
1420 Signalling_to_ERK5 7.32 9.4 1.88 9.6 6.37 1.85 0.77 3.8 7.73 8.67 0.44 6.98 1.92 0.76 4.33 6.92 2.34 3.7 
1421 ERK1_activation 9.85 9.85 3.3 7.89 0.34 2.55 9.19 5 3.93 3.88 3.38 0.08 3.2 1.77 2.53 0.88 0.84 8.97 
1422 ERK2_activation 1.94 4.47 2.06 5.28 3.83 9.55 0.96 4.63 9.2 6.31 6.58 4.87 9.42 1.96 0.37 8.04 8.78 0.83 
1423 RAF_activation 3.61 5.65 5.73 4.95 4.58 5.28 7.79 9.93 6.24 0.11 0.29 6.91 1.59 4.33 9.36 9.84 8.67 3.93 
1424 RAF_phosphorylates_MEK 2.11 0.51 9.84 8.21 3.96 3.6 6.5 1.94 5.25 1.05 4.01 4.59 9.2 5.94 0.23 1.15 8.89 5.67 
1425 p38MAPK_events 9.4 3.86 6.12 3.16 6.09 6.4 7.42 0.6 9 2.96 4.8 1.42 4.52 4.55 7.05 5.41 2.86 9.33 
1426 ERK1_activation 5.63 6.23 5.19 9.7 6.26 6.73 9.31 2.69 6.88 3.53 6.69 9.37 5.88 9.8 1.67 6.34 4.75 4.81 
1427 ERK2_activation 0.28 6.95 1.52 3.41 0.69 1.67 3.69 0.16 4.73 3.69 6.26 1.04 8.48 9.82 2.94 9.97 4.26 6.9 
1428 RAF_activation 8.9 6.12 7.55 3.47 0.36 9.12 6.74 5.45 9.32 3.66 9.71 9.67 4.75 1.36 2.89 4.48 0.97 2.77 
1429 RAF_phosphorylates_MEK 3.92 0.54 8.43 8.46 5.62 1.99 5.09 5.56 7.2 7.13 6.19 5.04 9.55 5.6 0.47 6.99 9.71 8.29 
1430 p38MAPK_events 0.54 2.71 6.96 0.17 2.67 4.21 1.51 3.38 1.05 2.17 8.48 1.17 4.27 6.75 3.34 2.21 5.34 6.24 
1431 Signalling_to_STAT3 4.7 1.14 2.02 0.08 9.88 8.22 8.04 9.21 0.42 5 3.68 5.4 4.1 3.38 4.53 6.46 0.45 9.13 
1432 ERK1_activation 9.45 2.1 7.81 0.26 5.59 8.04 1.21 7.87 8.37 9.45 6.31 9.54 5.39 7.9 0.71 4.58 8.65 1.74 
1433 ERK2_activation 7.08 1 9.69 7.04 7.42 5.35 4.37 5.76 1.75 0.59 1.78 7.01 3.87 3.62 9.33 0.91 4.35 0.32 
1434 RAF_activation 7.24 9.62 8.03 1.89 8 0.94 2.18 0.32 3.45 2.32 5.87 9.82 7.39 5.97 4.42 8.27 2.32 5.26 
1435 RAF_phosphorylates_MEK 4.64 0.97 3.83 8.48 1.07 4.31 3.31 0.84 0.4 2.03 4.39 0.26 8.9 9.15 6.48 7.37 0.15 6.89 
1436 Spry_regulation_of_FGF_signaling 0.99 4.26 0.73 3.25 6.73 8.22 3.63 0.79 3.03 8.85 7.16 7.73 5.71 2.73 7.37 2.57 6.45 9.94 
1437 Downregulation_of_TGF-beta_receptor_signaling 2.46 9.19 9.46 1.23 1.4 3.81 2.87 5.73 1.94 4.92 3.08 8.59 2.29 5.99 8.3 3.81 3.7 4.26 
1438 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 6.33 6.49 8.62 7.8 6.54 5.5 5.64 5.67 7.3 5.15 9.74 2.64 9.75 9.52 4.39 7.78 2.15 3.63 
1439 TRKA_activation_by_NGF 7.13 7.84 0.78 3.58 3.63 6.03 3.75 2.7 2.69 5.68 4.01 6.95 5.58 9.5 2.68 4.79 4.38 5.26 
1440 Tachykinin_receptors_bind_tachykinins 4.31 8.65 2.88 7.96 3.07 1.06 9.46 2.37 9.02 0.25 7.36 5.21 5.61 0.98 6.69 4.03 9.54 3.72 
1441 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 4.52 1.11 4.49 6.68 0.79 9.56 2.29 7.05 0.53 3.05 0.79 2.97 0.25 3.97 2.82 4.68 6.25 0.65 
1442 Activation_of_the_phototransduction_cascade 1.36 5.12 7.72 4.73 0.33 3.48 6.87 6.84 2.64 5.38 5.06 4.07 3.74 9.02 9.5 1.36 5.23 1.24 
1443 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 2.58 4.58 1.13 5.77 5.43 9.25 9.64 8.4 2.16 1.12 4.71 6 1.18 5.45 9.05 2.52 2.27 3.71 
1444 The_retinoid_cycle_in_cones_(daylight_vision) 2.88 1.23 5.82 5.94 8.36 1.05 8.38 6.03 1.03 8.38 3.86 1.28 8.2 7.65 2.23 4.82 3.26 0.8 
1445 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 9.16 2.63 7.46 7.54 6.51 3.35 0.39 7.97 7.45 6.58 8.36 7.57 6.72 2.76 1.31 1.49 4.42 2.99 
1446 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 4.86 9.77 1.7 4.4 2.23 4.35 4.85 2.52 9.56 0.97 2.79 7.74 9.86 8.15 0.99 0.34 7.13 6.73 
1447 VEGF_binds_to_VEGFR_leading_to_receptor_dimerization 1.62 8.35 3.37 7.32 2.88 8.52 4.75 1.41 5.87 1.72 5.71 8.26 7.98 9.44 0.45 2.4 3.57 7.74 
1448 Neurophilin_interactions_with_VEGF_and_VEGFR 3.57 4.77 0.18 7.03 0.11 9.11 6.15 7.87 2.95 4.44 2.21 9.72 0.82 4.43 9.33 0.2 4.93 1.39 
1449 VEGF_binds_to_VEGFR_leading_to_receptor_dimerization 1.96 8.32 1.33 5.71 1.08 1.46 9.27 3.86 6.81 3.93 8.09 9.68 1.45 8.68 6.74 8.84 9.52 9.99 
1450 Vasopressin-like_receptors 2.26 9.11 2.42 3.16 6.93 0.01 4.5 3.73 6.91 5.94 9.63 2.41 4.84 8.2 7.25 6.3 5.15 8.23 
1451 Activation_of_the_phototransduction_cascade 4.19 2.31 8.32 3.57 8.58 0.69 2.34 4.48 8.6 8.58 4.21 6.4 5.26 6.12 0 2.49 8.23 0.95 
1452 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 4.66 5.8 3.86 2.54 3.83 1.73 6.77 7.23 0.61 1.73 3.31 4.61 4.84 1.93 1.27 8.66 6.93 4.03 
1453 Retinoid_metabolism_and_transport 2.98 8.85 0.09 4.15 7.19 2.89 8.54 5.61 9.49 5.75 4.3 5.97 9.09 7.32 4.48 1.11 6.69 1.91 
1454 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 6.19 6.04 8.51 3.3 2.88 9.68 5.1 4.06 6 4.25 4.25 5.96 5.34 2.52 7.77 3.13 9.1 5.91 
1455 The_retinoid_cycle_in_cones_(daylight_vision) 0.58 8.81 6.13 0.63 9.33 7.12 0.75 3.07 1.01 0.12 7.83 1.2 9.06 7.83 0.97 3.67 6.13 3.33 
1456 WNT_ligand_biogenesis_and_trafficking 5.42 5 1.89 0.32 8.87 2.47 1.61 9.08 6.19 2.32 2.71 5.44 2.47 6.07 3.33 2.25 8.11 3.94 
1457 betaKlotho-mediated_ligand_binding 9.26 1.02 8.87 4.11 1.91 8.23 1.57 7.37 9.78 8.87 1.36 3.18 9.79 6.44 7.42 9.68 5.69 3.96 
1458 Inhibition_of_TSC_complex_formation_by_PKB 7.62 5.32 7.67 3.95 0.61 9.68 4.92 8.66 6.54 6.15 5.84 3.22 4.07 8.67 6.48 3.13 9.78 6.94 
1459 Regulation_of_AMPK_activity_via_LKB1 0.19 9.96 5.72 3.85 1.97 3.82 2.89 6.01 5.48 3.52 8.88 3.34 1.22 1.14 5.68 4.38 7.95 8.24 
1460 Regulation_of_Rheb_GTPase_activity_by_AMPK 9.79 9.86 1.91 2.88 2.98 6.79 5.06 2.75 6.73 1.6 0.18 4.75 6.93 3.86 6.16 2.36 3.39 0.88 
1461 Release_of_eIF4E 6.83 9.41 4.99 7.36 3.46 1.85 9.88 6.93 7.52 5.93 5.77 0.38 9.16 6.04 1.09 5.75 3.22 6.1 
1462 S6K1_signalling 4.36 6.15 1.48 4.37 8.9 7.86 2.29 5.06 7.67 1.68 0.64 4.22 5.47 2.38 5.24 4.92 4.06 5.31 
1463 Release_of_eIF4E 2.11 9.74 1.31 9.73 4.03 7.3 5.26 1.57 6.92 3.19 1.96 1.6 3.39 8.87 3.22 1.51 6.78 9.6 
1464 S6K1_signalling 7.21 5.54 6.73 8.14 4 4.73 0.97 5.39 3.63 2.91 7.75 9.86 5.78 4.74 1.04 4.96 4.85 9.34 
1465 p130Cas_linkage_to_MAPK_signaling_for_integrins 2.18 2.12 5.42 7.61 2.65 8.88 0.63 9.95 4.35 7.36 6.06 3.04 6.16 1.71 5.34 1.75 5.5 8.32 
1466 p38MAPK_events 4.17 6.43 0.36 7.47 4.99 7.67 5.34 3.99 5.12 5.01 6.4 9.34 9.92 1.68 1.5 9.83 2.18 3.4 
1467 Axonal_growth_inhibition_(RHOA_activation) 6.68 9.44 3.1 4.02 3.05 2.61 8.64 6.96 3.7 3.43 8.5 8.88 2.6 5.51 8.73 0.08 3.93 6.13 
1468 Axonal_growth_stimulation 9.79 5.54 3.27 5.01 8.63 5.33 0.21 5.77 3.74 3.31 8.15 7.81 5.36 8.28 0.52 9.9 3.86 0.68 
1469 Ceramide_signalling 3.83 5.88 3.67 7.76 6.99 8.51 4.28 5.35 9.38 6.84 9.84 1.1 1.92 5.77 1.4 8.36 4.91 0.81 
1470 NADE_modulates_death_signalling 5.19 1.68 5.65 8.89 7.34 2.16 8.69 5.96 1.78 3.79 9.23 9.39 7.46 9.76 8.35 4.08 3.15 8.33 
1471 NF-kB_is_activated_and_signals_survival 0.2 7.11 3.4 5.55 9.94 2.71 8.95 9.43 4.16 2.56 0.93 7.01 7.93 6.54 9.93 7.59 7.13 7.41 
1472 NFG_and_proNGF_binds_to_p75NTR 6.48 1.41 7.04 2.12 5.19 0.56 9.03 8.06 9.26 7.12 3.34 8.95 8.36 9.77 7.97 1.17 5.07 2.19 
1473 NRAGE_signals_death_through_JNK 0.34 8.39 6.77 4.82 8.66 1.38 7.98 7.66 0.43 0.57 0.28 1.07 0.25 8.77 3.09 3.31 4.48 4.38 
1474 NRIF_signals_cell_death_from_the_nucleus 3.28 9.78 7.38 3.2 0.07 2.27 2.88 0.18 9.87 4.66 9.18 6.67 8.56 8.65 7.07 1.73 0.98 8.47 
1475 Regulated_proteolysis_of_p75NTR 4.62 8.86 4.56 2.45 0.15 1.57 2.24 6.91 9.49 4.5 9.16 7.71 7.32 5.69 6.04 8.75 0.58 0.81 
1476 p75NTR_negatively_regulates_cell_cycle_via_SC1 9.16 7.69 8.41 0 9.82 5.38 8.55 0.65 6.27 9.64 6.28 1.52 0.87 9.81 2.44 0.37 6.5 1.88 
1477 p75NTR_recruits_signalling_complexes 2.23 3.04 9.5 9.74 5.17 7.88 5.17 3.47 3.89 2.31 7.39 9.94 0.79 5.6 0.53 4.18 4.09 8.58 
1478 p75NTR_negatively_regulates_cell_cycle_via_SC1 7.36 1.15 9.67 1.92 1.4 5.16 1.51 8.41 2.66 6.7 9.08 3.03 2.04 0.09 6.81 6.42 4.29 4.06 
1479 p75NTR_recruits_signalling_complexes 6.48 5.54 9.37 4.76 0.59 7.65 2.86 7.99 1.39 9.42 2.02 3.9 6.07 6.31 6.22 6.36 7.36 3.36 
1480 Axonal_growth_inhibition_(RHOA_activation) 2.6 8.89 1.3 4 4.22 7.53 9.65 4.99 7.91 6.54 9.09 3.4 1.17 1.14 8.47 1.25 5.43 7.11 
1481 Axonal_growth_stimulation 5.82 0.77 7.95 4.34 2.28 7.46 1.56 1.97 5.56 8.48 6.42 6.85 9.92 4.24 6.26 2.83 1.58 4.76 
1482 NF-kB_is_activated_and_signals_survival 2.64 9.82 0.49 1.53 0.9 9.69 6.29 3.58 0.95 4.41 2.74 7.49 5.51 6.67 5.33 0.95 4.44 2.59 
1483 p75NTR_recruits_signalling_complexes 1.56 9.01 7.86 1.83 6.48 5.96 2.59 3.65 6.88 2.56 7.27 7.3 3.31 7.41 7.38 3.26 4.46 1.3 
1484 phospho-PLA2_pathway 3.97 3.32 3.67 1.43 4.42 1.81 2.09 3.12 9.54 7.91 7.62 2.35 5.69 6.18 3.85 2.78 7.41 0.6 
1485 POLRMT_chain_elongation 4.75 9.88 0.98 4.62 8.96 5.78 8.26 0.95 7.13 8.92 6.43 7.35 7.97 4.7 0.17 7.18 8.53 9.36 
1486 Inhibition_of_HSL 6.3 8.77 7.48 8.81 2.87 5.97 0.83 2.39 2.73 3.04 7.32 8.54 7.47 0.69 6.69 3.92 4.78 2.07 
1487 Transfer_of_LPS_from_LBP_carrier_to_CD14 8.07 0.04 4.99 6.08 6.4 1.85 0.11 0.74 3.26 3.88 7.97 4.71 7.81 0 5.23 7.53 1.78 6.22 
1488 Activation_of_C3_and_C5 1.66 5 5.85 8.06 7.48 5.55 3.64 0.13 0.78 1.2 2.93 9.67 8.79 5.84 9.66 7.9 6.34 2.62 
1489 Alternative_complement_activation 4.15 8.27 2.67 4.95 9.12 4.37 9.69 2.3 8.88 6.24 9.86 2.49 8.37 6.48 9.84 6.76 7.88 7.26 
1490 Classical_antibody-mediated_complement_activation 6.5 5.96 3.39 5.46 3.18 1.18 4.53 3.61 2.45 4.89 5.74 3.69 8.96 4.9 8.47 3.55 0.66 5.27 
1491 Classical_antibody-mediated_complement_activation 7.89 8.8 7.02 0.05 6.45 1.2 0.42 2.53 7.15 9.42 9.79 4.37 0.19 2.8 1 3.32 5.99 8.85 
1492 Ficolins_bind_to_repetitive_carbohydrate_structures_on_the_target_cell_surface 5.93 6.4 2.19 7.84 1.45 5.71 6.45 0.44 5.64 7.14 4.8 5.6 9.2 2.16 5.39 0.86 0.82 8.67 
1493 Ficolins_bind_to_repetitive_carbohydrate_structures_on_the_target_cell_surface 7.26 0.55 3.4 6.38 1.57 1.29 4.02 1.59 5.76 0.03 8.41 4.17 1.37 1.03 3.45 0.2 9.36 4.65 
1494 Alternative_complement_activation 1.46 9.24 0.83 2.96 1.58 2.64 5.94 0.27 3.42 2.92 1.71 5.98 6.72 7.2 8.41 7.89 2.94 4.9 
1495 Classical_antibody-mediated_complement_activation 3.94 5.44 5.78 8.18 4.89 9.91 3.13 1.89 1.37 4.48 3.26 7.32 1.47 1.27 4.41 0.93 4.5 4.77 
1496 Ficolins_bind_to_repetitive_carbohydrate_structures_on_the_target_cell_surface 0.47 9.94 7.41 8.28 2.35 4.65 7.41 8.33 8.77 8.37 4.39 7.07 4.1 8.1 4.76 3.24 1.49 4.54 
1497 Ficolins_bind_to_repetitive_carbohydrate_structures_on_the_target_cell_surface 5.27 8.3 6.53 1.98 5.99 8.07 8.3 0.79 6.7 2.8 6.84 6.06 3.53 5.78 3.74 1.3 4.4 5.94 
1498 Regulation_of_Complement_cascade 1.99 8.97 9.6 6.15 6.51 7.84 1.68 2.17 7.28 8.87 4.09 3.16 2.98 7.07 9.62 4.3 6.92 9.82 
1499 Terminal_pathway_of_complement 4.1 1.73 6.99 1.96 0.55 9.96 1.57 4.4 0.55 3.04 8.27 2.63 7.17 4.46 9.95 9.62 6.62 9.43 
1500 Activation_of_the_AP-1_family_of_transcription_factors 4.89 7.3 7.16 9.82 6.06 1.51 9.46 7.78 9.85 8.18 5.7 4.23 1.18 9.88 3.48 2.5 8.52 5.17 
1501 CREB_phosphorylation 5.91 0.68 9.08 2.49 7.09 1.58 7.1 7.45 5.62 0.63 3.1 4.86 4.93 6.9 9.67 2.11 5.06 6.91 
1502 ERK1_activation 4.06 0.2 3.35 2.99 7.87 3.21 0.94 2.34 3.88 4.15 0.03 6.13 7.54 6.09 0.7 0.8 8.39 2.11 
1503 ERK2_activation 2.83 8.93 3.36 8.31 4.72 3.82 0.64 5.08 2.94 3.67 4.38 2.92 9.32 5.92 8.8 1.24 3.36 9.53 
1504 ERKs_are_inactivated 5.19 8.89 7.83 5.43 5.81 6.81 3.92 4.78 6.44 8.72 4.84 6.39 0.88 9.48 4 8.29 5.6 0.75 
1505 ERK1_activation 4.46 8.26 0.34 0.52 4.89 6.63 5.65 1.71 8.88 1.88 0.1 3.13 1.33 1.48 6.13 4.91 3.9 3.57 
1506 ERK2_activation 4.73 8.81 3.47 4.7 1.46 0.02 4.01 3.78 6.47 9.98 2.7 9.97 3.19 3.96 9.9 6.84 2.27 8.22 
1507 ERKs_are_inactivated 0.86 3.69 3.24 3.46 7.75 7.03 4.06 1.14 4.93 6.99 7.42 6.93 8.65 6.36 7.68 3.27 5.87 8.53 
1508 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 5.89 8.31 0.52 9.52 2.74 6.48 7.55 5.33 8.6 2.42 0.38 6.59 8.11 7.38 5.16 9.9 0.04 4.47 
1509 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 1.93 2.26 3.72 5.74 6.09 3.67 1.93 6.65 9.68 9.02 0.99 0.83 7.22 0.66 9.15 2.55 9.42 8.1 
1510 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 3.55 4.02 0.72 9.82 4.39 9.66 1.04 3.2 1.14 7.04 5.65 3.66 4.36 6.36 3.17 7.97 9.06 8.87 
1511 Activation_of_the_AP-1_family_of_transcription_factors 7.21 2.48 0.3 6.38 1.25 4.64 7.93 3.57 7.1 6.54 6.14 2.34 3.11 8.87 9.69 2.12 7.89 2.96 
1512 CREB_phosphorylation 6.96 2.14 1.29 9.55 6.97 3.04 8.31 2.8 9.96 4.39 2.21 2.47 9.38 2.28 4.93 6.12 8.62 4.43 
1513 ERK1_activation 5.66 8.93 3.39 6.45 0.96 3.36 4.86 0.96 9.03 9.12 3.57 4.77 3.62 8.34 9.76 0.03 5.64 8.75 
1514 ERK2_activation 5.11 1.06 3.39 1.57 1.41 9.86 0.15 7.37 7.87 5.25 4.05 1.42 6.08 9.78 2.6 2.43 9.19 8.19 
1515 ERKs_are_inactivated 8.48 4.73 1.06 0.02 9.66 6.37 9.9 5.83 5.99 8.29 7.74 8.77 1.28 9.53 4.37 8.94 2.32 2.92 
1516 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 8.7 7 0.84 8.42 2.38 6.18 5.92 3.88 2.68 2.74 6.07 8.98 1.11 2.72 5.17 6.01 1.3 9.42 
1517 activated_TAK1_mediates_p38_MAPK_activation 9.47 8.37 9.64 3.61 4.27 9.2 8.27 2.85 9.72 5.48 0.49 1.33 2.4 3.89 9.59 3.73 4.76 7.71 
1518 Activation_of_the_AP-1_family_of_transcription_factors 0.02 7.95 7.76 6.15 6.19 1.23 5.83 4.99 9.55 8.42 7.77 3.59 5.26 9.74 7.99 5.45 8.39 8.6 
1519 CREB_phosphorylation 6.63 9.24 9.49 9.69 2.9 8.13 8.53 2.69 2.09 3.3 8 6.29 8.15 6.83 4.87 6.32 0.99 8.86 
1520 ERKs_are_inactivated 7.47 2.21 8.28 1.74 1.86 5.87 4.18 5.63 8.07 7.52 5.15 3.52 5.68 3.42 7.07 9.93 5.02 5.07 
1521 Activation_of_the_AP-1_family_of_transcription_factors 7.76 9.23 7.45 1.99 6.45 8.65 0.26 1.56 1.56 3 7.25 0.81 7.54 7.46 0.55 5.6 0.21 3.78 
1522 CREB_phosphorylation 9.32 0.09 3.53 6.71 4.92 3.02 5.16 3.39 3.34 5.2 0.79 7.58 9.26 0.73 3.26 3.11 6.19 8.04 
1523 ERK1_activation 8.66 1.54 1.16 0.1 0.6 5.95 9.81 8.47 3.56 8.42 7.16 5 3.48 8.24 0.17 8.29 6.14 7.76 
1524 ERK2_activation 2.53 9.42 5.01 3.77 7.14 5.54 7.23 4.19 6.67 4.45 3.42 4.33 9.97 6.43 0.8 2.3 0.95 3.11 
1525 ERKs_are_inactivated 3.6 8.02 6.78 8.48 1.07 2.31 7.56 4.65 4.23 7.11 1.94 2.16 5.85 1.53 2.35 5.94 9.01 3.63 
1526 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 2.1 1.25 8.62 1.22 7.91 6.93 7.27 3.04 0.95 2.59 3.85 8.37 5.3 0.11 8.53 4.81 1.68 4.53 
1527 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 5.57 9.12 7.42 7.11 6.71 3.36 1.41 0.89 5.38 7.11 6.61 0.09 8.83 4.49 7.92 0.55 1.45 4.16 
1528 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 6.01 0.27 8.88 4.28 8.23 6.46 4.59 0.54 3.01 6.63 0.78 9.11 5 2.47 6.83 4.54 2.5 0.94 
1529 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 7.15 1.78 2.37 5.11 3.28 2.37 8.35 7.7 1.2 5.78 8.2 1.54 5.72 7.28 2.5 7.18 4.34 3.34 
1530 TRAF6_mediated_IRF7_activation_in_TLR7/8_or_9_signaling 4.87 7.79 8.72 1.38 6 4.17 0.74 9.33 8.81 2.6 0.45 3.69 4.73 3.03 4.53 0.46 2.47 8.36 
1531 activated_TAK1_mediates_p38_MAPK_activation 2.36 9.21 8.37 0.63 0.2 9.5 3.48 2.12 0.31 1.2 4.33 3.34 0.13 3.42 8.54 3.13 3.1 2.16 
1532 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 3.96 9.54 6.16 8.74 4.47 7.42 7.87 5.76 3.78 0.88 9.79 5.4 4.05 3.27 3.58 1.31 2.92 1.35 
1533 TRAF6_mediated_IRF7_activation_in_TLR7/8_or_9_signaling 4.95 3.26 3.62 7.03 2.26 6 1.58 3.47 4.73 0.28 8.53 8.9 8.14 1.29 2.72 6.27 7.53 6.23 
1534 Activation_of_the_AP-1_family_of_transcription_factors 0.31 9.23 4.77 8.68 0.14 3.39 4.3 2.11 1.02 6.96 9.1 1.09 6.71 3.7 4.24 1.86 7.74 0.81 
1535 CREB_phosphorylation 2.84 2.81 2.1 7.57 9.33 7.58 1.07 8.29 5.43 2.84 2.84 7.78 9.65 5.56 6.24 4.85 0.34 4.44 
1536 ERK1_activation 6.67 4.7 1.42 4.75 4.27 1.75 7.63 7.32 4.55 9.12 1.93 3.38 1.9 4.84 9.19 6.83 2.19 7 
1537 ERK2_activation 0.18 1.59 4 2.02 0.11 8.02 1.05 4.25 7.72 3.76 6.82 7.87 7.31 9.13 2.43 0.35 7.23 7.02 
1538 ERKs_are_inactivated 1.63 1.4 3.75 8.26 2.03 8.09 6.88 3.08 6.12 7.99 9.61 7.33 8.28 3.76 7.85 8.77 9.8 7.61 
1539 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 9.2 9.07 9.5 3.42 4.3 7.4 0.54 9.41 1.92 2.9 9.57 6.48 2.85 0.49 9.5 4.87 3.2 3.19 
1540 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 7.87 6.37 7.66 1.87 2.71 5.94 1.31 7.67 7.54 0.49 3.28 3.52 4.88 4.74 7.19 9.98 5.79 9.79 
1541 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 9.3 8.63 0.5 5.07 4.65 9.28 2.66 9.91 3.71 4.71 1.96 0.24 2.95 5.47 8.55 8.77 5.55 0.85 
1542 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 7.92 8.85 7.33 7.63 0.31 5.83 2.47 2.82 4.91 0.62 3.52 1.15 0.65 7.75 2.33 7.54 6.09 2.61 
1543 activated_TAK1_mediates_p38_MAPK_activation 4.14 4.27 2.41 1.11 5.66 1.74 9.34 3.11 8.84 4.85 9.04 7.67 1.51 6.02 7.26 2.08 7.26 7.98 
1544 activated_TAK1_mediates_p38_MAPK_activation 0.02 2.11 3.44 1.52 0.22 6.19 2.75 7.07 2.54 3.06 3.39 9.08 6.64 6.59 7.9 1.86 7.3 8.88 
1545 Activation_of_the_AP-1_family_of_transcription_factors 7.26 3.9 8.91 5.89 2.55 0.53 4.37 4.52 1.53 6.67 5.53 0.11 6.55 4.35 0.19 4.59 6.89 9.41 
1546 CREB_phosphorylation 0.39 2.98 3.68 0.94 8.45 5.15 2.16 6.14 5.45 9.09 6.99 3.18 8.94 2.65 6.03 1.44 4.92 3.12 
1547 ERK1_activation 4.63 2.76 0.38 6.05 1.3 9.28 9.85 9.58 1.85 3.36 2.83 6.88 3.24 4.14 1.28 6.27 8.62 0.04 
1548 ERK2_activation 3.07 1.08 8 9.51 5.07 6.67 3.63 8.06 2.04 5.56 2.93 9.48 5.51 9.21 9.17 5.86 8.36 8 
1549 ERKs_are_inactivated 4.58 3.6 5.91 6.97 8.66 0.37 5.37 3.95 3.27 1.34 8.73 4.23 8.78 1.07 1.94 9.24 0.67 7.2 
1550 ERK1_activation 9.67 0.37 6.63 0.43 6.76 9.04 5.55 8.73 3.5 5.37 9.14 0.54 2.7 6.07 4.09 8.92 1.7 5.56 
1551 ERK2_activation 6.02 7.87 0.69 3.7 2.11 6.83 2.49 4.12 3.52 6.46 8.33 8.67 1.92 2.81 3.39 1.07 0.62 8.28 
1552 ERKs_are_inactivated 6.38 9.82 9.58 2.48 0.97 4.94 8.68 9.29 0.92 0.32 8.31 5.48 9.15 0.79 4.19 1.7 4.8 2.39 
1553 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 5.27 3.65 3.91 7.72 6.44 3.39 8.65 2.1 6.24 7.85 8.97 8.78 6.1 6.02 1.95 1.32 2.7 4.24 
1554 Activation_of_the_AP-1_family_of_transcription_factors 3.9 8.82 0.11 3.3 5.99 8.45 7.72 0.7 4.8 5.63 4.6 7.13 6.81 4.57 0.29 5.81 4.38 1.98 
1555 CREB_phosphorylation 6.98 4.74 0.08 2.87 7.79 8.73 1.45 8.68 5.45 9.08 2.98 2.27 9.95 7.78 0.63 7 0.01 7.86 
1556 ERK1_activation 3.98 4.13 7.83 7.65 4.51 2.14 7.56 8.17 1.28 6.15 7.39 4.51 3.79 5.29 3.45 8.21 7.6 4.99 
1557 ERK2_activation 3.45 2.08 2.09 0.46 1.56 7.71 6.75 7.39 9.09 7.09 3.39 1.63 8.44 2.32 6.41 4.71 1.53 1.91 
1558 ERKs_are_inactivated 8.04 4.58 3.88 0.57 3.58 8.35 1.86 1.18 6.72 1.27 0.03 7.13 9.29 3.82 9.77 2.47 4.51 0.61 
1559 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 1.55 3.19 1.35 7.4 7.55 6.42 9.07 4.73 6.69 4.77 0.25 8.21 9.06 9.33 2.09 4.69 3.96 1.14 
1560 activated_TAK1_mediates_p38_MAPK_activation 1.45 6.04 3.3 8.23 7.01 0.31 7.42 2.01 8.66 0.01 8.37 4.69 1.59 5.44 8.38 5.51 2.61 1.35 
1561 Activation_of_the_AP-1_family_of_transcription_factors 5.51 0.25 3.1 0.45 1.88 2.73 0.93 0.94 3.38 5.98 8.04 3.37 8.67 8.44 4.2 2.42 7.07 2.21 
1562 CREB_phosphorylation 5.44 7.29 2.18 2.02 7.71 5.54 0.51 3.79 2.43 3.42 8.53 1.8 7.18 1.22 5.11 3.29 6.28 2.07 
1563 ERKs_are_inactivated 5.37 7.07 3.97 7.54 7.12 8.19 1.17 9 0.11 2.78 8.12 1.33 2.84 0.65 9.07 4.61 7.45 0.47 
1564 Activation_of_the_AP-1_family_of_transcription_factors 0.84 3.07 0.2 9.69 8.49 9.85 5.03 0.21 9.44 8.07 1.24 0.51 7.98 8.07 6.68 5.79 5.69 6.33 
1565 CREB_phosphorylation 0.3 2.51 3.7 9.12 2.26 7.84 5.71 0.29 5.35 3.62 7.25 1.47 4.5 9.34 8.62 3.54 6.48 5.58 
1566 ERK1_activation 2.8 7.52 4.45 2.99 4.61 8.2 3.82 9.42 6.82 3.73 4.2 0.27 7.86 8.59 7.94 5.75 9.49 8.76 
1567 ERK2_activation 4.25 6.75 4.88 7.46 6.66 3.77 0.95 1.55 1.16 0.07 1.68 6.25 2.7 1.87 3.05 3.7 6.87 6.45 
1568 ERKs_are_inactivated 3.33 1.63 4.76 3.15 3.79 8.81 7.54 6.64 5.35 1.6 0.13 4.94 7.01 5.12 7.12 6.71 6.68 9.32 
1569 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 9.26 7.02 8.07 6.05 6.48 7.47 9.14 4.15 2.64 2.23 5.47 0.17 8.93 5.64 1.66 8.99 6.4 9.69 
1570 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 3.74 0.59 9.82 9.09 3.85 8.65 6.63 7.37 8.67 2.2 7.75 8.27 9.89 6.04 2.27 1.12 5.83 2.97 
1571 TRIF-mediated_programmed_cell_death 5.34 1.14 2.52 0.83 5.08 7.54 6.3 0.84 5.43 7.36 4.18 2.28 3.04 2.65 0.85 5.47 0.72 6.56 
1572 activated_TAK1_mediates_p38_MAPK_activation 3.74 3.64 2.23 0.56 1.5 6.16 4.22 6.8 4.13 0.72 0.56 2.48 7.67 0.15 9.18 6.35 7.19 0.55 
1573 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 0.83 4.3 3.39 4.11 7.72 4.8 7.84 1.09 4.05 2.82 8.55 7.38 5.76 9.05 6.96 6.5 9.11 4.58 
1574 TRIF-mediated_programmed_cell_death 6.46 3 1.16 3.33 4.44 0.17 5.67 7.01 4.7 9.92 5.27 7.83 0.9 8.9 3.41 9.21 8.48 5.9 
1575 activated_TAK1_mediates_p38_MAPK_activation 3.02 5.25 5.77 8.72 3.83 6.61 4.92 2.38 3.97 0.65 5.51 3.16 4.45 5.12 9.15 5.52 3.7 6.03 
1576 Activation_of_the_AP-1_family_of_transcription_factors 8.96 9.52 9.5 3.92 6.6 1.38 9.79 6.69 9.9 6.76 6.01 3.87 3.36 1.25 2.75 4.7 1.16 9.8 
1577 CREB_phosphorylation 1.81 8.34 4.29 8 0.97 9.52 6.81 4.8 2.82 2.73 4.46 4.04 3.52 1.78 1.31 6.83 1.34 7.28 
1578 ERK1_activation 5.37 6.54 2.4 8.14 5.86 6.37 4.57 5.49 8.32 2.73 8.84 3.24 0.33 6.57 9.45 7.2 0.97 2.33 
1579 ERK2_activation 5.86 0.21 9.12 9.36 3.82 3.58 8.86 0.32 1.18 1.53 5.89 1.56 7.83 1.42 6.94 1.17 3.99 6.1 
1580 ERKs_are_inactivated 0.54 0.61 4.67 3.83 3.7 7.36 9.76 0.38 5.76 4.95 0.89 2.64 7.84 9.51 1.29 1.37 6.12 2.34 
1581 ERK1_activation 9.05 1.02 8.12 6.69 3.08 4.96 7.16 6.09 0.64 3.94 1.86 6.21 4.32 6.24 9.54 3 4.64 6.56 
1582 ERK2_activation 8.37 8.99 5.21 1.33 6.98 6.86 5.34 2.01 0.11 1.96 8.78 0.35 6.91 0.64 8.18 4.02 4.94 9.21 
1583 ERKs_are_inactivated 6.81 3.53 8.1 4.2 3.47 4.27 4.61 9.44 6.67 2.96 8.55 8.42 7.12 6.25 1.21 8.99 6.05 8.4 
1584 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 7.34 4.87 4 2.92 6.89 8.15 3.36 3.96 1.43 1.77 5.23 9.45 1.34 1.49 8.86 5.05 9.43 2.6 
1585 Activation_of_the_AP-1_family_of_transcription_factors 0.38 5.13 6.64 8.45 5.51 4.75 6.36 2.4 0.51 1.05 9.67 3.18 1.33 2.64 0.29 7.52 8.47 7.84 
1586 CREB_phosphorylation 9.62 1.75 8.96 2.35 7.35 3.88 6.9 9.08 8.6 3.94 9.23 1.47 2.65 6.32 2.82 9.5 4.02 7.63 
1587 ERK1_activation 1.17 1.85 7.22 3.4 9.85 1.69 8.86 1.9 2.01 1.49 7.73 1.7 0.02 0.22 5.99 0.94 3.03 0.49 
1588 ERK2_activation 3.16 6.51 7.28 7.23 9.58 2.14 1.44 3.41 2.42 4.1 9.59 0.55 1.39 8.92 5.89 5.53 8.47 6.63 
1589 ERKs_are_inactivated 0.57 1.44 2.46 5.29 9.53 4.14 4 4.94 7.3 5.34 8.31 6.03 4.19 9.02 2.77 2.13 5.49 9.17 
1590 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 1.82 0.83 7.89 3.27 5.77 5.29 1.49 4.07 3.39 1.03 4.71 6.52 8.29 9.54 5.48 6.87 6.48 0.33 
1591 activated_TAK1_mediates_p38_MAPK_activation 7.25 6.2 7.26 6.1 6.32 9.43 0.5 4.14 4.6 0.33 5.54 6.9 0.32 7.39 6.76 9.2 2.17 9.86 
1592 Activation_of_the_AP-1_family_of_transcription_factors 3.59 7.57 7.39 6.04 8.59 7.16 4.59 8.9 4.92 1.63 7.06 1.74 5.47 1.49 9 1.98 5.73 9.36 
1593 CREB_phosphorylation 5.77 5.94 3.44 9.91 5.32 6.27 1.64 9.94 5.63 6.92 8.14 1.64 9.1 6.06 6.83 4.62 5.87 0.38 
1594 ERKs_are_inactivated 2.5 8.03 0.64 1.53 5.06 4.68 2.83 0.04 1.67 2.36 5.19 7.57 3.11 2.54 1.76 1.58 9.62 2.46 
1595 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 0.89 4.35 6.65 4.05 0.28 6.09 5.98 4.01 9.3 5.78 7.25 0.76 2.83 5.9 9.93 8.84 6.88 9 
1596 activated_TAK1_mediates_p38_MAPK_activation 3.21 7.15 3.03 9.05 1.24 1.76 2.06 5.44 1.56 9.5 0.04 0.28 8.47 5.39 2.45 6.9 3.95 0.35 
1597 Activation_of_the_AP-1_family_of_transcription_factors 0.52 0.42 7.23 7.34 7.66 2.38 4.37 4 1.56 4.68 9.59 9.27 8.49 2.97 4.65 2.82 9.89 5.59 
1598 CREB_phosphorylation 4.27 9.92 0.09 2.16 5.62 7.03 1.4 9.23 6.4 4.46 1.58 1.91 7.7 8.29 2.27 8.7 3.5 9.47 
1599 ERK1_activation 9.54 5.64 0.84 0.64 0.38 3.67 0.2 1.16 1.88 3.85 2.4 6.8 0.7 7.39 0.84 2.28 7.92 0.69 
1600 ERK2_activation 3.71 3.28 1.69 5.16 6.03 5.27 1.81 2.19 2.85 7.93 4.16 4.61 0.3 0.4 4.53 9.37 7.77 9.97 
1601 ERKs_are_inactivated 4.96 2.39 9.04 0.84 6.97 0.75 2.64 9.49 5.46 1.76 7.25 1.08 5.38 0.38 4.3 1.71 4.11 5.74 
1602 ERK1_activation 2.35 2.55 7.13 6.21 2.12 3.04 2.21 2.08 2.43 4.61 5.76 8.48 8.68 4.95 6.04 3.66 3.4 2.13 
1603 ERK2_activation 4.87 9.92 2.32 2.65 8.49 1.56 4.48 3.04 8.89 4.68 1.32 9.43 1.54 5.86 9.57 8.52 5.8 7.26 
1604 ERKs_are_inactivated 5.99 8.03 9.76 5.27 1.65 8.74 2.2 4.95 5.58 4.55 4 7.46 6.79 8 7.92 3.27 8.49 8.68 
1605 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 2.19 7.59 7.4 0.08 2.99 3.42 1.8 9.56 7.26 6 5.87 7.59 9.56 4.3 1.11 0.96 5.22 6.25 
1606 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 9.01 6.95 7.03 4.14 8.22 8.35 1.97 1.71 7.37 1.26 7.3 7.53 4.34 8.3 0.95 5.54 3.21 7.88 
1607 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 6.49 8.21 8.94 5.86 6.54 9.19 6.36 0.97 8.34 3.4 4.19 2.89 6.67 9.67 2.5 4.84 1.61 8.54 
1608 Activation_of_the_AP-1_family_of_transcription_factors 4.84 6.61 0.43 2.26 4.91 6.85 0.06 2.77 3.15 0.55 4.23 1.33 3.04 5.01 6.34 9.36 2.98 8.09 
1609 CREB_phosphorylation 7.4 1.04 0.8 2 1.66 1.69 2.75 0.84 4.91 0.4 6.37 3.22 3.88 6.31 3.77 0.92 1.85 9.82 
1610 ERK1_activation 8.44 1.91 2.12 0.84 3.64 5.83 8.81 4.15 7.28 9.13 8.4 3.6 0.33 8.97 9.82 0.42 5.2 3.9 
1611 ERK2_activation 1.84 8.04 7.44 7.87 2.73 1.25 4.84 1.99 7.59 0.4 6.44 3.51 6.81 0.72 1.64 0.34 2.91 7.66 
1612 ERKs_are_inactivated 0.7 4.46 6.54 5.04 0.98 7.77 9.69 1.72 2.82 0.26 1.88 3.42 7.87 4.33 5.43 5.42 1.29 5.33 
1613 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 1.03 9.9 6.09 8.61 3.05 4.82 2.77 9.6 7.85 3.84 4.44 5.92 0.77 5.54 1.6 1.16 6.61 3.7 
1614 activated_TAK1_mediates_p38_MAPK_activation 5.4 2.94 8.46 6.29 5.42 1.33 8.32 4.03 3.37 5.47 4.85 7.83 8.86 7.53 7.31 9.62 9.88 7.3 
1615 Activation_of_the_AP-1_family_of_transcription_factors 6.43 7.64 5.09 1.1 2.58 8.29 1.39 4.56 9.84 7.85 2.11 8.25 3.28 1.63 4.16 8.78 6.47 8.59 
1616 CREB_phosphorylation 8.51 8.24 9.61 6.5 8.58 9.31 9.04 8.7 7.11 5.53 4.86 6.25 8.27 2.16 5.09 3.35 1.87 7.53 
1617 ERKs_are_inactivated 5.96 5.76 4.01 6.66 0.85 0.42 5.73 1.74 0.45 8.99 0.14 9.31 6.68 3.97 5.63 7 2.86 2.99 
1618 Activation_of_the_AP-1_family_of_transcription_factors 1.99 2.33 5.13 0.19 6.13 0.28 3.6 8.21 7.28 1.73 7.58 0.5 1.67 2.09 7.99 3.52 7.74 7.09 
1619 CREB_phosphorylation 8.04 9.42 6.8 5.93 4.77 3.15 2.44 7.63 8.61 8.84 8.06 0.34 5.6 2.85 3.67 3.17 6.8 0.87 
1620 ERK1_activation 6.79 4.1 6.16 9.47 2.18 6.75 1.36 9.42 6.17 6.3 6.03 3.74 4.99 5.95 6.85 3.48 7.4 3.48 
1621 ERK2_activation 7.2 1.7 2.52 4.4 2.25 4.39 3.22 8.56 5.03 8.73 8.35 4.95 3.56 8.74 7.74 7.63 7.92 4.3 
1622 ERKs_are_inactivated 5.22 2.41 7.37 6.11 5.54 0 7.11 4.18 5.12 7.07 8.55 6.93 0.39 5.33 2.14 2.5 3.41 4.73 
1623 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 1.85 2.87 3.29 1.04 1.07 5.82 4.66 2.95 9.19 2.83 0.73 2.15 6.22 4.11 7.91 3.74 0.1 9.04 
1624 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 0.01 1.35 8.68 5.15 3.71 7.17 1 1.21 1.79 6.14 2.95 1.28 2.8 5.9 7.49 5.23 4.27 0.09 
1625 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 3.31 9.57 3.56 2.29 7.91 3.95 8.32 0.3 1.15 3.65 8.73 2.6 2.91 2.38 2.95 4.51 7.86 1.85 
1626 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 4.06 2.1 0.9 6.47 7.67 8.14 5.7 1.74 6.92 1.99 8.13 4.2 2.22 4.02 8.73 0.29 2.25 4.89 
1627 TRAF6_mediated_IRF7_activation_in_TLR7/8_or_9_signaling 8.21 3.93 3.15 0.01 2.47 0.18 2.41 8.34 0.36 9.72 0.82 1.96 9.13 0.45 8 9.84 7.78 6.95 
1628 activated_TAK1_mediates_p38_MAPK_activation 4.92 7.96 6.89 7.08 2.01 2.28 3.93 4.26 6.36 4.13 6.99 6.95 2.58 4.83 4.41 1.74 6.35 2.86 
1629 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 4.97 3.54 5.98 7.12 0.53 3.39 3.24 4.5 4.32 6.63 2.01 8.24 8.43 7.95 8.89 2.18 9.62 3.78 
1630 TRAF6_mediated_IRF7_activation_in_TLR7/8_or_9_signaling 5.91 7.49 8.56 8.6 9 8.41 7.46 4.98 7.98 6.03 2.02 7.38 6.79 8.78 8.51 9.19 5.76 7.26 
1631 Activation_of_the_AP-1_family_of_transcription_factors 2.69 7.46 5.25 8.94 8.01 1.66 4.18 9.62 4.79 1.84 7.34 8.71 5.09 8.54 0.39 5.86 9.24 9.15 
1632 CREB_phosphorylation 3.27 4.78 6.86 3.84 6.54 6.9 7.78 4.92 1.83 6.02 4.91 7.42 1.99 6.92 5.01 2.42 5 7.34 
1633 ERK1_activation 4.42 7.07 9.54 0.79 8.36 2.09 8.84 1.47 6.52 0.67 7.2 5.47 9.71 9.58 7 0.2 6.94 4.78 
1634 ERK2_activation 2.56 0.3 7.27 2.52 3.56 3.44 4.1 4.17 9.56 3.38 3.81 5.15 6.09 8.52 5.16 4.62 2.41 8.37 
1635 ERKs_are_inactivated 1.16 3.88 5.05 9.66 2.14 9.67 6.67 5.84 9.58 5.34 9.55 4.59 2.2 7.02 5.02 8.97 1.94 4.75 
1636 IRAK1_recruits_IKK_complex_upon_TLR7/8_or_9_stimulation 5.57 8.98 0.32 2.56 4.94 3.77 9.65 1.24 7.56 6.54 4.55 6.29 8.72 1.18 1.73 8.81 0.8 3.84 
1637 IRAK2_mediated_activation_of_TAK1_complex_upon_TLR7/8_or_9_stimulation 5.22 2.98 9.11 4.01 5 5.22 0.36 3.87 1.42 3.04 9.84 2.41 2.11 0.25 6.18 0.46 0.53 8.99 
1638 JNK_(c-Jun_kinases)_phosphorylation_and__activation_mediated_by_activated_human_TAK1 1.57 2.71 6.61 3.41 4.62 9.18 4.27 8.99 9.02 7.12 2.15 4.89 0.94 5.21 8.73 0.62 3.4 9.19 
1639 TAK1_activates_NFkB_by_phosphorylation_and_activation_of_IKKs_complex 7.99 5.15 4.32 9.96 3.81 7.15 4.52 0 9.3 6.38 9.88 2.46 9.04 4.73 2.18 3.97 4.6 7.76 
1640 activated_TAK1_mediates_p38_MAPK_activation 7.17 7.15 7.99 2.86 5.47 9.33 5.72 4.2 8.85 0.97 8.35 5.12 0.74 5.04 4.05 4.4 7.1 5.42 
1641 activated_TAK1_mediates_p38_MAPK_activation 0.57 4.64 8.2 5.56 8.55 2.24 8.9 4.81 7.55 8.98 1.08 1.16 0.11 7.46 1.32 4.84 9.8 2.95 
1642 The_AIM2_inflammasome 9.52 7.71 9.23 5.21 1 6.65 7.12 4.67 1.62 9.73 2.95 1.7 9.83 8.82 0.98 5.67 4.64 0.47 
1643 The_IPAF_inflammasome 6.09 1.06 8.6 3.34 0.44 1.19 9.56 6.98 3.14 1.42 3.2 4.99 3.46 2.21 4.2 6.68 6.03 0.48 
1644 The_NLRP1_inflammasome 1.63 0.71 7.75 7.64 8.11 6.63 4.93 2.17 6.73 9.34 8.63 8.31 9.18 7.52 7.05 7.06 2.11 7.59 
1645 NOD1/2_Signaling_Pathway 4.12 3.36 8.16 4.73 4.89 3.29 7.47 8.63 5.45 8.49 4.87 5.83 7.65 1.31 8.11 0.68 8.02 7.34 
1646 The_AIM2_inflammasome 1.57 5.16 2.15 7.32 9.82 9.87 4.5 3.2 6.48 7.03 2.39 6.24 8.7 0.03 0.02 5.4 4.42 3.75 
1647 The_IPAF_inflammasome 7.76 0.14 6.52 2.8 6.57 2.9 0.82 8.52 9.85 6.08 3.23 4.73 8.39 4.95 0.33 3.02 4.93 2.76 
1648 The_NLRP1_inflammasome 9.58 3.94 7.61 1.23 5.81 1.48 1.95 8.69 2.37 1.46 2.32 9.8 2.09 6.3 7.66 8.43 3.56 7.5 
1649 NF-kB_activation_through_FADD/RIP-1_pathway_mediated_by_caspase-8_and_-10 5.7 1.45 0.6 0.99 6.54 8.87 8.27 6.28 3.67 1.91 1.98 3.96 4.78 0.48 4.23 1.05 1.33 8.88 
1650 Negative_regulators_of_RIG-I/MDA5_signaling 2.7 7.83 6.76 0.89 8.64 4.04 7.16 6.95 4.94 1.41 7.09 3.36 1.86 6.41 1.39 0.37 9.73 0.92 
1651 TRAF3-dependent_IRF_activation_pathway 8.22 3.21 2.28 3.19 6.74 7.59 5.72 2.3 4.43 8.89 7.47 3.7 1.73 2.14 7.3 7.52 1.4 3.39 
1652 TRAF6_mediated_IRF7_activation 7.76 2.89 3.44 9.82 0.64 2.59 8.99 4.23 0.86 1.53 1.89 3.83 5.33 8.87 8.87 6.69 2.05 5.53 
1653 TRAF6_mediated_NF-kB_activation 4.79 6.23 7.71 6.11 3.16 0.46 1.46 3.39 4.59 5.66 9.05 4.15 9.29 7.8 8.44 3.77 7.38 9.28 
1654 Cdc20:Phospho-APC/C_mediated_degradation_of_Cyclin_A 6.15 0.9 8.25 9.01 0.08 0.86 8.16 0.87 9.17 6.84 8.34 7.96 2.86 0.09 5.44 7.66 3.4 6.37 
1655 APC-Cdc20_mediated_degradation_of_Nek2A 0.73 1.76 6.1 4.62 8.37 5.91 8.99 8.84 9.72 5.15 4.85 1.49 4.9 8.78 5.4 8.81 7.91 5.17 
1656 Feedback_control_in_the_MAPK_signaling_module 9.85 5.36 8.52 3.8 4.6 6.67 0.71 2.78 5.44 4.33 5.95 8.93 5.18 5.47 1.14 5.75 4.45 2.5 
1657 COPI_Mediated_Transport 1.25 2.66 0.49 1.83 8.53 2.89 6.57 3.79 4.66 9.68 3.9 1.68 9.88 8.84 8.24 9.68 8.65 2.15 
1658 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 8.9 4.68 3.58 0.26 5.94 8.64 8.65 8.03 9.38 3.33 1.9 1.78 7.3 3.51 6.41 5.91 5.46 3.2 
1659 Golgi_Associated_Vesicle_Biogenesis 5.08 7.18 4.02 9.08 2.65 5.89 4.13 3.99 7.29 0.29 1.81 6.76 1.58 1.03 7.04 2.4 2.71 1.29 
1660 Lysosome_Vesicle_Biogenesis 3.64 2.46 5.54 2.49 9.27 4.35 1.75 0.98 3.94 7.09 4.41 8.21 8.14 9.84 2.24 1.29 7.68 9.45 
1661 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 9.9 1.58 7.85 4.7 4.47 6.14 7.21 0.21 3.08 8.13 7.17 5.09 3.45 0.82 0.94 2.83 1.34 3.11 
1662 Endosomal_Sorting_Complex_Required_For_Transport_(ESCRT) 2.77 7.41 5.23 5.5 9.08 6.36 0.87 4.68 4.38 3.81 1.79 1.87 1.85 5.28 9.46 1.14 8.43 5.66 
1663 Formation_of_annular_gap_junctions 1.56 9.43 9.55 5 0.91 1.36 2.82 5.57 3.97 2.54 8.01 5.83 8.12 5.56 6.36 8.92 3.47 6.95 
1664 Microtubule-dependent_trafficking_of_connexons_from_Golgi_to_the_plasma_membrane 5.2 5.08 8.74 6.05 6.97 8.65 8.99 9.63 5.59 7.63 7.09 4.58 3.86 2.45 5.28 7.29 1.71 1.36 
1665 Oligomerization_of_connexins_into_connexons 3.23 8.89 6.05 6.46 8.99 9.57 3.48 2.82 7.65 1.12 4.21 4.38 1.1 5.64 5.58 7.65 0.65 3.28 
1666 Transport_of_connexins_along_the_secretory_pathway 2.63 3.06 0.33 9.37 8.74 8.88 3.59 1.41 6.06 0.52 3.57 8.6 9.7 3.2 2.52 9.12 3.6 9.54 
1667 Formation_of_annular_gap_junctions 4.43 8.38 3.76 6.52 4.41 8.28 9.03 9.16 3.98 5.98 6.63 7.51 1.97 4.52 0.41 4.9 1.16 7.67 
1668 Formation_of_annular_gap_junctions 9.6 4.41 9.43 4.44 9.28 2.83 2.5 3.27 2.63 2.78 9.33 0.68 6.11 4.07 7.41 4.89 0.68 7.97 
1669 Microtubule-dependent_trafficking_of_connexons_from_Golgi_to_the_plasma_membrane 0.24 8.8 8.18 0.79 9.13 1.08 0.18 3.38 3.1 8.9 3.26 1.83 2.7 2.11 6.59 0.21 0.14 6.7 
1670 Oligomerization_of_connexins_into_connexons 6.31 3.79 2.38 5.31 7.38 0.65 8.56 0.13 4.2 3.83 0.88 9.12 6.88 3.49 4.34 6.99 5.99 1.25 
1671 Transport_of_connexins_along_the_secretory_pathway 4.8 3.51 3.52 9.98 6.43 2.74 3.42 1.39 2.69 4.37 1.22 3.63 8.61 3.8 9.95 0.66 9.38 0.47 
1672 Formation_of_annular_gap_junctions 7 5.68 5.47 8.92 4.77 9.37 2.06 4.4 8.12 0.77 5.59 2.06 3.01 2.4 2.75 4.55 7.03 0.36 
1673 Microtubule-dependent_trafficking_of_connexons_from_Golgi_to_the_plasma_membrane 7.1 0.27 7.78 7.89 7.06 7.9 8.14 0.37 2.74 3.9 6.93 2.18 8.54 3.24 9.24 5.09 5.03 4.09 
1674 Oligomerization_of_connexins_into_connexons 3.97 6.44 8.61 3.55 0.25 3.47 3.26 8.81 2.12 2.86 3.62 9.55 6.58 1.22 7.57 5.97 7.13 0.13 
1675 Transport_of_connexins_along_the_secretory_pathway 8.29 4.86 5.1 1.38 0.13 0.75 3.24 6.89 8.41 2.17 8.02 9.75 7.23 9.88 4.93 9.94 2.46 1.13 
1676 c-src_mediated_regulation_of_Cx43_function_and_closure_of_gap_junctions 5.26 0.56 6.32 9.95 0.13 1.13 3.89 0.28 4.14 4.57 7.69 4.57 6.91 6.75 0.06 3.8 7.62 4.34 
1677 Golgi_Associated_Vesicle_Biogenesis 8.8 3 1.84 3.21 8.77 9.91 0.38 3.5 1.77 1.47 7.72 4.58 9.04 5.06 5.23 0.05 8.77 5.4 
1678 COPI_Mediated_Transport 6.15 2.47 6.59 7.21 8.77 3.78 2.34 8.71 8.8 6.22 9.57 2.72 2.02 4.53 3.37 2.56 4.98 6.33 
1679 Lysosome_Vesicle_Biogenesis 0.56 0.14 5.77 3.86 1.03 1.29 6.34 7.24 7.33 2.69 3.05 5.2 6.61 0.69 3.22 7.38 0.61 5.63 
1680 Microtubule-dependent_trafficking_of_connexons_from_Golgi_to_the_plasma_membrane 3.34 0.52 3.76 8.22 2.17 6.17 7.53 0.68 7.75 0.91 4.26 0.88 6.49 3.61 5.95 1.33 9.78 8.99 
1681 Oligomerization_of_connexins_into_connexons 4.78 9.64 7.11 3.92 5.15 0.1 9.35 0.67 6.24 3.9 5.99 7.77 1.39 8.81 0.81 7.1 1.55 6.23 
1682 c-src_mediated_regulation_of_Cx43_function_and_closure_of_gap_junctions 7.25 4.01 3.55 0.77 2 8.45 3.85 5 7.17 4.57 8.3 9.97 5.78 5.37 4.78 9.4 4.92 3.5 
1683 Translocation_of_GLUT4_to_the_Plasma_Membrane 6.19 7.46 5.57 6.37 1.41 1.02 3.73 5.4 0.21 7.16 2.62 6.5 0.34 0.73 6.61 9.35 6.11 7.9 
1684 Transport_of_connexins_along_the_secretory_pathway 2.78 2.73 1.9 7.55 2.47 0.88 4.49 7.33 0.24 5.49 8.55 9.07 4.64 3.99 0.69 1.33 6.28 3.57 
1685 Microtubule-dependent_trafficking_of_connexons_from_Golgi_to_the_plasma_membrane 5.57 8.3 5 9.55 9.55 7.48 7.98 0.71 2.14 5.33 2.08 6.27 1.85 0.29 1.2 5.36 3.23 3.01 
1686 c-src_mediated_regulation_of_Cx43_function_and_closure_of_gap_junctions 8.69 6.4 2.6 3.42 5.08 0.13 0.25 1.98 7.4 5.53 2.41 0.02 3.79 6.53 7.2 6.85 9.96 8.62 
1687 Golgi_Associated_Vesicle_Biogenesis 0.76 5.28 1.53 4.69 6.31 0.83 7.1 8.69 3.97 0.98 0.78 8.58 9.98 2.19 7.54 1.76 1.9 6.95 
1688 Lysosome_Vesicle_Biogenesis 0.7 6.1 6.75 9.44 6.62 0.45 8.63 8.26 8.9 8.52 7.5 3.4 5.74 3.17 8.74 7.85 8.69 1.71 
1689 Androgen_biosynthesis 9.57 1.3 2.07 7.34 9.18 6.38 6.56 8.32 7.05 0.05 1.55 5.13 0.56 8.41 9.91 0.85 9.98 2.94 
1690 Estrogen_biosynthesis 7.36 5.56 3.18 1.8 4.81 2.74 1.99 4.91 6.41 3.6 1.87 8.86 0.36 5.71 9.04 3.38 9 2.76 
1691 Glucocorticoid_biosynthesis 5.42 4.65 8.31 3.44 1.3 2.5 3.3 1.45 0.26 4.68 3.98 7.8 9.22 6.59 8.58 5.16 8.07 3.53 
1692 Mineralocorticoid_biosynthesis 3.21 1.43 8.9 3.21 2.3 7.11 5.12 8.4 0.53 9.64 6.15 8.6 6.84 7.68 9.47 2.66 4.26 4.2 
1693 Pregnenolone_biosynthesis 4.66 8.03 1.58 7.85 6.2 6.71 9.63 1.05 3.43 2.37 9.22 0.38 1.86 9.68 6.57 5.15 6.89 5.74 
1694 Vitamin_D_(calciferol)_metabolism 6.03 8.43 9.28 0.62 8.65 9.42 7.39 1.76 1.51 3.95 6.3 4.42 8.09 6.1 4.08 5.35 7.51 8.97 
1695 ABCA_transporters_in_lipid_homeostasis 2.46 1.86 6.71 8.34 4.29 4.84 6.82 9.15 6.63 3.63 9.78 9.74 3.54 2.51 1.87 9.06 4.05 6.09 
1696 Mitochondrial_ABC_transporters 7.26 1.62 1.97 0.21 2.86 6.28 7.43 1.92 6.61 6.04 3.9 8.07 6.14 3.22 8.95 1.59 2.81 0.41 
1697 ABCA_transporters_in_lipid_homeostasis 0.83 4.17 1.22 2.26 5.66 7.43 8.5 0.09 2.22 1.44 3.31 5.01 4.93 7.12 4.38 8.78 6.42 6.2 
1698 Amino_acid_transport_across_the_plasma_membrane 7.68 0.82 5.57 9.65 4.36 1.53 3.46 0.75 9.46 9.54 7.52 6.03 6.33 7.01 1.79 7.72 3.84 4.26 
1699 Passive_Transport_by_Aquaporins 3.42 1.9 6.92 1.7 0.61 7.64 3.17 7.49 1.69 9.4 8.81 7.15 7.01 7.57 9.73 3.59 6.97 5.44 
1700 Regulation_of_Water_Balance_by_Renal_Aquaporins 2.09 6.09 1.81 9.78 1.07 0.66 5.13 7.13 8.79 5.5 8.59 6.12 3.1 2.61 7.92 9.6 9.25 8.42 
1701 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 4.46 7.2 8.88 9.12 4.57 3.41 9.42 3.61 5.01 2.39 4.37 0.42 6.76 8.9 5.21 6.19 0.71 0.2 
1702 Bicarbonate_transporters 6.9 2.19 8.34 0.86 7.16 6.92 7.72 7.22 1.32 6.18 3.72 7.16 5.19 4.73 6.18 1.08 4.12 2.4 
1703 Cation-coupled_Chloride_cotransporters 5.73 2.98 3.57 5.69 6.73 8.98 6.25 3.95 8.2 0.67 3.02 9.69 3.92 4.27 3.74 1.16 9.55 6.61 
1704 Class_II_GLUTs 3.83 8.3 9.97 4.45 5.44 9.05 3.54 9.95 5.21 8.8 6.26 0.47 9.54 9.63 7.81 3.72 1.74 4.57 
1705 Class_II_GLUTs 8.18 2.87 9.29 8.97 8.81 6.18 7.19 7.38 7.92 6.76 3.75 9.8 6.99 8.52 6.65 9.66 4.24 3.82 
1706 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 4.04 2.1 6.66 7.4 0.59 7.09 4.84 9.13 0.4 9.95 7.68 9.94 6.82 9.79 8.08 8.22 2.03 0.14 
1707 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 1.97 4.24 7.89 1.42 6.54 3.46 9.98 9.49 3.16 4.11 9.61 0.03 3.71 9.24 0.31 0.69 8.19 5.36 
1708 Inositol_transporters 2.7 4.42 1.76 6.43 3.61 9.99 0.39 3.09 5.52 1.49 4.83 6.38 6.97 8.89 7.58 0.04 0.71 1.57 
1709 Ion_transport_by_P-type_ATPases 6.35 1.94 5.46 3.74 8.68 0.36 9.11 6.06 7.35 4.88 1.38 0.02 9.83 9.11 8.33 6.22 7.28 6.61 
1710 Ligand-gated_ion_channel_transport 7.62 7.83 7.54 2.6 4.64 5.85 4.18 1.28 5.86 8.83 3.74 8.23 9.01 4.32 8.23 0.79 9.47 3.59 
1711 TRP_channels 3.08 5.24 2.35 8.05 3.08 9.78 3.63 9.77 6.76 7.28 8.12 1.6 3.62 9.5 7.89 4.43 4.25 0.4 
1712 Ion_transport_by_P-type_ATPases 4.1 7.34 4.63 2.43 5.11 3.38 7.39 2.16 2.31 3.73 3.46 3.43 5.94 6.88 2.44 6.22 1.98 0.01 
1713 Transferrin_endocytosis_and_recycling 9.22 8.57 8.12 9.46 0.03 0.28 7.43 8.02 8.08 9.83 9.13 4.51 9.16 9.45 6.95 6.44 2 1.92 
1714 Ligand-gated_ion_channel_transport 5.02 8.15 6.7 6.96 2.54 2.93 3 1.22 5.73 3.61 3.31 1.75 1.43 1.22 6.81 0.78 7.49 5.41 
1715 Zinc_efflux_and_compartmentalization_by_the_SLC30_family 4.92 2.58 0.11 5.87 0.64 7.91 5.35 3.35 5.14 3.74 1.67 1.94 1.82 9.75 0.57 0.18 8.7 1.1 
1716 Zinc_influx_into_cells_by_the_SLC39_gene_family 2.41 2.64 0.52 0.42 8.31 8.26 6.51 9.78 9.59 4.65 1.2 9.2 5.97 3.79 4.86 5.07 7.76 6.91 
1717 Mitochondrial_ABC_transporters 3.31 8.95 5.18 7.67 7.89 2.08 9.84 5.62 2.33 0.79 0.64 9.39 6.29 2.51 5.44 2.63 4.04 0.52 
1718 Multifunctional_anion_exchangers 0.77 5.15 0.98 9.25 5.4 1.56 0.48 1.52 2.44 7.54 9.87 2.7 2.76 1.22 3.12 6.06 5.82 6.35 
1719 Na+-dependent_glucose_transporters 4.99 4.3 6.2 5.95 3.76 3.2 8.73 2.51 3.53 0.87 2.92 3.28 9.62 0.59 6.49 3.08 9.93 0.88 
1720 Na+/Cl-_dependent_neurotransmitter_transporters 9.36 9.25 0.09 7.97 7.38 4.83 3.45 1.48 0.65 1.84 2.17 2.61 6.79 5.79 9.89 4.33 0.9 3.65 
1721 Organic_anion_transport 4.45 4.68 7.66 8.4 3.39 9.21 1.56 3.33 5.35 8.28 5.78 3.01 4.72 9.48 8.99 7.94 0.51 4.4 
1722 Organic_anion_transporters 8.24 5.27 2.65 4.52 4.7 5.49 7.56 4.52 6.9 1.51 7.22 2.48 9.55 3.84 9.34 3.84 4.15 2.76 
1723 Organic_cation_transport 2.35 0.02 8.88 2.12 2.02 3.14 5.92 0.38 5.58 0.89 7.95 9.25 9.58 1.53 4.05 5.96 1.07 8.31 
1724 Organic_anion_transport 1.32 7.21 8.42 5.62 4.22 8.88 0.52 3.16 6.21 6.92 1.48 6.55 9.54 6.45 8.09 6.81 5.53 2.71 
1725 Organic_cation_transport 0.13 7.95 0.44 0.48 1.65 8.06 7.7 7.72 2.49 3.35 3.13 8.52 0.46 4.13 7.69 0.36 6.59 0 
1726 Passive_Transport_by_Aquaporins 8.43 5.4 1.45 7.16 7.38 9.3 5.91 6.54 6.81 7.17 7.16 0.23 2.22 6.45 5.18 5.75 2.85 5.37 
1727 Proton-coupled_monocarboxylate_transport 7.87 9.64 0.47 3.93 9.5 3.38 0.77 9.02 9.16 1.25 1.11 6.62 1.27 1.97 6.18 0.76 8.26 9.37 
1728 Proton-coupled_neutral_amino_acid_transporters 5.7 5.68 8.07 7.84 1.24 9.39 4.3 4.27 5.83 3.02 7.74 4.47 0.59 4.67 8.09 9.06 3.95 4.43 
1729 Proton/oligonucleotide_cotransporters 0.51 8.44 1.51 1.05 8.99 1.44 7.34 3.68 6.69 8.42 5.7 3.77 8.07 1.07 1.56 9.11 0.03 2.35 
1730 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 8.97 2.79 8.45 2.38 3.33 2.73 0.37 9.95 8.07 4.76 1.99 0.81 1.25 6.42 8.17 5.54 9.22 5.03 
1731 Regulation_of_Water_Balance_by_Renal_Aquaporins 3 4.45 7.57 9.84 6.79 4.14 7.55 6.09 6.16 7.61 0.8 8.64 9.65 6.87 6.18 6.16 6.74 9.04 
1732 Rhesus_glycoproteins_mediate_ammonium_transport 2.46 9.6 6.03 5.94 3.6 6.54 1.16 3.44 8.61 3.1 4.8 8.95 6.99 5.83 5.43 7.17 0.76 9.43 
1733 Amino_acid_transport_across_the_plasma_membrane 8.19 6.5 0.86 8.54 4.37 3.08 2.38 1.61 6.75 6.13 8.3 8.16 0.53 5.84 8.77 5.94 9.68 1.09 
1734 Bicarbonate_transporters 0.14 6.07 2.34 4.24 7.72 8.31 5.43 8.49 9.56 8.17 9.4 0.55 4.35 5.1 9.54 0.78 7.06 4.07 
1735 Cation-coupled_Chloride_cotransporters 8.05 8.67 6.07 3.72 0.86 2.77 7.02 9.58 9.33 0.07 6.23 4.71 4.35 9.63 7.62 0.89 9.51 7.61 
1736 Class_II_GLUTs 1.04 7.25 7.11 9.6 6.28 8.93 8.5 8.92 1.23 5.47 9.88 4.81 6.87 0.12 6.09 1.27 9.38 8.95 
1737 Inositol_transporters 9.57 6.62 4.01 5.7 1.56 3.8 8.94 4.87 2.05 8.37 9.87 8.35 1.8 3.62 6.52 2.72 9.61 7.25 
1738 Multifunctional_anion_exchangers 5.8 1.79 8.27 3.72 4.34 7.52 0.24 4.36 2.62 1.64 6.25 7.19 2.95 7.32 4.82 0.81 7.19 3.96 
1739 Na+-dependent_glucose_transporters 6.8 2.48 9.45 3.71 0.54 6.66 7.69 3.33 7.93 7.16 7.49 6.56 7.71 2 2.99 7.95 0.05 5.1 
1740 Na+/Cl-_dependent_neurotransmitter_transporters 0.51 1.16 2.08 5.42 5.9 0.41 7.49 9.16 0.55 9.46 1.23 3.33 6.8 3.97 5.86 3.3 0.4 4.49 
1741 Organic_anion_transport 7.26 9.47 1.17 2.15 7.1 6.46 2.77 1.25 8.21 4.64 2.73 5.41 6.41 9.62 8.91 7.67 1.14 8.88 
1742 Organic_anion_transporters 7.59 8.02 9.97 1.66 1.36 2 8.5 7.79 1.65 9.79 0.74 9.87 0.6 1.14 9.33 6.64 9.65 8.65 
1743 Organic_cation_transport 5.07 1.53 7.31 7.6 0.65 6.21 1.5 2.02 1.1 7.94 9.56 8.96 3.59 1.21 3.21 5.19 9.68 4.84 
1744 Proton-coupled_monocarboxylate_transport 0.05 7.6 0.61 2.67 8.21 7.67 9.28 9.87 8.92 3.58 8.9 5.92 1.8 1.15 1.11 8.76 0.79 7.03 
1745 Proton-coupled_neutral_amino_acid_transporters 9.57 8.01 9.71 2.4 9.1 7.07 7.89 2.97 2.95 1.46 4.53 0.16 9.2 1.35 9.71 1.85 7.32 6.68 
1746 Proton/oligonucleotide_cotransporters 1.52 6.01 8.19 5.05 9.69 0.06 3.19 5.32 5.51 0.13 5.71 6.32 1.38 2.35 1.55 3.86 0.07 3.36 
1747 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 8.87 5.84 0.15 8.25 2.42 6.58 3.3 3.33 6.91 7.18 1.24 1.71 2.73 4.15 1.27 5.38 0.76 8.21 
1748 Rhesus_glycoproteins_mediate_ammonium_transport 5.69 4.8 4.42 3.07 5.68 8.23 2.87 5.73 0.35 9.33 3.53 7.84 1.54 6.91 7.79 1.74 0.33 9.36 
1749 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 0.23 6.1 7.53 9.59 7.78 0.1 0.95 9.42 3.62 4.27 6.41 0.8 0.75 1.6 5.18 2.7 6.83 9.98 
1750 Sodium/Calcium_exchangers 6.46 2.57 0.83 7.94 4.42 9.71 6.79 7.32 3.09 8.79 6.72 8.72 5.55 9.18 7.36 9.78 4.48 8.28 
1751 Sodium/Proton_exchangers 2.6 8.9 8.29 6.26 8.81 4.16 5.18 9.49 6.16 6.18 6.48 6.94 7.4 2.44 5.93 2.44 0.63 5.67 
1752 Transport_of_fatty_acids 3.44 3.59 8.39 1.49 7.59 2.3 7.74 2.44 6.05 6.59 9.07 7.61 3.77 8.61 3.39 9.51 5.8 6.47 
1753 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 5.16 3.52 5.11 0.79 3.15 2.34 4.05 6.74 0.44 1.74 2.18 6.94 2.9 7.33 7.32 7.04 2 0.52 
1754 Transport_of_nucleotide_sugars 1.84 0.54 4.15 4.99 5.2 3.44 3.37 7.52 3.56 4.27 1.01 8.88 9.19 4.93 1.56 9.93 2.99 8.56 
1755 Transport_of_organic_anions 9.8 6.17 7.83 7.29 5.3 9.39 4.16 6.64 1.09 6.12 9.82 9.09 4.01 9.45 4.97 5.77 0.42 4.84 
1756 Type_II_Na+/Pi_cotransporters 1.79 0.59 8.65 9.98 1.99 1.08 7.55 5.74 1.87 0.21 4.24 3.55 2.58 8.79 9.3 0.87 7.81 4.43 
1757 Zinc_efflux_and_compartmentalization_by_the_SLC30_family 8.71 2.52 0.83 4.99 2.88 6.28 4.79 0.16 5.87 1.23 5.37 0.06 9.9 6.87 0.07 6.53 9.97 8.04 
1758 Zinc_influx_into_cells_by_the_SLC39_gene_family 1.16 9.38 3.25 7.53 5.78 6.85 2.18 0.15 1.57 7.32 2.14 6.03 2.48 9.99 9.39 5.45 0.44 2.21 
1759 Type_II_Na+/Pi_cotransporters 9.47 8.43 1.49 1.28 6.38 1.39 3.04 5.33 6.44 5.42 7.38 1.11 5.07 8.01 2.43 9.31 2.59 3.44 
1760 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 2.91 2.38 6.32 5 2.27 9.1 1.6 9.97 3.43 8.79 4.14 5.77 5.14 3.04 5.58 5 2.35 1.81 
1761 Sodium/Calcium_exchangers 1.7 3.36 7.26 2.62 5.8 8.14 4.22 4.79 6.76 5.74 4.1 7.85 3.57 3.72 3.74 8.01 8.03 4.36 
1762 Sodium/Proton_exchangers 8.6 6.63 5.2 5.1 2.34 4.66 9.44 5.97 4.05 2.03 2.48 4.77 8.22 9.43 5.34 3.15 4.28 0.48 
1763 TRP_channels 9.57 2.18 4.19 4.06 2.88 8.03 3.79 9.46 7.7 5.72 8.84 3.24 8.35 9.32 9.12 4.54 6.3 3.26 
1764 TRP_channels 9.37 4.4 1.44 6.44 5.58 0.53 9.63 0.62 0.08 5.5 5.88 7 9.61 1.97 0.57 3.36 8.63 6.05 
1765 Transferrin_endocytosis_and_recycling 3.27 1.19 0.7 5.44 7.71 0.17 7.24 0.57 5.68 8.94 0.96 6.59 9.45 1.96 0.13 5.45 9.03 2.47 
1766 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 5.08 7.44 0.69 6.49 2 6.66 9.22 9.06 2.7 4.61 5.1 1.6 7.4 9.23 2.81 4.82 0.97 9.22 
1767 Transport_of_fatty_acids 5.2 7.22 5.74 1.51 1.14 7.14 6.59 1.74 5.78 3.53 5.65 6.62 0.77 2.62 9.51 8.43 7.51 3.39 
1768 Class_II_GLUTs 3.51 0.91 6.33 6.05 2.98 5.74 3.73 0.91 2.74 9.67 6.77 8.78 0.06 6.4 2.97 3.44 1.95 2.85 
1769 Inositol_transporters 0.16 1.12 1.7 5.76 6.89 5.96 0.1 7.33 5.62 0.32 2.79 1.34 0.81 3.42 2.59 4.58 7.84 2.62 
1770 Na+-dependent_glucose_transporters 8.45 9.53 9.82 1.69 0.71 2.51 7.08 0.08 0.36 4.74 4.3 4.11 3.54 7.41 3.95 5.27 9.64 8.87 
1771 Na+/Cl-_dependent_neurotransmitter_transporters 6.3 4.38 3.07 7.67 6.86 9.25 0.45 6.17 2.5 2.74 7.34 6.93 9.45 8.29 9.43 7.66 0.97 0.73 
1772 Organic_anion_transport 9.81 3.5 1.43 9.07 8.2 8.8 9.74 8.58 2.03 1.66 0.35 1.91 0.01 1.16 8.01 2.63 2.64 1.4 
1773 Organic_cation_transport 2.8 3.34 2.64 2.76 8.04 9.27 4.32 8.61 9.54 8.17 7.85 8.61 3.66 6.6 9.31 1.36 4.11 0.93 
1774 Proton-coupled_monocarboxylate_transport 6.85 0.66 4.99 5.66 3.66 5.04 9.92 8.97 7.05 4.87 0.25 8.62 9.29 2.93 2.17 2.11 5.77 0.07 
1775 Rhesus_glycoproteins_mediate_ammonium_transport 9.41 1.96 0.15 0.91 8.53 2.27 4.9 0.71 4.84 8.89 1.62 6.17 9.87 6.46 6.55 6.88 7.63 9.82 
1776 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 3.16 0.67 5.94 3.89 8.93 9.05 4.8 8.99 4.31 0.32 5.69 4.59 0.87 6.9 4.46 3.85 2.29 5.73 
1777 Zinc_efflux_and_compartmentalization_by_the_SLC30_family 1.84 1.55 8.74 1.38 3.4 8.97 4.57 4.01 0.78 3.67 6.82 6.18 1.11 0.35 8.36 4.63 3.68 5.06 
1778 Zinc_influx_into_cells_by_the_SLC39_gene_family 8.44 2.56 9.24 9.84 7.45 4.63 1.44 8.47 5.94 4.21 4.55 7.43 1.3 6.37 9.96 1.11 1.46 3.28 
1779 Amino_acid_transport_across_the_plasma_membrane 8.7 9.96 9.12 8.56 8.59 1.52 8.79 6.41 0.06 2.2 7.19 6.68 1.15 0.41 9.98 4.14 0.06 8.26 
1780 Bicarbonate_transporters 3.19 2.88 0.22 3.26 0.58 2.81 7.59 8.54 3.16 1.37 3.04 4.74 7.45 5.83 6.66 8.33 3.99 0.22 
1781 Cation-coupled_Chloride_cotransporters 5.47 8.48 2.85 8.27 0.34 5.14 3.72 7.22 8.35 8.81 4.92 1.61 0.29 3.16 9.86 8.13 2.51 4.09 
1782 Multifunctional_anion_exchangers 6 2.6 5.04 4.77 9.33 0.67 3.98 3.38 7.35 8.33 4.4 0 4.07 6.99 7.9 8.64 6.36 1.61 
1783 Organic_anion_transporters 8.97 9.96 2.11 8.01 5.68 4.03 3.89 4.99 3.47 7.48 5.84 4.05 3.82 1.68 5.71 5.68 9.52 5.49 
1784 Proton-coupled_neutral_amino_acid_transporters 4.37 4.82 3 3.6 4.13 9.17 0.23 7.3 6.63 5.91 2.76 6.31 5.97 8.44 6.52 6.19 7.32 8.41 
1785 Proton/oligonucleotide_cotransporters 3.22 4.7 1.45 9.47 7.34 5.22 2.68 8 4.72 3.94 9.47 9.31 7.2 1.09 1.3 5.02 0.03 6.83 
1786 Sodium/Calcium_exchangers 6.98 1.94 0.65 8.95 9.75 6.99 6.6 6.06 7.59 0.58 2.43 0.47 9.76 6.83 6.08 0.43 2.17 4 
1787 Sodium/Proton_exchangers 7.83 2.15 2.67 0.29 7.77 4.39 1.69 2.23 5.44 6.06 0.22 1.5 0.03 0.12 5.1 7.06 4.04 0.06 
1788 Type_II_Na+/Pi_cotransporters 4.64 8.53 1.04 5 6.42 6.69 7.34 2.79 5.26 4.61 6.76 5.7 9.15 0.44 2.78 8.1 8.23 7.26 
1789 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 5.93 3.77 8.36 0.66 8.15 8.95 0.4 4.44 0.68 5.38 3.94 7.08 6.97 5.2 5.61 4.87 7.34 0.5 
1790 Transport_of_nucleotide_sugars 9.27 7.55 7.73 0.28 8.14 1.45 7.4 7.54 5.54 2.06 2.83 9.33 0.23 8.9 1.83 1.41 2.44 7.66 
1791 Transport_of_organic_anions 9.75 0.09 3.53 3.03 1.65 0.14 8.21 9.04 2.55 4.61 2.42 6.31 4.87 5.52 5.25 1.5 6.63 1.09 
1792 Transport_of_fatty_acids 5.13 0.69 0.57 0.91 2.99 5.02 2.86 8.45 5 0.49 5.49 0.86 6.18 6.1 8.86 3.16 6.72 4.79 
1793 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 7.68 9.11 4.95 9.82 4.4 3.32 2.6 6.15 1.95 0.21 9.72 8.29 2.93 9.79 9.1 6.35 0.83 3.35 
1794 Transport_of_nucleotide_sugars 5.52 9.24 1.26 2.2 4.29 8.68 9.61 4.26 3.41 3.33 7.65 1.27 7.89 0.2 8.51 7.98 7.44 0.78 
1795 Transport_of_organic_anions 5.7 7.41 2.14 9.01 4.97 8.01 2.69 2.88 2.07 0.37 3.01 8.41 5.45 5.63 8.72 9.84 7.64 3.7 
1796 Type_II_Na+/Pi_cotransporters 5.3 0.73 8.92 0.97 2.61 8.89 1.8 6.27 8.08 3.43 1.27 9.63 5.93 5.44 2.46 4.73 2.48 2.51 
1797 Zinc_efflux_and_compartmentalization_by_the_SLC30_family 7.71 9.58 5.74 7.03 7.65 5.56 8.31 7.53 1.41 8.1 5.16 8.74 2.8 7.83 6.03 9.93 8.54 5.96 
1798 Zinc_influx_into_cells_by_the_SLC39_gene_family 6.18 2.13 5.87 9.43 3.78 4.62 8.12 7.17 5.29 1.8 2.6 6.48 2.83 0.24 3.59 1.13 9.78 4.66 
1799 Zinc_efflux_and_compartmentalization_by_the_SLC30_family 7.51 6.8 6.51 0.34 8.37 4.34 8.98 7.71 3.38 2.82 9.93 2.52 5.59 9.07 3.49 1.53 5.62 3.08 
1800 Zinc_influx_into_cells_by_the_SLC39_gene_family 4.58 9.22 3.21 9.33 8.96 7.71 2.2 6.33 0.86 1.79 8.78 1.49 0.3 1.85 7.64 4.96 9.93 1.8 
1801 Activation_of_Chaperone_Genes_by_ATF6-alpha 8.02 2.83 1.32 0.65 0.26 1.71 3.55 6.11 9.9 8.05 8.53 3.09 2.64 5.93 7.84 1.72 8.8 9.7 
1802 Activation_of_Chaperone_Genes_by_XBP1(S) 8.07 7.79 6.22 5.97 2.01 9.74 9.12 7.36 6.76 6.84 2.94 7.33 6.33 2.87 2.44 9.98 7.22 0.61 
1803 Activation_of_Chaperone_Genes_by_ATF6-alpha 2.48 3.23 8.89 8.92 1 3.22 3.87 9.61 7.42 6.15 1.73 9.54 1.43 2.13 9.97 4.21 3.13 4.19 
1804 Activation_of_Chaperone_Genes_by_XBP1(S) 4.85 0.32 5.48 8.02 5.55 4.67 7.15 2.22 1.96 2.83 3.38 4.75 1.71 8.16 7.95 0.9 1.08 7.52 
1805 Activation_of_Genes_by_ATF4 3.45 0.52 4.38 1.41 9.32 0.62 7.52 8.45 0.39 6.05 1.31 5.94 0.3 6.2 1.04 5.77 8.44 0.68 
1806 Translation_initiation_complex_formation 2.36 7.9 7.56 2.76 5.45 3.92 2.3 1.69 6.07 3.68 3.48 3.91 8.35 6.8 6.85 8.4 1.9 7.94 
1807 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 3.54 2.61 1.93 0.22 2.32 3.47 5.67 6.4 6.29 8.23 7.73 1.29 8.94 9.74 2.13 5.89 7.28 0.06 
1808 ER_Quality_Control_Compartment_(ERQC) 3.93 9.74 3.34 2.57 0.86 9.03 1.71 0.91 9.02 7.63 0.48 7.93 4.51 6.14 6.48 9.48 7.13 2.6 
1809 N-Glycan_antennae_elongation 8.89 1.27 3.63 6.57 5.5 3.65 5.13 8.08 7.63 8.23 1.44 7.85 3.69 7.73 2.27 2.21 5.71 2.42 
1810 Progressive_trimming_of_alpha-1,2-linked_mannose_residues_from_Man9/8/7GlcNAc2_to_produce_Man5GlcNAc2 1.28 1.23 4.16 2.29 5.26 6.88 8.65 0.37 4.94 7.46 3.41 2.68 8.39 3.98 3.8 1.92 9.67 1.87 
1811 Reactions_specific_to_the_complex_N-glycan_synthesis_pathway 1.21 6.86 8.94 1.03 4.83 1.03 9.17 7.44 9.97 5.04 3.83 6.21 5.97 3.49 4.14 6.46 5.86 4.14 
1812 Reactions_specific_to_the_hybrid_N-glycan_synthesis_pathway 3.94 4.41 0.74 0.28 7.5 0.15 0.82 0.05 1.79 1.1 6.47 8.14 2.89 4.56 5.57 4.01 7.95 0.28 
1813 Synthesis_of_Dolichyl-phosphate 3.58 4 0.42 0.51 0.53 3.04 4.37 0.3 5 1.29 5.52 6.07 3.06 9.65 5.78 6.05 5.77 4.07 
1814 Synthesis_of_GDP-mannose 8.83 9.95 1.03 3.5 5.82 6.67 7.63 5.22 6.35 4.39 8.91 2.31 4.08 5.04 6.6 2.48 4.97 5.07 
1815 Synthesis_of_UDP-N-acetyl-glucosamine 3.29 2.21 5.82 9.05 7.11 6.23 0.76 0.53 3.21 8.43 3.91 1.32 7.83 9.1 6.46 4.8 5.24 3.68 
1816 Synthesis_of_dolichyl-phosphate_mannose 2.79 9.41 9.12 6.36 5.4 7.92 5.79 6.07 4.7 2.12 7 2.79 4.18 5.9 0.41 1.02 7.85 9.96 
1817 Synthesis_of_dolichyl-phosphate-glucose 3.27 8.95 2.2 2.5 2.61 8.8 2.23 5.01 6.04 7.6 3.26 1.72 3.53 2.99 5.1 1 1.74 5 
1818 Association_of_TriC/CCT_with_target_proteins_during_biosynthesis 1.65 9.22 6.61 0.66 2.6 7.34 9.91 8.46 4.03 5.34 4.53 0.44 5.58 4.24 7.17 8 3.75 4.45 
1819 Attachment_of_GPI_anchor_to_uPAR 1.1 3.15 7.81 3.3 6.87 9.74 2.99 2.97 4.13 2.54 8.27 9.12 6.68 1.76 1.33 3.83 2.97 3.19 
1820 Synthesis_of_Dolichyl-phosphate 9.06 1.84 7.81 8.6 9.1 2.5 4.84 2.46 2.62 3.74 9.83 4.5 6.3 1.02 4.38 3.32 3.1 0.66 
1821 Synthesis_of_GDP-mannose 6.5 8.23 1.74 2.22 1.86 5.21 3.27 5.13 4.84 5.95 9.96 0.14 7.67 4.15 5.45 5.76 5.9 7.23 
1822 Synthesis_of_UDP-N-acetyl-glucosamine 1.62 6.34 1.75 7.81 2.64 6.29 7.33 7.51 2.32 8.29 4.67 6.85 3.72 4.54 3.79 3.72 4.86 6.02 
1823 Synthesis_of_dolichyl-phosphate_mannose 2.7 0.29 1.85 1.03 7.48 4.03 4.66 7.99 4.7 6.5 3.92 6.88 6.74 6.24 7.76 0.29 1.5 6.64 
1824 Synthesis_of_dolichyl-phosphate-glucose 2.44 8.04 5.45 8.6 1.25 2.9 5.43 8.35 0.7 6.04 4.99 7.08 1.63 0.07 8.5 1.14 1.22 1.78 
1825 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 0.21 5.04 9.52 4.74 1.59 8.87 4.39 1.98 4.88 7.81 7.59 9.97 6.89 5.52 9.63 3.49 4.97 9.64 
1826 ER_Quality_Control_Compartment_(ERQC) 1.81 0.61 5.92 1.21 8.2 4.61 3.7 4.08 5.97 4.52 7.66 2.15 4 9.06 9.03 3.64 5.57 4.56 
1827 Formation_of_a_pool_of_free_40S_subunits 2.42 1.66 5.27 3.16 0.65 2.02 1.19 3.13 4.24 7.41 7.24 3.11 9.42 2.69 2.01 1.67 9.67 2.85 
1828 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 3.51 5.69 0.87 6.08 1.09 7.05 2.09 7.17 3.65 2.15 1.93 7 0.1 6.79 7.11 9.37 2.71 3.85 
1829 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 1.01 6.14 4.89 2.01 3.38 3.98 6.07 8.01 6.64 7.75 9.12 8.46 0.67 9.43 9.34 7.69 2.52 4.67 
1830 Recycling_of_eIF2:GDP 1.78 2.14 9.57 6.44 3.69 6.34 1.97 2.59 0.37 2.24 9.09 2.85 5.99 0.45 5.64 8.42 1.95 1.01 
1831 Ribosomal_scanning_and_start_codon_recognition 3.05 6.35 3.08 5.33 2.55 7.39 7.39 0.91 9.5 6.56 1.54 0.35 1.99 6.34 7.49 4.11 9.76 6.59 
1832 Translation_initiation_complex_formation 3.79 8.25 2.57 5.74 9.92 9.24 6.06 9.41 9.83 5.36 1.58 6.62 0.32 9.01 3.15 2.06 7.64 8.18 
1833 Association_of_TriC/CCT_with_target_proteins_during_biosynthesis 7.39 4.41 7.28 8.07 7.9 8.56 3.69 8.72 5.37 0.84 1.57 9.45 5.15 0.66 3.71 9.82 3.82 4.4 
1834 Folding_of_actin_by_CCT/TriC 9.23 5.21 6.16 0.39 9.76 4.66 8.58 4.09 4.13 2.42 9.45 7.32 7.58 4.96 4.11 1.84 9.29 6.48 
1835 Formation_of_tubulin_folding_intermediates_by_CCT/TriC 8.84 3.82 7.89 9.21 5.38 5.14 6.66 3.74 2.46 3.46 4.01 6.63 3.88 6.71 3.4 0.49 9.48 3.55 
1836 Prefoldin_mediated_transfer_of_substrate__to_CCT/TriC 9.05 2.03 8.42 2.11 4.52 6.74 1.94 2.48 8.51 0.79 8.41 2.97 5.5 1.84 1.12 9.47 1.66 8.85 
1837 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 8.18 4.11 7.72 0.11 9.6 6.19 3.01 7.26 0.59 1.07 3.81 4.5 6.58 0.74 1.79 7.87 5.56 6.86 
1838 Folding_of_actin_by_CCT/TriC 7.24 5.02 1.12 9.6 6.82 8.4 2.59 8.99 1.89 7.33 2.42 6.7 0.26 2.99 8.88 0.56 5.96 1.52 
1839 Formation_of_tubulin_folding_intermediates_by_CCT/TriC 0.35 1.08 9.84 9.3 1.46 8.45 6.46 1.18 4.57 7.88 9.81 7.86 4.17 4.71 9.65 9.43 1.69 1.8 
1840 Prefoldin_mediated_transfer_of_substrate__to_CCT/TriC 6.67 1.85 4.74 3.67 9.12 0.65 9.29 6.16 9.79 3.01 8.38 9.84 7.21 2.38 5.01 5.18 6.74 5.62 
1841 ER_Quality_Control_Compartment_(ERQC) 6.74 3.09 6.61 4.27 4.11 9.6 3.43 3.68 3.44 0.01 3.04 7.31 1.9 1.65 0.7 5.87 7.25 5.64 
1842 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 7.1 3.94 4.15 1.84 9.44 6.26 1.86 7.57 8.91 4.59 4.39 1.2 3.69 5.12 4.03 6.42 1.16 9.71 
1843 Peptide_chain_elongation 4.7 4.63 5.37 3.02 7.63 7.29 1 5.16 5.83 2.75 1.64 3.5 7.58 2.19 7.36 9.22 8.26 7.19 
1844 Formation_of_a_pool_of_free_40S_subunits 6.18 5.38 7.25 9.56 7.79 2.25 8.89 1.31 1.51 2.67 5.97 5.49 3.94 7.89 9.39 3.44 4.52 1.86 
1845 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 8.32 1.38 1.05 9.28 1.8 0.45 3 3.79 3.55 4.76 6.05 2.96 6.43 6.69 0.08 4.36 9.83 1.91 
1846 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 9.84 1.58 9.38 1.74 6.43 3.79 4.88 4.53 8.08 1.37 7.06 9.88 7.51 4.54 6.81 9.62 3.04 5.85 
1847 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 6.29 4.2 3.74 4.08 7.33 3.42 0.93 3.8 4.66 4.25 9.7 3.22 2.23 8.62 3.38 7.96 5.64 9.78 
1848 Recycling_of_eIF2:GDP 0.14 7.68 0.44 1.07 3.65 4.87 8.51 2.58 4.1 6 9.4 9.61 3.04 2.45 2.33 2.15 3.63 2.39 
1849 Ribosomal_scanning_and_start_codon_recognition 3.8 3.14 1.37 4.86 7.82 0.2 3.68 9.55 4.47 8.56 7.62 1.94 6.29 4.47 7.43 4.18 2.72 7.5 
1850 Translation_initiation_complex_formation 4.65 7.59 2.69 5.87 7.18 7.22 2.81 6.88 4.09 1.9 8.81 8.87 2.5 0.38 7.52 3.75 1.35 9.1 
1851 Eukaryotic_Translation_Termination 4.33 5.89 6.11 5.36 9.25 8.54 1.75 3.2 5.82 8.92 3.9 3.77 3.81 9.51 2.05 0.89 2.1 1.19 
1852 Folding_of_actin_by_CCT/TriC 7.38 0.5 0.42 9.51 6.19 1.47 1.17 6.03 8.67 0.39 3.44 8.38 6.5 3.96 3.77 2.13 9.54 4.87 
1853 Formation_of_a_pool_of_free_40S_subunits 8.98 5.6 4.25 8.93 7.59 4.98 5.23 5.97 3.15 2.3 3.75 8.29 3.44 1.01 3.82 8.1 5.97 1.17 
1854 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 0.95 5.24 3.01 1 5.91 8.41 0.86 2.7 9.35 3.68 1.59 3.79 1.98 6.73 3.42 7.01 9.84 0.83 
1855 Formation_of_tubulin_folding_intermediates_by_CCT/TriC 8.48 3.92 3.27 7.9 0.58 6.66 9.29 5.47 9.28 7.25 8.03 8.97 0.6 2.75 9.25 2.49 4.49 0.58 
1856 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 3.41 3.39 9.44 2.64 6.4 5.38 7.47 9.12 1.5 7.18 7.36 7.97 5.57 5.05 4.25 2.71 4.57 0.37 
1857 Gamma-carboxylation_of_protein_precursors 7.93 3.64 5.15 2.59 8.01 5.2 5.35 7.35 2.77 3.04 6.59 1.62 6.96 5.64 5.81 2.63 8.55 6.67 
1858 Gamma-carboxylation_of_protein_precursors 6.44 9.95 6.93 1.15 0.02 3.83 0.66 0.89 7.75 9.91 4.17 3.1 9.53 0.16 4.42 4.51 7.08 1.98 
1859 Removal_of_aminoterminal_propeptides_from_gamma-carboxylated_proteins 9.97 7.26 1.25 1.15 6.01 6.45 2.43 3.19 7.64 0.42 8.55 2.44 4.91 3.52 4.51 3.45 6.68 8.62 
1860 Transport_of_gamma-carboxylated_protein_precursors_from_the_endoplasmic_reticulum_to_the_Golgi_apparatus 4.18 7.22 2.82 1.45 6.63 3.58 1.05 5.58 8.64 4.73 1.95 3.12 4.76 0.42 5.94 6.87 6.58 6.63 
1861 Glycoprotein_hormones 3.51 4.58 3.16 7.6 0.27 1.66 0.2 9.06 5.64 5.19 7.98 8.77 4.65 5.02 4.47 3.92 6.09 0.2 
1862 Hypusine_synthesis_from_eIF5A-lysine 9.4 3.32 1.93 9.35 3.17 7.5 7.49 1.22 0.19 2.24 0.98 9.21 0.72 0.66 1.21 6.94 4.46 9.73 
1863 Synthesis,_Secretion,_and_Inactivation_of_Glucagon-like_Peptide-1_(GLP-1) 4.46 4.05 9.39 5.45 4.49 5.51 5.8 0.96 7.64 9.57 3.76 4.18 4.71 3.31 7.9 3.94 6.65 5.36 
1864 Synthesis,_Secretion,_and_Inactivation_of_Glucose-dependent_Insulinotropic_Polypeptide_(GIP) 2.16 2.57 2.32 0.82 6.98 3.21 8.27 5.91 3.1 6.12 7.01 0.97 3.62 8.95 8.68 1.78 3.25 2.17 
1865 Insulin_Processing 3.31 6.97 8.53 4.88 0.61 0.91 5.73 1.19 3.32 1.81 7.89 2.4 4.65 0.97 3.14 5.36 5.8 4.16 
1866 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 0.32 1.95 9.89 7.27 1.65 1.9 6.92 4.36 0.23 4.44 4.95 0.75 4.33 8.82 1.3 3.88 1.38 9.91 
1867 Metabolism_of_Angiotensinogen_to_Angiotensins 5.08 1.75 4.86 6.46 0.87 6.99 2.1 4.79 3.52 9.95 6.02 6.61 1.6 8.35 0.05 8.56 6.82 3.05 
1868 Mitochondrial_Protein_Import 2.03 5.18 3.58 1.99 0.14 9.89 4.13 0.24 8.31 0.29 1.98 9.21 3.46 2.2 3.77 3.54 8.04 5.21 
1869 N-Glycan_antennae_elongation 2.1 8.05 7.16 2.37 4.39 5.5 6.88 3.03 1.49 6.11 9.94 8.31 3.53 1.75 5.39 6.13 7.71 9.69 
1870 N-Glycan_antennae_elongation 6.13 1.15 0.63 6.66 8.63 5.12 6.95 3.11 8.53 5.42 0.59 1.8 5.99 0.95 0.67 2.1 9.71 5.55 
1871 Reactions_specific_to_the_complex_N-glycan_synthesis_pathway 4.94 6.49 7.25 5.01 1.56 8.1 6.05 7.92 8.01 5.9 1.3 6.27 9.7 8.19 7.98 8.52 0.05 2.09 
1872 Reactions_specific_to_the_hybrid_N-glycan_synthesis_pathway 9.54 0.2 5.16 8.31 1.96 7.75 7.63 6.12 1.81 0.16 6.03 3.47 2.64 2.26 8.69 6.61 6.4 3.61 
1873 Progressive_trimming_of_alpha-1,2-linked_mannose_residues_from_Man9/8/7GlcNAc2_to_produce_Man5GlcNAc2 8.26 2.13 0.73 9.3 9.47 6.81 9.46 5.45 9.65 0.77 7.05 2.18 1.51 1.08 0.71 8.42 7.59 0.81 
1874 ER_Quality_Control_Compartment_(ERQC) 6.06 1.82 8.89 7.14 7.12 0.68 9.61 2.07 5.78 4.89 5.72 2.9 6.73 0.5 0.1 3.99 3.23 1.19 
1875 Termination_of_O-glycan_biosynthesis 5.99 5.17 8.02 6.45 8.02 8.62 1.64 6.75 0.69 3.88 4.94 5.6 7.9 1.48 7.07 0.11 8.85 0.31 
1876 Activation_of_Genes_by_ATF4 1.27 3.3 7.91 8.06 8.25 2.63 1.94 4.15 1.44 8.72 0.59 5.02 7.49 2.14 6.85 2.77 5.22 5.77 
1877 Gamma-carboxylation_of_protein_precursors 9.62 8.54 9.37 1.37 9.1 0.16 8.16 8.96 4.82 1.45 3.55 1.9 6.23 6.75 9.07 2.53 7.07 4.18 
1878 Hypusine_synthesis_from_eIF5A-lysine 6.14 2.22 2.17 3.24 9.18 4.27 3.64 3.78 1.34 9.83 9.48 0.79 5.47 5.87 7.33 6.86 9.43 4.99 
1879 Removal_of_aminoterminal_propeptides_from_gamma-carboxylated_proteins 7.15 8.33 4.04 0.96 6.75 2.07 7.99 3.99 5.58 9.33 1.47 1.14 5.99 3.37 9.43 7.17 4.71 1.78 
1880 The_activation_of_arylsulfatases 6.34 1.47 9.82 2.12 9.59 4.82 3.25 1.47 7.88 4.53 6.02 5.5 7.99 1.05 1.08 0.86 7.06 5.46 
1881 Transport_of_gamma-carboxylated_protein_precursors_from_the_endoplasmic_reticulum_to_the_Golgi_apparatus 9.44 0.31 9.82 9.98 2.67 0.38 1.83 4.9 3.21 4.19 0.47 8.52 1.41 0.81 5.49 8.32 0.09 1.4 
1882 Peptide_chain_elongation 0.95 9.11 5.69 1.14 5.41 0.86 5.63 1.97 0.48 2.83 6.01 4.32 4.83 4.6 9.07 0.32 0.09 5.63 
1883 Glycoprotein_hormones 4.46 7.89 4.31 0.93 7.7 2.41 7.79 6.43 8.35 4.72 3.9 3.47 0.45 3.93 1.82 4.55 5.49 5.56 
1884 Glycoprotein_hormones 1.1 9.97 3.42 5.64 9.3 2.73 3.62 1.67 5.02 5.84 8.42 4.19 4.46 8.86 6.79 6.99 6.2 6.99 
1885 Insulin_Processing 2.73 7.07 4.61 0.9 9.76 9.68 5.01 1.54 1.22 6.91 1.8 5.12 0.28 6.16 8.8 2.28 9.4 2.18 
1886 Metabolism_of_Angiotensinogen_to_Angiotensins 3.09 0.67 6.06 2.26 3.79 3.33 6.06 1.91 0.24 9.76 9.02 9.2 7.89 9.17 2 6.72 1.08 4.09 
1887 Synthesis,_Secretion,_and_Deacylation_of_Ghrelin 1.1 3.61 7.7 7.82 0.79 7.8 8.18 6.99 1.17 9.19 7.79 1.86 0.21 1.44 8.18 3.37 4.39 9.53 
1888 Synthesis,_Secretion,_and_Inactivation_of_Glucagon-like_Peptide-1_(GLP-1) 0.43 6.51 4.87 3.73 3.96 2.87 6.34 9.39 2.18 9.53 3.49 0.88 3.61 0.32 6.67 3.13 3.98 1.28 
1889 Synthesis,_Secretion,_and_Inactivation_of_Glucose-dependent_Insulinotropic_Polypeptide_(GIP) 7.25 4.26 2.15 3.12 8.15 4.24 5.09 8.79 5.93 4.22 1.76 2.75 6.19 3.34 1.96 0.82 0.44 7.09 
1890 Post-chaperonin_tubulin_folding_pathway 1.48 4.92 8.21 7.24 3.4 0.81 3.29 3.97 0.9 0.71 2 1.31 5.92 3.82 6.04 4.21 6.51 4 
1891 Attachment_of_GPI_anchor_to_uPAR 7.07 0.36 3.92 3.79 0.95 3.87 1.04 2.17 4.91 5.26 8.57 0.02 5.75 2.7 7.91 4.8 9.89 1.17 
1892 Synthesis_of_dolichyl-phosphate_mannose 8.26 9.39 7.16 0.6 5.62 6.22 6.13 2.93 1.76 1.06 9.96 3.5 6.39 4.57 4.97 5.31 9.87 5.9 
1893 Synthesis_of_glycosylphosphatidylinositol_(GPI) 4.72 3.99 9.45 4.83 5.18 5.64 5.83 1.55 1.1 1.53 5.33 3.53 0.19 8.27 6.6 2.33 8.22 3.36 
1894 Attachment_of_GPI_anchor_to_uPAR 5.02 7.65 1.61 3.84 7.51 6.9 6.85 0.52 3.14 6.61 3.13 3.24 4.7 7.84 6.37 3.07 2.75 3.78 
1895 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 2.86 1.18 7.84 0.45 4.18 7.09 5.11 8.97 2.14 7.45 9.07 7.29 6.94 9.67 0.32 7.25 7.58 6.99 
1896 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 6.92 5.92 9.58 6.24 0.44 9.39 5.63 0.07 2.58 5.29 3.07 0.55 0.62 8.84 7.29 0.36 8.75 6.16 
1897 ER_Quality_Control_Compartment_(ERQC) 5.39 5.47 2.52 8.79 4.64 3.96 4.06 3.33 6.53 2.57 5.03 0.12 8.98 8.71 9.91 8.67 0.73 7.22 
1898 Gamma-carboxylation_of_protein_precursors 8.22 6.66 6.14 8.13 1.5 7.62 8.69 5.38 9.71 2.02 4.4 8.07 5.84 8.05 7.13 8.34 5.16 0.5 
1899 Hypusine_synthesis_from_eIF5A-lysine 2.39 9.51 0.77 0.12 4.52 9.99 8.91 0.52 7.34 7.07 6.48 9.39 0.2 4.89 8.71 9 1.16 8.46 
1900 N-Glycan_antennae_elongation 4.19 7.13 5.14 9.81 5.93 7.49 8.27 7.91 7.2 6.82 2.19 2.27 2.23 8.44 6.68 7.52 6.17 5.66 
1901 Progressive_trimming_of_alpha-1,2-linked_mannose_residues_from_Man9/8/7GlcNAc2_to_produce_Man5GlcNAc2 4.17 3.13 6.37 4.83 2.34 4.24 9.76 9.92 8.32 6.3 8.07 2.16 3.71 1.53 1.83 5.19 8.65 3.28 
1902 Proteolytic_Processing_of_SUMO 6.8 9.23 7.22 2.91 8.66 3.84 5.38 9.42 6.86 1.4 7.67 2.47 8 8.59 5.4 0.38 3.4 9.31 
1903 Reactions_specific_to_the_complex_N-glycan_synthesis_pathway 2.53 8.77 3.66 8.81 7.4 1.04 7.1 8.7 5.72 6.55 6.44 0.77 3.55 0.81 2.17 8.06 7.73 7.16 
1904 Reactions_specific_to_the_hybrid_N-glycan_synthesis_pathway 6.86 1.84 6.54 6.82 2.16 5.7 6 5.97 7.17 1.23 6.23 0.39 2.96 6.98 5.37 3.31 7.55 2.24 
1905 Removal_of_aminoterminal_propeptides_from_gamma-carboxylated_proteins 7.14 1.28 8.21 7.98 2.62 9.11 4.74 4.17 8.48 5.39 0.43 9.25 2.83 4.17 3.89 1.12 0.55 9.44 
1906 Synthesis_of_Dolichyl-phosphate 7.5 4.46 4.23 5.3 4.61 1.9 8.96 5.07 7.3 0.74 9.48 1.54 8.54 5.4 9.92 4.78 7.71 4.56 
1907 Synthesis_of_GDP-mannose 5.71 8.9 4.95 8.69 4.8 9.48 9.98 3.28 1.41 8.51 9.58 5.7 7.33 0.15 6.87 2.96 3.07 4.85 
1908 Synthesis_of_UDP-N-acetyl-glucosamine 9.78 1.88 8.65 3.55 0.24 5.62 3.99 4.25 4.55 8.78 5.51 4.17 9.61 2.12 2.81 7.36 7.73 6.63 
1909 Synthesis_of_dolichyl-phosphate_mannose 8.91 4.21 3.14 2.06 1.23 6.49 9.93 0.93 8.8 9.04 5.87 6.32 9.81 7.75 9.87 8.45 3.04 2.86 
1910 Synthesis_of_dolichyl-phosphate-glucose 0.29 3.46 7.62 3.29 8.94 6.52 1.03 0.01 6.46 1.86 2.97 9.28 4.52 7.93 9.2 0.21 3.84 5.05 
1911 Synthesis_of_glycosylphosphatidylinositol_(GPI) 3.57 3.16 1.03 2.08 1.91 7.14 1.7 6.46 9.9 8.88 8.24 4.89 4.21 0.29 9.82 5.94 7.25 4.57 
1912 Termination_of_O-glycan_biosynthesis 5.88 3.43 3.28 3.11 7.78 4.1 8.75 6.59 2.18 6.18 4.48 6.05 5.99 6.16 6.27 3 2.07 3.49 
1913 The_activation_of_arylsulfatases 4.03 5.02 3.89 7.46 5.31 6.46 5.3 5.12 6.98 3.36 5.89 9.22 0.96 5.78 4.96 5.67 9.46 6.83 
1914 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 0.05 4.36 6.23 9.92 3.05 0.98 5.55 8.2 4.4 1.47 5.32 1.52 5.37 0.11 6.84 8.83 3.55 3.25 
1915 Transport_of_gamma-carboxylated_protein_precursors_from_the_endoplasmic_reticulum_to_the_Golgi_apparatus 9.27 5.88 2.96 9.07 1.18 2.14 9.45 6.98 8.02 7.95 5.87 4.69 6.44 2.44 1.36 7.28 0.37 8.64 
1916 Prefoldin_mediated_transfer_of_substrate__to_CCT/TriC 7.92 2.56 5.93 3.39 1.54 9.22 3.3 6 8.7 5.22 4.74 4.99 5.73 4.53 8.49 8.88 5.55 4.96 
1917 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 6.32 2.32 6.11 4.34 6.6 6.93 2.11 7.91 8.47 9.15 4.42 9.67 7.32 1.54 5.36 9.5 4.18 0.89 
1918 Proteolytic_Processing_of_SUMO 6.13 2.13 8.59 0.14 0.6 5.78 7.17 0.11 0.09 1.87 0.88 8.27 8.17 9.37 4.65 4.45 0.73 3.94 
1919 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 0.7 1.91 9.62 6.47 7.15 3.36 5.87 5.83 4.45 6.15 1.68 4.03 3.17 2.55 6.17 7.41 8.48 6.31 
1920 Progressive_trimming_of_alpha-1,2-linked_mannose_residues_from_Man9/8/7GlcNAc2_to_produce_Man5GlcNAc2 5.1 4.03 7.88 1.09 3.29 0.32 5.57 8.6 1.4 4.84 0.41 4.7 2.14 0.58 5.52 3.87 5.12 6.75 
1921 Association_of_TriC/CCT_with_target_proteins_during_biosynthesis 4.48 4.73 1.64 6.9 4.96 4.06 1.68 9.03 3.88 5.81 4.31 9.76 1.44 4.06 6.25 3.57 6.41 9.69 
1922 Folding_of_actin_by_CCT/TriC 5.89 4.74 5.2 6.19 6.6 4.59 8.24 6.42 1.43 3.55 2.82 2.46 6.11 4.21 9.1 0.17 2.28 8.46 
1923 Formation_of_tubulin_folding_intermediates_by_CCT/TriC 8.61 0.96 3.28 8.03 9.25 8.34 2.46 3.03 7.17 8.57 1.99 6.32 6.58 0.94 5.39 6.83 1.29 6.1 
1924 Post-chaperonin_tubulin_folding_pathway 2.87 5.48 4.77 8.58 5.98 6.59 0.19 6.82 2.53 7.23 7.72 9.82 7.63 5.97 1 1.25 4.49 5.89 
1925 Prefoldin_mediated_transfer_of_substrate__to_CCT/TriC 4.97 0.39 8.78 6.27 1.17 9.84 0.31 9.48 7.27 4.77 8.61 8.1 8.87 9.75 0.15 5.05 1.69 8.06 
1926 Proteolytic_Processing_of_SUMO 3.14 3.31 4.12 7.11 0.45 2.55 6.76 8.73 3.78 9.34 1.96 3.4 4.1 0.46 6.4 4.75 1.44 9.94 
1927 Reactions_specific_to_the_complex_N-glycan_synthesis_pathway 7.85 3.56 4.65 6.97 0.1 9.02 9.3 6.86 1.88 4.98 6.11 1.45 1.09 6.61 8.83 1.8 9.25 5.24 
1928 Reactions_specific_to_the_hybrid_N-glycan_synthesis_pathway 1.4 5.2 9.96 2.17 9.12 0.64 4.14 9.98 1.72 5.58 3.93 9.83 4.83 9.74 8.17 0.21 6.94 8 
1929 Recycling_of_eIF2:GDP 8.66 6.4 2.83 1.29 7.74 9.08 1.56 4.2 3.98 6.23 1.3 9.96 4.46 9.54 6.97 1.58 3.81 3.35 
1930 Regulation_of_Insulin-like_Growth_Factor_(IGF)_Transport_and_Uptake_by_Insulin-like_Growth_Factor_Binding_Proteins_(IGFBPs) 1.33 4.13 2.1 9.94 9.33 1.1 3.02 6.58 5.67 8.13 3.57 5.94 9.17 7.75 9.26 2.91 3.83 9.38 
1931 Removal_of_aminoterminal_propeptides_from_gamma-carboxylated_proteins 5.1 0.37 8.09 5.78 7.19 9.17 2.7 4.85 9.83 4.73 4.92 3.37 9.1 5.7 9.7 6.2 3.92 4.01 
1932 Ribosomal_scanning_and_start_codon_recognition 2.79 9.8 1.09 6.21 4.61 9.77 9.73 4.04 1.83 7.44 5.59 7.12 6.22 8.25 6.11 8.92 7.38 4.67 
1933 SRP-dependent_cotranslational_protein_targeting_to_membrane 7.19 0.95 9.83 8.7 3.6 9.6 3.1 8.25 2.41 7.55 0.45 0.05 3.52 6.26 0.34 8.18 5.99 0.16 
1934 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 1.56 3.76 8.16 6.5 5.46 1.21 1.01 4.79 8.57 4.86 9.51 3.53 4.95 7.67 7.81 8.92 1.09 5.18 
1935 Proteolytic_Processing_of_SUMO 0.56 7.03 7.81 7.58 9.24 0.49 1.45 6.4 3.7 7.9 1 8.7 7.55 0.1 1.08 9.08 1.59 9.41 
1936 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 6.8 4.6 9.28 2.63 5.66 6.01 2.16 4.78 3.37 5.26 0.26 1.41 4.17 0.87 9.04 0.95 3.15 5.68 
1937 Synthesis_of_Dolichyl-phosphate 8.57 3.33 9.79 2.77 6.13 8.85 4.63 6.82 3.71 7.96 1.66 9.16 3.94 9.88 7.28 1.43 8.47 9.93 
1938 Synthesis_of_GDP-mannose 4.64 5.3 7.52 9.6 9.03 3.2 3.1 1.62 3.71 1.44 6.24 2.4 8.64 2.87 8.29 0.47 4.93 6.52 
1939 Synthesis_of_UDP-N-acetyl-glucosamine 0.66 5.42 3.46 3.97 9.02 5.89 8.73 9.6 5.69 9.84 9.87 0.84 4.76 3.16 4.2 0.81 2.53 3.7 
1940 Synthesis_of_dolichyl-phosphate_mannose 8.42 0.93 5.29 2.98 5.93 7.05 5.2 1.13 4.59 7.79 4.43 8.86 7.18 1.81 9.05 8.01 5.9 7.58 
1941 Synthesis_of_dolichyl-phosphate-glucose 0.75 6.3 7.01 8.16 0.12 4.57 4.56 3.3 6.29 7.45 4.68 5.82 3.04 9.86 8.8 3.89 0.11 6.85 
1942 Synthesis_of_glycosylphosphatidylinositol_(GPI) 6.37 5.38 5.51 5.63 6.76 2.77 2.66 5.71 2.22 2.65 5.86 1.12 8.1 3.43 8.91 4.14 0.5 9.4 
1943 Synthesis_of_Dolichyl-phosphate 0.1 3.42 2.87 5.29 0.91 9.76 1.03 5.05 3.04 6.56 2.92 8.17 3.55 7.16 2.86 8.59 2.63 6.13 
1944 Synthesis_of_GDP-mannose 6.35 5.39 3.69 6.13 6.62 5.18 7.56 7.92 7.02 5.59 3.18 9.98 0.17 3.08 6.69 7.51 3.37 8.57 
1945 Synthesis_of_UDP-N-acetyl-glucosamine 2.22 0.32 2.13 3.07 0.79 9.41 6.59 8.15 8.99 5.75 4.13 5.64 3.18 9.28 3.05 2.3 7.94 7.81 
1946 Synthesis_of_dolichyl-phosphate_mannose 9.25 7.73 8.81 1.08 9.71 8.78 2.91 9.25 8.57 8.08 9.79 9.02 3.81 6.25 0.45 1.93 1.51 1.94 
1947 Synthesis_of_dolichyl-phosphate-glucose 0.35 5.05 1.11 1.93 2.49 9.33 8.88 0.69 2.69 3.48 6.61 7.75 8.51 8.66 2.92 7.75 3.11 6.58 
1948 Synthesis,_Secretion,_and_Deacylation_of_Ghrelin 1.68 1.4 0.2 5.32 7.55 5.44 5.17 9.52 1.31 9.8 0.9 5.32 4.28 5.2 4.69 9.55 0.87 2.85 
1949 Synthesis,_Secretion,_and_Inactivation_of_Glucagon-like_Peptide-1_(GLP-1) 4.46 0.23 5.13 7.02 0.2 0.48 9.91 7.32 0.52 6.85 0.41 7.86 2.87 7.54 3.89 0.17 2.15 9.47 
1950 Synthesis,_Secretion,_and_Inactivation_of_Glucose-dependent_Insulinotropic_Polypeptide_(GIP) 5.89 8.37 7.46 9.36 4.51 3.59 6.91 3.77 4.84 1.55 2.61 0.04 5.71 3.33 5.69 3.32 7.12 0.08 
1951 Termination_of_O-glycan_biosynthesis 3.62 6.85 8.96 2.63 7.19 3.1 5.42 9.84 6.33 8.13 5.06 0.13 7.89 2.49 1.7 9.89 7.88 5.24 
1952 The_activation_of_arylsulfatases 4.46 3.39 3.13 5.43 2.24 8.85 7.15 5.39 3.95 1.03 6.68 1.41 9.08 7.45 9.05 4.82 2.87 0.55 
1953 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 6.03 9.08 1.63 0.63 2.92 6.59 2.4 6.96 6.94 3.83 6.95 2.17 8.09 3.32 0.67 5.6 5.32 7.11 
1954 Eukaryotic_Translation_Termination 1.75 4.76 1.82 3.21 6.32 5.01 2.93 9.86 1.49 4.26 6.79 6.08 3.88 9.31 7.27 0.63 6.62 6.33 
1955 Formation_of_a_pool_of_free_40S_subunits 0.98 5.23 0.86 2.35 0.82 0.12 3.66 2.58 4.02 3.13 2.74 9.58 5.88 7.45 0.97 9.14 4.4 8.21 
1956 Formation_of_the_ternary_complex,_and_subsequently,_the_43S_complex 4.34 7.26 5.01 6.58 7.15 7.08 0.69 8.7 4.32 7.81 8.52 2.24 4.97 5.17 4.65 0.45 6.2 1.64 
1957 GTP_hydrolysis_and_joining_of_the_60S_ribosomal_subunit 3.77 8.25 2.38 5.26 9.75 3.63 6.44 1.42 2.24 8.36 1.43 3.98 8.47 3.12 0.31 5.78 3.16 5.1 
1958 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 7.43 9.98 8.11 4.85 2.65 0.92 7.06 5.59 2.83 5.23 2.34 9.71 4.27 3.16 7.38 0.69 5.99 8.87 
1959 Peptide_chain_elongation 5.92 0.17 9.92 2.46 4.58 6.64 1.6 8.08 6.52 5.46 2.01 4.57 2.66 3.81 3.68 1.51 7.61 3.08 
1960 Recycling_of_eIF2:GDP 5.14 1.84 0.57 0.28 1.01 1.38 2.93 7.55 7.06 1.24 2.94 7.13 8.98 1.87 4.37 4.52 9.83 2.39 
1961 Ribosomal_scanning_and_start_codon_recognition 5.04 4.7 9.24 7.76 6.87 1.46 7.27 8.27 6.15 4.39 8.86 2.41 8.94 0.68 5.76 6.73 6.4 6.13 
1962 SRP-dependent_cotranslational_protein_targeting_to_membrane 1.9 6.04 9.54 1.89 4.33 0.82 4.45 2.85 5.09 9.56 2.77 4.83 5.91 6.9 6.19 7.5 1.39 8.46 
1963 Translation_initiation_complex_formation 4.39 3.77 0.1 7.52 3.62 5.74 7.53 7.87 3.07 4.37 4.69 0.79 9.28 3.25 7.18 0.72 3.44 0.1 
1964 Translation_initiation_complex_formation 5.93 8.24 3.27 3.36 5.07 2.41 5.37 1.03 0.34 7.65 2.58 4.87 4.38 0.82 5.18 9.1 9.93 3.6 
1965 Transport_of_gamma-carboxylated_protein_precursors_from_the_endoplasmic_reticulum_to_the_Golgi_apparatus 7.8 6.96 1.22 0.6 2.16 9.58 2.16 2.18 3.62 1.94 0.13 4.46 7.85 5.93 3.21 5.08 8.11 4.42 
1966 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 3.53 2.34 4.57 4.07 6.79 4.66 1.51 7.62 1.48 6.92 3.46 0.58 6.28 1.47 1.09 0.45 0.73 4.78 
1967 N-Glycan_antennae_elongation 9.57 3.52 1.54 5.06 9.56 2.76 6.36 3.11 1.07 1.87 2.25 4.32 7.39 9.01 9.77 6.47 7.01 2.04 
1968 Progressive_trimming_of_alpha-1,2-linked_mannose_residues_from_Man9/8/7GlcNAc2_to_produce_Man5GlcNAc2 5.99 0.88 9.92 3.74 9.9 1.72 7.72 5.4 4.83 4.41 0.93 8.14 6.12 9.76 9.86 6.74 6.97 6.56 
1969 Reactions_specific_to_the_complex_N-glycan_synthesis_pathway 6.22 8.85 5.38 0.01 8.71 2.16 7.62 1.87 7.57 8.7 2.34 3.36 5.17 6.38 0.17 0.63 9.83 1.48 
1970 Reactions_specific_to_the_hybrid_N-glycan_synthesis_pathway 9.15 1.62 4.6 7.17 1.35 8.66 4.44 5.23 9.09 1.7 5.75 6.93 0.39 2.82 0.82 1.22 8.32 5.33 
1971 Activation_of_Chaperone_Genes_by_ATF6-alpha 9.17 5.11 1.63 7.33 7.14 4.64 1.41 6.77 2.72 7.96 8.61 8.86 8.26 7 2.67 2.86 4.98 3.56 
1972 Activation_of_Chaperone_Genes_by_XBP1(S) 0.07 1.83 1.45 1.79 3.63 8.92 9.55 0.48 6.84 5.29 2.54 1.18 6.28 6.03 5.08 2.41 7.4 8.62 
1973 Activation_of_Genes_by_ATF4 6.58 3.53 4.09 4.94 2.24 6.38 4.44 6.55 9.61 4.37 3.18 3.85 5.57 0.98 5.31 2.14 1.5 3.5 
1974 Smooth_Muscle_Contraction 9.99 1.9 6.39 7.88 4.46 6.78 5.64 0.22 8.96 1.96 7.25 0.53 3.49 6.62 9.81 6.97 6.78 0.59 
1975 Striated_Muscle_Contraction 2.11 7.66 6.21 7.61 0.3 2.55 8.05 5.13 6.62 2.95 2.2 8.49 9.13 0.94 0.71 0.96 5.63 6 
1976 BMAL1:CLOCK/NPAS2_Activates_Circadian_Expression 6.87 7.67 4.74 2.45 0.68 2.06 8.41 9.32 3.91 3.57 9.7 9.85 5.16 8.6 9.62 7.21 2.56 7.32 
1977 Circadian_Repression_of_Expression_by_REV-ERBA 2.48 0.76 0.87 1.76 7.25 8.66 8.97 1.1 3.95 4.88 6.93 7.87 2.47 8.13 0.79 2.78 1.13 9.85 
1978 RORA_Activates_Circadian_Expression 5.02 9.79 4.06 8.06 1.13 4.67 9.55 1.93 4.2 8.33 3.24 1.54 2.93 1.6 4.94 6.09 7.56 8.6 
1979 Amino_acid_transport_across_the_plasma_membrane 5.46 4.44 1.62 3.19 2.91 9.43 9.77 7.25 0.99 9.31 3.72 6.81 8.8 6.98 4.88 6.09 6.29 7.06 
1980 Organic_anion_transporters 0.04 6.48 2.3 5.52 0.45 8.99 2.67 1.19 5.25 7.02 9.21 8.25 3.33 9.67 7.41 9.96 4.64 1.62 
1981 Proton-coupled_neutral_amino_acid_transporters 2.67 0.49 1.94 5.19 6.46 5.61 5.6 5.86 2.17 6.33 0.1 8.74 3.73 6.08 3.99 0.84 9 8.55 
1982 Proton/oligonucleotide_cotransporters 2.79 4.24 5.73 8.48 2.15 1.48 1.85 2.49 9.61 6.47 3.5 9.71 2.58 8.57 2.57 2.62 7.76 2.98 
1983 Na+/Cl-_dependent_neurotransmitter_transporters 0.01 0.24 2.51 4.32 2.26 0.62 6.74 7.64 3.2 3.61 1.78 3.27 1.96 1.49 6.35 9.93 9.87 9.1 
1984 Rhesus_glycoproteins_mediate_ammonium_transport 2.44 3.55 6.77 9 0.16 2.7 2.28 1.53 0.8 5.23 1.66 9.91 8.51 8.68 1.64 7.43 0.59 7.23 
1985 Proton-coupled_monocarboxylate_transport 0.52 5.12 0.9 2.57 2.68 2.21 5.33 5.29 4.64 2.75 0.88 6.39 5.33 3.53 8.02 4.75 5.27 0.48 
1986 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 8.02 8.83 1.2 7.33 7.78 5.76 1.7 9.72 2.44 2.55 7.91 0.15 2.18 5.62 5.75 5.36 2.57 7.76 
1987 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 9.06 3.15 4.33 1.39 9.42 5.6 7.74 3.76 6.59 5.6 3.23 7.97 5.97 0.61 7.84 5.18 6.58 3.11 
1988 Activation_of_the_pre-replicative_complex 7.45 0.32 6.45 6.6 4.02 9.29 8.18 6.16 1.99 6.55 4.11 2.45 1.04 4.25 0.42 7.16 6.93 9.71 
1989 Assembly_of_the_ORC_complex_at_the_origin_of_replication 6.79 1.25 2.94 6.7 3.97 0.92 8.55 6.71 4.88 4.92 1.22 6.55 0.58 8.96 9.17 9.71 0.07 8.4 
1990 Assembly_of_the_ORC_complex_at_the_origin_of_replication 0.05 5.8 1.41 6.57 5.55 7.69 6.79 7.04 2.54 0.6 0.68 6 6.73 6.75 1.55 1.14 1.03 2 
1991 CDC6_association_with_the_ORC:origin_complex 6.66 1.48 2.2 8.19 8.4 9.89 3.66 7.58 6.56 3.68 5.4 6.09 6.39 0.15 6.61 6.47 7.03 8.9 
1992 CDT1_association_with_the_CDC6:ORC:origin_complex 9.17 2.72 4.69 8.4 2.59 2.17 2.63 3.18 7.42 9.61 4.26 4.62 4.25 3.26 5.07 3.37 5.56 4.87 
1993 CDC6_association_with_the_ORC:origin_complex 7.25 9.19 3.02 2.03 2.11 5.5 9.44 4.58 4.3 0.18 1.39 7.13 1.05 7.8 9.25 5.96 3.71 7.66 
1994 CDT1_association_with_the_CDC6:ORC:origin_complex 0.64 1.84 7.96 6.3 8.83 1.43 4.44 5.93 1.09 9.27 5.44 1.38 3.11 0.61 2.55 9.79 1.05 8.86 
1995 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 9.96 8.35 4.64 0.94 4.68 1.68 1.34 1.16 5.31 3.59 0.67 5.42 4.82 6.9 8.43 9.29 1.88 4.01 
1996 Cohesin_Loading_onto_Chromatin 0.88 1.32 9.68 7.24 4.66 7.97 2.89 2.08 4.75 2.2 7.41 5.84 4.15 3.83 0.11 8.62 5.16 9.97 
1997 Condensation_of_Prometaphase_Chromosomes 8.81 8.1 2.71 6.39 5.89 1.38 6.08 9.72 8.66 3.07 9.34 6.36 5.4 6.71 1.98 1.35 4.96 0.95 
1998 Activation_of_the_pre-replicative_complex 4.32 9.43 1.42 6.11 3.54 7.79 0 7.11 4.97 7.18 5.36 8.4 5.97 4.07 7.65 3.12 6.37 0.5 
1999 Assembly_of_the_ORC_complex_at_the_origin_of_replication 9.34 9.66 3.55 5.83 6.26 3.38 6.01 7.05 6.15 6.55 8.28 2.66 4.9 7.38 9.43 1.25 0.86 5.14 
2000 CDC6_association_with_the_ORC:origin_complex 7.95 8.52 8.88 5.92 6.14 6.67 2.75 9.21 2.1 2.37 4.87 6.01 9.44 7.97 6.48 8.66 9.64 6.72 
2001 CDT1_association_with_the_CDC6:ORC:origin_complex 3 5.26 0.35 2.17 2.92 6.74 1.38 3.96 9.18 4.03 5.6 2.47 9.95 2.61 1.91 1.5 6.93 4.82 
2002 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 6.55 9.19 2.83 8.96 1.72 3.89 6.16 5.58 9.04 3.12 3.93 5.03 8.68 1.33 6.94 6.4 3.56 7.7 
2003 Initiation_of_Nuclear_Envelope_Reformation 8.02 2.23 1.36 3.01 7.18 1.73 0.74 7.33 0.91 3.74 5.49 4.49 2.07 6.61 9.7 9.12 2.02 4.29 
2004 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 9.13 6.73 9.93 9.26 3.18 7.08 9.54 9.49 8.1 1.59 3.53 2.39 6.12 8.78 7.3 6.71 8.39 5.17 
2005 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 6.33 6.14 1.34 4.56 4.87 4.74 3.49 6.61 7.25 2.03 0.73 7.68 0.94 1.29 5.71 9.59 1.91 6.34 
2006 Cohesin_Loading_onto_Chromatin 5.21 0.79 2.35 1.47 3.1 5.43 3.25 3.72 5.48 0.35 3.16 7.93 3.42 4.84 8.38 8.55 1.54 9.66 
2007 Condensation_of_Prometaphase_Chromosomes 6.46 8.28 9.19 2.26 8.16 4.33 4.04 5.89 8.4 9.4 6.65 9.53 5.25 9.37 9.38 7.38 7.95 9.86 
2008 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 5.05 4.44 3.93 6.47 0.67 1.87 6.16 5.43 0.54 7.06 0.14 7.43 6.4 8 3.86 4.1 6.68 7.2 
2009 Initiation_of_Nuclear_Envelope_Reformation 7.12 9.38 3.29 6.97 2.07 2.85 7.24 1.89 0.42 3.48 2.23 2.13 2.44 4.57 5.38 0.85 0.79 9.27 
2010 MASTL_Facilitates_Mitotic_Progression 7.69 4.92 1.1 7.42 1.58 5.19 3.45 4.54 8.64 4.79 1.77 5.32 2.43 0.16 4.53 0.91 6.82 0.9 
2011 Mitotic_Metaphase/Anaphase_Transition 6.21 1.57 8.91 8.05 2.93 1.71 4.26 7.13 8.44 7.29 8.65 9.88 4.05 1 4.15 0.96 6.29 6.24 
2012 Nuclear_Pore_Complex_(NPC)_Disassembly 9.18 3.24 7.51 6.54 7.21 4.33 0.76 9.15 1.41 3.52 8.15 8.31 4.55 9.86 7.84 2.6 7.82 7.68 
2013 Resolution_of_Sister_Chromatid_Cohesion 3.35 1.97 8.27 4.28 9.8 6.09 2.55 5.76 1.32 0.8 2.27 0.54 8.23 2.93 1.42 6.55 8.87 7.97 
2014 Separation_of_Sister_Chromatids 8.02 0.8 2.59 2.23 1.68 2.65 7.74 0.44 0.3 3.52 5.93 4.01 6.3 8.78 1.92 7.78 0.96 0 
2015 Activation_of_the_pre-replicative_complex 3.88 3.14 0.19 5.69 9.88 0.32 0.56 1.73 7.62 7.96 1.83 3.45 9.15 3.63 8.62 8.18 5.58 2.23 
2016 Assembly_of_the_ORC_complex_at_the_origin_of_replication 9.1 4.28 3.45 9.46 0.25 3 2.96 5.64 4.42 7.67 3.92 7.55 6.03 0.51 6.92 1.63 5.49 2.87 
2017 CDC6_association_with_the_ORC:origin_complex 9.73 4.55 9.79 7.11 8.71 2.86 2.4 8.27 7.29 3.21 1.14 9.61 6.21 0.92 0.31 8.07 2.81 2.42 
2018 CDT1_association_with_the_CDC6:ORC:origin_complex 4.47 9.97 7.25 3.74 5.38 6.67 1.98 2.96 1.08 6.55 0.99 9.57 2.45 8.82 5.9 7.95 2.38 3.71 
2019 MASTL_Facilitates_Mitotic_Progression 6.93 0.9 7.53 3.63 7.3 9.66 7.04 3.39 7.51 6.45 9.69 7.39 5.34 1.96 5.37 4.53 6 3.27 
2020 Initiation_of_Nuclear_Envelope_Reformation 5.5 8.74 3.8 5.2 6.01 5.63 4.74 2.96 1.24 5.7 5.45 0.6 0 6.09 3.58 9.45 7.79 0.51 
2021 Separation_of_Sister_Chromatids 2.86 8.51 4 9.3 0.69 6.43 4.78 8.57 3.28 3.27 3.9 4.99 2.96 8.62 4.23 2.84 6.72 8.76 
2022 Initiation_of_Nuclear_Envelope_Reformation 4.68 0.47 0.33 0.27 4.41 7.03 5.8 0.51 3.62 0.25 1.84 4.59 6.13 5.86 0.36 2.48 9.68 9.97 
2023 Mitotic_Metaphase/Anaphase_Transition 8.87 4.13 1.58 9.28 1.58 6.44 1.02 3.44 4.71 0.6 8.76 3.93 0.83 3 5.56 2.9 3.44 5.66 
2024 Separation_of_Sister_Chromatids 0.69 1.61 6.4 0.56 1.15 5.07 7.72 6.47 9.35 7.27 8.22 2.92 3.38 1.8 5.65 7.64 8.47 2.47 
2025 Mitotic_Metaphase/Anaphase_Transition 9.54 2.51 3.93 7.14 7.39 1.04 9.42 7.61 3.57 0.55 1.06 2.3 0.95 2.75 6.54 9.6 9.41 1.54 
2026 Condensation_of_Prometaphase_Chromosomes 2.11 0.88 9.14 1.66 4.34 3.72 5.22 3.04 8.29 6.39 1.19 8.4 2.35 2.48 6.82 2.02 2.16 0.18 
2027 Resolution_of_Sister_Chromatid_Cohesion 5.32 1.23 7.31 5.48 9.74 5.89 0.53 7.14 6.3 3.84 6.22 1.8 8.98 4.49 5.3 7.82 4.5 0.79 
2028 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 5.72 1.76 9.85 4.67 2.26 7.5 6.84 7.28 5.53 4.26 2.79 8.84 1.46 6.48 4.04 8.85 1.33 9.79 
2029 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 3.81 2.15 0.29 3.42 3.4 0.69 2.45 7.34 7.37 0.71 6.49 3.58 8.76 8.59 4.32 6.99 7.95 1.5 
2030 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 0.08 8.01 2.14 1.56 5.78 1.09 4.17 1.67 2.23 9.09 2.58 7.97 1.16 8.76 0.67 7.33 5.94 3.95 
2031 MASTL_Facilitates_Mitotic_Progression 8.1 0.75 5.7 5.96 8.8 6.34 0.71 7.28 5.75 6.17 0.99 0.29 0.4 8.17 2.79 8.32 8.51 9.58 
2032 Nuclear_Pore_Complex_(NPC)_Disassembly 3.97 2.25 0.39 9.48 4.16 6.23 4.21 6.75 6.55 6.65 7.2 4.3 9.33 9.03 4.4 3.93 2.61 4.16 
2033 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 4.88 0.82 4.6 7.89 5.16 8.74 5.11 1.58 5.43 6.51 3.75 5.63 5.56 6.75 1.78 7.66 0.59 4.5 
2034 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 6.2 5.27 0.38 2.09 1.1 0.64 3 9.23 2.29 5.79 7.5 8.16 6.86 2.96 2.25 6.16 9.45 1.87 
2035 Nuclear_Pore_Complex_(NPC)_Disassembly 7.87 2.53 6.11 8.38 6.33 1.64 7.93 2.35 1.76 9.58 3.29 0.92 8.91 0.81 8.91 8.78 1.41 0.28 
2036 Initiation_of_Nuclear_Envelope_Reformation 0.81 6.99 7.35 3.16 8.27 5.83 9.16 6.16 8.29 3.18 2.58 6.91 0.45 7.16 8.28 3.23 4.24 9.57 
2037 Nuclear_Pore_Complex_(NPC)_Disassembly 6.06 8.22 9.56 4.62 1.45 6.29 6.43 6.27 6.88 3.47 7.5 0.75 8.82 8.71 7.12 9.52 2.25 2.71 
2038 Resolution_of_Sister_Chromatid_Cohesion 2.29 8.28 6.97 4 7.55 0.17 7.25 7.88 9.76 6.87 5.03 2.92 2.84 2.35 0.3 1.82 2.16 3.81 
2039 Separation_of_Sister_Chromatids 0.85 3.84 1.51 3.95 5.7 0.06 8.76 2.69 9.96 6.48 5.32 3.45 1.69 1.75 8.69 9.04 2.06 7.21 
2040 Cohesin_Loading_onto_Chromatin 7.68 6 0.32 9.47 6.51 0.91 4.91 7.75 0.73 2.24 2.09 7.59 8.54 5.77 9.01 3.28 9.66 7.17 
2041 Deadenylation_of_mRNA 4.65 3.06 8.77 0.62 8.77 1.43 5.41 4.61 0.08 7.38 6.43 6.2 9.79 7.7 0.18 1.09 5.56 9.27 
2042 Deadenylation_of_mRNA 3.73 1.38 3.61 4.93 2.15 5.41 6.47 9.26 8.45 0.8 1.53 7.41 5.1 0.47 7.32 0.56 2.9 0.37 
2043 mRNA_Decay_by_3_to_5_Exoribonuclease 0.35 0.85 8.17 4.84 1.5 1.61 8.37 7.69 6 8.44 2.03 1.11 1.77 0.49 6.78 4.83 2.65 8.77 
2044 mRNA_Decay_by_5_to_3_Exoribonuclease 4.45 1.68 6.55 2.46 0.93 6.76 2.89 0.06 5.21 9.06 2.37 8.55 3.46 6.9 7.99 3.06 2.9 4.3 
2045 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 7.39 4.35 9.73 0.54 8.45 9.51 5.62 5.42 7.43 6.56 7.26 7.66 7.79 4.64 8.11 3.86 7.46 6.05 
2046 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 8.95 2.91 1.09 4.52 5.11 6.47 3.46 2.57 4.37 2.68 6.88 8.13 3.59 3.79 6.54 0.41 6.59 9.3 
2047 Destabilization_of_mRNA_by_KSRP 5.38 9.7 6.48 4.74 1.42 3.49 1.42 0.75 0.63 1.97 4.41 3.8 1.68 3.79 7.78 3.75 9.96 7.42 
2048 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 0.7 2.2 9.32 9.07 6.51 4.69 2.72 4.86 5.77 7.79 0.49 5.54 0.37 0.71 1.58 4.21 3.24 9.71 
2049 Deadenylation_of_mRNA 6.93 7.52 4.77 4.82 3.97 6.61 7.04 3.24 2.09 5.05 6.62 0.55 7.59 0.21 5.68 4.11 8.34 1.75 
2050 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 2.37 2.04 0.06 3.83 1.98 1.42 0.42 7.35 1.09 8.28 5.38 4.65 7.66 0.01 5.25 2.8 4.44 9.71 
2051 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 4.12 8.48 0.46 0.68 5.89 1.75 1.64 6.75 2.54 0 4.53 0.66 6.3 7.57 1.38 8.33 7.69 1.97 
2052 Destabilization_of_mRNA_by_KSRP 8.65 8.12 2.58 2.07 5.7 5.37 6.3 4.38 9.26 3.64 1.98 6.05 4.5 2.78 3.97 9.25 5.34 7.55 
2053 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 0.67 8.36 5.94 7.95 2.97 1.04 7.15 4.03 1.66 8.37 2.27 9.33 7.22 4.99 9.91 2.69 8.25 7.79 
2054 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 5.81 2.14 2.74 3.15 8.37 3.88 3.12 4.24 8.31 5.87 2.24 1.64 9.33 1.28 6.04 4.97 8.91 4.23 
2055 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 9.84 8.61 4.28 7.01 2.59 8.54 3.03 0.62 6.81 7.99 5.38 7.54 3.02 5.87 9.25 3.95 1.25 7.13 
2056 Stabilization_of_mRNA_by_HuR 0.74 0.74 4.34 2.25 8.51 2.98 8.85 0.15 3.97 2.29 2 6.53 9.88 3.19 2.98 9.74 6.71 8.4 
2057 mRNA_Decay_by_3_to_5_Exoribonuclease 2.3 8.08 0.94 4.61 5.81 4.81 5.45 4.09 5.95 5.58 6.18 9.92 0.33 8.87 7.57 1.8 1.02 7.51 
2058 mRNA_Decay_by_5_to_3_Exoribonuclease 4.71 2.6 2.59 7.95 0.85 2.33 8.23 3.61 2.15 1.55 6.49 0.19 6.05 5.32 9 7.24 2.56 3.54 
2059 snRNP_Assembly 2.48 5.7 0.6 9.07 7.34 5.72 0.68 9.73 8.92 2.7 3.19 8.36 6.58 0.03 2.74 3.03 5.8 7.71 
2060 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 2.38 3.8 1.77 3.97 0.59 5.87 4.91 5.18 7.01 5.53 2.96 1.14 3.74 6.46 3.2 2.66 7.48 2.89 
2061 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 0.96 6.07 3.8 4.5 2.55 9.34 0.39 5.36 8.79 3.09 6.12 7.08 4.3 5.4 6.39 7.42 7.01 8.64 
2062 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 2.41 7.19 1.69 0.92 7.43 8.15 4.8 2.81 7.27 2.23 0.94 6.4 2.8 1.93 7.21 1.25 5.85 5.19 
2063 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 0.26 8.22 6.69 5.38 0.45 9.47 9.26 2.04 0.5 6.49 3.84 7.59 3.41 1.22 1.03 8.71 6.82 7.76 
2064 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 5.23 7.58 4.86 0.9 7.55 1.91 9.86 1.73 4.08 3.25 6.89 8.46 4.12 4.92 2.28 0.55 3.46 7.68 
2065 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 4.76 0.64 6.55 7.33 0.32 2.8 1.13 3.99 5.43 7.88 2.23 3.48 3.12 7.76 6.82 1.9 0.8 3.56 
2066 Destabilization_of_mRNA_by_KSRP 8.27 1 2.28 7.52 4.29 4.52 8.15 8.19 2.11 3.62 0.07 3.92 4.45 9.16 1.55 2.18 8.63 2.25 
2067 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 5.51 0.26 7.79 7.67 4.92 2.7 5.69 1.32 0.65 4.04 1.71 5.19 3.03 4.56 7.74 9.52 2.43 9.06 
2068 Stabilization_of_mRNA_by_HuR 1.82 2.45 8.85 8.11 3.36 8.71 8.57 0.01 1.9 0.37 1.07 8.34 8.47 2.87 4.41 5.82 8.77 0.29 
2069 Stabilization_of_mRNA_by_HuR 3.4 2.31 8.03 1.92 4.62 1.49 9.51 4.49 3.94 3.25 0.52 2.66 5.05 8.02 3.55 3.7 9.53 3.83 
2070 mRNA_Decay_by_3_to_5_Exoribonuclease 5.31 2.13 9.31 9.24 3.5 5.54 8.6 8.23 0.62 5.1 8.84 3.56 9.84 1.86 5.1 8.96 7.51 1.77 
2071 mRNA_Decay_by_5_to_3_Exoribonuclease 2.15 1.39 8.28 2.85 6.35 8.52 1.18 9.38 6.76 0.17 8.76 9.3 0.44 8.87 4.66 0.26 9.65 1.43 
2072 snRNP_Assembly 2.36 4.21 1.42 5.86 1.24 9.36 9.53 0.94 4.5 6.06 1.63 2.09 4.69 7.17 6.2 9.09 1.57 6.97 
2073 Advanced_glycosylation_endproduct_receptor_signaling 7.36 2.53 5.14 3.83 7.01 3.03 5.22 0.21 9.18 1.62 5.11 4 0.47 7.46 4.72 9.57 7.21 3.86 
2074 IRAK1_recruits_IKK_complex 3.46 5.88 3.04 2.49 7.09 1.86 4.28 4.41 8.67 6.62 0.93 4.04 0.63 4.23 2.18 9.99 5.55 4.67 
2075 IRAK2_mediated_activation_of_TAK1_complex 9.48 9.79 3.8 8.75 3.74 6.09 1.94 9.41 6.88 4.62 7.62 3.14 5.65 9.04 9.66 4.02 7.13 6.16 
2076 AKT-mediated_inactivation_of_FOXO1A 9.69 7.24 4.71 5.84 0.91 3.07 9.37 4.39 5.24 2.61 8.01 8.18 9.42 2.69 9.04 6.14 0.83 3.24 
2077 Activation_of_Rac 4.14 1.15 7.37 4.03 2.17 7.31 0.51 4.76 1.45 6.83 1.55 0.66 6.11 6.97 5.16 3.18 8.92 9.59 
2078 Activation_of_Rac 2.13 1.64 2.73 4.71 2.9 6.13 7.09 0 3.09 5.49 6.43 3.43 2.7 7.28 5.4 1.29 0.62 2.89 
2079 CHL1_interactions 0.82 0.96 8.98 7.95 4.38 2.2 7.74 4.84 0.16 5.64 1.84 1.27 3.33 3.74 6.95 9.6 4.13 8.99 
2080 CRMPs_in_Sema3A_signaling 1.96 4.77 9.02 3.18 4.47 5.87 1.23 0.15 9.65 3.51 2.25 3.54 7.12 5.51 1.55 7.41 6.4 3.84 
2081 DCC_mediated_attractive_signaling 1.56 3.39 0.81 2.4 2.94 7.7 3.49 2.14 1.68 6.6 2.35 8.73 7.17 2.28 0.79 6.87 8.43 3.43 
2082 ERK1_activation 3.81 0.4 4.25 8.13 4.32 9.85 9.81 7.51 4.64 3.57 5.88 2.6 9.24 2.57 5.15 1.19 5.63 9.02 
2083 ERK2_activation 2.38 9.71 2.33 4.05 7.43 6.74 1.52 2.94 2.01 9.06 3.97 1.38 7.33 6.65 7.57 8.5 9.81 8.66 
2084 Inactivation_of_Cdc42_and_Rac 7.84 7.91 2.87 0.72 0.21 3.23 7.25 4.19 7.1 2.63 6.99 6.65 3.32 4.87 4.56 4.62 3.02 6.59 
2085 Interaction_between_L1_and_Ankyrins 9.04 8.31 2.31 5.99 2.32 7.16 6.14 8.62 5.08 9 4.57 6.42 1.11 7.09 6.76 5.27 5.93 0.92 
2086 NCAM1_interactions 7.11 2.81 7.25 0.9 5.02 7.78 6.27 5.68 7.33 4.57 6.75 4.84 8.67 0 0.04 2.68 1.82 3.08 
2087 Netrin_mediated_repulsion_signals 3 1.54 5.04 6.5 3.76 9.21 7.53 2.56 4.86 2.15 5.4 4.82 3.85 3.8 8.62 0.47 4.05 3.22 
2088 Neurofascin_interactions 1.17 8.51 0.28 7.49 7.33 7.97 2.81 3.8 5.53 8.2 3.62 9.13 4.16 9.97 0.11 8.21 6.93 2 
2089 NrCAM_interactions 9.77 3.92 8.43 9.81 8.99 2 8.89 8.49 1.2 2.23 4.27 3.49 1.65 5.7 1.46 2.88 5.26 3.83 
2090 Other_semaphorin_interactions 3.01 8.68 2.4 6.71 9.91 8.07 5.72 2.53 9.62 3.87 8.62 7.25 2.76 2.71 9.9 2.32 3.93 0.87 
2091 RAF_activation 4.94 8.87 3.14 3.46 2.22 2.38 5.89 4.35 0.61 3.95 7.97 2.67 5.53 1.35 4.91 3.16 6.41 7.49 
2092 RAF_phosphorylates_MEK 4.29 4.81 1.92 4.96 0.86 4.12 1.64 0.5 7.34 6.88 6 9.22 2.27 5.28 0.71 1.41 6.47 8.31 
2093 Recycling_pathway_of_L1 1.55 5.28 9.25 4.66 9.65 3.01 5.19 5.62 2.77 9.97 8.97 7.03 4.6 1.81 3.55 2.66 0.55 6.43 
2094 Regulation_of_Commissural_axon_pathfinding_by_Slit_and_Robo 4.43 9.93 8.87 8.51 5.53 6.41 4.23 6.61 3.27 0.06 0.14 6.97 3.37 4.55 5.82 7.58 9.37 5.84 
2095 Role_of_Abl_in_Robo-Slit_signaling 1.72 4.31 6.07 2.47 8.33 2.16 1.99 5.71 4.88 4.07 8.74 8.1 1.93 4.86 9.21 4.99 3.49 8.24 
2096 Role_of_second_messengers_in_netrin-1_signaling 0.71 3.87 8.83 9.78 3.75 9.07 5.95 7 8.39 9.69 4.41 5.44 8.27 3.82 7.95 5.7 1.33 5.29 
2097 SEMA3A-Plexin_repulsion_signaling_by_inhibiting_Integrin_adhesion 6.3 5.28 5.39 1.46 7.11 0.44 0.97 9.69 1.42 3.04 0.33 5.12 7.59 6.1 8.64 7.82 6.04 1.2 
2098 Sema3A_PAK_dependent_Axon_repulsion 7.47 0.62 4.37 2.37 4.57 4.95 4.02 1.33 4.91 4.37 8.34 3.73 2.49 9.12 2.77 2.3 5.27 1.71 
2099 Sema4D_induced_cell_migration_and_growth-cone_collapse 9.27 3.48 4.48 5.92 7.09 9.38 5.22 0.66 6.77 4.17 3.55 5.14 4.81 6.64 9.77 8.23 5.17 9.65 
2100 Sema4D_mediated_inhibition_of_cell_attachment_and_migration 2.72 9.12 1.06 1.89 4.47 7.71 1.77 4.41 8.84 5 6.52 6.42 3.94 3.02 2.89 4.46 2 6.61 
2101 Signal_transduction_by_L1 6.72 2.51 9.88 1.75 0.15 7 2.8 3.36 6.12 6.74 5.31 9.17 4.67 0.2 6.75 7.72 4.65 7.06 
2102 CDO_in_myogenesis 2.17 6.26 2.96 2.46 8.13 9.96 9.07 3.4 0.69 4.11 1.41 6.43 6.32 2.25 3.09 8.28 0.32 0.73 
2103 CHL1_interactions 3.41 7.15 9.19 1.34 1.31 2.37 3.36 1.3 5.03 6.41 6.02 1.55 8.94 4.65 9.45 9.21 5.51 4.35 
2104 CRMPs_in_Sema3A_signaling 8.21 4.02 8.6 6.9 9.43 5.85 8.75 6.51 3.37 9.33 8.69 5.81 4.13 1.34 0.38 2 0.97 0.94 
2105 DCC_mediated_attractive_signaling 1.43 2.33 9.45 3.89 4.97 9.41 0.69 5.09 4.75 9.73 4.69 3.27 6.53 7.6 7.71 8.54 1.33 3.19 
2106 ERK1_activation 8 8.98 0.02 0.53 2.17 4.96 1.04 6.77 0.51 7.92 1.47 9.93 1.81 2.3 7.2 0.32 6.05 8.38 
2107 ERK2_activation 9.04 5.11 6.37 5.78 3.98 2.91 3.27 1.98 2.03 9.18 0.71 7.82 3.19 8.73 3.52 1.02 4.59 8.41 
2108 ERK1_activation 4.9 9.93 0.37 0.77 5.63 6.22 8.28 1.1 3.87 1.6 7.41 3.27 7.96 6.05 5.33 5.12 6.41 2.42 
2109 ERK2_activation 9.84 7.42 2.14 6.37 1.53 7.09 4.41 9.87 5.14 0.24 7.76 1.63 2.31 6.48 9.15 5.7 8.94 4.6 
2110 Inactivation_of_Cdc42_and_Rac 4.91 1.84 8.25 9.04 7.07 0.99 5.2 3.05 8.54 2.66 6.16 0.47 2.66 6.77 3.61 2.04 5.23 6.6 
2111 Interaction_between_L1_and_Ankyrins 8.07 8.76 9.14 5.65 7.82 2.38 6.39 2.66 9.56 0.5 7.97 2.02 1.69 8.35 0.78 2.54 7.7 9.75 
2112 CHL1_interactions 6.78 3.27 8.71 4.04 3.48 6.14 2.01 0.93 4.7 4.28 3.92 2.77 0.37 0.35 8.92 2.68 2.97 9.8 
2113 Interaction_between_L1_and_Ankyrins 6.91 0 9.74 5.79 6.26 1.9 2.87 4.64 5.59 4.65 9.53 0.56 1.82 7.22 1.48 7.23 1.15 3.92 
2114 Neurofascin_interactions 0.05 4.23 2.24 8.02 5.27 3.33 9.11 3.55 5.4 4.42 4.18 6.76 2.47 2.97 3.12 2.89 4.35 1.82 
2115 NrCAM_interactions 8.91 9.25 5.45 5.34 8 8.71 4.46 0.3 3.99 2.57 8.11 2.33 8.44 9.9 4.81 6.14 9.72 9.65 
2116 Recycling_pathway_of_L1 7.89 3.69 0.2 6.19 4.4 8.49 5.83 9.97 4.26 1.06 2.22 8.7 4.48 9.08 2.13 7.5 0.44 1.15 
2117 Signal_transduction_by_L1 3.64 3.64 5.8 8.32 4.11 3.33 6.05 9.36 3.13 7.82 5.93 3.96 3.91 2.46 6.14 8.09 7.92 5.11 
2118 RAF_phosphorylates_MEK 0.74 6 1.72 3.03 3.48 9.05 4.29 3.06 5.25 0.35 1.77 0.34 5.66 8.15 6.9 0.49 5.39 5.66 
2119 CDO_in_myogenesis 3.31 5.74 5.45 6.72 5.88 5.35 3.88 1.19 2.39 4.86 2.12 7.55 0.35 2.63 4.73 7.91 8.57 3.05 
2120 ERK1_activation 3.01 7.16 9.81 4.11 4.08 2.93 7.91 5.52 7.46 3.06 7.23 5.18 9.72 3.21 6.22 7.8 7.28 4.17 
2121 ERK2_activation 4.67 3.46 3.06 4.25 7.01 9.33 5.67 4.49 5.97 3.63 3.66 7.35 6.61 1.23 8.83 9.33 4.3 0.25 
2122 NCAM1_interactions 7.71 3.92 1.11 2.57 9.17 5.56 1.44 3.86 3.82 8.63 3.34 6.22 2.56 7.47 9.51 7.98 7.16 5.6 
2123 RAF_activation 0.08 9.38 2.05 4.26 7.57 3.22 6.39 9.58 1.94 2.87 2.4 5.46 2.95 0.13 4.46 4.94 0.81 9.73 
2124 RAF_phosphorylates_MEK 3.37 6.7 1.35 0.62 0.42 9.45 4.73 1.8 0.83 5.35 0.8 8.04 6.81 5.98 8.18 7.98 2.72 0.53 
2125 NCAM1_interactions 8.37 9.08 1.1 6.69 2.54 6.58 5.95 0.77 8.34 2.63 9.59 2.06 3 1.63 9.65 8.14 6.16 9.77 
2126 Netrin_mediated_repulsion_signals 8.46 5.36 5.6 7.11 9.37 2.51 0.94 2.27 1.93 9.86 3.69 6.81 3.84 3 3.55 2.18 5.23 0.61 
2127 DCC_mediated_attractive_signaling 6.9 5.83 7.17 9.49 8.05 6.86 7.68 8.87 1.86 4.68 1.45 7.57 0.13 5.88 6.2 2.82 3.07 3.43 
2128 Netrin_mediated_repulsion_signals 8.57 9.68 0.4 2.6 4.05 9.23 5.58 9.3 5.39 7.34 1.04 0.68 3.16 5.4 7.74 7.4 9.17 8.82 
2129 Role_of_second_messengers_in_netrin-1_signaling 7.05 2.19 4.88 8.11 8.09 1.67 4.62 3.32 7.16 6.06 6.52 5.85 0.1 8.43 4.27 8.23 8.63 3.51 
2130 Neurofascin_interactions 1.64 2.91 8.65 9.93 9.79 2.19 3.79 8.33 8.59 1.96 5.94 7.53 0.51 4.28 3.01 0.53 4.32 0.01 
2131 NrCAM_interactions 8.26 6.45 1.15 7.37 6.22 7.68 3.88 7.55 0.85 3.87 0.79 5.5 8.52 9.71 2.46 7.21 1.22 2.63 
2132 Other_semaphorin_interactions 0.23 9.87 9.1 3.78 9.12 1 8.93 1.19 5.92 7.39 7.95 7.09 6.07 1.61 7.8 7.65 3.12 4.69 
2133 RAF_activation 1.31 3.7 9.74 6.26 8.35 5.61 2.54 7.19 1.88 6.17 1.24 2.93 5.85 2.36 0.72 3.34 9.99 3.58 
2134 RAF_phosphorylates_MEK 4.65 3.07 0 7.42 4.82 3.35 1.93 4.26 4.13 2.11 3.37 4.96 5.74 6.25 6.11 1.95 1.77 9.41 
2135 ERK1_activation 3.81 3.55 4.71 4.96 6.34 0.4 6.6 7.67 5.57 1.19 5.32 9.24 6.16 2.22 9.04 7.87 8.99 9.33 
2136 ERK2_activation 0.51 4.96 9.36 4.69 7.15 0.55 7.43 6.78 5 6.68 7.02 2.84 7.66 6.6 2.67 8.65 0.26 1.15 
2137 RAF_activation 3.81 7.85 1.84 8.87 7.68 6.89 8.94 4.85 7.67 9.05 0.76 2.59 3.9 1.08 0.99 4.06 5.04 8.94 
2138 RAF_phosphorylates_MEK 5.35 2.77 6.71 0.94 4.66 5.89 0.11 0.04 9 7.27 3.89 1.32 0.64 6.39 6.6 1.87 1.84 6.13 
2139 Recycling_pathway_of_L1 2.96 4.33 7.23 3.45 1.96 9.04 2.22 1.23 6.97 3.97 0.41 5.45 1.13 7.8 8.27 4.45 6.09 4 
2140 Regulation_of_Commissural_axon_pathfinding_by_Slit_and_Robo 1.61 2.86 8.83 9.8 4.35 3.02 2.27 0.67 7.35 4.99 9.04 3.03 0.75 1.22 5.73 7.12 8.29 1.29 
2141 Regulation_of_Signaling_by_NODAL 3.85 4.35 2.77 9.95 6.28 2.61 8.37 7.62 1.79 0 0.07 3.43 9.33 6.62 3.52 1.82 9.35 5.55 
2142 AKT-mediated_inactivation_of_FOXO1A 3.88 2.25 9.16 9.92 0.42 1.93 0.49 5.16 7.37 0.36 1.53 2.94 8.67 8.27 7.81 8.09 8.73 2.43 
2143 Regulation_of_gene_expression_in_early_pancreatic_precursor_cells 1.1 8.79 2.23 9.67 9.25 1.45 3.46 4.36 1.39 1.17 5.83 3.01 5.16 1.7 4.69 5.52 7.14 6.32 
2144 Regulation_of_gene_expression_in_endocrine-committed_(NEUROG3+)_progenitor_cells 7.58 2.8 3.03 4.67 6.74 4.28 4.75 5.86 5.73 8 8.71 0.59 8.02 3.79 1.92 7.61 7.84 1.37 
2145 Regulation_of_gene_expression_in_late_stage_(branching_morphogenesis)_pancreatic_bud_precursor_cells 2.4 3.68 8.84 4.02 8.42 3.44 9.42 0.35 1.81 7.52 3.2 3.23 4.59 5.89 2.05 2.24 0.74 2.84 
2146 AKT-mediated_inactivation_of_FOXO1A 6.23 1.23 5.62 6.36 9.24 1.69 1.12 2.4 5.53 6.67 2.74 1.31 8.79 1.53 8.2 6.12 2.85 4.43 
2147 Regulation_of_gene_expression_in_early_pancreatic_precursor_cells 0.11 8.61 3.66 3.04 2.89 0.22 5.09 0.26 1.12 6.39 3.18 4.81 0.41 1.9 7.11 0.87 0.95 6.7 
2148 Regulation_of_gene_expression_in_endocrine-committed_(NEUROG3+)_progenitor_cells 7.43 1.88 9.28 2.01 0.05 3.56 1.8 5.5 1.8 6.53 0.97 5.42 9.1 3.65 7.34 0.6 5.66 9.32 
2149 Regulation_of_gene_expression_in_late_stage_(branching_morphogenesis)_pancreatic_bud_precursor_cells 3.99 1.88 7.63 3.65 2.88 1.98 5.06 1.79 0.86 5.94 7.62 5.78 3.38 7.81 6.3 7.15 7.83 5.81 
2150 Role_of_Abl_in_Robo-Slit_signaling 2.7 8.36 0.14 5.22 9.04 4.15 9.35 3.82 2.78 8.02 9.87 2.78 7.99 0.39 8.08 0.17 0.42 4.93 
2151 Role_of_second_messengers_in_netrin-1_signaling 9.57 3.2 7.91 7.42 6.63 7.67 5.29 5.3 6.75 4.76 8.02 9.01 1.08 5.09 0.85 2.52 8.39 4.22 
2152 SEMA3A-Plexin_repulsion_signaling_by_inhibiting_Integrin_adhesion 3.46 0.46 7.73 3.79 1.41 9.92 3.3 9.55 4 8.09 0.84 7.66 1.62 0.08 9.01 7.04 9.76 4.26 
2153 Sema3A_PAK_dependent_Axon_repulsion 1.25 1.66 6.91 7.93 1.45 4.32 9.46 7.29 3.04 1.36 4.17 7.33 0 0.35 5.78 4.49 4.85 0.37 
2154 Sema4D_induced_cell_migration_and_growth-cone_collapse 1.07 6.97 2.1 9.38 2.49 5.62 5.31 0.18 9.4 0.31 0.97 9.88 1.7 3.2 8.63 1.1 6.24 2.7 
2155 Sema4D_mediated_inhibition_of_cell_attachment_and_migration 6.06 6.68 3.66 0.89 8.12 4.07 3.95 3.17 2.66 5.52 7.53 8.98 4.45 4.22 0.17 8.92 9.64 2.52 
2156 Sema4D_induced_cell_migration_and_growth-cone_collapse 7.7 6.83 4.2 0.78 5.83 8.27 1.05 1.49 5.67 8.78 5.43 8.72 8.65 2.4 5.68 1.42 1.42 8.6 
2157 Sema4D_mediated_inhibition_of_cell_attachment_and_migration 0.38 2.9 3.05 0.3 7.54 0.38 7.97 0.32 5.34 5.47 6.39 2.32 7.45 2.56 4.68 3.86 5.29 0.41 
2158 CRMPs_in_Sema3A_signaling 2.27 4.1 8.37 1.06 5.98 6.21 4.91 2.84 8.77 5.05 1.28 4.54 6.67 8.26 1.26 0.08 9.01 8.78 
2159 Other_semaphorin_interactions 9.39 5.01 7.21 2.51 1.36 5.27 6.67 3.59 3.58 0.23 3.9 7.21 1.36 7.96 7.05 2.46 0.93 4.19 
2160 SEMA3A-Plexin_repulsion_signaling_by_inhibiting_Integrin_adhesion 3.11 9.02 8.44 2.01 0.52 7.76 0.38 6.14 6.44 8.35 7.26 5.78 0.94 0.15 9.48 2.84 0.74 0.91 
2161 Sema3A_PAK_dependent_Axon_repulsion 6.02 7.28 4.23 5.92 9.66 4.96 3.6 3.34 2.58 9.51 0.08 0.14 7.92 5.22 2.99 6.71 7.06 9.68 
2162 Sema4D_induced_cell_migration_and_growth-cone_collapse 2.46 7.49 8.65 4.99 5.54 5.67 4.52 0.39 9.57 8.8 7.24 4.43 7.22 9.2 7.89 2.38 9.94 0.03 
2163 Sema4D_mediated_inhibition_of_cell_attachment_and_migration 8.48 2.6 8.19 7.07 6.47 9.77 5.92 0.74 2.07 0.21 1.61 9.46 6.85 4.88 9.4 1.04 6.03 1.67 
2164 Signal_transduction_by_L1 7.24 5.34 9.62 9.2 7.93 8.24 6.36 1.39 0.72 1.7 5.22 0.1 3.25 3.44 4.03 0.74 6.78 3.82 
2165 Regulation_of_Signaling_by_NODAL 5.58 7.62 3.05 3.05 7.3 9.32 8.81 3.42 5.88 6.9 8.45 2.01 8.26 5.46 2.58 8.48 1.1 0.77 
2166 Activation_of_Rac 5.3 1.85 8.68 9.4 8.44 4.09 6.63 9.48 5.9 3.51 1.52 5.72 0.01 0.41 9.85 0.6 6.92 5.01 
2167 Inactivation_of_Cdc42_and_Rac 6.41 1.44 9.16 0.74 8.01 9.89 8.34 6.16 4.63 7.4 8.04 2.21 2.56 0.85 3.29 9.78 4.92 8.21 
2168 Regulation_of_Commissural_axon_pathfinding_by_Slit_and_Robo 0.71 7.34 5.08 7.47 1.28 4.41 9.67 7.91 5.57 8.91 6.54 3.4 2.24 4.37 0.36 1.84 1.04 4.24 
2169 Role_of_Abl_in_Robo-Slit_signaling 6.02 3.62 9.37 3.74 0.98 4.91 8.59 6.62 4.98 0.8 9.73 7.39 6.99 3.99 5.6 8.39 1.63 8.95 
2170 Transcriptional_Regulation_of_White_Adipocyte_Differentiation 4.32 7.8 6.08 4.13 4.97 5.07 0.3 8.69 3.02 3.37 2.02 5.26 7.6 5.03 3.12 8.08 8.84 2.49 
2171 ISG15_antiviral_mechanism 6.66 4.18 6.94 7.77 9.7 2.23 7.1 1.48 0.35 4.65 2 7.89 9.3 1.38 4.64 4.49 1.86 2.94 
2172 ERK1_activation 7.49 0.67 8.49 9.33 0.21 8.73 2.45 7.43 5.77 7.91 5.23 8.16 0.99 4.66 4.57 3.11 1.25 7.75 
2173 ERK2_activation 7.06 9.3 4.84 6.37 6.98 9.16 1.89 9.45 8.51 2.42 5.75 0.49 7.03 1.62 7.85 0.42 8.14 0.76 
2174 ERK1_activation 6.37 2.37 6.19 8.21 4.93 8.32 2.58 6.66 1.65 1.62 6.45 1.39 2.81 6.97 0.8 6.4 6.32 8.55 
2175 ERK2_activation 4.73 0.56 5.05 2.65 2.36 7.67 3.49 0.9 9.73 1.51 3.9 5.04 1.35 4.03 3.34 7.66 2.05 9.2 
2176 Growth_hormone_receptor_signaling 0.59 2.34 8.15 4.29 8.26 9.91 5.27 4.37 3.69 6.45 9.01 8.18 4.17 3.6 2.64 1.32 2.04 0.79 
2177 ISG15_antiviral_mechanism 3.65 7.62 9.95 3.01 2.37 2.72 6.59 8.93 9.86 5.06 9.93 5.46 6.98 0.72 3 7.41 9.92 4.34 
2178 ISG15_antiviral_mechanism 8.26 2.91 9.83 4.54 3.73 0.93 7.12 9.51 3.35 2.33 3.26 7.28 1.16 2.41 7.92 0.66 1.84 1.63 
2179 Regulation_of_IFNA_signaling 0.87 2.43 0.01 9.45 8.16 5.36 6.53 3.46 4.52 9.47 3.91 3.93 5.58 0.32 9.98 3.8 5.49 8.45 
2180 Regulation_of_IFNG_signaling 3.58 3.44 8.67 3.2 5.07 2.34 5.73 6.06 6.91 9.77 2.68 3.12 5.16 0.67 2.34 1.2 8.3 9.97 
2181 Regulation_of_IFNA_signaling 0.41 5.98 0.5 9.19 4.01 3.96 7.48 0.62 0.17 6 1.72 2.6 3.44 6.03 3.95 7.65 3.8 2.29 
2182 Regulation_of_IFNG_signaling 5.16 3.4 2.67 6.99 0.81 1.1 8.16 6.2 9.84 6.2 2.08 1.37 1.81 2.15 3.49 6.59 8.49 2.31 
2183 Interleukin_receptor_SHC_signaling 1.39 9.05 0.99 7.57 9.13 5.37 5.75 9.13 3.78 6.63 4.04 5.58 5.4 7.01 3.39 9.73 0.25 0.5 
2184 Interleukin-1_processing 3.56 5.28 1.97 4.37 8.11 9.52 7.27 3.95 6.27 3.68 3.96 4.08 6.41 7 3.03 8.35 4.85 7.8 
2185 Interleukin-1_signaling 9.89 2.68 8.92 5.41 7.77 6.02 6.18 2.9 9.07 0.88 1.82 5.43 5.83 1.05 2.94 9.5 9.07 3.96 
2186 ERK1_activation 3.81 7.98 0.96 7.13 9.86 0.57 3.41 5.56 9.46 4.2 4.96 4.89 0.25 2.68 7.27 2.41 4.37 7.91 
2187 ERK2_activation 7.9 4.04 2.76 3.61 4.73 7.68 8.79 6.72 3.33 7.2 2.86 6.98 9.46 9.92 0.06 7.18 9.71 2.4 
2188 Interleukin_receptor_SHC_signaling 2.25 9.44 0.81 6.08 2.13 7.77 3.65 0.43 8.47 9.58 6.45 9.27 7.53 7.59 2.49 6.92 6.98 4.67 
2189 RAF_activation 0.38 6.02 4.93 8.98 7.14 9.28 2.69 9.23 0.49 2.1 1.59 6.48 8.96 5.39 7.84 2.95 2.48 0.92 
2190 RAF_phosphorylates_MEK 0.49 2.97 4.45 3.15 9.28 4.16 6.96 0.55 3.13 7.57 6.41 9.62 2.84 6.72 6.01 2.49 4.81 2.76 
2191 Interleukin_receptor_SHC_signaling 5.91 3.29 9.53 6.09 6.9 2.9 7.75 2.76 5.34 3.44 9.52 9.72 9.78 7.91 2.94 7.26 6.25 5.27 
2192 Regulation_of_signaling_by_CBL 0.19 0.44 1.04 9.12 9.8 6.17 8.08 6.56 2.11 6.4 6.67 3.86 9.94 5.42 1.81 7.7 9.01 5.72 
2193 Interleukin-6_signaling 0.75 2.63 9.51 9.7 9.03 0.31 5.6 6.73 3.75 5.13 1.81 3.27 2.18 3.11 1.84 8.4 3.64 2.75 
2194 Interleukin-7_signaling 3.14 7.79 9.4 0.83 1.98 3.31 4.76 4.88 1.12 6.47 8.17 4.35 4.46 2.29 4.53 1.85 7.1 6.18 
2195 RAF_phosphorylates_MEK 9.05 0.81 5.2 3.88 3.5 8.59 1.01 5.08 5.81 9.4 0.32 6.38 4.05 4.79 5.71 9.71 1.18 9.66 
2196 Prolactin_receptor_signaling 0.46 0.73 7.72 5.13 8.44 7.61 4.22 1.5 2.38 5.94 7.35 1.37 7.72 4.84 0.29 4.54 9.84 0.15 
2197 RAF_activation 7.12 6.85 4.46 8.93 9.65 0.93 2.5 3.33 4.28 3.49 1.68 3.69 5.42 8.95 0.97 0.27 2.67 2.13 
2198 RAF_phosphorylates_MEK 3.56 4.99 3.39 6.8 4.68 2.12 6.43 2.23 0.17 1.2 6.51 6.77 7.21 9.77 8.45 4.07 6.96 6.26 
2199 ERK1_activation 2.72 5.56 8.38 4.21 9.03 7.33 2.16 8.3 7.64 1.74 2.41 6.47 9.44 5.98 0.51 6.93 7.27 4.36 
2200 ERK2_activation 4.08 7.64 0.95 0.34 0.22 7.59 0.34 2.23 0.43 0.66 3.33 3.91 1 7.63 2.24 5.9 0.36 7.66 
2201 RAF_activation 7.34 0.38 9.88 1.92 4.55 6.76 4.46 2.94 5.25 0.01 9.5 3.92 4.03 1.6 8.75 9.92 2.85 2.59 
2202 RAF_phosphorylates_MEK 5.22 0.79 2.6 9.71 0.36 1.38 2.64 3.36 7.61 8.08 4.27 0.29 4.69 7.6 0.99 1.6 2.18 5.12 
2203 Regulation_of_IFNA_signaling 1.76 9.85 2.22 6.25 6.96 7.12 5.43 6.26 7.67 8.44 4.6 0.09 9.07 5.38 9.49 9.77 8.31 9.06 
2204 Regulation_of_IFNG_signaling 6.38 4.17 6.93 9.6 0.16 7.85 8.42 4.17 7.68 1.63 4.45 7.88 2.68 0.63 3.04 7.88 6.27 3.58 
2205 Regulation_of_signaling_by_CBL 1.86 5.79 4.77 3.4 1.07 2.81 6.03 2.24 0.9 0.69 4.32 1.02 0.68 1.88 0.24 4.23 7.18 2.4 
2206 ERK1_activation 3.6 8.63 0.84 6.34 6.46 3.35 6.51 8.66 4.98 0.27 4.04 9.5 7.97 1.19 1.54 4.74 0.96 4.62 
2207 ERK2_activation 0.63 7.43 5.21 6.44 0.01 0.79 7.22 2.44 1.79 3.84 7.54 2.76 6.33 1.75 2.17 9.6 3.55 5.02 
2208 Interleukin_receptor_SHC_signaling 8.22 9.32 8.7 8.97 1.22 8.78 0.95 7.42 8.74 2.91 0.34 5.24 6.73 1.37 9.3 6.05 7.41 8.76 
2209 Interleukin-1_processing 7.78 8.14 5.71 7.17 0.27 7.02 6.29 4.64 2.39 5.57 9.39 4.45 7.41 2.56 6.32 9.78 5.26 3.38 
2210 Interleukin-1_signaling 3.58 4.63 6.48 3.09 8.52 6.25 5.28 4.17 6.39 7.23 8.21 6.52 8.71 5.94 5.95 0.11 5.88 7.44 
2211 Interleukin-6_signaling 5.26 2.23 2.96 7.71 6.07 6.68 5.75 9.03 1.48 4.62 1.88 3.29 2.42 5.09 2.77 6.85 6.86 4.34 
2212 Interleukin-7_signaling 4.99 2.43 7.73 3.3 1.22 2.61 7.37 3.07 5.28 0.69 0.61 7.33 3.8 5.33 2.42 2.03 4.12 8.14 
2213 RAF_activation 2.43 5.77 5.64 1.32 4.37 1.69 3.79 9.06 1.48 6.81 9.52 0.58 9.54 0.78 4.29 5.6 9.45 2.31 
2214 RAF_phosphorylates_MEK 1.79 3.12 5.63 4.03 4.07 4.05 8.24 7.65 9.47 2.75 0.96 3.05 2.47 3.43 6.89 1.51 8.1 6.14 
2215 Regulation_of_signaling_by_CBL 9.87 9.92 7.08 9.95 1.06 6.86 8.46 1.49 3.16 8.41 2.68 8.24 1.88 3.43 0.25 8.11 0.06 9.47 
2216 AKT_phosphorylates_targets_in_the_cytosol 5.16 3.06 9.64 2.18 2.18 8.44 6.64 0.66 8.51 6.4 4.59 7.4 1.46 5.79 1.33 0.27 4.55 9.49 
2217 AKT_phosphorylates_targets_in_the_nucleus 4.85 3.81 3.51 6.7 7.56 7.3 7.19 8.83 1.5 9.15 8.76 7.49 9.61 2.84 4.07 0.04 3.68 6.93 
2218 Activation_of_NF-kappaB_in_B_Cells 8.15 3.27 3.38 1.97 2.8 3.51 3.35 2.56 3.3 4.77 2.58 9.4 6.77 9.53 3.89 1.1 3.24 0.85 
2219 Activation_of_RAS_in_B_Cells 3.78 6.26 2.63 1.85 2.14 7.54 2.69 4.96 6.03 9.34 9.45 4.03 8.94 8.13 2.93 0.28 1.65 5.15 
2220 Antigen_Activates_B_Cell_Receptor_Leading_to_Generation_of_Second_Messengers 9.72 1.9 0.69 8.68 2.85 8.99 4.03 1.05 2.77 5.58 4.26 5.44 4.75 7.7 6.37 5.84 2.26 2.42 
2221 Antigen_Presentation:_Folding,_assembly_and_peptide_loading_of_class_I_MHC 5.01 3.89 5.07 7.07 3.01 3.6 5.37 9.35 3.64 2.27 5.93 6.99 0.1 5.48 3.77 0.03 1.51 7.68 
2222 Cross-presentation_of_particulate_exogenous_antigens_(phagosomes) 3.92 9.57 7.29 0.02 1.67 6.11 9.4 0.76 0.55 6.21 1.1 3.01 7.14 1.66 6.35 9.07 2.86 4.14 
2223 Cross-presentation_of_soluble_exogenous_antigens_(endosomes) 0.07 3.63 9.04 4 8.75 3.75 8.93 0.76 9.3 1.59 0.23 1.68 3.39 4.03 6.61 9.79 9.77 2.88 
2224 ER-Phagosome_pathway 6.44 3.3 2.42 6.57 6.29 2.14 2.61 3.44 9.11 9.01 7.44 4.21 9.99 9.37 0.25 1.5 3.08 1.26 
2225 Endosomal/Vacuolar_pathway 2.59 9.52 5.28 3.43 0.27 1.57 4.44 4.28 5.95 7.82 3.31 2.05 0.14 2.58 7.07 2.26 6.85 4.96 
2226 Antigen_processing:_Ubiquitination_&_Proteasome_degradation 7.67 3.41 1.38 4.58 2.4 4.56 1.56 2.99 1.96 5.08 3.14 8.74 3.27 1.13 8.51 6.79 7.62 9.01 
2227 AKT_phosphorylates_targets_in_the_cytosol 0.61 4.53 0.26 5.91 1.49 4 5.71 6.27 1.26 6.18 7.4 9.47 0.53 8.25 9.64 2.43 4.45 7.94 
2228 AKT_phosphorylates_targets_in_the_nucleus 2.77 9.73 2.38 9.32 1.28 1.11 4.2 0.22 6.17 8.9 4.21 0.67 0.2 5.96 9.14 6.72 4.64 0.64 
2229 Activation_of_NF-kappaB_in_B_Cells 9.7 5.46 9.4 4.53 4.19 9.41 1.35 4.36 9.38 6.67 1.08 3.74 4.69 1.45 3.02 1.26 5.6 5.05 
2230 Activation_of_RAS_in_B_Cells 9.68 6.42 0.05 0.27 8.41 8.15 3.11 8.85 9.57 4.93 2.8 0.05 2.31 8.57 5.29 5.32 4.62 8.03 
2231 Antigen_Activates_B_Cell_Receptor_Leading_to_Generation_of_Second_Messengers 3.47 9.81 1.33 0.07 3.64 5.34 7.84 9.43 6.2 1.75 7.48 7.21 7.28 4.57 0.54 9.81 3.9 9.61 
2232 Negative_regulation_of_the_PI3K/AKT_network 7.43 3.86 0.66 1.56 8.54 8.73 0.48 1.25 3.42 0.41 5 6.93 0.89 3.17 7.91 3.62 9.81 2.67 
2233 CD28_dependent_PI3K/Akt_signaling 3.94 4.99 0.39 3.03 1.92 7.23 5.18 0.96 7.83 2.53 1.85 7.6 7.11 7.67 3.79 8.57 9.66 2.33 
2234 CD28_dependent_Vav1_pathway 4.53 9.98 6.91 8.07 6.61 5.2 3.61 3.89 1.66 5.47 4.46 6.52 0.08 9.6 0.61 8.9 7.77 5.56 
2235 CD28_dependent_PI3K/Akt_signaling 6.02 2.7 3.64 2.57 5.72 3.8 5.53 9.87 9.91 3.33 5.81 1.58 7.94 4.2 8.92 0.46 2.62 4.68 
2236 CD28_dependent_Vav1_pathway 8.28 7.99 7.93 4.7 5 7.98 6.66 7.53 0.85 3.59 1.34 0.58 6.71 2.56 0.81 7.03 3.51 2.06 
2237 CTLA4_inhibitory_signaling 3.77 1.19 8.15 9.59 1.44 6.53 0.3 9.76 0.72 1.16 3.06 1.75 4.76 7 0.28 9.8 4.44 8.77 
2238 Antigen_Presentation:_Folding,_assembly_and_peptide_loading_of_class_I_MHC 5.95 0.52 3.85 5.16 3.96 6.38 6.5 3.8 4.8 9.38 0.55 5.51 5.5 8.45 5.16 2.37 7.86 8.82 
2239 Antigen_processing:_Ubiquitination_&_Proteasome_degradation 8.96 1.24 4.14 9.02 8.22 4.41 6.88 5.31 1.63 9.66 2.92 4.64 7.7 5.09 5.8 2.78 6.61 1.95 
2240 Cross-presentation_of_particulate_exogenous_antigens_(phagosomes) 4.37 5.02 8.52 0.24 7.32 0.49 7.62 2.14 6.49 1.44 5.1 8.31 2.1 9.5 4 0.93 2.67 2.9 
2241 Cross-presentation_of_soluble_exogenous_antigens_(endosomes) 8.05 3.08 7.25 1.69 7.41 1.39 4.29 0.19 6.58 5.87 5.82 1.25 9.71 3.82 2.49 2.55 2.51 8.77 
2242 ER-Phagosome_pathway 5.8 5.59 3.32 8.03 3.44 3.66 9.19 9.49 2.96 5.69 3.92 4.7 1.35 3.95 5.17 6.53 3.37 8.97 
2243 Endosomal/Vacuolar_pathway 2.8 2.66 0.21 2.46 0.38 0.58 5.85 9.91 0.78 3.83 4.15 8.02 0.94 1.55 1.03 3.47 4.74 5.34 
2244 CD28_dependent_PI3K/Akt_signaling 4.12 4.47 5.03 7.34 1.07 8.29 4.96 6.47 4.09 5.37 1.9 2.04 0.69 7.39 2.05 2.68 2.7 8.07 
2245 CD28_dependent_Vav1_pathway 0.36 1.92 0.38 1.9 1.65 3.71 3.67 8.77 3.66 3.31 8.45 0.45 3.27 2.64 1.72 0.83 5.26 2.83 
2246 CTLA4_inhibitory_signaling 7.07 5.68 9.19 3.53 0.26 1 3.27 4.07 3.92 6.31 0.59 9.36 3.84 7.36 0.53 9.81 8.52 5.53 
2247 PD-1_signaling 7.67 1.65 7.78 8.18 5.55 6.69 5.1 1.97 8.42 0.25 4.89 3.38 7.55 7.87 3.21 3.08 7.58 4.91 
2248 Cross-presentation_of_particulate_exogenous_antigens_(phagosomes) 6.97 0.68 4.02 0.41 0.1 2.61 9.72 7.75 6.49 3.59 4.57 7.46 3.31 0.56 5.41 7.54 1.67 4.87 
2249 Cross-presentation_of_soluble_exogenous_antigens_(endosomes) 8.85 3.84 7.31 0.99 6.26 7.2 5.38 1.08 6.95 1.59 3.32 7.84 2.3 1.43 9.82 0.25 6.21 1.36 
2250 AKT_phosphorylates_targets_in_the_cytosol 4.83 7.65 7.26 6.25 8.99 9.1 8.87 5.27 1.72 9.62 2.64 2.37 3.66 6.54 3.15 3.25 0.67 4.95 
2251 AKT_phosphorylates_targets_in_the_nucleus 1.05 1.98 3.43 1.21 5.86 1.03 5.88 4.84 6.68 9.54 4.49 6.19 4.65 7.48 1.4 4.95 9.94 2.69 
2252 Activation_of_NF-kappaB_in_B_Cells 5.09 6.12 1.85 6.91 8.38 9.13 0.61 4.2 9.84 1.5 0.79 7.55 7.75 3.45 8.93 6.42 4 9.38 
2253 Activation_of_RAS_in_B_Cells 1.72 5.78 3.3 2.72 5.31 0.55 5.15 8.66 6.14 1.91 3.96 2.51 7.28 1.31 9.36 3.6 9.97 0.95 
2254 Negative_regulation_of_the_PI3K/AKT_network 4.17 8.36 1.83 2.15 7.08 1.02 0.71 8.03 2.69 0.57 6.54 1.81 8.22 4.85 9.33 8.72 2.6 3 
2255 Downstream_TCR_signaling 8.58 4.43 1.39 0.79 7.87 5.66 9 5.85 6.08 7.41 4.11 5.8 4.04 8.5 9.25 5.71 5.32 1.75 
2256 ER-Phagosome_pathway 2.34 3.12 3 3.17 8.96 2.56 7.1 8.15 2.64 9.87 0.84 2.26 4.77 4 3.44 9.93 0.57 1.68 
2257 Endosomal/Vacuolar_pathway 6.74 0.04 9.94 1.93 8.26 1.04 0.14 0.63 9.9 3.97 3.07 9.42 0.62 0.28 6.42 5.71 1.34 1.68 
2258 Generation_of_second_messenger_molecules 6.93 7.8 9.64 4.87 6.94 5.01 5.78 2.08 5.38 8.52 0.38 7.51 0.86 4.15 9.29 8.86 6.48 2.92 
2259 Immunoregulatory_interactions_between_a_Lymphoid_and_a_non-Lymphoid_cell 5.33 0.31 8.34 4.33 8.43 6.64 7.38 4.53 9.15 1.41 4.85 8.07 0.52 0.2 6.3 6.86 7.43 4.77 
2260 MHC_class_II_antigen_presentation 3.21 2.17 6.39 8.73 1.65 4.56 1.08 1.73 3.53 6.26 2.49 3.91 2.94 7.76 9.3 5.76 2.7 3.78 
2261 Negative_regulation_of_the_PI3K/AKT_network 5.54 8.34 2.51 1.29 2.84 2.91 1.62 5.48 2 5.63 6.02 4.79 4.24 2.42 5.04 8.57 4.59 8.38 
2262 PD-1_signaling 7.73 3.88 8.42 5.88 5.3 9.79 5.3 4.85 0.58 7.59 8.73 1.31 8.02 9.54 9.16 4.19 8.76 1.36 
2263 AKT_phosphorylates_targets_in_the_cytosol 7.84 3.57 3.86 6.18 9.92 5.06 4.33 1.09 8.07 4.14 6.11 2.75 7.34 4.38 9.38 5.77 1.12 7.32 
2264 AKT_phosphorylates_targets_in_the_nucleus 8.34 2.48 9.4 0.88 4.62 5.67 8.02 4.97 4.54 5.13 5.3 6.52 5.03 3.95 8.49 9.32 4.12 4.41 
2265 Negative_regulation_of_the_PI3K/AKT_network 5.81 0.52 1.08 0.5 2.76 9.61 7.87 6.25 1.28 5.7 7.01 7.01 2.13 7.48 0.24 0.43 3.82 9.85 
2266 Phosphorylation_of_CD3_and_TCR_zeta_chains 7.22 9.78 8.13 1.14 7.95 5.43 6.57 3.25 2.52 2.75 3.33 7.12 2.72 8.1 6.23 4.94 0.74 1.48 
2267 Rap1_signalling 3.34 3.29 0.23 6.58 5.76 9.22 7.25 8.17 2.58 6.53 4.76 4.99 4.97 9.12 7.48 7.51 1.21 3.65 
2268 Downstream_TCR_signaling 7.04 0.61 3.72 4.85 4.02 3.58 6.78 5.68 6.14 0.43 9.74 3.15 9.39 5.41 1.43 5.37 8.55 7.25 
2269 Generation_of_second_messenger_molecules 7.51 6.69 9.06 2.7 7.84 6.38 5.75 4.23 8.93 1.64 6.14 0.93 9.91 9.7 3.73 9.85 9.46 4.37 
2270 Phosphorylation_of_CD3_and_TCR_zeta_chains 6.97 4.46 9.05 4.76 3.27 8.29 2.97 0.89 0.07 2.76 9.09 5.43 1.32 0.12 0.61 0.11 5.33 3.14 
2271 Translocation_of_ZAP-70_to_Immunological_synapse 3.72 5.36 4.8 9.21 9.86 0.62 5.51 4.3 8.8 3.63 5.39 7.64 1.54 0.45 7.37 7.85 2.33 1.26 
2272 Translocation_of_ZAP-70_to_Immunological_synapse 1.46 4.57 6.9 8.8 2.07 3.85 2.65 7.15 7.09 9.98 6.5 9.42 5.89 1.91 2.65 5.86 9.67 1.6 
2273 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 6.24 4.13 0.24 6.33 5.93 3.1 2.49 2.15 0.45 4.28 8.9 8.41 6.93 3.07 5.83 5.09 2.87 5.45 
2274 AMPK_inhibits_chREBP_transcriptional_activation_activity 2.34 3.48 1.95 7.58 8.26 0.67 1.65 7.07 5.22 3.56 5.9 9.01 5.88 6.76 1.59 3.54 8.88 7.9 
2275 Abacavir_metabolism 5.25 5.23 3.27 4.48 8.67 4.98 3.81 5.24 4.36 2.22 2.31 7.07 1.93 4.28 4.09 8.61 0.34 6.24 
2276 Abacavir_transmembrane_transport 1.95 1.31 9.92 3.49 6.37 9.44 2.9 7.69 2.08 8.37 4.46 5.08 6.95 9.73 9.55 3.55 2.14 4.81 
2277 Abacavir_metabolism 3.72 8.88 8.98 7.32 2.71 7.08 9.93 8.33 4.79 2 9.79 8.36 2.4 2.96 1.45 4.7 0.17 6.98 
2278 Abacavir_transmembrane_transport 4.69 0.77 9.66 3.49 4.66 0.75 8.46 7.56 1.57 1.66 0.5 0.29 5.89 8.56 8.16 5.58 0.55 5.76 
2279 Acetylation 0.55 5.52 7.81 9.69 0.27 2.54 8.88 6.33 9.23 0.07 5.47 4.28 3.29 7.7 2.5 0.9 3.38 9.78 
2280 Activation_of_Gene_Expression_by_SREBP_(SREBF) 8.51 1.91 6.87 3.06 6.83 1.05 5.63 1.78 9.8 7.19 4.22 4.91 1.66 8.48 8.33 1.04 5.88 0.98 
2281 Acyl_chain_remodeling_of_CL 3.79 5.41 0.08 5.96 0.12 0.92 2.82 7.18 8.24 9.82 0.68 7.67 9.42 6.31 3.94 2.79 0.33 0.85 
2282 Acyl_chain_remodeling_of_DAG_and_TAG 6.08 7.42 1.34 3.78 4.6 8.13 4.55 3.92 1.66 3.24 4.72 1.96 2.53 7.31 8.89 2.7 3.72 7.49 
2283 Acyl_chain_remodelling_of_PC 3.23 5.28 8.44 3.46 5.98 1.66 2.44 3.4 7.37 1.57 1.35 5.72 2.19 3.5 1.97 9.42 7.55 3.08 
2284 Acyl_chain_remodelling_of_PE 6.44 7.14 3.79 2.92 9.92 4.6 9.55 9.97 0.88 5.18 1.07 4.41 2.43 8.68 7.91 4.67 5.07 9.21 
2285 Acyl_chain_remodelling_of_PG 4.82 4.81 5.61 5.61 0.37 3.47 4.98 3.66 3.19 3.08 6.41 0.87 5.37 5.21 6.92 0.61 3.94 7.12 
2286 Acyl_chain_remodelling_of_PI 2.03 2.32 9.21 6.19 0.22 1.7 0.89 5.41 5.1 6.42 4.74 9.32 0.87 4.2 5.81 1.11 8.92 5.58 
2287 Acyl_chain_remodelling_of_PS 5.04 0.98 3.8 2.54 3.71 2.64 8.28 4.74 4.82 0.48 6.13 0.96 9.72 7.31 8.23 5.28 3.63 0.45 
2288 Agmatine_biosynthesis 7.57 6.95 1.65 6.18 7.55 7.41 7.78 1.24 4.78 1.13 9.67 7.3 1.08 7.47 9.23 2.5 0.6 7.3 
2289 Alpha-oxidation_of_phytanate 9.2 2.41 0.38 1.52 9.4 4.9 4.21 4.26 3.2 1.5 8.04 4.52 0.89 6.68 0.8 0.05 0.93 9.78 
2290 Monoamines_are_oxidized_to_aldehydes_by_MAOA_and_MAOB,_producing_NH3_and_H2O2 2.6 8.23 0 3.46 1.22 8.74 2.16 3.35 0.09 4.56 9.66 7.46 8.26 5.88 0.14 8.24 2.48 6.15 
2291 Polyamines_are_oxidized_to_amines,_aldehydes_and_H2O2_by_PAOs 8.48 1.59 2.14 1.88 3.84 8.65 4.91 0.93 0.99 5.19 3.16 0.76 4.43 9.46 6.97 4.54 7.88 6.14 
2292 Catecholamine_biosynthesis 7.71 1.73 6.4 8.81 0.19 9.98 6.56 7.06 7.43 4.51 4.37 8.53 6.65 0.41 3.34 7.02 4 6.52 
2293 Regulation_of_thyroid_hormone_activity 8.42 7.23 4.59 9.85 2.08 0.39 5.71 1.8 2.13 8.77 9.68 7.24 1.42 2.82 1.83 0.12 0.55 4.14 
2294 Serotonin_and_melatonin_biosynthesis 5.63 3.63 1.39 8.92 2.58 5.42 7.08 4.23 5.85 3.56 5.73 7.11 9.3 3.87 1.11 9.01 9.08 3.45 
2295 Conjugation_of_benzoate_with_glycine 1.21 0.76 0.28 7.25 4.44 1.44 1.39 6.31 4.85 6.44 5.04 0.62 2.44 4.7 6.88 2.96 9.09 7.01 
2296 Conjugation_of_phenylacetate_with_glutamine 8.27 9.19 8.52 1.9 3.04 1.7 3.99 4.19 5.32 3.29 8.79 2.94 0.39 9.1 6.63 5.81 9.51 1.84 
2297 Conjugation_of_salicylate_with_glycine 1.43 1.5 6.66 3.93 2.91 6.36 1.17 2.9 2.64 8.42 9.06 9.9 3.51 7.12 4.5 2.37 8.62 0.68 
2298 Agmatine_biosynthesis 5.11 0.74 9.94 6.98 7.82 7.1 8.01 1.27 9.07 0.94 7.76 2.18 6.13 6.27 0.56 0.85 4.67 9.77 
2299 Branched-chain_amino_acid_catabolism 4.54 2.99 2.55 9.62 9.07 6.5 8.9 0.83 2.01 3.7 4.4 2.16 9.99 2.22 5.9 1.08 8.95 8.27 
2300 Carnitine_synthesis 5.69 6.67 0.38 1.11 8 7.63 9.88 9.89 3.65 4.23 4.29 8.61 1.6 4.95 6.87 3.85 1.57 2.45 
2301 Catecholamine_biosynthesis 1.65 9.65 0.07 4.33 0.83 7.66 1.88 1.75 2.66 1.51 8.51 2.95 0.62 7.27 0.2 0.94 4.87 7.51 
2302 Creatine_metabolism 1.67 7.63 4.85 6.03 1.03 8.45 0.15 4.88 5.2 3.47 3.58 7.49 6.79 8.35 8.37 1.88 5.53 1.11 
2303 Cysteine_formation_from_homocysteine 9.72 9.3 8.63 5 6.3 3.01 3.04 3.41 5.03 9.58 8.79 0.25 5.46 8.07 3.83 3.92 8.01 1.11 
2304 Glyoxylate_metabolism 8.04 9.23 5.34 9.23 4.84 0.77 1.86 4.23 1.5 5.64 6.93 9.74 2.17 4.04 9.65 2.3 7.12 7.11 
2305 Histidine_catabolism 5.62 6.8 3.48 1.65 8.81 2.55 6.67 5.54 8.15 0.62 7.52 9.29 5.94 5.02 4.51 8.27 2.1 2.24 
2306 Interconversion_of_polyamines 4.51 9.81 0.13 3.13 0.48 3.28 6.99 2.36 6.86 0.5 2.79 5.16 7.59 0.86 8.07 0.89 0.8 9.03 
2307 Lysine_catabolism 9.82 2.26 9.83 6.11 9.36 8.61 2.75 5.66 6.38 4.11 8.76 5.56 7.71 6.31 9.81 0.35 7.97 2.64 
2308 Methionine_salvage_pathway 3.27 8.55 8.64 2.13 5.04 0 7.11 4.33 1.08 8.1 3.09 0.48 2.9 6.76 1.72 8.88 2.03 4.91 
2309 Phenylalanine_and_tyrosine_catabolism 2.84 2.67 1.1 2.47 0.61 5.72 6.88 1.73 9.12 0.16 5.62 7.35 6.19 4.63 5.55 7.06 9.32 8.66 
2310 Proline_catabolism 4.47 6.54 2.56 3.44 6.4 1.31 5.16 1.72 9.33 5.14 4.76 4.33 0.16 5.53 9.7 6.73 3.48 1.32 
2311 Regulation_of_ornithine_decarboxylase_(ODC) 1.13 2.01 5.74 1.12 8.34 6.65 3.79 1.85 1.43 0.36 5.39 2.71 3.82 1.79 4.52 1.64 1.85 0.14 
2312 Regulation_of_thyroid_hormone_activity 0.82 1.29 1.48 7.97 8.86 9.7 2.7 6.2 1.89 2.23 0.75 4.22 5.38 0.61 9.29 0.83 7.66 1 
2313 Serine_biosynthesis 2.41 7.33 7.75 3.13 4.57 7.51 4.71 3.11 4.32 6.95 3.82 5.94 9.61 3.18 1.71 9.49 8.92 5.17 
2314 Serotonin_and_melatonin_biosynthesis 4.95 7.4 0.49 4.58 4.98 2.92 9.51 7.23 6.26 0.9 9.96 7.14 0.41 4.65 0.37 3.22 7.9 1.92 
2315 Sulfide_oxidation_to_sulfate 2.32 2.49 0.15 6.51 8 4.47 7.98 7.6 6.33 3.02 7.21 8.69 6.37 0.18 4.95 8.09 6.63 2.9 
2316 Tryptophan_catabolism 5.67 3.84 6.85 9.67 2.51 2.59 9.23 9.25 4.85 9.03 9.34 0.97 3.93 1.08 4.93 1.14 2.2 9.45 
2317 Urea_cycle 1.75 2.58 6.51 1.58 8.33 6.54 0.94 4.67 8.47 7.08 5.5 3.03 0.78 6.37 7.97 1.87 3.35 6.43 
2318 Serine_biosynthesis 2.14 8.24 4.38 0.29 7.33 4.06 8.43 7.45 7.11 3.35 9.21 8.01 3.73 9.15 5.17 7.45 1.25 7.33 
2319 Androgen_biosynthesis 6.17 4.71 7.3 9.17 1.86 0.2 7.89 3.36 1.51 1.22 8.99 7.57 9.95 9.59 7.77 1.85 6.21 1.37 
2320 Synthesis_of_(16-20)-hydroxyeicosatetraenoic_acids_(HETE) 2.62 5.66 6.45 9.78 5.68 5.91 7.77 6.39 8.42 1.83 2.9 4.75 7.96 7.15 3.93 4.89 8.43 2.29 
2321 Synthesis_of_12-eicosatetraenoic_acid_derivatives 2.86 1.77 4.99 2.34 0.9 0.82 6.66 2.14 7.3 6.82 3.66 7.99 4.39 8.42 7.94 8.07 0.28 7.66 
2322 Synthesis_of_15-eicosatetraenoic_acid_derivatives 4.85 0.46 2.16 6.67 3.08 9.03 6.21 6.49 4.01 9.45 9.2 0.83 7.31 2.41 8.18 4.28 1.28 5.43 
2323 Synthesis_of_5-eicosatetraenoic_acids 2.22 7.25 6.65 2.78 5.72 8.37 3.33 2.64 2.13 8.4 6.64 1.53 8.8 8.67 1.41 8.5 7.41 2.62 
2324 Synthesis_of_Hepoxilins_(HX)_and_Trioxilins_(TrX) 9.94 8.26 9.84 8.82 4.43 5.52 0.79 0.38 9.29 3.95 6.56 5.09 8.21 2.53 9.97 1.3 0.08 9.66 
2325 Synthesis_of_Leukotrienes_(LT)_and_Eoxins_(EX) 8.25 4.71 7.24 9.33 1.52 0.02 2.16 4.6 8.25 5.29 3.76 6.05 9.75 7.43 2.04 5.35 2.81 8.88 
2326 Synthesis_of_Lipoxins_(LX) 7.46 3.42 8.71 5.45 8.94 9.62 9.42 2.51 1.85 3.42 9.81 5.54 6.55 1.96 7.61 6.57 9.81 3.03 
2327 Synthesis_of_Prostaglandins_(PG)_and_Thromboxanes_(TX) 0.46 8.4 8.75 6.49 7.59 0.97 4.95 1.26 4.31 3.03 4.82 2.16 9.21 8.64 1.35 3.41 4.13 4.37 
2328 Synthesis_of_epoxy_(EET)_and_dihydroxyeicosatrienoic_acids_(DHET) 0.17 0.46 5.57 6.71 4.52 6.97 3.27 6.6 5.75 4.17 6.91 2.58 0.08 9.24 5.75 7.4 6.08 2.38 
2329 Aromatic_amines_can_be_N-hydroxylated_or_N-dealkylated_by_CYP1A2 7.77 8.67 7.29 4.45 9.73 5.42 7.57 8.84 2.8 8.04 5.93 0.19 9.48 1.85 0.74 5.83 1.16 8.8 
2330 Beta_oxidation_of_butanoyl-CoA_to_acetyl-CoA 3.18 7.26 6.11 9.85 5.83 4.46 1.28 6.27 4.03 4.94 5.41 2.59 6.95 3.49 7.84 9.26 7.02 0.42 
2331 Beta_oxidation_of_decanoyl-CoA_to_octanoyl-CoA-CoA 8.17 6.99 9.64 3.87 5.41 9.56 8 8.34 8.35 6.7 8.5 3.41 2.05 7.11 6.4 7.49 9.93 4.72 
2332 Beta_oxidation_of_hexanoyl-CoA_to_butanoyl-CoA 5.03 9.29 3.2 9.08 6.24 9.24 0.94 6 7.29 9.32 3.48 1.54 5.02 8.45 0.67 1.91 3.52 4.05 
2333 Beta_oxidation_of_lauroyl-CoA_to_decanoyl-CoA-CoA 3.22 3.59 0.61 6.89 7.85 4.12 9.75 6.88 2.14 3.24 2.01 8.38 9.84 2.42 7.76 8.12 7.87 2.68 
2334 Beta_oxidation_of_myristoyl-CoA_to_lauroyl-CoA 6.63 8.78 2.76 3.68 0.77 2.37 8.45 4.56 9.14 5.34 1.78 5.37 4.8 4.5 7.41 0.78 4.47 7.03 
2335 Beta_oxidation_of_octanoyl-CoA_to_hexanoyl-CoA 6.31 1.06 8.59 8.24 7.36 3.66 0.18 7.45 7.53 7.51 3.13 9.41 7.84 6.68 8.3 1.63 4.77 5.82 
2336 Beta_oxidation_of_palmitoyl-CoA_to_myristoyl-CoA 4.19 4.14 0.82 2.24 1.13 4.69 4.95 2.02 4.52 6.34 1.91 6.65 1.18 4.46 0.93 5.53 4.54 7.81 
2337 Beta-oxidation_of_pristanoyl-CoA 3.31 7.41 1.94 4.38 0.53 3.98 4.1 6.94 5.37 5.55 4.39 8.77 9.77 5.92 2.84 1.45 6.77 4.1 
2338 Beta-oxidation_of_very_long_chain_fatty_acids 2.04 9.94 9.46 7.53 4.52 9.02 2.64 2.31 2.34 4.69 4.75 7.28 7.91 4.23 8.31 6.82 6.01 1.01 
2339 Recycling_of_bile_acids_and_salts 2.9 9.92 6.04 8.14 7.72 9.37 9.61 0.27 8.74 2.3 2.07 7.09 4.44 2.21 7.54 3.65 8.83 7.03 
2340 Synthesis_of_bile_acids_and_bile_salts_via_24-hydroxycholesterol 6.73 7.96 0.55 6.8 1.16 0.04 9.68 0.16 2.14 2.15 5.72 1.41 7.35 9.02 9.2 2.12 8.13 8.77 
2341 Synthesis_of_bile_acids_and_bile_salts_via_27-hydroxycholesterol 4.9 5.44 5.65 8.37 6.87 4.33 0.36 7.54 9.36 6.57 7.23 1.26 7.06 6.67 1.54 3.89 9.34 8.69 
2342 Synthesis_of_bile_acids_and_bile_salts_via_7alpha-hydroxycholesterol 4.75 2.67 6.54 6.72 0.75 4.51 8.57 6.29 5.57 6.9 5.93 1.47 4.32 5.23 8.91 4.3 8.09 7.47 
2343 Acetylation 2.87 5.45 7 2.24 7.45 9.75 3.03 9.66 2.38 4.38 4.79 4.26 2.35 9.82 2.56 6.9 4.27 1.29 
2344 Aromatic_amines_can_be_N-hydroxylated_or_N-dealkylated_by_CYP1A2 3.43 2.6 4.95 9.15 4.18 5.27 5.39 5.24 9.3 7.6 4.47 9.07 7.2 4.13 1.31 5.49 1.34 4.31 
2345 COX_reactions 1.26 6.87 5.43 5.55 8.89 2.16 0.09 4.09 7.99 2.26 7.94 3.85 8.4 9.23 2.25 8.35 7.98 0.23 
2346 CYP2E1_reactions 1.34 9.26 3.44 4.8 6.29 4.28 8.29 5.44 2.47 9.4 0.99 8.38 1.22 2.15 9.13 8.64 4.9 5.5 
2347 Conjugation_of_benzoate_with_glycine 1.85 0.72 7.19 9.8 6.66 0.66 8.89 2.17 7.97 5.33 5.45 7.34 2.78 3.03 9.14 1.52 2.46 5.58 
2348 Conjugation_of_phenylacetate_with_glutamine 8.56 6.63 2.87 4.69 7.36 4.14 8.87 4.43 9.92 0.88 3.68 6.03 8.16 5.2 5.43 4.87 8.25 8.41 
2349 Conjugation_of_salicylate_with_glycine 9.16 2.21 7.33 4.96 3.21 0.79 1.36 3.51 4.87 5.98 9.65 1.48 0.69 1.75 2.52 9.69 1.95 5.29 
2350 Eicosanoids 9.94 3.72 0.78 5.73 6.17 0.9 0.28 7.19 4.26 0.16 9.62 5.8 3.92 5.3 1.32 7.4 7.51 4.47 
2351 Ethanol_oxidation 5.58 3.22 9.09 1.41 1.76 2.34 3.51 3.05 5.27 1.55 7.67 4.5 2.74 9.01 7.57 7.99 1.45 5.4 
2352 FMO_oxidizes_nucleophiles 4.12 0.93 1.65 1.25 8.47 3.41 1 4.16 4.91 1.82 3.32 1.59 2.22 3.51 5.38 6.62 3.2 6.95 
2353 Fatty_acids 1.39 6.36 8.33 5.37 6.82 4.97 8.99 2.74 6.75 2.48 4.58 8.93 3.77 8.31 4.09 3.37 7.87 4.52 
2354 Formation_of_the_active_cofactor,_UDP-glucuronate 8.39 9.45 1.95 6.26 5.78 9.96 8.02 2.69 6.58 0.94 3.42 9.07 9.06 3.67 1.34 9.47 6.34 8.99 
2355 Glutathione_synthesis_and_recycling 9.52 3.06 2.24 4.41 8.24 7.95 1.52 8.4 4.84 3.42 1.13 8.95 4.05 8.93 3.22 0.27 1.45 5.55 
2356 Methylation 8.14 3.1 1.03 4.22 5 8.54 0.1 2.71 2.09 6.44 8.9 8.72 1.38 4.3 1.75 6.29 8.61 5.52 
2357 Miscellaneous_substrates 1.11 7.17 1.27 2.7 9.94 8.43 8.75 1.33 5 3.6 3.77 4.67 8.92 1.87 5.1 2.19 7.62 4.6 
2358 Monoamines_are_oxidized_to_aldehydes_by_MAOA_and_MAOB,_producing_NH3_and_H2O2 3.47 7.17 8.62 8.45 8.56 6.14 4.06 6.02 8.9 1.56 0.08 6.19 7.06 0.37 2.01 0.55 0.64 4.97 
2359 Polyamines_are_oxidized_to_amines,_aldehydes_and_H2O2_by_PAOs 0.93 5.07 3.6 3.24 5.93 8.6 0.12 6.64 5.72 3.77 2.18 7.23 5.09 7.8 2.63 5.25 4.09 8.91 
2360 Sterols_are_12-hydroxylated_by_CYP8B1 5.48 6.61 1.88 1.22 1.28 7.8 9.94 6.03 5.03 1.62 7.26 8.01 8.74 3.51 3.15 6.89 0.06 5.01 
2361 Transport_and_synthesis_of_PAPS 6.34 3.53 2.33 1.64 9.07 1.58 8.02 1.18 6.46 0.41 9.37 5.65 7.48 5.45 9.99 7.69 9.38 4.39 
2362 Vitamins 7.91 9.9 0.31 5.5 0.05 0.21 0.54 5.06 0.93 5.78 5.5 0.74 1.03 0.63 8.47 8.97 3.7 4.94 
2363 Biotin_transport_and_metabolism 7.35 2.01 2.07 0.68 9.11 9.21 5.2 8.05 5.6 8.89 0 5.22 6.33 5.86 2.04 1.54 1.33 0.68 
2364 Branched-chain_amino_acid_catabolism 5.79 3.12 8.25 7.46 7.22 1.37 1.08 2.97 1.78 5.45 9.62 4.97 5.18 1.67 2.5 0.51 9.2 5.33 
2365 COX_reactions 5.42 3.56 8.6 1.96 9.46 1.04 6.55 5.68 9.85 6.19 1.61 3.92 9.73 7.08 8.33 7.94 6.46 5.87 
2366 CS/DS_degradation 1.51 7.4 5.81 3.96 1.44 2.45 6.73 4.92 9.33 3.73 5.3 1.95 7.42 8.42 2.84 6.11 1.97 6.76 
2367 CYP2E1_reactions 5.97 7.84 8.45 1.56 4.42 8.49 3.81 5.05 2.71 5.9 9.91 5.94 6.31 4.18 0.07 0.11 7.55 0.51 
2368 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 3.84 0.58 9.49 7.04 4.96 2.89 7.76 9.94 4.79 3.85 6.16 1.34 4.68 0.92 0.88 1.61 2.97 3.64 
2369 CS/DS_degradation 7.24 1.49 7.44 2.75 9.39 3.16 5.18 9.06 6.26 1.22 0.71 5.58 2.29 0.47 6.66 0.15 7.26 7.49 
2370 Chondroitin_sulfate_biosynthesis 8.54 5.39 5.39 2.16 3.25 9.23 7.56 2.36 3.04 8.12 5.78 4.11 9.8 1.05 7.5 8.78 0.59 1.67 
2371 Dermatan_sulfate_biosynthesis 9.37 8.19 7.25 7.53 9.83 8.33 5.21 2.05 0.26 1.12 2.31 4.46 6.76 5 2.8 1.96 2.61 5 
2372 Digestion_of_dietary_carbohydrate 7.12 7.45 4.22 9.49 4.98 3.48 8.84 0.45 2.44 8.92 9.46 4.21 8.29 8.61 8.8 9.82 2.37 9.91 
2373 Fructose_catabolism 2.56 0.15 5.32 2.24 2.19 3.81 4.7 5.1 7.43 3.89 9.72 3.14 9.64 6.62 1.5 0.41 3.03 8.67 
2374 Galactose_catabolism 7.69 7.33 1.74 2.87 6.83 0.67 2.38 9.53 4.87 5.58 5.05 5.54 4.53 6.12 5.72 6.21 1.36 1.03 
2375 Gluconeogenesis 3.04 8.63 4.79 9.67 0.7 3.35 8.28 1.66 5.61 9.27 6.97 3.01 1.27 5.31 5.33 9.09 9.68 9.3 
2376 Glycogen_breakdown_(glycogenolysis) 9.69 2.72 2.9 4.43 3.91 8.32 6.68 9.3 3.17 3.68 9.54 6.27 5.98 7.79 1.29 2.05 7.38 4.09 
2377 Glycogen_synthesis 6.11 0.51 6.72 4.73 3.16 3.91 4.89 6.11 0.54 1.2 1.34 3.41 6.74 2.46 0.84 8.17 2.72 5.79 
2378 Glycolysis 8.31 0.13 0.41 6.76 3.89 9.15 0.03 2.64 5.73 9.38 1.25 2.32 7.36 2.61 2.12 5.04 2.54 6.34 
2379 HS-GAG_biosynthesis 9.17 3.25 6.68 8.93 2.83 2.24 3.09 6.38 8.19 6.1 5.58 0.08 3.19 6.08 2.54 4.12 4.88 7.69 
2380 HS-GAG_degradation 4.7 6.69 9.83 0.92 9.5 1.81 3.81 4.08 0.4 5.45 0.66 4.55 0.24 5.68 3.31 3.38 7.64 1.3 
2381 Hyaluronan_biosynthesis_and_export 7.51 2.99 0.25 1.58 5.17 5.75 2.31 2.84 8.38 8.02 5.73 2.52 9.2 5.2 2.07 4.87 9.66 3.93 
2382 Hyaluronan_uptake_and_degradation 2.39 3.25 3.38 0.68 7.63 3.5 0.28 9.19 8.22 6.45 9.52 2.86 0.08 6.73 5.95 7.54 6.42 4.78 
2383 Keratan_sulfate_biosynthesis 7.66 0.28 4.85 6.85 4.38 6.9 6.27 7.43 4.42 9.53 2.57 4.47 2.23 0.05 4.18 7.04 3.22 4.92 
2384 Keratan_sulfate_degradation 7.91 3.64 7.64 7.05 9.5 3.76 2.9 8.24 0.17 9.4 9.89 5.57 9.85 8.55 2.22 3.38 2.5 5.46 
2385 5-Phosphoribose_1-diphosphate_biosynthesis 7.67 5.92 6.48 0.76 4.39 9.66 8.9 3.02 3 2.56 6.23 0.32 2.45 8.34 3.98 8.76 6 8.77 
2386 Pentose_phosphate_pathway_(hexose_monophosphate_shunt) 1.06 3.28 4.42 0.88 4.14 4.82 0.77 9.31 0.37 5.28 8.23 9.76 0.69 8.05 6.73 0.84 3.33 3.55 
2387 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 2.52 0.92 6.2 1.01 4.75 0.35 6.84 3.07 1.41 8.83 5.6 4.68 4.41 5.22 9.85 9.83 3.92 7.83 
2388 Transport_and_synthesis_of_PAPS 9.03 8.43 5.09 6.61 9.42 9.52 4.64 8.23 9.59 9.97 0.43 7.64 5.37 4.36 5.08 8.14 5.75 4.9 
2389 Carnitine_synthesis 2.29 4.85 3.63 6.75 6.96 8.42 4.03 8.62 6.23 2.88 3.72 0.36 4.75 0.93 5.01 2.39 4.35 0.18 
2390 Catecholamine_biosynthesis 3.09 2.65 0.88 3.99 7.82 7.22 1.98 0.27 5.8 6.23 2.54 1.78 8.89 1.83 8.5 7.76 5.79 0.31 
2391 ChREBP_activates_metabolic_gene_expression 1.84 0.84 5.29 3.04 9.86 5.45 8.18 6.31 6.85 3.05 2.3 9.5 2.09 5.31 9.05 5.86 2.96 6.31 
2392 Cholesterol_biosynthesis 9.49 1.81 4.99 2.87 4.06 6.68 1.21 7.12 7.8 4.91 8.25 3.29 1.81 4.87 9.95 0.92 3.86 9.48 
2393 Chondroitin_sulfate_biosynthesis 6.42 2.18 7.31 8.96 0.6 3.48 7.32 5.52 4.53 8.23 1.94 2.51 2.72 0.88 7.13 9.4 0.4 6.8 
2394 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 1.92 3.07 1.66 0.49 0.08 3.25 3.8 3.62 2.48 0.67 6.41 7.52 7.32 4.73 6.7 4.94 9.83 6.4 
2395 CS/DS_degradation 6.01 5.57 6.55 9.9 5.27 7.03 8 0.44 6.24 9.77 8.04 5.6 8.85 2.08 2.73 7.24 7.25 2.29 
2396 Chondroitin_sulfate_biosynthesis 6.43 6.63 7.77 6.51 4.84 0.83 9.88 1.28 1.05 1.58 1.19 5.79 1.43 1.89 5.88 4.45 7.26 8.06 
2397 Dermatan_sulfate_biosynthesis 0.65 0.75 2.76 9.65 7.75 2.19 5.65 0.41 3.72 8.2 1.46 5.51 3.26 9.31 3.03 3.12 4.81 1.56 
2398 Chylomicron-mediated_lipid_transport 0.58 9.91 3.23 1.57 1.2 8.85 8.45 4.73 1.7 7.84 9.56 3.96 2.17 3.77 1.3 3.3 6.37 2.3 
2399 Citric_acid_cycle_(TCA_cycle) 5.03 5.33 8.84 9.12 0.35 2.63 0.01 4.05 3.12 0.12 9.15 2.16 4.6 6.99 7.6 2.31 9.81 1.83 
2400 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 1.7 1.33 3.68 4.33 7.2 8.81 5.31 6.65 7.12 3.76 8.25 1.17 2.92 5.03 7.74 3.52 4.26 2.99 
2401 Coenzyme_A_biosynthesis 2.2 3.02 4.96 3.48 4.53 4.31 9.52 8.47 6.5 8.27 1.52 4.59 9.55 9.57 4.94 6.78 0.16 9.71 
2402 Conjugation_of_benzoate_with_glycine 9.14 1.53 9.51 2.2 3.4 8.41 2.23 1.79 3.43 6.64 6.05 9.8 4.7 1.63 9.33 5 1.43 4.29 
2403 Conjugation_of_benzoate_with_glycine 5.63 0.93 7.33 5.09 7.94 8.74 6.5 7.79 8.21 1.04 3.4 8.96 0.84 9.26 7.27 7.18 5.13 1.35 
2404 Conjugation_of_phenylacetate_with_glutamine 5.4 6.46 9 6.77 5.93 8.09 6.68 6.64 5.36 0.65 9.91 6.71 4.52 6.09 8.83 0.06 0.5 4.1 
2405 Conjugation_of_salicylate_with_glycine 3.01 4.32 3.65 2.79 5.79 6.55 0.36 7.63 6.05 0.91 1.35 4.5 6.33 8.87 2.96 2.61 9.36 4.02 
2406 Conjugation_of_phenylacetate_with_glutamine 4.63 2.5 9.86 9.88 2.25 6.28 4.09 6.55 5.61 5.98 2.37 8.89 8.47 5.18 6.19 8.87 8.73 4.96 
2407 Conjugation_of_salicylate_with_glycine 8.12 8.19 4.55 3.19 5.79 3.53 5.07 8.99 5.43 5.99 6.73 2.24 6.1 0.99 6.11 7.48 1.69 7.13 
2408 Creatine_metabolism 4.48 3.07 4.77 5.49 8.38 3.26 3.37 0.3 5.41 9.37 7 6.44 1.42 4.12 6.89 6.76 5.48 7.41 
2409 Cysteine_formation_from_homocysteine 8.14 0.89 9.06 0.67 6.67 5.65 2.78 6.7 0.11 3.04 6.2 5.09 7.83 0.07 6.61 6.96 2.17 7.77 
2410 Aromatic_amines_can_be_N-hydroxylated_or_N-dealkylated_by_CYP1A2 0.41 4 2.46 1.98 1.63 8.35 9.28 1.38 8.37 2.28 8.03 9.45 2.76 9.63 5.5 1.62 5.56 9.37 
2411 CYP2E1_reactions 2.44 7.21 4.95 7.99 1.24 5.76 4.66 2.63 9.09 6.77 6.33 9.14 8.54 7.14 6.28 6.43 9.17 7.29 
2412 Eicosanoids 9.85 2.13 7.27 0.54 5.49 1.29 3.28 5.22 2.13 0.58 0.66 5.33 3.78 7.09 4.03 1.08 5.56 4.1 
2413 Fatty_acids 0.42 2.67 3.58 1.12 0.51 1.72 6.75 4.49 4.2 8.33 9.82 8.65 8.86 6.7 6.64 4.37 2.56 8.75 
2414 Miscellaneous_substrates 0.3 7.45 3.28 1.77 1.77 6.99 0.76 6.5 4.51 0.3 6.24 7.09 7.02 9.05 7.6 9.86 8.95 4.5 
2415 Sterols_are_12-hydroxylated_by_CYP8B1 8.33 1.16 1.79 6.21 1.47 5.57 6.48 3.21 5.77 9.42 0.95 4.04 4.12 3.35 4.97 3.9 2.21 8.51 
2416 Vitamins 8.32 3.16 3.3 4.48 0.87 9.98 7.39 9.18 7.88 7.47 5.41 5.97 6.05 5.79 2.3 2.36 3.13 8.14 
2417 Cytosolic_Iron-sulfur_Cluster_Assembly 7.7 6.39 6.33 7.15 5.34 1.05 2.55 1.47 5.95 7.3 0.93 8.95 7.73 5.95 3.84 7.83 0.85 9.6 
2418 Transport_and_synthesis_of_PAPS 2.22 4.6 7.71 9.96 6.79 0 1.52 5.23 7.13 7.89 5.71 4.36 5.58 7.8 7.63 0.86 3.37 5.03 
2419 Sulfide_oxidation_to_sulfate 6.52 8.94 6.62 5.28 1.73 3.09 5.86 0.04 4.1 1.66 3.55 9.62 0.29 1.69 4.89 4.08 0.26 8.49 
2420 Dermatan_sulfate_biosynthesis 7.82 5.6 0.98 6.77 3.69 0.47 8.41 7.97 7.05 5.67 1 1.63 6.24 2.85 7.17 9.17 6.86 4.77 
2421 Digestion_of_dietary_carbohydrate 0.18 4.16 7.44 4.44 9.06 4.31 0.41 6.23 8.89 3.88 2.15 1.22 4.62 5.57 1.21 1.56 3.87 5.31 
2422 Digestion_of_dietary_lipid 8.88 8.41 6.06 7.35 8.59 1.27 4.94 6.94 2.87 1.81 8.63 1.91 1.66 7.53 5.05 6.5 7.28 6.25 
2423 Eicosanoids 3.89 8.92 8.16 8.28 1.31 1.84 1.21 7.95 3.92 8.4 9.6 1.14 9.95 0.44 8.11 5.71 5.54 8.41 
2424 Electron_Transport_from_NADPH_to_Ferredoxin 8.98 4.04 3.93 9.9 5.09 9.91 1.15 1.4 3.27 2.52 9.79 1 3.93 2.42 1.09 9.97 3.7 2.43 
2425 Sterols_are_12-hydroxylated_by_CYP8B1 1.85 3.82 1.58 6.01 5.52 2.89 6.44 8.27 6.34 7.36 3.08 0.85 0.31 6.52 0.16 7.83 7.48 3.88 
2426 Estrogen_biosynthesis 9.39 5 3.13 0.59 1.68 6.29 0.56 4.13 7.56 5.99 2.01 2.99 1.66 3.63 5.24 3.65 9.02 6.29 
2427 Ethanol_oxidation 9.58 4.4 5.96 5.19 0.55 6.16 4.74 5.19 1.95 2.72 2.53 8.7 2.49 7.83 1.52 9.38 4.88 1.89 
2428 FMO_oxidizes_nucleophiles 4.65 6.78 3.2 2.62 5.28 2.88 3.84 7.58 7.49 5.16 0.52 2.38 3.93 0.23 0.49 7.02 2.48 7.83 
2429 Synthesis_of_very_long-chain_fatty_acyl-CoAs 2.12 4.84 6.38 6.17 0.95 7.48 6.56 7.14 3.18 5.6 6.52 9.86 7.22 1.05 6.11 7.9 8.59 8.07 
2430 Beta_oxidation_of_butanoyl-CoA_to_acetyl-CoA 3.49 3.49 8.03 5.09 2.06 3.98 4.8 6.65 3.68 5.36 6.18 1.23 1.13 0.41 7.91 1.63 5.18 1.79 
2431 Beta_oxidation_of_decanoyl-CoA_to_octanoyl-CoA-CoA 1.31 5.36 5.85 8.92 8.84 6.62 3.35 5.41 7.49 0.96 2.36 8.85 4.96 5.35 0.19 7.35 6.5 5.61 
2432 Beta_oxidation_of_hexanoyl-CoA_to_butanoyl-CoA 1.69 2.33 1.86 1.01 9.54 2.06 5.78 1.58 2.46 0.15 7.53 7.34 7.65 1.49 1.27 9.65 7.12 5.78 
2433 Beta_oxidation_of_lauroyl-CoA_to_decanoyl-CoA-CoA 6.11 7.54 0.98 2.49 6.58 5.53 0.55 0.19 7.93 8.86 5.71 9.16 7.73 5.61 3.5 1.49 3.52 7.23 
2434 Beta_oxidation_of_myristoyl-CoA_to_lauroyl-CoA 9.75 2.19 1.91 4.4 7.83 5.59 5.61 8.36 7.2 2.24 9.55 7.71 0.21 0.14 8.98 2.92 6.92 9.04 
2435 Beta_oxidation_of_octanoyl-CoA_to_hexanoyl-CoA 6.57 2.77 6.25 3.12 5.8 3.97 8.92 2.77 1.39 1.02 2.38 8.02 1.31 0.34 4.16 0.45 3.77 9.36 
2436 Beta_oxidation_of_palmitoyl-CoA_to_myristoyl-CoA 4.05 0.59 1.13 5.98 8.89 0.1 1.42 0.97 0.41 5.75 4.19 0.59 8.69 8.16 8.41 2.44 9.8 2.53 
2437 Import_of_palmitoyl-CoA_into_the_mitochondrial_matrix 6.58 3.24 1.02 4.91 0.69 8.8 1.68 4.48 1.79 0.27 4.92 0.7 8.74 3.27 7.99 8.02 3.43 1.72 
2438 Utilization_of_Ketone_Bodies 2.39 4.04 5.7 7.28 6.12 1.64 2.76 7.91 0.05 9.79 8.92 5.33 7.67 0.88 7.94 2.5 4.82 8.36 
2439 PPARA_Activates_Gene_Expression 0.04 2.3 7.17 9.44 3.52 7.17 2.75 3.57 0.72 1.64 0.37 3.72 9.24 2.69 3.62 6.79 2.37 0.87 
2440 Propionyl-CoA_catabolism 3.48 8.23 3.82 7.86 1.73 8.32 3.76 4.01 1.78 5.06 5.66 7.12 7.75 8.82 5.02 4.32 8.43 7.44 
2441 Synthesis_of_Ketone_Bodies 3.13 1.45 8.38 0.25 7.16 6.4 2 1.84 0.32 3.22 8.51 6.25 2.63 0.07 7.15 6.55 6.17 5.93 
2442 Synthesis_of_very_long-chain_fatty_acyl-CoAs 1.41 5.67 9.82 5.11 1.82 4.19 9.8 5.74 5.81 8.75 0.11 4.07 9.8 8.33 1.59 6.79 6.43 8.04 
2443 mitochondrial_fatty_acid_beta-oxidation_of_unsaturated_fatty_acids 6.7 5.87 9.1 2.56 2.75 0.9 1.53 4.84 8.9 7.27 9.52 8.28 8.29 7.91 8.35 2.88 9.82 4 
2444 Fatty_acids 3.62 1.8 3.18 9.55 2.69 2.81 7.97 4.11 1.76 8.68 0.27 1.02 8.53 7.09 1.5 7.8 8.74 4.35 
2445 Formation_of_ATP_by_chemiosmotic_coupling 8.37 8.21 7.16 1.75 7.09 3.6 3.8 6.46 3.69 5.14 8.81 6.18 3.04 0.11 7.74 6.67 8.26 9.99 
2446 Formation_of_the_active_cofactor,_UDP-glucuronate 0.62 0.1 7.78 9.47 2.53 4.95 2.5 8.31 0.17 6.68 0.28 0.99 1.05 4.01 5.65 5.57 6.13 1.37 
2447 Fructose_catabolism 1.99 1.94 0.94 9.41 6.31 6.18 0.62 0.95 2.27 9.29 0.91 5.94 0.24 8.75 6.48 7.28 9.96 0.88 
2448 Galactose_catabolism 3.49 0.36 4.39 0.01 1.53 3.61 7.59 6.02 3.97 4.34 8.84 5.92 3.78 9.56 1.93 1.56 2.7 6.81 
2449 PKA_activation_in_glucagon_signalling 6.69 5.2 8.59 4.7 9.21 6.82 7.6 2.72 1.7 7.75 6.44 0.1 8.41 0.82 1.44 5.7 9.37 0.05 
2450 Glucocorticoid_biosynthesis 7.4 3.8 1.52 2.14 8.53 6.47 1.14 2.46 7.1 7.35 4.11 0.47 8.6 8.98 3.48 8.92 6.78 4.8 
2451 Gluconeogenesis 3.68 1.33 3.09 6.12 4.86 6.82 5.93 4.16 8.25 5.84 1.64 3.12 8.23 5.62 3.47 0.69 4.39 2.74 
2452 Gluconeogenesis 6.57 2.14 9.19 6.32 2.3 4.9 1.57 3.78 1.29 6.89 9.64 4.29 8.58 0.75 2.09 3.22 8.11 3.6 
2453 Glycogen_breakdown_(glycogenolysis) 4.7 5.33 7.35 4.9 5.82 8.9 1.79 3.12 9.14 1.13 5.4 2.21 6.68 2.92 0.02 9.12 8.59 1.18 
2454 Glycogen_synthesis 2.6 9.89 6.22 2.3 1.88 0.52 6.2 6.19 6.6 1.2 4.35 4.67 1.13 5.55 3.52 8.95 9.34 9.2 
2455 Glycolysis 8.63 9.37 8.04 6.81 5.3 8.89 0.49 8.42 7.75 8.84 6.95 1.17 5.33 8.63 8.15 6.8 1.2 3.94 
2456 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 3.89 7.48 6.22 2.08 5.1 2.31 6.96 1.17 9.11 1.41 3.33 5.21 0.55 6.82 7.71 0.69 9.68 3.63 
2457 Formation_of_the_active_cofactor,_UDP-glucuronate 4.95 9.15 2.98 6.21 8.15 6.11 5.53 2.7 8.15 2.83 5.36 9.95 3.13 7.67 9.33 9.06 0.08 9.62 
2458 Glutathione_synthesis_and_recycling 2.95 2.41 4.54 7.71 6.77 8.22 1.16 4.91 3.53 8.96 5.31 0.37 8.38 4.38 8.33 2.39 1.02 9.99 
2459 Glutathione_synthesis_and_recycling 9.66 3.69 7.02 6.41 0.07 8.2 5.25 0.46 7.54 1.89 7.95 2.52 0.91 6.73 8.31 6.6 0.63 5.63 
2460 Acyl_chain_remodeling_of_CL 1.96 2.06 6.79 6.04 0.13 2.02 0.23 2.34 7.34 5.14 3.75 6.28 7.41 8.62 9.86 5.33 5.84 6.4 
2461 Acyl_chain_remodeling_of_DAG_and_TAG 6.86 7.03 5.84 6.97 1.15 6.03 7.99 5.8 1.51 1.58 3.27 9.86 9.93 0.37 3.31 1.97 1.96 7.56 
2462 Acyl_chain_remodelling_of_PC 9.14 9.21 9.43 9.23 4.48 5.67 6.19 9.47 6.55 7.8 2.92 8.16 1.83 2.01 1.63 6.55 6.73 2.61 
2463 Acyl_chain_remodelling_of_PE 8.83 8.97 0.1 5.12 7.39 0.24 2.22 9.29 0.68 6.1 9.55 2.99 1.16 7.96 8.64 8.19 8.74 3.13 
2464 Acyl_chain_remodelling_of_PG 8.53 4.05 8.67 7.79 9.8 6.07 8.83 3.37 3.29 6.3 0.24 7.22 9.11 9.6 9.72 2.96 8.75 0.42 
2465 Acyl_chain_remodelling_of_PI 6.09 1.36 5.8 8.83 0.02 1.06 0.19 8.48 8.55 1.32 0.63 4.17 5.21 4.84 6.68 9 3.91 2.69 
2466 Acyl_chain_remodelling_of_PS 7.81 8.09 1.85 3.93 0.96 2.94 2.83 9.04 8.82 3.07 6.44 7.36 3.14 4.57 5.51 6.14 9.3 9.9 
2467 Hydrolysis_of_LPC 6.25 5.24 7.87 2.44 1.01 9.63 9.44 1.48 9.41 9.23 0.86 2.92 4.33 0.49 5.14 9.05 4.36 1.51 
2468 Hydrolysis_of_LPE 4.03 1.61 9.97 2.98 0.98 4.95 5.16 0.24 6.32 4.12 7.9 3.69 4.95 3.08 3.55 9.69 0.67 7.92 
2469 PI_and_PC_transport_between_ER_and_Golgi_membranes 5.09 4.42 0.98 1.94 8.44 9.9 6.81 8.86 2.72 5.41 8.65 5.58 9.98 4.2 9.47 2.62 1.9 7.2 
2470 Synthesis_of_BMP 4.64 3.94 0.92 6.09 3.72 6.29 5.9 1.06 1.23 4.12 4.94 7.2 9.8 7.86 4.73 5.85 0.45 4.21 
2471 Synthesis_of_CL 7.58 9.9 0.39 5.84 3.87 9.64 6.84 4.18 3.49 7.2 5.03 5.35 1.58 7.77 3.47 6.3 2.28 5.79 
2472 Synthesis_of_PA 1.58 4.27 7.19 7.84 8.94 0.22 2.35 6.98 4.21 1.95 8.87 1.27 4.66 4.43 8.69 0.99 0.56 3.56 
2473 Synthesis_of_PC 7.63 0.2 7.46 1.16 6.25 3.7 1.59 9.07 3.97 8.7 8.11 5.06 8.99 9.65 1.58 9.58 3.77 8.52 
2474 Synthesis_of_PE 0.49 1.46 3.53 9.98 1.34 7.48 1.52 8.28 2.71 0.22 7.11 1.32 7.07 7.68 8.88 2.06 9.88 1.96 
2475 Synthesis_of_PG 0.12 1.71 7.79 2.1 4.42 8.86 5.44 0.77 2.02 9.03 3.89 2.06 8.03 6.22 7.55 1.68 7.46 0.53 
2476 Synthesis_of_PI 6.4 8.44 1.72 4.73 2.31 2.05 1.74 3.14 9.75 7.58 7.54 0.41 5.77 7.22 8.84 7.94 5.4 5.72 
2477 Synthesis_of_PS 0.3 2.74 6.99 3.13 1.22 7.06 8.74 9.87 2.06 8.21 1.09 7.6 9.64 0.06 5.38 8.74 2.82 4.06 
2478 Glycogen_breakdown_(glycogenolysis) 8.79 9.52 8 2.77 4.63 7.88 5.52 0.7 5.37 6.7 6.67 7.84 1.61 4.9 4.01 9.69 1.24 9.33 
2479 Glycogen_synthesis 6.89 5.58 9.5 4.86 8.34 2.73 1.34 5.06 3.76 8.75 4.36 1.36 8.6 6.9 8.41 4.39 7.17 0.6 
2480 Glycolysis 0.08 6.92 7.48 8.6 8.92 2.32 9.75 6.28 9.79 5.22 2.99 7 0.57 3.37 8.95 0.5 2.64 4.13 
2481 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 5.99 2.91 3.18 2.06 2.38 5.45 5.59 9.89 0.16 7.18 7.4 0.58 1.75 0.39 5.32 3.65 5.4 2.36 
2482 CS/DS_degradation 0.59 3.53 7.05 6.87 8.01 8.29 2.04 9.87 4.36 9.09 7.82 9.51 7.76 6.17 9.88 5.15 0.05 6.44 
2483 Chondroitin_sulfate_biosynthesis 6.94 6.18 1.38 3.92 3.67 8.33 5.93 1.85 3.09 8.39 8.02 8.39 8.65 5.82 3.81 8.87 9.44 9.6 
2484 Dermatan_sulfate_biosynthesis 2.83 6.35 3.31 8.37 8.92 4.81 0.44 1.33 9.9 0.1 3.87 7.68 3.08 8.21 7.04 7.98 7.17 8.35 
2485 HS-GAG_biosynthesis 7.29 2.44 1.11 1.08 8.38 8.84 0.59 6.74 1.63 0.01 6.67 6.75 5.98 6.25 6.25 5.33 4.01 2.83 
2486 HS-GAG_degradation 2.18 3.33 9.62 6.42 7.23 1.05 5.22 9.71 1.94 8.79 6.51 6.6 9.2 4.77 9.58 3.42 9.34 8.67 
2487 Hyaluronan_biosynthesis_and_export 9.07 5.41 9.26 5.65 3.77 9.25 1.15 7.74 2.25 7.27 1.08 4.09 8.71 9.16 1.32 2.65 4.72 9.37 
2488 Hyaluronan_uptake_and_degradation 3.34 4.76 5.54 3 8.63 0.2 2.72 2.61 1.48 0.06 1.09 6.16 6.3 9.5 9.4 3.55 2.67 7.39 
2489 Keratan_sulfate_biosynthesis 6.53 2.75 8.55 6.86 7.38 4.92 7.87 2.89 9.3 5.85 0.52 4.54 0.94 5.76 4.95 3.01 3.79 1.85 
2490 Keratan_sulfate_degradation 9.08 5.86 1.19 2.25 1.12 7.1 5.11 2.74 6.96 0.61 3.21 9.73 5.63 7.85 4.05 7.63 4.79 1.33 
2491 Transport_and_synthesis_of_PAPS 6.33 2.48 2.62 4.91 2.77 3.93 5.54 5.94 2.36 0.64 1.91 3.55 9.33 0.85 6.16 6.75 7.04 1.19 
2492 Glycosphingolipid_metabolism 6.05 7.09 2.29 0.83 7.87 3.53 2.49 4.52 3 6.64 5.54 3.56 9.69 0.49 5.98 0.34 2.14 9.37 
2493 Glyoxylate_metabolism 3.43 4.69 9.09 8.3 6.57 5.44 1.81 7.09 5.83 0.14 9.71 5.25 8.19 1.51 4.25 7.24 8.29 0.68 
2494 HDL-mediated_lipid_transport 0.23 9.6 2.77 2.56 2.8 8.64 2.2 8.15 7.75 8.2 3.68 2.27 6.33 3.78 2.95 5.01 3.17 7.55 
2495 HS-GAG_biosynthesis 2.39 0.33 0.73 8.05 5.06 4.77 3.5 4.34 9.11 4.03 2.23 3.05 0.79 2.76 4.53 9.31 3.82 2.56 
2496 HS-GAG_degradation 6.15 0.09 7.95 9.24 5.04 0.45 5.69 1.47 0.58 3.98 8.06 6.64 9.06 9.43 7.48 7.22 4.83 9.14 
2497 Heme_biosynthesis 5.42 0.01 8.24 8.41 5.5 6.64 4.2 8.37 7.89 7.8 2.84 8.35 5.86 4.28 4.96 2.52 1.74 9.54 
2498 Heme_degradation 6.93 3.07 7.11 2.17 7.98 1.8 2.84 9.26 1.97 6.52 3.04 4.44 8.76 1.4 1.07 9.07 9.29 1.69 
2499 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 4.22 2.97 7.54 7.69 9.65 4.43 8.84 9.18 1.05 4.61 1.23 6.47 2.23 5.05 5.73 1.04 6.59 5.73 
2500 HS-GAG_biosynthesis 0.15 9.74 6.41 2.8 4.77 1.2 6.13 6.7 2.59 4.19 0.49 7.7 8.26 5.24 5.67 3.71 0.4 9.15 
2501 HS-GAG_degradation 6.56 8.5 6.22 6.46 2.05 3.79 0.08 7.79 5.4 6.66 5.36 4.51 6.29 6.88 6.44 1.63 9.88 2.06 
2502 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 1.22 0.37 5.7 0.49 6.49 2.87 4.88 1.91 1.37 5.29 1.47 8.33 1.02 6.92 1.1 4.49 7.21 6.98 
2503 Histidine_catabolism 5.72 1.49 2.8 6.01 9.98 5.49 6.71 2.76 7.24 2.1 9.34 8.91 2.47 7.43 9.72 0.74 1.18 3.33 
2504 Hormone-sensitive_lipase_(HSL)-mediated_triacylglycerol_hydrolysis 4.45 3.44 5.11 3.29 6.49 4.88 2.09 4.97 8.45 2.77 0.79 1.03 8.69 2.02 7.12 3.8 7.7 8.95 
2505 Hyaluronan_biosynthesis_and_export 4.36 0.57 4.56 4.91 4.02 4.26 2.12 2.06 5.36 7.24 3.32 3.5 0.9 4.49 2.87 7.9 4.79 0.65 
2506 Hyaluronan_biosynthesis_and_export 6.07 3.85 6.16 8.91 2.52 2.85 5.87 5.41 6.83 2.69 7.83 5.52 4.62 2.79 9.68 5.83 3.74 4.56 
2507 Hyaluronan_uptake_and_degradation 0.05 8.01 5.82 6.85 7.12 7.01 8.98 6.67 2.06 7.34 8.95 6.57 7.2 8.39 6.53 9.56 4.25 6.48 
2508 Hyaluronan_uptake_and_degradation 3.15 3.23 8.57 2.1 4.74 9.25 2.97 3.2 5.8 4.32 9.04 8.46 5.26 5.15 2.3 9.02 6.92 8.06 
2509 Hydrolysis_of_LPC 1.35 0.17 2.92 5.76 5.38 3.95 3.02 5.77 0.66 3.46 1.22 1.54 9.72 8.08 1.06 9.05 6.18 1.19 
2510 Hydrolysis_of_LPE 1.78 4.81 8.88 7.48 4.29 1.7 0.62 2.87 7.14 4.6 8.93 4.74 2.71 5.78 6.69 5.76 0.68 0.77 
2511 IP3_and_IP4_transport_between_cytosol_and_nucleus 2.77 8.17 0.83 4.78 0.85 3.07 2.78 6.09 5.53 0.5 2.42 8.38 1.02 9.95 7.31 3.93 5.39 0.05 
2512 IP6_and_IP7_transport_between_cytosol_and_nucleus 6.25 6.04 5.28 9.06 8.97 5.32 9.29 6.69 5.9 6.09 9.13 0.03 4.73 3.86 9.69 2.55 3.59 1.93 
2513 IPs_transport_between_ER_lumen_and_cytosol 0.8 4.65 3.14 1.7 5.11 4.63 4.19 5.3 2.77 8.95 6.94 1.01 8.89 4.35 7.9 4.48 5.9 9.58 
2514 IPs_transport_between_ER_lumen_and_nucleus 2.67 1.85 6.28 5.1 2.33 1.08 2.04 7.14 4.51 9.35 0.44 1.42 5.6 3.12 6.28 3.57 3.49 6.7 
2515 IPs_transport_between_cytosol_and_ER_lumen 0.8 5.42 3.39 9.89 8.47 1.3 0.9 2.61 3.95 7.89 9.34 2.45 5.78 7.23 8.73 8.6 1.64 4.29 
2516 IPs_transport_between_nucleus_and_ER_lumen 0.97 3.45 3.82 6.84 3.39 0.68 2.87 7.81 9.68 3.33 2.73 7.74 1.99 3.87 6.1 4.24 3.24 5.19 
2517 IPs_transport_between_nucleus_and_cytosol 0.2 0.37 1.04 9.78 1.69 4.6 3.04 3.71 0.19 5.06 5.3 4.46 8.34 0.36 8.53 9.62 2.55 3.78 
2518 Import_of_palmitoyl-CoA_into_the_mitochondrial_matrix 1.68 4.18 6.02 8.86 3.35 5.1 2.95 5.33 0.73 0.5 5.74 1.17 9.33 7.92 7.39 4.4 6.14 3.38 
2519 Inhibition_of_Insulin_Secretion_by_Adrenaline/Noradrenaline 4.43 4.79 4.61 0.34 7.12 4.03 1.42 5.09 5.18 2.72 4.85 6.61 1.35 7.48 1.31 7.59 7.8 8.06 
2520 IP3_and_IP4_transport_between_cytosol_and_nucleus 0.27 7.73 7.1 4.74 4.1 3.72 5.64 5.72 5.75 3.12 6.85 2.58 4.3 8.78 2.64 2.87 8.11 5.79 
2521 IP6_and_IP7_transport_between_cytosol_and_nucleus 6.58 9.97 6.14 1.39 7.52 0.28 8.26 9.8 0.7 6.08 6.5 6.2 1.99 8.39 9.58 8.08 5.73 4.6 
2522 IPs_transport_between_ER_lumen_and_cytosol 0.42 7.44 5.24 6.13 2 4.15 0.42 3.64 7.52 5.83 8.73 9.64 7.72 3.4 8.97 6.65 2.41 5.67 
2523 IPs_transport_between_ER_lumen_and_nucleus 6.56 3.65 9.47 0.54 1.47 9.61 5.44 7.46 8.89 6.17 5.83 2.09 1.41 3.79 7.3 0.77 2.85 7.05 
2524 IPs_transport_between_cytosol_and_ER_lumen 3.06 2.69 7.3 1.89 0.11 4.19 7.91 9.97 0.72 0.94 4.36 5.75 2.47 3.12 0.05 9.18 7.68 0.83 
2525 IPs_transport_between_nucleus_and_ER_lumen 8.87 9.01 7.86 7.91 6.99 9.47 9.03 3.27 1.75 1.44 6.97 6.61 2.64 2.56 4.69 6.43 4.04 9.58 
2526 IPs_transport_between_nucleus_and_cytosol 7.99 8.04 4.96 7.46 5.18 6.09 0.21 1.5 3.21 2.72 1.6 0.29 7.54 6.35 3.14 2.45 8.18 1.65 
2527 Synthesis_of_IP2,_IP,_and_Ins_in_the_cytosol 1.33 0.46 7.65 4.18 1.69 4.59 5.59 0.71 5.33 0.09 0.39 3.67 9.94 8.46 6.36 6 2.84 2.84 
2528 Synthesis_of_IP3_and_IP4_in_the_cytosol 4.62 5.58 6.66 0.7 3.1 6.3 6.01 9.14 9.11 1.09 7.24 6 0.06 7.22 8.15 0.02 2.57 0.34 
2529 Synthesis_of_IPs_in_the_ER_lumen 3.55 7.48 6.29 7.95 7.48 6.53 4.5 6.43 8.58 8.94 9.7 6.57 8.05 0.19 0.32 9.07 3.56 8.08 
2530 Synthesis_of_IPs_in_the_nucleus 2.22 4.82 9.28 9.66 5.62 2.03 6.12 5.99 6.49 3.04 9.52 8.46 8.52 0.95 2.39 7.61 1.46 3.05 
2531 Synthesis_of_pyrophosphates_in_the_cytosol 2.21 7.47 9.1 1.97 1.65 0.94 4.1 2.69 3.61 7.66 2.05 9.94 5.79 6.28 5.29 9.08 3.96 4.49 
2532 Insulin_effects_increased_synthesis_of_Xylulose-5-Phosphate 1.04 9.8 5.16 8.97 4.32 6.62 4.09 9.46 4.92 8.17 2.91 2.77 2.78 5.21 0.79 0.28 9.37 4.31 
2533 AMPK_inhibits_chREBP_transcriptional_activation_activity 2.83 7.65 7.96 9.5 8.42 7.5 7.32 4.49 0.23 5.13 0.96 6.68 3.11 4.98 9.47 3.37 4.02 9.43 
2534 ChREBP_activates_metabolic_gene_expression 0.45 0.68 6.35 3.83 5.07 7.84 7.2 0.22 1.21 3.47 8.76 1.04 9.01 5.03 8.51 9.47 5.9 1.95 
2535 Inhibition_of_Insulin_Secretion_by_Adrenaline/Noradrenaline 7.9 3.71 6.77 0.42 9.52 5.44 2.5 2.74 3.99 7.3 8.1 7.68 0.47 6.72 0.31 7.05 9.64 3.41 
2536 Insulin_effects_increased_synthesis_of_Xylulose-5-Phosphate 6.97 6.44 0.06 3.56 4.68 3.67 9.78 9.9 4.1 9.43 4.79 4.74 7.22 6.44 5.65 1.32 4.17 0.68 
2537 PKA_activation_in_glucagon_signalling 2.93 7.52 2.48 6.86 7.41 3.29 0.29 0.66 1.95 8.13 1.67 9.75 8.52 6.43 4.77 4.13 5.97 0.57 
2538 PKA-mediated_phosphorylation_of_key_metabolic_factors 0.38 9.17 4.1 3.43 9.18 3.42 5.09 5.03 0.47 2.25 9.53 7.13 8.7 9.58 2.47 4.98 7.36 3.12 
2539 PP2A-mediated_dephosphorylation_of_key_metabolic_factors 0.01 4.21 4.13 1.59 7.89 8.86 3.88 0.29 3.41 8.26 8.07 4.04 6.77 7.62 9.44 4.77 7.8 9.94 
2540 Regulation_of_Insulin_Secretion_by_Acetylcholine 4.27 1.95 5.58 6.13 3.5 7.78 3.21 6.67 0.39 9.78 5.18 6.3 8.29 7.77 4.99 0.09 3.85 5.04 
2541 Regulation_of_Insulin_Secretion_by_Fatty_Acids_Bound_to_GPR40_(FFAR1) 8.15 1.3 5.58 9.31 8.93 7.62 1.91 5.27 9.33 0.66 7.6 8.16 3.51 6.48 4.8 2.24 2.1 0.1 
2542 Regulation_of_Insulin_Secretion_by_Glucagon-like_Peptide-1 8.06 1.27 3.88 4.9 9.29 9.19 7.78 5.55 3.32 9.19 9.06 2.67 3.78 4.59 7.59 3.45 2.37 4.97 
2543 Interconversion_of_2-oxoglutarate_and_2-hydroxyglutarate 0.21 4.97 4.46 2.95 3.26 8.86 9.92 8.44 2.05 4.16 9.34 5.88 5.52 8.54 8.23 5.44 5.31 0.13 
2544 Interconversion_of_polyamines 6.3 2.45 2.03 6.33 9.11 0.27 7.84 2.44 9.02 6.81 5.42 8.93 3.78 2.24 4.29 7.22 1.63 0.53 
2545 Keratan_sulfate_biosynthesis 2.48 6.33 3.04 9.94 0.76 0.51 9.56 9.75 4.1 8.66 2.01 5.17 7.1 7.81 3.09 1.8 2.4 8.58 
2546 Keratan_sulfate_degradation 7.65 3.74 2.75 1.63 7.83 8.91 8.92 3.16 1.64 8.22 8.69 7.63 5.5 2.07 3.63 7.37 5.9 6.11 
2547 Keratan_sulfate_biosynthesis 5.89 7.12 4.9 4.41 1.1 0.22 9.73 7.51 7.73 6.73 1.43 0.84 7.7 6.35 1.82 6.78 4.12 3.52 
2548 Keratan_sulfate_degradation 3.89 9.44 9.69 0.22 4.04 9.88 7.49 1.25 0.56 5.35 6.07 1.9 8.36 7.89 4.16 2 0.96 3.38 
2549 Utilization_of_Ketone_Bodies 9.49 3.21 0.26 3.96 6.87 0.5 1.54 3.81 9.45 7.03 9.15 1.09 5.78 0.85 3.98 7.59 9.72 3.72 
2550 Utilization_of_Ketone_Bodies 3.68 0.99 5.96 1.83 2.08 8.76 3.47 4.73 7.94 5.38 8.84 4.91 5.75 3.87 4.95 7.88 4.8 8.21 
2551 Synthesis_of_Ketone_Bodies 7.73 0.72 3.77 3.28 4.21 5.87 6.43 5.86 8.15 2.72 2.68 3.22 8.39 0.53 0.26 7.45 2.92 7.22 
2552 LDL-mediated_lipid_transport 6.14 6.7 9.93 0.9 6.06 3.85 2.11 6.64 8.06 3.7 0.52 4.7 3.84 3.79 4.72 3.78 6.89 7.79 
2553 Linoleic_acid_(LA)_metabolism 5.9 5.38 7.42 9.4 2.09 4.65 5.34 9.84 4.72 4.74 7.38 2.71 8.35 9.33 8.91 4.2 9.19 3.36 
2554 Chylomicron-mediated_lipid_transport 3.46 7.69 9.63 9.76 9.82 2.08 1.24 2.08 9.45 3.32 5.74 7.12 5.16 4.23 5.8 3.62 7.48 2.21 
2555 Digestion_of_dietary_lipid 0.41 0.89 8.13 9.29 2.8 3.71 5.58 9.34 3.45 6.49 5.01 2.32 0.06 5.32 0.13 1.16 2.93 0.9 
2556 HDL-mediated_lipid_transport 0.69 5.82 0.22 0.97 5.31 6.98 2.95 9.95 0.57 5.49 2.54 1.23 8.94 9.96 4.07 5.12 9.6 4.04 
2557 Hormone-sensitive_lipase_(HSL)-mediated_triacylglycerol_hydrolysis 4.07 7.35 4.72 2.05 2.96 5.73 6.87 8.09 8.69 4.85 5.36 0.65 7.77 5.43 6.53 0.74 2.59 4.9 
2558 LDL-mediated_lipid_transport 5.11 9.39 9.01 2.51 3.6 9.71 9.81 4.46 8.03 2.09 2.91 7.41 4.47 2.59 5 2.79 3.92 5.39 
2559 Trafficking_of_dietary_sterols 0.47 1.22 7.66 9.19 8.62 3.32 3.06 9.36 0.39 5.1 5.58 5.66 0.83 0.67 3.4 7.37 0.78 2.15 
2560 Chylomicron-mediated_lipid_transport 4.82 1.78 8.65 6.75 3.32 3.24 7.97 8.88 7.54 9.41 7.13 3.46 1.56 8.42 8.45 2.8 0.68 1.62 
2561 HDL-mediated_lipid_transport 6.07 9.28 1.07 8.01 8.94 8.8 6.86 7.68 7.82 6.91 0.1 2.19 3.32 9.6 3.26 4.19 7.46 9.45 
2562 LDL-mediated_lipid_transport 9.6 2.53 3.8 7.79 2.1 9.63 3.96 6.97 3.02 2.33 9.87 5.1 7.68 5.06 9.29 6.91 6.51 6.44 
2563 Lysine_catabolism 7.44 1.09 4.87 5.3 0.76 8.58 8.34 7.29 8.21 5.02 3.4 3.09 7.35 9.53 1.67 1.24 6.17 3.39 
2564 Metabolism_of_folate_and_pterines 1.5 4.35 9.42 4.19 5.25 2.8 9.61 6.13 5.86 9.83 6.92 2.9 1.15 7.37 5.71 3.64 2.57 4.58 
2565 Metabolism_of_lipids_and_lipoproteins 7.24 2.5 1.23 5.95 2.89 4.96 7.49 8.31 1.46 3.46 2.89 9.77 9.72 6.75 7.59 5.34 7.11 8.57 
2566 Metabolism_of_nitric_oxide 2.18 5.35 3.03 5.64 5.55 6.9 4.24 1.91 2.98 7.28 5.52 1.49 5.3 0.66 6.87 1.04 3.49 8.24 
2567 Agmatine_biosynthesis 9.06 7.02 6.23 4.99 3.29 6.37 8.95 1.4 2.61 7.61 9.96 8.04 0.3 9.15 1.64 2.29 7.4 9.8 
2568 Interconversion_of_polyamines 2.5 8.57 9.97 1.14 0.01 0.18 1.42 4.5 6.92 1.61 7.33 4.55 6.8 8.75 8.87 3.61 0.45 1.92 
2569 Methionine_salvage_pathway 0.69 5.22 9.44 6.22 6.52 9.81 9.01 8.54 2.69 2.16 1.47 3.49 8.18 6.52 0.24 0.13 9.46 8.02 
2570 Androgen_biosynthesis 6.46 2.21 2.23 8.16 6.7 9.19 5.26 8.21 6.77 4.89 1.03 2.81 9.4 8.54 1.9 0.24 8.61 3.41 
2571 Estrogen_biosynthesis 2 1.28 5.22 8.9 5.3 1.77 8.07 5.56 1.99 7.09 6.11 2.87 8.48 0.24 1.24 4.02 7.93 5.14 
2572 Glucocorticoid_biosynthesis 7.05 8.12 0.74 2.82 3.63 0.19 5.47 2.13 0.14 5.65 2.51 4.23 2.28 5.06 3.15 4.02 5.24 4.17 
2573 Mineralocorticoid_biosynthesis 3.5 0.05 0.17 9.63 6.68 7.58 4.53 4.05 7.11 3.39 4.8 8.42 4.38 1.42 8.12 9.12 2.8 6.39 
2574 Pregnenolone_biosynthesis 9.23 1.05 7.95 5.5 0.5 1.65 7.82 7.93 5.59 2.38 0.59 1.06 3.46 8.44 8.41 9.33 0.4 4.34 
2575 Vitamin_D_(calciferol)_metabolism 8.97 9.76 1.42 3.93 1.19 7.96 9.24 0.35 3.96 0.12 0.87 6.59 3.94 2.52 2.35 2.99 8.47 3.23 
2576 Biotin_transport_and_metabolism 6.09 1.66 5.81 6.91 0.62 8.71 3.13 2.57 2.04 8.74 5.47 6.8 6.05 5.13 6.77 2.51 7.4 4.09 
2577 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 0.88 2.35 6.63 1.59 7.23 7.73 9.38 7.89 5.58 2.72 3.41 9.05 7.5 7.41 3.3 0.72 4.17 2.4 
2578 Coenzyme_A_biosynthesis 8.71 4.95 6.13 2.06 9.31 2.74 0.51 7.59 8.3 7.29 6.18 5.74 9.29 1.43 3.69 0.55 9.93 9.08 
2579 Metabolism_of_folate_and_pterines 9.01 5.53 3.18 6.38 7.25 3.39 9.77 6.76 7.45 3.48 8.61 0.59 5.62 0.45 5.16 1.09 0.78 4.82 
2580 Molybdenum_cofactor_biosynthesis 5.97 9.5 3.71 2.42 3.01 2.88 9.82 8.82 1.65 1.86 5.24 6.09 2.1 8.92 2.25 2.79 9.54 1.42 
2581 Nicotinamide_salvaging 0.46 1.19 8.05 0.42 1.21 1.67 2.34 6 7.92 2.77 7.56 9.28 9.49 0.2 1.25 1.01 5.61 1.52 
2582 Vitamin_B1_(thiamin)_metabolism 5.3 1.52 9.22 4.46 4.46 4.26 7.75 8.08 7.71 9.34 4.14 3.59 1.9 5.34 9.47 0.66 4.19 4.21 
2583 Vitamin_B2_(riboflavin)_metabolism 8.2 5.58 7.22 2.29 0.82 5.9 7.44 1.54 8.91 1.65 9.76 5.27 4.14 8.41 4.19 1.91 1.74 2.51 
2584 Vitamin_C_(ascorbate)_metabolism 6.22 5.82 6.19 1.24 2.92 0.74 2.37 3.07 6.11 1.8 8.18 4.28 5.71 9.79 1.38 0.58 6.76 6.19 
2585 Vitamins_B6_activation_to_pyridoxal_phosphate 4.5 2 3.27 4.34 8.46 5.97 1.6 6.27 6.9 6.86 1.06 0.31 8.26 3.85 7.8 2.08 5.92 9.83 
2586 Biotin_transport_and_metabolism 0.83 3.36 1.18 0.41 4.16 7.46 0.92 4.06 2.43 2.62 2.61 8.43 9.92 7.39 8.78 5.81 2.81 6.32 
2587 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 9.5 4.75 7.64 8.67 4.2 7.83 3.51 9.74 6.21 1.11 6.25 2.23 1.25 3.67 1.54 1.92 1.36 1.21 
2588 Coenzyme_A_biosynthesis 0.45 2.62 8.65 0.63 2.77 1.01 7.23 4.96 8.79 1.55 8.55 6.9 0.79 0.6 9.25 2.96 6.53 3.11 
2589 Metabolism_of_folate_and_pterines 3.74 3.24 1.44 0.78 6.56 5.65 6.35 6.11 2.27 0.52 9.04 7.93 6.53 0.52 5.55 0.58 0.41 4.17 
2590 Molybdenum_cofactor_biosynthesis 7.45 2.4 4.14 2.42 0.88 0.37 6.04 5.85 5.83 0.14 0.73 4.99 0.02 8.53 5.18 4.51 6.39 0.78 
2591 Nicotinamide_salvaging 1.48 8.28 8.37 1.89 8.75 3.03 1.98 0.46 4.51 4.41 7.77 5.96 4.92 2.73 4.13 6.38 1.08 9.45 
2592 Vitamin_B1_(thiamin)_metabolism 4.51 6.15 0.87 0.42 3.56 4.7 8.92 6.29 0.67 2.22 6.29 4.07 3.79 1.58 4.31 3.16 3.32 3.71 
2593 Vitamin_B2_(riboflavin)_metabolism 0.11 9.44 2.9 3 2.03 7.69 0.87 4.06 5.93 0.01 9.07 0.09 7.01 6.44 5.77 7.23 9.98 6.29 
2594 Vitamin_C_(ascorbate)_metabolism 4.19 1.56 6.92 1.73 1.12 7.46 6.83 1.5 9.09 2.54 4.25 3.88 5.38 4.06 0.83 5.18 6.71 5.88 
2595 Vitamins_B6_activation_to_pyridoxal_phosphate 6.29 9.96 1.74 3.11 9.22 4.57 0.82 7.44 2.11 4.83 1.53 0.24 3.07 1.68 4.22 4.8 6.74 4.92 
2596 Methionine_salvage_pathway 0.18 0.49 1.59 6.64 1.64 2.14 4.76 2.77 1.1 6.06 8.13 1.3 2.18 2.3 1.05 4.17 0.37 0.39 
2597 Methylation 8.61 5.2 4.91 6.83 2.37 5.51 6.43 0.14 9.48 0.46 4.76 2.98 6.21 5.85 1.36 8.92 0.43 4.94 
2598 Mineralocorticoid_biosynthesis 2.4 4.06 7.42 1.58 8.56 6.52 1.19 4.43 5.09 1.54 8.95 5.05 9.88 8.45 9.95 0.95 0.76 8.82 
2599 Miscellaneous_substrates 2.66 5.76 5.91 2.53 3.61 1.33 6.21 2.19 9.75 6.29 2.02 0.97 5.17 4.4 9.29 3.42 2.72 5.44 
2600 Beta_oxidation_of_butanoyl-CoA_to_acetyl-CoA 0.57 2.86 1.95 3.06 5.11 3.45 8.46 8.35 8.84 1.23 6.43 8.78 4.8 1.49 6.75 3.89 0.86 2.05 
2601 Beta_oxidation_of_decanoyl-CoA_to_octanoyl-CoA-CoA 7.24 0.94 0.58 2.97 2.94 9.04 7.29 3.21 8.06 5.57 4.88 0.54 0.02 8.91 8.4 6.22 1.99 8.94 
2602 Beta_oxidation_of_hexanoyl-CoA_to_butanoyl-CoA 4.24 6.97 6.95 6.96 8.91 5.6 3.99 0.52 5 4.37 1.92 5.35 5.27 0.94 1.79 8.48 6.82 2.7 
2603 Beta_oxidation_of_lauroyl-CoA_to_decanoyl-CoA-CoA 9.55 4.01 7.72 8.21 8.7 4.62 5.64 2.54 4.52 5.26 1.09 2.98 7.95 1.76 6.09 5.56 7.62 2.48 
2604 Beta_oxidation_of_myristoyl-CoA_to_lauroyl-CoA 9.56 2.12 5.89 1.29 4.02 9.84 1.29 4.29 8.59 2.8 9.12 1.07 0.85 6.24 7.58 9.85 6.99 9.16 
2605 Beta_oxidation_of_octanoyl-CoA_to_hexanoyl-CoA 6.37 4.91 7.34 8.7 0.3 1.86 6.17 8.6 9.21 6.07 3.53 0.16 0.23 2.9 1 4.32 7.42 1.11 
2606 Beta_oxidation_of_palmitoyl-CoA_to_myristoyl-CoA 6.09 4.07 2.21 3.6 5.69 4.19 0.73 8.41 4.84 5.29 0.87 6.23 4.23 5.25 5.38 5.39 2.68 0.47 
2607 Propionyl-CoA_catabolism 7.27 7.82 8.91 3.78 1.76 4.36 8.72 8.55 5.74 0.3 6.61 9.38 4.26 2.51 4.73 6.11 7.89 5.6 
2608 mitochondrial_fatty_acid_beta-oxidation_of_unsaturated_fatty_acids 2.25 3.03 3.19 5.76 0.94 3.67 4.45 2.28 9.35 4.02 7.43 2.94 3.68 6.07 9.61 5.63 2.35 5.26 
2609 Electron_Transport_from_NADPH_to_Ferredoxin 7.35 3.99 5.43 0.64 5.58 5.49 5.18 0.51 7.13 3.68 0.43 4.1 5.06 3.64 7.07 0.2 5.05 5.6 
2610 The_fatty_acid_cycling_model 7.55 2.76 9.94 1.2 0.03 8.98 9.22 9.33 3.94 6.64 9.62 7.2 3.38 1.11 7.43 5.59 9.73 6.18 
2611 The_proton_buffering_model 8.49 8.71 0.95 6.19 1.06 7.63 7.58 6.06 4.66 0.52 9.04 4.91 5.29 6.02 7.72 5.35 9.4 4.89 
2612 Molybdenum_cofactor_biosynthesis 2.44 1.97 4.84 6.56 1.68 7.04 6.19 8.54 5.91 7.01 5.44 4.69 3.94 9.43 8.29 1.23 6.65 3.95 
2613 Monoamines_are_oxidized_to_aldehydes_by_MAOA_and_MAOB,_producing_NH3_and_H2O2 3.83 0.71 5.22 6.77 5.81 0.09 5.51 7.7 0.21 5.34 8.4 9.44 9.16 1.7 5.12 7.79 3.4 4.54 
2614 NADPH_regeneration 9.08 9.69 4.03 6.68 5.38 0 7.54 4.72 5.02 1.42 0.75 1.46 9.71 8.89 3.58 8.74 1.68 6.25 
2615 NOSIP_mediated_eNOS_trafficking 8.85 7.95 9.28 4.43 5.82 4.43 6.55 9.83 9.06 9.37 2.82 2.6 3.72 5.76 2.94 1.46 9.08 5.79 
2616 NOSTRIN_mediated_eNOS_trafficking 1.95 5.44 2.6 4.01 1.54 0.71 9.78 5.8 1.41 2.87 5.12 8.52 4.55 3.6 2.96 3.77 8.6 6.92 
2617 Nicotinamide_salvaging 0.84 2.09 0.01 5.8 0.13 6.71 7.99 3.2 9.62 8.29 3.96 9.06 3.8 5.71 1.95 9.33 9.2 6.48 
2618 Nicotinamide_salvaging 6.69 0.34 5.88 3.12 0.8 2.99 5.97 4.06 5.35 0.12 0.88 5.96 2.5 8.39 5.99 2.02 4.31 4.15 
2619 Phosphate_bond_hydrolysis_by_NUDT_proteins 9.27 6.59 8.57 0.07 0 7.42 5.2 3.71 8.84 5.71 7.13 5.99 7.88 6.28 9.92 7.83 5.35 5.66 
2620 Purine_catabolism 0.03 2.39 8.68 9.6 5.61 9.24 1.87 7 0.1 1.94 2.39 3.47 5.84 8.48 9.9 3.66 3.27 1.29 
2621 Purine_ribonucleoside_monophosphate_biosynthesis 1.08 4.02 5.93 3.4 3.72 6.84 9.34 1.1 7.29 0.13 2.98 0.54 3.4 7.43 9.02 2.5 0.87 2.65 
2622 Purine_salvage 3.07 4.24 5.69 5.76 9.01 5.11 0.83 8.31 6.37 4.55 6.67 5.91 6.25 1.66 8.78 9.22 0.08 3.65 
2623 Pyrimidine_biosynthesis 4.52 1.17 6.56 7.94 5.74 5 1.55 0.31 4.11 8.83 8.5 0.75 2.12 7.94 2.48 7.52 6.36 2.88 
2624 Pyrimidine_catabolism 2.26 5.33 9.48 3.96 0.85 7.96 0.06 6.15 7.12 1.26 1.76 9.02 0.84 2.14 0.11 4.87 6.89 6.52 
2625 Pyrimidine_salvage_reactions 1.25 8.09 5.95 3.47 2.04 6.65 4.62 5.24 4.76 0.42 7.81 6.68 3.71 0.05 8.33 6.76 9.22 7.38 
2626 Synthesis_and_interconversion_of_nucleotide_di-_and_triphosphates 1.92 3.43 9.42 8.22 8.59 6.18 6.01 5.01 0.69 5.67 8.99 0.49 9.21 4.42 4.52 4.51 0.43 3.84 
2627 Uptake_of_Carbon_Dioxide_and_Release_of_Oxygen_by_Erythrocytes 3.67 1.78 2.02 7.72 8.47 0.66 0.04 8.44 6.45 6.07 8.82 1.15 5.25 8.82 8.46 3.21 7.65 4.67 
2628 Uptake_of_Oxygen_and_Release_of_Carbon_Dioxide_by_Erythrocytes 4.19 6.16 4.88 9.04 6.03 6.24 7.78 2.36 5.51 0.61 1.33 1.95 3.86 4.39 1.31 1.49 0.06 2.91 
2629 PI_and_PC_transport_between_ER_and_Golgi_membranes 7.97 4.1 4.04 9.36 4.51 3.09 8.46 1.64 8.53 1.08 4 4 1.85 5.18 7.5 3.94 6.78 5.5 
2630 PIPs_transport_between_Golgi_and_plasma_membranes 3.27 7.29 4.33 1.19 5.55 4.7 9.42 8.33 6.72 7.93 0.81 4.83 4.27 9.21 9.97 4.09 7.01 8.16 
2631 PIPs_transport_between_early_and_late_endosome_membranes 1.33 5.04 7.4 1.98 6.65 4.87 1.33 2.38 4.27 0.48 0.62 0.54 9.79 1.36 7.36 5.14 7.68 4.11 
2632 PIPs_transport_between_early_endosome_and_Golgi_membranes 2.21 6.91 1.6 1.8 6.46 9.4 6.89 9.55 3.28 3.34 9.28 4.23 2.4 0.37 1.55 2.23 1.25 4.26 
2633 PIPs_transport_between_late_endosome_and_Golgi_membranes 7.62 3.48 9.49 6.33 4.43 7.69 3.39 8.38 7.03 6.85 5.59 5.24 8.06 6.96 6.85 6.54 3.38 0.76 
2634 PIPs_transport_between_plasma_and_early_endosome_membranes 4.43 8.26 3.15 9.82 8.14 4.98 5.02 8.37 5.96 9.01 3.32 6.75 6.4 4.22 6.8 2.74 5.21 4.43 
2635 Synthesis_of_PIPs_at_the_ER_membrane 2.33 3.36 8.75 5.12 4.33 9.42 4.5 5.17 4.61 2.69 5.56 0.46 9.98 3.86 4.31 6.09 1.35 9.24 
2636 Synthesis_of_PIPs_at_the_Golgi_membrane 3.72 2.85 9.03 2.91 7.38 1.61 9.05 1.72 4.69 0.59 9.23 6.42 3.76 8.98 6.85 5.1 2.8 2.14 
2637 Synthesis_of_PIPs_at_the_early_endosome_membrane 1.86 2.1 4.59 4.7 4.59 5.31 5.94 9.22 1.62 7.66 6.03 4.35 9.8 4.76 7.3 8.64 0.51 2.16 
2638 Synthesis_of_PIPs_at_the_late_endosome_membrane 5.6 2.5 3.95 2.01 3.4 8.09 4.99 3.87 5.06 9.84 8.06 2.27 7.05 9.11 7.87 0.5 0.98 5.76 
2639 Synthesis_of_PIPs_at_the_plasma_membrane 7.21 5.21 0.29 7.08 8.23 3.59 9.5 1.27 0.35 5.11 2.32 4.65 6.02 3.01 1.92 3.5 2.8 6.58 
2640 PI_and_PC_transport_between_ER_and_Golgi_membranes 2.94 7.44 6.87 3.98 5.99 6.68 9.57 0.62 6.15 1.71 4.9 2.78 2.69 7.05 4.47 4.56 1.75 3.55 
2641 PIPs_transport_between_Golgi_and_plasma_membranes 4.77 1.02 3.2 9.57 6.04 8.44 6.95 4.57 4.83 7.94 6.18 3.27 0.88 0.8 4.5 7.69 9.69 1.23 
2642 PIPs_transport_between_early_and_late_endosome_membranes 9.68 0.62 6.18 9.99 0.17 0.9 8.23 0.37 8.78 0.19 2.61 9.6 1.91 1.83 8.92 9.54 0.26 9.48 
2643 PIPs_transport_between_early_endosome_and_Golgi_membranes 1.11 8.6 0.86 2.73 0.55 6.62 0.52 0.27 0.05 1.07 9.36 0.82 3.27 5.69 9.25 0.3 9.25 1.27 
2644 PIPs_transport_between_late_endosome_and_Golgi_membranes 9.99 4.36 5.88 4.24 6.85 2.85 9.06 7.6 4.78 1.12 0.35 6.68 8.42 5.74 3.32 8.86 0.77 4.07 
2645 PIPs_transport_between_plasma_and_early_endosome_membranes 2.54 4.33 1.04 5.16 7.97 8.58 7.29 7.89 0.18 9.28 6.36 4.2 8.3 2.46 4.25 7.37 2.47 6.3 
2646 PKA_activation_in_glucagon_signalling 9.12 5.58 4.8 7.6 2.83 5.9 1.48 7.15 6.35 9.86 6.99 8.91 4.93 4.93 6.8 4.28 6.13 5.37 
2647 PKA-mediated_phosphorylation_of_key_metabolic_factors 1.22 0.22 8.12 2.88 7.3 2.58 5.03 9.92 1.72 0.27 2.4 8.89 8.42 8 7.13 3.44 6.61 2.73 
2648 PP2A-mediated_dephosphorylation_of_key_metabolic_factors 6.3 9.69 6.69 6.64 8.02 8.56 4.59 0.19 1.65 6.89 2.05 9.19 8.12 8.18 5.22 9.99 7.85 0.45 
2649 PPARA_Activates_Gene_Expression 9.58 3.32 8.53 2.58 1.44 0.15 1.63 3.88 6.11 4.06 1.67 0.58 3.22 4.83 6.23 8.97 8.47 0.35 
2650 5-Phosphoribose_1-diphosphate_biosynthesis 6.01 7.69 5.17 5.17 7.01 5.25 2.04 2.73 0.92 5.35 1.25 0.6 4.89 6.59 4 7.21 1.74 6.42 
2651 Pentose_phosphate_pathway_(hexose_monophosphate_shunt) 3.62 9.29 9.95 7.94 5.3 1.75 2.83 6.36 6.14 7.49 9.11 3.91 3.62 9.07 7.51 5.23 1.29 0.42 
2652 Alpha-oxidation_of_phytanate 7.9 3.6 7.9 3.47 8.45 8.47 4.13 1.17 6.11 7.94 2.54 0.15 8.83 0.88 4.9 8.98 0.78 2.67 
2653 Beta-oxidation_of_pristanoyl-CoA 3.13 8.59 2.28 4.62 6.51 0.72 6.85 9.93 1.65 1.53 3.64 9.03 6.71 6.57 9.66 9.22 8.11 0.2 
2654 Beta-oxidation_of_very_long_chain_fatty_acids 5.52 5.97 2.89 7.23 6.15 9.45 4.57 0.62 3.23 2.2 0.8 6.9 0.71 0.32 4.78 4.67 4.02 3.68 
2655 NADPH_regeneration 8.23 3.23 2.17 1.52 9.46 3.64 7.85 3.73 8.7 6.03 7.76 6.99 8.51 7.33 6.91 6.06 2.4 1.42 
2656 Plasmalogen_biosynthesis 8.13 6.74 4.49 5.03 3.03 8.79 5.71 9.44 4.03 6.79 4.43 7.99 8.29 8.66 9.47 5.51 3.24 8.45 
2657 Aromatic_amines_can_be_N-hydroxylated_or_N-dealkylated_by_CYP1A2 8.95 2.29 5.17 1.5 1.12 4.55 5.37 3.14 9.98 8.78 6.72 1.47 1.07 4.37 2.94 4.44 4.05 0.02 
2658 COX_reactions 0.21 5.83 9.89 4.76 3.56 8.66 4.3 4.46 2.3 7.56 1.91 4.44 5.97 1.82 1.73 6.19 2.24 1.28 
2659 CYP2E1_reactions 5.95 7.34 9.55 9.93 8.43 1.74 7.59 7.08 3.86 9.21 9.21 7.11 2.39 2.46 3.75 3.74 0.12 5.12 
2660 Eicosanoids 9.85 3.11 4 4.89 7.88 7.51 8.43 8.65 7.08 5.73 4.44 5.03 4.99 4.21 1.76 3.67 9.73 0.24 
2661 Ethanol_oxidation 1.8 3.65 7.51 2.25 3.89 4.73 1.75 3.71 3.65 1.8 1.89 2.02 6.73 3.77 6.58 6.4 5.12 0.31 
2662 FMO_oxidizes_nucleophiles 0.79 0.09 5.43 0.15 4.1 7.92 8.75 1.05 1.65 3.55 0.63 6.19 8.48 7.57 8.39 4.52 5.36 3.86 
2663 Fatty_acids 8.51 9.18 7.75 3.12 7.04 7.71 2.13 0.05 5.87 3.46 2.87 2.35 7.36 7.37 6.08 6.75 0.5 5.73 
2664 Miscellaneous_substrates 4.62 9.13 6.04 9.04 6.7 7.08 3.51 2.34 4.5 6.81 6.21 6.91 0.02 7.92 3.25 9.52 0.57 5.59 
2665 Monoamines_are_oxidized_to_aldehydes_by_MAOA_and_MAOB,_producing_NH3_and_H2O2 3.76 7.8 3.61 9.33 0.28 3.29 6.33 6.18 4.7 7.59 5.74 1.1 2.46 0.19 7.04 1.43 2.69 4.04 
2666 Polyamines_are_oxidized_to_amines,_aldehydes_and_H2O2_by_PAOs 1.59 2.38 9.54 2.91 3.57 5.8 0.62 6.65 6.62 7.93 7.88 4.46 1.33 9.66 7.73 9.9 7.77 8.2 
2667 Sterols_are_12-hydroxylated_by_CYP8B1 1.54 1.1 6.96 1.4 1.55 2.72 1.06 1.2 6.65 0.83 2.89 9.85 0.15 6.71 7.03 1.55 2.06 8.15 
2668 Vitamins 2.97 0.7 2.01 6.79 7.23 6.55 2.62 9.12 6.6 2.22 7.9 2.1 2.27 2.49 4.06 6.5 3.22 2.17 
2669 Acetylation 6.63 0.12 0.26 7.31 8.92 8.27 1.44 5.45 7.22 4.86 0.7 1.14 0.28 1.65 2.37 6.72 5.83 8.29 
2670 Conjugation_of_benzoate_with_glycine 8.57 3.92 1.95 5.03 6.05 0.8 2.92 7.36 9.45 4.84 9.52 5.48 6.73 0.97 6.74 4.37 7.84 4.13 
2671 Conjugation_of_phenylacetate_with_glutamine 9.34 7.23 5.09 7.58 2.38 1.96 1.89 5.23 2.28 1.82 2.25 1.28 9.53 0.01 3.61 2.38 6.21 0.11 
2672 Conjugation_of_salicylate_with_glycine 2.48 4.26 8.8 4.23 3.22 7.73 4.72 0.46 9.16 6.28 0.68 3.28 0.59 3.92 3.85 4.2 4.72 1.6 
2673 Formation_of_the_active_cofactor,_UDP-glucuronate 6.82 1.66 6.83 9.34 1.98 2.73 6.21 6.24 8.61 5.74 7.62 3.36 2.26 4.03 1.82 4.46 4.24 1.51 
2674 Glutathione_synthesis_and_recycling 4.47 0.43 6.06 7.89 0.68 0.26 9.96 9.6 4.6 8.03 7.23 6.7 3.62 1.19 9.12 2.55 3.36 1.87 
2675 Methylation 9.85 5.59 5.62 8.7 2.91 7.14 9.8 5.81 5.16 5.2 5.42 1.54 7.64 2.9 3.35 9.77 0.41 0.68 
2676 Transport_and_synthesis_of_PAPS 9.2 0.35 8.11 6.26 9.86 9.97 0.13 1.68 3.54 0.67 2.86 6.45 6.28 2.66 9.91 0.32 2.63 1.8 
2677 Phenylalanine_and_tyrosine_catabolism 7.33 3.82 3.99 0.87 6.49 6.1 2.4 1.68 2.46 5.34 1.62 1.64 1.22 3.44 3.44 7.67 9.05 4.17 
2678 Phosphate_bond_hydrolysis_by_NUDT_proteins 1.01 0.8 7.43 7.14 1.69 0.37 5.97 2.4 9.68 6.75 9.66 3.23 4.84 4.65 7.13 0.25 0.28 6.45 
2679 Acyl_chain_remodeling_of_CL 3.69 3.28 8.05 7.03 9.48 2.99 8 7.17 5.45 1.88 5.24 1.66 6.38 6.75 1.98 8.35 4.49 0.54 
2680 Acyl_chain_remodeling_of_DAG_and_TAG 0.7 6.59 9.81 7.38 6.91 0.62 5.51 4.72 5.29 9.32 4.25 8.84 1.06 0.31 0.78 9.7 7.72 0.38 
2681 Acyl_chain_remodelling_of_PC 6.87 5.62 0.5 8.92 1.26 3.42 8.85 0.08 1.06 5.36 8.28 4.94 8.58 8.02 4.01 6.3 7.01 3.92 
2682 Acyl_chain_remodelling_of_PE 2.94 3.63 5.05 9.28 5.51 9.27 8.67 9.9 8.02 2.37 7.59 7.05 9.89 0.55 5.51 7.86 6.39 4.65 
2683 Acyl_chain_remodelling_of_PG 8.01 1.9 0.02 9.02 1.4 6.26 2.39 2.73 7.48 2.14 5.14 2.46 3.67 1.81 7.35 6.59 1.74 0.11 
2684 Acyl_chain_remodelling_of_PI 4.77 8.57 2.4 0.96 6.75 1.67 0.51 4.13 3.85 6.97 5.96 7.64 2.23 1.25 8.57 5.25 1.55 2.86 
2685 Acyl_chain_remodelling_of_PS 6.14 8.94 8.39 3.72 5.49 7.23 3.78 6.36 2.49 8.7 1.36 0.12 5.56 9.85 2.44 1.94 7.83 2.81 
2686 Hydrolysis_of_LPC 7.49 0.13 6.43 3.09 6.62 2.76 6.14 7.76 1.55 0.78 4.72 5.47 7.77 7.38 5.98 7.82 5.01 1.35 
2687 Hydrolysis_of_LPE 8.14 6.32 9.68 5.26 4.28 0.22 5.45 4.71 0.05 4.48 9.39 7.78 4.02 1.14 4.4 1.12 1.83 5.54 
2688 PI_and_PC_transport_between_ER_and_Golgi_membranes 8.39 1.68 9 3.57 9.46 6.77 9.4 5.59 7.71 5.92 1.33 7.54 4.88 4.27 6.79 6.54 5.72 9.42 
2689 PIPs_transport_between_Golgi_and_plasma_membranes 4.16 6.83 7.04 7.65 2.23 7.15 1.22 2.81 3.43 9.55 1.65 3.18 5.99 4.11 2.41 3.49 4.88 8.36 
2690 PIPs_transport_between_early_and_late_endosome_membranes 0.36 7.95 9.1 8.1 8.89 5.54 8.34 5.3 5.28 7.9 7.03 9.09 3.27 2.75 9.97 2.29 5.19 8.37 
2691 PIPs_transport_between_early_endosome_and_Golgi_membranes 8.02 2 2.01 4.39 7.51 9.55 1.95 8.64 0.1 0.89 5.1 0.91 9.12 3.32 5.62 2.15 3.82 1.87 
2692 PIPs_transport_between_late_endosome_and_Golgi_membranes 4.28 6.94 2.15 1.57 7.42 7.53 7.28 1.56 8.4 9.8 4.58 9.89 5.9 3.82 2.24 7.28 1.29 3.56 
2693 PIPs_transport_between_plasma_and_early_endosome_membranes 5.78 9.87 2.67 8.07 5.85 8.99 2.93 5.7 4.45 2.22 8.19 7.04 2.43 4.51 9.95 3.82 5.94 4.03 
2694 Synthesis_of_BMP 4.81 5.25 3.2 5.64 1.03 6.51 8.24 6.19 6.75 4.74 0.16 5.3 4.01 4.33 7.44 4.82 0.43 0.41 
2695 Synthesis_of_CL 1.49 0.99 8.54 4.91 3.26 9.05 0.31 0.16 2.7 7.69 5.1 8.17 0.28 5.97 9.54 0.64 5.6 1.72 
2696 Synthesis_of_PA 1.16 1.75 3.19 0.3 2.32 2.4 1.29 2.46 8.26 2.04 1.36 8.97 1.17 2.87 6.44 8.14 2.34 9.24 
2697 Synthesis_of_PC 8.37 0.38 6.55 8.14 8.24 2.54 9.02 5.67 7.73 5.55 1.35 2.44 7.2 1.97 9.6 5.04 9.75 3.91 
2698 Synthesis_of_PE 6.44 1.83 6.36 6.22 2.9 7.34 4.52 7.11 2.4 6.42 1.34 8.14 7.84 0.06 2.24 8.37 7.7 5.14 
2699 Synthesis_of_PG 1.51 3.54 7.13 2.64 1.25 4.2 0.9 6.87 8.88 7.27 2.58 7.26 7.92 1.97 4.56 0.97 1.93 1.11 
2700 Synthesis_of_PI 6.91 2.24 0.5 6.61 6.29 7.21 2.69 0.43 6.32 4.74 7.04 7.73 3.84 2.11 0.83 6.92 2.66 3.72 
2701 Synthesis_of_PIPs_at_the_ER_membrane 5.8 2.89 6.5 4.67 5.75 7.93 1.79 2.25 9.7 8.97 4.43 6.85 5.76 5.08 0.05 1.68 3.31 5.07 
2702 Synthesis_of_PIPs_at_the_Golgi_membrane 6.59 2.83 5.83 5.48 7.55 8.94 5.33 5.75 2.01 9.87 1.1 5.32 1.9 7.23 6.73 5.85 5.04 1.03 
2703 Synthesis_of_PIPs_at_the_early_endosome_membrane 3.43 5.31 2.02 7.53 7.48 2.67 2.37 8.67 2.16 5.47 7.5 2 4.31 8 6.34 3.78 5.02 0.9 
2704 Synthesis_of_PIPs_at_the_late_endosome_membrane 9.04 6.68 1.67 5.3 3.9 3.69 0.7 3.16 8.95 6.77 9.09 2.21 8.03 0.99 1.74 4.86 8.87 1.26 
2705 Synthesis_of_PIPs_at_the_plasma_membrane 8.71 5.7 4.7 7.79 1.3 6.04 2.96 2.46 2.21 1.17 5.55 9.65 0.32 5.33 9.11 5.63 5.65 4.15 
2706 Synthesis_of_PS 7.42 1.02 9.25 3.54 8.68 4.98 7.6 6.68 3.95 4.06 6.37 6.1 5.7 9.92 5.15 6.3 6.31 7.73 
2707 Plasmalogen_biosynthesis 6.86 9.28 2.51 0.68 0.79 2.89 5.81 2.2 3.01 1.47 6.17 8.74 9.61 7.97 7.46 1.44 2.17 5.98 
2708 Polyamines_are_oxidized_to_amines,_aldehydes_and_H2O2_by_PAOs 9.09 7.46 9.7 6.55 5.21 4.26 1.87 2.62 1.32 3.67 8.96 9.92 9.75 1.86 6.76 9.43 3.01 0.25 
2709 Heme_biosynthesis 3.47 1.73 5.68 3.03 0.95 8.47 4.77 0.35 7.85 2.69 3.53 6.72 6.83 4.09 1.31 8.13 0.19 9.34 
2710 Heme_degradation 1.15 7.74 6.34 6.75 3 5.63 7.33 2.96 6.15 4.96 7.08 7.12 2.16 8.45 6.42 6.48 7.64 0.54 
2711 Pregnenolone_biosynthesis 0.13 9.51 7.23 7.73 7.42 6.78 3.71 5.42 1.06 3.22 6.53 6.92 8.9 5.12 8.12 8.18 9.04 4.88 
2712 Proline_catabolism 8.11 2.61 1.8 3.65 1.25 7.04 5.1 9.4 5.39 0.16 7.8 1.55 4.18 2.97 3.1 1.88 5.96 1.84 
2713 Propionyl-CoA_catabolism 5.04 6.65 3.76 5.94 1.6 9.78 4.44 2.05 7.69 1.9 4.01 8.38 8.14 7.5 4.79 2.03 4.27 8.88 
2714 Purine_catabolism 0.11 2.58 4.65 5.06 1.27 9.3 6.17 8.53 6.33 3.04 8.27 1.57 4.86 1.96 2.47 6.62 5.69 8.85 
2715 Purine_catabolism 6.35 9.61 0.14 7.78 6.46 7.91 6.04 0.99 7.64 1.49 4.34 7.35 1.71 2.72 9.37 0.55 5.42 3.95 
2716 Purine_ribonucleoside_monophosphate_biosynthesis 1.47 2.75 2.08 4.63 7.46 5.63 2.92 4.03 4.92 8.01 6.5 0.52 0.77 9.17 2.12 1.9 4.21 1.29 
2717 Purine_salvage 7.14 1.64 8.36 3.11 0.42 7.8 5.8 0.31 5.4 7.18 2.62 2.05 8.29 5.35 3.11 8.75 4.19 9.61 
2718 Purine_ribonucleoside_monophosphate_biosynthesis 2.52 0.1 5.53 8.05 8.59 3.59 1.3 0.84 4.92 4.12 1.55 0.66 0.32 1.16 1.32 4.12 6.73 6.35 
2719 Purine_salvage 2.88 6.11 8.99 3.33 4.7 9.14 2.74 8.06 5.34 9.57 8.75 3.14 0.08 3.46 5.75 3.34 8.09 1.88 
2720 Pyrimidine_biosynthesis 3.09 5.26 3.03 7.25 5.67 0.72 8.48 5.56 5.28 6.57 1.02 2 6.2 7.52 0.29 5.56 6.89 0.16 
2721 Pyrimidine_catabolism 0.96 8.75 9.57 8.65 9.85 6.37 1.76 0.8 5.44 6.43 2.99 9.01 1.49 0.15 6.41 0.94 3.61 9.68 
2722 Pyrimidine_biosynthesis 2.13 7.47 3.3 3.41 3.64 7.38 5.58 6.79 4.12 4.84 9.15 6.28 2.53 9.83 0.59 1.06 6.87 1.41 
2723 Pyrimidine_catabolism 3.97 4.24 0.93 9.57 0.98 8.99 2.41 7.61 0.14 1.6 5.03 3.84 1.6 5.96 8.06 5.72 6.91 2.04 
2724 Pyrimidine_salvage_reactions 6.12 7.1 4.05 2.58 6.41 6.4 4.08 0.22 5.12 2.76 5.04 9.02 5.37 6.12 8.04 8.06 8.19 3.29 
2725 Pyrimidine_salvage_reactions 1.76 9.55 6.08 2.48 1.94 5.96 7.84 0.82 5.95 6.5 8.83 5.95 2.09 1.06 5.85 9.89 8.19 4.41 
2726 Regulation_of_pyruvate_dehydrogenase_(PDH)_complex 3.64 0.13 1.65 5.68 3.93 9.98 5.4 8.15 0.43 1.65 6.6 4.46 0.88 4.13 0.88 9.06 5.36 0.76 
2727 Citric_acid_cycle_(TCA_cycle) 9.05 2.45 4.51 2.45 5.32 9.62 6.74 6.15 9.81 6.47 6.74 3.59 1.76 4.51 3.32 0.74 6.57 9.7 
2728 Interconversion_of_2-oxoglutarate_and_2-hydroxyglutarate 9.04 3.17 7.86 1.91 3.63 4.4 2.38 6.49 1.82 7.91 8.11 1.05 0.9 2.43 4.13 8.99 3.2 6.9 
2729 Regulation_of_pyruvate_dehydrogenase_(PDH)_complex 3.37 6.19 5.74 5.78 9.91 0.66 5.83 9 1.24 5.37 4.57 5.1 4.78 6.45 8.3 5.37 1.29 6.28 
2730 Recycling_of_bile_acids_and_salts 1.23 2.93 4.65 5.91 2.29 8.09 6.65 2.32 7.96 8.95 8.68 2.93 6.8 1.35 1.15 5.02 6.68 7.15 
2731 Activation_of_Gene_Expression_by_SREBP_(SREBF) 3.42 2.44 5.6 2.92 8.14 7.38 8.12 9.95 1.06 3.45 8.01 4.9 8.88 7.5 1.06 0.28 6.23 6.23 
2732 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 5.95 4.81 8.66 1.5 3.45 6.95 0.8 5 4.34 3.66 7.06 9.78 4.38 1.7 4.92 0.04 3.98 5.83 
2733 Inhibition_of_Insulin_Secretion_by_Adrenaline/Noradrenaline 5.99 3.51 7 8.8 1.42 7.65 2.27 1.44 4.24 2.06 5.61 6.29 1.1 7.37 2.66 3.53 6.7 3.55 
2734 Regulation_of_Insulin_Secretion_by_Acetylcholine 8.14 2.19 4.39 7.67 0.3 2.29 2.21 7.44 3.63 3.03 0.15 0.43 9.68 3.49 6.39 6.96 0.49 2.69 
2735 Regulation_of_Insulin_Secretion_by_Fatty_Acids_Bound_to_GPR40_(FFAR1) 7.7 9.37 0.6 5.31 0.65 2.04 1.26 8.32 4.47 3.34 0.01 3.36 8.36 5.29 5.17 0.27 6.89 7.51 
2736 Regulation_of_Insulin_Secretion_by_Glucagon-like_Peptide-1 6.93 1.74 9.73 9.83 5.48 2.27 1.44 1.6 4.55 3.02 7.58 6.52 2.52 4.1 8.3 3.75 3.31 5.15 
2737 Regulation_of_Insulin_Secretion_by_Acetylcholine 6.43 6.71 3.72 5.89 5.06 6.86 1.05 4.05 3.25 6.77 6.93 6.62 2.32 7.48 4.94 2.48 5.47 1.36 
2738 Regulation_of_Insulin_Secretion_by_Fatty_Acids_Bound_to_GPR40_(FFAR1) 0.23 1.96 3.91 6.36 0.49 4.5 8.2 8.19 8.59 8.38 7.45 6.92 3.84 7.93 4.94 0.96 0.96 3 
2739 Regulation_of_Insulin_Secretion_by_Fatty_Acids_Bound_to_GPR40_(FFAR1) 2.79 0.08 9.61 3.7 3.7 2.98 2.07 5.82 0.51 6.93 2.81 3.31 2.61 2.02 2.86 2.19 9.96 0.87 
2740 Regulation_of_Insulin_Secretion_by_Glucagon-like_Peptide-1 7.92 1.7 4.24 5.9 8.89 0.04 8.29 1.47 5.71 4.27 1.53 2.22 7.24 2.77 6.46 6.21 4.97 4.06 
2741 PPARA_Activates_Gene_Expression 7.04 6.78 9.22 2.27 0.17 6.99 4.47 1.35 4.04 2.06 7.61 5.2 7.1 3.04 5 6.68 9.07 9.17 
2742 Regulation_of_ornithine_decarboxylase_(ODC) 5.15 5.69 5.12 4.02 8.61 7.78 1.97 0.5 3.75 8.89 8.38 2.52 1.86 7.53 2.66 1.29 0.94 2.51 
2743 Regulation_of_pyruvate_dehydrogenase_(PDH)_complex 1.23 7.49 2.31 4.36 3.03 6.6 4.94 0.04 4.78 7.19 0.68 2.18 1.09 2.39 3.07 4.14 8.11 7.61 
2744 Regulation_of_thyroid_hormone_activity 2.29 5.75 1.7 9.07 0.97 8.78 2.08 8.06 5.78 2.51 2.63 9.88 9.07 5.27 9.45 4.68 8.81 6.1 
2745 Respiratory_electron_transport 2.56 8.67 5.35 0.93 8.28 1.73 9.36 6.9 8.38 2.53 0.64 6.35 1.66 4.73 9.63 6.09 3.52 0.74 
2746 Formation_of_ATP_by_chemiosmotic_coupling 6.35 5.1 2.28 2.9 0.04 2.68 6.38 6.15 2.42 6.07 7.15 8.87 4.93 1.69 5.25 6.92 3.24 5.89 
2747 Respiratory_electron_transport 1.76 3.78 0.88 5.58 1.74 2.14 7.46 3.12 8.32 8.9 6.64 5.03 2.95 6.94 6.6 7.27 7.22 6.57 
2748 The_fatty_acid_cycling_model 1.01 6.12 0.72 6.25 1.38 5.63 0.16 9.83 1.72 6.17 6.47 9.5 2.27 8.1 5.22 9.89 8.2 5.88 
2749 The_proton_buffering_model 1.65 6.35 2.42 6.7 9.55 0.03 0.11 2.51 7.5 3.28 2.36 9.23 4.02 9.63 8.23 0.83 5.17 4.27 
2750 Reversible_Hydration_of_Carbon_Dioxide 3.31 8.44 7.86 2.99 8.69 3.62 8.94 0.18 0.78 2.94 7.54 5.35 5.09 9.18 3.62 0.52 3.67 4.51 
2751 Serine_biosynthesis 0.29 9.81 6.92 1.4 7.43 1.68 6.6 2.41 0.99 9.75 2.01 6.18 1.25 6.84 4.86 9.52 6.15 8.6 
2752 Serotonin_and_melatonin_biosynthesis 3.12 8.76 2.74 8.32 3.33 4.88 6.47 4.16 5.39 2.83 0.54 7.92 4.01 6.17 9.75 3.99 4.76 0.57 
2753 Sphingolipid_de_novo_biosynthesis 0.32 8.21 3.87 2.72 4.62 2.62 5.07 2.15 3.19 6.21 1.94 7.69 9.12 2.58 5.42 2.32 2.98 0.46 
2754 Glycosphingolipid_metabolism 6.78 3.6 7.94 9.75 3.72 4.83 0.33 6.71 4.81 2.7 9.93 9.38 4.41 2.6 8.82 7.6 2.65 2.9 
2755 Sphingolipid_de_novo_biosynthesis 3.31 4.07 6.3 4.75 7.25 1.81 2.07 6.93 5.08 0.28 9.1 5.64 2.15 3.43 1.95 7.89 4.43 4.28 
2756 Sterols_are_12-hydroxylated_by_CYP8B1 0.18 6.14 8.27 0.67 7.42 8.04 7.07 4.54 2.14 3 7.56 9.44 3.74 5.5 1.3 7.95 2.33 8.31 
2757 Sulfide_oxidation_to_sulfate 7.73 6.37 7.42 8.06 0.53 8.83 3.13 3.77 0.09 9.61 4.27 6.41 1.94 4 3.32 4.44 9.31 8.41 
2758 Cysteine_formation_from_homocysteine 4.8 5.21 8.6 9.78 1.92 3.29 1.6 8.22 7.23 5.24 8.67 7.53 2.92 5.45 0.96 7.49 1.74 4.03 
2759 Methionine_salvage_pathway 8.49 8.7 9.57 7.04 1.68 3.97 3.11 9.95 5.35 9.23 4.11 2.69 8.83 4.2 1.52 7.11 7.82 8.78 
2760 Sulfide_oxidation_to_sulfate 1.61 3.31 5.64 9.38 9.43 9 9.74 0.18 3.28 7.15 8.3 3 5.75 7.63 0.18 2.14 3.64 7.12 
2761 Synthesis_and_interconversion_of_nucleotide_di-_and_triphosphates 1.48 4.02 4.78 3.79 3.05 9 1.97 9.85 1.85 4.82 1.41 1.09 9.19 4.67 6.08 8.9 9.45 5.55 
2762 Synthesis_of_(16-20)-hydroxyeicosatetraenoic_acids_(HETE) 6.67 8.14 4.66 4.3 9.4 0.36 0.78 8.66 4.1 0.8 8.7 5.46 5.97 1.68 6.77 5.21 0.24 5.37 
2763 Synthesis_of_12-eicosatetraenoic_acid_derivatives 6.97 4.12 4.13 3.2 3.1 9.63 0.63 4.35 1.44 6.97 4.05 8.86 0.15 7.29 9.18 8.5 4.8 7.72 
2764 Synthesis_of_15-eicosatetraenoic_acid_derivatives 5.04 2.67 2.18 2.8 8.38 0.65 5.34 9.07 2.65 6.02 2.18 0.89 6.69 4.29 7.91 6.42 6.24 0.66 
2765 Synthesis_of_5-eicosatetraenoic_acids 0.02 3.6 3.91 3.21 3.76 1.59 4.33 3.36 4.54 7.73 8.8 5.76 2.72 4.68 7.09 3.06 5.92 1.66 
2766 Synthesis_of_BMP 2.51 1.1 4.89 4.41 2.87 9.81 2.04 1.63 8.3 6.96 0.19 2.55 4.08 9.19 7.41 6.56 8.27 9.19 
2767 Synthesis_of_CL 4.25 8.54 4.19 3.18 7.5 5.59 7.37 0.09 2.18 8.16 5.54 8.08 5.85 4.04 1.29 2.87 6.41 4.67 
2768 Synthesis_of_Hepoxilins_(HX)_and_Trioxilins_(TrX) 4.31 4.97 3.39 1.27 3.86 4.96 7.01 4.83 6.52 1.04 5.1 3.97 2.38 2.93 9.85 4.21 1 7.45 
2769 Synthesis_of_IP2,_IP,_and_Ins_in_the_cytosol 0.54 4.46 7.62 1.47 8.13 2.85 5.83 5.65 0.13 8.96 7.21 9.56 7.08 7.14 9.38 7.81 0.63 6.2 
2770 Synthesis_of_IP3_and_IP4_in_the_cytosol 8.41 9.02 5.08 7.33 0.92 6.75 2.62 8.44 4.13 2.59 1.05 1.41 2.9 1.3 5.59 5.87 2.26 9.03 
2771 Synthesis_of_IPs_in_the_ER_lumen 6.75 9.9 4.2 2.01 7.31 3.41 1.3 6.21 2.99 5.49 6.63 2.27 7.84 7.7 9.32 2.03 0.02 5.89 
2772 Synthesis_of_IPs_in_the_nucleus 7.05 8.26 2.21 5.92 8.42 3.13 9.53 2.38 3.51 2.79 4.25 3.9 5.61 7.1 7.7 6.81 2.34 1.72 
2773 Synthesis_of_Ketone_Bodies 0.29 6.89 6.93 0.03 9.1 9.81 0.06 3.62 1.81 0.34 5.54 4.37 5.57 9.73 0.82 2.75 0.43 4.86 
2774 Synthesis_of_Leukotrienes_(LT)_and_Eoxins_(EX) 1.72 9.35 0.49 2.71 7.23 9.06 8.52 0.54 3.6 6.78 1.87 7.5 9.68 7.66 7.69 9.17 9.04 3.4 
2775 Synthesis_of_Lipoxins_(LX) 8.53 4.25 9.11 2.42 6.71 3.56 7.63 7.9 9.74 2.82 8.23 1.12 9.6 6.33 7.47 2.85 8.01 9.76 
2776 Synthesis_of_PA 6.2 2.49 4.72 0.35 6.78 3.69 9.02 5.34 6.47 3.35 4.8 7.92 1.89 0.17 8.63 7.06 8.67 5.96 
2777 Synthesis_of_PC 4.07 4.71 3.12 9.64 6.36 4.87 8.41 2.56 6.36 6.95 8.4 5.08 9.68 4.99 8.04 9.18 4.2 3.5 
2778 Synthesis_of_PE 9.63 3.25 4.74 4.73 6.06 1.35 4.98 5.7 1.32 4.03 4.94 7.51 2.09 1.42 2.74 1.4 6.48 3.45 
2779 Synthesis_of_PG 8.17 4.97 8.95 2.26 0.06 2.88 1.14 9.62 4.32 6.21 6.51 5.84 8.74 5.03 1.28 5.4 1.21 4.14 
2780 Synthesis_of_PI 9.57 1.82 8.23 0.69 5.48 8.48 9.52 2.01 0.5 5.05 6.67 6.11 6.11 5.32 3.71 6.35 7.53 8.4 
2781 Synthesis_of_PIPs_at_the_ER_membrane 2.07 6.61 2.33 2.25 7.27 5.37 7.75 5.19 4.4 0.21 2.44 2.21 8.73 6.14 6.6 8.61 0.31 3.59 
2782 Synthesis_of_PIPs_at_the_Golgi_membrane 6.45 6.17 7.98 8 2.76 6.05 7.13 4.59 5.06 3.4 5.79 0.91 4.95 2.81 1.83 4.78 7.18 7.83 
2783 Synthesis_of_PIPs_at_the_early_endosome_membrane 4.38 3.09 1.06 8.26 9.99 2.25 3.11 5.6 1.87 7.36 6.84 1.54 8.97 5.36 7.91 7.27 9.43 6.99 
2784 Synthesis_of_PIPs_at_the_late_endosome_membrane 6.25 7.31 2.75 9.8 5.64 8.03 7.69 6.97 2.82 5.65 0.78 7.3 0.88 6.46 8.04 1.77 1.87 4.43 
2785 Synthesis_of_PIPs_at_the_plasma_membrane 9.34 6.9 2.57 4.28 1.03 5.49 8.44 3.42 9.34 7.21 3.54 4.09 9.57 4.59 3.77 2.33 7.22 7.99 
2786 Synthesis_of_PS 4.09 4 4.61 2.31 2.82 5.4 7.71 2.02 7.19 5.01 9.55 0.22 0.35 1.37 8.31 0.17 4.75 1.47 
2787 Synthesis_of_Prostaglandins_(PG)_and_Thromboxanes_(TX) 7.81 7.64 9.64 6.1 1.58 0.57 5.59 8.06 9.9 2.79 3.54 0.65 9.26 2.6 1.3 5.95 2.23 8.02 
2788 Synthesis_of_bile_acids_and_bile_salts_via_24-hydroxycholesterol 2.77 8.86 4.16 3.97 9.88 2.51 0.65 3.64 5.12 0.44 3.12 3.65 7.49 0.2 5 7.34 7.17 1.32 
2789 Synthesis_of_bile_acids_and_bile_salts_via_27-hydroxycholesterol 3.21 7.13 0.94 5.84 3.16 7.68 4.62 4.73 9.59 0.34 5.09 7.64 5.1 2.36 2.93 8.83 3.63 1.48 
2790 Synthesis_of_bile_acids_and_bile_salts_via_7alpha-hydroxycholesterol 6.62 0.18 2.71 3.62 7.97 5.97 2.02 6.15 7.89 3.35 6.62 6.82 5.5 7.58 6.79 8.81 5.73 3.18 
2791 Synthesis_of_bile_acids_and_bile_salts_via_24-hydroxycholesterol 3.25 4.05 6.13 6.11 9.32 5.14 9.56 0.35 4.35 6.93 2.01 6.43 0.05 0.06 6.69 1.37 7.57 1.2 
2792 Synthesis_of_bile_acids_and_bile_salts_via_27-hydroxycholesterol 8.39 8.26 5.97 4.39 0.05 0.61 0.17 7.78 2.23 6.31 4.55 7.76 5.42 3.36 2.98 8.47 3.33 9.26 
2793 Synthesis_of_bile_acids_and_bile_salts_via_7alpha-hydroxycholesterol 9.27 8.83 1.11 7.52 9.27 0.45 1.85 5.74 7.02 3.16 1.69 6.24 8.27 8.48 4.4 5.96 0.97 3 
2794 Synthesis_of_epoxy_(EET)_and_dihydroxyeicosatrienoic_acids_(DHET) 5 6.12 7.42 5.23 5.77 7.27 9.14 8.71 2.4 8.78 8.66 3.9 3.92 9.29 7.58 1.18 7.73 9.4 
2795 Synthesis_of_pyrophosphates_in_the_cytosol 7.99 0.34 4.38 2.21 3.17 9.82 7.15 2.47 4.4 1.59 6.39 1.39 7.34 6.87 7.7 3.89 5.24 9.03 
2796 Synthesis_of_very_long-chain_fatty_acyl-CoAs 4.59 8.53 5.2 9.65 5.32 7.04 2.47 7.37 1.73 2.7 7.46 2.19 9.02 3.73 7.58 5.11 9.99 7.26 
2797 Tetrahydrobiopterin_(BH4)_synthesis,_recycling,_salvage_and_regulation 9.16 3.95 5.54 2.22 9.1 0.8 0.92 2.16 3.47 5.75 0.08 7.76 7.81 7.02 7.97 9.55 4.73 8.11 
2798 Citric_acid_cycle_(TCA_cycle) 2.81 4.86 8.47 2.33 3.01 8.92 9.47 6.73 9.22 7.4 3.23 0.34 4.52 9.94 6.01 2.04 8.63 4.45 
2799 Formation_of_ATP_by_chemiosmotic_coupling 8.99 2.73 0 7.21 9.77 7.33 3.33 0.7 9.75 9.51 8.31 7.36 2.45 4.89 7.43 6.48 1.23 0.93 
2800 Interconversion_of_2-oxoglutarate_and_2-hydroxyglutarate 7.83 1.07 6.88 7.6 6.5 7.14 4.37 8.04 1.58 8.34 2.13 3.84 9.77 5.64 1.92 0.42 5.7 6.16 
2801 Regulation_of_pyruvate_dehydrogenase_(PDH)_complex 7.05 7.2 5.61 7.81 2.28 0.19 3.46 8.04 0.43 7.98 1.02 5.26 4.19 4.78 0.99 5.23 9.63 5.53 
2802 Respiratory_electron_transport 1.33 9.49 8.61 1.24 0.92 1.16 3.28 4 6.96 6.75 6.93 6.36 8.58 4.59 2.72 3.53 4.37 9.43 
2803 The_fatty_acid_cycling_model 4.74 9.14 4.37 0.63 8.13 6.34 4.71 2.08 7.35 4.19 3.45 8.84 1.06 3.8 8.11 0.15 7.79 2.43 
2804 The_proton_buffering_model 7.02 5.46 4.9 9.71 4.44 3.23 1.93 8.71 2.33 1.08 2.33 4.72 3.28 9.62 3.05 3.55 7.45 2.49 
2805 The_fatty_acid_cycling_model 4.65 8.47 4.25 4.63 3.5 3.57 3.94 4.62 1.18 5.92 0.53 9.98 1.91 2.8 5.89 6.59 2.82 3.78 
2806 The_proton_buffering_model 4.14 0.34 8.38 0.42 8.38 5.53 8.75 9.4 3.7 5.36 2.03 3.98 2.2 2.35 7.2 8.42 9.32 8.09 
2807 Regulation_of_thyroid_hormone_activity 2.74 3.71 4.29 4.34 2.71 7.98 9.22 1.32 2.16 7.64 0.56 3.58 7.22 1.56 6.53 0.17 1.22 5.5 
2808 Trafficking_of_dietary_sterols 1.29 8.52 4.53 6.45 3.24 5.03 4.63 2.77 1.29 6.51 9.61 0.54 6.57 4.48 7.93 7.18 9.47 7.34 
2809 Transport_and_synthesis_of_PAPS 3.41 9.34 6.42 1.68 3.99 6.3 7.91 0.77 6.32 8.67 1.37 2.33 4.3 2.02 8.75 8.92 9.6 5.01 
2810 Synthesis_of_very_long-chain_fatty_acyl-CoAs 8.77 2.25 0.36 8.61 5.09 2.66 6.14 9.36 4.23 0.26 0.84 9.9 2.18 2.03 3.03 8.87 1.34 3.05 
2811 Tryptophan_catabolism 5.65 4.55 4.91 1.51 2.69 8.6 8.43 5.52 4.98 4.47 3.87 1.61 6.6 4.41 1.81 7.41 4.59 4.33 
2812 Ubiquinol_biosynthesis 2.5 4.48 8.37 2.03 2.86 9.45 9.78 4.9 5.96 9.78 9.43 6.41 0.12 6.57 4.96 2.23 9.31 6.76 
2813 Uptake_of_Carbon_Dioxide_and_Release_of_Oxygen_by_Erythrocytes 9.29 9.77 8.34 6 9.5 1.4 0.57 2.11 3.21 1.96 7.81 3.07 9.24 9.1 2.47 0.94 5.28 3.57 
2814 Uptake_of_Oxygen_and_Release_of_Carbon_Dioxide_by_Erythrocytes 3.91 0.51 1.25 3.95 7.45 7.93 2.43 1.33 2.87 8.55 2.56 0.21 4.31 4.2 6.43 6.18 9.42 4.48 
2815 Urea_cycle 7.61 5.46 8.21 1.94 3.74 4.43 9.16 6.27 4.39 6.23 4.76 0.02 3.17 1.58 4.17 1.06 0.59 2.88 
2816 Vitamin_B1_(thiamin)_metabolism 1.03 2.18 1.56 8.59 6.6 9.79 1.03 6.49 6.23 9.11 8.77 6.7 8.56 3.83 2.61 8.01 6.24 8.62 
2817 Vitamin_B2_(riboflavin)_metabolism 5.96 4.97 7.54 6.21 2.03 5.38 2.26 5.02 3.4 3.91 9 1.57 2.06 6.26 1.92 6.51 6.73 8.74 
2818 Coenzyme_A_biosynthesis 7.65 7.89 1.07 0.13 9.16 0.45 6.69 5.82 7.27 3.75 4.32 2.16 0.25 2.63 4.28 6.2 9.27 9.61 
2819 Vitamin_C_(ascorbate)_metabolism 4.65 2.63 0.96 2.89 4.71 4 8.41 1.64 8.04 8.08 0.76 0.94 7.56 1.87 9.29 7.97 2.3 4.22 
2820 Vitamin_D_(calciferol)_metabolism 3.33 3.18 2.6 2.9 4.03 1.43 8.43 9.76 1.29 5.81 3.48 3.32 9.24 4.63 3.62 8.15 6.94 8.9 
2821 Vitamins 0.84 0.16 6.31 0.71 5.18 3.39 8.97 3.78 6.35 3.65 6.41 9.63 5.5 3.67 3.71 2.9 6.26 5.21 
2822 Vitamins_B6_activation_to_pyridoxal_phosphate 1.24 0.87 1.81 4.4 5.82 2.96 0.36 2.51 4.64 4.63 1.47 6.18 4.76 6.67 2.93 3.28 6.62 5.01 
2823 Aromatic_amines_can_be_N-hydroxylated_or_N-dealkylated_by_CYP1A2 5.95 1.31 0.41 6.3 9.76 0.01 0.83 9.28 5 4.38 9.08 3.54 0.14 0.27 8.27 3.59 7.92 6.09 
2824 CYP2E1_reactions 8.1 2.57 2.14 7.1 1.96 2.09 9.67 7.35 4.43 8.11 4.08 7.51 4.14 0.64 4.05 2.71 5.07 8.84 
2825 Linoleic_acid_(LA)_metabolism 4.81 9.43 8.33 8.5 6.31 1.71 0.66 2.68 8.74 3.53 1.43 2.55 0.66 1.22 8.53 8.38 8 8.4 
2826 alpha-linolenic_acid_(ALA)_metabolism 6.94 9.34 5.49 6.39 3.71 3.46 3.18 1.9 3.68 5.84 2.02 7.2 0.72 4.67 5.9 5.98 6.99 0.34 
2827 alpha-linolenic_acid_(ALA)_metabolism 3.85 2.07 5.81 8.57 9.24 7.63 8.65 3.59 5.89 2.6 9.9 0.88 7.56 0.22 9.28 8.52 5.08 9.05 
2828 eNOS_activation 4.18 8.96 3.42 8.05 1.63 3.31 0.59 6.13 5.91 5.39 2.49 8.62 6.48 5.37 5.52 3.62 1.95 0.1 
2829 NOSIP_mediated_eNOS_trafficking 6.21 6.16 7.12 3.99 7.59 7.11 1.17 5.84 4.72 4.35 8.66 8.61 0.45 8.22 4.5 9.17 5.38 0.83 
2830 NOSTRIN_mediated_eNOS_trafficking 3.68 5.62 2.4 4.23 6.96 6.28 8.32 4.25 0.4 3.97 2.77 0.91 9.66 9.81 9.25 4.57 3.32 8.56 
2831 Tetrahydrobiopterin_(BH4)_synthesis,_recycling,_salvage_and_regulation 8.64 5.7 1.38 7.32 6.13 5.09 3.3 3.03 5.52 7.82 9.46 6.97 0 2.32 7.09 4.45 8.25 1.01 
2832 eNOS_activation 3.31 7.9 2.93 2.28 2.35 8 3.6 2.59 2.62 8.6 7.64 6.93 8.37 4.24 5.46 3.41 0.37 5.42 
2833 Beta_oxidation_of_butanoyl-CoA_to_acetyl-CoA 1.14 2.36 3.78 2.76 7.01 1.2 9.31 3.56 0.25 7.89 1.48 9 2.45 7.04 7.53 9.85 2.46 0.1 
2834 Beta_oxidation_of_decanoyl-CoA_to_octanoyl-CoA-CoA 4.5 6.8 4.17 3.69 5.29 5.66 5.69 6.85 7.32 7.12 3.31 4.02 5.75 3.89 3.45 0.97 2.26 3.22 
2835 Beta_oxidation_of_hexanoyl-CoA_to_butanoyl-CoA 8.2 7.4 9.71 6.14 1.81 2.42 5.01 0.64 1.26 1.59 5.29 4.69 1.16 5.28 8.99 1.91 4.87 5.66 
2836 Beta_oxidation_of_lauroyl-CoA_to_decanoyl-CoA-CoA 2.25 0.82 2.78 1.21 4.48 8.49 3.33 7.66 1.28 1.76 7.12 5.96 2.48 6.67 8.92 7.95 9.48 2.55 
2837 Beta_oxidation_of_myristoyl-CoA_to_lauroyl-CoA 0.04 4.06 8.14 7.51 3.7 8.75 0.04 3.31 5.26 0.33 4.25 9.31 1.96 1.69 1.18 5.3 7.93 9.44 
2838 Beta_oxidation_of_octanoyl-CoA_to_hexanoyl-CoA 8.81 8.73 0.86 6.28 5.42 1.77 5.92 0.28 0.54 2.86 1.83 2.37 8.22 4.32 5.33 1.22 8.33 7.63 
2839 Beta_oxidation_of_palmitoyl-CoA_to_myristoyl-CoA 5.38 0.6 3.68 0.25 3.74 0.99 3.29 7.18 5.18 6.03 5.9 3.25 2.91 5.86 3.2 8.1 9.43 8.18 
2840 mitochondrial_fatty_acid_beta-oxidation_of_unsaturated_fatty_acids 2.83 2.63 8.65 9.46 8.75 8.34 1.47 2.65 7.91 3.59 7.78 9.5 1.58 3.46 8.45 4.01 5.91 0.72 
2841 Alpha-defensins 7.54 7.9 0.77 5.83 0.86 4.68 7.31 7.15 1.48 0.41 5.16 6.66 1.43 5.76 3.58 6.02 1.47 6.93 
2842 Beta_defensins 4.08 1.85 8.25 6.48 4.42 0.85 5.53 3.13 3.87 7.34 7.89 6.91 4.17 0.57 0.35 1.95 0.6 0.06 
2843 Acrosome_Reaction 1.16 5.39 7.8 3.16 7.79 3.22 6.13 1.31 2.8 7.83 5.52 4.98 5.57 8.7 5.08 9.62 3.76 3.29 
2844 Acrosome_Reaction 8.28 4.91 3.39 0.51 2.82 0.7 0.56 1.29 2.04 9.3 8.57 1.94 3.67 9.15 4.79 6.97 2.18 8.08 
2845 Interaction_With_Cumulus_Cells 8.01 4.72 9.88 3.4 8.32 1.91 4.96 7.83 1.85 1.01 4.95 7.01 8.5 6.61 3.9 8.24 8.88 8.69 
2846 Interaction_With_The_Zona_Pellucida 7.63 2.49 6.88 3.24 0.9 2.45 5.24 9.22 7.81 9.9 0.97 2.29 6.03 7.03 1.03 7.85 8.72 4.12 
2847 Sperm_Motility_And_Taxes 4 4.95 8.3 6.57 6.21 5.69 3.13 1.54 1.09 6.36 5.77 3.95 9.91 1.91 6.76 3.85 3.07 5.23 
2848 Sperm:Oocyte_Membrane_Binding 7.55 8.49 1.48 3.08 9.42 5.91 8.48 8.32 0.42 1.13 3.07 5.81 4.97 4.53 4 2.63 2.74 9.2 
2849 Interaction_With_Cumulus_Cells 7.3 1.78 1.39 8.25 2.1 6.53 1.49 5.82 3.38 0 1.03 0.37 4.26 6.15 9.57 1.89 8.08 7.67 
2850 Interaction_With_The_Zona_Pellucida 2.58 2.94 6.61 8.41 9.48 9.82 7.74 2.05 7.19 4.78 4.4 7.05 8.61 4.37 8.08 6.25 5.4 3.63 
2851 Sperm_Motility_And_Taxes 2.57 9.85 4.08 8.96 9.59 7.69 7.47 4.45 4.44 8.96 4.66 3.15 0.89 2.76 5.3 6.59 5.84 0.01 
2852 Sperm:Oocyte_Membrane_Binding 0.51 3.19 5.99 5.61 3.95 7.19 9.43 2.02 1.66 9.02 1.9 3.98 7.81 9.34 0.1 8.47 5.08 1.44 
2853 Activation_of_Matrix_Metalloproteinases 7.83 7.61 0.09 3.69 3.47 0.69 4.33 1.06 5.43 0.67 9.49 1.59 0.89 4.63 6.22 2.66 3.84 2.72 
2854 Anchoring_fibril_formation 2.36 9.28 9.91 7.81 0.77 3.8 1.82 2.4 8.2 3.87 3.49 7.92 8.4 9.68 3.14 4.97 9.83 4.81 
2855 Anchoring_fibril_formation 0.05 4.79 7.15 5.06 9.94 1.63 7.08 7.84 6.95 4.84 2.45 2.64 4.63 5.22 6.51 7.69 7.1 1.04 
2856 Crosslinking_of_collagen_fibrils 0.27 2.32 3.58 9.2 7.79 7.87 7.37 0.83 4.13 1.43 4.88 8.25 1.6 4.37 6.43 1.09 3.19 0.59 
2857 Collagen_biosynthesis_and_modifying_enzymes 4.66 8.44 3.89 4.39 5.79 0.32 0.49 5.86 6.77 7.53 2.79 5.86 4.21 4.75 9.91 4.16 4.95 9.97 
2858 Collagen_degradation 7.06 1.8 5.27 8.57 0.1 9.73 2.8 5.44 2.57 1.1 3.73 3.52 2.61 1.41 7.9 6.48 5.06 0.13 
2859 Anchoring_fibril_formation 0.37 4.1 7.05 1.02 6.02 1.94 3.84 0.12 7.96 6.07 7.93 7.26 6.41 5.2 5.76 5.27 1.91 3.53 
2860 Collagen_biosynthesis_and_modifying_enzymes 9.59 8.98 0.99 0.14 6.2 8.18 8.91 2.39 3.33 4.96 2.31 6.68 4.99 8.4 9.49 8.67 5.01 0.54 
2861 Crosslinking_of_collagen_fibrils 7.82 5.68 1.58 5.89 3.22 6.2 4.98 3.2 5.79 3.29 0.6 3.09 3.21 0.6 9 8.86 9.3 6.2 
2862 Crosslinking_of_collagen_fibrils 0.56 0.98 5.48 9.79 1.76 1.64 5.57 2.59 2.7 0.1 8.51 5.22 4.3 4.41 8 3.85 0.26 0.78 
2863 Activation_of_Matrix_Metalloproteinases 9.13 0.41 5.53 4.24 8.31 0.55 9.93 6.85 8.61 2.66 3.22 0.42 6.5 0.02 0.69 9.35 2.82 1.15 
2864 Collagen_degradation 7.41 0.17 5.76 7.95 5.81 7.54 6.31 9.04 6.35 1.66 6.73 7.17 0.35 4.56 8.31 5.03 6.46 5.57 
2865 ECM_proteoglycans 4.19 5.87 9 2.62 8.74 2.02 1.84 5.32 7.18 3.59 7.88 5.27 6.83 6.72 7.57 2.95 7.6 6.76 
2866 Molecules_associated_with_elastic_fibres 9.59 0.55 5.28 9.49 2.68 1.99 2.26 3.57 6.97 1.45 4.61 5.81 7.78 1.42 3.36 0.68 2.39 8.66 
2867 Fibronectin_matrix_formation 0.81 5.09 8.31 1.25 7.89 3.8 5.72 8.27 1.6 7.78 4.94 0.71 6.21 0.95 5.57 8.83 6.71 2.32 
2868 Integrin_cell_surface_interactions 0.25 5.71 4.81 8.89 6.85 0.91 7.71 9.56 7.96 9.01 8.46 2.02 3.94 3.04 2.5 4.66 6.13 6.54 
2869 Laminin_interactions 2.54 7.76 9.41 9.32 7.76 4.32 8.42 4.79 1.74 9.63 2.22 3.49 3.08 9.69 6.83 6.82 9.66 9.2 
2870 Molecules_associated_with_elastic_fibres 3.66 8.44 3.85 0.19 3.24 1.53 9.49 1.83 9.07 6 5.73 2.26 4.28 5.49 0.1 8.2 5.76 4.57 
2871 Syndecan_interactions 7.17 5.79 1.61 2.57 6.36 5.22 7.3 0.85 2.71 7.85 3.29 7.64 1.79 8.51 2.68 0.14 2.78 4.99 
2872 Syndecan_interactions 7.62 0.5 6.12 7.61 7.88 6.9 8.26 1.16 7.88 0.75 4.57 5.04 6.2 1.61 7.49 5.7 4.25 2.03 
2873 Meiotic_Recombination 2.63 4.97 7.86 4.03 8.16 7.12 0.6 1.13 6.54 5.69 6.16 1.2 5.48 3 3.59 8.08 0.77 9.44 
2874 Meiotic_Synapsis 4.36 2.62 6.73 1.05 4.43 0.97 7.31 3.79 1.45 8.62 5.3 0.94 3.88 2.55 5.11 9.46 0.2 5.99 
2875 Nectin/Necl__trans_heterodimerization 2.46 8.85 0.51 8.57 8.97 7.55 5.61 8.98 1.77 9.65 6.74 0.11 5.5 2.29 7.16 4.52 1.29 3.37 
2876 Localization_of_the_PINCH-ILK-PARVIN_complex_to_focal_adhesions 9.95 5.42 7.04 2.54 6.16 9.83 0.66 7.82 8.82 8.75 3.39 1.09 9.95 6.49 2.9 9.21 3.26 0.28 
2877 Nectin/Necl__trans_heterodimerization 3.78 1.12 1.83 2.99 9.66 2.15 5.08 8.44 7.44 2.08 6.5 3.8 0.99 2.91 5.88 9.37 2.15 7.28 
2878 Regulation_of_cytoskeletal_remodeling_and_cell_spreading_by_IPP_complex_components 9.59 4.68 7.9 6.75 5.13 8.97 9.81 8.58 9.64 5.13 2.6 2.35 1.49 8.82 6.09 1.37 4.9 4.93 
2879 Tight_junction_interactions 6.02 8.73 0.44 0.17 6.43 4.24 9.6 0.78 0.71 3.91 3.72 6.44 9.13 4.26 0.33 4.77 4.13 6.85 
2880 Type_I_hemidesmosome_assembly 2.03 7.52 8.67 4.79 3.45 3.67 3.56 7.24 6.33 1.16 3.04 0.46 6.51 8.63 1.99 9.4 4.74 6.11 
2881 Nectin/Necl__trans_heterodimerization 8.94 7.5 5.26 5.62 1.89 4.71 6.53 8.54 8.78 2.27 8.51 6.18 0.73 1.31 9.51 1.68 9.34 3.59 
2882 Tight_junction_interactions 2.49 8.36 1.3 3.88 8.97 9.52 4.46 1.5 0.65 4.73 1.47 8.23 3.02 0.74 7.23 5.45 9.23 6.01 
2883 Localization_of_the_PINCH-ILK-PARVIN_complex_to_focal_adhesions 1.8 4.64 4.38 5.91 6.94 2.68 3.59 1.79 0.24 9.74 7.66 2.41 6.22 3.68 9.48 9.9 2.53 4.02 
2884 Regulation_of_cytoskeletal_remodeling_and_cell_spreading_by_IPP_complex_components 6.77 2.15 9.86 7.14 7.57 1.39 4.96 8.03 3.45 6.15 7.84 9.62 1.19 1.05 4.3 2.53 5.84 2.47 
2885 DSCAM_interactions 4.49 0.12 7.32 9.68 1.07 5.81 5.03 1.31 8.74 9.39 4.11 6.54 2.87 0.46 7.18 3.3 3.81 3.29 
2886 Localization_of_the_PINCH-ILK-PARVIN_complex_to_focal_adhesions 4.46 1.26 1.8 5.68 9.62 1.12 7.74 4.08 0.82 7.39 3.69 5.88 7.94 5.1 7.35 4.12 0.02 7.05 
2887 Nectin/Necl__trans_heterodimerization 0.5 7.29 7.94 5.98 8.36 2.23 3.01 5.65 1.42 3.13 0.75 0.15 5.91 0.76 3.16 6.08 4.87 2.13 
2888 Nephrin_interactions 8.25 9.75 5.89 8.52 4.05 6.16 3.9 6.29 2.44 6.68 1.11 6.76 4.34 3.26 9.33 8.33 1.19 2.34 
2889 Regulation_of_cytoskeletal_remodeling_and_cell_spreading_by_IPP_complex_components 6.9 7 1.38 4.41 3.15 5.31 8.84 3.6 5.44 8.26 1.75 8.18 2.91 4.74 1.51 4.43 3.96 7.49 
2890 Signal_regulatory_protein_(SIRP)_family_interactions 3.75 0.62 1.65 1.77 9.58 8.41 6.42 3.39 4.51 5.2 4.91 1.82 4.31 2.31 8.21 3.4 9.79 9.88 
2891 Tight_junction_interactions 7.25 9.71 0.58 8.2 6.71 4.76 0.64 5.96 1.18 7.29 0.03 6.59 3.33 5.8 2.08 6.23 7.89 2.08 
2892 Type_I_hemidesmosome_assembly 2.73 7.49 1.28 6.58 6.38 8.85 2.78 2.39 8.33 0.77 8.85 1.33 7.35 8.21 8.78 5.46 8.2 8.42 
2893 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 9.09 1.78 4.14 8.39 6.18 5.27 6.85 7.61 8.06 6.17 0.49 5.22 9.44 0.33 8.36 9.44 8.73 6.8 
2894 APC/C:Cdc20_mediated_degradation_of_Securin 8.09 7.75 7.32 6.45 6.7 6.28 5.06 8.63 0.14 3.07 3.96 2.72 4.74 3.16 1.63 8.75 3.53 5.85 
2895 APC/C:Cdh1_mediated_degradation_of_Cdc20_and_other_APC/C:Cdh1_targeted_proteins_in_late_mitosis/early_G1 0.21 2.95 3.49 7.88 1.92 1.55 9.68 5.02 9.64 6.76 3.03 8.11 1.48 2.46 1.74 4.52 9.5 6.08 
2896 Autodegradation_of_Cdh1_by_Cdh1:APC/C 5.97 3.41 5.79 3.39 3.53 4.96 7.92 6.44 3.33 8.89 6.06 7.67 9.38 0.92 2.16 0.94 9.24 0.76 
2897 Conversion_from_APC/C:Cdc20_to_APC/C:Cdh1_in_late_anaphase 3.71 9.79 7.36 4.53 7.7 0.35 4.11 7.96 7.31 6.83 8.69 7.02 3.07 5.83 3.5 7.34 9.69 6.25 
2898 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 9.83 1.87 1.62 9.58 7.88 5.77 6.17 6.15 3.84 1.35 9.06 9.35 1.85 0.97 9.59 2 2.78 0.14 
2899 Phosphorylation_of_Emi1 4.02 4.12 9.75 4.85 6.68 8.8 9.56 4.51 1.41 8.27 2.09 3.92 2.77 5.76 2.96 8.6 4.9 7.59 
2900 Phosphorylation_of_the_APC/C 3.11 2.28 6.11 6.67 1.39 8.65 9.89 9.28 9.17 0.83 3.08 6.51 2.2 0.41 0.2 7.51 5.87 9.88 
2901 SCF-beta-TrCP_mediated_degradation_of_Emi1 2.08 9.81 9.65 9.17 6.02 0.75 9.99 0.36 1.41 5.36 3.8 4.43 1.12 9.27 3.82 2.9 9.71 1.94 
2902 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 2.76 7.24 4.07 5.93 7.51 9.38 2.73 4.92 3.45 3.02 6.71 4.05 1.52 5.55 1.03 1.53 8.15 4.59 
2903 APC/C:Cdc20_mediated_degradation_of_Securin 9.64 1.68 0.87 9.13 6.33 4.11 2.52 6.16 0.19 7.49 5.62 2.75 0.5 4.93 3.3 0.63 7.61 6.28 
2904 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 5.59 0.94 4.47 6.02 1.34 8.53 9.89 8.29 1.17 4.96 6.08 8.21 8.91 1.89 6.17 1.21 4.57 1.74 
2905 APC/C:Cdc20_mediated_degradation_of_Securin 0.99 1.26 3.19 9.71 0.2 9.22 7.22 2.95 0.08 4.2 9.97 4.5 2.35 8.3 5.97 5.83 9.26 4.21 
2906 APC/C:Cdh1_mediated_degradation_of_Cdc20_and_other_APC/C:Cdh1_targeted_proteins_in_late_mitosis/early_G1 9.94 1.26 2.6 9.6 0.1 9.57 4.85 9.68 2 8.99 8.42 2.87 5.65 5.01 6.17 8.68 9.9 6.2 
2907 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 3.48 7.81 7.43 7.58 6.69 5.5 9.01 4.36 4.37 9.46 1.3 2.69 5.42 6.46 4.93 8.41 5.89 0.7 
2908 APC/C:Cdc20_mediated_degradation_of_Securin 1.36 9.13 9.24 8.35 9.82 3.64 5.02 4.98 4.84 1.73 7.72 8.43 2.95 8.19 5.12 8.39 8.87 7.45 
2909 Phosphorylation_of_the_APC/C 6.65 0.19 3.63 0.23 0.22 8.21 7.33 6.16 0.94 9.97 6.63 6.31 7.36 6.06 8.78 7.07 9.26 1.49 
2910 Activation_of_ATR_in_response_to_replication_stress 4.06 8.1 3.51 6.89 2.94 8.37 8.84 2.83 9.65 3.45 7.55 9.44 6.6 3.26 0.59 9.88 3.98 6.59 
2911 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 3.04 2.5 5.27 1.53 6.56 9.85 6.97 3.42 5.8 8.89 3.96 2.13 4.59 7.35 2.62 4.45 2.59 9.73 
2912 Activation_of_the_pre-replicative_complex 6.89 4.39 0.09 2.13 6.53 4.2 8.28 6.55 6.46 4.78 7.25 1.05 8.79 7.74 7.13 1.27 9.42 7.74 
2913 Amplification__of_signal_from_unattached__kinetochores_via_a_MAD2__inhibitory_signal 8.02 6.11 7.14 8.07 5.86 4.14 6.99 2.06 2.26 9.04 1.12 1.55 4.51 7.97 6.07 5.22 9.39 1.45 
2914 Amplification__of_signal_from_unattached__kinetochores_via_a_MAD2__inhibitory_signal 7.13 1.81 6.74 1.73 2.03 4.74 7.33 5.77 2.13 2.49 0.34 5.24 2.6 4.41 3.09 2.03 7.62 5.39 
2915 Assembly_of_the_ORC_complex_at_the_origin_of_replication 1.07 3.18 0.33 9.9 4.37 4.57 3.72 0.45 2.71 0.9 8.31 2.3 7.37 1.5 8.88 2.85 5.9 8.01 
2916 Assembly_of_the_ORC_complex_at_the_origin_of_replication 3.09 1.84 8.92 8.69 1.28 4.12 9.39 1.54 2.33 9.44 4.57 0.4 5.86 8 3.81 6.09 0.33 0.05 
2917 CDC6_association_with_the_ORC:origin_complex 0.34 7.54 1.53 9.71 9.51 1.15 9.22 0.03 6.69 5.57 1.54 0.66 4.56 0.19 9.48 3.14 0.49 2.36 
2918 CDT1_association_with_the_CDC6:ORC:origin_complex 1.2 1.11 6.83 1.37 9.95 6.77 7.98 4.98 3.21 5.36 2.33 0.06 5.68 9.87 6.98 9.46 0.31 9.33 
2919 Association_of_licensing_factors_with_the_pre-replicative_complex 0.74 3.13 5.18 1.86 5.01 4.85 1.12 8.46 0.4 4.85 6.46 1.67 7.18 4.23 0.78 8.03 1.8 2.32 
2920 Autodegradation_of_Cdh1_by_Cdh1:APC/C 9.24 0.95 6.19 6.74 1.03 1.37 6.06 5.65 3.6 5.05 6.13 9.06 9.74 4.52 5.78 5.31 0.37 8.81 
2921 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 0.42 7.75 5.93 3.92 2.29 9.57 0.13 1.1 9.85 7.34 8.17 7.66 9.24 8.4 2.43 0.21 6.41 4.56 
2922 CDC6_association_with_the_ORC:origin_complex 1.57 9.81 3.34 7.51 1.36 2.61 9.31 6.01 6.47 7.26 2.85 2.58 7.43 3.29 5.31 5.94 0.53 1.51 
2923 CDK-mediated_phosphorylation_and_removal_of_Cdc6 8.01 3.71 7.37 8.81 3.71 7.28 3.13 8.9 5.32 5.36 7.21 5.77 1.6 7.55 4.74 4.27 5.99 9.72 
2924 CDT1_association_with_the_CDC6:ORC:origin_complex 4.72 2.56 8.44 1.84 8.73 4.05 1.4 0.86 9.07 6.02 4.82 1.35 1.8 0.93 3.46 5.36 9.76 5.11 
2925 Activation_of_ATR_in_response_to_replication_stress 6.68 9.9 5.43 1.17 2.76 0.01 6.69 7.86 6.72 2.76 9.02 7.47 7.06 7.39 7.21 3.23 9.75 6.7 
2926 Amplification__of_signal_from_unattached__kinetochores_via_a_MAD2__inhibitory_signal 9.4 8.87 4.38 8.54 8.81 0.69 3.73 3.1 8.23 8.65 8.81 2.04 0.44 6.32 6.36 1.27 3.38 5.37 
2927 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 2.44 0.9 4.79 6.64 4.09 4.42 5.21 1.97 3.11 9.73 3.14 8.92 7.57 2.6 5.29 2.54 8.29 4.35 
2928 Chk1/Chk2(Cds1)_mediated_inactivation_of_Cyclin_B:Cdk1_complex 5.61 2.32 9.57 1.26 7.57 3.31 2.37 4.62 4.92 2.44 0.75 5.39 2.26 4.52 1.79 8.36 5.52 1.31 
2929 G2/M_DNA_replication_checkpoint 8.75 7.74 5.72 2.48 4.94 2.34 2.27 9.97 0.54 0.18 5.51 5.69 3.83 9.48 9.24 6.61 7.22 5.43 
2930 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 9.19 0.35 1.36 1.1 9.53 8.75 2.16 3.48 2 9.2 4.11 6.07 1.34 9.39 0.05 5.11 2.22 8.22 
2931 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 6.14 2.57 9.81 9.64 0.02 9.59 5.42 5.75 7.58 0.82 9.53 9.86 8.92 8.51 7.08 0.41 9.53 0.54 
2932 Ubiquitin_Mediated_Degradation_of_Phosphorylated_Cdc25A 6.01 1.89 3.32 7.68 4.1 9.08 1.54 4.82 0.19 1.36 3.12 9.18 5.68 8.23 4.56 6.5 1.75 2.59 
2933 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 2.41 6.59 7.34 0.02 1.92 0.04 4.8 7.45 6.59 5.91 6.84 3.25 3.43 3.71 6.95 9.14 6.63 9.67 
2934 APC/C:Cdc20_mediated_degradation_of_Securin 4.03 9.04 5.13 6.46 5.43 9.06 7.4 8.19 6.33 8.33 6.93 1.98 4.17 6.4 6.1 9.52 8.24 7.93 
2935 APC/C:Cdh1_mediated_degradation_of_Cdc20_and_other_APC/C:Cdh1_targeted_proteins_in_late_mitosis/early_G1 5.82 4.51 1.13 4.65 2.54 5.66 1.03 8.47 1.55 0.16 7.28 6.1 1.85 2.1 7.2 7.72 4.07 6.9 
2936 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 3.53 9.61 5.05 5.25 1.37 4.21 0.43 7.89 1.64 4.69 9.9 4.59 3.63 5.72 9.43 1.03 3.09 5.77 
2937 Activation_of_the_pre-replicative_complex 1.1 3.66 3.82 0.15 5.89 3.47 5.82 2.06 1.46 7.13 2.99 4.32 4.14 8.47 1.77 1.5 0.23 9.09 
2938 Assembly_of_the_ORC_complex_at_the_origin_of_replication 9.6 6.03 6.5 2.54 1.83 9.37 4.61 0.63 6.72 9.47 4.13 2.79 9.96 3.47 9.31 6.07 8.64 2.21 
2939 Association_of_licensing_factors_with_the_pre-replicative_complex 1.96 1.32 1.44 3.88 9.93 7.87 4.67 9.48 4.6 2.92 9.83 1.51 5.17 5.62 6.79 6.11 2.44 0.66 
2940 Autodegradation_of_Cdh1_by_Cdh1:APC/C 4.82 8.36 3.75 6.66 6.94 5.1 9.42 7.08 2.52 1.02 3.89 9.3 5.9 5.38 6.5 5.48 3.82 2.85 
2941 CDC6_association_with_the_ORC:origin_complex 4.48 9.28 3.21 3.68 5.95 3.06 5.88 7.1 6.44 4.05 7.97 8.94 2.07 8 2.21 0.22 8.2 9.64 
2942 CDK-mediated_phosphorylation_and_removal_of_Cdc6 0.69 9.97 6.75 9.89 3.99 2.34 4.28 2.31 5.26 0.2 7.41 6.43 2.73 0.18 7.33 4.98 8.11 9.56 
2943 CDT1_association_with_the_CDC6:ORC:origin_complex 9.85 5.77 8.87 4.01 3.32 8.45 9.78 3.46 7.4 7.45 2.65 9.51 3.87 9.1 3.65 4.33 8.04 8.99 
2944 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 8.36 0.39 9.59 4.29 8.02 1.73 3.82 1.04 1.76 6.09 0.41 3.42 5.88 4.24 9.18 4.32 7.84 4.02 
2945 Cohesin_Loading_onto_Chromatin 0.13 0.83 3.51 8.49 6.99 2.92 8.61 6.79 8.7 4.8 3.11 7.52 9.45 0.85 5.08 5.73 3.99 7.73 
2946 Condensation_of_Prometaphase_Chromosomes 0.1 4.83 6.05 3.32 1.55 3.8 5.31 7.99 7.61 7 2.68 3.75 4.96 7.19 3.19 5.75 6.67 9.61 
2947 Conversion_from_APC/C:Cdc20_to_APC/C:Cdh1_in_late_anaphase 2.92 0.1 4.98 5.58 3.31 4.41 3.3 1.07 2.97 1.4 6.69 7.96 1.32 6.94 9 3.52 7.94 2.94 
2948 Cyclin_B2_mediated_events 1.95 0.18 1.73 7.63 8.36 9.29 0.97 7.83 3.18 7.3 1.53 3.36 6.78 4.6 8.47 3.39 0.47 3.08 
2949 Cyclin_D_associated_events_in_G1 3.39 0.5 3.11 8.67 9.5 9.91 1.22 1.97 8.14 7.21 3.86 6.98 4.52 6.71 2.15 7.38 1.33 9.22 
2950 DNA_replication_initiation 2.44 4.69 7.51 4.4 3.22 3.38 9.24 3.34 7.61 8.73 0.43 8.94 0.84 4.81 4.29 1.22 7.64 3.82 
2951 E2F-enabled_inhibition_of_pre-replication_complex_formation 5.74 5.11 7.44 3.98 8.37 8.69 6.12 1.23 7.41 4.78 2.87 6.62 3.16 4.53 8.81 3.62 9.96 5.38 
2952 Establishment_of_Sister_Chromatid_Cohesion 6.61 8.14 0.09 4.03 7.55 6.39 9.86 1.64 3.37 4.62 8.75 7.3 6.67 9.17 4.98 2.12 1.93 3.2 
2953 G0_and_Early_G1 3.28 9.47 5.76 6.74 6.35 4.44 4.91 2.05 8.98 5.56 0.36 6.3 7.21 1.39 0.29 2.64 5.17 3.24 
2954 G1/S-Specific_Transcription 8.92 1.84 0.58 8.12 5.43 4.65 7.55 9.69 1.56 2.57 6.33 2.45 6.68 4.84 1.53 0.19 2.8 3.83 
2955 G2_Phase 2.31 1.69 4.52 3.83 2.55 2.22 6.92 2.83 8.61 4.86 6.69 6.23 8.35 2.12 6.37 3.79 8.36 3.75 
2956 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 2.13 5.4 0.46 9.6 0.61 0.97 7.81 4.03 9.85 0.08 4.46 1.72 1.15 7.3 0.49 8.92 6.41 2.76 
2957 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 8.03 7 5.29 2.4 3.14 4.57 1.3 4.27 3.14 1.28 8.45 0.8 7.11 7.96 4.75 3.33 7.64 8.47 
2958 Inhibition_of_replication_initiation_of_damaged_DNA_by_RB1/E2F1 3.76 1.16 8.6 6.53 2.01 0.78 7.76 2.87 4.02 1.79 8.88 2.62 7.71 1 9.25 7.97 3.88 1.72 
2959 Initiation_of_Nuclear_Envelope_Reformation 7.9 3.4 2.78 0.44 8.09 0.03 3 8.23 7.33 1.96 4.66 3.26 1.97 7.97 7.88 4.44 1.44 0.68 
2960 Loss_of_Nlp_from_mitotic_centrosomes 2.19 4.76 2.87 2.67 9.24 8.74 5.1 5.66 7.05 3.67 7.42 0.42 0.35 2.01 1.22 5.29 5.2 9.06 
2961 MASTL_Facilitates_Mitotic_Progression 9.13 9.47 2.5 8.96 5.32 0.31 1.69 8.29 0.65 0.02 6.82 1.92 0.23 1.99 9.51 8.2 7.86 5.05 
2962 Mitotic_Metaphase/Anaphase_Transition 0.89 9.43 7.21 7.33 2.43 6.53 1.1 2.9 9.37 8.94 2.62 1.25 5.76 0.45 9.54 1.68 3.36 4.99 
2963 Nuclear_Pore_Complex_(NPC)_Disassembly 3.97 4.68 8.08 9.88 3.59 6.79 0.65 9.2 7.78 3.99 9.26 5.56 3.55 9.52 3.05 1.94 2.18 6.34 
2964 Orc1_removal_from_chromatin 3.37 4.38 9.25 3.5 9.47 0.35 0.5 5.7 4.79 0.94 5.32 5.96 1.25 8.16 2 7.8 9.92 5.46 
2965 Phosphorylation_of_Emi1 3.45 0.68 9.45 8.68 2.72 9.64 9.1 7.34 5.76 8.17 8.37 1.87 5.85 2.46 9.48 7.31 5.15 8.94 
2966 Phosphorylation_of_proteins_involved_in_G1/S_transition_by_active_Cyclin_E:Cdk2_complexes 1.55 6.24 1.41 7.84 8.04 7.47 4.47 7.16 4.17 2.47 9.33 1.82 5.67 3.11 9.49 4.33 1.86 7.96 
2967 Phosphorylation_of_proteins_involved_in_the_G2/M_transition_by_Cyclin_A:Cdc2_complexes 4.91 3.65 2.9 4.65 5.38 0.99 1.8 9.3 9.9 9.52 1.15 9.06 4.79 7.77 8.08 8.77 6.17 4.87 
2968 Phosphorylation_of_the_APC/C 6.72 3.01 5.38 0.43 8.69 1.77 4.76 2.27 4.64 6.9 4.43 2.92 6.53 3.76 8.41 1.79 4.55 4.61 
2969 Polo-like_kinase_mediated_events 5.29 2.87 9.9 1.12 7.2 5.45 8.86 6.37 1.54 9.52 5.47 2.26 9.08 1.1 2.81 8.85 0.78 5.74 
2970 Polymerase_switching 1.36 1.32 2.92 1.78 9.2 6.93 2.29 9.6 6.01 2.64 7.79 1.57 6.47 2.66 3.4 4.29 8.52 9.39 
2971 Recruitment_of_NuMA_to_mitotic_centrosomes 7.2 4.57 1.58 7.3 3.81 8.58 0.1 0.15 0.31 7.25 6.09 2.25 3.79 1.04 4.99 1.62 5.02 6.36 
2972 Regulation_of_PLK1_Activity_at_G2/M_Transition 9.53 6.23 0.5 5.39 2.15 3.32 6.49 9.24 3.45 0.24 0.37 8.28 0.45 9.97 5.18 7.59 1.38 8.27 
2973 Removal_of_the_Flap_Intermediate 7.33 9.6 6.95 6.44 6.58 0.45 7.12 5.79 4.89 2.15 7 9.93 8.1 6.8 1.94 9.2 8.49 6.22 
2974 Resolution_of_Sister_Chromatid_Cohesion 6.06 9 9.15 5.11 8.78 1.75 6.5 8.13 2.41 9.24 7.62 4.68 8.1 0.94 5.25 7.45 3.3 1.22 
2975 SCF(Skp2)-mediated_degradation_of_p27/p21 0.44 4.22 1.88 8.73 4.24 7.47 6.45 1.07 5.76 1.91 7.48 3.21 5.39 8.24 3.5 5.05 9.28 8.95 
2976 SCF-beta-TrCP_mediated_degradation_of_Emi1 6.52 2.95 1.8 7.35 3.45 2.74 9.88 1.67 7.03 8.37 8.04 4.94 5.7 9.75 8.71 3.83 1.83 5.65 
2977 Separation_of_Sister_Chromatids 4.71 7.97 9.34 1.26 9.76 2.97 3.33 1.6 3.04 5.53 4.15 1.29 3.94 6.19 0.86 0.24 2.03 9.71 
2978 Ubiquitin-dependent_degradation_of_Cyclin_D1 6.52 2.77 5.48 1.53 4.24 9.59 1.21 9.75 4.63 9.48 8.65 3.29 6.89 7.1 6.56 0.21 0.93 1.96 
2979 Unwinding_of_DNA 8.41 6.93 2.15 6.06 8.32 0.11 4.66 7.42 5.99 1.72 9.05 8.35 4.23 9.2 1.54 4.55 2.17 3.61 
2980 Loss_of_Nlp_from_mitotic_centrosomes 6.61 8.91 5.33 5.15 7.53 6.98 1.79 2.99 9.36 1.96 2.01 3.3 0.44 9.08 3.56 2.52 4.34 4.27 
2981 Recruitment_of_NuMA_to_mitotic_centrosomes 7.78 1.15 3.26 7.58 2.56 2.18 6.87 2.62 8.87 7.75 7.72 4.71 3.56 3.68 3.43 2.03 0.64 9.3 
2982 Chk1/Chk2(Cds1)_mediated_inactivation_of_Cyclin_B:Cdk1_complex 6.49 3.99 7.81 0.46 0.06 5.11 9.07 6.61 7.06 5.33 8.25 2.53 1.09 2.24 5.36 3.48 2.83 8.11 
2983 Deposition_of_New_CENPA-containing_Nucleosomes_at_the_Centromere 6.6 7.56 4.79 7.46 0.76 2.16 8.17 9.73 2.13 3.9 0.13 2.94 2.42 3.65 9.82 1.41 2.95 1.21 
2984 Meiotic_Synapsis 5.22 9.74 4.69 2.05 6.24 0.97 6.72 1.53 9.04 4.27 0 2.12 7.86 9.79 2.29 9.63 7.13 4.88 
2985 Packaging_Of_Telomere_Ends 9.75 7.14 6.01 5.93 3.88 0.5 2.23 8.6 5.63 6.84 8.16 7.63 9.28 5.57 4.21 9.71 3.93 4.83 
2986 Polymerase_switching_on_the_C-strand_of_the_telomere 0.37 5.35 4.41 9.75 5.63 7.66 3.39 4.67 4.42 5.6 4.97 1.9 5.98 0.54 3.01 9.98 8.28 8.75 
2987 Removal_of_the_Flap_Intermediate_from_the_C-strand 3.69 6.13 8.37 7.33 3.3 5.42 8.39 7.84 3.14 2.58 4.13 2.53 1.49 1.99 1.13 0.71 0.28 4.56 
2988 Telomere_C-strand_synthesis_initiation 8.39 6.39 1.53 6.66 0.91 8.33 8.9 8.94 8.85 3.82 8.17 1.23 3.63 1.15 2.27 7.5 5.68 0.41 
2989 Telomere_Extension_By_Telomerase 7.44 8.52 7.4 1.74 8.99 7.67 8.29 6.37 4.82 9.2 9.48 3.05 2.16 9.72 0.99 2.08 8.49 6.17 
2990 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 1.97 7.58 8.78 9.38 6.38 9.35 7.14 0.98 5.33 8.25 1.55 5.42 1.35 5.12 3.49 8.54 0.63 1.88 
2991 Cohesin_Loading_onto_Chromatin 2.52 2.69 4.66 7.69 5.68 7.02 3.35 5.89 1.42 5.38 9.51 7.68 5.01 1.51 4.57 5.11 6.62 1.31 
2992 Condensation_of_Prometaphase_Chromosomes 4.66 5.44 6.87 2.58 8.27 4.29 7.69 9.4 3.39 2.43 1.21 7.39 5.82 6.9 8.28 8.91 5.1 6.66 
2993 Conversion_from_APC/C:Cdc20_to_APC/C:Cdh1_in_late_anaphase 3.91 0.9 2.25 2.6 2.94 8.1 0.83 1.42 9.87 6.61 1.9 2.51 9.53 6.17 8.24 8.75 4.73 4.28 
2994 Phosphorylation_of_proteins_involved_in_the_G2/M_transition_by_Cyclin_A:Cdc2_complexes 4.28 8.71 7.33 3.05 7.54 8.56 0.04 0.27 2.35 0.64 4.37 0.98 3.84 6.4 3.67 9.56 2.67 5.64 
2995 SCF(Skp2)-mediated_degradation_of_p27/p21 5.84 8.53 0.32 0.6 9.24 2.58 1.81 8.2 8.89 7.15 1.76 1.91 4.72 2.23 6.8 2.39 5.99 4.05 
2996 Cyclin_B2_mediated_events 8.06 3.44 5.17 4.95 8.85 6.78 7.73 5.29 3.6 6.04 7.19 6.59 4.99 5.02 9.71 1.39 8.06 5.45 
2997 Cyclin_D_associated_events_in_G1 1.28 6.15 3.73 0.42 9.56 1.54 0.66 2.84 8.92 5.16 8.55 9.1 8.06 4.15 9.27 3 0.77 1.75 
2998 Phosphorylation_of_proteins_involved_in_G1/S_transition_by_active_Cyclin_E:Cdk2_complexes 3.25 0.44 1.18 7.69 4.87 8.36 3.36 3.52 9.63 9.87 8.41 7.8 0.27 4.53 4.55 6.6 9.42 9.55 
2999 SCF(Skp2)-mediated_degradation_of_p27/p21 7.63 3.01 0.47 6.18 9.09 7.39 4.58 4.02 3.8 3.83 6.27 6.1 4.44 8.9 0.41 4.26 4.06 9.7 
3000 Activation_of_the_pre-replicative_complex 6.6 9.14 6.82 9.78 5.55 4.49 3.92 7.58 6.33 0.08 9.6 3.44 6.88 5.12 0.38 1.65 8.22 1.85 
3001 Assembly_of_the_ORC_complex_at_the_origin_of_replication 2.02 8.11 8.48 7.56 7.67 7.66 7.32 5.32 5.06 4.89 6.83 3.04 1.57 2.27 0.15 0.12 6.53 4.34 
3002 CDC6_association_with_the_ORC:origin_complex 6.33 0.02 4.81 0.04 7.99 7.3 7.4 6.43 3.4 9.53 8.61 3.93 0.32 8.09 6.53 6.77 8.49 1.57 
3003 CDT1_association_with_the_CDC6:ORC:origin_complex 4.64 6.6 6.1 9.2 2.63 8.43 5.95 6.07 0.13 2.76 3.05 3.72 6.49 4.8 2.55 2.04 0.84 0.84 
3004 DNA_replication_initiation 5.49 5.07 3.23 0.95 3.21 6.62 9.67 5.78 4.68 4.5 1.8 8.4 2.14 0.76 8.54 3.36 1.71 1.6 
3005 Polymerase_switching 8.43 0.81 2.8 7.09 5 0.3 2.89 6 5.73 8.27 6.37 3.69 7.6 6.71 9.88 2.91 2.77 1.85 
3006 Removal_of_the_Flap_Intermediate 5.19 0.08 9.1 4.15 1.62 5.96 4.4 5.25 3.9 3.6 7.47 9.39 4.09 0.03 7.17 8.91 7.06 9.72 
3007 Unwinding_of_DNA 2.68 7.37 8.07 9.06 0.67 7.48 1.53 7.19 1.91 3.8 2.27 6.35 6.74 4.99 4.47 5.73 1.28 2.41 
3008 Deposition_of_New_CENPA-containing_Nucleosomes_at_the_Centromere 7.62 8.71 2.88 2.83 2.17 1.47 4.61 0.21 0.91 5.68 2.54 9.12 4.65 2.02 5.47 3.56 0.12 2.57 
3009 E2F-enabled_inhibition_of_pre-replication_complex_formation 2.73 5.38 8.77 4.64 4.79 4.67 4.59 9.21 2.5 3.41 0.8 9.27 9.5 1.04 3.89 1.96 3.9 3.87 
3010 Inhibition_of_replication_initiation_of_damaged_DNA_by_RB1/E2F1 9.99 4.84 0.45 5.41 0.66 2.73 1.66 4.17 3.82 4.25 4.58 1.84 8.31 0.61 3.04 7.49 3.45 0.27 
3011 E2F-enabled_inhibition_of_pre-replication_complex_formation 0.09 8.3 4.18 3.66 0.84 8.07 5.54 5.48 2.87 3.87 5.46 3.21 6.08 6.69 9.69 4.03 8.27 0.99 
3012 Establishment_of_Sister_Chromatid_Cohesion 9.57 3.65 0.61 0.93 4.4 8.79 0.08 9.97 0.4 7.18 5.43 7.27 4.83 0.48 3.57 7.7 3.86 0.19 
3013 Polymerase_switching_on_the_C-strand_of_the_telomere 9.21 0.16 9.34 9.02 9.41 8.83 5.13 9.04 7.75 9.84 7.51 3.83 7.91 1.68 2.36 4.6 3.54 9.57 
3014 Removal_of_the_Flap_Intermediate_from_the_C-strand 5.51 2.54 0.23 1.38 4.23 7.64 3.44 3.02 1.49 6.15 6.83 2.34 4.91 2.94 7.77 8.8 7.47 6.68 
3015 Telomere_C-strand_synthesis_initiation 8.3 5.59 3.47 5.91 2.99 4.45 4.31 1.22 8.09 9.32 1.52 2.38 6.63 0.48 3.23 4.53 9.81 8.95 
3016 Telomere_Extension_By_Telomerase 0.77 5.67 5.61 6.34 1.26 0.32 2.66 8.04 8.67 9.05 4.04 8 6.81 9.73 2.28 0.24 9.51 7.04 
3017 G0_and_Early_G1 4.84 9.55 7.95 5.31 5.68 1.42 4.95 2.11 6.42 4.31 7.57 5.95 4.83 1.97 1.77 3.27 0.2 6.04 
3018 Cyclin_D_associated_events_in_G1 6.63 0.51 5.08 4.72 9.64 3.94 8.26 7.36 8.17 9.31 5.25 7.57 0.05 3.21 4.41 9.07 2.5 7.39 
3019 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 4.14 2.63 3.71 7.23 3.8 4.25 3.17 0.18 4.81 6.12 2.12 3.08 5.83 4.2 3.98 4.08 1.59 4.07 
3020 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 3.1 4.43 2.66 1.35 4.66 3.33 2.34 4.15 2.7 6.6 0.2 2.52 4.36 5.52 8.09 3.98 9.64 2.55 
3021 Ubiquitin_Mediated_Degradation_of_Phosphorylated_Cdc25A 7.73 6.07 6.25 5.05 2.79 3.47 6.76 9.1 5.46 2.41 4.37 5.19 8.6 1.13 9.75 0.27 4.53 2.38 
3022 Activation_of_the_pre-replicative_complex 1 7.23 9.86 2.94 2.81 7.68 4.99 1.99 3.86 7.63 0.33 7.56 0.01 0.45 1.49 6.49 7.71 2.88 
3023 E2F-enabled_inhibition_of_pre-replication_complex_formation 0.68 5.55 1.47 0.62 0.15 3.24 5.08 5.52 6.03 8.05 5.77 9.54 6.19 3.08 8.87 5.57 3.03 3.29 
3024 G1/S-Specific_Transcription 6.54 7.57 7.35 7.47 5.95 1.48 7.92 2.57 2.18 4.7 1.07 4.06 4.66 3.51 9.3 7.24 2.81 8.26 
3025 Inhibition_of_replication_initiation_of_damaged_DNA_by_RB1/E2F1 2.92 4.12 3.38 3.56 0.35 8.04 2.75 4 9.64 6.34 3.88 2.75 5.19 6.33 5.49 5.71 0.16 3.85 
3026 Phosphorylation_of_proteins_involved_in_G1/S_transition_by_active_Cyclin_E:Cdk2_complexes 7.2 1.64 3.73 1.56 7.35 5.07 9.84 8.3 6.55 3.58 5.27 2.85 7.41 5.63 1.87 2.74 2.79 9.93 
3027 SCF(Skp2)-mediated_degradation_of_p27/p21 8.54 6.05 0.78 8.36 7.28 5.28 8.58 3.01 6.27 4.21 9.03 2.89 6.69 9.29 5.75 7.13 7.19 6.53 
3028 G1/S-Specific_Transcription 9.13 8.9 3.88 5.95 4.4 1.89 8.76 3.1 0.39 2.34 4.74 7.01 1.47 7.44 1.78 3.45 0.01 1.04 
3029 G2_Phase 3.5 5.57 0.18 9.72 9.71 6.22 2.67 5.21 4.56 1.46 2.1 6.84 3.59 5.9 1.91 0.29 3.59 6.98 
3030 Activation_of_ATR_in_response_to_replication_stress 3.19 1.73 4.17 7.44 6.95 1.65 9.69 5.1 9.19 1.06 7.12 8 9.08 1.08 7.76 0.81 2.1 3.74 
3031 Chk1/Chk2(Cds1)_mediated_inactivation_of_Cyclin_B:Cdk1_complex 7.83 7.31 9.7 2.43 1.75 9.01 2.97 1.82 1.73 6.76 3.21 6.26 9.77 0.94 5.56 3.88 4.05 7.07 
3032 G2/M_DNA_replication_checkpoint 8.45 2.14 4.58 5.4 2.66 7.89 8.16 3.85 6.71 1.18 6.84 2.53 0.12 0.44 6.46 1.89 3.47 2.61 
3033 Chk1/Chk2(Cds1)_mediated_inactivation_of_Cyclin_B:Cdk1_complex 3.63 0.09 7.38 5.26 9.29 8.02 6 4.51 0.57 0.61 7.34 5.95 7.54 7.26 0.98 6.04 9.24 4.25 
3034 G2/M_DNA_replication_checkpoint 2.52 4.19 4.33 4.6 0.11 7.03 2.59 9.45 3.92 7.35 7.3 6.11 1.18 4.48 5.24 3.83 0.63 9.47 
3035 Cyclin_B2_mediated_events 0.5 2.61 6.35 1.75 3.85 9.03 9.73 0.03 1.9 4.34 4.46 1.58 9.26 2.82 9.42 9.07 6.29 4.9 
3036 Loss_of_Nlp_from_mitotic_centrosomes 4.23 7.99 4.21 5.88 2.45 8.77 3.93 7.18 0.11 2.76 4.34 4.23 0.32 1.99 0.1 4.56 5.78 4.61 
3037 Phosphorylation_of_proteins_involved_in_the_G2/M_transition_by_Cyclin_A:Cdc2_complexes 2.47 1.81 2.49 5.7 8.66 4.06 6.55 9.98 4.57 7.93 4.86 3.09 5.86 5.79 9.48 4.06 8.25 6.39 
3038 Polo-like_kinase_mediated_events 9.31 6.55 0.44 8.7 0.67 5.86 6.04 0.16 7.95 4.81 9.35 7.29 1.25 4.15 4.36 7.11 0.03 9.38 
3039 Recruitment_of_NuMA_to_mitotic_centrosomes 5.18 0.91 0.39 3.79 0.13 3.58 8.07 4.32 6.09 7.74 2.4 3.57 4 5.78 9.7 7.02 7.46 1.38 
3040 Regulation_of_PLK1_Activity_at_G2/M_Transition 6.37 7.44 7.48 1.46 2.02 9.05 3.06 2.96 8.21 1.32 4.8 8.68 0.65 9.61 7.7 1.12 2.21 0.85 
3041 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 5.94 2.4 2.14 5.34 8.9 7.64 4.29 8.5 5.07 1.4 0.42 0.97 9.17 1.63 8.49 2.55 1.52 5.18 
3042 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 0.28 8.7 2.59 7.83 2.17 6.12 4.1 2.85 2.7 9.45 8.29 4.3 3.7 8.04 9.35 1.2 4.13 3.18 
3043 Inhibition_of_replication_initiation_of_damaged_DNA_by_RB1/E2F1 4.37 5.73 0.27 1.51 3.12 0.85 0.6 9.03 3.23 5.28 4.48 6.88 0.01 6.28 7.46 9.22 9.77 4.51 
3044 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 9.46 3.83 4.6 6.17 3.03 9.45 7.93 4.85 7.33 7.52 5.1 5.42 1.07 4.72 6.81 4.72 0.16 3.54 
3045 Initiation_of_Nuclear_Envelope_Reformation 1.83 7.34 7.92 8.66 1.58 2.26 4.17 6.73 0.54 9.95 2.19 3.56 0.7 9.74 9.51 8.77 1.32 7.77 
3046 Polymerase_switching 3.18 6.97 8.76 0.52 1.02 7.45 5.25 0.01 3.93 1.32 6.39 5.33 5.34 3.89 7.62 3.59 0.04 7.13 
3047 Removal_of_the_Flap_Intermediate 4.28 1.2 5.88 9.8 5.05 3.96 0.07 1.48 4.96 4.32 9.52 0.54 2.03 0.04 1.62 1.52 1.83 8.52 
3048 Polymerase_switching 0.45 4.31 2.29 3.21 5.26 6.5 4.48 3.09 4.2 5.51 8.87 0.95 6.26 3.88 2.62 4.83 5.7 9.04 
3049 Loss_of_Nlp_from_mitotic_centrosomes 8.16 1.66 3.66 7.95 5.68 0.09 9.81 2.43 8.81 7.23 0.76 7.12 8.65 4.76 7.47 5.95 5.33 5.83 
3050 Loss_of_Nlp_from_mitotic_centrosomes 9.94 5.94 3.62 4.56 8.99 4.31 4.4 0.31 2.09 5.15 9.07 9.95 2.82 6.45 1.89 8.98 4.81 1.67 
3051 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 4.86 6 9.19 0.66 4.13 9.9 9.95 5.28 0.36 1.57 8.63 5.47 1.59 1.23 9.09 4.45 7.57 2.69 
3052 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 2.02 2.23 2.67 8.14 0.74 4.7 5.01 2.07 7.24 1.62 3.26 6.72 6.95 6.57 5.69 9.73 1.17 0.52 
3053 Cohesin_Loading_onto_Chromatin 2.49 0.44 5.51 8.96 0.86 5.34 2.01 4.32 7.93 0.68 6.16 7.37 3.63 2.21 8.73 4.86 9.53 3.49 
3054 Condensation_of_Prometaphase_Chromosomes 1.64 3.09 2.98 8.47 9.04 3.21 1.31 8.95 2.8 1.05 7.23 0.01 3.11 2.58 8.75 6.86 5.36 4 
3055 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 8.33 4.24 0.42 5.31 8.61 5.71 8.5 3.83 3.3 1.91 3.05 3.08 5.85 3.31 3.51 3.04 3.71 2.85 
3056 Initiation_of_Nuclear_Envelope_Reformation 4.47 2.81 3.18 2.31 9.73 5.68 7.38 2.68 0.14 3.38 9.8 7.39 9.03 7.69 4.43 7.47 5.13 1.86 
3057 MASTL_Facilitates_Mitotic_Progression 2.89 0.4 0.43 0.48 0.91 3.96 3.6 9.13 9.89 9.45 9.71 9.43 9.84 5.26 2.16 8.02 7.98 6.01 
3058 Mitotic_Metaphase/Anaphase_Transition 1.33 7.8 5.27 9.97 2.81 7.82 5.24 0.52 6.03 2.49 2.04 5.98 5.18 0.39 7.42 6.74 7.88 0.74 
3059 Nuclear_Pore_Complex_(NPC)_Disassembly 5.02 5.31 2.89 8.21 4.91 9.35 5.21 9.3 6.81 7.57 9.24 7.08 4.5 9.49 1.2 9.99 8.9 5.17 
3060 Resolution_of_Sister_Chromatid_Cohesion 7.12 4.44 2.03 7.28 6.77 0.01 9.9 7.13 8.1 6.32 8.51 6.97 1.4 3.27 5.39 3.97 1.13 9.2 
3061 Separation_of_Sister_Chromatids 3.88 3 6.56 1.86 9.65 4.96 0.58 1.92 9.63 7.78 9.19 8.55 4.43 3.31 7.56 2.46 6.8 4.32 
3062 Activation_of_the_pre-replicative_complex 9.31 4.01 0.95 4.69 1.48 0.39 0.58 5.9 3.15 8.14 7.62 4.34 6.34 9.3 2.48 0.65 2.64 5.41 
3063 Assembly_of_the_ORC_complex_at_the_origin_of_replication 3.9 7.43 9.54 2.76 2.25 3.13 2.09 0.38 2.25 1.2 8.68 1.71 1.25 5.48 0.31 3.46 4.01 4.18 
3064 CDC6_association_with_the_ORC:origin_complex 3.72 4.67 2.33 8.57 4.58 5.26 3.86 4.89 4.99 8.68 6.07 0.45 0.9 8.85 3.94 8.35 1.88 0.49 
3065 CDT1_association_with_the_CDC6:ORC:origin_complex 8.59 1.06 5.98 3.79 3.26 6.67 1.2 5.7 7.44 7.87 1.05 1.06 1.38 9.83 6.35 6.52 7.53 5.61 
3066 MASTL_Facilitates_Mitotic_Progression 8.72 2.09 4.45 5.87 9 6.52 5.04 5.45 6.45 7.12 3.06 2.84 9.53 1.99 9.95 4.28 3.91 6.94 
3067 Meiotic_Synapsis 0.24 1.65 0.57 8.61 6.42 3.49 9.75 7.07 9.63 7.65 8.64 2.33 4.98 4.87 0.93 9.82 3.93 8.55 
3068 Initiation_of_Nuclear_Envelope_Reformation 8.06 7.31 4.85 4.28 5.29 0.4 0.37 0.09 9.84 0.15 0.31 8.79 2.83 2.46 1.84 9.82 0.7 0.59 
3069 Separation_of_Sister_Chromatids 2.67 2.27 6.27 1.56 5.79 7 0.67 6.12 8.52 7.46 0.49 0.21 5.03 5.98 2.64 9.22 2.92 8.15 
3070 Activation_of_the_pre-replicative_complex 1.11 0.99 3.89 0.35 0.25 3.11 8 7.8 9.7 2.85 2.54 3.57 3.99 7.8 7.3 6.69 2.05 3.72 
3071 Cyclin_D_associated_events_in_G1 3.48 2.03 0.28 0.92 3.98 1.71 3.65 6.46 7.02 5.27 6.34 1.03 7.1 0.82 8.46 8.03 5.12 3.29 
3072 E2F-enabled_inhibition_of_pre-replication_complex_formation 6.69 5.77 1.74 7.79 2.36 5.06 1.05 9.38 7.56 9.36 1.85 7.15 5.47 0.29 9.8 0.26 1.48 2.73 
3073 G0_and_Early_G1 7.62 1.53 0.56 1.61 0.4 4.59 8.21 7.56 2.59 9.32 9.58 2.79 4.48 5 0.51 0.59 9.93 2.43 
3074 G1/S-Specific_Transcription 8.66 8.21 9.63 2.47 7.02 8.07 5.18 6.59 9.59 2.46 8.44 8.66 0.66 1.23 7.66 3.41 3.71 3.18 
3075 Inhibition_of_replication_initiation_of_damaged_DNA_by_RB1/E2F1 3.79 9.22 2.72 1.91 6.58 0.22 2.96 6.39 3.55 7.95 6.19 1.43 6.01 1.01 8.03 3.58 6.34 5.13 
3076 Phosphorylation_of_proteins_involved_in_G1/S_transition_by_active_Cyclin_E:Cdk2_complexes 1.08 7.37 8.18 8.24 3.68 5.91 3.56 2.91 7.35 1.39 2.75 1.75 7.17 8.53 0.08 7.79 5.15 3.22 
3077 SCF(Skp2)-mediated_degradation_of_p27/p21 9.01 5.67 4.03 6.75 9.78 1.03 3.66 2.76 8.45 7.68 1.52 1.58 5.83 3.07 3.91 4.39 2.13 0.88 
3078 Cyclin_B2_mediated_events 9.35 8.47 1.24 5.08 9.54 7.19 5.85 5.82 6.62 7.18 7.99 0.7 8.55 3.56 2.5 5.76 7.51 1.62 
3079 G2_Phase 1.8 7.2 8.27 5.05 7.74 7.57 7.12 5.47 8.58 6.03 5.09 6.87 5.66 0.51 4.43 0.16 5.72 9.02 
3080 Loss_of_Nlp_from_mitotic_centrosomes 5.31 5.6 7.99 8.19 4.7 7.77 5.12 2.45 9.07 6.37 6.34 3.12 7.4 0.94 2.51 3.49 3.86 1.76 
3081 Phosphorylation_of_proteins_involved_in_the_G2/M_transition_by_Cyclin_A:Cdc2_complexes 4.76 9.96 2.11 7.66 1.63 3.21 5.04 3.22 7.11 8.74 1.4 0.81 2.43 7.29 3.54 9.59 4.55 8.61 
3082 Polo-like_kinase_mediated_events 1.02 6.46 2.59 3.89 5.99 5.73 3.25 5.28 6.99 1.43 2.93 5.66 6.68 5.36 0.07 0.44 0.73 2.71 
3083 Recruitment_of_NuMA_to_mitotic_centrosomes 5.53 7.18 4.24 5.53 9.82 9.73 2.02 1.71 5.7 4.19 6.24 2.74 1.27 2.45 9.09 1.58 2.71 2.33 
3084 Regulation_of_PLK1_Activity_at_G2/M_Transition 9.39 6.36 4.91 0.71 6.51 7.31 7.63 1.25 9.11 5.93 1.59 6.45 8.83 5.03 6.69 9.94 6.99 1.86 
3085 Initiation_of_Nuclear_Envelope_Reformation 9.88 5.55 7.34 4.68 1.05 2.79 3.16 0.02 5.92 9.94 4.75 5.91 9.01 6.79 9.44 4.34 1.07 7.42 
3086 Mitotic_Metaphase/Anaphase_Transition 5.49 1.95 7.73 4.15 1.34 4.91 2.27 6.4 3.84 8.12 8.08 9.88 4.67 5.59 7.69 3.17 7.67 5.33 
3087 Separation_of_Sister_Chromatids 9.84 0.19 7.18 1.68 6.66 6.93 0.09 9.07 8.53 7.35 7.09 1.03 3.5 4.37 7.35 6.23 5.55 4.71 
3088 Mitotic_Metaphase/Anaphase_Transition 6.62 2.06 0.12 5.89 5.52 8.4 3.83 4.13 0.16 9.1 4.05 5.15 2.62 9.1 7.67 7.6 1.99 3.95 
3089 Condensation_of_Prometaphase_Chromosomes 3.64 4.14 4.14 5.84 4.87 5.86 1.07 9.15 9.01 2.35 0.19 5.51 6.92 7.31 6.01 5.46 5.15 8.43 
3090 Resolution_of_Sister_Chromatid_Cohesion 7.56 6.01 3.97 9.24 8.72 7.77 7.11 6.59 1.05 8.96 0.61 0.29 6.7 4.42 2.08 5.56 0.58 0.16 
3091 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 5.15 0.56 6.25 4.38 4.78 3.13 1.37 7.32 3.54 0.43 9.02 3.84 7.73 7.79 2.91 6.33 5.05 5.14 
3092 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 8.77 5.27 4.73 0.56 1.14 6.97 1.31 6.91 8.19 8.31 2.2 2.39 7.02 3.46 4.64 1.44 7.59 8.4 
3093 Golgi_Cisternae_Pericentriolar_Stack_Reorganization 6.97 1.02 7.51 5.96 1.31 3.6 2.93 1.9 7.97 5.65 9.17 1.51 9.46 6.54 9.5 1.27 9.77 4.96 
3094 MASTL_Facilitates_Mitotic_Progression 8.01 5.07 1.29 0.89 4.14 9.85 1.61 3.77 0.33 6.29 0.55 7.23 5.49 6.57 5.2 2.91 4.55 3.29 
3095 Nuclear_Pore_Complex_(NPC)_Disassembly 9.68 5.78 8.15 8.05 0.98 8.56 0.19 1.22 0.81 6.17 3.24 3.79 7.84 3.32 6.04 7.32 0.23 6.72 
3096 Amplification__of_signal_from_unattached__kinetochores_via_a_MAD2__inhibitory_signal 5.36 8.56 5.27 1.35 9.71 4.43 8.25 3.04 8.84 7.22 5.69 3.59 0.01 5.61 1.61 0 5.87 5.97 
3097 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 9.23 8.68 9.79 6.6 9.26 9.23 2.38 6.82 6.53 4.03 5.89 4.62 6.69 5.27 8.08 7.64 5.5 0.12 
3098 Activation_of_NIMA_Kinases_NEK9,_NEK6,_NEK7 5.25 2.75 9.63 8.08 6.59 4.65 5.09 8.11 6.03 1.42 3.57 2.67 7.37 0.71 4.89 3.06 0.4 1.64 
3099 Clearance_of_Nuclear_Envelope_Membranes_from_Chromatin 3.13 6.59 0.12 7.32 0.82 1.1 3.56 7.67 5.78 6.87 1.67 6.29 5.01 4.53 4.69 8.29 4.8 5.62 
3100 Nuclear_Pore_Complex_(NPC)_Disassembly 6.18 3.84 9.72 6.39 6.39 5.99 6.3 7.3 2.42 0.25 0.52 8.98 6.71 4.1 7.3 6.26 0.47 1.29 
3101 Initiation_of_Nuclear_Envelope_Reformation 3.73 3.4 8.23 9.37 3.12 2.88 3.24 6.67 3.18 2.37 9.74 5.61 5.75 5.35 5.14 3.41 0.94 1.62 
3102 Nuclear_Pore_Complex_(NPC)_Disassembly 4.13 4.43 0.98 6.14 0.85 8.61 8.36 6.99 5.06 4.62 2.48 7.27 7.49 2.33 4.96 5.42 9.12 4.75 
3103 Deposition_of_New_CENPA-containing_Nucleosomes_at_the_Centromere 8.53 8.73 0.71 4.62 9.75 3.94 3.65 8.39 7.27 1.02 7.14 8.02 7.47 4.2 1.55 4.04 3.06 7.82 
3104 Orc1_removal_from_chromatin 0.98 3.46 0.32 4.86 8.72 0.64 5.96 2.75 6.08 5.4 4.57 4.19 7.02 5.65 5.38 3.95 2.8 6.62 
3105 Packaging_Of_Telomere_Ends 7.21 2.13 2.04 0.15 6.09 2.81 5.94 9.9 5.38 7.83 5.63 4.25 3.82 5.07 6.58 5.43 1.06 0.58 
3106 Phosphorylation_of_Emi1 4.9 4.08 3.18 7.57 4.24 3.79 0.01 9.32 4.34 3.75 2.86 4.45 0.64 2.83 4.68 7.73 6.74 8.89 
3107 Phosphorylation_of_proteins_involved_in_G1/S_transition_by_active_Cyclin_E:Cdk2_complexes 7.09 9.57 0.75 5.68 5.8 1.04 9.56 8.98 3.41 4.69 9.16 3.5 0.24 7.76 3.1 6.71 1.5 9.98 
3108 Phosphorylation_of_proteins_involved_in_the_G2/M_transition_by_Cyclin_A:Cdc2_complexes 5.4 3.72 8.39 8.33 5.79 2.89 6.75 7.92 3.82 6.37 1.67 1.78 4.23 0.14 4.03 7.32 6.92 1.94 
3109 Phosphorylation_of_the_APC/C 4.9 4.98 1.19 6.63 7.85 9.87 6.4 7.98 7.23 4.88 9.1 4.75 1.08 3.01 6.12 5.12 7.25 6.65 
3110 Polo-like_kinase_mediated_events 4.65 3.71 6.31 3.07 5.07 6.37 2.76 7.9 0.28 0.84 1.86 3.1 4.53 6.59 0.81 4.03 5.3 5.44 
3111 Polymerase_switching 7.36 0.21 0.71 4.47 8.75 0.65 3.3 8.93 6.31 3.08 0.72 1.6 0.73 4.6 4.2 4.37 9.72 2.71 
3112 Polymerase_switching_on_the_C-strand_of_the_telomere 4.85 7.93 2.17 5.26 2.24 3.16 6.76 0.34 7.5 5.87 2.12 7.47 5.28 8.13 2.67 9.41 8.31 4.57 
3113 Removal_of_the_Flap_Intermediate_from_the_C-strand 6.55 9.39 3.04 7.5 2.81 8.32 2.01 4.34 8.76 0.44 3.97 7.51 0.96 9.07 4.46 4.51 9.19 7.97 
3114 Removal_of_the_Flap_Intermediate 4.44 3.75 8.39 6.57 9.84 6.66 7.06 4.83 9.82 9.59 6.42 5.2 7.87 1.24 7.45 8 1.95 7.8 
3115 Recruitment_of_NuMA_to_mitotic_centrosomes 4.32 5.63 2.86 3.6 3.26 4.95 8.11 2.57 0.59 7.77 2.94 0.17 2.78 0.33 0.46 8.35 7.64 8.75 
3116 Recruitment_of_NuMA_to_mitotic_centrosomes 8.66 9.52 3.54 5.87 8.54 4.52 4.05 6.41 4.16 5.04 5.59 8.21 5.92 7.05 6.53 9.01 2.31 2.56 
3117 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 1.19 4.53 7.75 6.51 9.67 1.5 7.79 2.69 4.62 2.26 3.2 7.94 4.27 9.51 1.89 5.65 7.57 0.58 
3118 Phosphorylation_of_Emi1 3.35 6.77 0.59 6.62 2.08 7.89 2.5 7.41 2.48 2.27 7.91 8.13 1.81 2.76 9.18 2.79 2.55 3.1 
3119 SCF-beta-TrCP_mediated_degradation_of_Emi1 8.82 8.68 6.63 0.46 3.74 0.89 4.82 7.94 3.87 6.29 9.84 2.25 9.47 6.89 7.77 0.02 3.9 7.43 
3120 Association_of_licensing_factors_with_the_pre-replicative_complex 9.62 2.35 9.38 3.17 8.44 7.32 8.88 2.12 8.95 7.07 8.92 4.28 9.89 5.92 1.5 2.51 0.17 0.19 
3121 CDK-mediated_phosphorylation_and_removal_of_Cdc6 6.55 6.62 6.74 5.97 8.62 2.23 6.67 7.17 2.28 5.27 4.61 7.8 3.72 5.25 5.58 6.99 7.83 3.36 
3122 Orc1_removal_from_chromatin 9.88 0.51 3.34 6.5 6.05 1.32 2.5 3.09 5.69 3.07 3.05 9.54 7.62 2.3 6.81 7.04 7.38 8.74 
3123 Regulation_of_PLK1_Activity_at_G2/M_Transition 6.5 7.54 6.62 1.91 6.39 8.77 3.62 2.73 7.98 5.2 6.53 6.35 9.12 0.68 2.14 5.35 3.39 3.18 
3124 APC/C:Cdc20_mediated_degradation_of_Cyclin_B 6.95 2.01 8.62 1.22 5.85 2.45 7 5.78 5.93 0.14 3.32 3.04 9.05 0.49 6.72 1.21 7.06 3.28 
3125 APC/C:Cdc20_mediated_degradation_of_Securin 1.9 3.7 6.16 2.67 1.16 1.11 2.14 0.28 1.91 1.13 7.56 9.14 3 3.52 7.9 4.65 8.72 3.94 
3126 APC/C:Cdh1_mediated_degradation_of_Cdc20_and_other_APC/C:Cdh1_targeted_proteins_in_late_mitosis/early_G1 4.87 1.12 5.74 3.63 9.82 3.07 2.24 2.69 8.72 5.29 5.04 6.25 8.46 4.81 9.27 3.59 2.88 4.57 
3127 Autodegradation_of_Cdh1_by_Cdh1:APC/C 5.89 8.59 5.21 9.99 9.86 5.6 0.05 9.71 6.68 4.57 8.25 2.36 4.66 8.38 7.23 1.31 2.89 6.52 
3128 Conversion_from_APC/C:Cdc20_to_APC/C:Cdh1_in_late_anaphase 2.5 4.13 4.77 7.36 4.94 4.04 7.7 4.45 6.74 7.6 0.99 9.88 6.73 2.9 9.07 9.63 1.67 2.66 
3129 Inactivation_of_APC/C_via_direct_inhibition_of_the_APC/C_complex 4.02 5.21 0.5 8.66 5.46 2.81 8.17 9.62 4.9 2.61 5.95 4.37 7.87 5.01 4.91 1.64 4.1 5.61 
3130 Phosphorylation_of_Emi1 0.91 4.41 2.85 6.99 8.63 6.47 2.26 6.56 1.55 3.6 3.4 8 5.19 0.79 0.46 1.31 9.06 5.11 
3131 Phosphorylation_of_the_APC/C 9.25 6.47 3.25 9.23 6.02 9.6 1.77 3.84 4.37 3.03 6.51 5.28 9.2 3.91 3.75 6.96 6.83 6.11 
3132 SCF-beta-TrCP_mediated_degradation_of_Emi1 0.92 4.53 7.95 0.91 1.19 3.14 2.81 0.81 0.25 8.2 2.64 3.19 9.81 8.02 6.15 4.84 4.53 4.63 
3133 CDK-mediated_phosphorylation_and_removal_of_Cdc6 6.56 2.55 6.28 8.43 1.91 1.62 9.14 7.69 7.99 4.34 7.55 3.7 7.14 5.82 6.57 0.89 8 7.43 
3134 Orc1_removal_from_chromatin 1.07 4.08 2.42 4.63 4.46 9.39 5.98 0.36 6.83 5.47 3.1 3.59 8.49 5.27 0.12 2.56 1.09 0.62 
3135 Removal_of_the_Flap_Intermediate 3.53 0.53 3.11 5.19 6.47 6.19 7.98 6.45 7.87 8.84 0.95 3.01 7.35 8.49 5.94 9.54 8.54 0.1 
3136 Removal_of_the_Flap_Intermediate_from_the_C-strand 5.49 9.47 1.7 9.55 0.45 5.39 5.94 5.53 0.1 8.89 7.68 1.02 1.71 8.09 1.15 8.25 4.18 2.43 
3137 Resolution_of_Sister_Chromatid_Cohesion 0.31 4.34 5.37 9.22 8.94 5 5.56 3.6 2.97 9.08 7.45 1.76 8.71 8.89 7.18 2.6 5.3 6.12 
3138 CDK-mediated_phosphorylation_and_removal_of_Cdc6 0.26 0.16 8.69 9.14 4.39 1.58 2.9 4.15 2.94 3 7.88 5.02 8.91 4.67 2.57 6.22 1.62 0.49 
3139 DNA_replication_initiation 1.46 2.15 4.35 9.78 9.9 9.74 1.22 7.46 3.95 9.8 1.14 8.22 7.34 7.26 8.18 9.71 7.26 0.01 
3140 Establishment_of_Sister_Chromatid_Cohesion 4.88 3.11 1.48 1.48 4.22 1.99 8.05 7.46 3.95 3.21 8.99 9.52 0.27 6.27 5.45 2.92 5.05 6.27 
3141 Orc1_removal_from_chromatin 7.49 3.59 9.8 3.2 4.19 7.33 6.71 4.09 5.76 3.46 0.06 3.09 8.04 2.46 5.18 8.5 1.8 2.04 
3142 Polymerase_switching 6.6 6.18 9.5 6.32 9.05 7.63 7.34 2.15 7.16 3.98 9.05 8.68 0.16 6.11 7.84 8.64 0.39 7.7 
3143 Removal_of_the_Flap_Intermediate 2.87 0.73 1.76 9.33 1.18 5.43 3.33 1.48 1.68 4.91 7.36 4.17 9.63 5.84 2.71 1.89 1.27 8.7 
3144 SCF(Skp2)-mediated_degradation_of_p27/p21 0.13 3.55 8.1 9.96 2.03 6.28 2.35 7.19 0.63 1.38 0.37 3.85 6.44 6.48 2.31 2.67 7.22 8.34 
3145 Ubiquitin-dependent_degradation_of_Cyclin_D1 3.94 8.77 0.08 1.3 9.3 4.45 3.58 7.14 8.08 7.75 2.16 6.89 3.6 5.81 7.84 7.19 6.79 3.67 
3146 Unwinding_of_DNA 6.26 4.91 5.91 0.28 0.55 1.76 1.89 7.69 3.7 0.27 0.66 7.53 6.47 9.2 4.02 7.02 1.65 5.01 
3147 SCF(Skp2)-mediated_degradation_of_p27/p21 6.26 9.99 2.17 2.79 5.33 2.9 1.49 6.44 7.92 5.24 1.29 0.81 3.24 1.91 3.53 9.17 6.84 8.51 
3148 SCF-beta-TrCP_mediated_degradation_of_Emi1 9.42 0.61 1.92 4.24 4.18 8.89 4.98 3.79 6.7 5.99 9.51 1.6 1.02 3.35 9.11 6.78 1.52 2.47 
3149 Separation_of_Sister_Chromatids 9.2 6.65 8.88 2.63 4.56 3.32 5.04 2.64 5.38 1.25 1.42 5.12 3.48 1.89 2.22 4.97 4.3 5.52 
3150 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 2.18 6.68 3.49 8.66 7.51 5.75 2.8 8.83 8.1 3.11 2.59 4.21 3.15 5.86 2.58 4.59 1.77 5.07 
3151 CDK-mediated_phosphorylation_and_removal_of_Cdc6 4.32 3.48 4.45 3.87 3.14 0.8 4.51 6.38 9.97 6.82 4.71 7.17 0.95 0.71 3.64 5.46 7.96 3.42 
3152 Orc1_removal_from_chromatin 6.99 9.21 6.71 0.64 2.1 1.64 5.64 0.34 1.71 0.95 1.07 0.24 4.54 0.14 7.6 2.53 4.97 7.08 
3153 CDK-mediated_phosphorylation_and_removal_of_Cdc6 6.81 2.24 6.63 5.66 7.04 0.73 2.72 3.19 5.78 4.61 3.76 1.57 9.03 3.42 0.97 5.39 8.34 3.82 
3154 DNA_replication_initiation 3.81 0.08 5.39 2.69 4.94 4.08 4.59 2.02 5.53 6.42 5.28 6.7 0.52 2.42 1.06 2.87 3.23 3.2 
3155 Orc1_removal_from_chromatin 1.25 2.83 8.25 9.68 7.76 4.59 9.32 5.79 0.85 8.11 6.1 3.99 5.22 3.11 8.67 4.74 3.2 2.15 
3156 Polymerase_switching 8.39 7.56 1.14 6.22 3.06 4.62 7.11 3.28 0.44 4.45 3.24 4.83 2.06 8.36 5.72 1.75 3.38 4.65 
3157 Removal_of_the_Flap_Intermediate 0.89 3.6 1.78 8.78 8.8 7.96 4.44 0.67 2.23 3.44 3.73 1.06 8.58 9.04 6.03 4.35 0.71 7.11 
3158 Unwinding_of_DNA 3.99 9.93 4.07 6.67 1.87 5.33 5.74 5.88 9.44 5.7 9.4 4.14 3.32 1.36 8.85 9.5 1.85 7.97 
3159 Polymerase_switching_on_the_C-strand_of_the_telomere 1.74 2.9 3.53 7.13 1.61 7.71 5.29 7.36 9.95 0.07 1.96 1.09 8.35 3.78 7.54 7.41 8.3 6.94 
3160 Removal_of_the_Flap_Intermediate_from_the_C-strand 2.72 5.54 0.65 0.99 4.02 8.9 4.78 9.12 4.05 6.79 8.04 0.34 4.18 0.64 2.8 9.24 1.68 5.67 
3161 Telomere_C-strand_synthesis_initiation 2.96 6 1.3 8.04 6.89 6.05 8.73 7.39 8.78 0.98 9.14 4.25 3.17 1.3 6.35 4.6 2.77 6.08 
3162 Telomere_C-strand_synthesis_initiation 3.7 9.16 8.59 9.16 7.04 6.21 6.85 2.14 0.36 6.22 7.9 2.03 7.3 6.95 3.23 1.67 1.97 8.06 
3163 Telomere_Extension_By_Telomerase 0.21 8.82 8.98 8.83 7.12 5.97 4.24 9.09 5.55 5.66 4.61 9.64 6.58 6.58 0.34 4.48 3.37 8.51 
3164 Packaging_Of_Telomere_Ends 1.46 5.54 1.77 5.78 4.31 8.65 7.19 8.07 7.26 2.96 9.79 0.62 1.48 3.83 1.91 7.32 1.52 2.38 
3165 Polymerase_switching_on_the_C-strand_of_the_telomere 8.17 0.91 4.51 1.13 1.22 0.03 4.05 1.44 6.24 3.54 8.1 5.02 5.2 0.12 5.01 4.37 5.92 5.42 
3166 Removal_of_the_Flap_Intermediate_from_the_C-strand 0.84 6.32 9.73 8.23 1.56 3.3 6.64 1.36 3.26 9.25 9.82 1.58 7.54 4.92 4.08 1.26 6.27 1.01 
3167 Telomere_C-strand_synthesis_initiation 9.44 0.8 2.76 4.49 1.66 5.91 7.37 3.11 9.06 6.4 5.44 2.96 2.82 0.08 4.73 7.48 5.02 6.75 
3168 Telomere_Extension_By_Telomerase 0.29 8.92 5.86 0.27 5.39 5.05 0.68 5.66 6.73 0.06 4.39 2.67 7.44 9.21 3.03 0.78 5.84 8.56 
3169 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 4.05 7.54 0.87 3.21 8.77 3.1 6.68 7.54 1.03 9.07 0.08 4.83 4.51 2.69 2 6.8 9.21 6.32 
3170 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 2.2 1.8 7.75 7.73 4.19 6.66 1.32 8.04 7.55 6.05 1.33 4.52 4.59 9.39 5.73 2.5 5.24 4.29 
3171 Ubiquitin_Mediated_Degradation_of_Phosphorylated_Cdc25A 8.67 5.43 5.04 0.35 1.1 1.89 9.53 3.26 0.12 8.42 3.01 1.49 5.8 4.06 0.32 2.2 4.8 2.34 
3172 Ubiquitin-dependent_degradation_of_Cyclin_D1 2.82 4.98 9.12 5.85 8.43 3.29 7.22 2.99 3.41 4.12 0.3 2.8 1.77 5.16 4.98 2.66 7.64 1.23 
3173 Ubiquitin-dependent_degradation_of_Cyclin_D1 8.65 5.98 1.07 7.49 0.33 5.81 0.44 1.96 2.12 5.25 0.31 8.11 9.83 8.13 1.66 0.52 2.42 2.5 
3174 Unwinding_of_DNA 3.53 7.9 9.44 5.87 2.12 5.13 4.8 8.35 5.65 1.41 9.78 5.12 0.08 2.1 1.98 3.68 3.58 1.36 
3175 Cohesin_Loading_onto_Chromatin 4.81 5.4 9.18 7.07 5.05 4.95 7.38 4.23 9 2.48 9.81 0.18 5.56 9.26 0.19 8.98 3.25 4.59 
3176 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 0.66 0.84 5.22 8.61 1.36 8.47 8.69 2.57 2.69 9.45 9.1 2.88 8.26 8.56 6.78 4.15 4.9 7.07 
3177 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 5.79 3.06 0.64 4.42 2.7 4.49 1.85 1.47 0.2 7.65 8.11 4.79 2.83 7 5.1 5.64 1.02 3.95 
3178 Autodegradation_of_the_E3_ubiquitin_ligase_COP1 3.39 6.28 3.85 5.8 1.94 4.14 3.04 1.77 7.92 2.59 0.62 0.79 1.04 8.2 8.26 9.74 3.85 6.98 
3179 Transcriptional__activation_of__cell_cycle_inhibitor_p21_ 7.19 9.68 0.81 0.23 5.39 7.12 8.57 3.39 2.8 5.01 9.29 2.25 8.26 7.35 9.4 4.59 3.28 7.38 
3180 Ubiquitin_Mediated_Degradation_of_Phosphorylated_Cdc25A 9.76 0.02 8.86 3.36 2.31 3.79 9.62 0.44 9.53 1.98 3.74 3.08 0.06 0.09 2.21 7.66 5.18 0.61 
3181 Ubiquitin_Mediated_Degradation_of_Phosphorylated_Cdc25A 2.89 7.35 6.75 0.4 4.37 9.27 7.86 1.71 8.07 4.33 2.46 2.27 3.84 3.94 3.49 1.57 9.66 8.64 
3182 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 2.79 4.62 2.9 6.93 0.04 1.3 0.86 1.4 6.22 1.74 4.09 6.75 3.51 0.47 4.14 8.25 5.55 5.16 
3183 AKT_phosphorylates_targets_in_the_cytosol 7.61 2.18 5.53 5.69 4.28 0.64 4.14 3.42 5.94 3.17 3.63 6.96 0.58 8.79 7.69 7.42 8.45 3.55 
3184 AKT_phosphorylates_targets_in_the_nucleus 7.7 9.66 0.99 5.57 6.25 9.05 2.67 9.34 0.52 0.6 7.94 4.63 1.04 7.61 8.46 4.85 7.83 7.25 
3185 Abnormal_conversion_of_2-oxoglutarate_to_2-hydroxyglutarate 8.11 2.29 0.7 8.91 8.85 9.86 8.42 2.65 1.76 2.93 6.92 3.62 7.81 4.61 8.41 6.6 5.17 6.71 
3186 Abnormal_metabolism_in_phenylketonuria 6.39 6.66 1.3 7.27 8.69 3.16 3.48 4.56 4.67 1.42 4.02 7.84 8.74 2.38 0.42 0.88 9.97 4.1 
3187 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 7.71 9.86 4.56 5.78 0.72 2.75 5.04 9.85 3.68 6.2 3.55 9.94 4.12 6.2 3.77 6.01 4.56 5.76 
3188 Activated_point_mutants_of_FGFR2 3.63 7.91 4.29 3.33 8.75 5.46 0.3 5.08 9.33 3.09 7.14 5.2 6.76 1.87 6.5 5.41 4.23 7.14 
3189 Activation_of_the_phototransduction_cascade 0.04 4.81 2.85 9.57 5.35 0.79 9.92 8.18 8.95 3.29 3.18 8.38 5.87 4.06 6.37 3.66 8.93 9.49 
3190 Amyloids 5.6 5.43 6.82 7.61 9.81 9.68 1.55 1.97 2.82 4.22 0.43 8.18 7.35 0.48 9.62 6.62 3.48 0.69 
3191 Transport_of_HA_trimer,_NA_tetramer_and_M2_tetramer_from_the_endoplasmic_reticulum_to_the_Golgi_Apparatus 0.26 4.95 5.1 3.47 2.8 7.53 7.99 9.53 9.88 3.24 3.4 9.83 6.36 6.49 1.47 9.16 4.3 9.82 
3192 Biosynthesis_of_A2E,_implicated_in_retinal_degradation 7.48 0.8 7.33 3.52 6.15 3 8.22 0.89 2.3 3.26 9.08 2.91 9.32 0.97 4.72 3.96 2.15 8.61 
3193 Biotin_transport_and_metabolism 6.85 3.3 3.86 9.7 9.39 0.72 9.67 4.19 7.54 8.01 9.55 4.33 4.66 3.24 3.45 1.09 4.8 9.37 
3194 Budding 4.75 9.87 5.15 8.04 5.26 8.91 8.4 3.99 9.02 0.33 6.27 2.53 1.86 2.39 1.27 0.6 8.09 6.66 
3195 CS/DS_degradation 9.12 0.34 7.9 5.14 0.78 7.96 4.64 7.74 3.33 2.74 8.92 5.84 4.67 4.63 5.19 3.32 4.66 0.48 
3196 CaMK_IV-mediated_phosphorylation_of_CREB 7.82 6.15 7.27 7.39 1.21 5.49 5.93 8.74 3.52 1.95 1.98 2 7.24 4.95 4.26 0.03 3.93 0.13 
3197 Cam-PDE_1_activation 7.14 5.87 0.82 1.39 2.32 0.33 0.54 3.99 5.03 9.31 6.34 6.31 6.74 5.52 0.07 5.06 5.04 3.91 
3198 PKA_activation 8.45 0.69 3.63 7.81 4.16 5.04 9.21 0.3 7.14 1.3 6.58 4.11 3.69 6.5 7.32 0.77 4.5 4.08 
3199 CaMK_IV-mediated_phosphorylation_of_CREB 4.11 1.37 1.1 5.16 9 9.01 6.36 7.01 9.56 4.5 4.48 4.04 1.49 9.22 4.9 9.3 2.81 5.95 
3200 CaMK_IV-mediated_phosphorylation_of_CREB 1.62 3.1 1.3 8.53 2.91 6.92 1.37 3.29 4.61 6.03 9.41 4.99 8.31 9.1 3.1 0.65 5.8 7.25 
3201 Cam-PDE_1_activation 1.7 1.88 5.02 5 3.2 5.18 7.37 4.45 6.04 4.6 4.73 2.18 8.11 3.51 1.5 5.89 3.19 7.66 
3202 PKA_activation 6.63 0.51 0.44 2.38 8.85 2.7 1.88 8.76 4.17 9.55 9.53 1.7 0.65 6.52 8.65 6.32 1.35 5.1 
3203 Cam-PDE_1_activation 5.9 7.09 5.14 6.69 5.5 8.54 2.97 2.38 5.36 2.55 2.53 3.81 7.93 3.52 9.67 9.93 6.14 7.93 
3204 Chondroitin_sulfate_biosynthesis 9.38 4.93 7.55 1.85 6.33 0.72 4.83 2.11 4.76 2.87 5.04 0.98 3.67 3.54 7.1 0.79 9.64 8.76 
3205 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 4.03 2.8 2.35 4.38 9.3 3.87 4.22 0.95 0.56 7.56 7.3 0.53 5.02 7.55 2.26 8.71 9.6 7.29 
3206 CS/DS_degradation 5.26 7.02 6.29 1.25 0.37 6.88 1.13 4.74 4.95 1.75 5.11 8.59 5.82 0.02 8.51 1.69 4.13 3.23 
3207 Chondroitin_sulfate_biosynthesis 2.79 4.68 3.86 6.65 8.84 6.09 4.8 6.78 7.15 2.91 9.04 1.4 3.24 0.69 6.09 5.71 3.11 1.83 
3208 Dermatan_sulfate_biosynthesis 7.49 7.42 6.82 6.71 9.74 5.67 4.1 6.89 7.12 0.48 7.81 4.42 1.93 5.39 2.96 3.94 1.83 7 
3209 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 0.2 1.04 6.01 8.38 8.46 9.78 2.01 3.31 6.39 7.89 5.52 5.53 4.97 6.02 9.23 1.69 4.76 3.94 
3210 Coenzyme_A_biosynthesis 6.52 8.01 2.48 0.83 9.39 3.8 8.91 3.47 0.95 9.52 5.09 1.64 1.67 8.01 4.81 9.21 9.42 1.8 
3211 Constitutive_PI3K/AKT_Signaling_in_Cancer 6.79 5.68 3.59 8.46 2.01 2.64 9.57 2.7 0.43 0.05 9.51 2.89 7.26 8.34 6.09 9.01 9.1 9.59 
3212 Constitutive_Signaling_by_NOTCH1_HD_Domain_Mutants 6.94 6.63 5.39 6.19 7.97 1.77 1.01 2.59 2.34 2.38 4.84 5.31 2.78 8 2.78 1.48 4.65 9.16 
3213 Constitutive_Signaling_by_NOTCH1_HD+PEST_Domain_Mutants 5.06 3.59 8.87 0.28 6.92 1.21 0.01 2.54 1.7 2.08 8.54 5.71 9.43 6.45 1.86 1.62 1.26 0.18 
3214 Constitutive_Signaling_by_NOTCH1_PEST_Domain_Mutants 4.45 7.41 8.42 9.58 5.9 5.81 5.15 1.98 0.82 7.78 1.31 5.19 3.84 0.69 5.53 7.29 7.99 1.14 
3215 Constitutive_Signaling_by_NOTCH1_t(7;9)(NOTCH1:M1580_K2555)_Translocation_Mutant 5.42 8.54 5.54 8.16 0.46 0.59 0.18 4.99 7.78 1.1 4.69 9.72 5.56 8.65 1.1 9.26 9.22 0.22 
3216 CaMK_IV-mediated_phosphorylation_of_CREB 7.57 6.92 7.98 6.76 9.85 6.42 3.09 8.16 0.59 7.37 3.83 0.55 0.76 0.32 8.07 5.15 1.69 0.23 
3217 Cam-PDE_1_activation 5.63 8.84 7.34 8.21 6.62 7.29 3.77 7.88 1.64 2 4.89 6.91 5.82 5.46 0.31 1.09 2.95 5.06 
3218 PKA_activation 7.79 1.36 3.09 8.88 9.78 1.13 4.68 8.09 5.66 1.97 2.88 0.57 4.15 2.91 4.33 7.39 2.57 1.21 
3219 Biotin_transport_and_metabolism 7.32 7.51 5.17 1.4 0.96 6.22 0.45 9.8 7.18 5.71 5.54 1.27 2.36 2.59 4.88 2.2 6.75 6.86 
3220 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 1.73 2.91 7.84 9.5 2.78 0.83 2.08 0.71 9.38 6.36 1.04 4.71 3.07 9.67 0.12 3.68 3.46 3.87 
3221 Coenzyme_A_biosynthesis 6.94 9.88 8.66 4.17 5.77 0.09 4.8 1.77 2.86 5.25 7.61 3.02 6.07 5.71 9.89 6.64 5.79 2.3 
3222 Metabolism_of_folate_and_pterines 1.47 0.01 1.45 7.9 4.68 6.03 2.96 4.17 5.32 1.43 8.78 1.07 6.31 7.2 5.75 7.13 2 3.78 
3223 Molybdenum_cofactor_biosynthesis 0.65 1.79 8.08 7.57 9.17 3.84 7.09 0.07 6.57 3.1 3.13 2.24 0.68 4.26 0.37 0.87 4.89 6.21 
3224 Nicotinamide_salvaging 7.41 8.7 9.28 7.04 7.41 8.82 0.57 2.09 1.48 9.33 5.55 1.66 5.28 9.19 1.32 8.09 5.47 1.94 
3225 Vitamin_B1_(thiamin)_metabolism 0.33 0.13 3.73 9.41 2.64 3.12 8.81 7.96 2.04 3.38 7.4 8.53 0.58 8.45 5.71 7.18 4.25 4.85 
3226 Vitamin_B2_(riboflavin)_metabolism 4.37 0.94 1.67 0.17 7.54 1.13 4.9 0.43 4.89 3.12 3.87 2.69 3.2 4.16 3.46 5.4 7.19 3.93 
3227 Vitamin_C_(ascorbate)_metabolism 4.54 3.93 6.7 8.02 2.12 0.21 7.45 5.64 7.86 1.49 3.2 1.88 4.84 3.99 2.84 9.8 9.42 0.52 
3228 Vitamins_B6_activation_to_pyridoxal_phosphate 3.83 4.84 2.03 8.31 6.52 0.45 0.94 7.96 9.91 4.15 7.67 4.2 1.09 1 9.05 0.08 5.03 9.64 
3229 Biotin_transport_and_metabolism 2.81 0.92 6.99 4.66 1.93 3.98 4.28 9.9 9.98 4.15 4.11 1.17 7.03 4.74 9.82 1.02 2.55 9.7 
3230 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 7.44 8.22 5.65 5.77 2.72 7.83 1.78 5.98 6.71 3.16 8.82 2.54 5.16 3.68 1.1 8.86 1.78 9.52 
3231 Coenzyme_A_biosynthesis 1.53 5.6 3.41 1.34 3.7 7.57 3.37 8.31 1.94 0.82 3.4 5.51 7.11 2.29 9.57 5.64 9.99 6.66 
3232 Metabolism_of_folate_and_pterines 4.2 7.12 2.65 0.41 8.51 2.11 7.68 4.02 8.54 7.04 3.62 0.68 2.23 1.66 7.28 0.1 1.25 6.91 
3233 Molybdenum_cofactor_biosynthesis 2.71 1.36 2.78 4.36 2.07 3.16 2.59 0.88 1.36 4 6.43 6.37 4.86 7.59 2.34 4.58 1.49 5.1 
3234 Nicotinamide_salvaging 8.67 1.68 6.05 5.97 2.76 9.55 9.72 5.58 2.65 2.37 2.64 3.01 0.84 8.68 5.72 5.92 1.47 1.55 
3235 Vitamin_B1_(thiamin)_metabolism 9.57 5.61 6.18 7.27 3.01 7.62 8.51 0.91 2.32 4.97 8.27 6.46 2.21 7.88 5.58 7.86 4.79 6.22 
3236 Vitamin_B2_(riboflavin)_metabolism 7.82 4.73 6.13 7.63 4.32 4.35 2.95 6.24 3.68 1.71 4.18 6.55 0.15 9.63 2.45 5.37 3.77 6.21 
3237 Vitamin_C_(ascorbate)_metabolism 7.81 3.88 0.2 2.6 0.3 8.56 6.21 6.58 3.79 1.48 9.97 6.51 4.4 9.74 9.89 6.73 6.93 1.87 
3238 Vitamins_B6_activation_to_pyridoxal_phosphate 7.81 3.22 1.74 2.76 6.75 9.35 9.21 8.74 8.82 5.18 7.59 1.39 5.05 2.19 8.15 9.1 0.54 6.26 
3239 Biotin_transport_and_metabolism 5.6 5.23 5.86 3.19 4.85 9.58 1.11 2.58 0.46 9.49 5.19 5.73 5.88 5.2 2.95 3.68 3.72 2.65 
3240 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 0.12 4 4.65 5.96 4.45 4.59 3.07 2.08 8.17 3.35 4.52 9.1 0.18 4.19 8.53 5.23 0.02 2.14 
3241 Coenzyme_A_biosynthesis 1.4 7.69 8.28 6.23 8.17 0.9 0.79 7.88 4.81 5.43 1.18 2.63 0.19 4.7 1.64 0.3 1.69 4.18 
3242 Metabolism_of_folate_and_pterines 7.9 8.74 2.81 1.52 1.37 3.86 9.4 5.35 4.39 7.85 5.99 0.55 6.91 5.25 2.16 2.3 2.37 6.74 
3243 Molybdenum_cofactor_biosynthesis 0.91 5.1 1.46 2.3 2.22 2.99 6.27 9.1 8.25 6.43 7.62 4.97 3.54 7.35 0.08 0.67 7.28 3.22 
3244 Nicotinamide_salvaging 1.38 5.49 7.99 4.87 0.05 3.87 0.68 4.96 5.59 8.06 3.21 7.08 8.16 3.23 3.22 2.64 8.18 4.11 
3245 Vitamin_B1_(thiamin)_metabolism 4.65 3.13 5.89 1.97 6.23 4.81 4.46 6.97 3.81 1.93 0.4 7.9 2.82 4.78 4.99 4.39 2.85 4.23 
3246 Vitamin_B2_(riboflavin)_metabolism 7.96 5.69 8.85 3.25 5.18 6.72 2.62 1.32 2.8 6.98 0.88 0.49 6.62 9.8 0.67 6.76 7 9.24 
3247 Vitamin_C_(ascorbate)_metabolism 1.33 7.84 7.04 1.98 3.44 2.33 2.96 0.11 4.61 4.85 5.16 6.63 8.53 3.26 1.25 1.22 0.98 1.99 
3248 Vitamins_B6_activation_to_pyridoxal_phosphate 3.26 8.02 6.57 4.53 4.98 6.07 6.19 2 6.3 5.75 3.88 4.98 5.85 6.42 8.91 0.63 0.33 8.65 
3249 Biotin_transport_and_metabolism 0.75 7.82 1.11 4.5 9.06 9.19 4.94 9.67 5.36 6.69 4.63 8.24 8.02 6.46 2.89 2.46 5.52 1.12 
3250 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 5.04 6.1 1.95 6.94 9.15 5.09 5.24 1.47 5.62 3.53 6.25 3.99 5.44 3.92 6.08 5.6 7.49 9.72 
3251 Coenzyme_A_biosynthesis 6.09 9.23 8.16 6.94 2.62 4.83 9.79 6.66 2.87 1.37 2.54 8.83 2.68 1.08 0.25 7.16 7.54 4.51 
3252 Metabolism_of_folate_and_pterines 5.56 3.91 6.1 0.17 1.14 5.04 8.78 5.83 5.89 0.76 5.49 8.49 1.71 9.59 4.49 1.22 8.74 4.84 
3253 Molybdenum_cofactor_biosynthesis 7.67 2.89 4.64 0.89 1.19 2.48 1.5 6.57 3.97 4.66 2.53 8.43 1.19 7.26 1.38 6.59 6.79 2.89 
3254 Nicotinamide_salvaging 9.5 2.96 0.83 5.12 3.69 0.46 9.4 6.46 7.28 7.08 8.92 4.75 4.44 5.77 5.23 3.98 4.78 2.11 
3255 Vitamin_B1_(thiamin)_metabolism 0.59 7.33 1.44 8.8 1.95 9.3 2.37 9.68 6.97 7.19 0.19 3.54 1.07 4.05 8.72 0.71 2.56 0.26 
3256 Vitamin_B2_(riboflavin)_metabolism 6.27 2.6 3.23 5.14 4.69 7.32 0.56 8.87 5.43 0.45 9.69 1.47 6.69 4.41 2.19 2.13 5.56 9.28 
3257 Vitamin_C_(ascorbate)_metabolism 4.93 3.39 2.56 4.44 0.17 5.03 1.77 3.49 7.02 8.29 4.47 4.62 0.69 0.68 6.51 5.12 9.79 4.99 
3258 Vitamins_B6_activation_to_pyridoxal_phosphate 9.04 0.61 6.46 1.33 4.98 5.6 0.51 1.28 4.54 5.63 5.27 4.91 1.78 0.09 5.56 2.54 5.18 3.73 
3259 Biotin_transport_and_metabolism 7.27 3.26 0.6 3.47 7.76 0.49 6.35 2.45 5.46 7.59 8.1 9.6 4.59 2.09 1.71 8.73 0.22 6.3 
3260 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 7.18 6.26 2.15 4.92 3.36 6.49 1.02 2.37 4.19 9.31 1.52 7.94 1.6 3.09 3.63 3.07 4.98 6.51 
3261 Coenzyme_A_biosynthesis 1.45 3.44 5.57 1.81 8.3 8.58 4.79 2.94 2.85 7.41 8.7 0.94 5.91 7.38 1.54 3.47 1.1 8.8 
3262 Metabolism_of_folate_and_pterines 8.19 9.16 8.82 0.67 9.26 1.02 0.89 5.68 7.09 7.86 8.12 9.75 3.33 6.31 5.92 2.5 7.96 7.8 
3263 Molybdenum_cofactor_biosynthesis 1.86 5.33 6.5 1.05 7.11 7.51 5.27 5.66 7.23 1.52 0.7 3.55 1.92 9.55 3.36 3.3 9.21 9.34 
3264 Nicotinamide_salvaging 1.96 2.27 8.39 7.43 1.57 2.54 5.48 4.98 7.16 2.54 1.74 3.28 0.96 7 2.3 8.26 3.24 5.13 
3265 Vitamin_B1_(thiamin)_metabolism 4.98 1.5 6 4.16 0.64 5.13 5.06 1.87 1.16 9.42 1.74 3.09 1.64 7.34 0.35 6.08 6.81 7.44 
3266 Vitamin_B2_(riboflavin)_metabolism 1.93 9.12 4.65 2.19 8.8 0.88 9.15 1.62 8.98 3.47 4.66 7.19 8.12 0.05 9.1 8.75 9.36 1.48 
3267 Vitamin_C_(ascorbate)_metabolism 4.55 3.32 3.51 6.73 5.08 7.84 1.57 4.83 4.43 2.34 0.29 9.18 8.65 2.51 1.28 1.76 8.12 5.86 
3268 Vitamins_B6_activation_to_pyridoxal_phosphate 8.32 2.28 3.43 5.91 8.01 5.79 7.5 5.32 7.38 1.35 1.79 1.17 3.84 7.86 7.84 0.66 5 0.15 
3269 Biotin_transport_and_metabolism 7.98 7.54 1.98 9.34 8.69 3.79 8.42 1.26 6.05 7.35 2.74 1.42 4.21 9.92 1.24 4.44 7.21 5.52 
3270 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 3.33 4.66 0.57 5.3 0.38 8.22 0.4 6.29 4.15 8.01 3.63 5.06 9.29 9.39 6.19 6.12 4.4 7.25 
3271 Coenzyme_A_biosynthesis 2.84 9.84 9.12 7.98 1.58 4.61 5.67 8.9 7.79 4.69 1.56 0.31 5.87 3.96 4.87 2.98 2.53 3.85 
3272 Metabolism_of_folate_and_pterines 9.61 2.82 9.67 6.51 1.97 3.47 8.55 6.21 9.27 8.47 3.38 1.41 1.87 5.99 8.06 0.42 7.61 3.36 
3273 Molybdenum_cofactor_biosynthesis 9.8 9.48 6.4 1.8 9.6 1.52 1.05 1.18 9.07 5.72 4.14 0.42 0.16 8.72 5.3 0.99 9.34 9.82 
3274 Nicotinamide_salvaging 5.94 0.95 7.42 7.87 3.25 1.29 5.97 9.18 6.72 0.54 9.8 6.48 4.53 7.38 0.3 2.05 8.2 5.24 
3275 Vitamin_B1_(thiamin)_metabolism 6.9 8.9 6.9 1.99 6.9 5.51 4.26 1.86 4.51 9.43 0.82 6.9 4.22 1.42 6.31 8.62 4.62 0.19 
3276 Vitamin_B2_(riboflavin)_metabolism 2.67 8.51 0.03 7.74 5.9 4.97 1.66 6.11 3.62 8.38 5.42 5.67 5.96 8.82 2.82 6.34 4.8 8.35 
3277 Vitamin_C_(ascorbate)_metabolism 4.48 5.26 7.64 3.62 2.46 9.6 2.63 3.01 3.43 7.48 2.59 7.5 7.36 7.42 4.42 8.36 6.67 3.34 
3278 Vitamins_B6_activation_to_pyridoxal_phosphate 2.61 3.2 1.47 3.07 6.42 2.99 7.14 6.27 3.83 6.62 1.68 9.77 2.82 1.86 1.24 7.85 6.66 9.54 
3279 Biotin_transport_and_metabolism 2.08 1.53 8.04 4.77 4.16 3.68 1.27 4.72 7.07 2.51 0.81 0.43 6.7 4.77 4.69 8.99 2.93 3.59 
3280 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 0.6 8.49 7.15 2.32 2.93 2.56 4.35 2.23 2.88 4.77 9.36 5.67 6.95 5.62 0.34 1.62 6.7 4.35 
3281 Coenzyme_A_biosynthesis 0.99 8.97 0.41 5.64 8.73 7.87 4.96 0.34 1.32 8.76 9.27 0.58 3.22 1.91 6.25 5.84 9.85 7.91 
3282 Metabolism_of_folate_and_pterines 5.98 9.69 2.21 0.11 9.3 2.98 1.38 6.73 9.44 4.66 0.05 8.04 2.15 3.81 2.78 9.52 5.07 9.39 
3283 Molybdenum_cofactor_biosynthesis 0.8 9.25 3.11 1.28 3.72 6.9 2.74 5.33 3.79 1.73 4.24 6.64 4.67 4.32 0.35 8.55 8.52 1.57 
3284 Nicotinamide_salvaging 9.53 3.06 6.51 6.94 5.99 9.3 0.55 2.3 2.62 4.28 4.18 2.44 9.57 2.59 0.66 1.86 1.59 5.49 
3285 Vitamin_B1_(thiamin)_metabolism 9.84 6.4 3.11 3.49 8.88 8.46 8.57 6.17 3.07 8.42 7.31 9.56 4.73 3.51 9.48 9.9 4.35 4.79 
3286 Vitamin_B2_(riboflavin)_metabolism 6.11 6.66 4.72 0.73 0.19 5.21 4.15 6.7 7.49 6.38 1.49 4.97 5.19 3.53 7.58 7.02 3 4.4 
3287 Vitamin_C_(ascorbate)_metabolism 2.33 8.61 6.36 2.67 6.87 5.02 5.1 2.22 3.48 2.22 2.83 2.05 1.86 3.63 0.2 6.02 1.3 5.33 
3288 Vitamins_B6_activation_to_pyridoxal_phosphate 7.03 3.63 6.68 9.9 4.05 6.34 0.73 8.91 4.16 8.93 2.95 6.43 6.67 7.27 8.45 5.04 4.82 8.06 
3289 Biotin_transport_and_metabolism 9.92 6.11 3.57 8.23 3.97 5.09 1.03 3.34 3.35 2.43 8.67 8.83 5.56 5.21 0.73 0.97 0.83 9.15 
3290 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 9.09 3.29 4 5.76 1.84 8.87 8.59 4.88 7.64 8.1 5.82 7.75 7.3 4.9 8.78 9.3 4.87 9.09 
3291 Coenzyme_A_biosynthesis 1.24 8.9 3.98 8.99 2.84 8.06 3.51 8.67 6.29 0.54 7.37 3.97 2.98 7.18 6.35 1.78 8.08 3.99 
3292 Metabolism_of_folate_and_pterines 1.7 8.88 7.54 5.16 8.7 2.74 3.46 0.11 4.93 1.75 7.37 2.42 5.08 0.82 1.52 3.81 7.07 2.51 
3293 Molybdenum_cofactor_biosynthesis 4.71 2.29 8.32 5.96 8.86 3.23 0.79 5.34 4.58 6.94 1.93 1.56 6.35 3.85 0.99 5.12 7.88 5.68 
3294 Nicotinamide_salvaging 1.93 6.85 2.34 7.24 4.25 7.82 6.96 5.88 1.88 1.57 2.26 7.11 8.75 8.06 3.05 7.12 1.35 6.28 
3295 Vitamin_B1_(thiamin)_metabolism 1.43 3.93 7.96 0.76 4.43 6.27 8.14 9.21 5.67 6.61 1.73 5.12 7.36 7.39 4.05 7.57 1.58 0.65 
3296 Vitamin_B2_(riboflavin)_metabolism 4.97 5.97 8.52 8 9.92 9.34 4.42 7.11 5.28 8.11 9.3 2.46 4.75 9.01 1.75 2.72 1.27 2.63 
3297 Vitamin_C_(ascorbate)_metabolism 1.01 6.31 1.95 8.8 1.09 5.32 9.75 3.98 3.43 9.18 8.02 2.57 1.49 5.95 9.86 9.73 1.09 9.65 
3298 Vitamins_B6_activation_to_pyridoxal_phosphate 6.16 3.57 3.2 3.91 3.69 8.84 9.93 8.48 7.64 4.05 5.76 8.39 6.25 0.95 5.51 3.04 9.59 5.85 
3299 Biotin_transport_and_metabolism 7.24 9.41 5.61 5.88 1.61 7.13 9.13 5.6 8.97 5.13 4.86 8.63 8.03 1.96 8.42 8.9 4.27 6.28 
3300 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 6.47 4.72 8.8 0.21 3.79 5.1 0.56 0.78 9.21 1.72 8.83 0.38 1.22 8.76 1.58 2.41 3.72 3.28 
3301 Coenzyme_A_biosynthesis 4.06 0.59 6.58 5.64 9.04 6.6 1.32 2.82 7.74 3.96 4.56 4.45 7.57 2.48 9.21 5.52 4.77 3.66 
3302 Metabolism_of_folate_and_pterines 5.51 1.03 2.16 4.54 6.55 2.3 2.23 9.46 9.33 7.37 5.77 6.56 0.87 6.28 8.69 9.16 6.51 1.48 
3303 Molybdenum_cofactor_biosynthesis 3.31 2.83 8.36 8.45 3.66 7.26 6.33 3.82 3.48 4.11 0.63 7.7 8.73 6.67 5.12 7.52 2.4 5.35 
3304 Nicotinamide_salvaging 3.15 7.65 1.32 0.04 0.3 6.72 7.34 3.53 0.02 9.34 7.76 9.66 4.38 3.36 6.9 8.07 8.94 7.7 
3305 Vitamin_B1_(thiamin)_metabolism 4.26 3.69 0.13 0.45 4.33 2.21 9.53 3.03 9.64 8.03 1.19 2.41 7.36 7.6 3.98 4.09 4.42 1.39 
3306 Vitamin_B2_(riboflavin)_metabolism 5.19 0.97 2.69 6.04 6.53 2.24 0.85 9.82 4.9 9.04 6.12 7.6 3.07 3.36 7.71 0.7 6.29 4.58 
3307 Vitamin_C_(ascorbate)_metabolism 0.6 4.21 0.88 9.27 8.45 3.74 2.26 3.38 3.6 0.5 2.47 8.58 7.2 0.72 8.96 6.44 9.42 8.58 
3308 Vitamins_B6_activation_to_pyridoxal_phosphate 4.25 5.37 5.65 6.95 4.4 8.44 8.51 0.77 4.59 6.55 7.21 5.24 2.08 3.97 9.33 6.27 7.39 2.51 
3309 Biotin_transport_and_metabolism 3.5 3.09 7.8 4.91 4.23 8.92 7.51 1.77 0.4 3.14 1.2 6.98 0.97 4.35 2.46 8.17 8.8 3.91 
3310 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 9.19 8.28 7.41 1.02 7.4 2.06 3.32 7.57 1.75 7.83 3.39 1.68 4.9 2.49 8.13 2.56 4.9 3.64 
3311 Coenzyme_A_biosynthesis 3.58 9.51 3.4 4.92 2.08 6.34 5.43 5.53 7.33 5.99 5.86 5.36 0.38 1.5 6.47 2.8 8.11 3.56 
3312 Metabolism_of_folate_and_pterines 6.24 7.67 3.96 0.46 3.44 8.22 6.87 9.4 4.7 4.26 8.43 1.9 9.26 3.73 7.17 2.99 9.92 9.97 
3313 Molybdenum_cofactor_biosynthesis 7.69 8.23 9.81 2.59 2.03 7.16 9.99 5.34 4.78 5.41 5.76 5.36 8.69 6.95 8.94 2.49 9.76 4.65 
3314 Nicotinamide_salvaging 9.97 4.04 2.74 7.82 3.5 6.55 2.48 0.4 8.87 3.1 8.68 6.47 7.63 2.5 0.03 6.98 1.79 5.42 
3315 Vitamin_B1_(thiamin)_metabolism 2.11 7.97 8.12 7.15 3.78 6.92 5.87 4.52 9.15 9.19 3.43 3.24 3.38 3.42 3.42 0.95 7.45 9.43 
3316 Vitamin_B2_(riboflavin)_metabolism 6.5 1.75 3.4 0.61 3.33 0.24 1.39 1.15 0.19 8.77 4.61 0.98 2.72 1.16 3.49 5.6 4.33 5.83 
3317 Vitamin_C_(ascorbate)_metabolism 9.52 6.82 7.19 0.29 9.96 4.67 3.77 3.37 0.16 2.6 9.77 2.17 8.71 7.74 6.67 7.53 9.34 5.34 
3318 Vitamins_B6_activation_to_pyridoxal_phosphate 9.21 5.05 3.69 4.65 1.38 8.69 8.97 6.57 8.6 3.71 3.29 8.3 8.15 4.74 8.49 4.56 7.08 5.53 
3319 Biotin_transport_and_metabolism 3.54 4.19 4.14 3.9 2.82 3.64 7.36 5.36 3.07 3.4 4.72 7.59 8.16 2.27 9.3 7.3 3.59 0.94 
3320 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 3.43 5.13 3.33 7.24 2.4 4.53 9.82 0.7 6.85 5.56 9.88 6.77 4.51 6.9 2.75 4.96 9.5 4.92 
3321 Coenzyme_A_biosynthesis 9.14 2.86 8.43 2.7 5.24 0.4 5.21 6.96 0.4 4.67 4.08 8.92 7.25 8.13 1.71 4.67 5.3 7.49 
3322 Metabolism_of_folate_and_pterines 3.3 1.85 9.57 3.84 3.88 3.66 5.63 8.02 0.75 6.22 7.04 3.62 2.56 1.79 6.55 9.85 9.84 3.86 
3323 Molybdenum_cofactor_biosynthesis 4.19 2.19 9.75 8.28 3.99 8.38 4.92 3.97 2.03 8.36 3.97 4.5 7.52 6.68 5.17 6.06 3.27 3.58 
3324 Nicotinamide_salvaging 2.74 1.98 9.64 7.74 5.64 9.83 7.05 7.84 4.52 1.24 9.84 6.05 7.05 7.64 4.72 3.25 1.44 3.23 
3325 Vitamin_B1_(thiamin)_metabolism 8.85 9.5 3.17 3.35 6.49 0.19 1.81 7.82 4.63 6.72 6.46 9.74 2.81 6.05 2.41 0.22 3.2 6.34 
3326 Vitamin_B2_(riboflavin)_metabolism 3.67 8.51 9.25 1.7 4.34 5.25 6.54 9.23 0.85 5 2.83 7.49 8.15 8.76 2.97 4.32 4.11 5.45 
3327 Vitamin_C_(ascorbate)_metabolism 8.06 0.91 9.23 6.15 9.34 9.78 6.55 7.6 8.3 2.24 8.01 3.32 7.99 3.74 3.95 2.92 4.38 8.74 
3328 Vitamins_B6_activation_to_pyridoxal_phosphate 4.11 4.88 1.53 8.99 0.61 4.42 5.72 7.55 1.53 5.54 6.36 7.11 7.67 5.46 0.04 4.92 6.4 9.33 
3329 Biotin_transport_and_metabolism 1.03 1.3 2.47 8.84 4.05 1.81 7.04 9.94 7.69 7.77 4.16 0.49 5.94 3.5 1.34 8.75 7.05 0.52 
3330 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 2.64 1.18 1.78 0.17 8 2.5 4.07 1.61 0 0.76 2.25 2.29 3.55 5.52 7.12 3.91 5.19 4.82 
3331 Coenzyme_A_biosynthesis 2.53 0.84 5.52 7.02 1.02 1.87 1.99 6.18 7.06 2.3 4.35 2.24 2.69 6.95 2.54 5.04 8.3 6.13 
3332 Metabolism_of_folate_and_pterines 0.11 4.61 8.48 7.9 9.58 8.54 0.38 7.9 6.37 6.56 4.74 0.49 4.93 6.74 0.47 7.18 7.21 4.5 
3333 Molybdenum_cofactor_biosynthesis 4.05 6.7 9.03 4.06 9.02 5.55 1.54 8.3 5.43 8.59 5.19 3.28 0.72 7.27 8.18 7.47 7.04 5.59 
3334 Nicotinamide_salvaging 8.81 2.8 1.31 2.33 4.37 9.57 8.37 9.53 8.92 4.93 5.07 7.39 8.97 1.33 5.6 8.47 3.84 5.75 
3335 Vitamin_B1_(thiamin)_metabolism 4.29 4.69 7.48 3.56 4.93 9.05 0.12 9.98 8.72 4.88 5.66 2.68 6.86 2.2 4.74 7.38 0.79 0.91 
3336 Vitamin_B2_(riboflavin)_metabolism 6.43 5.36 7.52 4.39 8.25 4.89 7.77 2.1 8.5 1.75 4.13 3.69 6.58 9.64 4.25 0.59 6.81 0.68 
3337 Vitamin_C_(ascorbate)_metabolism 0.56 4.49 3.08 3.7 0.14 4.31 6.78 4.81 5.48 7.8 3.68 2.92 8.11 2.39 0.63 8.39 9.09 6.34 
3338 Vitamins_B6_activation_to_pyridoxal_phosphate 6.38 3.59 3.52 6.04 3.55 5.99 7.8 3.7 6.7 1.66 3.76 2.85 4.95 2.93 6.72 5.94 2.15 8.21 
3339 Biotin_transport_and_metabolism 9.37 4.29 5.87 7.44 4.72 0.39 8.2 7.58 1.44 9.55 7.46 6.12 9.62 6.91 0.66 3.2 8.5 2.64 
3340 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 0.37 7.99 5.19 3.14 8.27 6.83 1.23 5.16 2.8 9.59 7.48 5.4 9.34 1.01 4.35 0.66 0.35 9.47 
3341 Coenzyme_A_biosynthesis 6.83 5.91 0.85 4 7.08 6.95 0.51 4.29 3.76 0.18 3.09 2.66 4.69 9.43 0.63 2.3 4.53 3.86 
3342 Metabolism_of_folate_and_pterines 6.98 0.04 1.62 7.6 8.99 2.9 9.66 4.4 5.92 0.19 4.18 7.97 6.16 3.44 3.73 5.13 5.79 1.62 
3343 Molybdenum_cofactor_biosynthesis 5.59 5.56 6.5 7 2.79 8.14 1.92 0.78 8.34 5.69 3.77 6.44 9.09 5.62 7.77 6.01 8.05 4.33 
3344 Nicotinamide_salvaging 6.01 4.14 7.4 0.06 5.49 9.92 1.51 7.19 6.98 0.25 2.38 9.12 1.1 5.09 3.39 2.74 7.6 7.35 
3345 Vitamin_B1_(thiamin)_metabolism 8.39 5.35 7.7 3.17 6.17 9.41 7.71 6.98 1.84 6.09 7.22 0.9 5.55 5.89 1.04 9.87 2.23 9.73 
3346 Vitamin_B2_(riboflavin)_metabolism 0.22 2.59 7.85 1.03 1.91 9.08 7.09 4.5 9.51 2.79 8.07 4.56 6.76 0.72 7.27 1.98 2.59 7.58 
3347 Vitamin_C_(ascorbate)_metabolism 6.82 4.99 0.46 1.1 0.78 3.19 6.53 1.44 1.98 4.63 9.79 8.02 3.03 3.34 6.9 6.67 5.94 0.94 
3348 Vitamins_B6_activation_to_pyridoxal_phosphate 3.21 9.79 1.88 5.11 3.01 3.7 3.78 4.23 2.38 6.86 0.48 5.39 8.04 9.28 7.08 6.28 6.17 8.97 
3349 Biotin_transport_and_metabolism 8.95 2.06 8.48 8.09 9.4 3.89 5.67 1.77 3.72 8.73 6.97 5.86 4.32 4.75 6.23 5.89 8.81 5.76 
3350 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 2.88 8.2 5.17 8.3 0.62 0.8 7.14 8.53 2.44 5.01 2.64 0.48 1.41 2.11 6.74 1.08 2.85 1.19 
3351 Coenzyme_A_biosynthesis 3.42 8.8 8.3 8.01 5.57 6.29 5.8 8.31 5.81 9.75 1.78 9.22 6.61 0.77 7.37 4.23 8.8 2.78 
3352 Metabolism_of_folate_and_pterines 6.13 5.92 8.37 4.61 8.11 4.36 2.7 4.22 3.52 2.69 9.61 8.89 1 6.24 8.52 8.55 1.99 9.63 
3353 Molybdenum_cofactor_biosynthesis 7.24 4.34 0.34 6.66 3.67 4.26 1.45 9.94 4.39 2.37 0.95 8.81 1.7 2.39 1.31 6.93 8.01 9.38 
3354 Nicotinamide_salvaging 2.01 8.37 5.34 2.87 0.68 1.17 4.98 6.7 1.23 4.86 9.65 3.38 9.54 0.13 0.07 3.77 2.19 1.06 
3355 Vitamin_B1_(thiamin)_metabolism 7.74 8.35 4.6 8.85 8.65 8.41 0.42 6.52 7.49 5.92 9.34 3.83 1.9 8.85 2.71 7.92 4.48 3.55 
3356 Vitamin_B2_(riboflavin)_metabolism 8.81 1.73 3.02 0.58 3.48 9.2 1.39 0.67 4.56 9.05 7.43 5.7 2.23 3.13 6.76 8.51 1.39 2.75 
3357 Vitamin_C_(ascorbate)_metabolism 0.89 1.6 4.19 4.07 0.95 0.89 1.2 7.98 6.27 4.61 3.4 6.05 8.27 2.09 9.25 3.79 8.93 7.59 
3358 Vitamins_B6_activation_to_pyridoxal_phosphate 4.63 2.85 6.44 1.12 3.04 6.53 7.71 6.84 2.95 1.98 7.59 9.93 2.07 2.12 6.97 4.91 7.61 4.97 
3359 Biotin_transport_and_metabolism 0.41 1.95 0.96 6.02 9.37 7.79 1.21 5.64 5.37 8.41 1.86 8.17 5.26 9.62 8.5 6.95 1.05 4.89 
3360 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 4.82 8.75 9.73 3.44 3.78 6.58 3.69 4.94 3.03 2.72 8.47 6.89 9.96 2.6 3.07 7.1 5.82 3.64 
3361 Coenzyme_A_biosynthesis 9.84 0.47 0.21 8.69 8.64 6.52 4.23 6.3 4.27 1.17 5.19 7.09 5.7 0.87 6.79 0.18 8.91 2.69 
3362 Metabolism_of_folate_and_pterines 1.13 4.99 2 1.53 3.08 1.67 8.99 5.63 0.52 4.79 4.29 6.09 6.11 1.78 0.64 1.92 6.08 7.04 
3363 Molybdenum_cofactor_biosynthesis 6.81 9.14 1.73 5.61 0.9 4.64 7.09 3.35 1.34 9.69 5.01 1.29 8.79 6.68 5.31 5.14 8.37 7.15 
3364 Nicotinamide_salvaging 4.84 6.73 1.83 0.17 9.46 3.86 1.35 2.77 9.9 2.77 2.81 4.71 1.46 2.37 7.48 8.42 3.55 1.88 
3365 Vitamin_B1_(thiamin)_metabolism 9.8 2.66 8.21 7.97 5.51 3.05 2.63 0.9 7.19 7.73 5.92 7.11 6.79 0.99 3.38 3.99 0.66 4.42 
3366 Vitamin_B2_(riboflavin)_metabolism 6.93 9.65 2 2.01 3.76 4.21 1.7 8.59 3.64 5.49 4.08 7.57 3.61 3.82 0.65 8.12 9.49 3.03 
3367 Vitamin_C_(ascorbate)_metabolism 4.59 2.04 8.9 8.44 0.03 8.39 4.88 5.47 5.52 5.63 4.51 7.83 1.15 0.23 7.02 6.48 8.25 5.82 
3368 Vitamins_B6_activation_to_pyridoxal_phosphate 1.99 7.39 3.08 1.25 8.45 4.7 4.31 1.54 6.64 6.87 8.17 6.46 5.84 7.41 3.15 6.52 8.56 7.03 
3369 Biotin_transport_and_metabolism 5.25 1.46 0.36 4.6 6.3 3.04 1.85 6.35 9.39 4.31 8.44 7.79 7.94 9.56 4.37 7.25 4.71 8.28 
3370 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 1.73 2.81 6.31 4.02 3.51 8.71 6.75 6.39 4.43 7.52 9.99 2.73 4.08 2.75 8.12 7.67 5.15 8.03 
3371 Coenzyme_A_biosynthesis 9.06 3.96 5.15 0.57 5.78 1.31 3.83 2.23 2.43 8.02 1.46 4.05 4.75 0.17 5.57 7.11 2.49 0.44 
3372 Metabolism_of_folate_and_pterines 2.14 9.1 5.84 8.47 8.72 1.18 4.39 6.35 8.75 5.36 6.63 0.3 3.65 4.49 3.32 3.19 6.57 7.55 
3373 Molybdenum_cofactor_biosynthesis 8.8 1.46 0.47 2.9 9.64 2.4 9.24 1.69 3.36 0.68 6.68 4.7 1.09 4.97 6.61 0.04 9.92 4.24 
3374 Nicotinamide_salvaging 6.78 1.44 9.86 4.08 8.95 0.62 6.15 5.18 9.55 9.48 9.08 7.28 6.75 7.99 8.92 9.89 9.57 7.41 
3375 Vitamin_B1_(thiamin)_metabolism 1 2.64 6.85 2.43 5.73 3.08 3.38 7.2 6.9 3.53 4.13 0.25 3.15 7.75 3.65 5.82 1.14 6.75 
3376 Vitamin_B2_(riboflavin)_metabolism 6.55 9.57 1.72 3.76 1.16 3.02 7.53 6.16 4.1 7.91 3.99 4.27 6.96 5.53 9.16 0.39 8.84 9.14 
3377 Vitamin_C_(ascorbate)_metabolism 9.79 3.93 8.64 0.68 5.22 8.43 1.97 3.74 4.73 3.35 2.94 6.33 3.41 9.22 1.12 4.62 3.41 0.04 
3378 Vitamins_B6_activation_to_pyridoxal_phosphate 3.04 2.62 6.45 6.87 7.82 6.98 4.58 0.22 7.76 1.48 2.6 3.76 2.9 6.06 7.79 2.37 1.65 8.73 
3379 Biotin_transport_and_metabolism 3.23 8.4 5.89 8.17 8.9 0.21 3.6 7.11 1.48 0.46 8.44 6.47 4.04 0.57 9.76 4.92 9.42 7.48 
3380 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 4.85 0.88 0.9 1.23 3.34 9.36 1.72 7.21 4.46 2.71 2.34 7.73 1.61 4.09 6.3 8.55 9.42 9.55 
3381 Coenzyme_A_biosynthesis 7.25 0.84 5.47 4.5 0.63 0.46 4.34 6.49 8.39 5.19 4.42 1.75 1.25 7.83 0.65 5.93 5.94 3.4 
3382 Metabolism_of_folate_and_pterines 2.73 7.71 9.72 6.98 5.12 9.96 5.79 9.64 6.29 6.99 8.67 5.77 6.87 4.53 3.39 2.58 0.72 9.29 
3383 Molybdenum_cofactor_biosynthesis 2.69 6.34 7.78 2.05 6.31 3.27 4.81 6.41 3.3 4.17 3.05 6.77 4.65 3.05 1.21 4.95 4.03 0.36 
3384 Nicotinamide_salvaging 8.89 3.99 0.85 7.92 5.75 4.47 3.46 5.65 8 3.41 6.68 3.03 3.1 4.43 5.36 8.6 8.53 8.81 
3385 Vitamin_B1_(thiamin)_metabolism 0.36 7.45 5.62 9.69 7.4 1.46 6.06 4.04 4.7 9.05 3.35 8.59 3.31 4.07 5.91 7.68 6.87 4.97 
3386 Vitamin_B2_(riboflavin)_metabolism 4.02 5.73 4.26 5.56 8.02 9.49 3.12 7.72 5.65 0.42 2.86 7.14 6.42 0.79 7.42 5.24 3.19 4.55 
3387 Vitamin_C_(ascorbate)_metabolism 7.33 1.77 9.11 6.7 1.14 5.89 8.34 3.67 4.34 3.54 8.77 3.81 1.3 1.12 7.39 9.81 4.29 3.9 
3388 Vitamins_B6_activation_to_pyridoxal_phosphate 5.24 7.39 9.11 2.41 0.7 1.49 5.28 0.6 2.09 0.3 4.77 2.09 3.11 0.75 7.31 2.87 1.72 4.35 
3389 Biotin_transport_and_metabolism 4.05 8.29 1.62 2.02 0.49 8.29 6.16 6.55 1.26 4.61 8.44 0.23 7.21 6.18 1.1 2.41 0.72 5.41 
3390 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 7.51 4.76 1.58 1.71 6.99 3.33 4.72 3.67 7.95 7.9 8.15 7.31 9.57 5.63 5.51 0.48 8.63 0.7 
3391 Coenzyme_A_biosynthesis 4 6.58 9.22 6.06 3.55 8.55 6.68 7.31 5.59 1.28 2.49 2.78 9.08 2.97 4.67 4.15 1.91 4.94 
3392 Metabolism_of_folate_and_pterines 0.31 8.86 3.92 5.91 4.17 7.74 9.53 1.02 8.43 9.1 8 3.02 1.06 8.18 7.58 6.06 5.22 5.46 
3393 Molybdenum_cofactor_biosynthesis 5.37 3.98 6.27 6.58 0.86 9.86 9.4 5.78 2.67 6.2 2.31 5.74 2.29 8.15 4.37 9.52 7.09 4.97 
3394 Nicotinamide_salvaging 2.91 6.52 9.28 4 4.85 2.37 3.67 0.64 5.22 2.78 3.56 3.16 9.2 3.88 3.59 4.52 5.3 2.66 
3395 Vitamin_B1_(thiamin)_metabolism 2.64 6.61 7.27 1.65 5.01 1.83 7.57 2.41 7.58 8.59 9.25 8.59 3.27 9.56 2.25 4.96 4.14 5.68 
3396 Vitamin_B2_(riboflavin)_metabolism 0.83 1.34 9.74 6.7 1.36 4.98 9.39 0.66 9.33 6.42 4.78 9.34 1.12 0.04 4.75 2.68 2.35 6.62 
3397 Vitamin_C_(ascorbate)_metabolism 9.3 6.82 9.16 2.24 1.55 7.64 1.2 7.67 9.58 6.32 6.49 3.63 9.69 8.86 9.18 7.23 0.75 9.43 
3398 Vitamins_B6_activation_to_pyridoxal_phosphate 2.03 5.11 2.09 3.12 1.52 6.54 5.9 4.87 5.74 7.69 9.21 3.25 0.94 9.91 3.77 3 0.44 0.11 
3399 Dermatan_sulfate_biosynthesis 3.8 7.7 8.85 4.36 7.45 4.47 2.29 5.23 5.06 5.8 2.77 0.26 8.63 4.28 6.03 4.91 4.54 3.83 
3400 Activation_of_the_phototransduction_cascade 7.85 8.3 3.59 0.77 5.06 4.39 2.24 4.56 5.54 7.44 1.72 7.81 6.38 7.7 0.49 2.93 9.33 4.58 
3401 Biosynthesis_of_A2E,_implicated_in_retinal_degradation 1.05 8.78 7.89 9.3 5.21 7.43 5.28 3.65 2.65 3 6.8 9.03 7.8 0.15 2.81 9.48 1.85 1.6 
3402 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 4.3 3.44 5.92 9.98 8.71 5.03 1.45 1.26 3.53 1.9 5.93 1.55 5.19 2.57 1.9 1.28 3.11 5.18 
3403 Retinoid_metabolism_and_transport 7.02 6.5 1.2 4.26 4.83 1.52 7.07 1.23 2.5 1.19 9.35 8.46 2.03 9.85 0.97 4.9 5.87 6.23 
3404 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 6.12 9.89 5.61 1.27 0.78 6.37 3.34 0.55 4.43 6.25 8.88 7.22 4.77 4.41 0.17 4.42 2.76 1.95 
3405 The_retinoid_cycle_in_cones_(daylight_vision) 4.51 4.4 8.83 5.12 9.75 9.44 0.51 9.66 8.23 0.56 8.84 4.07 6.56 7.14 4.25 7.54 4.91 0.63 
3406 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 5.55 9.29 2.46 8.63 5.85 8.82 3.59 9.11 4.31 2.98 6.25 6.74 9.96 0.23 3.06 5.71 5.68 1.08 
3407 Downregulation_of_TGF-beta_receptor_signaling 7.24 6.81 3.18 0.43 1.87 9 6.3 5.34 3.66 7.6 7.34 1.82 2.09 7.75 5.3 8.64 1.22 0.92 
3408 AKT_phosphorylates_targets_in_the_cytosol 6.02 7.17 9.63 2.69 1.71 1.37 5.03 7.68 8.97 3.26 2.24 5.14 8.19 7.05 8.49 9.31 8.95 7.17 
3409 AKT_phosphorylates_targets_in_the_nucleus 6.4 6.06 3.35 0.63 4.06 4.24 0.44 2.58 2.57 5.91 9.07 6.92 8.74 1.25 6.93 4.16 3.31 8.6 
3410 CaMK_IV-mediated_phosphorylation_of_CREB 6.99 9.89 2.83 6.28 3.69 1.2 3.49 2.6 3.87 5.41 5.89 3.97 7.9 9.24 3.33 7.49 9.28 3.3 
3411 Cam-PDE_1_activation 0.48 4.75 8.66 2.6 1.49 3.98 2.12 6.43 0.69 5.22 6.74 3.33 0.64 7.73 6.38 1.04 1.81 9.59 
3412 ERK1_activation 3.51 2.53 0.97 0.57 1.84 5.38 5.38 7.28 3.23 4.32 8.52 1.62 0.32 7.27 9.87 6.24 3.28 8.38 
3413 ERK2_activation 8.99 3.4 5.11 6.31 8.61 4.85 6.02 6.5 0.34 1.2 6.13 1.77 5.32 4.09 0.88 4.05 3.15 9.47 
3414 Negative_regulation_of_the_PI3K/AKT_network 2.83 3.67 9.42 4.44 8.23 8.41 8.19 0.05 4.31 0.22 9.69 2.24 5.67 4.7 2.59 8.18 1.87 5.51 
3415 PKA_activation 2.88 6.2 6.12 1.53 0.81 5.72 3.35 3.52 3.3 0.33 1.42 6.24 6.6 2.24 2.19 1.48 8.66 7.04 
3416 RAF_activation 2.33 1.19 0.59 9.25 6.05 5.03 9.28 2.66 7.98 4.7 2.55 5.6 3.93 9.79 9.75 1.75 1.52 2.24 
3417 RAF_phosphorylates_MEK 5.48 7.54 2.84 7.57 1.49 5.28 3.84 7.18 9.88 2.08 6.88 2.17 0.3 8.45 7.38 5.3 6.68 8.26 
3418 SHC-mediated_cascade 7.31 3.7 8.49 3.84 7.81 7.49 3.41 2.45 1.36 2.42 9.7 8.07 9.83 5.45 2.85 1.53 7.96 9.69 
3419 EGFR_downregulation 6.86 2.3 4.62 1.67 4.27 7.8 8.5 8.21 5.06 6.1 1.36 7.06 4.78 9.41 6.08 5.75 1.4 6.15 
3420 CaMK_IV-mediated_phosphorylation_of_CREB 5.89 5.14 7.83 1.14 6.56 3.5 3.68 0.43 8.72 3.95 5.7 4.42 4.4 7.78 9.89 1.13 1.05 9.79 
3421 Cam-PDE_1_activation 3.05 3.08 4.9 4.98 7.18 0.8 0.05 1.12 2.89 9.9 2.69 7.5 0.25 6.41 6.05 1.11 2.75 1.98 
3422 PKA_activation 1.22 2.94 9.23 5.89 4.35 4.22 2.6 6.21 1.75 4.25 7.62 3.32 3.52 5.31 9.89 4.15 8.55 4.63 
3423 ERK1_activation 7.45 0.46 4.65 5.06 9.4 9.48 9.04 5.11 1.52 3.18 2.21 1.79 3.22 0.18 3.24 7.47 5.05 0.18 
3424 ERK2_activation 6 5.7 4.11 9.45 1.93 9.02 2.92 6.77 2.52 0.29 8.17 2.85 1.22 8.45 4.84 4.05 9.46 5.53 
3425 ERK1_activation 2.4 1.2 6.35 9.23 2.16 1.41 4.45 7.26 0.91 8.86 8.24 1.31 8.75 8.52 3.04 1.51 8.14 4.63 
3426 ERK2_activation 5.43 3.46 7.56 5.81 6.99 9.79 8.59 1.28 3.94 8.26 4.87 7.65 9.62 4.46 9.65 5.29 2.78 2.64 
3427 NEP/NS2_Interacts_with_the_Cellular_Export_Machinery 1.06 7.11 0.62 8.24 5.6 1.37 2.7 7.83 0.73 7.15 0.98 7.73 7.67 4.78 2.72 4.11 4.51 3.47 
3428 Viral_RNP_Complexes_in_the_Host_Cell_Nucleus 9.03 0.19 6.92 6.37 7.03 9.67 6.58 5.33 8.01 7.43 1.63 2.24 0.39 0.32 7.58 5.72 1.67 1.45 
3429 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 6.71 1.31 3.09 5.59 8.67 4.07 7.75 4.12 3 5.5 8.2 2.03 4.87 9.92 0.79 8.55 3.95 8.39 
3430 Loss_of_Function_of_FBXW7_in_Cancer_and_NOTCH1_Signaling 0.09 5.8 7.89 3.65 0.61 0.7 6.18 3.49 5.92 1.69 3 6.75 4.01 6.57 1.05 4.85 7.49 2.27 
3431 NOTCH1_Intracellular_Domain_Regulates_Transcription 0.72 5.98 9.74 8.76 9.5 5.69 3.24 5.04 9.36 6.35 2.92 7.89 2.5 7.08 2.01 4.26 2.55 2.55 
3432 FGFR1b_ligand_binding_and_activation 8.88 4.18 8.49 2.31 3.05 6.05 1.4 0.76 9.47 2.32 0.46 8.39 7.9 7.72 3.94 3.71 8.79 8.05 
3433 FGFR1c_and_Klotho_ligand_binding_and_activation 2.21 3.73 3.11 0.84 1.52 8.05 3.81 1.91 5.75 3.16 0.94 2.47 3.21 3.68 5.06 3.06 8.82 7.59 
3434 FGFR1c_ligand_binding_and_activation 4 1.79 1.09 0.09 0.69 0.39 4.14 1.6 8.65 9.28 8.87 2.12 2.18 9.03 8.89 1.3 5.41 6.94 
3435 FGFR2b_ligand_binding_and_activation 1.41 6.69 2.66 0.28 6.59 4.56 2 4.68 3.71 5.15 6.81 1.6 7.07 6.12 8.71 2.5 1.61 3.43 
3436 FGFR2c_ligand_binding_and_activation 3.43 0.76 8.64 3.69 5.65 5.77 4.96 0.18 8 0.11 4.65 4.97 1.67 9.97 0.32 8.04 4.12 8.68 
3437 FGFR3b_ligand_binding_and_activation 5.26 4.8 1.92 7.3 1.41 3.74 9.59 4.67 3.57 9.59 3.33 0.92 5.98 3.61 1.22 1.76 7.9 1.77 
3438 FGFR3c_ligand_binding_and_activation 6.42 8.85 5.17 5.56 9.76 0.31 4.31 4.57 8.04 4.11 3.05 9.62 8.26 8.07 4.72 9.95 6.69 6.56 
3439 FGFR4_ligand_binding_and_activation 4.87 3.37 4.99 2.43 2.95 5.27 0.99 7.28 0.76 9.8 8.37 5.4 6.22 8.57 3.13 3.98 1.33 0.02 
3440 betaKlotho-mediated_ligand_binding 8.74 1.64 5.37 9.48 4.6 0.31 3.28 4.62 8.28 6.13 9.93 8.66 6.95 3.17 3.84 1.33 7.02 9.44 
3441 FGFR1b_ligand_binding_and_activation 2.59 5.33 4.08 6.3 1.41 5.31 6.96 4.3 2.25 1.69 9.53 7.15 1.14 7.1 7.03 9.79 2.72 2.31 
3442 FGFR1c_ligand_binding_and_activation 8.4 9.37 0.53 8.72 0.5 8.14 8.56 5.16 7.27 2.35 6.98 6.66 8.15 0.18 4.87 9.84 6.6 9.5 
3443 FGFR1b_ligand_binding_and_activation 4.56 9.8 2.2 9.44 5.03 8.96 8.66 8.11 8.82 3.66 7.5 4.11 3.23 8.28 3.42 4.25 0.87 0.98 
3444 FGFR1c_and_Klotho_ligand_binding_and_activation 4.37 0.74 5.66 8.58 9.15 1.45 8.75 2.47 6.3 8.17 9.57 9.13 4.87 5.92 2.68 9.35 0.08 7.76 
3445 FGFR1c_ligand_binding_and_activation 7.91 6.15 2.84 4.16 4.46 6.02 5.43 6.91 1.88 5.15 5.28 7.03 3.91 4.49 9.4 1.21 3.63 3.63 
3446 FGFR2b_ligand_binding_and_activation 5.74 9.99 2.52 0.6 7.15 2.21 8.43 3.76 9.14 9.08 0.18 1.81 2.04 9.2 0.03 9.25 1.36 4.73 
3447 FGFR2c_ligand_binding_and_activation 7.02 2.27 9.95 1.17 5.61 8.6 1.18 2.67 2.77 8.8 1.28 7.47 7.59 7.6 4.77 7.33 2.85 4.67 
3448 FGFR2b_ligand_binding_and_activation 2.55 2.47 8.97 4.52 8.92 4.66 6.58 3.74 7.29 0.39 9.45 9.15 2.77 6.06 8.97 6.16 4.89 8.88 
3449 FGFR2c_ligand_binding_and_activation 4.12 6.86 8.31 7.58 1.77 2.85 5.75 8.8 6.98 0.33 5.62 9.63 0.13 6.97 6.73 2.05 5.37 4.78 
3450 FGFR3b_ligand_binding_and_activation 3.02 7.47 1 8.09 3.49 7.89 7.7 2.32 7.24 9.59 1.69 8.59 7.93 7.31 9.07 1.45 4.75 5.66 
3451 FGFR3c_ligand_binding_and_activation 4.11 6.64 9.39 5.13 1.63 9.57 9.24 7.53 1.33 3.93 2.41 5.44 4.49 3.49 7.19 2.85 0.71 7.27 
3452 FGFR3b_ligand_binding_and_activation 8.43 9.62 5.26 5.49 1.88 0.52 2.36 6.81 9.15 7.44 4.86 3.42 6.26 9.96 4.18 6.58 1.88 4.68 
3453 FGFR3c_ligand_binding_and_activation 6.43 3.33 8.92 6.87 6.94 3.69 0.08 2.41 8.27 6.82 6.47 2.25 1.89 2.39 6 4.14 0.69 0.25 
3454 FGFR4_ligand_binding_and_activation 5.41 6.93 7.07 6.84 9.44 0.86 0.95 9.41 7.17 6.41 4.56 8.51 0.65 6.35 0.59 9.84 1.84 4.93 
3455 ERK1_activation 0.94 5.45 1.01 8.7 8.29 6.52 5.18 7.68 4.2 5.62 0.22 3.69 9.9 1.49 1.19 6.03 0.78 6.44 
3456 ERK2_activation 2.79 2.85 8.76 8.61 6.43 2.35 9.71 6.98 3.94 0.36 3.68 7.59 4.51 8.83 1.57 7.86 1.92 1.45 
3457 RAF_activation 8.87 2.28 1.57 4.88 6.21 1.6 0.52 1.15 0.82 3.61 4.19 4.84 4.29 2.08 6.33 3.97 0.15 5.83 
3458 RAF_phosphorylates_MEK 2.28 5 2.28 0.64 5.43 2.25 2.69 7.61 2.66 5.53 9.89 2.92 2.66 5.36 4.03 0.97 1.55 4.83 
3459 AKT_phosphorylates_targets_in_the_cytosol 2.32 2.96 4.83 7.72 4.1 9.64 0.96 2.57 9.59 2.01 4.93 3.83 8.94 0.74 9.93 3.7 6.11 9.16 
3460 AKT_phosphorylates_targets_in_the_nucleus 4.24 8.88 4.25 8.87 6.71 6.48 8.85 2.06 0.82 4.21 5.12 2.77 4.24 5.27 5.81 1.78 8.81 2.92 
3461 Negative_regulation_of_the_PI3K/AKT_network 5.4 6.79 2.71 5.22 7.58 0.87 4.27 7.29 4.02 3.27 8.49 2.31 3.91 7.03 2.62 5.47 5.39 0.57 
3462 ERK1_activation 3.29 5.26 9.56 8.49 4.8 4.71 6.21 2.69 6.44 3.82 8.83 1.91 1.28 2.27 0.08 8.57 9.9 6.32 
3463 ERK2_activation 2.64 2.01 7.79 0.6 4.66 1.25 4.04 4.5 1.93 4.4 3.61 0.17 5.16 2.14 9.04 4.61 9.71 1.08 
3464 RAF_activation 8.45 9.58 1.07 8.35 8.88 4.87 7.07 0.55 4.16 9.61 8.56 0.35 6.95 6.17 0.38 5.91 7.42 2.96 
3465 RAF_phosphorylates_MEK 6.8 5.09 9.63 0.74 7.62 8.56 0.31 7.14 7.64 7.9 9.17 0.11 0.5 5.84 6.4 2.17 8.5 8.31 
3466 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 1.56 0.34 2.05 6.65 4.8 4.79 8.58 8.44 2.9 4.95 9.92 1.07 5.15 9.58 6.74 3.11 7.56 9.05 
3467 CS/DS_degradation 9.6 7.83 4.34 1.9 4.27 5.46 8.87 8.82 4.32 7.48 1.05 7.22 6.98 2.96 1.42 8.94 1.85 0.94 
3468 Chondroitin_sulfate_biosynthesis 6 0.59 2.95 8.69 6.05 9.61 6.93 6.1 3.78 1.64 8.17 3.86 4.1 8.86 7.71 4.6 2.73 7.57 
3469 Dermatan_sulfate_biosynthesis 1.53 7.3 1.9 2.96 7.11 2.49 7.92 7.04 5.38 1.35 9.36 1.57 8.07 2.85 9.04 1.19 1.83 7.9 
3470 HS-GAG_biosynthesis 6.34 6.94 2.95 9.99 9.24 8.68 4.45 0.78 0.1 2.49 3.01 3.04 2.61 8.63 3.25 6.13 2.03 1.59 
3471 HS-GAG_degradation 5.97 6.07 5.66 0.67 4.6 4.36 6.25 3.58 3.5 0.55 7.61 3.69 5.06 0.06 0.64 8.24 8.36 4.15 
3472 Hyaluronan_biosynthesis_and_export 2.88 0.84 7.02 2.93 3.42 1.38 2.36 6.02 4.92 7.88 8.32 0.28 9.24 0.54 6.91 2.13 0.66 4.75 
3473 Hyaluronan_uptake_and_degradation 8.22 3.82 3.86 7.85 9.84 9.32 1.53 1.23 2.88 7.1 5.12 4.62 9.41 3.41 1.5 6.62 6.28 9.56 
3474 Keratan_sulfate_biosynthesis 0.45 6.81 6.9 2.83 0.73 1.08 5.3 5.27 8.2 8.53 7.13 9.4 5.49 4.97 1.85 8.77 1.61 4.07 
3475 Keratan_sulfate_degradation 6.91 5.47 8.43 5.24 5.2 3.49 2.89 1.68 8.9 4.31 5.03 5.85 8.38 4.86 2.96 4.54 3.57 2.18 
3476 Transport_and_synthesis_of_PAPS 6.49 3.03 5.47 2.21 5.12 8.04 1.99 2.27 5.09 2.27 1.48 3.86 5.21 4.06 8.8 1.73 1.32 0.83 
3477 HS-GAG_biosynthesis 1.63 7 3.31 7.18 3.14 2.13 4.18 3.64 1.49 6.25 3.57 4.82 5.18 8.48 7.18 6.13 9.79 4.78 
3478 HS-GAG_degradation 0.9 4.43 8.77 4.59 2.93 3.62 5.13 3.97 4.95 1.83 5.43 2.57 1.74 8.42 2.18 4.9 8.06 5.68 
3479 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 1.99 1.6 9.75 6.49 1.13 0.69 9.58 5.39 4.12 8.6 0.15 1.83 6.57 4.59 2.65 4.5 5.22 8.91 
3480 HS-GAG_biosynthesis 2.5 7.35 1.18 1.17 7.41 5.86 7.91 8.88 3.6 2.08 8.82 7.76 8.11 1.58 4.15 0.8 1.02 3.83 
3481 HS-GAG_degradation 3.22 6.11 5.23 3.14 7.93 5.11 6.6 4.51 6.86 5.8 2.14 2.57 5.67 9.56 1.18 1.68 0.05 6.19 
3482 Hyaluronan_biosynthesis_and_export 9.14 6.8 6.26 5.61 9.31 9.57 6.3 8.69 8.33 9.12 1.87 4.92 5.04 1.1 0.32 7.63 6.35 2.48 
3483 Hyaluronan_biosynthesis_and_export 6.03 0.01 0.14 4.59 1.38 2.8 8.07 7.44 5.64 1.9 3.36 9.26 7.16 1.59 2.94 5.11 6.3 6.45 
3484 Hyaluronan_uptake_and_degradation 4.38 6.25 9.01 5.7 8.25 9.34 6.27 0.21 9.64 9.74 0.74 5.96 8.06 2.27 6.03 4.01 5.16 3.09 
3485 Hyaluronan_uptake_and_degradation 3.57 7.92 0.79 0.07 6.49 6.08 7.28 2.66 3 3.2 6.26 0.41 5.08 6.83 2.09 6.52 6.38 7.75 
3486 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 6.66 5.44 1.99 4.66 2.75 4.15 4.81 4.39 2.44 5.89 9.77 1.92 9.18 4.75 1.19 8.35 2.19 3.59 
3487 Viral_Messenger_RNA_Synthesis 6.14 0.26 8.95 3.47 5.4 9.42 5.81 7.48 3.88 0.92 8.84 5.42 2.9 3.31 3.96 2.79 4.86 5 
3488 Viral_mRNA_Translation 8.44 7.77 0.21 6.43 3.18 8.84 7.25 2.61 7.49 4.91 7.76 4.58 1.17 5.58 6.02 2.06 9.8 3.92 
3489 cRNA_Synthesis 9.58 8.9 9.91 0.26 4.45 4.64 1.84 8.63 2.73 6.47 7.51 1.21 1.94 9.71 0.87 1.65 1.98 5.85 
3490 vRNA_Synthesis 0.9 8.82 7.34 1.37 1.52 4.95 1.11 4.29 3.56 5.81 1.1 8.49 2.07 4.59 8.08 8.2 6.17 0.17 
3491 vRNP_Assembly 7.45 0.3 8.36 5.52 2.75 1.54 3.96 8.08 3.77 5.98 5 8.17 5.56 6.64 0.19 3.34 7.82 9.88 
3492 Keratan_sulfate_biosynthesis 7.43 6.86 6.45 3.07 6.8 8.53 2.9 4.62 3.44 6.67 6.19 1.07 6.82 7.79 2.38 8.95 1.85 6.07 
3493 Keratan_sulfate_degradation 9.51 3.09 9.22 9.86 9.8 0.45 1.24 0.38 8.38 5.37 3.26 1.35 6.91 1.57 7.54 4 9.38 6.77 
3494 Keratan_sulfate_biosynthesis 5.3 7.8 3.42 7.94 9.36 2.72 1.19 4.56 8.02 8.87 2.29 1.06 5.81 3.97 6.95 8.23 0.81 2.89 
3495 Keratan_sulfate_degradation 2.99 5.46 3.1 7.33 5.26 1.88 5.57 4.71 2.46 0.92 1.94 7.33 7.5 9.14 5.05 9.88 4.26 1.68 
3496 FGFR1c_and_Klotho_ligand_binding_and_activation 3.74 8.26 0.76 5.94 0.57 0.61 3.74 5.84 9.22 0.51 4.01 2.01 3.22 7.95 5.17 8.1 1.86 6.36 
3497 betaKlotho-mediated_ligand_binding 3.7 5.52 2.55 4.37 2.79 1.86 1.51 6.85 3.44 8.82 9.01 0.12 9.81 8.46 5.95 4.81 4.57 9.7 
3498 Loss_of_Function_of_FBXW7_in_Cancer_and_NOTCH1_Signaling 1.52 5.41 9.85 1.2 9.52 1.35 2.38 2.03 5.56 5.7 4.04 6.56 4.97 5.49 8.59 8.93 1.25 1.13 
3499 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 5.09 7.03 7.19 5.52 2.58 0.07 1.74 9.07 6.41 5 3.1 2.21 7.36 3.59 7.9 2.47 1.89 2.19 
3500 Downregulation_of_TGF-beta_receptor_signaling 9.57 9.79 8.06 3.8 3.19 3.57 3.82 3.05 2.26 4.06 4.49 7.33 5.66 0.27 7.78 5.46 6.12 9.98 
3501 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 2.26 1.99 2.45 1.79 0.84 1.4 0.79 6.3 6.55 7.94 3 3.15 5.4 4.89 0.03 2.78 7.44 5.4 
3502 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 8.43 6.52 4.6 3.92 4.37 6.73 6.35 8.45 3.7 9.23 8.12 5.64 5.49 9.83 4.89 9.3 6.58 2.43 
3503 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 6.47 2.51 4.7 5.88 1.59 5.63 4.73 8.65 4.04 9.45 2.34 7.91 6.62 2.85 0.57 8.62 7.66 1.87 
3504 Downregulation_of_TGF-beta_receptor_signaling 2.75 1.8 3.47 5.68 7.93 7.61 1.56 9.4 3.3 0.67 5.59 1.61 9.55 0.35 7.86 6.6 6.68 8.79 
3505 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 6.96 7.45 0.29 1.61 8.06 2.43 3.36 6.48 4.38 4.68 0.48 1.49 0.83 6.02 8.91 5.93 7.83 9.56 
3506 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 2.52 9.49 7.78 5.71 5.32 1.79 3.8 6.44 3.06 1.71 3.08 3.64 0.96 8.15 9.85 4.45 0.8 5.23 
3507 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 3.53 4.49 0.79 2.72 3.85 9.72 3.69 1.2 0.13 9.58 5.17 1.75 6.48 3.93 6.26 1.12 2.29 6.89 
3508 Downregulation_of_TGF-beta_receptor_signaling 5.78 3.09 9.35 9.22 3.42 2.51 9.11 0.06 2.59 3.09 9.48 7.9 2.03 4.16 3.11 8 2.38 2.23 
3509 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 6.23 4.67 1.95 8.31 0.42 9.83 6.98 4.86 3.82 5.2 4.2 0.88 4.15 2.37 9 7.46 7.13 2.59 
3510 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 0.88 5.55 1.05 6.32 7.39 8.71 0.07 9.33 6.69 5.18 5.26 8.75 6.7 5.89 2.39 8.81 9.34 5.55 
3511 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 5.47 2.76 5.2 4.54 1.6 4.65 6 9.34 8.94 4.95 0.11 6.83 6.34 2.49 7.98 3.47 3.63 9.3 
3512 Downregulation_of_TGF-beta_receptor_signaling 8.98 8.47 0.91 5.13 3.74 4.94 9.68 1.92 3.1 5.94 2.91 1.67 1.54 5.46 4.88 6.14 6.18 8.39 
3513 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 1.28 6.83 0.64 1.55 5.79 9.2 5.02 6.06 6.58 7.37 3.54 3.39 6.69 9.97 6.4 8.75 6.32 2.67 
3514 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 4.47 4.57 7.23 9.11 8.7 5.26 1.05 0.69 5.84 9.73 7.13 4.12 7.01 2.33 4.68 8.87 6.36 7.01 
3515 RAF_phosphorylates_MEK 5.02 1.44 2.05 8.37 4.81 0.62 1 2.28 4.3 5.69 9.47 5.01 2.61 1.15 4.07 7.34 5.35 8.33 
3516 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 6.06 5.05 7.46 5.86 4.15 2.92 4.21 7.27 0.27 8.28 3.33 0.44 0.66 0.46 2.79 9.02 8.01 0.63 
3517 CS/DS_degradation 5.34 6.54 3.07 6.2 1.76 0.21 1.17 5.64 6.52 0.72 2.38 8.68 1.98 9.34 0.87 2.51 0.14 9.75 
3518 Chondroitin_sulfate_biosynthesis 9.99 3.36 7.02 0.23 6.27 1.12 8.43 1.47 0.36 0.37 9.5 1.07 0.49 0.35 9.87 8.97 4.07 4.13 
3519 Dermatan_sulfate_biosynthesis 5.53 1.38 2.21 7.35 6.75 4.1 0.85 0.85 9.27 5.25 9.6 5.48 2.13 8.19 6.17 4.55 9.94 4.03 
3520 HS-GAG_biosynthesis 1.49 9.42 9.26 9.79 1.53 8.09 1.38 3.11 1.81 5.71 2.78 7.36 2.96 8.77 7.94 3.43 6.44 2.88 
3521 HS-GAG_degradation 4.75 6.59 2.51 1.28 5.21 3.98 4.17 7.81 3.83 4.23 2.44 9.15 8.58 3.79 4.82 0.04 9.41 3.49 
3522 Hyaluronan_biosynthesis_and_export 7.22 4.12 5.88 7.05 5.82 3.9 2.8 9.07 2.63 8.06 0.19 0.05 8.49 0.94 9.32 6 0.4 8.84 
3523 Hyaluronan_uptake_and_degradation 6.69 9.15 4.27 1.64 5.31 6.5 0.16 4.98 2.06 3.37 1.29 5.87 7.53 5.53 2.06 8.77 3.96 8.89 
3524 Keratan_sulfate_biosynthesis 1.07 2.04 9.05 0.97 0.59 4.38 4.67 0.59 3.08 3.21 8.94 1.16 0.77 9.95 4.11 9.14 0.37 2.82 
3525 Keratan_sulfate_degradation 7.06 8.53 9.98 6.7 6.05 3.7 0.66 0.44 7.31 2.14 9.97 6.84 3.14 8.72 2.28 3.97 5.68 8.59 
3526 Transport_and_synthesis_of_PAPS 8.28 6.95 5 9.22 3.41 7.37 2.48 0.37 2.88 3.16 9.06 8.03 6.08 2.48 1.56 1.76 7.17 3.42 
3527 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 2.09 1.45 4.22 7.89 9.76 4.45 1.84 5.29 4.46 3.02 4.25 6.49 8.87 9.28 1.78 2.48 0.6 3.46 
3528 CS/DS_degradation 8.13 4.78 3.16 7.55 9.24 6.15 2.04 7.03 0.42 5.4 6.33 7.86 0.93 6.41 2.88 2.67 5.64 1.44 
3529 Chondroitin_sulfate_biosynthesis 0.99 3.81 7.81 3.24 7.11 6.98 0.27 7.04 9.8 9.05 8.78 2.16 5.16 2.58 1.31 9.76 2.24 1.51 
3530 Dermatan_sulfate_biosynthesis 2.3 9.48 7.03 6.05 0.21 2.4 3.93 4.11 7.43 6.81 2.35 9.87 9.4 1.88 4.43 1.83 9.67 1.97 
3531 HS-GAG_biosynthesis 9.9 7.57 3.69 2.1 2.4 3.41 6.24 9.37 8.2 2.27 0.16 2.63 5.33 4.33 8.48 7.47 3.88 1.42 
3532 HS-GAG_degradation 6.08 7.23 1.95 9.64 2.1 0.21 0.98 7.27 7.75 9.04 3.19 8.02 3.79 9.56 2.11 3.5 6.36 5.75 
3533 Hyaluronan_biosynthesis_and_export 0.27 3.49 8.06 6.58 2.76 9.96 9.63 7.39 0.75 5.28 8.81 7.33 6.67 3.54 5.72 7.33 2.32 4.53 
3534 Hyaluronan_uptake_and_degradation 9.66 6.69 9.72 2.47 1.4 8.06 0.8 2.15 0.51 3.93 1.9 6.86 7.86 5.76 6.68 2.97 7.46 6.83 
3535 Keratan_sulfate_biosynthesis 0.76 4.14 8.52 5.65 1.85 9.24 8.25 5.36 3 9.2 0.64 8.45 2.72 9.1 4.11 6.17 6.11 0.2 
3536 Keratan_sulfate_degradation 8.83 5.41 5.1 1.17 7.1 2.85 6.31 9.17 8.61 3.55 5.33 3.44 9.23 9.24 5.31 5.04 2.67 8.03 
3537 Transport_and_synthesis_of_PAPS 9.37 3.67 8.73 7.73 8.63 6.97 2.44 4.69 5.15 8.53 8.74 5.37 8.85 6.22 1.65 2.85 2.01 3.01 
3538 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 0.12 3.18 0.53 0.66 9.09 5.85 9.56 1.39 5.14 5.81 0.74 9.31 4.09 3.51 6.01 6.22 9.12 7.4 
3539 CS/DS_degradation 1.23 4.12 3.53 8.44 8.97 8.29 3.78 8.53 7.87 0.36 4.56 1.18 9.45 2.79 3.1 9.33 6.34 3.34 
3540 Chondroitin_sulfate_biosynthesis 5.92 3.07 0.1 6.57 8.53 5.34 4.89 7.67 7.89 6.31 4.9 4.84 9.91 7.18 4.33 2.02 1.73 0.42 
3541 Dermatan_sulfate_biosynthesis 1.61 9.4 1.08 6.69 8.93 4.23 0.07 8.8 2.69 8.9 1.15 2.51 9 7.92 3.52 1.59 0.39 8.27 
3542 HS-GAG_biosynthesis 5.1 8.8 6.8 4.91 9.27 9.73 6.52 5.35 0.84 9.69 4.97 8.43 8.03 9.67 4.85 7.79 1.74 3.06 
3543 HS-GAG_degradation 4.35 8.14 9.11 0.83 2.07 9.27 8.67 3.74 0.36 9.2 4.05 0.79 5.87 4.4 6.77 3.93 4.39 9.19 
3544 Hyaluronan_biosynthesis_and_export 1.92 9.99 1.03 6.15 8.65 4.39 1.39 5.18 8.8 6.59 7.79 7.29 1.54 2.98 9.96 6.5 2.74 7.67 
3545 Hyaluronan_uptake_and_degradation 8.29 5.09 7.03 8.56 0.41 6.08 5.81 3.7 4.69 4.73 4.73 3.7 3.73 1.16 7.27 9.35 1.3 8.21 
3546 Keratan_sulfate_biosynthesis 1.65 5.19 6.07 0.51 3.58 9.19 7.64 1.98 0.16 3.98 2.82 2.43 0.47 8.04 1.04 0.13 6.86 4.64 
3547 Keratan_sulfate_degradation 0.37 3.82 9.54 1.67 4.71 9.98 2.5 0.2 5.15 9.46 7.56 8.36 7.58 8.09 5.13 5.84 6.6 6.75 
3548 Transport_and_synthesis_of_PAPS 5 6.81 5.91 8.52 6.55 0.39 3.47 8.48 9.58 4.34 5.75 6.06 0.4 4.13 7.98 4.1 4.44 6.72 
3549 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 4.15 0.38 9.84 3.01 2.49 7.53 2.79 5.89 2.11 7.22 3.64 9.96 7.88 0.3 3.46 9.46 9.18 3.77 
3550 CS/DS_degradation 4.31 1.71 1.36 5.93 8.16 9.62 9.88 1.77 9.18 6.73 6.85 2.69 5.13 6.84 5.58 7.13 8.84 0.87 
3551 Chondroitin_sulfate_biosynthesis 3.11 2.15 3.77 4.52 5.21 0.33 3.34 0.26 5.25 8.59 0.17 0.82 9.03 7.89 0.96 6.6 9.45 0.16 
3552 Dermatan_sulfate_biosynthesis 2.04 2.9 5.89 9.42 7.03 1.23 9.46 9.43 1.71 6.03 4.28 0.96 7.81 2.32 5.57 9.59 9.06 4.4 
3553 HS-GAG_biosynthesis 6.88 3.97 7.36 6.98 5.28 8.51 7.12 9.86 4.44 2.89 6.34 5.85 1.89 5.22 0.19 3.88 1.31 3.72 
3554 HS-GAG_degradation 6.35 6.27 4.13 0.55 5.05 8.93 0.56 1.23 9.71 3.46 9.62 7.11 5.68 2.41 9.12 1.03 5.77 9.48 
3555 Hyaluronan_biosynthesis_and_export 1.08 3.34 1.03 6.88 1.71 1.72 8.86 0.09 1.74 4.66 4.67 5.9 5.66 7.32 1.86 4.97 3.42 1.01 
3556 Hyaluronan_uptake_and_degradation 6.12 6.18 2.12 1.45 4.46 4.12 6.24 1.43 0.77 8.39 2 8.55 0.25 4.64 1.63 2.75 0.15 0.54 
3557 Keratan_sulfate_biosynthesis 9.88 9.91 9.24 4.46 7.86 3.01 0.7 2.98 8.86 2.37 9.89 7.97 8.04 2.91 9.7 6.74 8.62 3.79 
3558 Keratan_sulfate_degradation 8.23 7.01 5.25 8.01 9.92 0.5 7.61 2.2 4.08 1.5 7.07 2.82 7.43 2.43 0.01 0.18 9.78 0.87 
3559 Transport_and_synthesis_of_PAPS 8.02 6.62 8.91 7.42 8.18 9.68 6.03 7.35 9.92 3.98 7.66 7.89 7.83 7.61 9.49 1.67 4.66 6.34 
3560 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 8.81 5.23 3.07 4.86 5.19 3.58 4.13 1.4 1.99 3.18 5.84 3.88 7.46 4.12 1.18 8.19 5.39 7.56 
3561 CS/DS_degradation 2.92 4.92 2.85 2.71 7.54 9.13 3.33 2.91 9.51 7.86 0.65 2.09 9.03 2.36 1.61 2.72 2.86 7.34 
3562 Chondroitin_sulfate_biosynthesis 0.77 1.2 2.33 7.37 8.4 1.05 8.51 1.9 5.47 2.77 2.13 6.84 7.01 7.71 2.74 6.34 4.49 3.49 
3563 Dermatan_sulfate_biosynthesis 5.22 1.94 4.81 8.05 8.45 6.7 8.74 4.43 4.11 6.07 7.91 6.1 6.49 3 9.63 2.2 8.47 9.04 
3564 HS-GAG_biosynthesis 1.29 5.63 8.8 0.71 1.66 0.58 9.93 3.46 6.09 7.47 7.01 2.41 2.1 0.58 6.16 0.09 8.65 0.89 
3565 HS-GAG_degradation 6.83 9.58 0.08 2.37 9.2 6.19 5.08 2.17 0.86 3.11 9.83 8.9 2.15 1.14 3.78 7.16 7.92 9.36 
3566 Hyaluronan_biosynthesis_and_export 3.14 8.11 9.44 9.97 0.4 5.48 0.13 7.22 8.37 0.04 1.71 7.67 4.53 9.68 1.83 2.18 7.23 1.03 
3567 Hyaluronan_uptake_and_degradation 4.76 8.55 1.26 0.7 0.19 6.88 4.11 3.47 9.52 9.42 4.43 1.88 1.38 7.13 6.31 5.76 9.07 5.4 
3568 Keratan_sulfate_biosynthesis 0.81 3.33 3.86 9.73 3 2.44 2.85 5.16 7.58 8.67 8.02 9.69 2.76 0.74 4.8 4.67 0.07 0.47 
3569 Keratan_sulfate_degradation 3.77 0.7 1.43 9.49 7.95 6.77 4.93 4.35 2.8 1.21 9.17 0.73 6.1 4.48 1.32 8.64 7.31 6.81 
3570 Transport_and_synthesis_of_PAPS 4.94 5.15 3.32 4.79 0.67 7.36 7.32 5.96 3.14 8.6 9.88 5.52 3.59 5.58 8.24 4.26 0.73 3.46 
3571 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 0.64 4.78 0.07 7.45 0.08 1.36 6.69 0.06 9.01 6.72 1.37 7.33 2.33 7.91 4.75 0.71 3.45 7.53 
3572 CS/DS_degradation 2.84 2.01 6.69 2.03 1.82 6.22 8.71 6.14 8.6 8.42 5.28 4.44 9.55 0.96 5.03 3.78 4.74 2.38 
3573 Chondroitin_sulfate_biosynthesis 1.55 7.6 8.46 2.96 9.79 5.01 3.53 3.62 5.08 8.06 7.64 5.46 4.76 6.09 5.54 1.81 0.44 6.84 
3574 Dermatan_sulfate_biosynthesis 3.82 0.4 4.27 2.6 8.08 5.06 6.24 1.39 7.73 7.45 9.04 3.53 9.97 6.34 7.53 0.14 2.64 5.41 
3575 HS-GAG_biosynthesis 9.34 6.31 3.47 0.08 2.12 9.51 0.4 6.27 2.28 4.24 8.68 8.91 7.95 1.94 1.16 1.71 7.66 8.11 
3576 HS-GAG_degradation 8.1 9.92 7.53 2.48 6.69 2.84 4.82 4.82 6.88 7.17 8.74 7.17 7.4 0.95 4.36 7.01 6.95 5.27 
3577 Hyaluronan_biosynthesis_and_export 5.05 0.09 9.11 3.77 2.26 5.17 9.94 2.21 0.56 6.75 5.12 3.57 4.25 9.22 7.15 5.71 0.6 8.34 
3578 Hyaluronan_uptake_and_degradation 4.85 9.2 8.06 7.9 9.71 6.4 7.89 9.38 7.13 7.56 8.14 4.55 3.58 3.76 7.46 7.89 6.81 1.5 
3579 Keratan_sulfate_biosynthesis 9.83 8.49 7.8 0.5 0.04 0.96 6.24 8.56 2.2 1.94 7.54 5.79 4.22 2.18 4.52 0.79 7.96 1.72 
3580 Keratan_sulfate_degradation 1.19 8.49 2.76 0.08 0.87 2.38 7.48 0.47 5.35 3.05 5.69 5.87 2.79 4.41 3.61 4.84 6.19 9.3 
3581 Transport_and_synthesis_of_PAPS 5.5 6.8 6.7 9.06 9.26 3.3 1.67 7.2 9.22 4.39 2.67 4 4.92 1.65 4.11 1.61 6.13 0.45 
3582 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 6.95 5.39 0.37 0.34 5.07 4.35 5.72 0.26 1.68 4.98 8.08 1.97 2.14 1.73 5.76 4.44 0.98 9.65 
3583 CS/DS_degradation 9.05 9.79 7.39 7.61 2.15 6.34 5.53 2.03 8.22 7.12 2.07 2.25 8.17 7.29 5.28 5.73 0.67 6.19 
3584 Chondroitin_sulfate_biosynthesis 8.64 1.83 6.28 2.19 3.65 0.17 9.66 8.69 8.14 9.95 4.64 6.59 9.78 1.68 3.31 6.61 1 0.73 
3585 Dermatan_sulfate_biosynthesis 3.88 1.94 3.26 5.6 2.98 1.66 8.76 7.52 6.4 6.93 0.42 2.35 8.76 4.07 9.76 0.99 8.09 0.69 
3586 HS-GAG_biosynthesis 1.89 9.1 5.21 3.23 2.1 1.4 1.04 6.22 0.8 6.35 3.41 3.03 8.93 0.85 2.66 0 6.02 4.55 
3587 HS-GAG_degradation 0.87 5.19 4.01 8.21 5.69 8.97 3.18 8.69 6.25 8.81 2.91 5.69 9.94 2.01 2.8 5.37 0.51 9.52 
3588 Hyaluronan_biosynthesis_and_export 5.06 4.88 1.18 1.88 8.67 7.02 3.51 4.74 3.71 5.98 7.13 7.24 2.54 3.92 9.42 1.7 5.42 5.78 
3589 Hyaluronan_uptake_and_degradation 3.66 5.56 6.67 2.66 8.26 6.95 7.99 5.04 7.28 1.02 2.78 4.74 7.86 3.95 6.54 2.15 0.99 7.02 
3590 Keratan_sulfate_biosynthesis 7.32 1.52 2.01 1.49 2.64 2.44 7.93 5.97 3.85 5.55 5.03 1.6 3.72 9.98 7.57 1.43 5.61 9.72 
3591 Keratan_sulfate_degradation 3.42 1.45 8.06 7.2 3.64 2.13 7.52 5.13 0.07 8.61 8.47 8.66 1.42 7.64 2.26 9.87 0.83 9.45 
3592 Transport_and_synthesis_of_PAPS 6.83 9.51 0.74 3.4 2.6 5.77 7.62 4 5.06 6.56 2.07 6.89 4 2.1 9.27 1.68 1.59 5.6 
3593 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 2.2 7.65 8.93 4.3 4.17 7.33 3.56 2.79 3.85 3.01 8.29 4.22 3.08 1.17 9.8 0.16 3.95 1.6 
3594 CS/DS_degradation 3.02 3.04 5.98 5.15 6.4 1.94 4.52 7.15 2.81 6.52 4.51 6.44 7.87 2.74 5.84 7.84 8.94 1.46 
3595 Chondroitin_sulfate_biosynthesis 3.06 5.72 7.65 6.63 3.94 7.29 4.85 1.22 7.73 8.66 1.24 3.33 2.61 1.3 3.99 3.37 2.45 4.64 
3596 Dermatan_sulfate_biosynthesis 7.1 3.87 1.96 5.33 6.91 9.55 9.07 0.2 3.93 6.37 0.18 7.79 8.01 8.67 6.16 8.1 7.39 0.59 
3597 HS-GAG_biosynthesis 2.42 7.22 5.31 9.65 7.98 4.96 3.22 0.96 5.2 2.73 5.99 4.21 2.85 3.84 8.05 5.39 8.78 4.78 
3598 HS-GAG_degradation 5.83 7.57 8.71 6.89 9.93 0.25 0.49 8.24 4.32 7.15 3.4 5.18 4.13 3.37 5.05 2.78 7.66 0.48 
3599 Hyaluronan_biosynthesis_and_export 2.87 9.5 3.98 8.63 4.52 6.38 6.47 8.18 9.59 8.18 7.16 3.22 4.43 1.42 8.35 8.43 5.75 2.18 
3600 Hyaluronan_uptake_and_degradation 1.47 6.46 2.44 0.15 6.91 7.92 6.62 1.77 0.75 2.03 2.63 1.17 3.83 6.83 4.96 3.48 9.53 2.6 
3601 Keratan_sulfate_biosynthesis 3.05 6 4.46 4.74 3.23 1.83 3.88 2.4 1.08 6.78 4.89 2.85 6.02 2.8 2.64 8.45 3.72 1.67 
3602 Keratan_sulfate_degradation 2.48 6.52 3.5 9.06 4.86 9.6 5.63 5.2 2.68 6.31 3.36 2.19 1.3 2.77 9.02 2.57 8.28 5.47 
3603 Transport_and_synthesis_of_PAPS 8.56 0.71 2.35 6.3 7.5 7.26 2.81 3 8.9 1.87 7.59 7.24 9.37 4.25 8.65 2.93 5.23 7.7 
3604 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 7.89 9.75 1.9 2.54 0.07 0.98 3.04 1.95 3.85 9.72 9.65 4.94 3.21 6.47 3.92 7.13 5.24 6.58 
3605 CS/DS_degradation 8.28 9.49 8.73 6.22 0.29 9.62 3.61 7.56 7.14 9.57 3.02 4.69 9.59 1.68 6 2.18 9.69 4.16 
3606 Chondroitin_sulfate_biosynthesis 1.12 8.13 7.84 6.2 4.87 4.64 0.2 9.93 3.82 1.33 5.77 2.14 8.28 3.25 7.65 5.72 0.91 9.01 
3607 Dermatan_sulfate_biosynthesis 4.28 9.65 8.76 7.81 4.49 4.18 4.77 6.11 2.48 6.77 9.2 4.88 1.54 8.22 4.85 8.81 5.12 4.04 
3608 HS-GAG_biosynthesis 5.14 2.41 3.32 1.54 3.95 0.45 4.84 8.53 7.33 2.32 4.16 5.39 2.23 9.99 1.51 9.66 8.9 1.68 
3609 HS-GAG_degradation 1.56 4.88 4.72 5.99 4.07 5.13 9.88 4.17 2.73 3.11 4.96 6.93 1.12 9.42 3.25 6.23 1.32 4.72 
3610 Hyaluronan_biosynthesis_and_export 6.7 8.7 5.37 3.19 4.38 5.77 9.82 1.21 7.15 5.34 3.81 9.06 0.67 4.19 0.52 1.76 8.3 0.65 
3611 Hyaluronan_uptake_and_degradation 2.68 0.67 8.92 2.37 1.28 0.52 6.73 5.52 5.59 9.6 6.21 7.62 3.9 1.64 6.81 0.82 2.8 1.71 
3612 Keratan_sulfate_biosynthesis 3.83 8.58 5.59 0.78 1.77 8.01 8.88 3.72 6.13 3.36 3.93 2.1 2.56 0.89 3.18 6.04 4.96 0.12 
3613 Keratan_sulfate_degradation 1.81 9.32 7.74 9.8 1.83 1.3 1.16 6.42 1.12 2.38 3.63 3.68 6.08 1.46 3.93 1.69 0.51 1.95 
3614 Transport_and_synthesis_of_PAPS 6.81 3.11 3.26 5.85 2.82 0.85 8.67 3.41 6.13 4.31 6.31 7.95 9.77 8.7 4.74 4 6.49 2.48 
3615 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 9.66 2.29 3.69 8.47 5.07 7.25 8.13 0.96 3.07 0.84 9.95 2.08 3.3 0.48 2.25 2.58 2.4 4.12 
3616 CS/DS_degradation 1.38 9 7.38 8.82 9.97 6.03 9.33 9.53 5.9 3.07 4.77 6.23 9.13 7.72 4.77 9.77 9.49 2.57 
3617 Chondroitin_sulfate_biosynthesis 5.19 9.13 0.53 3.87 5.11 7.68 6.37 5.01 7.71 2.36 9.71 1.21 2.22 3.55 5.55 3.8 1.65 4 
3618 Dermatan_sulfate_biosynthesis 3.6 7.97 3.05 0.29 3.68 8.83 9.34 0.98 8.07 2.56 4.04 9.65 5.02 8.88 3.64 6.51 8.06 8.07 
3619 HS-GAG_biosynthesis 4.77 8.54 7.03 4.1 9.51 8.48 0.06 7.56 8.23 6.3 4.55 6.52 1.17 9.52 4.23 1.89 4.11 1.52 
3620 HS-GAG_degradation 8.85 9.91 0.95 3.45 2.66 7.8 0.9 4.26 7.58 8.21 7.62 2.75 9.49 8.37 8.12 1.75 7.3 1.26 
3621 Hyaluronan_biosynthesis_and_export 2.54 5.31 1.15 5.39 6.45 0.22 0.69 9.82 2.98 6.9 7.61 4.03 5.71 8.58 5.67 3.89 6.39 6.03 
3622 Hyaluronan_uptake_and_degradation 1.54 4.8 6.97 0 4.53 9.66 8.64 9.12 0.6 2.45 7.82 6.67 2.62 4.41 2.64 9.58 7.76 5.26 
3623 Keratan_sulfate_biosynthesis 9.42 2.59 9.42 6.97 3.8 7.17 4.14 5.12 4.56 0.18 6.14 9.02 8.21 6.73 0.31 1 2.71 5.02 
3624 Keratan_sulfate_degradation 4.01 8.36 8.63 9.47 6.42 7.12 0.01 2.1 1.53 4.43 3.01 2.88 3.28 7.57 7.87 4.76 3.93 4.93 
3625 Transport_and_synthesis_of_PAPS 3.07 6.97 5.83 5.7 8.59 4.48 5.36 4.19 3.3 1.46 3.86 4.4 9.81 6.2 9.64 0.08 6.87 3.24 
3626 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 3.59 9 6.71 5.54 5.73 1.24 9.56 2.43 6.4 9.52 4.44 1.46 8.22 5.94 4.54 0.87 9.31 8.51 
3627 CS/DS_degradation 4.6 3.73 6.23 9.62 3.58 8.71 0.98 4.44 1.15 9.15 5.82 6.56 2.32 7.06 5.72 1.55 6.46 8.62 
3628 Chondroitin_sulfate_biosynthesis 4.65 2.36 7.91 5.64 6.74 8.16 9.93 2.2 9.41 3.6 5.42 0.63 2.82 3.05 7.55 6.57 7.79 0.85 
3629 Dermatan_sulfate_biosynthesis 8.32 1.83 5.12 0.4 3.12 6.59 4.69 7.9 4.34 0.85 8 5.71 1.34 9.32 8.54 4.35 8.68 4.85 
3630 HS-GAG_biosynthesis 8.53 2.67 8.65 9.87 2.39 2.15 4.2 5.92 6.21 6.38 6.64 2.67 1.46 2.43 7.22 9.79 8.98 1.41 
3631 HS-GAG_degradation 1.02 2.27 1.55 2.49 4.28 9.42 7.95 9.26 4.65 2.04 8.42 6.73 7.56 7.98 0.65 6.74 9.18 9.11 
3632 Hyaluronan_biosynthesis_and_export 2.83 1.83 5.09 9.71 3.95 4.64 6.91 6.52 7.18 6.51 4.26 9.47 6.9 5.69 3.63 6.36 4.8 2.4 
3633 Hyaluronan_uptake_and_degradation 8.56 7.81 7.02 2.1 8.54 8.32 7.75 7.34 2.23 5.5 8.23 8.54 5.9 8.63 1.86 3.53 2.04 4.48 
3634 Keratan_sulfate_biosynthesis 4.44 1.53 4.59 8.28 0.31 6.63 3.85 2.62 7.84 9.02 0.96 0.77 8.26 2.69 8.6 6.65 8.24 4.01 
3635 Keratan_sulfate_degradation 3.32 7.65 6.13 7.71 0.76 0.46 3.34 6.05 4.42 5.87 6.02 6.43 8.64 0.62 0.73 5.2 7.13 7.54 
3636 Transport_and_synthesis_of_PAPS 1.63 2.3 4.71 1.24 4.66 1.62 4.21 3.83 8.91 4.39 7.85 3.79 1.61 1.54 5.88 6.7 0.9 9.98 
3637 Metabolism_of_folate_and_pterines 3.24 9.17 5.02 9.45 3.86 0.05 2.69 1.1 1.2 4.13 5.13 5.97 3.17 0.3 5.08 8.32 3.64 5.26 
3638 Biotin_transport_and_metabolism 7.22 8.23 5.77 7.93 9.14 9.18 7.82 2.66 1.77 3.41 4.3 8.48 4.88 4.65 7.84 7.48 1.6 5.69 
3639 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 9.89 1.38 6.99 3.39 3.41 8.22 1.56 3.28 2.55 6.65 0.01 0.85 9.44 4.84 2.32 1.07 9.26 4.2 
3640 Coenzyme_A_biosynthesis 2.16 7.78 2.05 9.27 7.29 5.86 0.18 4.78 1.67 8.18 1.66 2.19 0.67 9.24 6.37 7.25 7.14 2.8 
3641 Metabolism_of_folate_and_pterines 6.31 1.69 3.22 7.13 6.31 3.07 6.59 6.69 5.94 2.7 8.34 3.84 4.1 5.52 8.92 0.83 9.08 5.21 
3642 Molybdenum_cofactor_biosynthesis 6 6.57 8.63 6.78 0.29 7.71 7.58 7.29 3.75 3.72 1.36 8.35 9.88 7.19 8.3 5.89 0.28 1.28 
3643 Nicotinamide_salvaging 9 7.07 0.4 0.96 2.03 1.78 5.3 5.41 3.98 3.48 8.86 5.69 7.16 1.61 2.71 8.42 1.34 4.4 
3644 Vitamin_B1_(thiamin)_metabolism 2.92 4.02 0.5 7.03 4.69 0.24 1.11 4.87 4.33 2.71 2.81 0.11 9.85 7.01 6.39 8.66 2.51 4.78 
3645 Vitamin_B2_(riboflavin)_metabolism 3.95 0.67 5.51 1.46 0.74 9.13 6.14 5 7.25 2.87 9.17 3.41 3.51 3.97 9.48 8.57 8.01 8.92 
3646 Vitamin_C_(ascorbate)_metabolism 6.59 4.4 0.74 5.67 8.07 6.15 0.66 6.18 5.3 0.08 5.44 5.83 7.05 7.59 7.62 5.11 5.22 5.19 
3647 Vitamins_B6_activation_to_pyridoxal_phosphate 5.1 6.86 6.45 7.41 7.67 1.3 3.38 1.06 3.86 5.89 0.67 1.11 9.7 7.69 8.84 6.28 4.24 1.39 
3648 Molybdenum_cofactor_biosynthesis 6.48 5.69 5.35 6.19 4.62 8.41 1.99 3.71 3.64 7.16 1.68 8.78 7.62 3.56 6.66 0.52 7.86 7.54 
3649 A_tetrasaccharide_linker_sequence_is_required_for_GAG_synthesis 1.78 8.75 5.66 7.69 2.31 6.95 0.35 7.39 0.22 8.29 3.09 5.8 1.47 3.72 8.03 2.44 4.73 0.14 
3650 CS/DS_degradation 0.45 2.08 5.4 8.46 2.67 9.55 2.12 0.97 9.83 4.09 3.17 2.66 1.57 8.36 4.93 0.33 0.26 7.15 
3651 Chondroitin_sulfate_biosynthesis 7.66 5.72 7.79 1.51 4.61 1.29 0.32 9.68 1.13 1.46 9.69 3.52 9.36 2.9 3.99 5.66 0.86 5.67 
3652 Dermatan_sulfate_biosynthesis 2.3 6.85 2.32 5.84 8.97 5.74 6.64 7.61 7.27 1.16 5.21 1.41 3.73 2.38 4.54 1.79 7.72 3.54 
3653 HS-GAG_biosynthesis 2.22 9.8 5.4 2.16 3.15 9.08 3.13 6.69 2.51 4.95 8.77 5.85 5.51 1.98 1.5 9.47 0.66 0.1 
3654 HS-GAG_degradation 0.73 4.99 4.91 8.41 7.03 7.84 3.43 9.9 8.87 6.2 1.84 1.89 7.97 6.52 2.83 1.83 5.53 4.28 
3655 Hyaluronan_biosynthesis_and_export 5.61 8.19 3.87 1.07 7.16 9.34 7.58 1.55 9.25 5.81 6.98 8.43 7.55 6.08 3.1 2.8 9.34 9.85 
3656 Hyaluronan_uptake_and_degradation 9.09 1.7 7 6.29 3.13 5.87 8.92 8.42 7.18 7.17 0.5 6.34 4.16 9.24 6.19 9.1 5.19 8.74 
3657 Keratan_sulfate_biosynthesis 8.25 9.35 4.82 6.1 6.25 9.61 3.94 8.47 9.14 6.34 3.37 4.62 5.53 5.45 1.78 8.96 9.15 8.98 
3658 Keratan_sulfate_degradation 5.54 6.21 1.7 8.57 6.39 0.54 9.72 1.8 9.36 2.41 5.36 6.22 0.46 0.1 6.51 8.5 4.18 2.72 
3659 Transport_and_synthesis_of_PAPS 1.86 6.93 7.67 4.94 0.57 8.31 5.04 5.71 7.23 5.14 4.21 1.88 7.39 1.96 2.1 1.12 7.3 5.22 
3660 NEP/NS2_Interacts_with_the_Cellular_Export_Machinery 0.49 7.65 0.01 9.98 8.5 1.29 7.86 8.03 6.87 1.55 6.98 8.21 6.29 1.39 9.62 0.7 6.56 9.19 
3661 NOTCH1_Intracellular_Domain_Regulates_Transcription 5.02 5.03 3.97 0.48 7.09 5.96 0.94 3.33 1.95 8.75 8.1 2.06 6.35 6.06 4.43 4.83 5.21 9.83 
3662 Spry_regulation_of_FGF_signaling 0.52 7.9 4.23 1.72 1.71 5.5 2.06 7.15 3.39 9.65 4.95 2.63 7.49 3.24 3.06 4.43 5.28 3.9 
3663 Negative_regulation_of_the_PI3K/AKT_network 3.59 2.94 9.66 7.55 0.44 6.17 2.73 9.58 8.39 4.45 8.62 7.44 7.23 3.6 6.72 4.06 6.24 8.57 
3664 Nicotinamide_salvaging 5.36 4.97 2.22 4.9 2.36 4.13 3.78 8.46 7.42 0.44 7.25 0.03 5.67 9.31 7.13 3.61 1.16 4.05 
3665 Nicotinamide_salvaging 7.82 3.55 7.51 4.07 8.76 8.54 1.92 3.81 0.01 6.08 6.94 0.75 2.21 3.95 1.36 1.33 4.6 8.26 
3666 AKT_phosphorylates_targets_in_the_cytosol 4.01 6.67 6.27 8.03 4.12 1.75 2.87 5.58 8.84 8.33 8.59 8.85 4 6.05 4.09 0.52 3.25 3.47 
3667 AKT_phosphorylates_targets_in_the_nucleus 4.03 2.18 0.99 8.24 0.17 6.96 5.64 6.43 0.93 7.3 8.67 9.63 6.7 1.96 6.1 2.87 3.06 9.92 
3668 Negative_regulation_of_the_PI3K/AKT_network 3.1 7.17 0.24 2.05 0.07 6.31 0.04 5.93 5.22 2.74 8.92 6.9 6.97 7.13 4.99 6.33 5.59 1.07 
3669 AKT_phosphorylates_targets_in_the_cytosol 6.36 1.52 1.96 9.44 3.14 1.41 9.35 7.85 5.73 8.64 3.33 8.88 6.71 4.42 8.37 9.66 7.03 3.67 
3670 AKT_phosphorylates_targets_in_the_nucleus 1.58 6.12 7.82 9.25 4.27 6.28 2.4 5.09 8.06 4.25 2.94 0.65 3.22 3.24 9.94 5.27 3.57 9.53 
3671 Constitutive_PI3K/AKT_Signaling_in_Cancer 5.38 1.57 8.62 7.69 1.6 0.45 2.04 2.33 7.93 8.27 4 8.18 0.61 4.93 7.23 2.82 6.39 4.26 
3672 Negative_regulation_of_the_PI3K/AKT_network 4.42 2.52 8.94 5.42 5.13 1.55 5.7 1.25 7.58 6.37 7.3 6.3 8.16 3.98 0.06 8.74 9.44 1.45 
3673 AKT_phosphorylates_targets_in_the_cytosol 3.93 5.88 0.14 0.63 4.01 4.59 2.55 0.01 3.38 7.5 3.17 8.24 9.12 5.12 1.36 7.92 3.32 6.13 
3674 AKT_phosphorylates_targets_in_the_nucleus 0.76 4.87 4.64 8.27 2.43 1.08 4.54 0.6 7.32 9.9 3.82 3.31 5.55 7.47 9.66 5.24 0.19 1.07 
3675 Negative_regulation_of_the_PI3K/AKT_network 0.4 0.58 4.34 6.11 2.78 6.35 4.13 1.74 5.21 3.1 9.23 2.65 2.34 2.65 2.14 2.22 2.32 5.96 
3676 PKA_activation 4.63 3.31 5.08 6.74 1.93 5.87 1.45 6.72 3.85 2.38 0.81 2.14 4.04 2.37 6.75 2.15 2.82 5.05 
3677 PKA_activation 1.29 9 9.46 9.48 8.09 0.53 9.98 9.83 3.22 1.38 8.07 3.74 2.5 4.95 4.2 4.97 5.09 3.51 
3678 CaMK_IV-mediated_phosphorylation_of_CREB 9.84 7.96 2.01 7.54 8.97 1.14 2.08 7.38 7.44 3.81 0.93 4.66 6.86 2.09 3.38 3.2 3.16 2.1 
3679 Cam-PDE_1_activation 7.06 1.49 8.62 8.59 2.82 0.58 2 7.12 0.14 2.29 4.25 6.3 8.09 7.64 8.15 2.09 2.68 0.01 
3680 PKA_activation 6.36 7.03 2.51 5.03 6.16 0.76 7.33 2.2 3.82 0.12 6.27 9.28 5.47 5.44 4.9 8.77 3.33 4.03 
3681 RAF_activation 7.72 7.1 3.6 3.81 1.39 9.09 5.67 1.22 7.28 6.08 3.28 0.99 9.55 3.16 6.89 9.33 3.88 4.05 
3682 RAF_phosphorylates_MEK 4.5 9.12 1.54 2.93 3.47 8.75 4.5 5.47 3.6 6.78 0.98 1.57 7.7 1.93 2.54 5.05 7.19 5.79 
3683 ERK1_activation 8.26 2.88 0.13 6.61 3.21 3 3.23 1.84 9.9 9.4 4.56 7.96 2.97 9.02 1.44 6.26 7.33 3.72 
3684 ERK2_activation 4.04 7.49 0 0.26 9.38 0.92 0.5 6.22 8.45 9.39 8.57 8.73 4.06 8.83 6.99 2.93 4.75 5.35 
3685 RAF_activation 4.54 3.52 0.63 1.69 2.21 0.56 1.13 6.52 3.96 1.67 2.9 7.07 5.02 3.22 9.21 7.21 9.72 2.36 
3686 RAF_phosphorylates_MEK 0.9 9.47 9.85 4.72 5.43 3.47 9.8 8.06 7.08 1.58 1.98 9.57 7.45 8.64 6.53 7.63 9.72 2.06 
3687 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 8.47 9.53 6.85 9.25 0.67 9.39 8.7 5.54 3.81 4.14 3.47 2.49 8 3.06 0.86 9.21 2.01 6.18 
3688 Release 3.91 5.59 0.65 2.49 3.05 6.43 6.51 2.56 6.24 1.36 4.87 5.58 6.34 2 9.58 8.63 9.71 6.39 
3689 Biosynthesis_of_A2E,_implicated_in_retinal_degradation 7.35 9.75 5.66 0.86 1.05 0.25 3.69 7.79 4.18 1.55 8.96 8.39 5.76 0.77 2.29 4.81 9.82 0.1 
3690 Retinoid_metabolism_and_transport 6.46 6.33 5.05 0.37 7.59 3.67 2.59 7.84 8.66 1.97 2.24 8.89 0.84 1.14 2.55 2.94 9.86 1.37 
3691 SHC-mediated_cascade 0.67 4.74 2.91 2.01 7.31 7.28 1.12 5.1 3.43 0.4 4.41 1.52 1.08 6.16 2.66 8.02 3.29 7.89 
3692 ERK1_activation 5.74 7.1 4.75 2.82 1.07 9.99 9.74 0.07 2.14 5.75 5.25 7.02 4.32 2.9 0.12 9.54 1.94 1.62 
3693 ERK2_activation 1.47 2.25 5.56 9.57 6.22 3.4 7.24 9.08 5.55 6.2 9.33 5.73 8.11 4.07 8.06 3.79 2.13 6.11 
3694 RAF_activation 2.61 6.2 1.2 6.74 7.96 0.04 4.07 2.63 1.38 8.09 8.02 0.65 4.69 4.46 5.78 4.05 2.14 1.87 
3695 RAF_phosphorylates_MEK 4.2 4.48 3.17 6.85 4.75 5.97 5.76 3.54 2.23 9.64 5.02 4.24 4.5 1.96 1.61 7.58 4.61 9.14 
3696 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 1.07 5.23 0.38 8.34 7.27 9.41 6.53 0.46 8.2 1.33 1.36 9.81 9.98 1.22 5.63 2.45 7.73 7.87 
3697 Downregulation_of_TGF-beta_receptor_signaling 2.19 9.16 5.86 6.97 2.61 6.35 0.22 4.91 2.02 8.77 5.66 8.6 6.87 9.26 5.09 8.5 9.86 5.27 
3698 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 2.88 6.16 4.39 3.13 4.95 9.03 5.08 5.28 7.46 6.65 2.97 0.19 7.23 0.46 8.77 9.69 9.79 4.42 
3699 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 6.69 0.05 2.71 0.62 5.25 3.57 6.28 2.85 5.32 3.19 3.68 2.35 6.27 4.77 8.36 7.45 8.46 3.88 
3700 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 0.55 8.04 5.11 5.75 9.96 7.03 4.55 9.29 5.75 6.62 0.39 6.35 0.03 5.73 6.14 6.02 9.28 4.47 
3701 Downregulation_of_TGF-beta_receptor_signaling 6.03 0.6 7.31 1.47 9.25 3.41 1.35 0.6 3.05 6.13 3.15 4.57 2.2 7.32 6.03 4.12 0.73 4.42 
3702 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 6.75 8.06 2.21 5.44 5.13 4.35 5.7 3.54 2.99 8.26 6.17 0.57 2.89 7.92 7.31 9.72 4.2 0.05 
3703 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 6.1 8.79 7.99 7.75 3.31 1.19 5.97 5.58 0.23 6.84 5.56 6.72 0.18 0.08 9.44 9.89 4.35 6.07 
3704 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 1.06 2.29 7.66 5.91 4.34 3.85 5.5 6.42 8.91 0.72 1.03 5.62 1.66 8.67 9.86 9.97 6.66 8.91 
3705 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 0.58 2.01 9.47 3.77 5.36 2.18 8.72 1.26 2.1 6.41 3.54 7.88 2.89 9.67 1.61 7.41 9.62 2.98 
3706 Downregulation_of_TGF-beta_receptor_signaling 2.09 6.5 4.05 0.39 8.85 6.31 7.17 0.97 1.38 7.25 2.71 6.32 8.16 8.24 2.7 8.62 3.96 3.86 
3707 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 2.3 4.86 5.93 1.51 0.16 7.34 1.53 6.51 3.26 4.15 7.98 0.33 2.32 9.86 0.46 2.38 8.29 8.69 
3708 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 1.99 3.4 5.41 8.63 1.27 0.19 8.71 1.28 9.43 5.17 7.91 5.88 2.96 8.09 3.95 5.13 3.03 6.52 
3709 AKT_phosphorylates_targets_in_the_cytosol 2.37 7.03 7.49 4.74 9.79 8.48 2.18 6.98 6.14 4.24 8.35 6.75 2.88 0.95 5.38 9.77 2.81 4.04 
3710 AKT_phosphorylates_targets_in_the_nucleus 9.25 6.37 2.43 4.68 9.85 7.48 1.81 1.96 5.36 3.19 6.69 7.31 3.6 2.03 4.82 7.55 2.47 6.73 
3711 CaMK_IV-mediated_phosphorylation_of_CREB 0.32 3.37 1.64 2.33 4.21 6.35 8.56 5.46 3.64 6.19 6.84 6.13 3.76 5.93 7.16 4.51 7.31 0.45 
3712 Cam-PDE_1_activation 7.25 6.6 7.35 4.53 8.59 0.34 8.85 7.47 9.74 9.1 5.56 5.87 4.46 3.45 1.57 5.96 9.25 4.28 
3713 EGFR_downregulation 1.65 7.4 8.51 0.44 2.98 6.81 2.72 1.52 7.69 4.86 3.81 7.82 7.99 6.58 4.92 2.3 7.18 2.23 
3714 ERK1_activation 7.05 8.28 1.55 2.74 1.29 2.43 7.74 2.22 5.38 4.96 6.1 7.42 0.99 9.09 1.65 2.75 7.26 6.47 
3715 ERK2_activation 6.82 7.7 4.03 0.99 6.77 2.34 9.59 9.32 5.66 2.12 3.88 2.64 6.66 0.92 9.79 4.83 0.15 4.31 
3716 Negative_regulation_of_the_PI3K/AKT_network 8.87 9.72 7.19 4.05 4.12 1.91 3.02 7.69 6 8.99 1.75 6.39 8.49 7.49 4.59 1.74 5.67 5.56 
3717 PKA_activation 7.48 0.14 1.87 1.18 2.02 0.91 1.35 8.67 6.19 4.34 2.08 7.69 3.52 5.15 3.22 0 1.74 4.4 
3718 RAF_activation 4.19 6.39 7.3 6.13 8.83 4.53 4.49 9.53 2.1 7.25 6.95 1.24 4.91 1.56 9.02 9.53 9.59 3.09 
3719 RAF_phosphorylates_MEK 5.29 2.46 9.25 0.47 8.17 6.49 3.84 6.69 1.76 6.93 1.21 5.26 4.28 1.18 7.68 2.62 5.1 3.13 
3720 AKT_phosphorylates_targets_in_the_cytosol 4.85 2.29 5.16 8.96 2.67 9.34 5.72 2.61 9.83 2.03 3.3 2.76 4.05 6.87 7.24 8.05 3.33 1.08 
3721 AKT_phosphorylates_targets_in_the_nucleus 7.72 9.3 1.96 3.83 8.45 3.1 7.49 3.52 5.05 7.91 6.65 2.38 9.14 0.86 1.81 1.78 8.72 6.37 
3722 CaMK_IV-mediated_phosphorylation_of_CREB 1.71 6.5 1.63 0.96 1.64 9.94 6.58 4.62 7.41 3.5 6.19 0.73 9.43 9.55 7.31 9.56 7.23 7.9 
3723 Cam-PDE_1_activation 6.08 0.46 6.77 8.77 7.01 3.01 7.12 6.53 0.3 0.2 1.31 1.56 5.17 1.35 4.67 3.6 8.92 5.5 
3724 EGFR_downregulation 4.65 2.63 3.16 2.48 7.17 9.13 0.93 6.9 4.19 7.86 4.47 2.01 9.73 5.24 2.97 8.28 5.29 3.33 
3725 ERK1_activation 2.79 8.13 2.04 5.81 6.01 3.78 5.03 7.79 4.18 1.43 3.94 0.72 7.67 7.18 0.94 9.72 4.01 3.93 
3726 ERK2_activation 1.75 6.71 2.2 7.75 2.02 7.07 8.72 1.58 1.86 1.28 1.67 3.85 4.02 2.48 2.41 4.5 5.98 3.09 
3727 Negative_regulation_of_the_PI3K/AKT_network 9.57 0.64 7.78 7.99 8.17 9 1.2 1.7 2.19 8.01 3.4 5.19 8.17 2.19 1.86 1.38 8.86 7.85 
3728 PKA_activation 0.43 1.16 9.98 1.17 2.27 6.66 2.92 1.56 2.38 5.18 8.57 4.25 8.13 5.72 0.8 6.23 7.47 0.32 
3729 RAF_activation 9.2 4.39 5.09 3.26 4.98 4.06 0.34 0.66 4.35 7.63 9.83 2.73 8.68 5.84 5.42 2.47 7.84 3.18 
3730 RAF_phosphorylates_MEK 4.23 3.46 8.62 4.54 5.27 4.07 6 9.09 1.61 3.24 7.71 0.07 7.47 8.94 2.08 0.48 8.18 1.24 
3731 Signaling_by_constitutively_active_EGFR 2.74 3.19 5.52 1.4 6.33 6.27 2.61 2.52 2.94 2.11 5.39 1.63 6.96 6.33 4.95 6.65 7.26 2.3 
3732 AKT_phosphorylates_targets_in_the_cytosol 3.01 4.76 2.14 6.28 8.83 7.32 2.54 8.07 4.25 6.34 3.61 5.74 5.34 3.64 8.04 9.61 1.19 1 
3733 AKT_phosphorylates_targets_in_the_nucleus 7.53 4.35 3.4 0.03 1.79 3.46 4.91 2.96 1.64 1.17 3.94 4.93 3.16 6.13 9.03 3.47 9.47 8.7 
3734 CaMK_IV-mediated_phosphorylation_of_CREB 4.5 4.12 3.36 0.24 5.09 5.62 0.98 1.22 7.7 5.99 9.27 8.62 4.3 1.4 6.44 2.99 0.04 5.98 
3735 Cam-PDE_1_activation 8.93 7.74 0.94 1.41 6.61 3.86 6.96 9.91 9.52 3.7 2.21 7.81 2.46 1.09 7.26 9.64 7.15 0.66 
3736 ERK1_activation 9.67 3.59 3.41 2.83 8.68 5.23 6.77 0.3 3.33 0.51 4.26 8.89 9.66 8.61 6.9 2.23 8.9 0.28 
3737 ERK2_activation 0.91 3.13 2.09 2.31 5.37 9.1 9.91 8.35 8.32 6.78 7.35 6.68 9.01 6.75 1.52 7.7 2.8 7.46 
3738 FGFR1b_ligand_binding_and_activation 7.99 3.53 1.32 0.4 9.16 4.57 8.83 9.04 0.97 8.32 6.43 8.28 7.37 8.84 3.97 0.98 1.34 2.7 
3739 FGFR1c_and_Klotho_ligand_binding_and_activation 6.32 2.81 1.9 6.99 1.61 6.35 9.66 7.89 8.31 8.46 8.87 1.37 0.76 3.82 5.28 7.54 0.3 6.45 
3740 FGFR1c_ligand_binding_and_activation 3.48 0.46 1.42 2.94 7.34 9.99 0.16 5.98 4.98 7.01 4.93 1.24 1.34 6.1 3.81 7.06 4.09 0.95 
3741 FGFR2b_ligand_binding_and_activation 4.25 8.28 8.34 0.37 7.93 9.05 3.8 6.38 1.61 9.28 8.81 3 2.25 5.41 5.72 1.06 9.96 2.68 
3742 FGFR2c_ligand_binding_and_activation 3.72 2.98 1.21 9.48 6.54 8.39 5.61 8.72 4.97 9.73 8.16 2.82 2.48 8.77 0.88 3.61 9.15 1.09 
3743 FGFR3b_ligand_binding_and_activation 4.26 0.53 0.8 0.47 9.34 0.71 1.45 0.89 1.58 7.59 1.49 5.25 5.09 3.61 6.67 8.82 9.25 1.67 
3744 FGFR3c_ligand_binding_and_activation 9.23 7.22 2.18 3.09 7.44 2.93 8.57 5.12 3.88 1.99 0.46 8.97 4.82 1.49 4.92 9.69 2.82 6.7 
3745 FGFR4_ligand_binding_and_activation 5.33 8.29 3.04 6.63 9.24 7.39 1.1 2.55 2.49 0.61 7.39 8.85 7.5 4.87 4.11 6.07 1.2 1.96 
3746 Negative_regulation_of_the_PI3K/AKT_network 5.54 9.56 4.72 5.41 0.52 8.12 0.02 8.2 9.66 9.82 4.05 6.7 8.26 4.82 3.64 9.35 5.02 7.84 
3747 PKA_activation 2.05 8.67 8.71 8.49 9.84 7.22 8.69 8.93 8.02 0.11 9.26 3.48 4.27 5.48 3.03 3.29 8.2 4.57 
3748 RAF_activation 7.76 2.99 6.29 8.43 2.64 1.82 6.3 3.47 3.28 2.18 8.04 4.55 8.12 1.23 5.67 8.6 0.88 6.89 
3749 RAF_phosphorylates_MEK 5.22 8.77 0.32 9.36 6.42 4.83 4.27 6.34 7.3 1.74 7.6 6.92 8.78 9.15 6.4 6.14 7.99 9.34 
3750 SHC-mediated_cascade 6.62 7.75 8.23 0.65 0.21 7.52 7.33 1.73 2.34 1.04 6.99 1.53 0.34 9.92 6.38 6.25 3.64 2.64 
3751 Spry_regulation_of_FGF_signaling 1.82 8.24 1.14 9.86 1.98 9.06 3.87 6.12 2.78 0.51 8.05 0.04 1.92 5.48 1.46 2.31 6.88 0.63 
3752 betaKlotho-mediated_ligand_binding 6.09 0.19 7.67 4.32 4.62 1.35 8.73 5.11 2.2 8.07 6.13 6.2 6.98 1.07 2.21 5.94 0.35 7.54 
3753 AKT_phosphorylates_targets_in_the_cytosol 8.96 0.63 8.83 8.03 0.04 5.7 4.38 5.49 6.87 7.02 6.27 0.08 5.84 2.22 1.78 7.87 2.57 6.01 
3754 AKT_phosphorylates_targets_in_the_nucleus 3.54 3.03 7.85 6.49 7.74 5.48 6.95 4.7 0.25 1.47 6.81 2.24 4.79 1.24 4.62 2.93 0.29 9.6 
3755 Activated_point_mutants_of_FGFR2 6.24 4.24 5.56 4.65 4.38 4.35 4.82 7.77 9.92 0.62 8.26 4.24 0.61 3.04 4.61 1.46 9.46 1.49 
3756 CaMK_IV-mediated_phosphorylation_of_CREB 0.65 1.61 4.04 1.12 0.33 7.43 8.32 0.91 8.85 6.46 7.36 1.98 6.11 9.95 3.61 5.96 4.86 2.64 
3757 Cam-PDE_1_activation 5.63 0.44 9.42 1.22 7.44 5.1 9.6 1.3 7.69 1.88 2.64 4.16 7.57 7.71 0.76 7.24 2.28 9.7 
3758 ERK1_activation 3.38 2.39 8.35 9.07 3.97 9.38 0.64 2.39 8.04 2.68 3.28 0.87 7.96 2.9 9.19 6.16 2.39 3.78 
3759 ERK2_activation 5.6 1.35 0.68 9.38 2.46 9.25 4.01 6.15 9.71 1.48 5.67 1.51 1.58 7.95 7.17 7.3 6.66 0.95 
3760 FGFR1b_ligand_binding_and_activation 5.44 4.47 5.24 8.35 4.81 8.91 6.85 9.28 4.38 4.88 6.34 4.96 9.98 8.67 7.44 6.8 6.47 7.1 
3761 FGFR1c_and_Klotho_ligand_binding_and_activation 7.88 7.48 9.79 1.6 7.61 5.52 6.11 6.49 6.91 5.24 1.77 4.58 4.92 9.51 8.6 6.84 9.33 1.92 
3762 FGFR1c_ligand_binding_and_activation 2.08 3.53 0.16 1.68 6.05 6.32 8.03 0.52 7.69 2.84 7.2 2.26 8.08 9.11 7.3 8.41 7.23 4.51 
3763 FGFR2b_ligand_binding_and_activation 5.86 1.98 0.54 7.94 2.91 7.24 3.51 4.14 2.99 1.8 1.96 2.99 6.11 3.1 1.79 9.64 4.89 6.55 
3764 FGFR2c_ligand_binding_and_activation 3.36 0.99 0.28 4.43 8.03 3.81 3.35 3.32 1.36 8.37 3.78 4.83 1.31 1.04 3.25 1.75 3.63 7.62 
3765 FGFR3b_ligand_binding_and_activation 6.94 3.8 5.66 2.7 9.57 5.9 4.77 0.03 3.82 6.78 3.54 8.77 6.95 1.8 2.15 3.3 6.43 8.54 
3766 FGFR3c_ligand_binding_and_activation 2.73 8.23 4.86 1.27 3.65 8.49 5.38 4.43 0.18 1.84 2.09 4.42 4.71 0.24 0.68 3.4 8.46 4.51 
3767 FGFR4_ligand_binding_and_activation 6.91 7 4.09 3.4 0.38 1.12 0.11 3.01 5.08 1.75 6.03 3.63 4.89 9.56 2.85 4.88 9.57 2.18 
3768 Negative_regulation_of_the_PI3K/AKT_network 7.05 6.73 7.55 7.45 7.36 2.01 5.91 9.04 4.68 1.9 1.56 4.03 3.75 0.59 8.45 1.35 2.39 6.86 
3769 PKA_activation 1.06 3.79 9.69 1.22 2.22 2.49 7.07 3.04 3.74 9.82 8.7 7.05 1.88 7.82 2.12 1.03 8.45 9.72 
3770 RAF_activation 4.94 4.21 7.11 3.37 1.45 6.28 1.36 6.97 2.66 1.83 6.51 9.26 8.32 2.49 1.56 3.44 8.97 6.78 
3771 RAF_phosphorylates_MEK 2.54 1.14 2.79 3.91 3.78 6.51 9.88 7.86 6.67 7.07 4.84 5.3 0.56 9.64 1.95 0.18 6.25 9.24 
3772 SHC-mediated_cascade 6.79 3.76 6.86 6.08 3.26 8.23 9.24 0.5 2.9 8.37 1.86 3.58 9.32 5.19 3.71 8.9 8.48 3.94 
3773 Signaling_by_FGFR1_amplification_mutants 5.48 0.12 5.28 2.6 3.05 9.84 4.35 4.09 6.75 5.86 2.07 9.22 0.45 4.89 0.2 0.03 9.91 0.05 
3774 Signaling_by_FGFR1_fusion_mutants 0.59 5 1.38 0.51 8 8.58 2.37 2.62 3.71 4.15 6.95 8.71 7.89 2.16 4.38 8.32 3.05 1.01 
3775 Signaling_by_FGFR2_amplification_mutants 3.67 7.82 5.2 5.66 7.27 7.26 5.23 5.08 0.34 2.65 6.66 4.45 7.38 0.9 5.94 1.8 3.47 4.16 
3776 Signaling_by_FGFR4_mutants 8.55 0.17 5.48 9.91 2.06 5.81 0 2.28 7.18 2.88 3.34 4.4 0.63 9.66 4.69 9.08 5.08 1.2 
3777 Signaling_by_activated_point_mutants_of_FGFR1 2.04 2.95 1.34 5.99 5.46 1.24 4.25 9.34 8.17 5.51 2.9 7.45 7.28 0.41 4.97 3.84 4.01 9.7 
3778 Signaling_by_activated_point_mutants_of_FGFR3 3.55 9.84 8.79 5.35 4.04 1.8 0.29 6.52 0.11 8 3.47 8.11 7.1 0.95 3.7 2.3 1.2 2.37 
3779 Spry_regulation_of_FGF_signaling 8.83 5.77 6.48 6.07 3.86 8.68 8.99 3.61 3.45 4.63 3.09 0.96 5.06 1.11 6.68 5.06 3.48 7.76 
3780 betaKlotho-mediated_ligand_binding 3.18 2.91 2.83 8.43 9.8 9.22 3.93 3.47 7.5 5.07 4.57 7.22 3.29 6.77 4.7 3.13 5.35 5.9 
3781 t(4;14)_translocations_of_FGFR3 1.11 5.44 6.38 3.42 6.13 0.9 9.55 8.9 1.52 4.21 9.2 7.78 2.39 8.08 5.48 3.17 1.27 8.78 
3782 Activated_point_mutants_of_FGFR2 0.34 1.71 0.47 5.47 5.65 2.76 9.69 2.92 0.02 1.59 3.14 6.59 5.26 6.85 8.54 5.71 1.14 7.51 
3783 Signaling_by_FGFR1_amplification_mutants 8.38 2.73 8.76 1 5.23 6.28 0.48 5.76 0.4 6.63 9.58 0.9 3.31 1.8 8.62 0.69 1.72 7.79 
3784 Signaling_by_FGFR1_fusion_mutants 6.33 1.54 6.09 1.79 5.38 8.35 8.49 5.84 6.78 7.54 5.19 2.7 1.67 0.99 1.38 7.01 3.59 3.6 
3785 Signaling_by_FGFR2_amplification_mutants 3.79 0.22 2.19 7.32 5.9 2.44 4.93 7.38 6.29 4.3 3.83 3.51 7.53 5.88 7.49 1.89 3.54 8.8 
3786 Signaling_by_FGFR4_mutants 0.34 6.09 8.57 6.96 0.54 9.59 2.12 4.49 2.62 3.48 0.58 5.42 7 6.69 9.12 6.08 2.25 2.22 
3787 Signaling_by_activated_point_mutants_of_FGFR1 8.5 4 4.08 7.57 0.3 5.64 6.77 5.05 8.22 6.94 2.46 7.97 9.16 7.55 0.49 0.65 7.07 0.1 
3788 Signaling_by_activated_point_mutants_of_FGFR3 5.66 8.27 0.75 9.39 3.26 4.41 4.94 5.31 2.76 0.9 5.85 9.57 5.54 2.38 3.65 3.14 2 7.08 
3789 t(4;14)_translocations_of_FGFR3 5.1 0.77 7.53 3.95 3.71 4.56 7.74 2.26 5.11 5.79 7.67 0.03 6.55 1.83 1.34 7.17 6.86 3.65 
3790 Signaling_by_FGFR1_amplification_mutants 4.47 0.02 9.25 3.48 7.74 0.57 5.99 4.27 3.91 9.57 1 1.15 7.47 7.49 5.48 7.21 7.77 9.41 
3791 Signaling_by_FGFR1_fusion_mutants 4.39 5.71 2.92 3.24 0.91 9.93 8.36 7.43 8.45 8.14 7.59 5.91 6.59 6.06 1.77 1.75 2.57 0.82 
3792 Signaling_by_FGFR1_amplification_mutants 6.58 0.65 6.58 6.34 8.47 7.69 3.78 8.03 1.71 1.05 1.3 7.37 3.84 2.07 9.56 9.82 3.04 4.68 
3793 Signaling_by_FGFR1_fusion_mutants 8.07 5.88 8.33 2.14 0.05 0.72 7.52 7.04 3.47 5.67 6.93 2.48 4.4 6.93 7.04 4.42 6.66 6.83 
3794 Signaling_by_activated_point_mutants_of_FGFR1 1.94 9.79 1.02 5.53 2.08 6.01 4.38 4.61 3.63 4.73 7.36 2.02 8.59 9.36 6.2 5.17 4.93 6.3 
3795 Signaling_by_FGFR2_amplification_mutants 9.82 6.04 9.7 2.16 0.69 9.44 4.02 4.93 6.19 7.8 7.69 1.16 3.35 2.38 1.69 4.12 0.63 1.82 
3796 Activated_point_mutants_of_FGFR2 8.32 6.59 4.65 9.48 2.04 7.71 1.8 9.19 8.52 0.74 6.9 9.55 2.48 6.57 2.81 3.95 8.12 2.79 
3797 Signaling_by_FGFR2_amplification_mutants 6.51 4.56 8.73 1.66 9.86 1.2 4.84 0.79 8.08 7.54 1.31 8.02 1.74 3.77 6.37 5.37 4.03 2.79 
3798 Signaling_by_activated_point_mutants_of_FGFR3 5.54 8.13 3.44 9.96 1.87 2.88 4.49 1.03 6.91 6.37 9.9 6.04 9.9 4.85 4.19 5.43 8.32 2.04 
3799 t(4;14)_translocations_of_FGFR3 1.57 1.28 7.94 6.91 2.7 1.76 9.05 4.07 4.67 0.02 2.23 7.85 4.12 0.93 9.89 5.27 0.99 4.02 
3800 Signaling_by_FGFR4_mutants 0.81 5.88 5.29 1.85 6.45 9 5.49 0.32 2.96 4.18 4.38 7.42 7.06 5.25 3.31 8.61 4.9 6.08 
3801 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 3.37 4.71 0.09 6.25 3.26 5.63 0.36 0.93 4.59 7.51 5.5 0.58 9.75 2.8 8.29 3.48 8.33 9.12 
3802 NOTCH1_Intracellular_Domain_Regulates_Transcription 7.9 9.88 0.54 6.55 2.99 7.98 7.4 3.09 3.8 7.3 8.3 0.15 0.68 6.22 4.33 6.32 1.25 6.1 
3803 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 7.9 9.7 7.66 2.12 9.46 7.09 6.68 9.96 8.5 4.15 5.03 7.06 7.7 5.56 0.39 6.63 9.52 3.2 
3804 Constitutive_Signaling_by_NOTCH1_HD_Domain_Mutants 1.1 1.78 3.97 8.27 3.68 1.72 8.6 2.29 9.44 0.54 9.5 9.78 8.6 9.61 9.49 7.75 4.84 7.25 
3805 NOTCH1_Intracellular_Domain_Regulates_Transcription 5.43 3.74 4.71 9.19 4.93 2.3 2.56 4.69 7.17 4.15 4.63 3.64 2.76 5.16 6.9 7.08 4.48 8.33 
3806 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 8.77 6.49 2.14 2.47 7.75 3.58 2.47 0.14 5.19 4.93 0.81 1.71 5.03 8.18 4.27 9.46 2.48 0.81 
3807 Constitutive_Signaling_by_NOTCH1_HD+PEST_Domain_Mutants 2.56 5.58 0.14 2.05 7.83 0.38 5.98 5.15 2.5 1.38 7.73 0.69 9.03 1.91 8.11 6.43 3.4 2.22 
3808 NOTCH1_Intracellular_Domain_Regulates_Transcription 7.6 2.87 9.58 3.4 7.97 2.4 2.83 9.9 9.82 5.06 9.74 9.55 7.5 7.24 3.79 6.38 5.56 3.86 
3809 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 3.55 7.72 8.37 9.87 3.78 4.91 8.73 6.14 0.4 7.88 0.02 6.17 2.69 9.46 1.79 7.3 4.49 2.75 
3810 Constitutive_Signaling_by_NOTCH1_PEST_Domain_Mutants 8.54 6.81 5.38 0.07 0.89 8.69 5.99 1.1 8.89 5.34 2.21 5.83 6.63 7.8 5.52 2.15 8.02 6.38 
3811 NOTCH1_Intracellular_Domain_Regulates_Transcription 3.56 2.86 8.86 6.85 8.76 2.32 2.11 0.18 1.55 3.86 3.93 8.69 0.57 4.68 7.79 5.12 1.84 8.7 
3812 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 6.09 3.55 9.2 2.22 2.74 1.85 4.95 6.81 2.01 9.87 6.93 7.59 8.16 7.71 6.96 3.4 1.78 5.32 
3813 Constitutive_Signaling_by_NOTCH1_HD_Domain_Mutants 1.63 2.28 5.9 2.08 8.04 1.51 0.01 7.22 1.58 2.86 8.18 6.45 2.12 3.33 5.64 4.76 8.23 5.85 
3814 Constitutive_Signaling_by_NOTCH1_HD+PEST_Domain_Mutants 9.04 0.28 8.01 8.59 5.77 2.07 9.07 0.53 8.2 3.7 5.65 1.81 7.35 2.33 1.56 4.32 5.21 0.66 
3815 Constitutive_Signaling_by_NOTCH1_PEST_Domain_Mutants 0.73 7.21 2.19 9.03 5.59 6.58 9.18 4.4 4.29 3.93 5.96 1.12 1.65 2.87 4.75 1.67 3.23 6.86 
3816 Constitutive_Signaling_by_NOTCH1_t(7;9)(NOTCH1:M1580_K2555)_Translocation_Mutant 5.12 2.4 7.54 0.01 7.6 7.07 9.48 6.72 5.49 1.66 8.49 5.95 5.5 6.16 0.1 7.51 2.72 6.3 
3817 Loss_of_Function_of_FBXW7_in_Cancer_and_NOTCH1_Signaling 8.78 7.67 9.48 4.73 3 0.85 3.53 6.72 8.42 6.73 9.16 8.5 9.01 1.37 0.36 9.5 0.66 6.02 
3818 NOTCH1_Intracellular_Domain_Regulates_Transcription 6.67 6.63 2.53 8.53 6.9 0.74 9.68 4.22 1.48 4.02 4.78 7.69 2.31 1.82 9.29 5.9 7.1 3.05 
3819 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 8.73 4.55 5.62 6.98 1.81 1.1 2.41 6.13 7.27 0.61 7.27 2.66 1.79 0.4 1.09 9.4 4.72 1.74 
3820 Constitutive_Signaling_by_NOTCH1_t(7;9)(NOTCH1:M1580_K2555)_Translocation_Mutant 5.44 7.65 7.46 7.12 4.84 8.8 2.31 0.16 9.44 4.39 2.65 5.9 6.99 1.74 0.83 5.83 4.95 7.99 
3821 NOTCH1_Intracellular_Domain_Regulates_Transcription 0.16 9.92 7.01 1.36 5.76 2.49 7.05 0.18 3.96 0.61 7.43 8.51 7.16 7.2 2.7 4.15 1.51 2.18 
3822 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 3.49 2.58 1.39 5.32 8.03 3.45 7.1 5.6 0.35 5.37 7.56 7.98 9.68 1.84 2.17 2.68 0.05 8.51 
3823 Downregulation_of_TGF-beta_receptor_signaling 4.17 3.66 4 7.99 2.94 9.66 4.56 2.29 9.87 9.9 8.77 4.96 1.19 2.51 5.35 1.92 4.27 8.36 
3824 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 0.49 2.12 0.55 2.44 0.71 0.67 5.3 5.32 6.46 8.91 8.57 6.13 9.55 4.06 4.98 4.83 3.26 1.06 
3825 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 8.81 5.5 5.28 3.52 8.67 5.82 6.12 8.48 6.25 1.48 2.26 7.86 4.39 3.21 6.97 4.16 5.98 4.81 
3826 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 0.86 4.18 7.02 0.88 4.32 0.26 7.44 2.56 1.18 1.29 2.59 5.45 7.71 9.61 9.73 0.91 2.4 9.5 
3827 Downregulation_of_TGF-beta_receptor_signaling 8.29 8.08 1.07 1.43 6.14 0.37 3.03 3.6 6.39 0.18 5.4 1.65 1.37 8.32 2.88 1.6 6.88 4.83 
3828 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 8.46 0.59 1.9 9.2 6.86 3.33 9.56 6.72 3.33 7.58 5.86 9.65 9.59 5.01 4.65 0.85 4.66 8.85 
3829 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 7.67 7.65 8.05 4.51 3.78 6 7.53 2.67 4.41 6.48 5.1 3.79 4.88 0.68 1.85 5.28 7.78 8.83 
3830 Signaling_by_activated_point_mutants_of_FGFR1 3.16 7.76 5 3.91 9.26 7.2 0.07 0.37 0.53 3.99 7.18 0.05 1.78 8.74 4.97 7.41 7 8.09 
3831 Signaling_by_activated_point_mutants_of_FGFR3 3.62 9.15 2.16 1.3 0.14 0.74 3.51 3.09 9.89 3.72 5.2 8 2.94 4.49 0.55 4.35 6.2 3.35 
3832 Signaling_by_constitutively_active_EGFR 2.38 6.71 2.62 4.27 2.83 2.5 4.22 0.31 9.7 5.82 4.95 1.64 1.89 6.36 8.77 4.5 9.61 6.9 
3833 Spry_regulation_of_FGF_signaling 6.32 7.41 0.35 7 2.01 0.98 3.07 3.78 0.24 6.43 1.83 7.35 4.68 3.11 8.03 9.62 3.41 8.14 
3834 Downregulation_of_TGF-beta_receptor_signaling 3.36 4.16 7.59 0.35 4.18 4.73 4.16 9.55 3.27 3.46 6.36 3.33 2.61 5.56 8.06 8.42 7.15 9.86 
3835 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 4.82 0.55 4.74 5.28 7.61 3.53 6.05 8.5 7.8 3.04 7.03 8.51 7.41 1.35 1.32 9.36 2.66 0.67 
3836 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 6.43 9.16 4.19 5.93 6.34 3.41 1.67 1.01 4.67 3.26 0.17 0.57 0.06 8.14 8.49 4.59 0.3 8.81 
3837 Downregulation_of_TGF-beta_receptor_signaling 2.64 8.82 6.88 8.7 1.8 4.02 0.25 6.57 2.29 5.81 4.48 2.98 9.03 2.77 5.4 3.41 4.01 5.83 
3838 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 3.27 9.31 4.21 1.62 4.75 2.73 7.86 6.25 6.84 2.8 1.34 7.01 8.3 2.05 3.35 3.99 7.28 8.66 
3839 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 8.76 1 4.74 7.64 7.75 1.37 5.23 7.42 9.1 9.93 0.86 0.14 9.94 6.85 7.81 1.82 1.68 8.67 
3840 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 4.94 1.98 2.94 2.75 6.85 2.32 0.56 2.78 7.39 2.6 2.04 5.59 1.82 8.93 9.63 3.02 7.61 9.24 
3841 Downregulation_of_TGF-beta_receptor_signaling 8.49 5.79 0.61 4.2 4.86 1.84 3.35 0.29 1.02 4.5 3 8.37 2.94 6.73 0.43 5 0.72 5.26 
3842 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 4.1 1.98 2.25 6.29 1.64 4.78 3.77 2.75 9.69 1.53 6.58 3.21 2.14 9.53 4.28 1.7 6.22 2.36 
3843 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 1.13 2.25 3.53 3.16 0.61 6.87 1.17 3.92 1.12 2.12 4.18 1.78 7.75 1.55 6.5 9.22 8.31 0.67 
3844 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 1.29 0.51 8.6 0.18 4.01 3.65 0.65 3.41 6.33 2.67 2.24 1.98 7.67 5.42 2.29 3.65 5.15 1.7 
3845 Downregulation_of_TGF-beta_receptor_signaling 0.14 9.95 9.27 0.22 2.14 7.55 7.64 2.98 1.7 2.65 4.3 8.28 9.55 5.43 1.3 8.44 6.29 7.49 
3846 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 7.18 6.97 1.04 7.21 2.03 5.79 6.85 2.8 6.79 1.38 5.55 7.96 0.46 1.82 3.06 2.31 2.82 1.21 
3847 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 1.51 9.82 2.32 2.91 1.54 9.13 1.64 6.28 0.29 1.86 8.16 4.79 9.34 2.2 3.93 5.33 5.82 6.94 
3848 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 3.47 2.71 5.31 9.84 7.75 0.4 2.35 8.13 4.09 3.14 5.53 2.74 5.02 5.28 7.57 4.46 8.22 6.53 
3849 Downregulation_of_TGF-beta_receptor_signaling 1.99 7.14 1.98 4.11 3.73 7.63 5.38 9.49 2.22 2.06 2.89 9.37 9.65 6.67 3.37 9.52 9.13 4.37 
3850 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 0.93 2.49 9.96 1.21 6.84 5.89 3.39 7.97 5.32 8.35 2.86 8.75 3.1 7.11 7.45 0.77 3.4 5.51 
3851 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 6.58 9.15 2.64 3.11 2.12 2.76 4.31 7.25 7.63 9.21 9.9 6.71 7.92 5.6 9.07 4.43 4.55 5.99 
3852 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 9.6 6.31 9.84 7.27 2.43 5.47 1.15 6.36 7.85 6.27 2 3.62 2.53 8.01 6.77 2.26 5.07 5.23 
3853 Activation_of_the_phototransduction_cascade 1.29 7.17 3.06 3.93 9.13 1.44 8.97 0.02 5.6 2.24 8.81 2.87 5.81 0 4.03 1.28 8.48 7.85 
3854 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 2.04 9.18 4.36 7.38 6.46 1.6 2.43 5.6 1.37 2.02 3.42 3.83 0.9 5.39 3.97 3.78 3.3 6.53 
3855 The_retinoid_cycle_in_cones_(daylight_vision) 7.03 4.31 2.66 1.23 4.17 1.66 3.73 8.94 2.28 7.16 7.28 1.36 7.22 1.79 4.45 8.85 0.97 5.96 
3856 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 0.7 6.7 5.24 0.8 5.12 4.72 6.85 0.19 3.81 4.45 7.12 8.98 0.79 2.02 0.04 5.19 7.78 2.72 
3857 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 7.63 8.42 6.73 8.22 6.05 3.14 9.56 7.75 6.71 6.76 8.56 3.68 8.33 2.67 0.8 5.82 9.61 6.57 
3858 Transport_and_synthesis_of_PAPS 4.35 7.81 3.22 1.01 5.25 9.31 2.73 6.38 0.58 4.14 8.82 7.83 4.96 0.59 9.65 7.31 9.97 6.17 
3859 Transport_of_HA_trimer,_NA_tetramer_and_M2_tetramer_from_the_endoplasmic_reticulum_to_the_Golgi_Apparatus 0.39 0.02 4.25 9.97 4.95 3.01 7.89 7.36 1.98 9.83 2.44 3.82 4.42 8.2 2.8 5.12 2.93 3.1 
3860 Viral_Messenger_RNA_Synthesis 2.81 7.48 4.81 2.85 2.34 6.5 6.79 7.75 2.6 9.23 2.01 1.06 4.87 0.38 9.8 3.97 2.46 1.23 
3861 Viral_RNP_Complexes_in_the_Host_Cell_Nucleus 2.66 1.01 0.58 8.03 6.3 0.79 1.38 4.63 5.93 8.16 9.62 8 2.21 1.97 4.17 4.79 0.09 7.85 
3862 Viral_mRNA_Translation 7.35 7.19 1.64 9.21 6.87 1.36 0.77 2.62 9.85 5.25 2.26 4.51 6.11 7.67 4.87 1.49 8.73 1.39 
3863 Activation_of_the_phototransduction_cascade 4.58 2.99 7.23 9.77 3.09 4.54 4.78 6.95 8.51 1.87 7.82 5.42 2.63 5.67 8.5 8.76 6.89 0.51 
3864 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 2.4 0.33 2.42 9.84 4.9 2.69 4.66 3.63 2.57 1.46 4.72 3.08 6.02 2.22 5.94 3.32 1.98 4.45 
3865 Retinoid_metabolism_and_transport 2.21 7.98 8.3 4.6 0.47 4.16 9.98 9.52 9.23 3.93 5.62 8.96 2.62 4.05 3.91 3.2 5.43 3.83 
3866 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 9.31 3.76 7.4 6.7 2.31 3.09 9.63 9.31 8.43 2.86 8.37 9.7 0.75 7.53 1.62 7.03 4.09 5.75 
3867 The_retinoid_cycle_in_cones_(daylight_vision) 0.25 3.55 7.72 5.57 3.35 7.43 7.83 9.33 4.74 3.28 2.28 7.64 8.7 2.92 9.31 4.69 9.76 5.48 
3868 Vitamin_B1_(thiamin)_metabolism 8.93 4.38 7.45 9.3 3.58 2.42 3.41 4.12 7.15 3.19 0.04 0.5 5.36 2.72 6.57 6.53 1.17 8.05 
3869 Vitamin_B2_(riboflavin)_metabolism 4.17 4.24 1.22 6.58 8.06 8.76 8.48 7.33 5.41 1.02 2.74 3.16 6.85 3.48 3.8 7.11 8.02 7.04 
3870 Coenzyme_A_biosynthesis 2.99 9.85 9.12 2.67 4.85 9.25 3.55 2.06 2.26 9.27 6.3 3.65 0.59 2.08 0.58 7.33 3.46 9.58 
3871 Vitamin_C_(ascorbate)_metabolism 0.9 9.76 8.9 6.6 9.18 2.3 4.4 4.37 0.36 8.3 1.39 9.75 1.57 4.45 8.16 0.93 4.07 0.15 
3872 Vitamins_B6_activation_to_pyridoxal_phosphate 8.33 9.57 5.58 8.68 4.23 6.68 0.57 4.2 2.37 8.79 3.47 9.9 9.19 8.67 2.78 4.28 6.11 1.11 
3873 betaKlotho-mediated_ligand_binding 0.95 3.48 8.38 3.36 7.82 6.27 4.66 6.05 8.04 1.39 9.19 6.61 8.74 3.11 7.52 8.62 9.27 6.83 
3874 cRNA_Synthesis 9.99 0.71 0.98 1.53 0.68 9.92 6.41 3.06 6.97 4.72 4.42 9.78 5.05 4.15 3.68 3.83 8.03 6.61 
3875 t(4;14)_translocations_of_FGFR3 7.93 7.79 6.66 3.47 7.01 2.55 8.47 9.29 1.76 4.51 5.45 1.51 0.44 3.96 7.55 6.96 1.05 0.77 
3876 vRNA_Synthesis 7.42 0.92 5.75 0.49 7.69 2.37 7.74 4.72 9.19 8.04 6.11 5.92 8.32 5.81 5.97 9.65 3.54 0.08 
3877 vRNP_Assembly 0.81 0.6 0.01 8.89 0.67 1.4 0.6 4.74 4.62 2.39 6.5 0.16 2.46 8.08 3.01 0.19 9.79 3.8 
3878 Trafficking_and_processing_of_endosomal_TLR 6.14 3.78 5.85 7.02 9.7 8.07 5.9 7.18 6.51 9.42 5.4 2.74 4.58 5.32 9.12 8.4 4.75 2.13 
3879 DEx/H-box_helicases_activate_type_I_IFN_and_inflammatory_cytokines_production_ 6.49 9.54 4.57 7.74 7.73 4.67 1.09 2.53 5.76 9.05 3.29 7.5 1.91 7.15 4.09 3.27 7.72 5.65 
3880 IRF3_mediated_activation_of_type_1_IFN 0.92 3.18 1.15 7.62 6.15 8.09 6.2 2.01 2.18 6.23 6.65 9.07 7.6 3.25 6.83 4.12 4.41 3.63 
3881 IRF3-mediated_induction_of_type_I_IFN 0 3.6 7.14 8.48 5.05 0.32 7.2 5.55 0.49 7.25 2.57 9.64 4.23 1.32 7.96 5.31 2.64 2.83 
3882 LRR_FLII-interacting_protein_1_(LRRFIP1)_activates_type_I_IFN_production 7.69 2.31 1.9 1.15 6.51 1.21 5.5 8.3 8.05 3.29 9.77 3.71 5.63 8.49 2.09 2.23 9.79 9.22 
3883 RIP-mediated_NFkB_activation_via_ZBP1 3.27 0.3 3.8 3.08 1.3 4.11 4.22 3.86 9.06 8.84 3.7 0.04 5.49 0.98 0.91 1.66 1.86 3.27 
3884 Regulation_by_TREX1 6.2 6.98 9.73 7.37 4.92 3.14 2.99 6.3 6.16 9.76 4.3 1.52 8.8 8.09 6.91 3.79 8.29 4.79 
3885 Regulation_of_innate_immune_responses_to_cytosolic_DNA 9.77 2.6 4 1.35 2.45 1.73 6.47 3.63 5.24 0.46 0.2 0.96 7.36 4.86 7.66 8.58 1.51 4.75 
3886 STAT6-mediated_induction_of_chemokines 8.6 0.46 9.28 6.3 0.07 7.84 6.64 7.3 2.47 0.63 5.96 1.98 5.93 8.38 1.76 7.85 5.44 9.72 
3887 IRF3-mediated_induction_of_type_I_IFN 1.19 9.9 3.06 5.98 9.4 9.93 6.2 4.12 0.16 1.84 2.72 1.69 5 2.21 6.45 5.1 1.06 4.51 
3888 STAT6-mediated_induction_of_chemokines 3.84 9.14 7.19 1.02 6.82 9.87 4.68 7.84 0.5 2.88 7.41 7.54 2.05 6.42 2.57 2.72 8.03 7.67 
3889 IRF3_mediated_activation_of_type_1_IFN 8.2 5.92 1.87 4.89 8.57 6.52 1.7 5.67 7.08 4.06 7.44 4.43 1.19 3.48 2.43 8.36 8.35 6.68 
3890 RIP-mediated_NFkB_activation_via_ZBP1 6.4 0.28 7.77 3.05 3.51 0.29 4.97 2.62 3.59 5.67 0.43 0.58 1.38 2.21 6.93 2.21 4.1 9.21 
3891 FCGR_activation 4.45 7.63 5 0.53 6.63 9.51 5.16 4.91 6.8 9.13 3.93 6.23 5.23 0.83 0.42 6.2 4.2 3.36 
3892 Regulation_of_actin_dynamics_for_phagocytic_cup_formation 1.93 8.6 4.68 1.25 4.47 1.57 2.13 5.65 3.92 7.52 5.19 3.52 6.73 7.47 0.82 7.96 3.83 2.25 
3893 Role_of_phospholipids_in_phagocytosis 5.24 1.03 4.81 2.88 0.85 4.51 1.85 6.44 0.33 7.95 5.03 1.78 1.09 8.61 1.19 1.83 4.14 9.53 
3894 AKT_phosphorylates_targets_in_the_cytosol 8.36 2.66 3.91 8.81 1.88 3.76 8.34 1.76 2.86 2.23 4.25 6.72 4.82 5.16 9.56 5.99 3.2 9.13 
3895 AKT_phosphorylates_targets_in_the_nucleus 7.49 1.38 7.47 1.69 5.79 0.45 0.31 5.66 2.12 7.37 9.13 4.61 3.67 1.43 0.54 9.68 3.21 0.37 
3896 CaMK_IV-mediated_phosphorylation_of_CREB 6.95 0.13 6.05 6.78 4.91 0.53 5.53 9.5 5.41 1.91 5.91 9.67 1.76 1.97 2.1 5.57 2.88 0 
3897 Cam-PDE_1_activation 1.86 5.61 3.31 0.96 2.17 2.28 7.43 7.58 0.94 5.86 3.26 0.14 5.62 1.69 9.28 6.47 5.38 8.66 
3898 PKA_activation 6.87 6.93 8.28 5.99 3.13 3.44 7.97 9.9 3.53 1.18 3.54 9.33 3.27 5.35 5.41 8.62 8.01 0.64 
3899 CaMK_IV-mediated_phosphorylation_of_CREB 4.27 7.73 2.5 2.02 1 9.6 8.03 4.43 3.31 0.54 1.43 0.94 1.43 0.03 5.07 7.43 8 7.63 
3900 CaMK_IV-mediated_phosphorylation_of_CREB 3.97 6.73 2.14 4.76 0.84 1.71 4.94 3.62 6.96 7.76 1.42 2.61 2.36 4.46 3.4 6.85 4.57 0.58 
3901 Cam-PDE_1_activation 8.57 9.69 7.97 6.73 7.32 1.8 6.76 7.7 5.97 9.13 9.73 3.23 6.06 9.21 1.69 9.37 2.17 0.27 
3902 PKA_activation 2.95 7.64 2.22 6.51 2.36 7.85 9.15 7.89 6.57 2.02 4.98 6.83 8.61 1.16 1.09 1.1 0.84 6.39 
3903 Cam-PDE_1_activation 4.53 1.38 7.12 9.23 8.83 6.77 2.72 0.01 7.34 0.34 0.86 2.64 3.83 2.64 8.45 8.25 3.21 7.12 
3904 CaMK_IV-mediated_phosphorylation_of_CREB 6.34 9.96 8.3 8.07 7.14 5.08 1.01 3.6 1.09 7.69 1.04 3.67 8.33 1.89 3.01 3.93 6.74 6.34 
3905 Cam-PDE_1_activation 4.19 8.63 8.17 0.25 0.96 6.29 3.79 8.45 3.28 0.7 7.47 4.26 1.61 0.98 1.22 1.36 0.53 1.63 
3906 PKA_activation 5.18 2.21 7.03 2.52 5.53 5.45 0.57 5.15 4.43 6.91 2.06 3.52 8.34 8.13 6.59 3.66 6.5 1.63 
3907 AKT_phosphorylates_targets_in_the_cytosol 6.52 4.11 3.6 7.06 6.36 5.79 9.47 1.59 2.28 5.37 4.77 3.01 5.6 4.96 1.09 9.47 7.43 9.98 
3908 AKT_phosphorylates_targets_in_the_nucleus 9.29 7.33 1.54 5.86 9.39 4.25 2.14 8.32 0.09 9.73 0.29 3.39 8.1 5.6 0.17 0.27 8.85 4.7 
3909 CaMK_IV-mediated_phosphorylation_of_CREB 1.63 2.55 8.52 5.28 1.31 1.64 5.53 6.51 9.93 4.7 6.88 2.07 0.12 1.82 9.82 7.55 3.85 1.74 
3910 Cam-PDE_1_activation 0.4 8.88 2.62 9.85 7.9 9.23 4.55 1.9 1.93 4.14 1.6 2.3 1.23 8.25 7.32 0.51 0.3 0.21 
3911 ERK1_activation 5.98 2.2 9.85 7.14 0.31 0.06 1.5 8.1 6.55 4.94 5.35 1.01 1.75 1.24 1.62 5.58 8.7 6.74 
3912 ERK2_activation 8.5 3.73 6.02 1.18 1.6 0.71 7.05 6.43 7.85 5.95 1.37 9.43 2.1 1.1 7.09 1.2 7.14 3.14 
3913 Negative_regulation_of_the_PI3K/AKT_network 0.89 8.16 0.87 1.7 4.72 7.95 1.88 6.25 9.87 7.75 6.49 3.64 6.77 6.36 7.07 5.65 6.37 5.79 
3914 PKA_activation 9.98 0.89 0.92 6.03 1.28 3.64 2.08 1.62 5.83 9.48 4.31 9.21 9.98 6.43 3.2 6.35 4.84 7.61 
3915 RAF_activation 0.79 3.6 3.9 4.81 4.87 7.89 0.06 4.5 2.13 2.46 5.87 3.38 9.3 8.22 6.91 7.82 8.81 5.5 
3916 RAF_phosphorylates_MEK 4.86 6.21 5.14 2.68 7.34 9.01 0.86 8.54 4.04 1.89 6.12 4.56 0.2 1.98 5.15 7.95 5.95 4.2 
3917 ERK1_activation 6.09 0.86 4.32 1.77 1.24 2.88 8.65 8.99 8.87 1.19 6.16 1.41 0.55 3.31 7.42 9.16 0.54 3.11 
3918 ERK2_activation 4.77 7.87 1.12 2.57 2.76 5.77 3.56 2.95 3.03 8.48 6.38 9.56 3.42 7.94 4.9 8.43 0.55 8.15 
3919 ERK1_activation 8.75 9.56 1.58 9.86 6.53 2.29 6.12 3.73 6.47 9.71 0.85 8.66 1.74 5.93 0.22 4.04 8.38 4.07 
3920 ERK2_activation 0.39 4.93 6.82 7.27 4.06 5.29 1.9 5 4.76 2.5 8.42 2.6 9.32 6.94 1.22 3.12 1.61 2.38 
3921 RAF_phosphorylates_MEK 3.4 2.41 6.79 1.36 3.45 5.97 2.53 6.87 1.12 9.78 7.37 5.38 1.76 6.9 4.28 6.9 4.52 0.48 
3922 Negative_regulation_of_the_PI3K/AKT_network 2.56 5.04 5.72 7.94 6.23 3.42 2.73 0.96 0.46 7.48 3.37 3.64 8.82 0.55 5.64 7.3 5.13 0.69 
3923 AKT_phosphorylates_targets_in_the_cytosol 9.57 2.82 5.25 1.96 1.49 5.87 2.2 3.47 9.25 6.66 7.23 2.89 8.03 1.15 7.81 2.53 4.64 8.48 
3924 AKT_phosphorylates_targets_in_the_nucleus 2.54 1.49 4.31 8.32 5.41 2.03 1.11 4.57 6.41 7.41 2.12 2.97 9.71 0.28 8.75 4.33 0.29 0.39 
3925 Negative_regulation_of_the_PI3K/AKT_network 3.01 7.95 2.33 0.49 2.39 3.02 2.13 2.4 0.71 8.08 0.69 2.4 5.05 7.71 8.5 5.83 4.67 2.75 
3926 PKA_activation 7.94 9.62 9.25 6.47 7.67 6.64 8.38 3.33 8.36 7.81 9.15 1.71 1.34 9.3 3.2 5.4 9.27 7.71 
3927 PKA_activation 1.56 6.71 3.37 7.93 6.32 4.94 6.01 6.09 3.85 1.57 7.38 4.6 5.02 9.54 8.04 3.77 3.79 0.93 
3928 RAF_activation 4.35 4.88 3.36 4.87 5.89 3.84 1.72 4.88 8.23 1.8 2.3 0.11 6.87 8.57 8.37 7.89 0.07 0.99 
3929 RAF_phosphorylates_MEK 5.26 1.02 3.2 4.88 6.78 3.98 4.86 5.89 1.6 9.56 0.35 7.83 6.57 3.63 5.98 7.81 2.67 4.31 
3930 ERK1_activation 4.05 2.69 7.03 0.15 0.88 7 4.86 4.26 0.56 0.98 2.58 5.42 2.16 6.05 1.36 5.83 6.35 4.53 
3931 ERK2_activation 6.17 3.66 8.14 4.48 8.01 1.62 1.11 9.66 5.99 2.03 8.23 6.4 6.95 6.28 8.52 3.88 3.8 5.6 
3932 RAF_activation 7.69 4.68 3.54 2.57 5.06 8.08 5.86 2.29 2.67 8.25 5.11 3.78 0.41 2.96 4.82 0.36 1.47 0.46 
3933 RAF_phosphorylates_MEK 5.21 4.04 1.21 9.25 6.29 4.58 3.82 7.59 7.23 7.99 4.26 9.1 9.63 8.04 4.83 0.59 2.96 5.36 
3934 Scavenging_by_Class_A_Receptors 4.38 9.06 0.39 3.2 7.76 4.06 9.71 4.87 8.02 2.57 7.44 5.6 2.92 9.91 9.19 8.41 7.76 8.76 
3935 Scavenging_by_Class_B_Receptors 8.26 1.55 6.99 9.71 6.57 9.19 8.56 1.45 7.95 0.67 3.9 8.81 5.12 7.81 9.46 1.36 2.55 6.24 
3936 Scavenging_by_Class_F_Receptors 9.04 2.92 5.72 1.65 5.74 3.29 1.57 9.63 2.97 2.6 3.32 4.26 2.53 4.84 0.87 9.56 4.39 6.37 
3937 Scavenging_by_Class_H_Receptors 5.35 2.93 4.93 4.62 1.1 8.45 4.96 1.74 4.76 5.39 5.2 3.87 4.59 8.92 5.85 0.27 6.42 6.92 
3938 Scavenging_of_Heme_from_Plasma 1.74 6.46 4.31 4.45 8.27 3.55 3.69 0.62 4.23 3.95 1.96 9.33 3.45 9.47 6.7 7.12 1.53 6.06 
3939 Formation_of_Senescence-Associated_Heterochromatin_Foci_(SAHF) 7.94 0.4 8.19 0.1 3.95 6.8 1.12 9.93 9.95 5.17 3.74 7.55 9.4 1.42 6.49 8.66 3.27 3.09 
3940 Oncogene_Induced_Senescence 5.53 9.18 2.99 9.82 5.5 9.38 5.93 7.99 4.73 2.31 3.42 2.25 8.13 0.71 7.84 6.63 4.54 2.93 
3941 Oxidative_Stress_Induced_Senescence 2.12 7.96 8.33 8.11 0.95 2.98 0.6 4.52 2.67 8.4 6.71 3.23 2.61 8.04 4.59 6.51 7.41 4.41 
3942 Senescence-Associated_Secretory_Phenotype_(SASP) 5.94 4.25 5.34 6.74 4.24 3.43 3.34 4.4 3.76 8.03 6.72 8.96 8.1 0.63 6.08 7.37 2.59 6.09 
3943 Oxygen-dependent_Asparagine_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 8.06 9.08 0.53 3.9 3.92 6.05 3.77 3.39 2.33 0.49 3.78 8.6 9.74 9.52 2.12 6.17 9.3 5.49 
3944 Oxygen-dependent_Proline_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 3.41 2.77 9.36 2.2 4.42 7.28 1.69 5.63 0.69 1.2 7.67 4.44 3.58 3.72 3.7 4.26 5.36 9.77 
3945 Regulation_of_Gene_Expression_by_Hypoxia-inducible_Factor 3.52 1.14 0.62 6.8 8.98 1.09 3.81 1.44 5.49 2.83 2.19 7.2 5.1 5.93 6.8 8.56 4.02 6.85 
3946 Formation_of_Senescence-Associated_Heterochromatin_Foci_(SAHF) 5.4 2.24 5.73 6.66 4.97 4 8.41 5.84 0.27 8.34 8.41 3.41 4.69 6.85 3.9 2.34 4.86 7.96 
3947 Formation_of_Senescence-Associated_Heterochromatin_Foci_(SAHF) 2.66 6.15 3.88 0.07 7.55 7.61 5.91 4.63 6.58 6.13 9.77 4.31 4.93 5.17 3.57 1.14 6.02 3.06 
3948 Oncogene_Induced_Senescence 1.34 6.72 0.21 0.74 6.25 4.13 3.96 7.81 6.61 5.87 7.85 1.55 5.69 6.54 9.27 9.12 0.96 7.12 
3949 Oxidative_Stress_Induced_Senescence 3.84 7.38 5.37 7.19 6.46 8.26 5.45 2.6 9.37 6.49 2.77 6.7 7.93 5.34 6.34 7.66 7.01 9.33 
3950 Oxygen-dependent_Asparagine_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 9.04 2.03 0.99 0.49 6.95 8.17 0.16 5.57 6.24 1.34 8.98 9.84 0.47 4.29 9.64 2.87 4.24 3.43 
3951 Oxygen-dependent_Proline_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 5.62 3.2 0.08 8.94 2.7 2.76 6.12 6.83 5.7 7.31 1.28 3.47 7.75 1.27 0.81 8.22 5.97 5.54 
3952 Regulation_of_Gene_Expression_by_Hypoxia-inducible_Factor 0.03 3.45 0.68 6.81 1.95 8.68 0.11 6.86 7.96 8.53 7.59 5.76 0.12 1.74 3.82 3.58 5.32 4.85 
3953 Oxygen-dependent_Asparagine_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 6.91 1.48 6.03 8.59 4.77 7.64 3.57 2.16 8.76 1.84 5.31 5.65 9.64 1.11 2.58 2.73 4.29 0.23 
3954 Oxygen-dependent_Proline_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 9.84 1.68 7.53 2.82 9.72 8.16 5.36 4.92 5.26 9.66 2.01 8.44 5.99 7.85 4.42 2.73 1.86 1.17 
3955 Regulation_of_Gene_Expression_by_Hypoxia-inducible_Factor 4.09 8.31 6.1 7 1.4 8.89 7.9 1.75 3.18 4.81 7.47 4.67 0.91 5.66 3.93 5.62 9.66 2.14 
3956 Senescence-Associated_Secretory_Phenotype_(SASP) 7.53 4.46 0.32 7.16 1.17 9.9 2.36 3.23 7.68 8.42 4.97 9.16 6.87 5.93 1.52 5.4 1.84 4.94 
3957 AKT_phosphorylates_targets_in_the_cytosol 4.38 8.18 6.26 1.5 2.04 7.59 7.66 4.61 4.77 3.91 2.13 7.94 8.4 7.91 6.26 2.4 2.55 9.52 
3958 AKT_phosphorylates_targets_in_the_nucleus 6.33 4.3 5.91 9.79 3.75 8.41 5.69 1.33 9 4.08 8.4 9.08 7.59 1.28 9.16 5.7 2 6.65 
3959 ERK1_activation 7.5 2.18 6.92 5.53 5.89 2.97 9.32 8.24 2.24 9.68 3.91 7.56 9.49 6.95 3.14 6.86 4.18 9.39 
3960 ERK2_activation 0.69 2.6 3.38 0.03 7.76 5.92 7.3 1.27 2.53 1.93 3.8 2.34 3.68 1.12 9.71 5.38 2.12 4.06 
3961 ERK1_activation 8.57 1.09 5.03 8.28 7.82 8.71 6.25 3.87 0.58 1.61 0.97 9.1 0.6 6.68 0.41 9.48 5.23 6.3 
3962 ERK2_activation 9.63 6.98 1.98 4.92 6.68 4.16 2.15 4.57 3.76 0.99 4.69 0.38 0.22 5.16 4.5 2.11 2.69 6.62 
3963 FCERI_mediated_Ca+2_mobilization 6.02 2.68 7.51 8.93 1.01 8.95 8.45 9.34 4.47 5.73 7.96 2.81 0.46 3.76 2.7 4.22 9.71 7.08 
3964 ERK1_activation 5.47 2.87 7.73 9.12 7.06 6.82 4.98 4.47 2.03 9.79 3.44 4.74 5.03 1.67 5.87 8 2.02 3.31 
3965 ERK2_activation 4.95 9.29 1.19 0.38 8.57 7.03 9.16 3.08 8.65 3.9 4.32 9.81 4.35 6.54 5.15 9.65 6.06 5.27 
3966 RAF_activation 9.97 9.01 4.35 3.64 3.06 7.23 9.46 7.94 9.39 3.97 5.3 2.83 4.88 1.23 2.32 8.54 6.37 2.54 
3967 RAF_phosphorylates_MEK 2.27 9.78 9.95 8.35 3.73 8.51 4.17 2.69 7.88 3.15 7.39 1.38 3.05 4.85 8.17 4.76 4.72 7.98 
3968 FCERI_mediated_NF-kB_activation 4.99 9.72 1.7 6.29 9.39 8.58 1.12 9.4 4.35 7.59 5.04 5.19 8.18 5.26 8.45 2.61 4.73 8.08 
3969 RAF_phosphorylates_MEK 0.02 1.89 0.5 1.68 6.55 3.87 1.63 3.26 1.99 2.98 1.27 8.8 4.57 9.32 9.58 8.54 1.98 9.2 
3970 Negative_regulation_of_the_PI3K/AKT_network 8.63 2.68 8.26 8.68 4.11 5.57 2.39 2.59 2.35 7.82 5.82 5.2 3.32 4.66 1.51 6.28 3.86 2.36 
3971 AKT_phosphorylates_targets_in_the_cytosol 4.76 1.33 8.11 1.85 5.84 9.67 6.54 4.95 3.57 0.55 7.08 0.25 6.47 4.06 9.25 5.65 5.95 5.7 
3972 AKT_phosphorylates_targets_in_the_nucleus 3.26 9.75 8.69 9.71 3.94 9.35 7.36 9.01 5.66 1.84 7.26 4.17 8.73 2.51 5.78 7.61 2.52 6.68 
3973 Negative_regulation_of_the_PI3K/AKT_network 0.28 7.48 2.15 4.58 4.94 3.98 5.48 2.77 9.41 0.76 5.75 8.99 9.22 1.91 1.74 2.28 3.29 3.43 
3974 RAF_activation 2.62 5.75 1.85 1.85 7.82 1 5.97 0.6 4.24 7.39 1.79 6.56 1.33 5.57 2.99 6.88 6.24 3.54 
3975 RAF_phosphorylates_MEK 3.06 0.66 8.22 1.62 4.72 7.17 1.89 1.04 4.3 0.5 7.22 4.36 5.24 5.5 1.99 7.44 1.62 7.99 
3976 ERK1_activation 1.33 7.89 6.77 0.84 1.1 1.42 3.09 5.38 6.47 2.37 9.73 3.96 3.23 2.13 1.22 8.03 4.91 9.05 
3977 ERK2_activation 8.31 5.99 5.33 9.95 8.64 3.4 8.19 2.47 6.3 7.93 0.3 0 5.55 3.41 5.46 0.51 0.78 8.1 
3978 RAF_activation 9.31 1.15 6.57 8.38 7.6 4.61 0.57 2 2.16 0.53 8.54 5.28 9.86 0.24 1.88 0.9 0.73 3.72 
3979 RAF_phosphorylates_MEK 0.88 8.93 8.56 4.44 0.23 0.63 9.7 0.49 8.36 2.83 0.29 3.58 4.16 5.81 5.84 0.66 0.31 5.57 
3980 AKT_phosphorylates_targets_in_the_cytosol 5.22 7.39 8.32 2.19 1.33 3.37 5.33 0.34 3.56 1.04 3.73 7.43 5.04 1.79 8.54 4.84 7.69 1.09 
3981 AKT_phosphorylates_targets_in_the_nucleus 1.18 3.76 9.31 1.13 3.64 7.38 3.67 4.78 8.11 9.98 9.24 3.15 5.91 9.43 2.93 4.89 5.46 5.97 
3982 Negative_regulation_of_the_PI3K/AKT_network 0.68 2.08 8.49 2.88 6.55 8.66 2.59 2.06 6.11 6.48 7.3 9.94 5.74 6.89 3.01 0.06 5.22 5.62 
